<SEC-DOCUMENT>0001628280-22-028463.txt : 20221104
<SEC-HEADER>0001628280-22-028463.hdr.sgml : 20221104
<ACCEPTANCE-DATETIME>20221104161855
ACCESSION NUMBER:		0001628280-22-028463
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221104
DATE AS OF CHANGE:		20221104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		221362587

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bcrx-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:f6ec4fab-a519-489e-b421-6c7ee3322750,g:f7084e6e-47c2-4faa-aed0-8ba33c516e4f,d:a4cd069c56504e93a883c91651012280--><html xmlns:bcrx="http://www.biocryst.com/20220930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bcrx-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80L2ZyYWc6OWIxYjY5MWVkNzkxNDA2NjhlNzhkNWIwMGYxNTZmOWYvdGFibGU6ZGZkZDI5MTg0MmZkNDA5MzhmYjc4YzRlNDMwMzU2NTUvdGFibGVyYW5nZTpkZmRkMjkxODQyZmQ0MDkzOGZiNzhjNGU0MzAzNTY1NV8yLTEtMS0xLTkzNjA_fef75201-25a8-43ca-9d7e-f78b411aa010">0000882796</ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80L2ZyYWc6OWIxYjY5MWVkNzkxNDA2NjhlNzhkNWIwMGYxNTZmOWYvdGFibGU6ZGZkZDI5MTg0MmZkNDA5MzhmYjc4YzRlNDMwMzU2NTUvdGFibGVyYW5nZTpkZmRkMjkxODQyZmQ0MDkzOGZiNzhjNGU0MzAzNTY1NV80LTEtMS0xLTkzNjA_f19a80c5-04cd-46d8-a15b-1141ee45cbdc">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80L2ZyYWc6OWIxYjY5MWVkNzkxNDA2NjhlNzhkNWIwMGYxNTZmOWYvdGFibGU6ZGZkZDI5MTg0MmZkNDA5MzhmYjc4YzRlNDMwMzU2NTUvdGFibGVyYW5nZTpkZmRkMjkxODQyZmQ0MDkzOGZiNzhjNGU0MzAzNTY1NV81LTEtMS0xLTkzNjA_fc4a3ed2-3056-4eb2-86e0-b6368bf661b8">2022</ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80L2ZyYWc6OWIxYjY5MWVkNzkxNDA2NjhlNzhkNWIwMGYxNTZmOWYvdGFibGU6ZGZkZDI5MTg0MmZkNDA5MzhmYjc4YzRlNDMwMzU2NTUvdGFibGVyYW5nZTpkZmRkMjkxODQyZmQ0MDkzOGZiNzhjNGU0MzAzNTY1NV82LTEtMS0xLTkzNjA_41d560ac-6bd5-418f-9ce6-69b8b071c012">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80L2ZyYWc6OWIxYjY5MWVkNzkxNDA2NjhlNzhkNWIwMGYxNTZmOWYvdGFibGU6ZGZkZDI5MTg0MmZkNDA5MzhmYjc4YzRlNDMwMzU2NTUvdGFibGVyYW5nZTpkZmRkMjkxODQyZmQ0MDkzOGZiNzhjNGU0MzAzNTY1NV83LTEtMS0xLTkzNjA_99559cc3-a113-4eff-8a81-c7015483ecb5">false</ix:nonNumeric><ix:nonNumeric contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfMi0xLTEtMS05MzYw_842fa9e2-603a-4d76-932f-26e9d70fccbc">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMTUvZnJhZzo0MjMxN2NhZjU4NDc0MTgwYjQ4NzczZTcwYWYyMjY4Yy90ZXh0cmVnaW9uOjQyMzE3Y2FmNTg0NzQxODBiNDg3NzNlNzBhZjIyNjhjXzEwOTk1MTE2Mjc5NjM_14196b86-b52b-4a5f-a62a-af498a366b99">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i726cc8c2bd0b4ed78ad0a2c84ed2479c_D20191105-20191105" name="bcrx:RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMzYzNw_a3daa0dc-7723-4501-842e-5ed805a38078">P10Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bcrx-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib45ffcc775c34a8ebd2fcae622dd7ea1_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="idb265a8308724c57833eccc5d77be8aa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie20bac9cd8014f8cb989d999d452c248_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i02cd59e16e0149199ce28d859c3ac6a8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03da29ccbd9f4d09beeb6288fdf053b4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id38b2ee116544f90a76e9d8b6d33f39b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if885f6f8cf8d4e339f135dd75b604594_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b2b8611a0384b2e8a19a43ecfab2135_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06ca5f40fc4b4aa98634268fcf2525a0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie51f3d3839d1472ea8a99419a9e1d1dd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69c7f898fb47496b80d856f7a82a5454_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d334c267d664d22a3b7769ac993451a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:MilestoneRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fa865c7a786428b8ce79ebf9351f4ad_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:MilestoneRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd8066819384bae8b29a1bc99808b48_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:MilestoneRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9435042756cd4d408e47bff42738cf8e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:MilestoneRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67cf7bf22deb4aff91b49db594f6a877_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7382589fe0034462aa011f377b6998da_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dde7334e062479ab641b4c89a0a55e4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89dd57b2bc7948769d0753db905659dd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41745e32b23b47e7a00caf0e1c1db339_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a3b74ad1e0f4442b522495e111be937_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91882c79d9d24c96aa878de55cbae53b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95ba6a07e68a459195b3cded3ca6d43a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2765f24346841dfa50adf712fcd6e0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50edc98ace4c4817bc584c2cd01683db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1da831eb386440a9ae03883cb9de9c2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2e88ed6e0ef4275a5cbc5b2259cb414_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib471f07fd4b04491b1575b8c3455d232_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if67232e493004bbe9a89d123b94f9781_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15308f75ade643a5bd5c3c0ad201bd13_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bbcac9495d54029ab8d5adb83847966_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if036eb5c6c274213bd73c03c974994a7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i153d098e317143b991cc8821cf708987_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i705ede78548e4661a484496cffb01473_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b50a0d24e4a41a098b3d1ead84b5e3d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fb8db5ef2e34b14ab9a1ba55b73c8cb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if913b8a18461412aaa90a9e59f28bbb9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b867b6cc56641799cba16d11bfa60a4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39c3785f664d490d93d4cc107acc6eab_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a1c4dc78aff440ba2b7ae2d04ee9ebb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia81363840c6d47819c0a0300f9de63ea_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc1eb8ebb6744a0a90475dfb612381f8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaaa54dd893e44a9ba927dae3ebc58fc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d973d539b60454bb3e347b4bb6c7431_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9896466435844fdaadb265c1f69482cc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia35fcc7c1df8404fa70855f6f2fe6cee_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib07b7833ec9c4f5ba79349d729d7e86a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcb838f1aea441109992ece58d5d1419_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41766aec3ee549cc9ffd2983c192fdc0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf830df2b86a45cd9f92bf47fec71ee6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29f30a466222458bb694b5b460e4b5fb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17fd2b8b68ab41d29358bf85ce87dc12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c4036a23a640018a70d37f4b27fb0b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1588d8fa978d43ecbc8214f1b4283763_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id581e5368d914277ac0ce9fee558e4ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5d58b9fd63041f3bc17cf6fc173034b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if076f350ff45436996af2f05839c8882_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9fa7ce59f8e428fba39af60c2c10e30_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i762c8172b9e54274a05337bb853015e5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a9b9d93a9dc4310ae5a5a00e96b249e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a3ae9e595754fd8b7b517f5d6502c61_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdcafea902a94b74806fbbc66676de9b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a87a730f5264586b524537e3168930d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f09c79fd6f5409491477c45b1543e48_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9086f7c6548c4033b8ecf3a3a2cc454e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb74c52ede444e4585f9077b04bd8f51_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife6d0af669364983a00fd3d0254f171b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99d7ba3d2a234849a4f237f0d5b55516_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7be39acc2a414f32b4108381b199c1d2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00f4f783bc4640caa49ae534564dda62_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49595be0c9ca44d8bdf145a82b2c37a0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fffddbb207f442684761c141969e63e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc7f6cadfe9a4eeab4afe3e1661f4099_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766e3bef22c54ee3bdab656c940663e9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4937c63164a42b3a6326fc7d4b4babe_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec324695fb5c455faa27509e51bd78b4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaea012f1493f49fd8a6586b2899d6b3a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac6aea1e78d3493ea6d07c8e22679e2e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7b7c292e90941a398476976288e3ff4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4fd1209b6f7440bb9686323eb1893fc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c7532d73a584500bbd44288b8006073_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5a7cdd440cf410c82c96bf461ca3e07_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb951a6478734d308e70fb7798d6529f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc1913ba4028440697583a0160c2c9a9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b656b9adf614afe8e4311bfc8c36b08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4bab20e161348dda0d3fc5277f3602c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff682572ef0b4643862b85d792331a8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c206d1885894084b6b64b92557dff74_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30f04607b9fd4fbd8d1e3b4e116511df_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f4820f68b75491386429192e255c412_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacbf3ec994f848c3afd3f6edf48b0963_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01b1e25bb16a4e61b3726d6578c74362_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i085d63dc06a84f6ea9de568acc4df142_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i451dda4c3a8e4ccfad33168494bc9c9d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaae1596b0387405c82740b7390d33d38_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadb0a3977d2e464381bb4a2a4912955b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72fe97c0b03a4aefa6351d9bbfc48eb8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2b500470aa1440998f2b21760e6893f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d1a5d14f8b040478c08a0ed5704b783_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20a97685da3b4dc781181f5228701bd4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:PERAMIVIRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95e09ca159fe4d35ad4cf6c7111aadae_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:PERAMIVIRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6355a4b7fee3482482574de4cadc4f2c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:PERAMIVIRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i530113c61c0045f5a77ebf99982dd4cf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:PERAMIVIRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i300f876718414e03a6d92b6eef13452b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a43835db50e40aa8dae8ed521e3d03c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc7c54d81f614da2bf398d8589ddba3d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ca21205297a4dce8632aec47144b369_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae7bd5bdeed04eb0a29ec0c7ed2a15cd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ae49712cd2e41b4952fd9e10638809f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7cb4025c8734daeb09b21962b869678_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icba59a9ed8954f15bb323330c2072dc7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9834b9d88aa64e0e826bd49839d8f0a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i138269de9639423b9754ab90611310ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d5cc209df4b4f158f63ba78067df1d3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bf1868a8c07401995c9209a9fed2a20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i822a4f18efa9407ca27d5a5c54dbf5e2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00f15b2faead42f68b751bfd1a5a76bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fad271ec831459885eb81d1bf350ac2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c255209851347d2823e94f1a619328e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i148b60adb92b488a9a9a9586b8ce630f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39ef3ff428bf4f4891cb088a64691907_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i575f84670ae346f3b0aaf66dac4ce33a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i555cad33b5d44135b244268bf4d08939_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6909fce5d6ea480fb5472075566b87fa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib207348a887d4eac8ea660147a235790_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30df1d46204d4ed3bcab448f681a0f99_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe28a0b9ba504c29a6bbfb22a00d691b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9164b1431b374f07841c05f4d2661cf0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5b5e996fc4f46a0bea68e7eae665edd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i527a858d3bdd48b4bbbc58eaa0c86127_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c931a38b8f4fb79cd7b1bfc15541af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifba625b9dbe14b648921db96471dc959_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib09e2423a7504296aafabf85a78b11e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06da809ae51d46f4a859c0e6d5105e1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie681521de8e8461695ee96dbd9571fcb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie154d98fc18c4a1bb3006dded763756f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97245d53c4b147daaf476637df025ab6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9144542bf0074b97b464b99a2e251ddb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ed0f773e01c46b0a1ec1a9b710e5c96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c2f2931216342fc952334687bc6784f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id71eb7a7f4934c329e8946aad8843f79_I20110309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cd2274f76d84f7d8aa1fecb06595801_D20210309-20210309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-09</xbrli:startDate><xbrli:endDate>2021-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa8c84cacb9b47f0858154719b4d86b1_D20210309-20210309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-09</xbrli:startDate><xbrli:endDate>2021-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9da1b8e68e3943f4b431a7f4b8c6ddb6_I20110309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6a9d2be26d104c7f88a240ce0bdae3b0_I20201201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc57076200334d0195d02ed18bd1d7f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3555a1cac734984b0bc78b41179373c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40eed59cc9974d4da70c7edd9d0d8c82_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i659ab2cd433f43e38df5288340793caf_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0d847dbf3cc433cb71781a71246c04d_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8229178c1776432b9a14327383dbd4e8_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c43924485804171baf9b85f8c65941c_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8038e6b568aa4157a7628b82914dffe6_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a1f4d036f7c4e5698e71c2f543364b0_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i131aea96e86e4fbbbd650ebc98f6ffca_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if618ed9fbfce4a02b7658195a856d8be_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver230000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67142cf4c13a4d68bc0ac1f76af05df3_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2021And2020IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f1b22877b3740e68dd9cfbae1ff0365_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42c79576567c4b2bbc81a0de713c8389_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c82dcc5f02c4662947d1881f5cc203e_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9cf1579776d4680a6bf379ea0a42c2c_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab0a5cddb915447c9e805b68ffc9d835_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930BCX10013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder15BillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeeda3897a624890bc65185aab3a382f_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930BCX10013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween15And3BillionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43d710969d584356a886f1c9563fef66_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930BCX10013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver3BillionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea24828b86d54f41a2b4874e96d088f2_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930BCX10013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver3BillionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c6e9851b8104036bbcd12e9aa0bc4a8_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930BCX10013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i922a1d857b42485f92214971ed78a0da_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7f72565b0f5439abca0ea90d3a6f24b_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11b7628d9fda491980452daac486f097_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b2bc1c2bed841eb99664d403903ea7f_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i178ec38dd6014b1d9adf94656a10b03e_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92914c34dfeb459cb7418faf28e8f5c5_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782dba101c4049a68737ea34eaa114a0_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96ce4725997d4522ab18ef4f78970321_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd9066e5a18b494489a571f56afaf09a_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d5e09b3fd4d49c3acbe8c9499ec13f9_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver230000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a099c2a65d543edbf8358cc0e472f2a_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a14b6aff29e4ab0899284236dbee713_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3387c2eb985849859a399492ce421ce8_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7810c48b6754267aa2a3f2a660bf13e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib01a977ea3bd4a78aca463e3dcbcae61_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6782cfa98ec4a439c817a6ffa240688_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0126a3e3d9242d79ce8101efe7c2a9f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0dc4b1e9eb848818b47548abe6e3324_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i492a9e744ab44aecb99a707368b9137a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibede6ebb23bb41718df5c414f9e0d733_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aa7623896fd466a8100ad400138b291_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fe7ee6d739f433bac2aa26b00c08cb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic215859d996647a59c854764e5c698e1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0a54a935fad483f8a7abc4b9481af07_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a395490d1fb4b4a89833e1ca81fdd7b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3864fa52358945bfbd68481e97ea6545_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2633d031d70949ebac044dd59a84d949_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7bfbb0963cd492f8cc0ff3fbce8c491_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i274b955cf1e1448988b54629cbefc21c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b0b77fa77814d6686ce59c957db2ab2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i106ce134a512494ea43edc85bb29e49c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic550bdd44f464d7e8684a82d73605d43_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fe7d973553d4d5abc3a63e8fec38c3a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11cfeff79ad34520b776332a393c0b35_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86233c8a15e74c029b96ae45ad9b3911_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63012785f2d64008b6eb5c1c19199d9b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b8c0ef1641d490bad48d0ce9744d424_I20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03bffbefba234cc0a1128fb5302a1f91_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermALoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7929cd2eb5634ff0ac5139d08ffc47a8_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice4776aac34540989938d21b8dfb4e97_I20220729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermBLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia003b9df8396437497d66b989248c2b6_I20220729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermCLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i709dd3e270264784bde603419255d61f_I20220729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermBAndCLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15ce1d8574044e7da22ce59b9f6dd167_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia232f6672e22447fb6af60f22e2ceb87_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf6c8a213e4c4e488e6eb643867a2197_D20220628-20220628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-28</xbrli:startDate><xbrli:endDate>2022-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icde5f4a46a1c4f8c83cf48af673b7a45_D20220928-20220928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-28</xbrli:startDate><xbrli:endDate>2022-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ce560e3ccb4a498fdff95231d6e1c9_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:PriorToTheSecondAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74fcf15aaa914945ab7836b9ee0ad9e5_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:BetweenTheSecondAndThirdAnniversariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad2a1f48ddac433db045de7d1a2ebd84_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:BetweenTheThirdAndFourthAnniversariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4ae9ab1e00c4d9bbb0a43e40f958d82_D20201207-20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:AfterFourthAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48c8f87e596a4a9797c757c4107dca8e_I20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:TermLoanADrawnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i029bc0b0132a43d3a133840d08bafae3_I20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:TermLoanAAndBDrawnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81bdcb366fcb440dac7cccb46bc6c432_I20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:TermLoansABAndCDrawnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1df07995b624c41ad1f4b2eb4c8b729_I20201207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:TermLoansABAndCDrawnAndCureRightExercisedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i577b5813966249238ff1a37dcadb61ec_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad15e5ebbe854d989fa28f085ec20706_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermBAndCLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c80142b202447dcb8ead43698b1102f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52f9872ea30d41b1879aa0576f67e92d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief8dcbde5b0e41c3bb5a8ebe4a804426_I20200424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8832490c13ad4270a151ea2cb8adc636_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcrx:CommonStockPurchaseAgreementWithRPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85cc5e9604864268a804d5d399fb8420_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcrx:CommonStockPurchaseAgreementWithRPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0f22034638c4665942e299d6fb219aa_I20211117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcrx:CommonStockPurchaseAgreementWithRPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>bcrx:plan</xbrli:measure></xbrli:unit><xbrli:context id="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd71d21d51204504b4c1150f43b3bc59_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id57db78843ad455581cbbe07f42c6f48_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c2fb0c425f946d798549cf02852e9ea_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i861f5991bef64ba4ae244c970bd11b45_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b5364d1d1904b7bb97eaee357c6a65b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bf5349aab0e46d5b3e8bc79f32bc420_D20141201-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i462f026921bb4afe83030f8fadf9da13_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib155b4c963014e029dd2f85fefc4a14e_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67e8248b60f64ce28584296c7129913e_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icacb2b425bc14f50b771626f8aa5b582_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcrx:NonEmployeeDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:ThirtysixEqualMonthlyInstallmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6112bb62bc84e76a366906fa6013306_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcrx:NonEmployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e78b10dfe9d40829b789acc025a272e_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i597f21b52a2341598aca37ab541e979b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33b8d296b67f42aa822d875c50677a2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f2ae249b8c14d8c879f0c3632532318_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5250a5d435e4416ea19390c093e8d969_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91216e37813c427d9f33a23eb389ed62_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41d42bfc79fc4caf8d758c368878895a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c9a5b90264d44ee9f8599fe14b89e37_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2932078af7f45c0bfcbbbc172f1e3f7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e4a49026de84920a3819232a6a19cd9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d8b3a042362474cbb230d0362f4776c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdd2f542ee4f472fbd033582bf493f66_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6d5329452f640458e577180ba9077a1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c0bfd7955ac4b51957fb2e28260133d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b8f1d28ff564258a3694150b17ecfbc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i612bfa266c9d4fdaabd216b7743222f3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6962c7b3c532429d9dc533d16085a1be_D20210915-20210915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-15</xbrli:startDate><xbrli:endDate>2021-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e86c77b3f93473aba60a62ad6ac9c1a_D20130930-20130930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-09-30</xbrli:startDate><xbrli:endDate>2013-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fe0f9acd7e14572953ee3262d1924ec_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i939d2e62994c419ba66434c3debb0192_I20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:BaseContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie89d5e9da1fb4552906ccc29db0c6910_I20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AdditionalDevelopmentOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5578f786012042cb8b526aad1347720f_I20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic71ceab0e4b64e95b2df289f6f3faaec_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id43ef6e8fa364fd8b928caaf91fbd1a6_D20180906-20180906"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-06</xbrli:startDate><xbrli:endDate>2018-09-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i535cf829316841bfa7015ff15880d35a_D20180906-20180906"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-06</xbrli:startDate><xbrli:endDate>2018-09-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="dose"><xbrli:measure>bcrx:dose</xbrli:measure></xbrli:unit><xbrli:context id="i285e93f7aad44dada9abb5c04565a489_D20220825-20220825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-25</xbrli:startDate><xbrli:endDate>2022-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic103b1fd563c46dbb16e1ab091c2bc47_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i726cc8c2bd0b4ed78ad0a2c84ed2479c_D20191105-20191105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-05</xbrli:startDate><xbrli:endDate>2019-11-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fb11f122dad4dbb93a70888951bbc85_I20191105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4097a995127f49fa8ee4dd7b99237dda_I20191105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabfffedc39c340fabce60b94d0d32249_I20191105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90941783cef64f03915cc4e7222642e6_D20000601-20000630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2000-06-01</xbrli:startDate><xbrli:endDate>2000-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cba6072ef5b463d92db14b5c09be6b9_I20000630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2000-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifba7c735102f46f692d875d1a37529f9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:UABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia4cd069c56504e93a883c91651012280_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTQ1_24694232-1591-4331-be92-dd1c0e51d702">10-Q</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTQ2_0f873daf-2a6d-4368-8862-69ff5ec255d5">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTA_1b631481-1c2c-4a08-bedc-052b184aef5e">September 30, 2022</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTUy_1e181d0d-a1c1-438b-85ad-65fe947a4fa8">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ______________________ to ______________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTQ3_4771dc9b-12d3-4f0b-ba3c-90012485f3f0">000-23186</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTQ4_47f8f985-db08-4fb5-9c45-ea3bef4eb334">BIOCRYST PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6NmQyYWEwMmU4N2MxNDIwODljMDkyZWE5MTJiMTQzZTQvdGFibGVyYW5nZTo2ZDJhYTAyZTg3YzE0MjA4OWMwOTJlYTkxMmIxNDNlNF8wLTAtMS0xLTkzNjA_fcaa8312-fa6c-4c4c-9ef1-3405a4960284">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6NmQyYWEwMmU4N2MxNDIwODljMDkyZWE5MTJiMTQzZTQvdGFibGVyYW5nZTo2ZDJhYTAyZTg3YzE0MjA4OWMwOTJlYTkxMmIxNDNlNF8wLTEtMS0xLTkzNjA_ab26b699-d154-4e26-9ed3-ff335b220dec">62-1413174</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6NmQyYWEwMmU4N2MxNDIwODljMDkyZWE5MTJiMTQzZTQvdGFibGVyYW5nZTo2ZDJhYTAyZTg3YzE0MjA4OWMwOTJlYTkxMmIxNDNlNF80LTAtMS0xLTkzNjA_6367c1d5-3938-43e9-8f8e-541a9e804d5e">4505 Emperor Blvd., Suite 200</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6NmQyYWEwMmU4N2MxNDIwODljMDkyZWE5MTJiMTQzZTQvdGFibGVyYW5nZTo2ZDJhYTAyZTg3YzE0MjA4OWMwOTJlYTkxMmIxNDNlNF81LTAtMS0xLTkzNjAvdGV4dHJlZ2lvbjplZTA4ZjYzNDE5OGM0MGYxOTM1MDllYTAzOTAzZGY1NF80_bbead806-b86a-414b-abba-45ea8387662f">Durham</ix:nonNumeric>, <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6NmQyYWEwMmU4N2MxNDIwODljMDkyZWE5MTJiMTQzZTQvdGFibGVyYW5nZTo2ZDJhYTAyZTg3YzE0MjA4OWMwOTJlYTkxMmIxNDNlNF81LTAtMS0xLTkzNjAvdGV4dHJlZ2lvbjplZTA4ZjYzNDE5OGM0MGYxOTM1MDllYTAzOTAzZGY1NF84_ce8a67f8-3410-4556-813a-00273f163fcb">North Carolina</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6NmQyYWEwMmU4N2MxNDIwODljMDkyZWE5MTJiMTQzZTQvdGFibGVyYW5nZTo2ZDJhYTAyZTg3YzE0MjA4OWMwOTJlYTkxMmIxNDNlNF81LTEtMS0xLTkzNjAvdGV4dHJlZ2lvbjpiODk0ZTA2MmQxNTc0NjhlOTRmYzI4ZmRiMWZlYzU2N180_36561f2a-538f-4b82-9c69-3cce5bcba237">27703</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">+1-<ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTUz_72ba082e-9168-4794-9560-b4c2449533cf">919</ix:nonNumeric>-<ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTU0_42ce0ed0-4849-4f78-b415-f28b923be4ce">859-1302</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6MWEzM2Q1ZjZhMTRlNDU0M2EzODMwYzc0M2ExMWNhOTIvdGFibGVyYW5nZToxYTMzZDVmNmExNGU0NTQzYTM4MzBjNzQzYTExY2E5Ml8xLTAtMS0xLTkzNjA_71a86ba1-5244-4839-b3bd-25881d523f7c">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6MWEzM2Q1ZjZhMTRlNDU0M2EzODMwYzc0M2ExMWNhOTIvdGFibGVyYW5nZToxYTMzZDVmNmExNGU0NTQzYTM4MzBjNzQzYTExY2E5Ml8xLTEtMS0xLTkzNjA_26db71fa-d420-451b-882d-e0318be72d56">BCRX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6MWEzM2Q1ZjZhMTRlNDU0M2EzODMwYzc0M2ExMWNhOTIvdGFibGVyYW5nZToxYTMzZDVmNmExNGU0NTQzYTM4MzBjNzQzYTExY2E5Ml8xLTItMS0xLTkzNjA_bb847fdc-5fee-4873-8584-dd6b0df96675">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTU1_a23a9739-1eea-436b-8c89-cfc83510d6a7">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTQ5_129c6f0e-4dc4-40f0-9a0a-7187e8b0d4cd">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6YzJiMmE3MjlmMWMyNDU3YWE2MWQ5NDQ3YzdhYzIyMzMvdGFibGVyYW5nZTpjMmIyYTcyOWYxYzI0NTdhYTYxZDk0NDdjN2FjMjIzM18wLTAtMS0xLTkzNjA_f67aaa12-8d31-4e9d-8e70-decd81aa00a9">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6YzJiMmE3MjlmMWMyNDU3YWE2MWQ5NDQ3YzdhYzIyMzMvdGFibGVyYW5nZTpjMmIyYTcyOWYxYzI0NTdhYTYxZDk0NDdjN2FjMjIzM18xLTMtMS0xLTkzNjA_9f6b630c-d56a-4ac4-ae7f-559fc60746ac">o</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6YzJiMmE3MjlmMWMyNDU3YWE2MWQ5NDQ3YzdhYzIyMzMvdGFibGVyYW5nZTpjMmIyYTcyOWYxYzI0NTdhYTYxZDk0NDdjN2FjMjIzM18yLTMtMS0xLTkzNjA_3a58d9f1-0bde-47a6-814e-b81235397921">o</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTUx_9f63d6fa-e8aa-439a-a377-9cb8e8229b8c">x</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of Common Stock, par value $0.01, of the Registrant outstanding as of October&#160;31, 2022 was <ix:nonFraction unitRef="shares" contextRef="ib45ffcc775c34a8ebd2fcae622dd7ea1_I20221031" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTQw_376c83db-d4f7-45e8-ba52-ec368887a330">186,423,835</ix:nonFraction>. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ia4cd069c56504e93a883c91651012280_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOCRYST PHARMACEUTICALS, INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Page No.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_10">Cautionary Note Regarding Forward-Looking Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_10">i</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_13">Risk Factor Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_13">ii</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_16">Part I. Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_19">Item 1. Financial Statements:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_22">Consolidated Balance Sheets - September 30, 2022 and December 31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_25">Consolidated Statements of Comprehensive Loss - Three and Nine Months Ended September 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_25">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_28">Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_28">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_31">Consolidated Statements of Stockholders&#8217; Deficit - Three and Nine Months Ended September 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_31">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_34">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_34">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_73">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_73">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_100">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_100">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_103">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_103">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_106">Part II. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_106">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_109">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_109">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_112">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_112">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_115">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_115">73</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit101-biocrystxbcx993.htm">EX-10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102-biocrystxamendm.htm">EX-10.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="bcrx-20220930xexhibit104.htm">EX-10.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="bcrx-20220930xexx311.htm">EX-31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="bcrx-20220930xexx312.htm">EX-31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="bcrx-20220930xexx321.htm">EX-32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="bcrx-20220930xexx322.htm">EX-32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ia4cd069c56504e93a883c91651012280_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">When used in this report, unless otherwise indicated, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">we,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">our,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">us,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Company,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioCryst</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> refer to BioCryst Pharmaceuticals, Inc. and, where appropriate, its subsidiaries.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q (this &#8220;report&#8221;) includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which are subject to the &#8220;safe harbor&#8221; created in Section 21E. In particular, statements about our expectations, beliefs, plans, objectives or assumptions of future events or performance are contained or incorporated by reference in this report. All statements other than statements of historical facts contained herein are forward-looking statements. These forward-looking statements can generally be identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; the negative of these words or similar expressions. Statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions containing these forward-looking statements are principally contained in the &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of this report, as well as any amendments we make to those sections in filings with the Securities and Exchange Commission (&#8220;SEC&#8221;). These forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the preclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO&#174; (berotralstat), BCX9930, BCX10013, BCX9250, peramivir, galidesivir, and early-stage discovery programs, and our plans regarding the same;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and success of our commercialization of ORLADEYO in the United States and elsewhere and expectations regarding the commercial market for ORLADEYO;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential for government stockpiling orders of our products and product candidates, including the timing or likelihood of entering into any U.S. Government stockpile order and our ability to execute any such order;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the closing out or expiration of our contracts with the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services (&#8220;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious Diseases within the HHS (&#8220;NIAID/HHS&#8221;) for the development of galidesivir and our plans regarding the galidesivir program;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional regulatory approvals, or milestones, royalties or profit from sales of our products by us or our partners;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of our business model, strategic plans for our business, products, product candidates and technology;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations or out-license rights to our products and product candidates;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">plans, programs, progress and potential success of our collaborations, including with Torii Pharmaceutical Co., Ltd. (&#8220;Torii&#8221;) for ORLADEYO in Japan and Shionogi &amp; Co., Ltd. (&#8220;Shionogi&#8221;) and Green Cross Corporation (&#8220;Green Cross&#8221;) for peramivir in their territories;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our and our subsidiary guarantors&#8217; ability to satisfy obligations under our Credit Agreement (as defined below) and to comply with the covenants as set forth in the agreements governing our debt obligations;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our products, product candidates, and technology;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to operate our business without infringing the intellectual property rights of others;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimates of our revenues, expenses, capital requirements, annual cash utilization, and our needs for additional financing;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings or regulatory agreements, deferrals, approvals, and other decisions;</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage our liquidity needs, including our ability to raise additional capital, to fund our operations or repay our recourse debt obligations;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance; and</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive companies, technologies, and our industry.</span></div><div id="ia4cd069c56504e93a883c91651012280_13"></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based any forward-looking statements on our current expectations about future events or performance. While we believe these expectations are reasonable, forward-looking statements are inherently subject to known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially from those suggested or implied by these forward-looking statements for various reasons, including those discussed in this report under the heading &#8220;Risk Factors&#8221; in Part II, Item 1A, some of which are summarized in the &#8220;Risk Factor Summary&#8221; below. Any forward-looking statement is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, industry, and future growth. Given these risks and uncertainties, you are cautioned not to place undue reliance on our forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof. We do not undertake, and specifically decline, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements to reflect future events or developments, except as may be required by U.S. federal securities laws.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in the Company involves risks. You should carefully read this entire report and consider the uncertainties and risks discussed in the &#8220;Risk Factors&#8221; section in Part II, Item 1A of this report, which may adversely affect our business, financial condition, or results of operations, along with the other information included in our other filings with the SEC, before making an investment decision in the Company. A summary of the principal factors that make an investment in the Company speculative or risky is set forth below.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ongoing novel coronavirus (&#8220;COVID-19&#8221;) pandemic could create challenges in all aspects of our business, including, without limitation, delays, stoppages, difficulties, and increased expenses with respect to our and our partners&#8217; development, regulatory processes, and supply chains, negatively impact our ability to access the capital or credit markets to finance our operations, or have the effect of heightening many of the risks described below or in the &#8220;Risk Factors&#8221; section in Part II, Item 1A of this report.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred losses since our inception, expect to continue to incur losses, and may never be profitable.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need to raise additional capital in the future. If we are unable to raise capital when needed, we may need to adjust our operations.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends upon our ability to manage our product candidate pipeline, advance our product candidates through the various stages of development, especially through the clinical trial process, to receive and maintain regulatory approval for the commercial sale of our product candidates, and to successfully commercialize any approved products. The development process and related regulatory processes are complex and uncertain, may be lengthy and expensive, and require, among other things, an indication that our products and product candidates are safe and effective. For example, applicable regulatory agencies could refuse to approve, or impose restrictions or warnings on, our product candidates, require us to conduct additional studies or adopt study designs that differ from our planned development strategies, suspend or terminate our clinical trials, or take other actions that could materially impact the cost, timing, and success of our planned development strategies.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely heavily upon third parties, including development partners, contractors, contract research organizations, and third-party suppliers, manufacturers, and distributors, for many important stages of our product candidate development and in the commercialization of certain of our products and product candidates. Our failure to establish and maintain these relationships, the failure of any such third party to perform its obligations under agreements with us, or the failure of such a relationship to meet our expectations could have a material adverse impact on our business, financial condition, and results of operations.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to obtain additional financing or acceptable partnership arrangements as and when needed, we may be unable to complete the development and commercialization of our products and product candidates or continue operations.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The commercial viability of any approved product could be compromised if the product is less effective than expected, causes undesirable side effects that were not previously identified, or fails to achieve market acceptance by physicians, patients, third-party payors, health authorities, and others.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There can be no assurance that our or our partners&#8217; commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to continue expanding our development and regulatory capabilities and implementing sales, marketing, and distribution capabilities, and as a result, we may encounter difficulties managing our growth, which could disrupt our operations.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced. In addition, developments by others may render our products, product candidates, or technologies obsolete or noncompetitive.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to various laws and regulations related to our products and product candidates, and if we or our employees, consultants, or partners do not comply with these laws and regulations, we could face substantial penalties and our reputation could be harmed. In addition, we and our partners may be subject to new legislation, regulatory proposals, and healthcare payor initiatives that may increase our costs of compliance and adversely affect our or our partners&#8217; ability to market and develop our products and product candidates, obtain collaborators, and raise capital.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of those rights would diminish. Legal proceedings to protect or enforce our patents, the patents of our partners, or our other intellectual property rights could be expensive, time consuming, and unsuccessful.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face an inherent risk of liability in the event that the use or misuse of our products or product candidates results in personal injury or death, and our product liability insurance coverage may be insufficient.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks related to our government-funded programs and are subject to various U.S. Government contract requirements, which typically contain a number of extraordinary provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to us as compared to competitors that do not rely on U.S. Government contracts.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to reach milestones or to make annual minimum payments or otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional remedies.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Credit Agreement contains conditions and restrictions that limit our flexibility in operating our business. We may be required to make a prepayment or repay our outstanding indebtedness under the Credit Agreement earlier than we expect if a prepayment event or an event of default occurs, including a material adverse change with respect to us, which could have a material adverse effect on our business.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">International expansion of our business exposes us to business, legal, regulatory, political, operational, financial, and economic risks. For example, our actual or perceived failure to comply with European governmental laws and regulations and other obligations related to privacy, data protection, and information security could harm our business. In addition, the United Kingdom&#8217;s withdrawal from the European Union could result in increased regulatory and legal complexity, which may make it more difficult for us to do business in Europe and impose additional challenges in securing regulatory approval of our product candidates in Europe.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our facilities incur damage or power is lost for a significant length of time, our business will suffer.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant disruption in our information technology systems or a cybersecurity breach could adversely affect our business.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our existing principal stockholders hold a substantial amount of our common stock and may be able to influence significant corporate decisions, which may conflict with the interests of other stockholders.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price has been, and is likely to continue to be, highly volatile, which could cause the value of an investment in our common stock to decline significantly.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Natural disasters, epidemic or pandemic disease outbreaks, trade wars, armed conflicts, political unrest, or other events could disrupt our business or operations or those of our development partners, manufacturers, regulators, or third parties with whom we conduct business now or in the future.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to legal proceedings, which could harm our reputation or result in other losses or unexpected expenditure of time and resources.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development of our product candidates, the commercialization of our products, and the related expansion of our business will be delayed or stopped. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iv</span></div></div></div><div id="ia4cd069c56504e93a883c91651012280_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="ia4cd069c56504e93a883c91651012280_19"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div id="ia4cd069c56504e93a883c91651012280_22"></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOCRYST PHARMACEUTICALS, INC.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.425%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Note 1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMy0xLTEtMS05MzYw_2217d0a6-cd2e-4bf5-bf39-2f7c786479bb">246,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMy0zLTEtMS05MzYw_10692ed0-d089-4b81-8715-4bcefde7a023">504,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNC0xLTEtMS05MzYw_82625ec1-7d31-4060-bf34-2b64811ca178">1,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNC0zLTEtMS05MzYw_867752e3-45ba-4fa0-8527-ad667bb67c11">3,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNS0xLTEtMS05MzYw_39d3cc02-8474-4cb5-9003-254b19833f3e">179,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNS0zLTEtMS05MzYw_f26d052c-7aed-4f55-b0a1-c6f54069409f">3,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNi0xLTEtMS05MzYw_896137d8-b4c7-471c-aee4-ceab86a21067">42,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNi0zLTEtMS05MzYw_9d9c0267-1653-4dd7-938c-feb19433ed39">29,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNy0xLTEtMS05MzYw_39bdbf6a-bcb1-4fe0-a445-8c742310620f">27,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNy0zLTEtMS05MzYw_54c1b4f0-1ef2-4972-8308-51be51790043">15,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfOC0xLTEtMS05MzYw_4d977bdd-51d9-45dd-9138-7ff0dfbaab70">11,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfOC0zLTEtMS05MzYw_86adebbd-974d-46e8-8677-3bec7bb8383f">9,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfOS0xLTEtMS05MzYw_797e7891-2dfc-4728-a06e-9a6bc003ae07">509,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfOS0zLTEtMS05MzYw_07235982-6ef0-4660-9d81-40d77a5e0453">566,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTAtMS0xLTEtOTM2MA_b5152f5f-2de0-4db1-ba57-e5c32f15b9a4">8,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTAtMy0xLTEtOTM2MA_869d97e1-f745-4265-8514-34089cc6e84c">8,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTEtMS0xLTEtOTM2MA_876e8390-1898-43f7-a87b-1a307f3e30ff">34,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTEtMy0xLTEtOTM2MA_7a0da62b-8e30-45e8-a486-a99997865630">6,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTItMS0xLTEtOTM2MA_ad18e57d-a757-4e13-84dd-5179b20009b0">6,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTItMy0xLTEtOTM2MA_23c69f1c-0726-4c2b-a3c5-f81e24fbee3a">6,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTMtMS0xLTEtOTM2MA_48fcc069-fc15-4326-8541-4847d893cd08">558,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTMtMy0xLTEtOTM2MA_db97eff1-eb80-4beb-95c6-25b558a1ba36">588,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTYtMS0xLTEtOTM2MA_8c461c3b-2d0b-4c9a-8327-31d22f55dbfc">8,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTYtMy0xLTEtOTM2MA_979b73f6-b7d6-42c3-b1d8-ee1e5639f42b">27,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTctMS0xLTEtOTM2MA_147edd62-f417-40f2-a002-7d9eb8a95d46">69,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTctMy0xLTEtOTM2MA_ffb3dfc1-867b-4048-a22d-23163ceeb6f8">72,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTgtMS0xLTEtOTM2MA_35f31b36-176f-4dba-adda-a09e80c9e973">1,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTgtMy0xLTEtOTM2MA_f4176efe-accd-4ed7-9b0c-10738e0a4cb5">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease financing obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTktMS0xLTEtOTM2MA_b5dfde4b-abd8-433b-891a-6ead7a567df3">2,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTktMy0xLTEtOTM2MA_01ab41fe-f219-490b-aeda-9394ea167109">1,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjAtMS0xLTEtOTM2MA_d3998fef-f32f-475e-a1f4-507441662e81">81,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjAtMy0xLTEtOTM2MA_ae1f5d88-231c-47fb-835e-5cd1f40055c7">103,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease financing obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjEtMS0xLTEtOTM2MA_91fdfe25-1931-457f-93c4-5e7d5f862251">5,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjEtMy0xLTEtOTM2MA_cd1998ad-a3ea-46e3-b5b4-882602f744a4">5,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjItMS0xLTEtOTM2MA_f7a0aaa2-00f5-46b2-ba07-3763142ec176">489,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjItMy0xLTEtOTM2MA_fbafdea5-7604-45f5-91cd-2b570d45d320">449,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secured term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjMtMS0xLTEtOTM2MA_0685e379-3752-4c5e-acb7-817c2e633b76">223,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjMtMy0xLTEtOTM2MA_4582e6eb-257a-4beb-9bcd-c69919d66009">136,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzIx_3fa1f264-9183-4bd6-a657-a2b62a292fcd"><ix:nonFraction unitRef="usdPerShare" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzIx_bd546421-3a7e-4192-b815-9e292217b4ce">0.01</ix:nonFraction></ix:nonFraction> par value; shares authorized - <ix:nonFraction unitRef="shares" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzU1_75757389-cb21-460b-bec8-5afea0fe8972"><ix:nonFraction unitRef="shares" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzU1_95d9ed0a-639c-4406-b2c3-36e3bf283364">5,000</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzU5_74d57ed2-df9b-49a0-b875-24838a7d56d7"><ix:nonFraction unitRef="shares" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzU5_ee3c95cb-f063-4d71-b31f-0ba16e614191"><ix:nonFraction unitRef="shares" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzU5_f66e40da-2781-4adc-9b1e-2d4a457e957e"><ix:nonFraction unitRef="shares" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzU5_fb314b80-b730-4c59-99a2-7401d1a38fd3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMS0xLTEtOTM2MA_14c5cf80-86f9-47da-88f0-2b778131e4b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMy0xLTEtOTM2MA_3eed53dd-9d46-4af4-982d-63866681a06e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3XzE4_4b466f41-8eb5-45da-a8e4-b818740b17d7"><ix:nonFraction unitRef="usdPerShare" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3XzE4_5313c748-87cd-4bbc-a2cd-c5a70fe5c055">0.01</ix:nonFraction></ix:nonFraction> par value; shares authorized - <ix:nonFraction unitRef="shares" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3XzUy_1c25e20f-01c4-4e64-9fa1-9c84d2c44639"><ix:nonFraction unitRef="shares" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3XzUy_e9f81dfb-d587-4b13-82f4-46d566023117">450,000</ix:nonFraction></ix:nonFraction>; shares issued and outstanding &#8211; <ix:nonFraction unitRef="shares" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3Xzg4_80becb38-b037-4861-b266-9919d9331380"><ix:nonFraction unitRef="shares" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3Xzg4_a2c2326f-ac65-448f-ab9b-333cc1974f51">186,411</ix:nonFraction></ix:nonFraction> as of September&#160;30, 2022 and <ix:nonFraction unitRef="shares" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3XzEwNA_9c8817a4-5f8e-40e6-bf7a-1a4f3f33d6df"><ix:nonFraction unitRef="shares" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3XzEwNA_e5f17ef2-40a7-4daf-b795-c052cd2afa99">184,350</ix:nonFraction></ix:nonFraction> as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMS0xLTEtOTM2MA_c20e4bde-fd58-41f1-b0df-ac466cb13b56">1,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMy0xLTEtOTM2MA_cd9fd33b-292f-48f5-9abd-9e5d339a70d5">1,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjctMS0xLTEtOTM2MA_9d1a6884-a2c6-4fc3-adac-36ca4facb4a3">1,138,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjctMy0xLTEtOTM2MA_b88c904a-9798-4d0f-9886-3801495685a1">1,098,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjgtMS0xLTEtOTM2MA_c68c051b-ef7a-443d-be4f-621aa2109837">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjgtMy0xLTEtOTM2MA_673f4f46-7b45-48d0-b950-1c65fd6377ff">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjktMS0xLTEtOTM2MA_7608fb56-eee1-4238-b827-25bdd456bab0">1,383,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjktMy0xLTEtOTM2MA_37b98674-d2da-4465-993c-44d40888a7a5">1,207,504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMzAtMS0xLTEtOTM2MA_ca07dc42-43d2-44d2-b640-be3363fd4e19">242,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMzAtMy0xLTEtOTM2MA_bb5aa3d4-f105-44f0-a8ac-a5546105f8f0">106,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMzEtMS0xLTEtOTM2MA_316051ed-fd67-4d3e-a97b-568823331c06">558,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMzEtMy0xLTEtOTM2MA_b5e3186b-369f-4763-b691-7e6ab83c1625">588,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><div id="ia4cd069c56504e93a883c91651012280_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOCRYST PHARMACEUTICALS, INC.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share data-Unaudited)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02cd59e16e0149199ce28d859c3ac6a8_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMy0xLTEtMS05MzYw_563ea358-6a11-4776-8556-4da4218971a5">75,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03da29ccbd9f4d09beeb6288fdf053b4_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMy0zLTEtMS05MzYw_aa74449b-248d-44e7-afda-14d8b70db439">39,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38b2ee116544f90a76e9d8b6d33f39b_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMy01LTEtMS05MzYw_bc03ed02-e294-4ebb-9906-1cbb05bbe8a8">189,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if885f6f8cf8d4e339f135dd75b604594_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMy03LTEtMS05MzYw_8b771fd3-e60e-4923-8821-2f429c587d1d">90,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2b8611a0384b2e8a19a43ecfab2135_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNC0xLTEtMS05MzYw_8bc819bb-54a2-4d52-a330-b92e8345073c">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ca5f40fc4b4aa98634268fcf2525a0_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNC0zLTEtMS05MzYw_71d4fcec-6703-4012-a5a5-268680830500">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51f3d3839d1472ea8a99419a9e1d1dd_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNC01LTEtMS05MzYw_520a2000-a3f8-41a8-a7f6-39fde32fd5fc">1,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69c7f898fb47496b80d856f7a82a5454_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNC03LTEtMS05MzYw_4a638a27-754b-477b-afa4-bd5711fe5cd5">447</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d334c267d664d22a3b7769ac993451a_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNS0xLTEtMS05MzYw_5532bd23-95e3-4219-a450-6f785b19f4af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa865c7a786428b8ce79ebf9351f4ad_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNS0zLTEtMS05MzYw_7752c5b1-8378-43aa-8eae-ef88dece4842">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd8066819384bae8b29a1bc99808b48_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNS01LTEtMS05MzYw_c15cc77d-5ffe-4c92-8725-4d47ddf38a81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9435042756cd4d408e47bff42738cf8e_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNS03LTEtMS05MzYw_84181fcf-4cba-4c1a-9bc0-b8e598083195">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67cf7bf22deb4aff91b49db594f6a877_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNi0xLTEtMS05MzYw_87bdffc3-011e-47b5-b254-c77f0f3b0324">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7382589fe0034462aa011f377b6998da_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNi0zLTEtMS05MzYw_e2c8eceb-e10d-44eb-8c4a-4778a55b928e">1,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dde7334e062479ab641b4c89a0a55e4_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNi01LTEtMS05MzYw_3e6fe43f-b6c7-4474-a8ef-7d558825dae0">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89dd57b2bc7948769d0753db905659dd_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNi03LTEtMS05MzYw_45895912-d372-4d23-9129-af6617d0fbb1">5,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNy0xLTEtMS05MzYw_8c176fc3-65eb-4cb5-a54a-99a8191a89bf">75,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNy0zLTEtMS05MzYw_2ceebb7a-ac1a-401a-825b-6fbbc1aa978b">40,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNy01LTEtMS05MzYw_3f747647-a01c-42cb-8e6f-50abc119ea59">191,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNy03LTEtMS05MzYw_bef2059d-618c-4065-93af-6e10980457bd">110,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfOS0xLTEtMS05MzYw_1f93c0a3-bf98-40d1-9b48-8c80d78788ba">3,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfOS0zLTEtMS05MzYw_736a5488-ef9d-4269-aa18-ea9c73e19f66">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfOS01LTEtMS05MzYw_81dadc5d-6975-4cbf-8383-615172b38e98">4,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfOS03LTEtMS05MzYw_c88ac079-5a0f-4dc1-b591-102ca5c63b42">6,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTAtMS0xLTEtOTM2MA_87371e60-7984-419a-8ab4-35dfd256edab">52,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTAtMy0xLTEtOTM2MA_866a043f-077d-4cff-a434-3bc5845bc5aa">49,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTAtNS0xLTEtOTM2MA_90d4cb67-7714-44d3-bf80-37c085aed2ca">180,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTAtNy0xLTEtOTM2MA_0a56967c-e2a0-4914-8d02-d09827a4e582">145,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTEtMS0xLTEtOTM2MA_54e6b77a-f20d-4492-a949-2eb2f4a164db">36,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTEtMy0xLTEtOTM2MA_f3e15a23-3567-4453-b60c-b5341382f3e2">34,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTEtNS0xLTEtOTM2MA_0cabf66c-1f0f-4cab-86e9-d7572aa1779d">109,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTEtNy0xLTEtOTM2MA_ba215954-e18e-49c6-a71b-437ed8b35a12">83,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="bcrx:RoyaltyExpenseReversalOfExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTItMS0xLTEtOTM2MA_63e31086-fea2-42b4-bfc3-ec8a8450b1ab">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="bcrx:RoyaltyExpenseReversalOfExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTItMy0xLTEtOTM2MA_4e5bdfd9-7e11-486d-8e32-c5dbba5b4f7b">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="bcrx:RoyaltyExpenseReversalOfExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTItNS0xLTEtOTM2MA_255b8e67-a783-41ee-8672-037c90d6683b">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="bcrx:RoyaltyExpenseReversalOfExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTItNy0xLTEtOTM2MA_2a288e67-fe06-46d1-8190-2572cfc608f7">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTMtMS0xLTEtOTM2MA_daa0add2-eebb-4fa6-a526-d90b5c3d8266">93,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTMtMy0xLTEtOTM2MA_4df57592-0a3f-44a5-8d94-a1cc68feda9d">85,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTMtNS0xLTEtOTM2MA_b1f63948-5686-44c0-bfa6-60dc4689863a">293,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTMtNy0xLTEtOTM2MA_bc7b2cab-ae16-49b7-8e77-422d4a90ce97">235,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTQtMS0xLTEtOTM2MA_727bf2ec-e343-494c-9d82-b97bd1164098">17,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTQtMy0xLTEtOTM2MA_5a4ff6ab-026e-446a-a496-cad20ba06d52">44,584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTQtNS0xLTEtOTM2MA_e9b4c5a7-cfa1-4a93-9f10-500941397851">102,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTQtNy0xLTEtOTM2MA_095bdf0a-97a3-4f73-a8bc-aedbb0748319">125,543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="bcrx:InterestAndOtherIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTUtMS0xLTEtOTM2MA_00ccc231-02f1-46b8-9eb9-ec547db35c49">1,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="bcrx:InterestAndOtherIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTUtMy0xLTEtOTM2MA_d753aa1e-f73e-4cdf-bce7-c559d9f0da96">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="bcrx:InterestAndOtherIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTUtNS0xLTEtOTM2MA_810671e8-863f-4e99-85bf-4e2778e91cb9">2,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="bcrx:InterestAndOtherIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTUtNy0xLTEtOTM2MA_39f57ea9-48df-4c31-896f-9b63fc1ae4a5">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTYtMS0xLTEtOTM2MA_f12328e2-1cba-4a19-b7e8-e1e5fe8c2fb3">24,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTYtMy0xLTEtOTM2MA_05746e41-7604-431c-bacf-0369daa99646">14,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTYtNS0xLTEtOTM2MA_0eb076bf-1795-4844-97d9-ca74efe13132">72,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTYtNy0xLTEtOTM2MA_c690294b-5066-4722-9ad7-621b8d7a7d58">40,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency losses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTctMS0xLTEtOTM2MA_483c648b-1688-44a1-ae42-c19729387fd2">538</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTctMy0xLTEtOTM2MA_1c6f9039-fd61-4b07-8cb0-2669180a926d">111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTctNS0xLTEtOTM2MA_5bda41c6-bca4-477a-bbde-c6e31cd8510b">583</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTctNy0xLTEtOTM2MA_21b4cfe4-8812-476b-8e03-f61ffa391a26">274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTgtMS0xLTEtOTM2MA_71c9a31e-245e-4849-8732-400b9bdcd9be">40,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTgtMy0xLTEtOTM2MA_d926a545-c27f-4ad1-96fd-a36695a37d98">58,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTgtNS0xLTEtOTM2MA_b489cca4-a01c-4e5b-b21a-d77582481600">172,918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTgtNy0xLTEtOTM2MA_e371bf96-9956-4813-905c-ea3ffaabfb91">166,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTktMS0xLTEtOTM2MA_395c10e0-3dfb-4cf7-b7a6-564b492bc7e4">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTktMy0xLTEtOTM2MA_e657ab6e-9cfd-4154-88ff-97619702ea8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTktNS0xLTEtOTM2MA_ce293273-e999-40d1-85e4-e099b7169424">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTktNy0xLTEtOTM2MA_25d0f90e-e094-4bdf-9123-fcef3004fcf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjAtMS0xLTEtOTM2MA_f8930804-3336-4d8f-a55e-8b598c882279">42,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjAtMy0xLTEtOTM2MA_884e881f-918b-4799-b0e2-a41216aebd4e">58,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjAtNS0xLTEtOTM2MA_e9796363-c667-4912-a55f-74761a59c749">175,575</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjAtNy0xLTEtOTM2MA_94f0857a-7ef6-4475-b04c-24d94652aa41">166,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjEtMS0xLTEtOTM2MA_eacacad2-d58c-4726-979e-ea91700a7ed2">695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjEtMy0xLTEtOTM2MA_45314a2e-4b7f-48d7-96fe-e7211eb060e0">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjEtNS0xLTEtOTM2MA_6f0cd2c1-61f5-48a0-ad9c-96d75b7ac92e">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjEtNy0xLTEtOTM2MA_7f00ccb7-59cb-441b-a0e0-af7ceddd559e">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on available for sale investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjItMS0xLTEtOTM2MA_289b9fb0-4fb0-40fb-8097-f36b874c64e6">808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjItMy0xLTEtOTM2MA_79de9c31-4193-4f2e-87b5-1ecddb51de8b">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjItNS0xLTEtOTM2MA_502b53eb-1af1-428c-ac51-df3e194a3c6b">1,152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjItNy0xLTEtOTM2MA_d22580f5-208e-4075-83a8-3e4be99a6bb7">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjMtMS0xLTEtOTM2MA_15788a50-74f6-4fc3-9b17-55a74c1ce1a5">42,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjMtMy0xLTEtOTM2MA_20507142-4bcd-4271-ae7f-300b36f7c7a9">58,774</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjMtNS0xLTEtOTM2MA_412c49ba-c056-4c33-96b8-9b0398ae4666">175,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjMtNy0xLTEtOTM2MA_4744f84c-e22f-4bf2-9934-75d69beed769">166,172</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtMS0xLTEtOTM2MA_a205f0d6-f97e-438f-a8b1-06e694ac8e21"><ix:nonFraction unitRef="usdPerShare" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtMS0xLTEtOTM2MA_be9f58b7-5ddf-49f3-958d-49fb1344d97a">0.23</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtMy0xLTEtOTM2MA_22a05470-5b12-4a97-ac00-97c917d436cd"><ix:nonFraction unitRef="usdPerShare" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtMy0xLTEtOTM2MA_f78f5783-847f-4759-9d57-b3ae8372eca6">0.33</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtNS0xLTEtOTM2MA_94c4e9ef-627f-4724-8529-197fb3e37e45"><ix:nonFraction unitRef="usdPerShare" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtNS0xLTEtOTM2MA_c0c33a74-9a1d-4608-a348-fad69ae51e4b">0.95</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtNy0xLTEtOTM2MA_1964df01-addc-4b95-ba6a-1576ee3e562f"><ix:nonFraction unitRef="usdPerShare" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtNy0xLTEtOTM2MA_de981f0f-213e-4c82-ac7c-23d27a27b45a">0.93</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtMS0xLTEtOTM2MA_47702e7b-d144-419e-b5bb-8802a89b403d"><ix:nonFraction unitRef="shares" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtMS0xLTEtOTM2MA_b1295ac6-de21-4c74-b5a6-1cd99f2548da">186,180</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtMy0xLTEtOTM2MA_a7de8f20-a2e7-484c-9111-d634662a1422"><ix:nonFraction unitRef="shares" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtMy0xLTEtOTM2MA_e98ed4c5-f052-4d01-a187-107aaa125e86">179,106</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtNS0xLTEtOTM2MA_0ffd1f08-5792-41ee-bccc-64e24d59ecda"><ix:nonFraction unitRef="shares" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtNS0xLTEtOTM2MA_da0e1e5c-6947-4220-9fcb-ca10b8d09c1d">185,566</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtNy0xLTEtOTM2MA_7da750ee-84bc-4165-8efb-6453219d478f"><ix:nonFraction unitRef="shares" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtNy0xLTEtOTM2MA_ce951d70-249e-41e3-a166-c185c0582f1e">178,199</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="ia4cd069c56504e93a883c91651012280_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOCRYST PHARMACEUTICALS, INC.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands-Unaudited)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMy0xLTEtMS05MzYw_48f4ed6b-0b02-4bf0-8aa9-c041a5589625">175,575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMy0zLTEtMS05MzYw_3be52fbe-f043-491d-81b0-38765fb8bc71">166,283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfNS0xLTEtMS05MzYw_9dfd7193-8768-4057-b75a-3684a807ee87">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfNS0zLTEtMS05MzYw_a835646a-e75a-49b0-a25b-843c035a63c7">606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfNi0xLTEtMS05MzYw_008039af-f6e8-4e2c-953a-285cf1a17d09">29,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfNi0zLTEtMS05MzYw_4bf1d0f3-af71-4808-be00-d82094e79e5f">26,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="bcrx:NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfNy0xLTEtMS05MzYw_24f721d4-b86d-474c-bb6c-7d12835dd3eb">55,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="bcrx:NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfNy0zLTEtMS05MzYw_c7a7c2b4-e407-4b20-b7fa-dc699779b17e">36,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premium/discount on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" sign="-" name="bcrx:AmortizationOfDiscountAndPremiumOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfOC0xLTEtMS05MzYw_2d62fee9-fe15-4558-8e09-8a0fd14c093a">818</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="bcrx:AmortizationOfDiscountAndPremiumOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfOC0zLTEtMS05MzYw_dc191bb2-963d-4e62-828f-ead115b0b803">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTAtMS0xLTEtOTM2MA_b4755114-6c54-4bca-b085-fcd1686eecc3">13,827</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTAtMy0xLTEtOTM2MA_da631d73-2c94-4bc5-8eea-9fc3a327b6f5">17,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTEtMS0xLTEtOTM2MA_1dd16f12-fcc8-4df0-93e0-e605eaecd031">11,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTEtMy0xLTEtOTM2MA_134e7d8e-922d-4228-9968-f1dc9d42024c">6,630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTItMS0xLTEtOTM2MA_d1fde3fe-eef0-4617-8728-2b9563884dc7">1,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTItMy0xLTEtOTM2MA_16e1cb8e-6833-4ff1-b672-1eaea407ef06">3,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTMtMS0xLTEtOTM2MA_6723cbc8-886a-483b-b81f-31287d720801">27,639</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTMtMy0xLTEtOTM2MA_e72413ac-17e6-4064-9b2e-4b6e3f2c5f77">16,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInInterestPayableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTQtMS0xLTEtOTM2MA_e75d45c7-c317-4b2f-8e2a-a5f687b4e64f">6,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInInterestPayableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTQtMy0xLTEtOTM2MA_0bc71ebb-135d-4386-b396-158c9d19267a">3,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTUtMS0xLTEtOTM2MA_04a51e83-2337-445c-9f40-aff1522f60a2">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTUtMy0xLTEtOTM2MA_71d2006a-bf7a-4b4f-8188-dcc211fb2410">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTYtMS0xLTEtOTM2MA_9690ae38-0bfd-4bc0-8b24-346f03c478b9">138,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTYtMy0xLTEtOTM2MA_43d78398-5a2c-4d4d-890b-815fb4210bd5">109,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTktMS0xLTEtOTM2MA_64b6b174-6993-48b5-857f-eae9f7fcc6c6">825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTktMy0xLTEtOTM2MA_04fc7e04-7e52-4f40-8a92-897c4986b98b">1,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjAtMS0xLTEtOTM2MA_2b0d3759-610b-4c5b-9b3c-2007347b991f">244,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjAtMy0xLTEtOTM2MA_9b2bfed6-d09f-460a-ad5c-104b3176d9f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjEtMS0xLTEtOTM2MA_51182d37-333c-4cb4-8997-f354e92d6a08">39,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjEtMy0xLTEtOTM2MA_53216bad-fa31-4f1b-9bb6-348813c07679">28,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjItMS0xLTEtOTM2MA_9738e853-0768-4447-bdc3-94e3c8eb0bc0">205,453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjItMy0xLTEtOTM2MA_14e5e94e-65f3-4ba7-82c1-6e939aebec50">26,924</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from common stock issued under stock-based compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjUtMS0xLTEtOTM2MA_62f399d7-5344-4409-a1cc-7341a7a86032">10,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjUtMy0xLTEtOTM2MA_f7cc51f0-ca44-4bce-af9c-112fb8865b18">12,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from secured term loans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjYtMS0xLTEtMTA3Nzc_f622cf7a-5792-4395-bac7-08b4cfbca045">73,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjYtMy0xLTEtMTA3ODU_9a4780b3-1380-4374-8df8-8a05ebb44762">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjYtMS0xLTEtOTM2MA_6acd5d3d-6e1c-4efb-82fd-25aa1f7ec179">83,828</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjYtMy0xLTEtOTM2MA_9b81aa57-31bd-40fe-945c-081b3f6f10a4">12,250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjctMS0xLTEtOTM2MA_a1bab8e0-8028-4dc2-8585-a7b83c9d8290">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjctMy0xLTEtOTM2MA_c2a141ad-613f-4281-b728-6cd0b1590f65">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjktMS0xLTEtOTM2MA_c96d5535-2f9e-4750-8c3b-38d523614d8a">259,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjktMy0xLTEtOTM2MA_70b8ff86-76b2-4c63-80e9-4a1820c1d6e0">70,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMzAtMS0xLTEtOTM2MA_c263b696-ee76-425e-8e00-1273a902ec6d">507,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41745e32b23b47e7a00caf0e1c1db339_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMzAtMy0xLTEtOTM2MA_af6be929-d0fe-4118-aff4-399040035d63">274,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMzEtMS0xLTEtOTM2MA_e8d60cc4-322b-4cbd-8483-eeb9db1b4940">248,343</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3b74ad1e0f4442b522495e111be937_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMzEtMy0xLTEtOTM2MA_af2544ac-75d6-4f04-9cb3-72d886f54317">203,893</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="ia4cd069c56504e93a883c91651012280_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOCRYST PHARMACEUTICALS, INC. </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> DEFICIT</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts-Unaudited)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Deficit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91882c79d9d24c96aa878de55cbae53b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMS0xLTEtMS05MzYw_4e5319ab-997e-45f4-bd07-c44ba2896120">1,843</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95ba6a07e68a459195b3cded3ca6d43a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMS0zLTEtMS05MzYw_a22abe83-f88a-4471-bf31-8e2e4b748e35">1,098,498</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2765f24346841dfa50adf712fcd6e0e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMS01LTEtMS05MzYw_504eab6d-0954-4d05-aa15-1a8c1db5f3cb">177</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50edc98ace4c4817bc584c2cd01683db_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMS03LTEtMS05MzYw_bca2ccad-d14e-42b8-a738-39b700d72bdb">1,207,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMS05LTEtMS05MzYw_c15c4a21-d297-40cb-9d04-ccd2eca2933b">106,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1da831eb386440a9ae03883cb9de9c2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMi03LTEtMS05MzYw_91797f6e-efa6-41b8-ad45-142a354f4f91">74,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMi05LTEtMS05MzYw_16b5fc3f-e8be-4dc9-be81-1ac49cfbf4a5">74,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e88ed6e0ef4275a5cbc5b2259cb414_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMy01LTEtMS05MzYw_e28a36d3-a4fa-4d76-af0d-08271b0e4cc0">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMy05LTEtMS05MzYw_32e6063f-a09b-4505-8021-81503423992b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan sales, <ix:nonFraction unitRef="shares" contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNC0wLTEtMS05MzYwL3RleHRyZWdpb246NDAzMTgwZTM0NzA4NGYxNGIzMDQxMTUxZmU5YWZmN2RfNDA_c6f540b5-6fb7-442b-8598-4385b8abc333">115</ix:nonFraction> shares, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib471f07fd4b04491b1575b8c3455d232_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNC0xLTEtMS05MzYw_a4bd4b0c-32c5-45d2-abeb-324cf0cf4502">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67232e493004bbe9a89d123b94f9781_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNC0zLTEtMS05MzYw_4172f4b3-815d-49c9-96c4-7eb8f7e7d8e6">1,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNC05LTEtMS05MzYw_836f985b-d059-4aca-b2ad-fb865a99f56e">1,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options, <ix:nonFraction unitRef="shares" contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNS0wLTEtMS05MzYwL3RleHRyZWdpb246NGYyMTFjNzVjMzBlNDYwOWI2ZDk0N2Q4YjVmZmQ3MWZfMzE_98f4f906-0ec0-4ef0-8c07-07b7ac84080a">1,108</ix:nonFraction> shares, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib471f07fd4b04491b1575b8c3455d232_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNS0xLTEtMS05MzYw_a7fbceb8-5566-4bc5-9c43-1ae82e5d7e64">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67232e493004bbe9a89d123b94f9781_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNS0zLTEtMS05MzYw_9dbbaa4e-bebf-4cb7-a636-4303620b4eee">5,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNS05LTEtMS05MzYw_c501a2e3-4ee0-4913-b84b-7876c66260b5">5,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67232e493004bbe9a89d123b94f9781_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNi0zLTEtMS05MzYw_1d6494ea-2e20-470e-9b1f-575257e97eec">9,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNi05LTEtMS05MzYw_1fc79ee3-7d83-49ae-86f4-dcfe163b1a56">9,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15308f75ade643a5bd5c3c0ad201bd13_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNy0xLTEtMS05MzYw_6355aad9-c1b8-4aa6-8177-d24312a442c2">1,856</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bbcac9495d54029ab8d5adb83847966_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNy0zLTEtMS05MzYw_782804d2-99c1-4a7f-83f1-6d4ebc67b65f">1,115,443</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if036eb5c6c274213bd73c03c974994a7_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNy01LTEtMS05MzYw_dee31ce2-9a75-42ac-9569-f0622ec1eb89">186</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153d098e317143b991cc8821cf708987_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNy03LTEtMS05MzYw_b44d5b06-bea5-4798-853a-a1d1c5f3f8bd">1,281,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i705ede78548e4661a484496cffb01473_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNy05LTEtMS05MzYw_8661de5a-329a-4815-9600-2c9a1203c0a1">164,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b50a0d24e4a41a098b3d1ead84b5e3d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfOC03LTEtMS05MzYw_f2425817-0567-445e-9a93-80e6e094838f">58,859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfOC05LTEtMS05MzYw_92c0a992-87fc-4428-bdeb-cc15dcd5db66">58,859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb8db5ef2e34b14ab9a1ba55b73c8cb_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfOS01LTEtMS05MzYw_337d5ec7-3511-4d9a-86e9-01255a0e485c">171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfOS05LTEtMS05MzYw_3d2e5c45-a41e-4549-be72-410afc61de2a">171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of warrants, <ix:nonFraction unitRef="shares" contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630" decimals="-3" name="bcrx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTAtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmM5NmM2YWY0ZWM2MTRmN2ViYjIzNWI2Mjg3OTE2YjJkXzI2_ca99b7a5-efcb-4b4a-8f86-3ffd89029a08">253</ix:nonFraction> shares</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if913b8a18461412aaa90a9e59f28bbb9_D20220401-20220630" decimals="-3" name="bcrx:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTAtMS0xLTEtOTM2MA_a86bc802-c140-4055-b2a4-c4bc2b9d5bbf">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630" decimals="-3" name="bcrx:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTAtOS0xLTEtOTM2MA_2a10aa90-de33-4b4c-93a2-782f6f3ee628">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options, <ix:nonFraction unitRef="shares" contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTEtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjI1NTI0MDNjYTBjZTQwOGRhZGVlNjE4Y2ExNjE2NjFiXzMx_af197400-65b4-481a-aee1-b14649194172">51</ix:nonFraction> shares, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b867b6cc56641799cba16d11bfa60a4_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTEtMy0xLTEtOTM2MA_082b82d7-7935-45a6-94ee-e813271a48b6">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTEtOS0xLTEtOTM2MA_4ba77d46-b9da-45e7-a8cf-96d75052a7ef">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b867b6cc56641799cba16d11bfa60a4_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTItMy0xLTEtOTM2MA_f293efdc-a682-4891-bd20-9e14beb738a9">9,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTItOS0xLTEtOTM2MA_4abe07fe-6d02-4f0a-88bd-fca4d14237c1">9,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39c3785f664d490d93d4cc107acc6eab_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTMtMS0xLTEtOTM2MA_21869673-20f8-46a0-aa17-bbd4ff43f321">1,859</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1c4dc78aff440ba2b7ae2d04ee9ebb_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTMtMy0xLTEtOTM2MA_25d82993-738d-4ab1-bd2b-3885ce7bc22a">1,125,453</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia81363840c6d47819c0a0300f9de63ea_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTMtNS0xLTEtOTM2MA_629b422c-6a5c-4a7c-aa0c-8898b44eafbf">15</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc1eb8ebb6744a0a90475dfb612381f8_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTMtNy0xLTEtOTM2MA_b1e8124f-ead1-4adc-b808-1c9b154b6f8c">1,340,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaaa54dd893e44a9ba927dae3ebc58fc_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTMtOS0xLTEtOTM2MA_7806d8af-24e4-4f90-bc04-46e01975d701">213,232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d973d539b60454bb3e347b4bb6c7431_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTQtNy0xLTEtOTY2Mg_8343e8c5-899d-47c5-8605-7f688f1352df">42,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTQtOS0xLTEtOTY2OQ_235186d3-79a4-42bb-8979-7c4f3ca786ee">42,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9896466435844fdaadb265c1f69482cc_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTUtNS0xLTEtOTY0OA_4fd64e60-1d4d-4344-a940-a0eeea405f55">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTUtOS0xLTEtOTY2OQ_2449f8b5-11b7-4dff-9856-487f91aaffa5">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan sales, <ix:nonFraction unitRef="shares" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTYtMC0xLTEtOTYxOC90ZXh0cmVnaW9uOjY5ZWRiOWIzMDM0YjRlYTc5ZTM2Y2JjNTg1N2JkOWMyXzU0OTc1NTgxMzk1MQ_be549de2-8a3f-4872-abc3-a855087a3704">145</ix:nonFraction> shares, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia35fcc7c1df8404fa70855f6f2fe6cee_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTYtMS0xLTEtOTYyOA_ca48af75-85c1-4d13-bd3e-a9e264f8e61e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib07b7833ec9c4f5ba79349d729d7e86a_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTYtMy0xLTEtOTY1NQ_31a4a654-6c28-411a-b2b3-0248a9e25251">1,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTYtOS0xLTEtOTY2OQ_999d9fe5-4943-42fa-a8cf-bf37855f3251">1,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options, <ix:nonFraction unitRef="shares" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTctMC0xLTEtOTYxOC90ZXh0cmVnaW9uOjJmMWMxMmMyZTA3YTRkMzdiYjY1YmNmNjc1YmZjMzEyXzU0OTc1NTgxMzk0MQ_cb53f641-919c-403b-9f2f-10fc4f745dfc">390</ix:nonFraction> shares, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia35fcc7c1df8404fa70855f6f2fe6cee_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTctMS0xLTEtOTYyOA_42a4a2a3-dfb5-4edf-aae6-2c6d593a4618">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib07b7833ec9c4f5ba79349d729d7e86a_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTctMy0xLTEtOTY1NQ_f849c24c-c52c-496a-af8d-b8266fde67cc">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTctOS0xLTEtOTY2OQ_f06cc886-6538-4eda-8439-eb5d19873141">1,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib07b7833ec9c4f5ba79349d729d7e86a_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTgtMy0xLTEtOTY1NQ_e2f8c5ac-0218-4ba6-8ad5-8849ed3c6368">9,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTgtOS0xLTEtOTY2OQ_d86785d1-f218-4f3a-b1c6-1dbbb9c75ba0">9,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcb838f1aea441109992ece58d5d1419_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTktMS0xLTEtOTYyOA_e47f842b-6e63-4871-a9e4-cb68116f0c66">1,864</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41766aec3ee549cc9ffd2983c192fdc0_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTktMy0xLTEtOTYzNQ_d788e7f6-f2b0-432e-9994-465b2ad6e8c1">1,138,654</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf830df2b86a45cd9f92bf47fec71ee6_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTktNS0xLTEtOTY0Mg_ac6d4026-0494-4523-b1d9-35108623712c">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f30a466222458bb694b5b460e4b5fb_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTktNy0xLTEtOTY2Mg_7b166a3e-fa64-45f8-9d07-c255b75723cc">1,383,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTktOS0xLTEtOTY2OQ_f3a81a9c-fb25-457d-b124-f913fb12cf04">242,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total <br/>Stockholders&#8217;<br/>Deficit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17fd2b8b68ab41d29358bf85ce87dc12_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMS0xLTEtMS05MzYw_fe79ead8-8a2b-43f2-abcd-fb1c842da995">1,769</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c4036a23a640018a70d37f4b27fb0b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMS0zLTEtMS05MzYw_2406aa13-7df0-4407-b9e1-d5a701dff421">1,002,408</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1588d8fa978d43ecbc8214f1b4283763_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMS01LTEtMS05MzYw_ecfc2165-9928-49dc-852d-d86f9bda7e42">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id581e5368d914277ac0ce9fee558e4ea_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMS03LTEtMS05MzYw_84d10b30-b183-4c5c-a32d-b9a01877da84">1,023,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41745e32b23b47e7a00caf0e1c1db339_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMS05LTEtMS05MzYw_b676fc18-230b-4993-8729-b2c2e9b1c197">19,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5d58b9fd63041f3bc17cf6fc173034b_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMi03LTEtMS05MzYw_de715f01-cf0b-4e39-9199-ca787d1c363a">64,284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if076f350ff45436996af2f05839c8882_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMi05LTEtMS05MzYw_89dc1edd-5e7d-4de7-9f53-240e3a44ce24">64,284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9fa7ce59f8e428fba39af60c2c10e30_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMy01LTEtMS05MzYw_c7cab485-e9be-4b64-9a29-30f6359ad1ad">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if076f350ff45436996af2f05839c8882_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMy05LTEtMS05MzYw_7ad1ab7e-54f7-4176-982e-6cadf5a9f4ef">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan sales, <ix:nonFraction unitRef="shares" contextRef="if076f350ff45436996af2f05839c8882_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNC0wLTEtMS05MzYwL3RleHRyZWdpb246MDkyNDYwMTEyYzk3NGI2ZGFmOGY2OGFjZjBlY2FlZjlfNDA_06a6d289-a364-462d-bb88-5c37e51b67ab">193</ix:nonFraction> shares, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i762c8172b9e54274a05337bb853015e5_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNC0xLTEtMS05MzYw_850339fb-d00f-401e-ad63-0007dcee8770">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9b9d93a9dc4310ae5a5a00e96b249e_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNC0zLTEtMS05MzYw_eb2590ab-2b85-41d7-a233-b0c697221af3">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if076f350ff45436996af2f05839c8882_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNC05LTEtMS05MzYw_554f3ce8-db4e-4b6b-8479-906a7250931d">723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options, <ix:nonFraction unitRef="shares" contextRef="if076f350ff45436996af2f05839c8882_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNS0wLTEtMS05MzYwL3RleHRyZWdpb246NmE2NWRkMzQ1OWM0NGEwMGFhNjljZmIyMzM4NDc1ZDNfMzE_bef03b73-49de-4818-be79-d048c885cf4f">593</ix:nonFraction> shares, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i762c8172b9e54274a05337bb853015e5_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNS0xLTEtMS05MzYw_05f75263-4ebd-43c9-ae41-dbcec2bbedb6">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9b9d93a9dc4310ae5a5a00e96b249e_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNS0zLTEtMS05MzYw_0d701c31-ef14-481e-9297-42e235cbb47c">2,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if076f350ff45436996af2f05839c8882_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNS05LTEtMS05MzYw_7bd932d6-cbe9-494d-8a61-fc39bdcd9051">2,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9b9d93a9dc4310ae5a5a00e96b249e_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNi0zLTEtMS05MzYw_9b57cd7d-dd5f-42cd-a154-2d1311077c37">5,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if076f350ff45436996af2f05839c8882_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNi05LTEtMS05MzYw_c46c8b4c-1356-4139-a921-190ea47eea8a">5,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3ae9e595754fd8b7b517f5d6502c61_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNy0xLTEtMS05MzYw_a6fdc4f7-700e-4eba-9049-2b7dc7f11ded">1,777</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdcafea902a94b74806fbbc66676de9b_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNy0zLTEtMS05MzYw_2e21d664-7727-48aa-b0b9-dff5a464c08b">1,010,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a87a730f5264586b524537e3168930d_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNy01LTEtMS05MzYw_66a63f83-aedc-4ed1-b541-5d3ec5c59614">182</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f09c79fd6f5409491477c45b1543e48_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNy03LTEtMS05MzYw_6ecb148e-57f6-4414-909b-e78f273fb171">1,087,726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9086f7c6548c4033b8ecf3a3a2cc454e_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNy05LTEtMS05MzYw_b85bde62-f843-4997-978b-db0a6768f068">74,988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb74c52ede444e4585f9077b04bd8f51_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfOC03LTEtMS05MzYw_61eb92d6-21ee-4a30-8ea8-74604b804892">43,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6d0af669364983a00fd3d0254f171b_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfOC05LTEtMS05MzYw_df844ea4-645a-4efc-b730-46f062733729">43,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99d7ba3d2a234849a4f237f0d5b55516_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfOS01LTEtMS05MzYw_d14d9fab-29e3-4410-9dfb-3f9c59b587c5">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife6d0af669364983a00fd3d0254f171b_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfOS05LTEtMS05MzYw_d144efee-30b6-4b47-8d1e-216c5f2e056b">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options, <ix:nonFraction unitRef="shares" contextRef="ife6d0af669364983a00fd3d0254f171b_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTAtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmExZjFiOWM0OTg2MzQ4MzFiMzI0YWE0MmYwZTRhN2ZiXzMx_aa100be0-948b-4608-8c20-8c18cfc2505e">1,056</ix:nonFraction> shares, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7be39acc2a414f32b4108381b199c1d2_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTAtMS0xLTEtOTM2MA_1383264a-d968-423c-b318-f9300bbe8683">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f4f783bc4640caa49ae534564dda62_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTAtMy0xLTEtOTM2MA_0b6507dc-7fb4-4948-a1c1-42ba890d9246">4,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6d0af669364983a00fd3d0254f171b_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTAtOS0xLTEtOTM2MA_9ec79dd5-8796-48f0-a798-6f582a81fb53">4,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f4f783bc4640caa49ae534564dda62_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTEtMy0xLTEtOTM2MA_f47225fd-2845-423f-b40b-2b4cac20a0e1">7,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6d0af669364983a00fd3d0254f171b_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTEtOS0xLTEtOTM2MA_03b1be3e-346d-45b1-b6fa-2898af9924e6">7,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49595be0c9ca44d8bdf145a82b2c37a0_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTItMS0xLTEtOTM2MA_73e43f1f-d819-4eb1-8a38-1b208ed3f8ba">1,787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fffddbb207f442684761c141969e63e_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTItMy0xLTEtOTM2MA_b82f91e2-571d-4cca-93a6-77fb693acf91">1,022,975</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc7f6cadfe9a4eeab4afe3e1661f4099_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTItNS0xLTEtOTM2MA_316b9bb9-3168-4e55-8760-877877bfb71d">87</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i766e3bef22c54ee3bdab656c940663e9_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTItNy0xLTEtOTM2MA_861cd323-f68c-4729-a620-5c18f3674586">1,130,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4937c63164a42b3a6326fc7d4b4babe_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTItOS0xLTEtOTM2MA_62424999-2091-45ae-8c6b-59586cd59879">106,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec324695fb5c455faa27509e51bd78b4_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTMtNy0xLTEtOTYwMQ_96452d32-8456-4e37-bf09-a05f8211c11b">58,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTMtOS0xLTEtOTYwOQ_d8cadcff-6ca9-4afb-be78-25af9f74237d">58,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea012f1493f49fd8a6586b2899d6b3a_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTQtNS0xLTEtOTU4OA_8a5b91bb-da31-45d5-a9e2-c44fb5d84082">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTQtOS0xLTEtOTYwOQ_33cc961e-d2c3-4d7d-a6b4-94f59e727fdb">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan sales, <ix:nonFraction unitRef="shares" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTUtMC0xLTEtOTU0Mi90ZXh0cmVnaW9uOjEwNWQ3ZTQzN2QzOTQ5M2ZhYmFlZmQ4ZmZjMzA0Yjg5XzU0OTc1NTgxMzk0Ng_81efd32e-b975-4954-a3d5-8d2402b8d15f">123</ix:nonFraction> shares, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6aea1e78d3493ea6d07c8e22679e2e_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTUtMS0xLTEtOTU0Mg_7072ff48-d180-429b-87d9-0821a1711f9b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7b7c292e90941a398476976288e3ff4_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTUtMy0xLTEtOTU3MA_09308d4c-ef9f-40db-bcac-c7c8689494e2">1,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTUtOS0xLTEtOTYwOQ_de89b243-8306-4718-a8e3-632520b20a28">1,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options, <ix:nonFraction unitRef="shares" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTYtMC0xLTEtOTU0Mi90ZXh0cmVnaW9uOmZiZmU1ZDAwOWJmZjQ0OTdiNTAyMzQzYWNiNTMyOGVkXzU0OTc1NTgxMzkzNw_c8fd8e00-6fcf-458f-bf21-9dec6ae8f8c6">942</ix:nonFraction> shares, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6aea1e78d3493ea6d07c8e22679e2e_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTYtMS0xLTEtOTU0Mg_7829df27-2ea6-4092-8809-5ce64c600a30">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7b7c292e90941a398476976288e3ff4_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTYtMy0xLTEtOTU3MA_2dfcaea6-a476-49a4-9dc4-f24b8afff408">3,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTYtOS0xLTEtOTYwOQ_7c709653-4453-4d33-9df8-f8f479e69563">3,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7b7c292e90941a398476976288e3ff4_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTctMy0xLTEtOTU3MA_873243b2-59a6-4bee-9645-b553ac6b65c3">13,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTctOS0xLTEtOTYwOQ_b9b2118a-23fc-494c-982c-845431a62cfd">13,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4fd1209b6f7440bb9686323eb1893fc_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTgtMS0xLTEtOTU0Mg_4e4d9691-ab20-4ac9-ab26-0022f1036af7">1,798</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c7532d73a584500bbd44288b8006073_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTgtMy0xLTEtOTU3OA_3d4d8c22-46a2-4c71-8055-bc148c24b33a">1,040,769</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a7cdd440cf410c82c96bf461ca3e07_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTgtNS0xLTEtOTU4OA_2321c8b5-e448-4eea-9d90-9bc4ee80ac7f">114</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb951a6478734d308e70fb7798d6529f_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTgtNy0xLTEtOTYwMQ_0a89f254-3bf3-4020-ae85-c6aa9ce9f926">1,189,725</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a3b74ad1e0f4442b522495e111be937_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTgtOS0xLTEtOTYwOQ_3e1b325a-11ee-43e0-96ca-7d744ac47baa">147,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="ia4cd069c56504e93a883c91651012280_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div><span><br/></span></div><div id="ia4cd069c56504e93a883c91651012280_37"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOCRYST PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMzI_ef2baa86-4b0b-4f66-b8da-1e3f7e04f893" continuedAt="ic64edd75c6804a64b7b5332e0ed520e6" escape="true">Significant Accounting Policies and Concentrations of Risk</ix:nonNumeric></span></div><ix:continuation id="ic64edd75c6804a64b7b5332e0ed520e6" continuedAt="i5e0d0dc1f66147aca3922f7da735ae9d"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="bcrx:DescriptionOfCompanyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMzM_01144fb4-bfe1-4ea2-b23b-9d4bae534397" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in 1986 and incorporated in Delaware in 1991, and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketed products include oral, once-daily ORLADEYO&#174; for the prevention of hereditary angioedema (&#8220;HAE&#8221;) attacks and RAPIVAB&#174; (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. ORLADEYO received regulatory approval in the United States in December 2020. ORLADEYO has also received regulatory approvals in multiple global markets. The Company is commercializing ORLADEYO in each of these territories directly or through distributors, except in Japan where Torii Pharmaceutical Co., Ltd., the Company&#8217;s collaborative partner, has the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in exchange for certain milestone and royalty payments to the Company. In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada, Australia, Japan, Taiwan and Korea. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s expectations for revenue and operating expenses, the Company believes its financial resources available at September&#160;30, 2022 will be sufficient to fund its operations for at least the next 12 months. The Company has sustained operating losses for the majority of its corporate history and expects that its 2022 expenses will exceed its 2022 revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#8217;s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company regularly evaluates other opportunities to fund future operations, including: (1) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (2) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestone payments; (3) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (4) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (5) reducing spending on one or more research and development programs, including by discontinuing development; and/or (6) restructuring operations to change its overhead structure. The Company may issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#8217;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events and its decisions in the future.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMzQ_3b18e4c4-a5f9-4c04-9489-6a4c0411cb99" continuedAt="ia7a5217e84004c2ea29ab3576d000e04" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the financial statements for the year ended December&#160;31, 2021 and the notes thereto included in the Company&#8217;s 2021 Annual Report on Form 10-K. Interim operating </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="i5e0d0dc1f66147aca3922f7da735ae9d" continuedAt="ia63e892d90dd4c7ea27f2c9023297b4f"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia7a5217e84004c2ea29ab3576d000e04">results are not necessarily indicative of operating results for the full year. The balance sheet as of December&#160;31, 2021 has been derived from the audited consolidated financial statements included in the Company&#8217;s most recent Annual Report on Form 10-K.</ix:continuation></span></div><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjQ_e9da6aea-13e7-4569-92b1-67b877015518" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the valuation of stock options, the ORLADEYO and Factor D inhibitors royalty financing obligations and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMzU_dc1add9a-3520-4043-9a40-0cc8049bbb94" continuedAt="i0083d7e4d32949b9952086b1a96c7aeb" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales, Net</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in December 2020, sales of peramivir to the Company&#8217;s licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) under the Company&#8217;s procurement contract. In the United States, the Company ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. In the European Union, United Kingdom and elsewhere, the Company sells ORLADEYO to specialty distributors as well as hospitals and pharmacies, which collectively are considered its customers.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue for sales when its customers obtain control of the product, which generally occurs upon delivery. For ORLADEYO, the Company classifies payments to its specialty pharmacy customer for certain services provided by its customer as selling, general and administrative expenses to the extent such services provided are determined to be distinct from the sale of its product.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or as a current liability. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government and Managed Care Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company contracts with government agencies and managed care organizations or, collectively, third-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="ia63e892d90dd4c7ea27f2c9023297b4f" continuedAt="i4ee27185e6754278a853b6157f17a56c"><ix:continuation id="i0083d7e4d32949b9952086b1a96c7aeb" continuedAt="i2318ee8737d24ddeb8f925f1af5cde32"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">establishment of a current liability. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) product distribution information obtained from the Company's specialty pharmacy.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company&#8217;s specialty pharmacy. These customers purchase the Company&#8217;s product under contracts negotiated between them and the Company&#8217;s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price the specialty pharmacy paid and the negotiated price paid by the contracted customers, which may be higher or lower than the specialty pharmacy&#8217;s purchase price from the Company. The Company estimates chargebacks and adjusts gross product revenues and accounts receivable based on the estimates at the time revenues are recognized.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance and patient assistance programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company is able to estimate the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#8217;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company does not provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Research and Development Arrangements and Royalties</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has collaboration and license agreements with a number of third parties, as well as research and development agreements with certain government entities. The Company&#8217;s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not probable at the inception of the agreement </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="i4ee27185e6754278a853b6157f17a56c" continuedAt="i4d8a3cdbad3d4d248d7192da4d7f7177"><ix:continuation id="i2318ee8737d24ddeb8f925f1af5cde32"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within the HHS (&#8220;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of the Company&#8217;s license agreements, the Company receives royalty payments based upon its licensees&#8217; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</span></div></ix:continuation><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMTg_5069224a-b27a-4054-b492-637edec4e629" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjU_0c2eb4a0-debd-4cde-9f1e-cb00222deebd" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash of $<ix:nonFraction unitRef="usd" contextRef="ibc1913ba4028440697583a0160c2c9a9_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMTczNTY_0a8c8a60-df9b-4841-b24c-2bf2eb688231">21</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2b656b9adf614afe8e4311bfc8c36b08_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMTczNjM_e70c4ebc-a997-41b5-a646-dce8469fee7b">1,924</ix:nonFraction> as of September&#160;30, 2022 and December&#160;31, 2021, respectively, reflects royalty revenue paid by Shionogi designated for interest on the PhaRMA Notes (defined in Note 6). Additionally, restricted cash of $<ix:nonFraction unitRef="usd" contextRef="ie4bab20e161348dda0d3fc5277f3602c_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMTc1Mzc_27f6bf51-dece-409f-a9dd-f481b2ba57dc">1,423</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iff682572ef0b4643862b85d792331a8b_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMTc1NDQ_7b72ab75-6e1f-4b56-82f6-ff780589ad2b">1,421</ix:nonFraction> as of September&#160;30, 2022 and December&#160;31, 2021, respectively, reflects collateral for a letter of credit the Company is required to maintain associated with the lease execution and build-out of its Birmingham research facilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMTk_1f20671a-3f8c-40ce-b26b-3c86f421ca08" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, certificates of deposits, municipal and corporate notes and bonds, and commercial paper, among others. The Company&#8217;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of <ix:nonNumeric contextRef="i3c206d1885894084b6b64b92557dff74_D20220101-20220930" name="bcrx:MaturityPeriodOfHighQualityMarketableSecurities" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMTg3MTM_781c2e3a-d62e-4cd6-9d78-3ec6199d1b0c">three years</ix:nonNumeric> and requires an average portfolio maturity of no more than <ix:nonNumeric contextRef="i3c206d1885894084b6b64b92557dff74_D20220101-20220930" name="bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMTg3NzU_cccf0489-e6b0-4116-8ba6-de9c3ae2cd9e">12</ix:nonNumeric> months. Some of the securities in which the Company invests may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#8217;s investments are not collateralized. The Company has not realized any significant losses from its investments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than <ix:nonNumeric contextRef="i3c206d1885894084b6b64b92557dff74_D20220101-20220930" name="bcrx:MaturityPeriodOfShortTermInvestment" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMjA0MTE_4e8cd441-cda7-4094-8d13-2ba641f49bff">12</ix:nonNumeric> months from the balance sheet date are classified as current. Investments with a maturity beyond <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="bcrx:LongTermInvestmentMaturityMinimum" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMjA1MDQ_629d8430-ac55-4f3c-941c-1e8b9f024c35">12</ix:nonNumeric> months from the balance sheet date are classified as long-term. At September&#160;30, 2022, the Company believes that the cost of its investments is recoverable in all material respects.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="i4d8a3cdbad3d4d248d7192da4d7f7177" continuedAt="i57c2f56718d44590bb7341d7e767dbaf"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMzY_03e1feec-e707-4e4c-a24d-f58c4c79fe10" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other third-party distributors, hospitals and pharmacies in the European Union, United Kingdom and elsewhere and have standard payment terms that generally require payment within 30 to 90 days.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the HHS, and royalty receivables from the Company&#8217;s partners, including Shionogi, Green Cross, and Torii.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monthly invoices are submitted to HHS related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not adjust its receivables for the effects of a significant financing component at contract inception if it expects to collect the receivables in one year or less from the time of sale.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides reserves against trade receivables for estimated losses that may result from a customer's inability to pay. Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company&#8217;s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMTU_4ce05801-1bdf-47c9-9325-288f8ad703cd" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, labor, manufacturing overhead and shipping and handling costs on a first-in, first-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labelled products.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventories are subject to expiration dating. The Company regularly evaluates the carrying value of its inventories and provides valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, the Company may experience spoilage of its raw materials and supplies. The Company&#8217;s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjM_e65840f3-0b85-41c9-aaad-534049774318" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of <ix:nonNumeric contextRef="i30f04607b9fd4fbd8d1e3b4e116511df_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMjM5MTU_a990bc7e-08b8-480a-97e6-ce6df4edfebd">three years</ix:nonNumeric>. Laboratory equipment, office equipment, and software are depreciated over a life of <ix:nonNumeric contextRef="i4f4820f68b75491386429192e255c412_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMjQwMDM_7c5648dd-e996-46c5-b53c-c234cb360851">five years</ix:nonNumeric>. Furniture and fixtures are depreciated over a life of <ix:nonNumeric contextRef="iacbf3ec994f848c3afd3f6edf48b0963_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMjQwNjE_9b862fa3-40df-4b05-8883-973c124d9b36">seven years</ix:nonNumeric>. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="i57c2f56718d44590bb7341d7e767dbaf" continuedAt="i36c01891f2ab449389dd039e56dbaead"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="bcrx:AccruedExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjg_01584f97-0501-4707-8073-c10bbc2e1958" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company&#8217;s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of September&#160;30, 2022 and December&#160;31, 2021, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjY_1828811d-3dac-4f3e-b428-7a7bbdcecb27" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including freight. In addition, shipping and handling costs for product shipments are recorded as incurred. Finally, cost of product sales may also include costs related to excess or obsolete inventory adjustment charges.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMTI_c5a75e68-1b40-4296-8b60-95e1d88547fb" continuedAt="i78f081c38966419796611f62f951b0c5" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts, and estimates are adjusted, if required, based upon the Company&#8217;s ongoing review of the level of services actually performed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;), and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i78f081c38966419796611f62f951b0c5">Deferred collaboration expenses represent sublicense payments, paid to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#8217;s academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="i36c01891f2ab449389dd039e56dbaead" continuedAt="i3b0f8a1916854e369d1a0a6080246ea2"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjc_79ecebf6-be56-4593-97d5-559564afe8bf" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense is primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other general and administrative costs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expenses related to ORLADEYO were $<ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzA4MDQ_0e241716-a40e-49bd-b60a-6d2757a7ea67">3,476</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzA4MTE_32d5c3fe-9f0c-45f4-bca1-0c27a85b973f">11,555</ix:nonFraction> for the three and nine months ended September&#160;30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzA4NjA_5deca40a-14ba-401f-b7e1-51af2e53878d">1,492</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzA4Njc_ed02a38b-6465-4f04-afd9-38b49c3d84b7">4,696</ix:nonFraction> for the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjk_dcb354c4-82cf-436a-9b6f-185b9cd78d8e" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of September&#160;30, 2022. The Company accounts for lease obligations in accordance with ASU 2016-02: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most operating leases.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#8217;s Consolidated Balance Sheets represent payments over the lease term, which includes renewal options for certain real estate leases that the Company is likely to exercise. As part of the Company&#8217;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of twelve months or less was not material.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used in the calculation of the Company&#8217;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#8217;s collateralized borrowing rate from lending institutions.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not made any residual value guarantees related to its operating leases; therefore, the Company has no corresponding liability recorded on its Consolidated Balance Sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjA_0b804a0f-1b59-4205-9aa1-aadfe64b11a5" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, the Company has outstanding performance-based stock options and restricted stock units for which no compensation expense is recognized until &#8220;performance&#8221; is deemed to have occurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjE_442a909e-4b47-4457-a87e-cca089fe8e6e" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Deferred Financing Costs</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three and nine months ended September&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzM1OTU_3a4afab4-1987-47cd-8fc0-3816aabb480f">24,775</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzM2MDI_5e2f871a-7a3a-4c74-bf31-09272aa221d8">72,634</ix:nonFraction>, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzM2MjQ_e7d6bf4f-9baf-4021-8ff5-f2bd9ded6ded">14,115</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzM2MzE_9bf594ae-f955-40b3-b527-ec38a07faae9">40,514</ix:nonFraction> for the three and nine months ended September&#160;30, 2021, respectively, and primarily relates to the royalty financing obligations (Note 6), the secured term loan borrowing from the Credit Agreement (Note 7) and the PhaRMA Notes (Note 6). Costs directly associated with the borrowings have been capitalized and are netted against the corresponding debt liabilities on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $(<ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" sign="-" name="bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzQyMjA_a1262cdd-4c69-4d94-9806-2507d9e3154a">258</ix:nonFraction>) and $(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" sign="-" name="bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzQyMjc_c55e9cc7-a553-4b0e-93b5-220ebcf34e62">597</ix:nonFraction>) for the three and nine months ended September&#160;30, 2022, respectively, and $(<ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" sign="-" name="bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzQyNzY_e3b3e493-be89-4e45-8b57-db67aef55baf">158</ix:nonFraction>) and $(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" sign="-" name="bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzQyODM_3ee59426-7863-46fb-8e05-1ec6cafa8504">369</ix:nonFraction>) for the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the PhaRMA Notes and associated accrued interest payable was written-off into other income as a debt extinguishment (Refer to &#8220;Note 6&#8212;Royalty Monetizations&#8212;RAPIACTA&#8212;Non-Recourse Notes Payable &#8211; Debt Extinguishment&#8221; for additional information regarding the debt extinguishment).</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="i3b0f8a1916854e369d1a0a6080246ea2" continuedAt="i7061625cd93e474093355d77f542c49e"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="bcrx:InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMTM_419e377b-d9d7-4184-bdc0-5ecd673ee485" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Royalty Financing Obligations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO, BCX9930, and another earlier stage Factor D inhibitor (BCX10013). Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMzA_1aa40edb-b121-44bc-9cd0-fd503ac9d626" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability method is used in the Company&#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in fiscal year 2021, the Company began accruing foreign income taxes as a result of increased nexus in foreign jurisdictions where historically the Company had no presence.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, starting in 2022, amendments to Section 174 of the Internal Revenue Code of 1986, as amended (&#8220;IRC&#8221;), will no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil. As a result of this tax law change, the Company has recorded a U.S. state tax provision for the nine months ended September 30, 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMTQ_dfbb4452-6c00-41d2-9167-d0619a7ac287" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company&#8217;s equity compensation plans were anti-dilutive. The calculation of diluted earnings per share does not include <ix:nonFraction unitRef="shares" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzcwNDk_09fc552f-4b51-4e60-8256-002cfee2abff">26,236</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzcwNTY_2db0c375-772f-4efe-a479-4727766ae336">25,918</ix:nonFraction> shares of potential common stock for the three and nine months ended September&#160;30, 2022, respectively, and <ix:nonFraction unitRef="shares" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzcxMzg_0bd5737f-c2b1-46cb-8fb5-2918ab941fef">28,472</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzcxNDU_83d3a07a-bbe6-4ab1-8e4c-4da6d96eea89">26,131</ix:nonFraction> shares of potential common stock for the three and nine months ended September&#160;30, 2021, respectively, as their impact would be anti-dilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMTc_04863f32-49d9-465c-b17b-2d968df9c2be" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income and recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. There were <ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="INF" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMTA5OTUxMTY2OTk0MA_714317eb-4b3d-4baf-9255-29fb901bf9ef">no</ix:nonFraction> realized gains or losses reclassified out of accumulated other comprehensive income for the nine months ended September 30, 2022.  For the nine months ended September 30, 2021, realized gains of $<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="INF" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzc5MDQ_03e6f564-ff9c-41b1-90a2-c24624a03292">1</ix:nonFraction> were reclassified out of accumulated other comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="bcrx:ConcentrationOfMarketRiskPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjI_b1cda0ef-a0cd-41c0-be54-180b04744a67" continuedAt="ifc45c984c56e4de6a974ec3014ed8c47" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers and Other Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Customers</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary sources of revenue and cash flow are the sales of ORLADEYO in the United States and other global markets as well as sales of RAPIVAB (peramivir injection) under the Company's procurement contract with the Assistant Secretary for Preparedness and Response within HHS. Additionally, the Company receives reimbursement of </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="i7061625cd93e474093355d77f542c49e" continuedAt="ic4a89109bdaf49c29fabb5d09b895222"><ix:continuation id="ifc45c984c56e4de6a974ec3014ed8c47"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">galidesivir (formerly BCX4430) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ORLADEYO is distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. The specialty pharmacy&#8217;s inability or unwillingness to continue these distribution activities could adversely impact the Company&#8217;s business, results of operations and financial condition.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company is distributing ORLADEYO in other global markets directly or through distributors, except in Japan where Torii, the Company&#8217;s collaborative partner, has the exclusive right to commercialize ORLADEYO.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses has represented a significant portion of the Company&#8217;s collaborative and other research and development revenues. All government funding for galidesivir is expected to expire in 2022. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, HHS is the primary customer for RAPIVAB, and it has exercised the remaining option for the purchase of RAPIVAB under the procurement contract with the Company.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Company&#8217;s drug development activities are performed by a limited group of third-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks from Third-Party Manufacturing and Distribution Concentration</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays or disruption in the manufacture or distribution of any product could adversely impact the future procurement stockpiling of the Company&#8217;s product candidates and commercial revenue, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 12 months or less.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables from sales of ORLADEYO are primarily due from one customer, resulting in a concentration of credit risk. Sales of ORLADEYO from the Company to the specialty pharmacy only occur once an order of product has been received by the specialty pharmacy from one of its customers, which include pharmacy benefit managers, insurance companies, government programs and group purchasing organizations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</span></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMzE_66eadb2e-d66f-4fe6-8e11-bef75d44854b" continuedAt="i1c756302ad2e48f291cc5b2cfb16bddd" escape="true">Recently Adopted Accounting Pronouncements</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic4a89109bdaf49c29fabb5d09b895222"><ix:continuation id="i1c756302ad2e48f291cc5b2cfb16bddd">There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the nine months ended September 30, 2022, as compared to the recent accounting pronouncements described in Note 1 of the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, that the Company believes are of s</ix:continuation></ix:continuation>ignificance or potential significance to the Company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><div id="ia4cd069c56504e93a883c91651012280_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RleHRyZWdpb246MDc1ZTlmZjQ0N2U3NDIwNmE3ODA0NWU5ODkwNWIyMmZfODI_641615c8-da14-4c07-b761-ed0a2bd08b5a" continuedAt="ib26198b158814c1d91527cb9cea099a1" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="ib26198b158814c1d91527cb9cea099a1"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RleHRyZWdpb246MDc1ZTlmZjQ0N2U3NDIwNmE3ODA0NWU5ODkwNWIyMmZfODM_aadfd7c4-0cb4-4ecf-9c3f-c508364b1a2d" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following revenues (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORLADEYO</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01b1e25bb16a4e61b3726d6578c74362_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMy0xLTEtMS05MzYw_b8ebd9d5-aedc-45bf-8f3c-2907d4837542">65,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085d63dc06a84f6ea9de568acc4df142_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMy0zLTEtMS05MzYw_de7381ca-02a4-4b99-b556-1d9581303a4e">36,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i451dda4c3a8e4ccfad33168494bc9c9d_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMy00LTEtMS05MzYw_df84e61f-fb14-4175-839a-97856c553b48">179,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaae1596b0387405c82740b7390d33d38_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMy02LTEtMS05MzYw_91f1a685-6b95-4e4d-961a-919f9d796e6b">76,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RAPIVAB</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadb0a3977d2e464381bb4a2a4912955b_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNC0xLTEtMS05MzYw_9dc57477-116a-4c80-9dec-9242815e5e42">6,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72fe97c0b03a4aefa6351d9bbfc48eb8_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNC0zLTEtMS05MzYw_d4af9960-6a79-4b7f-8020-f35da8de96fa">2,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b500470aa1440998f2b21760e6893f_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNC00LTEtMS05MzYw_c089d02a-f644-463d-acc4-57f59bb666d0">7,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d1a5d14f8b040478c08a0ed5704b783_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNC02LTEtMS05MzYw_f377fc84-e3ac-47e7-a55a-9f19cb3f7fd3">7,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peramivir</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a97685da3b4dc781181f5228701bd4_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNS0xLTEtMS05MzYw_4840ec8f-b77b-4e91-abff-86a85bd7a45e">2,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e09ca159fe4d35ad4cf6c7111aadae_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNS0zLTEtMS05MzYw_ed5ce43e-e554-4f3a-a319-bd0b94b433be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6355a4b7fee3482482574de4cadc4f2c_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNS00LTEtMS05MzYw_eb5d85db-5bc2-4d0e-b245-ad9f8a2d0d84">2,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530113c61c0045f5a77ebf99982dd4cf_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNS02LTEtMS05MzYw_d499d951-0bc8-48d8-8f7e-4288009106c7">7,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02cd59e16e0149199ce28d859c3ac6a8_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNi0xLTEtMS05MzYw_44407b3b-2974-4ecd-bab6-ff4387ecf8db">75,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03da29ccbd9f4d09beeb6288fdf053b4_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNi0zLTEtMS05MzYw_44db92e9-4990-4185-9462-9f103de132b2">39,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38b2ee116544f90a76e9d8b6d33f39b_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNi00LTEtMS05MzYw_b5135420-665a-40b8-8614-1f5e7c12e459">189,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if885f6f8cf8d4e339f135dd75b604594_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNi02LTEtMS05MzYw_c5c46b73-5bb6-4113-9848-a5aab38fad83">90,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2b8611a0384b2e8a19a43ecfab2135_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNy0xLTEtMS05MzYw_8b0972f7-adbb-4fb4-ba88-d6dce5e87779">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ca5f40fc4b4aa98634268fcf2525a0_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNy0zLTEtMS05MzYw_2fad5670-4e44-4336-be58-cdcb7c64acd2">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51f3d3839d1472ea8a99419a9e1d1dd_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNy00LTEtMS05MzYw_5e6278fa-3522-42a0-b70a-309db0ae4697">1,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69c7f898fb47496b80d856f7a82a5454_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNy02LTEtMS05MzYw_84edf291-9da2-4fbb-8811-c71588ddacb0">447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d334c267d664d22a3b7769ac993451a_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfOC0xLTEtMS05MzYw_e4d3826a-9009-4c68-a9be-296900265ead">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa865c7a786428b8ce79ebf9351f4ad_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfOC0zLTEtMS05MzYw_d82d5e05-4116-4a4b-9e44-33604e87fb65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd8066819384bae8b29a1bc99808b48_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfOC00LTEtMS05MzYw_cb6a38f8-2c9a-49d9-b405-85c764cb8b81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9435042756cd4d408e47bff42738cf8e_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfOC02LTEtMS05MzYw_8f5f901a-5fd9-49ee-8ab1-cde22cb0433f">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other research and development revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Health and Human Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i300f876718414e03a6d92b6eef13452b_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTAtMS0xLTEtOTM2MA_fc4ed698-32e1-4441-81fa-6317d4de26f9">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a43835db50e40aa8dae8ed521e3d03c_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTAtMy0xLTEtOTM2MA_0cac41ef-041e-43e4-96f6-31ec4b5a9157">1,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc7c54d81f614da2bf398d8589ddba3d_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTAtNC0xLTEtOTM2MA_7f2d8925-a73c-4cba-925f-0bb97f6ef91c">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ca21205297a4dce8632aec47144b369_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTAtNi0xLTEtOTM2MA_c125198b-0d56-4ced-af53-3c0fa10c1b21">5,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaborative and other research and development revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67cf7bf22deb4aff91b49db594f6a877_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTEtMS0xLTEtOTM2MA_dba9be61-3f3c-4c52-9363-04186d2edbf1">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7382589fe0034462aa011f377b6998da_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTEtMy0xLTEtOTM2MA_6894974a-a14c-420b-98fe-94c5425acfb9">1,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dde7334e062479ab641b4c89a0a55e4_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTEtNC0xLTEtOTM2MA_1beae52d-4f42-4312-9fef-dedfc57c9299">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89dd57b2bc7948769d0753db905659dd_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTEtNi0xLTEtOTM2MA_659323d6-0181-4233-bcbd-9908d44dac4f">5,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTItMS0xLTEtOTM2MA_f21f44b3-0567-4611-a98f-647728e7387b">75,827</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTItMy0xLTEtOTM2MA_948c06bd-aeec-4780-a225-4f6a0efd1fc7">40,994</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTItNC0xLTEtOTM2MA_06b83279-d502-4177-93e1-ebfb117d0b33">191,282</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTItNi0xLTEtOTM2MA_fccdee07-dac3-4f38-9c74-25bdd03222b3">110,012</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia4cd069c56504e93a883c91651012280_43"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RleHRyZWdpb246ZWE4N2YzMWU5NjBjNGNlYzgyMjUwZWM4OTljMjhmMDJfNjk1_5411bf54-06bc-4f1f-a754-024e0d8d5ac4" continuedAt="i055cd6a9b8ba4c95af3f2f8f3a8cb803" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="i055cd6a9b8ba4c95af3f2f8f3a8cb803" continuedAt="i54653588126747c48dff29db291ef573"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RleHRyZWdpb246ZWE4N2YzMWU5NjBjNGNlYzgyMjUwZWM4OTljMjhmMDJfNjk2_83e1e6aa-1df5-4718-8e60-7f84db5d00c2" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the fair value of the Company&#8217;s investments by type. The estimated fair values of the Company&#8217;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued<br/>Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae7bd5bdeed04eb0a29ec0c7ed2a15cd_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMi0xLTEtMS05MzYw_aef47285-8c3a-4174-87de-8c035868ab4b">205,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae7bd5bdeed04eb0a29ec0c7ed2a15cd_I20220930" decimals="-3" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMi0zLTEtMS05MzYw_4ed65118-f91a-4984-899e-1f6a7194ab68">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae7bd5bdeed04eb0a29ec0c7ed2a15cd_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMi01LTEtMS05MzYw_f75c472e-c9c5-4020-8603-c12d232c9731">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae7bd5bdeed04eb0a29ec0c7ed2a15cd_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMi03LTEtMS05MzYw_cbdf5871-80c2-4ad9-a316-b449c0fe7704">1,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae7bd5bdeed04eb0a29ec0c7ed2a15cd_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMi05LTEtMS05MzYw_43ea5b67-6e8c-4ec0-9fcc-317b1ebc6315">204,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ae49712cd2e41b4952fd9e10638809f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMy0xLTEtMS05MzYw_03681575-6080-4135-8ccc-bd2b80e82bf3">7,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ae49712cd2e41b4952fd9e10638809f_I20220930" decimals="-3" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMy0zLTEtMS05MzYw_8484ab4f-4694-4b7a-b1b6-12832809d81a">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ae49712cd2e41b4952fd9e10638809f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMy01LTEtMS05MzYw_d6f3cd0f-c906-40fe-9402-a4e21d0b9d67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ae49712cd2e41b4952fd9e10638809f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMy03LTEtMS05MzYw_291f22b6-9981-4f49-bded-063c0cfb9f68">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ae49712cd2e41b4952fd9e10638809f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMy05LTEtMS05MzYw_e8e332a8-9e31-4361-872a-e51bec533bdc">7,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cb4025c8734daeb09b21962b869678_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNC0xLTEtMS05MzYw_36cf66e8-57a3-4ef0-b918-3c3d42aa0e82">2,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cb4025c8734daeb09b21962b869678_I20220930" decimals="-3" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNC0zLTEtMS05MzYw_aee8960a-3d7f-41dd-9e1d-e6a60f128d40">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cb4025c8734daeb09b21962b869678_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNC01LTEtMS05MzYw_04fd1427-1975-40cc-82bf-05ba344a97c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7cb4025c8734daeb09b21962b869678_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNC03LTEtMS05MzYw_e002c944-8c4e-406f-93b0-0daf42c1a069">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cb4025c8734daeb09b21962b869678_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNC05LTEtMS05MzYw_03ab4031-5e2d-4b61-85d1-56ff8c7476bc">2,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNS0xLTEtMS05MzYw_861b73a8-42fd-4a8a-b4be-66c35bb4702e">215,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNS0zLTEtMS05MzYw_c23583e5-acc3-406b-8f7b-1c749aad7ab9">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNS01LTEtMS05MzYw_b72483ea-c639-475c-b15f-b06eac97fd28">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNS03LTEtMS05MzYw_452690dc-ffd2-410e-9fea-db04f2371b63">1,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNS05LTEtMS05MzYw_43667cc9-1cc6-4cd3-83fe-9ad07418aed6">214,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued<br/>Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba59a9ed8954f15bb323330c2072dc7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMi0xLTEtMS05MzYw_7db640ee-f673-42d1-ab05-94678b3e599c">4,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba59a9ed8954f15bb323330c2072dc7_I20211231" decimals="-3" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMi0zLTEtMS05MzYw_cc95416b-c3bd-4f0e-984a-67d8de2ffe89">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba59a9ed8954f15bb323330c2072dc7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMi01LTEtMS05MzYw_daf76fd9-caf3-4b18-9829-070236ffb1a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icba59a9ed8954f15bb323330c2072dc7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMi03LTEtMS05MzYw_18208e7b-c9f5-4cae-8592-2d68cf1dfd4c">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba59a9ed8954f15bb323330c2072dc7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMi05LTEtMS05MzYw_af374ccd-9d35-4a17-8639-eab779e19840">4,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9834b9d88aa64e0e826bd49839d8f0a4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMy0xLTEtMS05MzYw_bebfb2af-159d-4b12-b793-300f44cf4053">4,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9834b9d88aa64e0e826bd49839d8f0a4_I20211231" decimals="-3" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMy0zLTEtMS05MzYw_b71790cc-dd0c-4adb-8351-47deaa0fa7bf">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9834b9d88aa64e0e826bd49839d8f0a4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMy01LTEtMS05MzYw_20e49bfe-e7be-4b39-9cb2-0fadacb7e0e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9834b9d88aa64e0e826bd49839d8f0a4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMy03LTEtMS05MzYw_79b4f83f-ee74-4b1f-845f-d9220198a0e0">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9834b9d88aa64e0e826bd49839d8f0a4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMy05LTEtMS05MzYw_e36f4cb5-b1a8-469e-8572-aa9df458aa6e">4,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i138269de9639423b9754ab90611310ae_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNC0xLTEtMS05MzYw_c66f0075-d6f9-44f2-a83a-435674b783ee">1,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i138269de9639423b9754ab90611310ae_I20211231" decimals="-3" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNC0zLTEtMS05MzYw_b1f4fb5e-aeab-498f-a774-bd9da8abcf88">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i138269de9639423b9754ab90611310ae_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNC01LTEtMS05MzYw_d227015a-d916-4c46-b5a8-98524d18de2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i138269de9639423b9754ab90611310ae_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNC03LTEtMS05MzYw_4ed181c9-b89f-44ef-9418-9536107498d7">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i138269de9639423b9754ab90611310ae_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNC05LTEtMS05MzYw_8f1a180b-df4a-4673-a6f0-626167af246c">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNS0xLTEtMS05MzYw_790e67bf-18ba-41ae-b2e6-bfe8dd61f469">9,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNS0zLTEtMS05MzYw_f54b5a93-ae43-416d-a514-fe35e54d5471">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNS01LTEtMS05MzYw_d4207221-6a13-4964-8ce4-631a164c33d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNS03LTEtMS05MzYw_65d24cbb-f89a-4d33-9766-5570ede4f463">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNS05LTEtMS05MzYw_51aaf0a1-3aa5-41be-8d7e-2f8b4552f7b7">10,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="i54653588126747c48dff29db291ef573"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:HeldToMaturitySecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RleHRyZWdpb246ZWE4N2YzMWU5NjBjNGNlYzgyMjUwZWM4OTljMjhmMDJfNjk3_c078d663-bd3e-4536-92fd-7dae51fd43d8" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the scheduled maturity for the Company&#8217;s investments at September&#160;30, 2022 and December&#160;31, 2021:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjdjMDU1ODk1OTM4YjQ1NmE5NTkyOTQ3NzEzNWUwYjc4L3RhYmxlcmFuZ2U6N2MwNTU4OTU5MzhiNDU2YTk1OTI5NDc3MTM1ZTBiNzhfMS0xLTEtMS05MzYw_caa1214c-0518-467b-b25a-fb813897f76d">179,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjdjMDU1ODk1OTM4YjQ1NmE5NTkyOTQ3NzEzNWUwYjc4L3RhYmxlcmFuZ2U6N2MwNTU4OTU5MzhiNDU2YTk1OTI5NDc3MTM1ZTBiNzhfMS0zLTEtMS05MzYw_22430995-095c-47d8-bfc5-8fb4eb384465">3,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="bcrx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjdjMDU1ODk1OTM4YjQ1NmE5NTkyOTQ3NzEzNWUwYjc4L3RhYmxlcmFuZ2U6N2MwNTU4OTU5MzhiNDU2YTk1OTI5NDc3MTM1ZTBiNzhfMi0xLTEtMS05MzYw_9c8cbc6d-1acb-4dc7-899e-899d6e7e45bb">34,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="bcrx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjdjMDU1ODk1OTM4YjQ1NmE5NTkyOTQ3NzEzNWUwYjc4L3RhYmxlcmFuZ2U6N2MwNTU4OTU5MzhiNDU2YTk1OTI5NDc3MTM1ZTBiNzhfMi0zLTEtMS05MzYw_f20c3a7f-7648-4150-aec0-ade78ea25d17">6,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjdjMDU1ODk1OTM4YjQ1NmE5NTkyOTQ3NzEzNWUwYjc4L3RhYmxlcmFuZ2U6N2MwNTU4OTU5MzhiNDU2YTk1OTI5NDc3MTM1ZTBiNzhfMy0xLTEtMS05MzYw_81850704-179c-4359-8d2e-0ae896e4452e">214,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjdjMDU1ODk1OTM4YjQ1NmE5NTkyOTQ3NzEzNWUwYjc4L3RhYmxlcmFuZ2U6N2MwNTU4OTU5MzhiNDU2YTk1OTI5NDc3MTM1ZTBiNzhfMy0zLTEtMS05MzYw_d6885b47-7e3a-4104-9bc2-c65245d7482c">10,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia4cd069c56504e93a883c91651012280_46"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="bcrx:TradeReceivablesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfNjAz_cc2575ab-ac4f-45be-be5d-3810aac5feab" continuedAt="ic8c739cc2a5b4026aa14cea0fee0dd3e" escape="true">Trade Receivables</ix:nonNumeric></span></div><ix:continuation id="ic8c739cc2a5b4026aa14cea0fee0dd3e" continuedAt="i800fc50d31bd4b4d8cc99302f08d2ed2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO and RAPIVAB. At September&#160;30, 2022 and December&#160;31, 2021, receivables related to sales of ORLADEYO were $<ix:nonFraction unitRef="usd" contextRef="i6d5cc209df4b4f158f63ba78067df1d3_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfMjI0_e01514a5-20f4-41d6-8248-91730810c0cb">39,565</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0bf1868a8c07401995c9209a9fed2a20_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfMjMx_655376bb-4026-41f6-83a1-252c514e537d">27,384</ix:nonFraction>, respectively. At September&#160;30, 2022 and December&#160;31, 2021, receivables related to sales of RAPIVAB were $<ix:nonFraction unitRef="usd" contextRef="i822a4f18efa9407ca27d5a5c54dbf5e2_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfMzA4_76fda0f0-032d-44e9-b591-ee1bf0bd4dd1">28</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i00f15b2faead42f68b751bfd1a5a76bf_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfMzE1_3c80e4d4-8c2c-477f-b648-bbfde69b6da6">49</ix:nonFraction>, respectively. <ix:nonFraction unitRef="usd" contextRef="i3fad271ec831459885eb81d1bf350ac2_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfMzMz_8f54a784-a831-47a6-8c79-4fdb47c20130"><ix:nonFraction unitRef="usd" contextRef="i1c255209851347d2823e94f1a619328e_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfMzMz_c2942369-5260-4dbd-bab1-99dde6145227">No</ix:nonFraction></ix:nonFraction> reserve or allowance amounts were recorded as of both September&#160;30, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborations</span></div><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfNjA0_8b5c05bc-f4e5-496a-a09b-d489aa8ff4ba" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from collaborations were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Billed</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unbilled</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Health and Human Services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148b60adb92b488a9a9a9586b8ce630f_I20220930" decimals="-3" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMi0xLTEtMS05MzYw_8e4a0465-5e0c-494c-a3ac-5bf1979bbec1">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39ef3ff428bf4f4891cb088a64691907_I20220930" decimals="-3" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMi0zLTEtMS05MzYw_de26ac9f-f305-406c-b264-1139c56ad041">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i575f84670ae346f3b0aaf66dac4ce33a_I20220930" decimals="-3" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMi01LTEtMS05MzYw_7b28fee8-27f1-4a56-a9f7-1419ba49506f">536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shionogi &amp; Co. Ltd.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i555cad33b5d44135b244268bf4d08939_I20220930" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMy0xLTEtMS0xMzU3OQ_f169f31a-f8ec-4233-9624-afab1b941277">1,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6909fce5d6ea480fb5472075566b87fa_I20220930" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMy0zLTEtMS0xMzU2Mw_415f44ea-4468-4f1e-b994-850bb7a3662f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib207348a887d4eac8ea660147a235790_I20220930" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMy01LTEtMS0xMzU4Nw_8a8960a4-9be4-4898-9d12-03c670254eac">1,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty receivables from partners</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30df1d46204d4ed3bcab448f681a0f99_I20220930" decimals="-3" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMy0xLTEtMS05MzYw_1f14f93c-e6b4-4ac1-ae26-02889196fa16">588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe28a0b9ba504c29a6bbfb22a00d691b_I20220930" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMy0zLTEtMS05MzYw_11e31b54-3e09-4535-80e1-c8e1d7a1a871">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9164b1431b374f07841c05f4d2661cf0_I20220930" decimals="-3" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMy01LTEtMS05MzYw_d06653e5-42dc-41da-a7fa-d2398c9d0131">588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total receivables</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b5e996fc4f46a0bea68e7eae665edd_I20220930" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfNC0xLTEtMS05MzYw_7c93c1b9-2194-4eaf-84ac-1d12c987c303">2,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i527a858d3bdd48b4bbbc58eaa0c86127_I20220930" decimals="-3" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfNC0zLTEtMS05MzYw_3db26d46-c0bf-46a9-b08d-428f3677c703">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfNC01LTEtMS05MzYw_084f24ab-d065-4e85-bb68-ccf8f9f34ad8">3,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Billed</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unbilled</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Health and Human Services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c931a38b8f4fb79cd7b1bfc15541af_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfMi0xLTEtMS05MzYw_4f48cf20-8d8f-48e3-8f5a-279a76d14c43">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifba625b9dbe14b648921db96471dc959_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfMi0zLTEtMS05MzYw_a36d7dc1-86ad-46f7-b789-7766945d99e6">1,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib09e2423a7504296aafabf85a78b11e0_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfMi01LTEtMS05MzYw_a77e5d99-b289-47a1-abef-38cf92ed79e5">1,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty receivables from partners</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06da809ae51d46f4a859c0e6d5105e1a_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfMy0xLTEtMS05MzYw_020f06ef-be50-4680-89bf-cc1c4d3ee23b">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie681521de8e8461695ee96dbd9571fcb_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfMy0zLTEtMS05MzYw_ceb062ce-1744-401f-95ed-04e2936ab6d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie154d98fc18c4a1bb3006dded763756f_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfMy01LTEtMS05MzYw_2da418f3-3e53-4694-894d-94b288e39338">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total receivables</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97245d53c4b147daaf476637df025ab6_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfNC0xLTEtMS05MzYw_19a23bfd-cc2e-4208-9e30-2c0626342659">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9144542bf0074b97b464b99a2e251ddb_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfNC0zLTEtMS05MzYw_f8175485-f459-4ffb-9548-685d135efd99">1,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfNC01LTEtMS05MzYw_6f646f64-dfb2-4406-bc76-de2d58a82a05">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i800fc50d31bd4b4d8cc99302f08d2ed2">As of both September&#160;30, 2022 and December&#160;31, 2021, the Company maintained a reserve of $<ix:nonFraction unitRef="usd" contextRef="i1ed0f773e01c46b0a1ec1a9b710e5c96_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfNTUx_c47d299f-85d7-4cdc-b756-170883d5db2d"><ix:nonFraction unitRef="usd" contextRef="i3c2f2931216342fc952334687bc6784f_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfNTUx_f62e8aba-6e27-42a7-ba51-a42f435f6aac">701</ix:nonFraction></ix:nonFraction> related to royalties associated with Green Cross.</ix:continuation> </span></div><div id="ia4cd069c56504e93a883c91651012280_49"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RleHRyZWdpb246MWFmM2UyMjRkNDVhNGU3MzkxZTA1NmJjNDAxNzQyOTZfMjY4_1a9fd459-31d5-432f-999f-e646a39aee89" continuedAt="ie86b71cf5ccc4535a0dca2f3e888e9d0" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="ie86b71cf5ccc4535a0dca2f3e888e9d0"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022 and December&#160;31, 2021, the Company&#8217;s inventory primarily related to ORLADEYO. Additionally, inventory included RAPIVAB and peramivir, which is manufactured for the Company&#8217;s partners.</span></div><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RleHRyZWdpb246MWFmM2UyMjRkNDVhNGU3MzkxZTA1NmJjNDAxNzQyOTZfMjY5_55b3af29-400e-4b3c-9209-e605dfb97b2a" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventories consisted of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfMS0xLTEtMS05MzYw_a3670dee-36f8-43ca-af0a-0bb6e70d386a">8,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfMS0zLTEtMS05MzYw_6792c2f4-770f-4f3e-9bb1-0ed82745bba2">5,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfMi0xLTEtMS05MzYw_919c714f-e062-47b2-ab83-07776e98d644">15,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfMi0zLTEtMS05MzYw_bdb746af-9e08-484c-af64-fad15def17ce">9,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfMy0xLTEtMS05MzYw_0c04d94a-eb46-4719-ada3-b5ecbff9f132">3,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfMy0zLTEtMS05MzYw_cc687aff-86ca-4bdb-a141-e5eff4a14b6d">709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfNC0xLTEtMS05MzYw_d3eee699-35a8-4218-ad1b-644eead25013">27,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfNC0zLTEtMS05MzYw_d7c0c728-e511-4d42-be62-6abb134a20e5">16,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfNS0xLTEtMS05MzYw_63818b46-d04d-4027-80fd-0aeb34fcca01">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfNS0zLTEtMS05MzYw_d0e6233a-5b72-4d7d-8e8e-198d18807ff4">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfNi0xLTEtMS05MzYw_3bd7c83c-eafc-4818-ac12-3d0dece23475">27,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfNi0zLTEtMS05MzYw_b524819d-cfb0-47db-a8e3-156fdf1d2c06">15,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><div id="ia4cd069c56504e93a883c91651012280_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="bcrx:RoyaltyMonetizationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTYxNDM_e318d706-c5b6-4a8b-952d-7180a1e6e9be" continuedAt="i0c0908d3ae2b4efe8b22e61b6f6b6d19" escape="true">Royalty Monetizations</ix:nonNumeric></span></div><ix:continuation id="i0c0908d3ae2b4efe8b22e61b6f6b6d19" continuedAt="ic509015a92bf408d836068807d868ed9"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RAPIACTA </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;9, 2011, the Company completed a $<ix:nonFraction unitRef="usd" contextRef="id71eb7a7f4934c329e8946aad8843f79_I20110309" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODY_2faca55b-f127-46ea-8bbc-f779e2069fb3">30,000</ix:nonFraction> financing transaction to monetize certain future royalty and milestone payments under the Company&#8217;s agreement with Shionogi (the &#8220;Shionogi Agreement&#8221;), pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6cd2274f76d84f7d8aa1fecb06595801_D20210309-20210309" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMzgy_c911998f-f9d7-49a3-ac3e-ee6003f58555">22,691</ix:nonFraction> from the transaction after transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i6cd2274f76d84f7d8aa1fecb06595801_D20210309-20210309" decimals="-3" name="bcrx:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNDMz_b50bb979-dc77-4602-9b6d-c9fe6d9b7c0f">4,309</ix:nonFraction> and the establishment of a $<ix:nonFraction unitRef="usd" contextRef="i6cd2274f76d84f7d8aa1fecb06595801_D20210309-20210309" decimals="-6" name="bcrx:InterestReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNDYz_c185b219-bcf4-4cc3-92e1-9400212e2ab8">3,000</ix:nonFraction> interest reserve account by JPR Royalty Sub LLC, a wholly-owned subsidiary of the Company (&#8220;Royalty Sub&#8221;), available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, the Company entered into a purchase and sale agreement dated as of March 9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement and (ii) the right to receive payments under a Japanese yen/U.S. dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency Hedge Agreement&#8221;) put into place by the Company in connection with the transaction. Royalty payments are paid by Shionogi in Japanese yen, and any milestone payments will be paid in U.S. dollars. The Company&#8217;s collaboration with Shionogi was not impacted as a result of this transaction.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Recourse Notes Payable</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;9, 2011, Royalty Sub completed a private placement to institutional investors of $<ix:nonFraction unitRef="usd" contextRef="ifa8c84cacb9b47f0858154719b4d86b1_D20210309-20210309" decimals="-7" name="bcrx:PrivatePlacementOfSeniorSecuredNotes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTU4OA_ba24a0bd-8d07-4094-975e-6f2bf7e96dd7">30,000</ix:nonFraction> in aggregate principal amount of its PhaRMA Senior Secured <ix:nonFraction unitRef="number" contextRef="i9da1b8e68e3943f4b431a7f4b8c6ddb6_I20110309" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTY1MA_f222afdf-f6c9-4cf4-b77a-3817a7b24057">14.0</ix:nonFraction>% Notes due on December 1, 2020 (the &#8220;PhaRMA Notes&#8221;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March 9, 2011 (the &#8220;Indenture&#8221;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at <ix:nonFraction unitRef="number" contextRef="i9da1b8e68e3943f4b431a7f4b8c6ddb6_I20110309" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMjE5OA_a087f5c3-0dc1-49df-8618-9c2884e310dd">14</ix:nonFraction>% per annum, payable annually in arrears on September 1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty Sub&#8217;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#8217;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2014, Royalty Sub was unable to pay the accrued interest obligation due September 3, 2013. Under the terms of the Indenture, Royalty Sub&#8217;s inability to pay the full amount of interest payable in September 2013 by the next succeeding payment date for the PhaRMA Notes, which was September 1, 2014, constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the December 31, 2014 balance sheet and thereafter. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential foreclosure, the primary impact to the Company would be the loss of future royalty payments, if any, from Shionogi and legal costs associated with retiring the PhaRMA Notes. The PhaRMA Notes had a final legal maturity date of December&#160;1, 2020, at which time the outstanding principal amount of the PhaRMA Notes of $<ix:nonFraction unitRef="usd" contextRef="i6a9d2be26d104c7f88a240ce0bdae3b0_I20201201" decimals="-7" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNDI5NA_c0a71b35-5023-4c15-b1ce-995d99f78f17">30,000</ix:nonFraction>, together with accrued and unpaid interest of $<ix:nonFraction unitRef="usd" contextRef="i6a9d2be26d104c7f88a240ce0bdae3b0_I20201201" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNDM0Mw_e46d29ae-cffa-4e30-885a-5f391c8eeaa3">20,614</ix:nonFraction>, was due in full.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Recourse Notes Payable &#8211; Debt Extinguishment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the royalty-bearing patents associated with RAPIACTA in Japan expired. Accordingly, the Company evaluated the current circumstances of the PhaRMA Notes, including (i) their non-recourse nature relative to the Company, (ii) the current state of default since September 1, 2014 and the legal maturity on December 1, 2020 and (iii) the loss of patent protection relative to RAPIACTA in Japan, upon which any significant repayment of the PhaRMA Notes is </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="ic509015a92bf408d836068807d868ed9" continuedAt="i9d09a89195e34da6894996900fbab7f2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">predicated. As a result, the Company determined that it was no longer the financial obligor, and as a result, the principal balance of $<ix:nonFraction unitRef="usd" contextRef="ifc57076200334d0195d02ed18bd1d7f6_I20211231" decimals="-7" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNTAwOQ_d145efe8-2d4f-4ef8-87db-10a223a772a8">30,000</ix:nonFraction> and associated accrued interest payable balance of $<ix:nonFraction unitRef="usd" contextRef="ic3555a1cac734984b0bc78b41179373c_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNTA2Mw_998fbad0-c526-4233-9b27-95ca4a923ef8">25,838</ix:nonFraction> were written off, resulting in a gain on extinguishment recorded in other income (expense) for the year ended December&#160;31, 2021.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ORLADEYO and Factor D Inhibitors</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;7, 2020, the Company and RPI 2019 Intermediate Finance Trust (&#8220;RPI&#8221;) entered into a Purchase and Sale Agreement (the &#8220;2020 RPI Royalty Purchase Agreement&#8221;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i40eed59cc9974d4da70c7edd9d0d8c82_D20201207-20201207" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNTQ5Nw_098a2177-06f2-48d8-8457-8af844180d04">125,000</ix:nonFraction> in cash (the &#8220;2020 RPI Royalty Sale&#8221;). Under the 2020 RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the United States and certain key European markets (collectively, the &#8220;Key Territories&#8221;), and other markets where the Company sells ORLADEYO directly or through distributors (collectively, the &#8220;Direct Sales&#8221;) in an amount equal to: (i) <ix:nonFraction unitRef="number" contextRef="i659ab2cd433f43e38df5288340793caf_D20201207-20201207" decimals="4" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNTkxNQ_0454d435-046b-4a19-8533-fe0ea6fb19f5">8.75</ix:nonFraction>% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) <ix:nonFraction unitRef="number" contextRef="id0d847dbf3cc433cb71781a71246c04d_D20201207-20201207" decimals="4" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjAwNQ_5fc1ebcc-29d1-45dc-aa1a-1728d384943b">2.75</ix:nonFraction>% of annual net sales for annual net sales between $350,000 and $550,000. <ix:nonFraction unitRef="number" contextRef="i8229178c1776432b9a14327383dbd4e8_D20201207-20201207" decimals="-3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjA4MA_6bad363f-8531-42aa-ac9a-305541548f62">No</ix:nonFraction> royalty payments are payable on annual Direct Sales over $550,000. In addition, RPI will be entitled to receive <ix:nonFraction unitRef="number" contextRef="i6c43924485804171baf9b85f8c65941c_D20201207-20201207" decimals="3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjE5NQ_194b9ff7-5047-4c4e-8d4c-b2308121458b">1.0</ix:nonFraction>% of global net sales, if any, of BCX9930.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2020 RPI Royalty Purchase Agreement, RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories (the &#8220;Other Markets&#8221;) equal to: (i) <ix:nonFraction unitRef="number" contextRef="i8038e6b568aa4157a7628b82914dffe6_D20201207-20201207" decimals="2" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjQ2NQ_27804227-9bfc-4635-8912-26cc2365dcf4">20</ix:nonFraction>% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets; (ii) <ix:nonFraction unitRef="number" contextRef="i3a1f4d036f7c4e5698e71c2f543364b0_D20201207-20201207" decimals="1" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjYwMA_13d0cab9-fa8d-4342-8dd3-8e07f0868721">20</ix:nonFraction>% of proceeds received on annual net sales of up to $150,000 in the Other Markets; and (iii) <ix:nonFraction unitRef="number" contextRef="i131aea96e86e4fbbbd650ebc98f6ffca_D20201207-20201207" decimals="2" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjY5NA_8dde0c6f-4cad-4d41-8321-dba19faa95e8">10</ix:nonFraction>% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. <ix:nonFraction unitRef="number" contextRef="if618ed9fbfce4a02b7658195a856d8be_D20201207-20201207" decimals="-3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjgwNQ_038035e7-b1d4-42d3-8865-68d07e2aff3e">No</ix:nonFraction> royalty payments are payable on annual net sales above $230,000 in the Other Markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company and RPI entered into (i) a Purchase and Sale Agreement (the &#8220;2021 RPI Royalty Purchase Agreement&#8221; and together with the 2020 RPI Royalty Purchase Agreement, the &#8220;RPI Royalty Purchase Agreements&#8221;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i67142cf4c13a4d68bc0ac1f76af05df3_D20211119-20211119" decimals="-7" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNzIzOQ_fee4a38d-70cc-43a2-a33c-3dbf0e6991ce">150,000</ix:nonFraction> in cash, and (ii) a Purchase and Sale Agreement with OCM IP Healthcare Holdings Limited, an affiliate of OMERS Capital Markets (&#8220;OMERS&#8221;) (the &#8220;OMERS Royalty Purchase Agreement&#8221; and collectively with the RPI Royalty Purchase Agreements, the &#8220;Royalty Purchase Agreements&#8221;), pursuant to which the Company sold to OMERS the right to receive certain royalty payments from the Company for a purchase price of an additional $150,000 in cash.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2021 RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) <ix:nonFraction unitRef="number" contextRef="i7f1b22877b3740e68dd9cfbae1ff0365_D20211119-20211119" decimals="4" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNzgyNA_4ce2744f-2e75-4107-a8ae-6ba10b4f0433">0.75</ix:nonFraction>% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) <ix:nonFraction unitRef="number" contextRef="i42c79576567c4b2bbc81a0de713c8389_D20211119-20211119" decimals="4" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNzkxNA_2885e17b-0581-4462-823b-db80576df8d2">1.75</ix:nonFraction>% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000. <ix:nonFraction unitRef="number" contextRef="i42c79576567c4b2bbc81a0de713c8389_D20211119-20211119" decimals="-3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODAwMQ_5292a94d-9997-4afa-bd72-223de9ad47f2">No</ix:nonFraction> royalty payments are payable on Direct Sales over $550,000. RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to <ix:nonFraction unitRef="number" contextRef="i1c82dcc5f02c4662947d1881f5cc203e_D20211119-20211119" decimals="2" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODIxOQ_2df09c58-6955-4857-8a02-517e49707f2a">3.0</ix:nonFraction>% of proceeds received by the Company on annual net sales of up to $150,000 in the Other Markets, and (iii) <ix:nonFraction unitRef="number" contextRef="if9cf1579776d4680a6bf379ea0a42c2c_D20211119-20211119" decimals="2" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODMyOA_682712f0-1eae-409e-965c-ab9685b51447">2.0</ix:nonFraction>% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2021 RPI Royalty Purchase Agreement, RPI is also entitled to receive tiered, sales-based royalties on net product sales of BCX9930 and another earlier stage Factor D inhibitor (BCX10013) in an amount equal to: (i) <ix:nonFraction unitRef="number" contextRef="iab0a5cddb915447c9e805b68ffc9d835_D20211119-20211119" decimals="3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODc0MQ_7904f59d-acc6-4a78-9f58-7067df572b40">3.0</ix:nonFraction>% of worldwide aggregate annual net sales up to $1,500,000 and (ii) <ix:nonFraction unitRef="number" contextRef="ibeeda3897a624890bc65185aab3a382f_D20211119-20211119" decimals="3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODgxMg_34fa5a2b-6e3c-4b43-9da2-7bdaf870db4f">2.0</ix:nonFraction>% of worldwide aggregate annual net sales between $1,500,000 and $3,000,000. <ix:nonFraction unitRef="number" contextRef="i43d710969d584356a886f1c9563fef66_D20211119-20211119" decimals="-3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODg5NA_ca6361de-1434-4613-a4e4-684593a4d233">No</ix:nonFraction> royalty payments are payable on annual net sales above $<ix:nonFraction unitRef="usd" contextRef="iea24828b86d54f41a2b4874e96d088f2_D20211119-20211119" decimals="-8" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODk1Mg_da672764-24c8-49fd-abfa-a1ab8b468a4e">3,000,000</ix:nonFraction>. RPI is also entitled to receive tiered profit share amounts of up to <ix:nonFraction unitRef="number" contextRef="i7c6e9851b8104036bbcd12e9aa0bc4a8_D20211119-20211119" decimals="3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfOTAyNQ_456080f3-859b-4bc8-a332-3ff5f8fb4859">3.0</ix:nonFraction>% from certain other permitted sales in certain other markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalties payable under the 2021 RPI Royalty Purchase Agreement are in addition to the royalties payable to RPI under the 2020 RPI Royalty Purchase Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the OMERS Royalty Purchase Agreement, commencing with the calendar quarter beginning October 1, 2023, OMERS will be entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) <ix:nonFraction unitRef="number" contextRef="i922a1d857b42485f92214971ed78a0da_D20211119-20211119" decimals="3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfOTQ2Nw_3744944e-16b5-4dca-adf5-0f7f9c34698c">7.5</ix:nonFraction>% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) <ix:nonFraction unitRef="number" contextRef="ie7f72565b0f5439abca0ea90d3a6f24b_D20211119-20211119" decimals="2" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfOTU1Nw_01c6a7a3-5df2-4bcb-9db8-abd9f30da7bb">6.0</ix:nonFraction>% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000 (with <ix:nonFraction unitRef="number" contextRef="i11b7628d9fda491980452daac486f097_D20211119-20211119" decimals="-3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfOTY0OQ_b0ca583c-90c6-4d0c-a92c-5677faab19cd">no</ix:nonFraction> royalty payments payable on annual Direct Sales over $550,000) (the &#8220;Regime A Royalty Rate&#8221;). If annual Direct Sales for calendar year 2023 reach a specified amount set forth in the OMERS Royalty Purchase Agreement, then for each calendar quarter beginning on or after January 1, 2024, OMERS will be entitled to receive the Regime A Royalty Rate. If annual Direct Sales for calendar year 2023 are less than the specified amount, OMERS will be entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) <ix:nonFraction unitRef="number" contextRef="i1b2bc1c2bed841eb99664d403903ea7f_I20211119" decimals="1" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTAxODQ_8c3f5deb-b5ad-4eca-af5c-92a71f88a854">10.0</ix:nonFraction>% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) <ix:nonFraction unitRef="number" contextRef="i178ec38dd6014b1d9adf94656a10b03e_I20211119" decimals="2" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTAyNzQ_613a49f3-12d8-4c45-8080-9606b88e8fb4">3.0</ix:nonFraction>% of annual net sales of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="i9d09a89195e34da6894996900fbab7f2" continuedAt="i3ec4d3622db84ce8a69ae1395923f152"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ORLADEYO for annual net sales between $350,000 and $550,000 (with <ix:nonFraction unitRef="number" contextRef="i92914c34dfeb459cb7418faf28e8f5c5_I20211119" decimals="-3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTAzNjY_de5ea6ac-e81e-44d7-88fe-515310d0d1e4">no</ix:nonFraction> royalty payments payable on annual Direct Sales over $550,000) (the &#8220;Regime B Royalty Rate&#8221;).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the OMERS Royalty Purchase Agreement, OMERS is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to: (i) <ix:nonFraction unitRef="number" contextRef="i782dba101c4049a68737ea34eaa114a0_D20211119-20211119" decimals="1" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTA2Njk_3eecd63d-eb0b-43d1-a2e2-ea47ef3946f7">20.0</ix:nonFraction>% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets, (ii) <ix:nonFraction unitRef="number" contextRef="i96ce4725997d4522ab18ef4f78970321_D20211119-20211119" decimals="1" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTA4MDQ_dafd5b8e-6a29-4ba6-a6cd-3fc1cb6d09a3">20.0</ix:nonFraction>% of proceeds received by the Company on annual net sales of up to $150,000 in the Other Markets, and (iii) <ix:nonFraction unitRef="number" contextRef="ifd9066e5a18b494489a571f56afaf09a_D20211119-20211119" decimals="1" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTA5MTM_d99ea924-0b30-4526-821f-a421ce05497f">10.0</ix:nonFraction>% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. <ix:nonFraction unitRef="number" contextRef="i4d5e09b3fd4d49c3acbe8c9499ec13f9_D20211119-20211119" decimals="-3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTEwMjQ_240efd76-4d9f-4402-83b0-748814e45df5">No</ix:nonFraction> royalty payments are payable on annual net sales above $230,000 in the Other Markets. OMERS is also entitled to receive profit share amounts of up to <ix:nonFraction unitRef="number" contextRef="i782dba101c4049a68737ea34eaa114a0_D20211119-20211119" decimals="1" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTExNzc_2d6a7fe2-db5a-4e79-98db-e0c9b4eb952e">10</ix:nonFraction>% from certain other permitted sales in certain other markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2020 RPI Royalty Purchase Agreement, the Company is required to make royalty payments of amounts owed to RPI each calendar quarter following the first commercial sale of ORLADEYO in any country. Under the 2021 RPI Royalty Purchase Agreement, the Company is required to make payments to RPI in respect of net sales or sublicense revenue in each calendar quarter from and after October 1, 2021. Under the OMERS Royalty Purchase Agreement, the Company will be required to make payments to OMERS is respect of net sales or sublicense revenue in each calendar quarter from and after October 1, 2023. OMERS will no longer be entitled to receive any payments on the date in which aggregate payments actually received by OMERS equals either <ix:nonFraction unitRef="number" contextRef="i0a099c2a65d543edbf8358cc0e472f2a_D20211119-20211119" decimals="3" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTE5ODQ_062c691f-fac0-4ecf-a97a-e4ed37dd1f62">142.5</ix:nonFraction>% or <ix:nonFraction unitRef="number" contextRef="i1a14b6aff29e4ab0899284236dbee713_D20211119-20211119" decimals="2" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTE5OTA_06cf206e-74d2-47b9-b400-d832659109fb">155.0</ix:nonFraction>% of the $<ix:nonFraction unitRef="usd" contextRef="i3387c2eb985849859a399492ce421ce8_I20211119" decimals="-7" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTIwMDA_da337f6c-8ae7-4fd7-b9fd-2279e5c0bf81">150,000</ix:nonFraction> purchase price, depending on sales levels in calendar year 2023.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the &#8220;Royalty Sales&#8221;.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Royalty Purchase Agreements, the Company has agreed to specified affirmative and negative covenants, including covenants regarding periodic reporting of information by the Company to RPI and OMERS, third-party audits of royalties paid under the Royalty Purchase Agreements, and restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness other than certain royalty sales and as is permitted to be incurred under the terms of the Company&#8217;s Credit Agreement with Athyrium Opportunities III Co-Invest 1 LP. Refer to Note 7 for further details on the Credit Agreement. The restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness are eliminated after the achievement of certain specified milestones in the Royalty Purchase Agreements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash consideration obtained pursuant to the Royalty Purchase Agreements is recorded in &#8220;Royalty financing obligations&#8221; on the Company&#8217;s Consolidated Balance Sheets. The fair value for the royalty financing obligations at the time of the transactions was based on the Company&#8217;s estimates of future royalties expected to be paid to the counterparty over the life of the arrangement. The Company subsequently records the obligations at its carrying value using the effective interest method. In order to amortize the royalty financing obligations, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. The Company periodically assesses the amount and timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success, and sales price, among others. To the extent such payments are greater or less than the Company&#8217;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, the Company adjusted its forecasts related to its R&amp;D programs and ORLADEYO sales. Accordingly, this impacted the amount and timing of expected royalties to be made under the RPI Royalty Purchase Agreements. As a result, the effective interest rate related to the 2020 RPI Royalty Purchase Agreement decreased from <ix:nonFraction unitRef="number" contextRef="ib7810c48b6754267aa2a3f2a660bf13e_I20220630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTUwMjY_6205f401-ee0e-48c9-a6bd-4d244fe1d07d">25.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ib01a977ea3bd4a78aca463e3dcbcae61_I20220930" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTUwMzI_aac03459-c352-41e9-a9d0-1ef381d6e297">23.1</ix:nonFraction>%, and the effective interest rate related to the 2021 RPI Royalty Purchase Agreement decreased from <ix:nonFraction unitRef="number" contextRef="id6782cfa98ec4a439c817a6ffa240688_I20220630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTUxMzQ_cc1c4dce-db35-4d38-8641-7cac574ddbf5">12.1</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ie0126a3e3d9242d79ce8101efe7c2a9f_I20220930" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjU5NzA2OTc4Mjk0OA_4b263677-47f4-4bcf-b529-d2d64eb510bd">11.0</ix:nonFraction>%. Additionally, the effective interest rate related to the OMERS Agreement increased from <ix:nonFraction unitRef="number" contextRef="ib0dc4b1e9eb848818b47548abe6e3324_I20220630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjU5NzA2OTc4MzA2NA_0276b955-54b9-450f-a319-ba7d2cdd264a">8.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i492a9e744ab44aecb99a707368b9137a_I20220930" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjU5NzA2OTc4MzA3Mg_acc92db8-69f8-4198-8622-a9bf28e93208">10.6</ix:nonFraction>%.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="i3ec4d3622db84ce8a69ae1395923f152"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="bcrx:RoyaltyFinancingObligationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTYxNDQ_a5cf3aa3-1364-4895-a472-44100827260d" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the Royalty financing obligations account (in thousands) as well as the effective interest rate as of September&#160;30, 2022: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 RPI<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 RPI<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OMERS<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibede6ebb23bb41718df5c414f9e0d733_I20211231" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMS0xLTEtMS05MzYw_949ed4cc-0c4c-4c6c-86d4-fddd3760705a">147,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aa7623896fd466a8100ad400138b291_I20211231" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMS0zLTEtMS05MzYw_2ec20ae4-6876-4a7b-a165-80ab9d9276ae">153,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe7ee6d739f433bac2aa26b00c08cb9_I20211231" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMS01LTEtMS05MzYw_3a460c47-ad6b-4dd2-8e40-5001598a3d31">148,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMS03LTEtMS05MzYw_9db0cd6a-df3b-4723-9f78-fc35f368fde8">449,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic215859d996647a59c854764e5c698e1_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMi0xLTEtMS05MzYw_4def8534-d832-402a-bbb8-89d3141eb6fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a54a935fad483f8a7abc4b9481af07_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMi0zLTEtMS05MzYw_34aa96c7-0f1c-4643-a9ed-5b6a9e8b5ea9">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a395490d1fb4b4a89833e1ca81fdd7b_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMi01LTEtMS05MzYw_3c0baee4-e993-4be7-8a59-11c1498912af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMi03LTEtMS05MzYw_2f64f15e-b4c7-4467-aa96-19b4ef31324e">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash Interest expense on Royalty financing obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic215859d996647a59c854764e5c698e1_D20220101-20220331" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMy0xLTEtMS05MzYw_10117425-7a70-4e00-a5a8-b026ce55feac">10,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a54a935fad483f8a7abc4b9481af07_D20220101-20220331" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMy0zLTEtMS05MzYw_bc49d2c9-f6b7-4d33-b2ae-99e5e4acec03">6,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a395490d1fb4b4a89833e1ca81fdd7b_D20220101-20220331" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMy01LTEtMS05MzYw_4e53f0cd-33f3-4ce7-b3b7-74ce573d9cfc">3,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMy03LTEtMS05MzYw_289ca24d-af42-480e-a3ef-e4d2487879ce">19,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues paid and payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic215859d996647a59c854764e5c698e1_D20220101-20220331" decimals="-3" sign="-" name="bcrx:RoyaltiesRevenuesPaidAndPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNC0xLTEtMS05MzYw_98d53cef-cd37-4aca-9d1b-587d31d22398">4,385</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a54a935fad483f8a7abc4b9481af07_D20220101-20220331" decimals="-3" sign="-" name="bcrx:RoyaltiesRevenuesPaidAndPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNC0zLTEtMS05MzYw_ef88ded0-8485-471a-ad04-5cbc8cd2e631">380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a395490d1fb4b4a89833e1ca81fdd7b_D20220101-20220331" decimals="-3" name="bcrx:RoyaltiesRevenuesPaidAndPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNC01LTEtMS05MzYw_7b6c5e7d-517e-4906-8a24-c182f41fda80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331" decimals="-3" sign="-" name="bcrx:RoyaltiesRevenuesPaidAndPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNC03LTEtMS05MzYw_ce17dc20-3f6a-4bcb-b9ea-1aa52a76c7cc">4,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3864fa52358945bfbd68481e97ea6545_I20220331" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNS0xLTEtMS05MzYw_f72cca1e-7de0-412d-a922-3adda731e478">153,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2633d031d70949ebac044dd59a84d949_I20220331" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNS0zLTEtMS05MzYw_0fee1f9c-28f2-4842-95e9-4119f76e0cb1">159,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7bfbb0963cd492f8cc0ff3fbce8c491_I20220331" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNS01LTEtMS05MzYw_69cf494a-456c-4454-b222-996078721bc2">151,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i705ede78548e4661a484496cffb01473_I20220331" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNS03LTEtMS05MzYw_6e398850-9efb-41b3-bf81-689f04ab6486">464,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash Interest expense on Royalty financing obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274b955cf1e1448988b54629cbefc21c_D20220401-20220630" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNi0xLTEtMS05MzYw_e493de48-23f6-4f03-9abc-24c858d69449">10,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b0b77fa77814d6686ce59c957db2ab2_D20220401-20220630" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNi0zLTEtMS05MzYw_fd6dc88b-02c4-4b86-82cc-75d22299fc9b">6,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106ce134a512494ea43edc85bb29e49c_D20220401-20220630" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNi01LTEtMS05MzYw_ba06019e-b34a-49d1-b601-e3288cb2303b">3,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNi03LTEtMS05MzYw_b5c02d71-0526-47c6-86c6-e1ab7d497e6f">19,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues paid and payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274b955cf1e1448988b54629cbefc21c_D20220401-20220630" decimals="-3" sign="-" name="bcrx:RoyaltiesRevenuesPaidAndPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNy0xLTEtMS05MzYw_3c29683d-32e1-4107-978d-556b5e2a0470">5,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b0b77fa77814d6686ce59c957db2ab2_D20220401-20220630" decimals="-3" sign="-" name="bcrx:RoyaltiesRevenuesPaidAndPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNy0zLTEtMS05MzYw_bb3f594d-0fd5-4883-9f5c-ef295dff0d71">501</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106ce134a512494ea43edc85bb29e49c_D20220401-20220630" decimals="-3" name="bcrx:RoyaltiesRevenuesPaidAndPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNy01LTEtMS05MzYw_811af588-605e-430d-9fe5-adcc7b3c7a47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630" decimals="-3" sign="-" name="bcrx:RoyaltiesRevenuesPaidAndPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNy03LTEtMS05MzYw_4e1a63c1-82bb-47e7-a216-47c919686832">6,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7810c48b6754267aa2a3f2a660bf13e_I20220630" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOC0xLTEtMS05MzYw_bd09b12b-38cc-4428-8b80-b505cd9d2936">157,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6782cfa98ec4a439c817a6ffa240688_I20220630" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOC0zLTEtMS05MzYw_28d5798f-85d8-4dc0-9c50-f0a407a32f8a">164,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0dc4b1e9eb848818b47548abe6e3324_I20220630" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOC01LTEtMS05MzYw_d7a0e5ea-533a-4f3b-b982-d8d1b1c2c066">155,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaaa54dd893e44a9ba927dae3ebc58fc_I20220630" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOC03LTEtMS05MzYw_d891d4be-7658-4149-ba74-03de3ade25af">477,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash Interest expense on Royalty financing obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic550bdd44f464d7e8684a82d73605d43_D20220701-20220930" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOS0xLTEtMS05ODgw_6a8fb162-e360-4a68-9ccb-807520ba9f62">9,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe7d973553d4d5abc3a63e8fec38c3a_D20220701-20220930" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOS0zLTEtMS05ODg3_c1c3b570-1053-46a6-a9de-66a898701173">4,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11cfeff79ad34520b776332a393c0b35_D20220701-20220930" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOS01LTEtMS05ODk0_7abd77fc-68e5-42cd-a585-27cf00d22dcb">3,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOS03LTEtMS05ODk0_14f2e9e9-7194-40af-bfa1-5f54123e5ce4">18,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues paid and payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic550bdd44f464d7e8684a82d73605d43_D20220701-20220930" decimals="-3" sign="-" name="bcrx:RoyaltiesRevenuesPaidAndPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTAtMS0xLTEtOTg4MA_04e9574f-1ed6-4d31-b2f5-5dc46e26094a">5,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe7d973553d4d5abc3a63e8fec38c3a_D20220701-20220930" decimals="-3" sign="-" name="bcrx:RoyaltiesRevenuesPaidAndPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTAtMy0xLTEtOTg4Nw_d8cd235d-e69f-464a-a4fd-784da3002a33">508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11cfeff79ad34520b776332a393c0b35_D20220701-20220930" decimals="-3" name="bcrx:RoyaltiesRevenuesPaidAndPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTAtNS0xLTEtOTg5NA_08b4dd66-ddcd-4020-aff0-4eab77f31ab1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" sign="-" name="bcrx:RoyaltiesRevenuesPaidAndPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTAtNy0xLTEtOTg5NA_40dccf40-a8bb-410d-8798-3225f3439ab6">6,345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01a977ea3bd4a78aca463e3dcbcae61_I20220930" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTEtMS0xLTEtOTg4MA_a74ab290-4395-4e8d-a861-67d0f14a2d94">161,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0126a3e3d9242d79ce8101efe7c2a9f_I20220930" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTEtMy0xLTEtOTg4Nw_945e89c1-209c-4091-8668-4de9164540a7">169,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i492a9e744ab44aecb99a707368b9137a_I20220930" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTEtNS0xLTEtOTg5NA_7e4b411a-0300-4268-bc56-fc4e5ae4edbf">158,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="bcrx:FutureRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTEtNy0xLTEtOTg5NA_fe7d8de0-0b2c-456b-8020-1a8096c54b0a">489,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib01a977ea3bd4a78aca463e3dcbcae61_I20220930" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTAtMS0xLTEtOTM2MA_aac03459-c352-41e9-a9d0-1ef381d6e297">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0126a3e3d9242d79ce8101efe7c2a9f_I20220930" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTAtMy0xLTEtOTM2MA_4b263677-47f4-4bcf-b529-d2d64eb510bd">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i492a9e744ab44aecb99a707368b9137a_I20220930" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTAtNS0xLTEtOTM2MA_acc92db8-69f8-4198-8622-a9bf28e93208">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred issuance costs pursuant to the Royalty financing obligations, which consist primarily of advisory and legal fees, totaled $<ix:nonFraction unitRef="usd" contextRef="i86233c8a15e74c029b96ae45ad9b3911_I20220930" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTU0MzA_169e0f63-9b2c-43b2-b761-3bb6f305e12f">8,531</ix:nonFraction> as of September&#160;30, 2022. The Royalty financing obligations liabilities and the associated deferred issuance costs are amortized using the effective interest method over the term of the arrangement, in accordance with the respective guidance.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with entering into the 2021 RPI Royalty Purchase Agreement, the Company and RPI entered into a Common Stock Purchase Agreement (the &#8220;Common Stock Purchase Agreement&#8221;), pursuant to which the Company sold common stock to RPI for a premium of $<ix:nonFraction unitRef="usd" contextRef="i63012785f2d64008b6eb5c1c19199d9b_I20220930" decimals="-3" name="bcrx:SharesIssuedCommonStockPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTU5MTE_f2763923-f735-47d7-b2af-9cf8b29a9ac7">4,269</ix:nonFraction>. This premium has been deferred and is being amortized through interest expense using the effective interest method over the term of the applicable arrangement. Refer to Note 9 for further details on the common stock sale premium.</span></div></ix:continuation><div id="ia4cd069c56504e93a883c91651012280_55"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfOTc3NA_c7d5e2ea-3286-47e1-8830-2a785bdc6dc2" continuedAt="i3718e37a4bec43078d11c6b1c16a0a16" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i3718e37a4bec43078d11c6b1c16a0a16" continuedAt="iba9f158fca46472eae6606dde4a5036f"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;7, 2020, the Company entered into a $<ix:nonFraction unitRef="usd" contextRef="i7b8c0ef1641d490bad48d0ce9744d424_I20201207" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNzA_e2b85925-35c5-40c2-87ff-cd5ffd48f847">200,000</ix:nonFraction> Credit Agreement (the &#8220;Credit Agreement&#8221;) with Athyrium Opportunities III Co-Invest 1 LP (&#8220;Athyrium&#8221;), as lender and as administrative agent for the lenders. Certain of the Company&#8217;s direct and indirect subsidiaries are guarantors to the Credit Agreement. The Credit Agreement provides for an initial term loan in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="i03bffbefba234cc0a1128fb5302a1f91_D20201207-20201207" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNDEx_04d72157-61dd-4ce8-b72b-f2d93c62be8b">125,000</ix:nonFraction> (the &#8220;Term A Loan&#8221;), which was received by the Company on December&#160;7, 2020 and is recorded in &#8220;Secured term loan&#8221; on the Company&#8217;s balance sheet as of September&#160;30, 2022. The Company used a portion of the proceeds from the Term A Loan to repay $<ix:nonFraction unitRef="usd" contextRef="i7929cd2eb5634ff0ac5139d08ffc47a8_D20201207-20201207" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNjI4_a5827945-2d0f-4a27-a172-24f63b1ee335">43,298</ix:nonFraction> of outstanding indebtedness, including accrued interest, under its prior credit facility with MidCap Financial Trust. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement also provided for two additional term loans, at the Company&#8217;s option, in the respective principal amounts of $<ix:nonFraction unitRef="usd" contextRef="ice4776aac34540989938d21b8dfb4e97_I20220729" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfODgw_c56e6a88-7075-4d59-8f90-0cd22ba3f4f6">25,000</ix:nonFraction> (the &#8220;Term B Loan&#8221;) and $<ix:nonFraction unitRef="usd" contextRef="ia003b9df8396437497d66b989248c2b6_I20220729" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfOTA3_52d52b49-52b0-4a7c-b10a-08944b253267">50,000</ix:nonFraction> (the &#8220;Term C Loan&#8221; and, collectively with the Term A Loan and the Term B Loan, the &#8220;Term Loans&#8221;). Having achieved all required revenue-based milestones, the Company exercised its option to draw upon the additional funding available under the Credit Agreement, borrowing the principal amounts of $<ix:nonFraction unitRef="usd" contextRef="ice4776aac34540989938d21b8dfb4e97_I20220729" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNTQ5NzU1ODI2OTY5_c56e6a88-7075-4d59-8f90-0cd22ba3f4f6">25,000</ix:nonFraction> under the Term B Loan and $<ix:nonFraction unitRef="usd" contextRef="ia003b9df8396437497d66b989248c2b6_I20220729" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNTQ5NzU1ODI2OTg3_52d52b49-52b0-4a7c-b10a-08944b253267">50,000</ix:nonFraction> under the Term C Loan. Both the Term B Loan and the Term C Loan were funded on July 29, 2022 in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i709dd3e270264784bde603419255d61f_I20220729" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfMTA5OTUxMTYzODMzMg_9af24b6e-88f3-4289-8817-ef2d1c12ee99">75,000</ix:nonFraction>. The Term B Loan and the Term C Loan are subject to all the provisions under the Credit Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, the Company entered into an amendment to the Credit Agreement (i) to permit the Company to enter into the 2021 RPI Royalty Purchase Agreement, the OMERS Royalty Purchase Agreement, and the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="iba9f158fca46472eae6606dde4a5036f" continuedAt="i83e07d0720e746f59bca9f36cf16dfb4"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other definitive documentation related thereto and to perform its obligations thereunder; (ii) to require the Company to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that the Company did not draw the Term B Loan or the Term C Loan, as applicable, by the end of the applicable period available to draw the Term B Loan or the Term C Loan, subject to certain exceptions set forth in the Credit Agreement; and (iii) to require the Company to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that the Company either (x) terminated the commitments in respect of the Term B Loan or the Term C Loan, as applicable, on or prior to the end of the applicable period available to draw the Term B Loan or the Term C Loan, or (y) prepays or repays, or is required to prepay or repay, voluntarily or pursuant to mandatory prepayment obligations under the Credit Agreement (e.g., with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions), all of the then-outstanding Term Loans, in each case, subject to certain exceptions set forth in the Credit Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for quarterly interest-only payments until the maturity date, with the unpaid principal amount of the outstanding Term Loans due and payable on the maturity date. For each of the first eight full fiscal quarters following December 7, 2020, the Company has the option to make the applicable interest payment in-kind (a &#8220;PIK Interest Payment&#8221;) by capitalizing the entire amount of interest accrued during the applicable interest period with the unpaid original principal amount outstanding on the last day of such period. The Term Loans will bear interest at a rate equal to the three-month LIBOR rate, which shall be no less than <ix:nonFraction unitRef="number" contextRef="i7b8c0ef1641d490bad48d0ce9744d424_I20201207" decimals="4" name="bcrx:DebtInstrumentLiborFloor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfMzU4Ng_d208aa77-4972-4fff-85ed-94db18e9b3b6">1.75</ix:nonFraction>% and no more than <ix:nonFraction unitRef="number" contextRef="i7b8c0ef1641d490bad48d0ce9744d424_I20201207" decimals="3" name="bcrx:DebtInstrumentLiborCap" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfMzYwNg_c7f3a197-2971-4924-b8a2-ec23e6742970">3.50</ix:nonFraction>% (&#8220;LIBOR&#8221;), plus <ix:nonFraction unitRef="number" contextRef="i15ce1d8574044e7da22ce59b9f6dd167_D20201207-20201207" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfMzYyNQ_dcd54430-2db7-4afe-99da-ccd4cbb48dad">8.25</ix:nonFraction>%, or for each interest period in which a PIK Interest Payment is made, LIBOR plus <ix:nonFraction unitRef="number" contextRef="ia232f6672e22447fb6af60f22e2ceb87_D20201207-20201207" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfMzcwOQ_55ccfb3a-ac1a-439e-a5dc-391fc1116b90">10.25</ix:nonFraction>%.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-month LIBOR was 2.31% as of June 28, 2022, the LIBOR measurement date for the three-month interest period beginning July 1, 2022. Accordingly, this LIBOR rate plus <ix:nonFraction unitRef="number" contextRef="icf6c8a213e4c4e488e6eb643867a2197_D20220628-20220628" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfMTA5OTUxMTY0MTAyMw_98c2a7ba-150c-4851-94c6-b2fe4d0b0e16">10.25</ix:nonFraction>% was used to record interest expense for the three months ended September 30, 2022. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-month LIBOR was 3.67% as of September 28, 2022, the LIBOR measurement date for the three-month interest period beginning October 1, 2022.  As the LIBOR rate exceeds the LIBOR cap of 3.50%, the 3.50% cap plus <ix:nonFraction unitRef="number" contextRef="icde5f4a46a1c4f8c83cf48af673b7a45_D20220928-20220928" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfMzg4NA_66adb30d-759c-4989-9ead-19ec792c3abf">10.25</ix:nonFraction>% will be used to record interest expense for the three-month interest period beginning October 1, 2022. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions, the Company is required to make mandatory prepayments of the Term Loans with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events. The Company may make voluntary prepayments in whole or in part. Prepayments are subject to a premium equal to, (i) with respect to any voluntary prepayment and certain mandatory prepayments paid on or prior to the second anniversary of the applicable Term Loan borrowing date, the amount, if any, by which (a) the sum of (1) <ix:nonFraction unitRef="number" contextRef="i89ce560e3ccb4a498fdff95231d6e1c9_D20201207-20201207" decimals="2" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNDY5OQ_ed87ad3c-9a33-4962-81e6-68c670fef8c7">102.00</ix:nonFraction>% of the principal amount of the Term Loan being prepaid plus (2) the present value of all interest that would have accrued on the principal amount of the Term Loan being prepaid through and including the second anniversary of the date of the borrowing of such Term Loan, plus <ix:nonFraction unitRef="number" contextRef="i89ce560e3ccb4a498fdff95231d6e1c9_D20201207-20201207" decimals="3" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNDk3Nw_f38a091a-e6d7-4434-993d-07025a666934">0.50</ix:nonFraction>%, exceeds (b) the principal amount of the Term Loan being prepaid; (ii) with respect to any prepayment made between the second and third anniversaries of the applicable Term Loan borrowing date, <ix:nonFraction unitRef="number" contextRef="i74fcf15aaa914945ab7836b9ee0ad9e5_D20201207-20201207" decimals="2" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNTE3NA_009efdd5-9059-4a45-aaae-5185bc668fb1">2.00</ix:nonFraction>% of the principal amount of the Term Loan being prepaid; (iii) with respect to any prepayment made between the third and fourth anniversaries of the applicable Term Loan borrowing date, <ix:nonFraction unitRef="number" contextRef="iad2a1f48ddac433db045de7d1a2ebd84_D20201207-20201207" decimals="2" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNTM2Mg_0eb8b95f-961b-4403-b989-e611ab046357">1.00</ix:nonFraction>% of the principal amount of the Term Loan being prepaid; and (iv) with respect to any prepayment made after the fourth anniversary of the applicable Term Loan borrowing date, <ix:nonFraction unitRef="number" contextRef="id4ae9ab1e00c4d9bbb0a43e40f958d82_D20201207-20201207" decimals="-3" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNTUzOQ_ba47aa8f-715d-4c22-9a9d-8703f0d493e1">0.00</ix:nonFraction>% of the principal amount of the Term Loan being prepaid. Upon the prepayment or repayment, including at maturity, of all or any of the Term Loans, the Company is obligated to pay an exit fee in an amount equal to <ix:nonFraction unitRef="number" contextRef="i7b8c0ef1641d490bad48d0ce9744d424_I20201207" decimals="2" name="bcrx:DebtInstrumentExitFeePercentageOfPrincipal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNTc1NA_48906017-4232-431f-aca6-3ad58aba2eb7">2.00</ix:nonFraction>% of the principal amount of the Term Loans prepaid or repaid. In addition, each Term Loan is subject to a <ix:nonFraction unitRef="number" contextRef="i7b8c0ef1641d490bad48d0ce9744d424_I20201207" decimals="2" name="bcrx:DebtInstrumentCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNTg2Mg_80bbdc7c-27cd-4976-aacf-5ffd24ddc0a0">1.00</ix:nonFraction>% commitment fee at its respective borrowing date.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement also contains representations and warranties and affirmative and negative covenants customary for financings of this type, as well as customary events of default. Certain of the customary negative covenants limit the ability of the Company and certain of its subsidiaries to, among other things, grant liens, make investments, incur additional indebtedness, engage in mergers, acquisitions, and similar transactions, dispose of assets, license certain property, distribute dividends, make certain restricted payments, change the nature of the Company&#8217;s business, engage in transactions with affiliates and insiders, prepay other indebtedness, or engage in sale and leaseback transactions, subject to certain exceptions. Additionally, as of the last day of each fiscal quarter (a &#8220;Test Date&#8221;), beginning with the first Test Date occurring immediately after the Term C Loan is drawn, if applicable, the Company may not permit consolidated net revenues from ORLADEYO sales in the United States for the four-fiscal quarter period ending on such Test Date to be less than the specified amounts set forth in the Credit Agreement (collectively, the &#8220;Revenue Tests&#8221;). If the Company fails to satisfy the Revenue Tests as of any Test Date, it will have a one-time right (the &#8220;Cure Right&#8221;) to repay in full the entire </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="i83e07d0720e746f59bca9f36cf16dfb4"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount of the Term C Loan outstanding at such time together with all accrued and unpaid interest thereon plus the prepayment premium, exit fee, and any other fees or amounts payable under the Credit Agreement at such time. In addition, the Credit Agreement contains a minimum liquidity covenant requiring the Company to maintain at all times, as applicable, at least $<ix:nonFraction unitRef="usd" contextRef="i48c8f87e596a4a9797c757c4107dca8e_I20201207" decimals="-6" name="bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNzYxMA_74c4ec69-eb5e-445f-bd3a-cecaf9ef61e8">15,000</ix:nonFraction> of unrestricted cash and cash equivalents if only the Term A Loan has been drawn; at least $<ix:nonFraction unitRef="usd" contextRef="i029bc0b0132a43d3a133840d08bafae3_I20201207" decimals="-6" name="bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNzcwNA_0d9f0f5d-84d8-4e94-9af6-a52b1755b529">20,000</ix:nonFraction> of unrestricted cash and cash equivalents if the Term B Loan has been drawn but the Term C Loan has not been drawn; and at least $<ix:nonFraction unitRef="usd" contextRef="i81bdcb366fcb440dac7cccb46bc6c432_I20201207" decimals="-6" name="bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNzgzNg_3f9052d4-a3e8-4921-9843-2b129ed9fa9a">15,000</ix:nonFraction> (or, if the Cure Right has been exercised, $<ix:nonFraction unitRef="usd" contextRef="id1df07995b624c41ad1f4b2eb4c8b729_I20201207" decimals="-6" name="bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNzg4Mg_4c23d23f-f629-4dae-b128-c63c2d778eeb">20,000</ix:nonFraction>) of unrestricted cash and cash equivalents if the Term C Loan has been drawn, subject to certain exceptions.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A failure to comply with the covenants in the Credit Agreement could permit the lenders under the Credit Agreement to declare the outstanding principal as well as accrued interest and fees, to be immediately due and payable.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's obligations under the Credit Agreement are secured by a security interest in, subject to certain exceptions, substantially all of the Company's assets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had total borrowings of $<ix:nonFraction unitRef="usd" contextRef="i577b5813966249238ff1a37dcadb61ec_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfODQyNQ_10a3971f-22d7-4ce2-baa3-7dfd1cfddfdb">200,000</ix:nonFraction> under the Credit Agreement. Quarterly interest payments under the Credit Agreement for the nine months ended September 30, 2022 and 2021 totaled $<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNjU5NzA2OTc3NzUzMw_b9c1ffc8-0223-48f8-936b-90489dec7dfc">15,311</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="INF" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNjU5NzA2OTc3NzU0OQ_8ed1af3e-d926-4f83-b48a-9ad7d1099e4c">11,815</ix:nonFraction>, respectively, and have been designated and accounted for as PIK Interest Payments and added to the outstanding principal balance of the borrowing. As of September&#160;30, 2022, borrowings, including the PIK Interest Payments, totaled $<ix:nonFraction unitRef="usd" contextRef="i577b5813966249238ff1a37dcadb61ec_I20220930" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfODc2Mg_19a809ec-636d-4eb6-b041-7544e5fbea33">232,376</ix:nonFraction>. The principal balance of the borrowings, including PIK amounts, is accruing interest at an effective rate of <ix:nonFraction unitRef="number" contextRef="i577b5813966249238ff1a37dcadb61ec_I20220930" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfODg2NA_75027c4f-145a-46fb-9af2-91d22b390496">12.68</ix:nonFraction>%. The fair value of the debt approximates its carrying value based on prevailing interest rates as of the balance sheet date and is considered as Level 2 in the fair value hierarchy.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, the Company incurred deferred debt fees and issuance costs associated with the Term B and Term C Loans of $<ix:nonFraction unitRef="usd" contextRef="iad15e5ebbe854d989fa28f085ec20706_I20220930" decimals="INF" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNjU5NzA2OTc3NzY4OQ_736279b0-a89d-4cc6-a1e0-7fbac0f33a16">3,428</ix:nonFraction>. As of September&#160;30, 2022, deferred debt fees and issuance costs associated with all Term Loans under the Credit Agreement totaled $<ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNjU5NzA2OTc3NzY4Mw_4e26ca52-1ebd-4e0c-830f-b681b6d91d09">12,509</ix:nonFraction> and are being amortized as interest expense on an effective interest rate method over the remaining term of the Term Loans. When utilizing the effective interest method, in periods in which PIK interest is designated and those amounts are added to the outstanding principal balance of the borrowing, the amortization of the deferred debt fees and issuance costs is accretive. Deferred financing amortization of $(<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNjU5NzA2OTc3Nzc2Nw_fa109f1c-b48f-4af9-b9b9-77002e6cc0dc">597</ix:nonFraction>) and $(<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNjU5NzA2OTc3Nzc4Mw_bf4c3fc2-8c13-478e-9472-99ceab128988">369</ix:nonFraction>), was recognized for the nine months ended September 30, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains two provisions that, if deemed probable, would create the recognition of an embedded feature; however, at this time, the Company does not believe either provision is probable.</span></div></ix:continuation><div id="ia4cd069c56504e93a883c91651012280_58"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfMTAxMw_f8406d3c-97cd-4ab1-bfae-3327bd282207" continuedAt="ieee29ca6242c465182e0f848601a3965" escape="true">Lease Obligations </ix:nonNumeric></span></div><ix:continuation id="ieee29ca6242c465182e0f848601a3965" continuedAt="i76adc29e6f8d46cc9fb52cb837473c67"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of September&#160;30, 2022. Renewal options for the Company's leases range from <ix:nonNumeric contextRef="i7c80142b202447dcb8ead43698b1102f_I20220930" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfMjU4_5d374a27-ad8c-4ba9-8ac5-511422abde18">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i52f9872ea30d41b1879aa0576f67e92d_I20220930" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfMjY0_9b4c49dc-79bb-4c95-aaf4-6cca2ba22e85">5</ix:nonNumeric> years in length and begin from 2023 through 2026. </span></div><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfMTAxNA_ebe1f6db-9d11-4dff-a5c4-ce8f46ead2f4" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate lease expense under operating leases was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.609%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="bcrx:AggregateLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmRlZmE2NjMyMmNjYTRkNGRiZWYyZmRlYzgwNzIzNDk4L3RhYmxlcmFuZ2U6ZGVmYTY2MzIyY2NhNGQ0ZGJlZjJmZGVjODA3MjM0OThfMi0yLTEtMS05MzYw_ee94ae31-ae6e-4c71-b4a1-1f213d150eb8">634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="bcrx:AggregateLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmRlZmE2NjMyMmNjYTRkNGRiZWYyZmRlYzgwNzIzNDk4L3RhYmxlcmFuZ2U6ZGVmYTY2MzIyY2NhNGQ0ZGJlZjJmZGVjODA3MjM0OThfMi00LTEtMS05MzYw_11492b09-3e0c-4cae-aced-7ac88951fabb">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="bcrx:AggregateLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmRlZmE2NjMyMmNjYTRkNGRiZWYyZmRlYzgwNzIzNDk4L3RhYmxlcmFuZ2U6ZGVmYTY2MzIyY2NhNGQ0ZGJlZjJmZGVjODA3MjM0OThfMi02LTEtMS05MzYw_a4b4d4fd-2f0e-4352-a405-3640e942863a">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="bcrx:AggregateLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmRlZmE2NjMyMmNjYTRkNGRiZWYyZmRlYzgwNzIzNDk4L3RhYmxlcmFuZ2U6ZGVmYTY2MzIyY2NhNGQ0ZGJlZjJmZGVjODA3MjM0OThfMi04LTEtMS05MzYw_4975b023-77e0-47dc-8492-673ab253caf3">1,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="i76adc29e6f8d46cc9fb52cb837473c67"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="bcrx:OtherSupplementalInformationRelatedToLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfMTAxNQ_766b061b-141c-402e-b613-5682b5ab0288" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental information related to leases was as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjhhYTQ2MDA5ZDA5NDQxZDVhNDNkYTNhY2YwYzA3ZTEwL3RhYmxlcmFuZ2U6OGFhNDYwMDlkMDk0NDFkNWE0M2RhM2FjZjBjMDdlMTBfMS0yLTEtMS05MzYw_0bacf433-244c-4550-b3d0-9df5b8d5ebfc">8.4</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjhhYTQ2MDA5ZDA5NDQxZDVhNDNkYTNhY2YwYzA3ZTEwL3RhYmxlcmFuZ2U6OGFhNDYwMDlkMDk0NDFkNWE0M2RhM2FjZjBjMDdlMTBfMS00LTEtMS05MzYw_3d9f1cef-35cc-4060-a406-f719d6b4ffab">9.2</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjhhYTQ2MDA5ZDA5NDQxZDVhNDNkYTNhY2YwYzA3ZTEwL3RhYmxlcmFuZ2U6OGFhNDYwMDlkMDk0NDFkNWE0M2RhM2FjZjBjMDdlMTBfMi0yLTEtMS05MzYw_af379a57-9acd-4c13-9b92-ca38fdd94599">10.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjhhYTQ2MDA5ZDA5NDQxZDVhNDNkYTNhY2YwYzA3ZTEwL3RhYmxlcmFuZ2U6OGFhNDYwMDlkMDk0NDFkNWE0M2RhM2FjZjBjMDdlMTBfMi00LTEtMS05MzYw_0b3f5162-6a8a-48c1-bd07-e6dfc2185e04">11.2</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s leases qualify as operating leases. <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfMTAxNg_c7b54f13-48e2-49d4-86a2-6605fe6a75a8" continuedAt="i571beb96c8b748ec94186043486ba85e" escape="true">The following table summarizes the presentation in the Consolidated Balance Sheets of the Company&#8217;s operating leases: </ix:nonNumeric></span></div><div style="margin-top:10pt"><ix:continuation id="i571beb96c8b748ec94186043486ba85e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfMi0xLTEtMS05MzYw_842fa9e2-603a-4d76-932f-26e9d70fccbc">Other Assets</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfMi0zLTEtMS05MzYw_aa91e255-f3b8-45fa-b9d3-56339ed4ab0d">6,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfMi01LTEtMS05MzYw_d00d9e8f-a3a3-44f5-afc2-37250b4e499b">6,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lease financing obligation &#8211; current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfNC0zLTEtMS05MzYw_2dd7f8e7-7a60-4473-b0c0-ed5e11c6d7c9">2,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfNC01LTEtMS05MzYw_9099adbf-5f4c-4d2f-89c1-d65db4e41ef8">1,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lease financing obligation &#8211; long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfNS0zLTEtMS05MzYw_f6b80e36-b0da-474f-b56f-4953415db978">5,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfNS01LTEtMS05MzYw_9320d3bf-c055-4361-a108-8640ec1d31c4">5,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfNi0zLTEtMS05MzYw_fd79a8f1-ff4a-482f-aade-984ad298d7e6">8,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfNi01LTEtMS05MzYw_496710aa-c625-451f-9511-5b2dd7a07078">7,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets are recorded net of accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="bcrx:OperatingLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfNzA1_5c238b20-4e72-4983-8966-d95414e3b318">3,874</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231" decimals="-3" name="bcrx:OperatingLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfNzEy_cecd6556-8c08-401a-bfa5-07d51977bed1">2,626</ix:nonFraction> as of September&#160;30, 2022 and December&#160;31, 2021, respectively. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfODIy_34f0f020-ab42-4fc1-8d9e-49d2b247030e">615</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfODI5_614587c2-29c4-4a74-b8a3-baec386b0628">1,796</ix:nonFraction> for the three and nine months ended September&#160;30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfODc4_dba9333f-3c06-4183-84ef-cc9768c06e7f">306</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfODg1_de99e660-fbf5-43cc-88e2-ee8a3ff8e70b">1,125</ix:nonFraction> for the three and nine months ended September&#160;30, 2021, respectively.</span></div><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfMTAxNw_63f53e61-3ee7-4539-b4f6-e3840b9806bc" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of September&#160;30, 2022, are as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfMC0xLTEtMS05MzYw_d09697e7-abd3-419b-a9aa-8f4f40bcf481">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfMS0xLTEtMS05MzYw_cda5c3b6-4b44-4db3-a0f6-ab43db9f5d9d">2,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfMi0xLTEtMS05MzYw_79c6db0d-12df-4dbf-98b4-156793a20231">1,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfMy0xLTEtMS05MzYw_1a6eb2fa-d52e-47f3-be72-b74e4fe7209b">1,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfNC0xLTEtMS05MzYw_b0f962b6-8fa2-43e5-afcc-99bbce47bc46">651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="bcrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfNS0xLTEtMS05MzYw_e2635265-6fe2-42c1-9e3a-135bdf488422">6,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfNi0xLTEtMS05MzYw_a2bb0c73-81eb-4287-a4b6-a733252b804e">13,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfNy0xLTEtMS05MzYw_1ee64076-bc17-43fd-baab-f175f4363834">5,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfOC0xLTEtMS05MzYw_0413c2f1-eaf2-4e34-8a4f-59c532f189fc">8,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia4cd069c56504e93a883c91651012280_61"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTY3NQ_8b0bd401-3047-4ea4-9b4c-23268a557409" continuedAt="ibd7d97e9b7b4439ca258ebf3ac662b1d" escape="true">Stockholders</ix:nonNumeric></span><ix:continuation id="ibd7d97e9b7b4439ca258ebf3ac662b1d" continuedAt="i3df33699476c441a90135b8ebe5570ea"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Equity</span></ix:continuation></div><ix:continuation id="i3df33699476c441a90135b8ebe5570ea" continuedAt="ie118ce770a154f4d9d7e3b617b518514"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of Common Stock</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;24, 2020, the Company filed a shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective on May 14, 2020 and allows the Company to sell up to $<ix:nonFraction unitRef="usd" contextRef="ief8dcbde5b0e41c3bb5a8ebe4a804426_I20200424" decimals="-6" name="bcrx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMjQz_3dbc7bc2-4be8-4618-8f51-9db1f1fdd368">500,000</ix:nonFraction> in securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2021, the Company filed an automatic shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective automatically upon filing and allows the Company to sell an indeterminate number of securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, concurrent with the Company entering into the 2021 RPI Royalty Purchase Agreement, the Company and RPI entered into the Common Stock Purchase Agreement, pursuant to which the Company issued <ix:nonFraction unitRef="shares" contextRef="i8832490c13ad4270a151ea2cb8adc636_D20211119-20211119" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTEwMw_136f8507-faac-4ac0-8505-0dd44a12ca4e">3,846,154</ix:nonFraction> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie118ce770a154f4d9d7e3b617b518514">shares of the Company&#8217;s common stock to RPI for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i8832490c13ad4270a151ea2cb8adc636_D20211119-20211119" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTE4NQ_63b1eb1e-81cc-43eb-9b8c-be8f0dcf0617">50,000</ix:nonFraction>, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i85cc5e9604864268a804d5d399fb8420_I20211119" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTIwMw_c564b3a2-e696-4a55-b2a2-56735583972a">13.00</ix:nonFraction> per share, calculated based on the 20-day volume weighted average price. The $<ix:nonFraction unitRef="usdPerShare" contextRef="ic0f22034638c4665942e299d6fb219aa_I20211117" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTI4Mw_e637fecc-a957-4669-9328-4fb5a1caad20">13.00</ix:nonFraction> per share price represents a premium of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic0f22034638c4665942e299d6fb219aa_I20211117" decimals="2" name="bcrx:SharesIssuedPricePerSharePremium" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTMyNg_f9cf96ec-2d50-421e-95c7-1fed23bc7972">1.11</ix:nonFraction> over the closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic0f22034638c4665942e299d6fb219aa_I20211117" decimals="2" name="bcrx:SharesIssuedPricePerShareClosingPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTM1NQ_c63bdc64-7c8f-4c0a-9479-f48701c6ffb1">11.89</ix:nonFraction> of the Company&#8217;s common stock on November&#160;17, 2021, the last trading day prior to the execution of the Common Stock Purchase Agreement. The premium of $<ix:nonFraction unitRef="usd" contextRef="ic0f22034638c4665942e299d6fb219aa_I20211117" decimals="-3" name="bcrx:SharesIssuedCommonStockPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTQ5NA_d4cdcec3-6a98-4949-88ca-0bdda088a9d1">4,269</ix:nonFraction> paid by RPI on the purchase of the Company&#8217;s common stock has been deferred and is being amortized as a component of interest expense of the 2021 RPI royalty financing obligation.</ix:continuation></span></div><div id="ia4cd069c56504e93a883c91651012280_64"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODM1NA_6cb45329-65ba-4b51-a817-3846f95c6451" continuedAt="id18ccb2bea1e473db106db6ab452b66f" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="id18ccb2bea1e473db106db6ab452b66f" continuedAt="iaee953eb54f14b2e8f840d19ab2def31"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had <ix:nonFraction unitRef="plan" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="INF" name="bcrx:ShareBasedPaymentArrangementNumberOfPlans" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODM2MA_eef6d924-3165-4fee-a02f-f98dceb2dd1e">three</ix:nonFraction> stock-based employee compensation plans: the Amended and Restated Stock Incentive Plan (&#8220;Incentive Plan&#8221;), the Amended and Restated Inducement Equity Incentive Plan (&#8220;Inducement Plan&#8221;) and the Amended and Restated Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The Incentive Plan was most recently amended and restated on April 18, 2022 and approved by the Company&#8217;s stockholders on June 7, 2022. The Inducement Plan was most recently amended and restated by the Board of Directors on August 26, 2022. The ESPP was most recently amended and restated on April 1, 2021 and approved by the Company&#8217;s stockholders on May 25, 2021.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzI1_7c1c98ee-0be0-48cf-8017-035de380a1bd">29,421</ix:nonFraction> ($<ix:nonFraction unitRef="usd" contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzI5_cd037ac5-9a9b-49b5-bf64-5400e62b7898">23,687</ix:nonFraction> of expense related to the Incentive Plan, $<ix:nonFraction unitRef="usd" contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzc0_b754022f-2665-4fd7-8ec2-d75c6f6d3e0a">4,604</ix:nonFraction> of expense related to the Inducement Plan, and $<ix:nonFraction unitRef="usd" contextRef="ibd71d21d51204504b4c1150f43b3bc59_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODI0_c855a088-8f68-4c7a-b76d-400af1741b2e">1,130</ix:nonFraction> of expense related to the ESPP) was recognized during the nine months ended September 30, 2022, while $<ix:nonFraction unitRef="usd" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODk1_807f91e2-b268-419e-8e5e-7952e422a08b">26,140</ix:nonFraction> ($<ix:nonFraction unitRef="usd" contextRef="id57db78843ad455581cbbe07f42c6f48_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODk5_a614028a-60a2-4f91-9850-61fcc3bf3644">19,973</ix:nonFraction> of expense related to the Incentive Plan, $<ix:nonFraction unitRef="usd" contextRef="i3c2fb0c425f946d798549cf02852e9ea_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfOTQ0_5160387a-6121-4459-9da4-49d1abb96aa2">5,025</ix:nonFraction> of expense related to the Inducement Plan and $<ix:nonFraction unitRef="usd" contextRef="i861f5991bef64ba4ae244c970bd11b45_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfOTkz_bb842c87-929d-483c-ba71-4a687cef0dfe">1,142</ix:nonFraction> of expense related to the ESPP) was recognized during the nine months ended September 30, 2021.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was approximately $<ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMTA4Mg_6c1e257a-69fe-47c6-84d3-fe34beacb147">100,171</ix:nonFraction> of total unrecognized compensation expense related to non-vested stock option and restricted stock unit awards granted by the Company as of September&#160;30, 2022. As of September&#160;30, 2022, the Company expected to recognize that expense as follows: $<ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMTI5OA_419d5bcf-9293-4e1a-8cc5-22b262051815">10,707</ix:nonFraction> during the remainder of 2022, $<ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMTMyOQ_d57434c4-90d8-4273-bc69-75d08cdb2a61">35,987</ix:nonFraction> in 2023, $<ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMTMzOQ_7a9ae09c-e2ba-4465-bab5-dfa00f771347">31,537</ix:nonFraction> in 2024, $<ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMTM0OQ_40099e81-0e03-4703-814e-000f35650fbc">19,524</ix:nonFraction> in 2025 and $<ix:nonFraction unitRef="usd" contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930" decimals="-3" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMTM2Mg_0caa463e-15c8-4223-ade3-62edba8e760d">2,416</ix:nonFraction> in 2026. In addition, the Company has outstanding performance-based stock options and restricted stock unit awards for which no compensation expense is recognized until &#8220;performance&#8221; has occurred and the award vests.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plan</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants stock option awards, restricted stock and restricted stock units to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#8217;s common stock at the date of grant. Commencing March 1, 2011, stock option awards and restricted stock units granted to employees generally vest <ix:nonFraction unitRef="number" contextRef="i4b5364d1d1904b7bb97eaee357c6a65b_D20220101-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjAyNA_b8699760-646d-484e-9013-2c270831e25a">25</ix:nonFraction>% each year until fully vested after <ix:nonNumeric contextRef="i4b5364d1d1904b7bb97eaee357c6a65b_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjA2Mg_740ff352-a90b-4700-b977-ad9b65f7ab50">four years</ix:nonNumeric>.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2014, the Company issued <ix:nonFraction unitRef="shares" contextRef="i3bf5349aab0e46d5b3e8bc79f32bc420_D20141201-20141231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjA5Mg_219146ad-9958-49e6-a1d2-fedcb8575dbd">1,250</ix:nonFraction> performance-based stock options. These awards vest upon successful completion of specific development milestones. As of September&#160;30, 2022, <ix:nonFraction unitRef="number" contextRef="i3bf5349aab0e46d5b3e8bc79f32bc420_D20141201-20141231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjIxOQ_0cea133b-32b0-4f59-b6d1-00de0b49fa6b">85</ix:nonFraction>% of these grants have vested.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="i462f026921bb4afe83030f8fadf9da13_D20220101-20220131" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjI3Nw_afda35d7-ed01-4a6c-920e-4dbd6ac49f22">221</ix:nonFraction> performance-based restricted stock unit awards. Contingent upon successful achievement of specific commercial or operational objectives in 2022, the awards become eligible for vesting at <ix:nonFraction unitRef="number" contextRef="ib155b4c963014e029dd2f85fefc4a14e_D20220101-20220131" decimals="1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjQ2NQ_d7398cd2-de16-423a-833b-458cf0cf8ff5">50</ix:nonFraction>% on the first anniversary of the grant date and <ix:nonFraction unitRef="number" contextRef="i67e8248b60f64ce28584296c7129913e_D20220101-20220131" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjUxNQ_5736b735-a9c0-4d31-a7e7-d7bfcf60f1f3">25</ix:nonFraction>% on each of the second and third anniversaries of the grant date, until fully vested after <ix:nonNumeric contextRef="icacb2b425bc14f50b771626f8aa5b582_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjYwOA_d04827ff-378d-4422-8e9f-86c48c371eb2">three years</ix:nonNumeric>.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards and restricted stock unit awards granted to non-employee directors of the Company generally vest over <ix:nonNumeric contextRef="ia6112bb62bc84e76a366906fa6013306_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjczNA_a0e710b5-724d-4ac1-b5d2-339fc39383c4">one year</ix:nonNumeric>. Stock option awards granted to new non-employee directors when they first join the Company&#8217;s Board of Directors generally vest, subject to the terms of the Incentive Plan, in 36 equal monthly installments over a <ix:nonNumeric contextRef="i4e78b10dfe9d40829b789acc025a272e_D20220101-20220131" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODM1NQ_476e68a3-af8e-44d6-b3cc-3dddd27afbeb">three-year</ix:nonNumeric> period measured from the grant date. All stock option awards have contractual terms of <ix:nonNumeric contextRef="i597f21b52a2341598aca37ab541e979b_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMzA0NQ_01850a6d-381e-4c6a-8992-84551e3a9f4f">10</ix:nonNumeric> years. Restricted stock unit awards granted to new non-employee directors when they first join the Company's Board of Directors generally vest, subject to the terms of the Incentive Plan, in three equal annual installments beginning on the first anniversary of the grant date. The vesting and exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="iaee953eb54f14b2e8f840d19ab2def31" continuedAt="idf0a11dde93849bdab5c60cdddc26baa"><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODM2Mw_dc0866e6-c240-4d58-8279-7ea01759682e" continuedAt="i7bfe5783b830403fbd0842d59f201e0c" escape="true"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related activity under the Incentive Plan is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Awards<br/>Available</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33b8d296b67f42aa822d875c50677a2a_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfMS0xLTEtMS05MzYw_88aea31e-e64f-4356-baae-a316461adf75">3,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33b8d296b67f42aa822d875c50677a2a_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfMS0zLTEtMS05MzYw_8fab031b-ce59-4760-92b4-a447b6d97b89">28,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33b8d296b67f42aa822d875c50677a2a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfMS01LTEtMS05MzYw_5437a1ed-c6a8-4ec5-8ac7-d050f4729c56">7.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930" decimals="-3" name="bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfMi0xLTEtMS05MzYw_2c83f64b-b859-47ec-a137-9d5a8136bbb2">8,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfMy0xLTEtMS05MzYw_c6a80e74-1fae-42ee-a2d7-36d566c093c7">681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNC0xLTEtMS05MzYw_41172462-c5b9-47ac-a409-d68ad8d74dd5">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930" decimals="-3" name="bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNS0xLTEtMS05MzYw_05d6ed80-c9c0-403b-b41d-3542fe8541b3">813</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNS0zLTEtMS05MzYw_c6945b9d-8cef-4c8b-9f8c-f71a2e76f51a">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNS01LTEtMS05MzYw_4e105e44-be8c-493d-9fc9-17523f913d28">11.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNi0zLTEtMS05MzYw_684b7767-dee7-4fb4-8106-07dc0da8afc5">1,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNi01LTEtMS05MzYw_21f34941-3c3f-4b72-99aa-47ccb66c8798">5.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930" decimals="-3" name="bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNy0xLTEtMS05MzYw_baf0756a-de91-4a70-90c0-2f2a0be52420">787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNy0zLTEtMS05MzYw_4c88788f-b6f4-4df2-b4ff-91e961a2223c">787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNy01LTEtMS05MzYw_6a43b999-0a0f-43ea-b2d6-481b308881eb">10.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f2ae249b8c14d8c879f0c3632532318_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfOC0xLTEtMS05MzYw_e182c22e-d570-4640-8afe-536b82e07d46">11,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f2ae249b8c14d8c879f0c3632532318_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfOC0zLTEtMS05MzYw_802dfac5-6b4b-41d0-8a98-626f2752be79">27,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f2ae249b8c14d8c879f0c3632532318_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfOC01LTEtMS05MzYw_6fce1ad9-5160-4ca5-91d1-1fd2e860ba3b">8.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For stock option awards granted under the Incentive Plan during the first nine months of 2022 and 2021, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table following the next subsection. The weighted average grant date fair value of these awards granted during the first nine months of 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i5250a5d435e4416ea19390c093e8d969_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNDAwMw_3ed6bed0-c134-4d3a-a9f9-8ff98db3ff33">7.78</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i91216e37813c427d9f33a23eb389ed62_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNDAxMA_f5637b16-8ed5-4373-a90d-2c0d50e0792b">8.11</ix:nonFraction>, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. For restricted stock units granted under the Incentive Plan, the fair value of the awards was determined based on the market value of the Company&#8217;s shares on the grant date. The weighted average grant date fair value of these awards granted during the first nine months of 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i41d42bfc79fc4caf8d758c368878895a_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNDQ1Ng_32d114c7-e715-41f3-a301-a6c9b1853c83">13.18</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i9c9a5b90264d44ee9f8599fe14b89e37_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNDQ2Mw_8347050a-849e-47df-8d8b-162ae01417b8">10.17</ix:nonFraction>, respectively. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement Equity Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the ability to grant stock option and restricted stock unit awards to newly-hired employees as inducements material to each employee entering employment with the Company. Awards granted to newly hired employees generally vest <ix:nonFraction unitRef="number" contextRef="if2932078af7f45c0bfcbbbc172f1e3f7_D20220101-20220930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNDkwNw_3ac1aa98-da94-405c-b2ae-25144d94bb4f">25</ix:nonFraction>% each year until fully vested after <ix:nonNumeric contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNDk0NQ_5ec830bc-a79a-449a-b100-70e2c0358bae">four years</ix:nonNumeric> and are subject to the terms and conditions of the Inducement Plan. Each stock option has a term of <ix:nonNumeric contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNTA0OA_bccb0e83-5f6b-48d4-94a4-dfef9426a457">10</ix:nonNumeric> years. The vesting and exercise provisions of all awards granted under the Inducement Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Inducement Plan.</span></div><ix:continuation id="i7bfe5783b830403fbd0842d59f201e0c"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related activity under the Inducement Plan is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Awards<br/>Available</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e4a49026de84920a3819232a6a19cd9_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfMS0xLTEtMS05MzYw_13a8cda9-0e08-4581-b2b4-71656b11e58a">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e4a49026de84920a3819232a6a19cd9_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfMS0zLTEtMS05MzYw_5d4b60ba-839a-4c2c-bf5a-489ca84c55e1">4,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e4a49026de84920a3819232a6a19cd9_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfMS01LTEtMS05MzYw_6a16b79a-a627-414b-be9c-43dbc464e89a">6.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930" decimals="-3" name="bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfMi0xLTEtMS0xMDY0Ng_0f6237f7-c533-429a-bec0-3f33ac510fb0">1,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfMi0xLTEtMS05MzYw_6d2f0823-412c-4dd9-bc8e-27613a6de8e8">424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfMy0xLTEtMS05MzYw_2ca06759-bb91-40eb-8546-cc0c01a99721">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930" decimals="-3" name="bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNC0xLTEtMS05MzYw_5c958a4c-f52a-444f-9faf-47c660aabb58">1,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNC0zLTEtMS05MzYw_45690188-55ec-439a-a49a-277b3041a7e2">1,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNC01LTEtMS05MzYw_8ca43823-40fc-41d7-8342-f091cc6749ca">13.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNS0zLTEtMS05MzYw_2785fca9-515e-43af-a677-942bdfacddbc">196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNS01LTEtMS05MzYw_e0bdf765-4bba-4193-a606-50325d1020a6">3.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930" decimals="-3" name="bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNi0xLTEtMS05MzYw_5fd4eefd-6457-43f1-b94f-c0618083453c">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNi0zLTEtMS05MzYw_ee1a9c3b-f4fa-4ea0-b36f-388e4d96c922">323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNi01LTEtMS05MzYw_f1cb928e-4a7a-483b-b980-a2a615a8b1ce">7.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d8b3a042362474cbb230d0362f4776c_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNy0xLTEtMS05MzYw_e534f182-e1ac-404d-bd9e-1541b3dd521d">1,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d8b3a042362474cbb230d0362f4776c_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNy0zLTEtMS05MzYw_1094bce4-da60-4baa-b296-5dc5c11cd0bc">5,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d8b3a042362474cbb230d0362f4776c_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNy01LTEtMS05MzYw_5cd75049-3c6e-4d47-8d5a-878491c99b56">8.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For stock option awards granted under the Inducement Plan during the first nine months of 2022 and 2021, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during the first nine months of 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNTcxNQ_a6098c9f-fd2d-4254-b2de-b03ad7b0ceba">9.72</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i3c2fb0c425f946d798549cf02852e9ea_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNTcyMg_0993ac49-e91c-456f-bbee-48afe32e67c8">9.74</ix:nonFraction>, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. For restricted stock units granted under the Inducement Plan, the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="idf0a11dde93849bdab5c60cdddc26baa"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair value of the awards was determined based on the market value of the Company&#8217;s shares on the grant date. The weighted average grant date fair value of these awards granted during the first nine months of 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ibdd2f542ee4f472fbd033582bf493f66_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNjE2MQ_3e81a2f4-fff7-435b-ab5d-ecdc7bc8b1de">13.38</ix:nonFraction>. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method. No restricted stock unit awards were granted under the Inducement Plan during the first nine months of 2021.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the key assumptions used by the Company to value the stock option awards granted under all plans during the first nine months of 2022 and 2021, respectively. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#8217;s publicly traded common stock. The Company has assumed <ix:nonFraction unitRef="number" contextRef="ie6d5329452f640458e577180ba9077a1_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzA3Ng_d0312958-9626-4fa6-be90-4ae97e342815">no</ix:nonFraction> expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining term equal to the expected term.</span></div><ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODM1Nw_878ab84d-86e1-4ae7-8621-0bfc4575a01e" escape="true"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Assumptions for Stock Option Awards Granted to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Directors under the Plans</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:71.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected Life in Years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1c0bfd7955ac4b51957fb2e28260133d_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfMS0xLTEtMS05MzYw_db4c991c-4b80-46db-b22b-2d89e2cbe7cc">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b8f1d28ff564258a3694150b17ecfbc_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfMS0zLTEtMS05MzYw_25861126-5bd6-4252-b97a-5dcb31cbd616">5.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c0bfd7955ac4b51957fb2e28260133d_D20220101-20220930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfMi0xLTEtMS05MzYw_4ff3aa2b-9f32-41ae-862a-669935358a7e">84.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b8f1d28ff564258a3694150b17ecfbc_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfMi0zLTEtMS05MzYw_7b95ac31-3295-4501-bb12-26857aeb8371">84.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected Dividend Yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c0bfd7955ac4b51957fb2e28260133d_D20220101-20220930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfMy0xLTEtMS05MzYw_28f5cb1b-9543-4ca6-a84b-bed5d0343718">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b8f1d28ff564258a3694150b17ecfbc_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfMy0zLTEtMS05MzYw_26a4f733-d668-4a36-b427-7ee97a1f3cdc">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-Free Interest Rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c0bfd7955ac4b51957fb2e28260133d_D20220101-20220930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfNC0xLTEtMS05MzYw_1de0b9ad-1490-44ae-b849-6f0141424b91">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b8f1d28ff564258a3694150b17ecfbc_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfNC0zLTEtMS05MzYw_bca9be5c-a6ab-4287-9c70-bdaa903275c7">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved a total of <ix:nonFraction unitRef="shares" contextRef="i612bfa266c9d4fdaabd216b7743222f3_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzU1NA_50b5e948-0f29-491c-85a5-909a7355416c">7,975</ix:nonFraction> shares of common stock to be purchased under the ESPP, of which <ix:nonFraction unitRef="shares" contextRef="i612bfa266c9d4fdaabd216b7743222f3_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzYyMQ_52981341-daa7-4065-9322-9bf99e1bd769">5,792</ix:nonFraction> shares remain available for purchase as of September&#160;30, 2022. Eligible employees may authorize up to <ix:nonFraction unitRef="number" contextRef="ibd71d21d51204504b4c1150f43b3bc59_D20220101-20220930" decimals="2" name="bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzcxMA_c2a25547-9d85-4f7c-bef4-7c826753b2aa">15</ix:nonFraction>% of their salary to purchase common stock at the lower of <ix:nonFraction unitRef="number" contextRef="ibd71d21d51204504b4c1150f43b3bc59_D20220101-20220930" decimals="2" name="bcrx:PercentageOfCommonStockSharesBeginning" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzc3MA_91373f76-f165-4f24-b1df-1e1942b6507e">85</ix:nonFraction>% of the beginning or <ix:nonFraction unitRef="number" contextRef="ibd71d21d51204504b4c1150f43b3bc59_D20220101-20220930" decimals="2" name="bcrx:PercentageOfCommonStockSharesEnding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzc5Mw_375087b7-f844-454b-8d2f-73560d8cf587">85</ix:nonFraction>% of the ending price during six-month purchase intervals. No more than <ix:nonFraction unitRef="shares" contextRef="ibd71d21d51204504b4c1150f43b3bc59_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzg2Ng_3ee5a6dd-0d1a-4bfa-b0f4-12588a88a049">3</ix:nonFraction> shares may be purchased by any one employee at the six-month purchase dates, and no employee may purchase stock having a fair market value at the commencement date of $<ix:nonFraction unitRef="usd" contextRef="i612bfa266c9d4fdaabd216b7743222f3_I20220930" decimals="-3" name="bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODAzNg_7b552c0e-9866-455a-aec5-1c66a44b1ae1">25</ix:nonFraction> or more in any one calendar year. During the nine months ended September&#160;30, 2022, and 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODEzMg_d63dcd81-6540-49dc-9316-e573ddc254d9">260</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODEzOQ_1434f865-4a5a-4189-86bf-c104f751dde7">316</ix:nonFraction> shares under the ESPP, respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#8220;look-back&#8221; option were determined using a Black-Scholes option pricing model.</span></div></ix:continuation><div id="ia4cd069c56504e93a883c91651012280_67"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfOTE3Mw_1d8f72ee-4c26-4982-bf5c-b7517f1fbf17" continuedAt="ibe4286d2c589460886d62be8f49ecc6c" escape="true">Collaborative and Other Relationships</ix:nonNumeric></span></div><ix:continuation id="ibe4286d2c589460886d62be8f49ecc6c" continuedAt="i46b25530b41e4292ac83c330ce8181eb"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">National Institute of Allergy and Infectious Diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2013, NIAID/HHS contracted with the Company for the development of galidesivir as a treatment for Marburg virus disease and subsequently, Yellow Fever and Ebola virus disease. On September&#160;15, 2021, the Company entered into an amendment to pay for certain additional costs, including additional manufacturing development costs and overhead, and to change the total value of the contract, as amended, to $<ix:nonFraction unitRef="usd" contextRef="i6962c7b3c532429d9dc533d16085a1be_D20210915-20210915" decimals="-3" name="bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNDk2_f9ed595f-0775-4355-930a-f360431aae95">47,315</ix:nonFraction> from $<ix:nonFraction unitRef="usd" contextRef="i7e86c77b3f93473aba60a62ad6ac9c1a_D20130930-20130930" decimals="-3" name="bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNTA0_d2ebc1e7-6f05-414b-a04c-d658aab3b3c1">45,931</ix:nonFraction>. This is the commencement of closing out the contract. All options under the contract have been awarded.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, NIAID/HHS awarded the Company a contract, with potential aggregate funding of up to $<ix:nonFraction unitRef="usd" contextRef="i9fe0f9acd7e14572953ee3262d1924ec_D20200801-20200831" decimals="-3" name="bcrx:CollaborativeAgreementContractCovenantMaximumAmountOfFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNzAz_fab424e1-b135-4cca-a263-698124aa0e30">43,908</ix:nonFraction> if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir. NIAID/HHS made an initial award of $<ix:nonFraction unitRef="usd" contextRef="i9fe0f9acd7e14572953ee3262d1924ec_D20200801-20200831" decimals="-3" name="bcrx:CollaborativeAgreementContractValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfODYy_11e71f91-c3d3-47cc-8cb3-f5aa8dd20c53">6,326</ix:nonFraction> to the Company under this contract.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biomedical Advanced Research and Development Authority</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In March 2015, BARDA/HHS awarded the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract includes a base contract of $<ix:nonFraction unitRef="usd" contextRef="i939d2e62994c419ba66434c3debb0192_I20150331" decimals="-3" name="us-gaap:GovernmentContractReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMTE4OA_24db70d6-1695-41ad-a0f3-3c3be7e851d2">16,265</ix:nonFraction> to support galidesivir drug manufacturing, as well as $<ix:nonFraction unitRef="usd" contextRef="ie89d5e9da1fb4552906ccc29db0c6910_I20150331" decimals="-3" name="us-gaap:GovernmentContractReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMTI0NQ_fe62ef77-d41a-4db4-8026-f44cceff832b">22,855</ix:nonFraction> in additional development options that can be exercised by the government, bringing the potential value of the contract to $<ix:nonFraction unitRef="usd" contextRef="i5578f786012042cb8b526aad1347720f_I20150331" decimals="-4" name="us-gaap:GovernmentContractReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMTM3MQ_d6acaf6f-960d-4727-8701-42dd3a5a7c45">39,120</ix:nonFraction>. As of September&#160;30, 2022, a total of $<ix:nonFraction unitRef="usd" contextRef="ic71ceab0e4b64e95b2df289f6f3faaec_D20220101-20220930" decimals="-3" name="bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMTM5Ng_10a8db1a-da80-4c3f-a552-65e427733bf2">20,574</ix:nonFraction> has been awarded under exercised options within this contract. The most recent development option was completed as of September&#160;30, 2022.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contracts with NIAID/HHS and BARDA/HHS are cost-plus-fixed-fee contracts. The Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress, and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="i46b25530b41e4292ac83c330ce8181eb" continuedAt="i813ce9f2c3eb4a379db7e88d5b0ae25a"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the continuation of the contracts is based on the Company&#8217;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects all government funding for its galidesivir program to expire in 2022.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Department of Health and Human Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2018, HHS awarded the Company a $<ix:nonFraction unitRef="usd" contextRef="id43ef6e8fa364fd8b928caaf91fbd1a6_D20180906-20180906" decimals="-4" name="bcrx:CollaborativeAgreementContractValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMjI1OA_d68a9735-7b64-4e4c-8c3f-8bb9c37402e0">34,660</ix:nonFraction> contract for the procurement of up to <ix:nonFraction unitRef="dose" contextRef="i535cf829316841bfa7015ff15880d35a_D20180906-20180906" decimals="INF" name="bcrx:MaximumNumberOfProductsPermittedToBeObtainedDoses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMjI5OQ_6f78d068-7d75-4697-be53-8e9447c6b7b8">50,000</ix:nonFraction> doses of RAPIVAB (peramivir injection) over a <ix:nonNumeric contextRef="id43ef6e8fa364fd8b928caaf91fbd1a6_D20180906-20180906" name="bcrx:ContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfOTE2OQ_9379ae1b-97af-4def-ac93-4b9d4d832b30">five-year</ix:nonNumeric> period. On August 25, 2022, the Company announced that HHS had exercised its remaining option under the contract to purchase <ix:nonFraction unitRef="dose" contextRef="i285e93f7aad44dada9abb5c04565a489_D20220825-20220825" decimals="-3" name="bcrx:NumberOfProductsObtainedDoses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMTA5OTUxMTYzODkzMg_b377055d-02bb-4611-a943-0c0d0c468963">10,000</ix:nonFraction> doses of RAPIVAB for $<ix:nonFraction unitRef="usd" contextRef="i285e93f7aad44dada9abb5c04565a489_D20220825-20220825" decimals="-3" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMTA5OTUxMTYzODk0MA_4c44c8a6-eb47-4967-8fba-92573349601e">6,932</ix:nonFraction>. As of September&#160;30, 2022, the Company has delivered a total of <ix:nonFraction unitRef="dose" contextRef="ic103b1fd563c46dbb16e1ab091c2bc47_D20220101-20220930" decimals="-1" name="bcrx:NumberOfProductsObtainedDoses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNTQ5NzU1ODIzMDc5_0a03dd5e-9123-4d03-8c62-220df26bb3de">39,980</ix:nonFraction> RAPIVAB doses of the <ix:nonFraction unitRef="dose" contextRef="ic103b1fd563c46dbb16e1ab091c2bc47_D20220101-20220930" decimals="-3" name="bcrx:MaximumNumberOfProductsPermittedToBeObtainedDoses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMjQzNQ_d8b8e0b0-1e5b-4d4c-8df7-e0b65248bcb9">50,000</ix:nonFraction> RAPIVAB doses available under the contract with HHS for a total of $<ix:nonFraction unitRef="usd" contextRef="ic103b1fd563c46dbb16e1ab091c2bc47_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMjUwNQ_46ad263e-9028-4e34-a2e9-f6704e044595">27,714</ix:nonFraction>.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Torii Pharmaceutical Co., Ltd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On November&#160;5, 2019, the Company entered into a Commercialization and License Agreement with Torii (the &#8220;Torii Agreement&#8221;), granting Torii the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in Japan.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Torii Agreement, the Company received an upfront, non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="i726cc8c2bd0b4ed78ad0a2c84ed2479c_D20191105-20191105" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMjg0MQ_8a823abf-123a-4de3-8093-3d67f7042cc1">22,000</ix:nonFraction>. The Japanese National Health Insurance System&#8217;s (&#8220;NHI&#8221;) approval of the addition of ORLADEYO to the NHI drug price list in April 2021 triggered a $<ix:nonFraction unitRef="usd" contextRef="i2fb11f122dad4dbb93a70888951bbc85_I20191105" decimals="-6" name="bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMjk5MQ_eb13a3c9-f199-4432-b0bb-3ef746ca5916">15,000</ix:nonFraction> milestone payment from Torii to the Company, which was received in May 2021.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Torii Agreement, the Company is entitled to receive tiered royalty payments, ranging from <ix:nonFraction unitRef="number" contextRef="i4097a995127f49fa8ee4dd7b99237dda_I20191105" decimals="1" name="bcrx:RoyaltyRateIfMaintainsSakigakeDesignation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMzE4NA_945d97a6-3989-495e-a40c-057a9ba4091d">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="iabfffedc39c340fabce60b94d0d32249_I20191105" decimals="1" name="bcrx:RoyaltyRateIfMaintainsSakigakeDesignation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMzE5MA_f4401190-8ee2-450a-adb7-36a29657676a">40</ix:nonFraction>% of annual net sales of ORLADEYO in Japan during each calendar year. Torii&#8217;s royalty payment obligations are subject to customary reductions in certain circumstances, but may not be reduced by more than <ix:nonFraction unitRef="number" contextRef="i2fb11f122dad4dbb93a70888951bbc85_I20191105" decimals="1" name="bcrx:MaximumCustomaryReductionOnRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMzM5NQ_56e68cce-c9d7-450f-b9c9-709b82cf36f8">50</ix:nonFraction>% of the amount that otherwise would have been payable to the Company in the applicable calendar quarter. Torii&#8217;s royalty payment obligations commenced upon the first commercial sale of ORLADEYO in Japan and expire upon the later of (i) the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMzYzNw_a3daa0dc-7723-4501-842e-5ed805a38078">ten</span>th anniversary of the date of first commercial sale of ORLADEYO in Japan, (ii) the expiration of the Company&#8217;s patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. The Company is responsible for supplying Torii with its required amounts of ORLADEYO. The activities of the parties pursuant to the Torii Agreement are overseen by a joint steering committee, composed of an equal number of representatives from each party to coordinate the development and commercialization of ORLADEYO in Japan. Torii launched ORLADEYO in Japan on April 23, 2021.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified performance obligations related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the $<ix:nonFraction unitRef="usd" contextRef="i726cc8c2bd0b4ed78ad0a2c84ed2479c_D20191105-20191105" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNDUzNg_8a823abf-123a-4de3-8093-3d67f7042cc1">22,000</ix:nonFraction> upfront consideration to the identified performance obligations using estimation approaches to determine the standalone selling prices under ASC Topic 606. Specifically, in determining the value related to the license, a valuation approach utilizing risk adjusted discounted cash flow projections was used, and an expected cost plus margin approach was utilized for the other performance obligations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shionogi &amp; Co., Ltd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to UAB on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Green Cross Corporation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross is responsible for all development, regulatory, and commercialization costs in Korea and the Company is entitled to share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2000, the Company licensed a series of potent inhibitors of purine nucleoside phosphorylase from AECOM and IRL (together, the &#8220;Licensors&#8221;). The lead product candidate from this collaboration is forodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute this, or any other, product candidate that might arise from research on these inhibitors. The Company has the option to expand the agreement to include other inventions in the field made by the investigators or employees of the Licensors. Under this agreement, as amended and restated, the Company has agreed to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><ix:continuation id="i813ce9f2c3eb4a379db7e88d5b0ae25a"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use commercially reasonable efforts to develop these drugs, to pay certain milestone payments for each licensed product (which range in the aggregate from $<ix:nonFraction unitRef="usd" contextRef="i90941783cef64f03915cc4e7222642e6_D20000601-20000630" decimals="-5" name="bcrx:MilestonePaymentMinimum" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNzE3OQ_165b3fe4-8414-490a-83d3-fe6462b70683">1,400</ix:nonFraction> to almost $<ix:nonFraction unitRef="usd" contextRef="i90941783cef64f03915cc4e7222642e6_D20000601-20000630" decimals="-6" name="bcrx:MilestonePaymentMaximum" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNzE5Mg_31af111f-7757-43d2-bae5-e035771f7440">4,000</ix:nonFraction> per indication) for future development and single digit royalties on net sales of any resulting product made by the Company, and to share a portion of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $<ix:nonFraction unitRef="usd" contextRef="i8cba6072ef5b463d92db14b5c09be6b9_I20000630" decimals="-4" name="bcrx:AnnualLicenseFeeMinimum" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNzQ5Nw_17d5d5dc-f92d-4e4b-926a-78c0c069ee4d">150</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i8cba6072ef5b463d92db14b5c09be6b9_I20000630" decimals="-5" name="bcrx:AnnualLicenseFeeMaximum" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNzUwMw_09f4db41-0c2a-4820-af9b-3da65f36f349">500</ix:nonFraction>, that are creditable against actual royalties and other payments due to the Licensors. The Licensors have also granted the Company an exclusive worldwide license of galidesivir for any antiviral use.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The University of Alabama at Birmingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed by UAB with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements each have an initial <ix:nonNumeric contextRef="ifba7c735102f46f692d875d1a37529f9_D20220101-20220930" name="bcrx:PeriodOfAgreement" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfODQxNQ_232bef6e-8862-424f-abec-2d027539c94c">25</ix:nonNumeric>-year term, are automatically renewable for <ix:nonNumeric contextRef="ifba7c735102f46f692d875d1a37529f9_D20220101-20220930" name="bcrx:RenewablePeriodOfAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfOTE3Mg_33245462-dd29-482b-9c9f-36531879eab8">five-year</ix:nonNumeric> terms throughout the life of the last patent and are terminable by the Company upon three months&#8217; notice and by UAB under certain circumstances. Upon termination, both parties shall cease using the other parties&#8217; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross collaborations, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts received.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><div id="ia4cd069c56504e93a883c91651012280_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s Discussion and Analysis (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MD&amp;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">) is intended to help the reader understand our results of operations and financial condition. MD&amp;A is provided as a supplement to, and should be read in conjunction with, our unaudited consolidated financial statements and the accompanying notes to the financial statements and other disclosures included in this report (including the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cautionary Note Regarding Forward-Looking Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> at the beginning of this report and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> section in Part II, Item 1A of this report).</span></div><div id="ia4cd069c56504e93a883c91651012280_76"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. We focus on oral treatments for rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. We integrate the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. In addition to these discovery and development efforts, our business strategy includes the efficient commercialization of these drugs in the United States and certain other regions upon regulatory approval. By focusing on rare disease markets, we believe that we can more effectively control the costs of, and our strategic allocation of financial resources toward, post-approval commercialization.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products and Product Candidates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ORLADEYO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (berotralstat)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ORLADEYO is an oral, once-daily therapy discovered and developed by us for the prevention of hereditary angioedema (&#8220;HAE&#8221;) attacks. ORLADEYO is approved in the United States and multiple global markets for the prevention of HAE attacks in adults and pediatric patients 12 years and older.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We built out our U.S. commercial infrastructure in 2020 to support the launch of ORLADEYO in the United States and are continuing to build our commercial infrastructure to support additional launches in Europe and elsewhere. Based on proprietary analyses of HAE prevalence and market research studies with HAE patients, physicians, and payors in the United States and Europe, and our first full year of experience with the ORLADEYO launch in 2021, we anticipate the commercial market for ORLADEYO has the potential to reach a global peak of $1 billion in annual net ORLADEYO revenues. We expect at least 70 to 80 percent of our revenue at peak to come from the United States. These expectations are subject to numerous risks and uncertainties that may cause our actual results, performance, or achievements to be materially different. There can be no assurance that our commercialization methods and strategies will succeed, or that the market for ORLADEYO will develop in line with our current expectations. See &#8220;Risk Factors&#8212;Risks Relating to Our Business&#8212;Risks Relating to Drug Development and Commercialization&#8212;There can be no assurance that our or our partners&#8217; commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain&#8221; in Part II, Item 1A of this report for further discussion of these risks.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of ORLADEYO for the three and nine months ended September 30, 2022 is discussed under &#8220;Results of Operations&#8221; in this MD&amp;A, and expected ORLADEYO revenue for 2022 is discussed under &#8220;Financial Outlook for 2022&#8221; in this MD&amp;A. Revenue from sales of ORLADEYO in future periods is subject to uncertainties and will depend on several factors, including the success of our and our partners&#8217; commercialization efforts in the United States and elsewhere, the number of new patients switching to ORLADEYO, patient retention and demand, the number of physicians prescribing ORLADEYO, the rate of monthly prescriptions, reimbursement from third-party and government payors, the conversion of patients from our clinical trials and early access programs to commercial customers, our pricing strategy, and market trends. We are continuing to monitor and analyze this data as we continue to commercialize ORLADEYO.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Complement Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The goal of our overall complement program is to advance several oral compounds across multiple pathways in the complement system to treat many complement-mediated diseases.  These compounds include BCX9930 and BCX10013, which target the alternative pathway of complement.  In addition, we are pursuing oral medicines directed at other targets across the classical, lectin, and terminal pathways of the complement system.  </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BCX9930 is a novel, oral, potent, and selective small molecule inhibitor of Factor D discovered by us and in clinical development for the treatment of complement-mediated diseases. Based on the safety and proof-of-concept data generated in patients with paroxysmal nocturnal hemoglobinuria (&#8220;PNH&#8221;), the program has advanced to pivotal studies of oral BCX9930 in PNH and to a proof-of-concept trial of oral BCX9930 in three renal complement-mediated diseases, C3 glomerulopathy (&#8220;C3G&#8221;), IgA nephropathy (&#8220;IgAN&#8221;), and primary membranous nephropathy (&#8220;PMN&#8221;). The goal of the program is to develop oral BCX9930 as a monotherapy for complement-mediated diseases. Refer to the &#8220;Recent Developments&#8221; section below for updates on the BCX9930 program. Refer also to &#8220;Risk Factors&#8212;Risks Relating to Our Business&#8212;Risks Relating to Drug Development and Commercialization&#8212;Our success depends upon our ability to manage our product candidate pipeline, advance our product candidates through the various stages of development, especially </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">through the clinical trial process, and to receive regulatory approval for the commercial sale of our product candidates&#8221; in Part II, Item 1A of this report for a discussion of certain risks and uncertainties associated with our BCX9930 program. There can be no assurance that our development plan for the program will succeed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BCX10013 is a novel, potent, and specific Factor D inhibitor.  The preclinical and early clinical profile from approximately 90 healthy volunteers to date suggests BCX10013 could have the properties of a once-daily oral therapy, and we expect to report preliminary data from healthy volunteers in the first quarter of 2023. A goal of the ongoing clinical program is to confirm this once-daily profile with healthy volunteer and patient data.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Galidesivir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Galidesivir is a broad-spectrum antiviral (&#8220;BSAV&#8221;) that has been shown to be active against more than 20 RNA viruses in nine different families. The objective of our BSAV program is to develop galidesivir as a broad-spectrum therapeutic for viruses that pose a threat to national health and security. The primary focus of the program is treatment of hemorrhagic fever viruses. The galidesivir program has been substantially funded with federal funds from the National Institute of Allergy and Infectious Diseases within the U.S. Department of Health and Human Services (&#8220;NIAID/HHS&#8221;) and by the Biomedical Advanced Research and Development Authority within the HHS (&#8220;BARDA/HHS&#8221;). Refer to the &#8220;Recent Developments&#8221; section below for updates on the galidesivir program, including the expected expiration of government funding for galidesivir in 2022. The Company has no plans to continue the galidesivir program without government funding.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BCX9250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The goal of our activin receptor-like kinase-2 inhibitor program is to discover and develop orally administered kinase inhibitor drug candidates that are able to slow or prevent the irregular formation of bone outside the normal skeleton, also known as heterotopic ossification (&#8220;HO&#8221;), that affects patients with fibrodysplasia ossificans progressiva (&#8220;FOP&#8221;). In a phase 1 clinical trial in healthy volunteers, BCX9250 was safe and well tolerated at all doses studied, with linear and dose-proportional exposure supporting once-daily dosing. Refer to the &#8220;Recent Developments&#8221; section below for updates on the BCX9250 program, including our decision to stop the BCX9250 program and redirect the investment to the other opportunities we have to serve patients with complement-mediated diseases.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RAPIVAB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">/RAPIACTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">/PERAMIFLU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (peramivir injection).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues and Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are difficult to predict and depend on several factors, including those discussed in the &#8220;Risk Factors&#8221; section in Part II, Item 1A of this report. For example, our revenues depend, in part, on regulatory approval decisions for our products and product candidates, the effectiveness of our and our collaborative partners&#8217; commercialization efforts, market acceptance of our products, particularly ORLADEYO, the resources dedicated to our products and product candidates by us and our collaborative partners, and ongoing discussions with government agencies regarding contract awards for development and procurement, as well as entering into or modifying licensing agreements for our product candidates. Furthermore, revenues related to our collaborative development activities are dependent upon the progress toward, and the achievement of, developmental milestones by us or our collaborative partners. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses are also difficult to predict and depend on several factors, including research and development expenses (and whether these expenses are reimbursable under government contracts), drug manufacturing, clinical research activities, the ongoing requirements of our development programs, the costs of commercialization, the availability of capital and direction from regulatory agencies, which are difficult to predict, and the factors discussed in the &#8220;Risk Factors&#8221; section in Part II, Item 1A of this report. Management may be able to control the timing and level of research and development and selling, general and administrative expenses, but many of these expenditures will occur irrespective of our actions due to contractually committed activities and/or payments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, we believe that period-to-period comparisons are not necessarily meaningful, and you should not rely on them as an indication of future performance. Due to the foregoing factors, it is possible that our operating results will be below the expectations of market analysts and investors. In such event, the prevailing market price of our common stock could be materially adversely affected.</span></div><div id="ia4cd069c56504e93a883c91651012280_79"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared in accordance with accounting </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. We evaluate our estimates, judgments and the policies underlying these estimates on a periodic basis, as situations change, and regularly discuss financial events, policies, and issues with members of our audit committee and our independent registered public accounting firm. In particular, we routinely evaluate our estimates and policies regarding revenue recognition, administration, inventory and manufacturing, taxes, stock-based compensation, research and development, consulting and other expenses and any associated liabilities. Our estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The results of our estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. See &#8220;Critical Accounting Policies&#8221; at the end of this MD&amp;A for a description of accounting policies that we believe are the most critical to aid you in fully understanding and evaluating our reported financial results and that affect the more significant judgments and estimates that we use in the preparation of our financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of COVID-19 has severely impacted global economic activity and caused significant volatility in financial markets. To date, our financial condition, results of operations, and liquidity have not been materially impacted by the direct effects of the COVID-19 pandemic. Please refer to &#8220;Risk Factors&#8212;Risks Relating to Our Business&#8212;Risks Relating to COVID-19&#8221; in Part II, Item 1A of this report for a discussion of COVID-19 risks as they relate to our business. We are continuing to monitor developments with respect to the COVID-19 pandemic and to make adjustments as needed to assist in protecting the safety of our employees and communities while continuing our business activities. Our remote working arrangements continue to be flexible where it is both practical and possible for the business. Business-related travel has resumed, and we will continue to monitor developments with respect to COVID-19 going forward. To date, implementation of specific COVID-19 measures has not required material expenditures or significantly impacted our ability to operate our business or our internal control over financial reporting and disclosure controls and procedures. We continue to monitor the potential impacts of COVID-19 on our operations and those of our partners, suppliers, customers, and regulators.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ORLADEYO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (berotralstat)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2022, we announced new long-term efficacy and safety data from the APeX-2 and APeX-S clinical trials evaluating ORLADEYO for the prophylactic treatment of HAE showing sustained reductions in attack rates and improvement in quality of life among patients living with HAE, as well as improved management of symptoms after switching to ORLADEYO from an injectable long-term prophylactic treatment.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2022, we announced that pricing for ORLADEYO was finalized in Germany, France, and Switzerland in the second quarter of 2022.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 18, 2022, we announced that the Saudi Food and Drug Authority has approved ORLADEYO to prevent attacks of HAE in adults and pediatric patients 12 years of age and older in Saudi Arabia.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Complement-Mediated Diseases</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BCX9930</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2022, we announced that the FDA lifted its partial clinical hold on the BCX9930 program and that we will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice-daily of BCX9930. This includes the REDEEM-1 and REDEEM-2 pivotal trials in patients with PNH and the RENEW proof-of-concept trial in patients with C3G, IgAN, and PMN. Clinical evidence and recent laboratory and nonclinical studies have informed our hypothesis that crystals form in the kidneys of some patients. We believe that lowering the dose to 400 mg and ensuring adequate hydration will dilute the concentration of drug in the urine below the threshold where crystals can form. Our goal is to find a safe and effective dose for BCX9930. We expect this can be accomplished in a reasonable timeframe after resuming enrollment, in a relatively small number of patients given the rate and timing of the serum creatinine rises in patients prior to the enrollment pause. If successful, we plan to invest more significantly in BCX9930 to tap the full potential of reaching many patients suffering from a number of alternative pathway diseases, and, if not successful, we will stop investment in BCX9930 and move on to other molecules in the pipeline. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2022, we announced that screening has begun for new patients to participate in the clinical trials with BCX9930, and we expect to have data from approximately 15 newly-enrolled patients by the middle of 2023 to inform our decision to either fully invest in the pivotal program, or to discontinue the BCX9930 program.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BCX10013</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2022, we announced that we have begun a clinical program with BCX10013, a novel, potent, and specific Factor D inhibitor, and we expect to report preliminary data from healthy volunteers in the first quarter of 2023. The preclinical and early clinical profile from approximately 90 healthy volunteers to date suggests BCX10013 could have the properties of a once-daily oral therapy. A goal of the ongoing clinical program is to confirm this once-daily profile with healthy volunteer and patient data.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional Complement Targets</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2022, we announced that, in addition to BCX9930 and BCX10013, which target the alternative pathway of complement, we are pursuing oral medicines directed at other targets across the classical, lectin and terminal pathways of the complement system. The goal of our overall complement program is to advance several oral compounds across multiple pathways in the complement system to treat many complement-mediated diseases.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Galidesivir</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously disclosed that we are commencing the close out of our September 2013 galidesivir contract with NIAID/HHS. On August 25, 2022, we announced that our other government funding for galidesivir is expected to expire in 2022 and that we have no plans to continue the galidesivir program without government funding.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fibrodysplasia Ossificans Progressiva</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On November 1, 2022, we announced that we believe that patients with FOP, an ultra-rare disease, are likely to benefit from other oral ALK-2 inhibitors that currently are substantially ahead of BCX9250 in development. Considering the expectation that patients will be well-served by these other products, and the approximately $100 million in additional investment that would be required to advance BCX9250 to approval, we are stopping the BCX9250 program and redirecting this investment to the other opportunities we have to serve patients with complement-mediated diseases.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RAPIVAB (peramivir injection)</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2022, we announced that the U.S. Department of Health and Human Services has exercised its option to purchase an additional 10,000 doses of RAPIVAB for $6.9 million.  The order is the final of five purchase options from a $34.7 million contract the Centers for Disease Control and Prevention awarded in 2018 for the procurement of up to 50,000 doses of RAPIVAB over a five-year period.</span></div><div id="ia4cd069c56504e93a883c91651012280_82"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations (three months ended September 30, 2022 compared to the three months ended September 30, 2021)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2022, total revenues were $75.8 million as compared to $41.0 million for the three months ended September 30, 2021. The increase was primarily due to ORLADEYO net revenue, including royalties, of $66.0 million, an increase of $29.0 million. RAPIVAB revenue increased $4.5 million for the three months ended September 30, 2022 due to a stockpiling sale of 10,000 units to HHS for $6.9 million as compared to a partial delivery of 3,420 units of RAPIVAB for $2.4 million for the same period in the prior year. Additionally, there was an increase in peramivir revenue of $2.9 million on a sale to one of our partners for the three months ended September 30, 2022.  Contract revenue for the three months ended September 30, 2022 decreased $1.5 million compared to the same period in the prior year as existing contracts continue to close out.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales for the three months ended September 30, 2022 and 2021 was $3.5 million and $0.6 million, respectively. The cost of product sales in 2022 was primarily associated with the peramivir product sales to our partners and the RAPIVAB stockpiling sale to HHS whereas the cost of product sales in 2021 relates primarily to the partial RAPIVAB stockpiling sale to HHS.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses increased to $52.7 million for the three months ended September 30, 2022 from $50.0 million for the three months ended September 30, 2021, primarily due to additional investment in the berotralstat program and expenses for BCX9250 prior to its discontinuation, partially offset by a reduction in spend on the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factor D program, primarily BCX9930, as a result of the paused enrollment in clinical trials with BCX9930 that we announced on April 8, 2022.  On August 4, 2022, it was announced that we would resume enrollment for the BCX9930 program.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our R&amp;D expenses for the periods indicated (amounts are in thousands). Certain prior period amounts have been reclassified for consistency with the current year presentation.  These reclassifications had no effect on the total R&amp;D expenses.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:71.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expenses by program:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Factor D program</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Berotralstat</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FOP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Galidesivir</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peramivir</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research, preclinical and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total R&amp;D expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52,740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,971</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses for the three months ended September 30, 2022 were $36.9 million compared to $35.0 million in the three months ended September 30, 2021. The increase was primarily due to increased investment to support the U.S. commercial launch of ORLADEYO and the expansion of international operations.  SG&amp;A expenses for the three months ended September 30, 2021 included a one-time non-cash stock compensation charge of $7.0 million in connection with the accelerated vesting of certain outstanding stock options.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended September 30, 2022 was $24.8 million compared to $14.1 million for the three months ended September 30, 2021. The increase in interest expense was primarily associated with the sale of certain royalty payments under the 2021 RPI Royalty Purchase Agreement and the OMERS Royalty Purchase Agreement, which were entered into in November 2021, as well as the additional borrowing of $75.0 million by way of the Term B and Term C Loans under the Credit Agreement, which were funded on July 29, 2022. The nature of the royalty sales requires that we recognize a liability (the &#8220;Royalty Financing Obligations&#8221;) for the future sale of royalties under these agreements. These liabilities are amortized using the effective interest rate method, resulting in the recognition of non-cash interest expense over the estimated term of the Royalty Purchase Agreements (as defined in &#8220;Note 6&#8212;Royalty Monetizations&#8212;ORLADEYO and Factor D Inhibitors&#8221; in the Notes to Consolidated Financial Statements in Part I, Item 1 of this report).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended September 30, 2022 included $18.5 million of non-cash interest expense due to the amortization of interest associated with the Royalty Financing Obligations and $6.3 million of interest expense, net of deferred financing amortization, associated with the borrowings under the Credit Agreement. Interest expense for the three months ended September 30, 2021 included $8.5 million of non-cash interest expense due to the amortization of interest associated with the Royalty Financing Obligation under the 2020 RPI Royalty Purchase Agreement and $3.9 million of interest expense, net of deferred financing amortization, associated with the Term A Loan under the Credit Agreement. Additionally, we recognized $1.7 million in interest expense on the non-recourse PhaRMA Notes issued in March 2011, which were written-off in December 2021. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2022, other income, net of $1.2 million was comprised primarily of interest income of $1.8 million and net foreign currency losses of $0.5 million. Other expense for the three months ended September 30, 2021 was primarily related to net foreign currency losses of $0.1 million.</span></div><div id="ia4cd069c56504e93a883c91651012280_85"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations (nine months ended September 30, 2022 compared to the nine months ended September 30, 2021)</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, total revenues were $191.3 million as compared to $110.0 million for the nine months ended September 30, 2021. The increase was primarily due to ORLADEYO net revenue, including royalties, of $180.9 million, an increase of $104.5 million.  Additionally, other royalties increased $0.9 million for the nine months ended September 30, 2022 as compared to the nine months ended September 30, 2021.  These increases were partially offset by a decrease in peramivir revenue of $4.4 million on sales to our partners.  Additionally, a $15.0 million </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone payment related to the NHI approval of ORLADEYO in Japan was recognized in the prior year.  Contract revenue for the nine months ended September 30, 2022 decreased $4.9 million compared to the same period in the prior year as existing contracts continue to close out.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales for the nine months ended September 30, 2022 and 2021 was $4.0 million and $6.8 million, respectively. The cost of product sales in both 2022 and 2021 was primarily associated with the peramivir product sales to our partners and RAPIVAB stockpiling sales to HHS. For the nine months ended September 30, 2021, sales of peramivir were higher than for the nine months ended September 30, 2022.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses increased to $180.1 million for the nine months ended September 30, 2022 from $145.3 million for the nine months ended September 30, 2021, primarily due to increased investment in the development of the Factor D program (including BCX9930 and BCX10013), the FOP program, as well as other research, preclinical and development costs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our R&amp;D expenses for the periods indicated (amounts are in thousands). Certain prior period amounts have been reclassified for consistency with the current year presentation.  These reclassifications had no effect on the total R&amp;D expenses.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expenses by program:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Factor D program</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Berotralstat</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FOP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Galidesivir</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peramivir</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research, preclinical and development costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total R&amp;D expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">180,090</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145,279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses for the nine months ended September 30, 2022 were $109.2 million compared to $83.4 million in the nine months ended September 30, 2021. The increase was primarily due to increased investment to support the U.S. commercial launch of ORLADEYO and the expansion of international operations. SG&amp;A expenses for the nine months ended September 30, 2021 included a one-time non-cash stock compensation charge of $7.0 million in connection with the accelerated vesting of certain outstanding stock options.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the nine months ended September 30, 2022 was $72.6 million compared to $40.5 million for the nine months ended September 30, 2021. The increase in interest expense was primarily associated with the sale of certain royalty payments under the 2021 RPI Royalty Purchase Agreement and the OMERS Royalty Purchase Agreement, which were entered into in November 2021, as well as the additional borrowing of $75.0 million by way of the Term B and Term C Loans under the Credit Agreement, which were funded on July 29, 2022. The nature of the royalty sales requires that we recognize the Royalty Financing Obligations for the future sale of royalties under these agreements. These liabilities are amortized using the effective interest rate method, resulting in the recognition of non-cash interest expense over the estimated term of the Royalty Purchase Agreements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the nine months ended September 30, 2022 included $57.8 million of non-cash interest expense due to the amortization of interest associated with the Royalty Financing Obligations and $14.7 million of interest expense, net of deferred financing amortization, associated with the borrowings under the Credit Agreement.  Interest expense for the nine months ended September 30, 2021 included $24.1 million of non-cash interest expense due to the amortization of interest associated with the Royalty Financing Obligation under the 2020 RPI Royalty Purchase Agreement and $11.4 million of interest expense, net of deferred financing amortization, associated with the Term A Loan under the Credit Agreement. Additionally, we recognized $4.9 million in interest expense on the non-recourse PhaRMA Notes issued in March 2011, which were written-off in December 2021.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, other income, net of $1.8 million was comprised of interest income of $2.4 million, partially offset by net foreign currency losses of $0.6 million. Other expense for the nine months ended September 30, 2021 was primarily related to net foreign currency losses of $0.3 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><div id="ia4cd069c56504e93a883c91651012280_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have principally been funded through public offerings and private placements of equity securities; cash from collaborative and other research and development agreements, including U.S. Government contracts for RAPIVAB and galidesivir; to a lesser extent, the PhaRMA Notes financing; our credit facilities; and more recently, the Royalty Sales and revenues from ORLADEYO. To date, we have been awarded a BARDA/HHS RAPIVAB development contract totaling $234.8 million, which expired on June 30, 2014; a NIAID/HHS galidesivir development contract totaling $47.3 million, which is in the process of being closed out; a second NIAID/HHS galidesivir development contract with a potential value totaling $43.9 million; and a BARDA/HHS galidesivir development contract with a potential value totaling $39.1 million. The total amount of funding obligated under awarded options under the active NIAID/HHS and BARDA/HHS galidesivir contracts is $53.6 million and $20.6 million, respectively. All government funding for galidesivir is expected to expire in 2022. In addition to the above, we have previously received funding from other sources, including other collaborative and other research and development agreements, government grants, equipment lease financing, facility leases, research grants, and interest income on our investments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Credit Agreement with Athyrium provides for three term loans. We received the proceeds from the $125.0 million Term A Loan in December 2020. The Term B Loan and the Term C Loan were both funded in the respective principal amounts of $25.0 million and $50.0 million on July 29, 2022. The maturity date of the Credit Agreement is December 7, 2025. See &#8220;Note 7&#8212;Debt&#8212;Credit Agreement&#8221; in the Notes to Consolidated Financial Statements in Part I, Item 1 of this report for additional information about the Credit Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we had net working capital of $427.4 million, a decrease of approximately $35.0 million from $462.4 million at December&#160;31, 2021. The decrease in working capital was primarily due to normal operating expenses associated with the development of our product candidates and commercialization of ORLADEYO. Our principal sources of liquidity at September&#160;30, 2022 were approximately $246.9 million in cash and cash equivalents and approximately $180.0 million in investments considered available-for-sale.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to contain costs and cash flow requirements by closely managing our third-party costs and headcount, leasing scientific equipment and facilities, contracting with other parties to conduct certain research and development projects, and using consultants. We expect to incur additional expenses, potentially resulting in significant losses, as we continue to pursue our research and development activities, commercialize ORLADEYO, and hire additional personnel. We may incur additional expenses related to the filing, prosecution, maintenance, defense, and enforcement of patent and other intellectual property claims and additional regulatory costs as our clinical programs advance through later stages of development. The objective of our investment policy is to ensure the safety and preservation of invested funds, as well as to maintain liquidity sufficient to meet cash flow requirements. We place our excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of our credit exposure. We have not realized any significant losses on our investments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to finance our needs in both the short-term and long-term principally from the following:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lease, royalty, or loan financing and future public or private equity and/or debt financing;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our existing capital resources and interest earned on that capital;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenues from product sales;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payments under existing, and executing new, contracts with the U.S. Government; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payments under current or future collaborative and licensing agreements with corporate partners.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our commercialization activities and research and development programs continue to advance, our costs will increase. Our current and planned clinical trials, plus the related development, manufacturing, regulatory approval process requirements, and additional personnel resources and testing required for the continuing development of our product candidates and the commercialization of our products will consume significant capital resources and will increase our expenses. Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including our ability to raise additional capital, the development progress of our collaborative agreements for our product candidates, the amount of funding or assistance, if any, we receive from new U.S. Government contracts or other new partnerships with third parties for the development and/or commercialization of our products and product candidates, the progress and results of our current and proposed clinical trials for our most advanced product candidates, the progress made in the manufacturing of our lead product candidates, the success of our commercialization efforts for, and market acceptance of, our products, and the overall progression of our other programs. The impact of the ongoing COVID-19 pandemic on one or more of the foregoing factors could negatively affect our expenses, revenues, and cash utilization rate.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our expectations for revenue and operating expenses, we believe our financial resources will be sufficient to fund our operations for at least the next 12 months. However, we have sustained operating losses for the majority of our corporate history and expect that our 2022 expenses will exceed our 2022 revenues. We expect to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. Our liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of our products and the future progression of our product candidates. We regularly evaluate other opportunities to fund future operations, including: (1) securing or increasing U.S. Government funding of our programs, including obtaining procurement contracts; (2) out-licensing rights to certain of our products or product candidates, pursuant to which we would receive cash milestone payments; (3) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (4) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (5) reducing spending on one or more research and development programs, including by discontinuing development; and/or (6) restructuring operations to change our overhead structure. We may issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, through private placement transactions or registered public offerings. Our future liquidity needs, and our ability to address those needs, will largely be determined by the success of our products and product candidates; the timing, scope, and magnitude of our research and development and commercial expenses; and key developments and regulatory events and our decisions in the future.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term capital requirements and the adequacy of our available funds in both the short-term and long-term will depend upon many factors, including:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of approved products and successful commercialization of such products by either us or our partners;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to perform under our government contracts and to receive reimbursement and stockpiling procurement contracts;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the magnitude of work under our government contracts;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress and magnitude of our research, drug discovery and development programs;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in existing collaborative relationships or government contracts;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies and governmental agencies or other third parties;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our partners, including governmental agencies, will share in the costs associated with the development of our programs or run the development programs themselves;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to negotiate favorable development and marketing strategic alliances for certain products and product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any decision to build or expand internal development and commercial capabilities;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and results of preclinical studies and clinical trials to identify and develop product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to engage sites and enroll subjects in our clinical trials;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of manufacturing of our products to support our commercial operations and of our product candidates to support our preclinical research and clinical trials;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in personnel and related costs to support the development and commercialization of our products and product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of manufacturing of our drug substance and product candidates required for future new drug application (&#8220;NDA&#8221;) filings;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive and technological advances;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-approval commitments for ORLADEYO, RAPIVAB, and other products that receive regulatory approval; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in all aspects of intellectual property strategy and protection, including the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will be required to raise additional capital to complete the development and commercialization of our current products and product candidates, and we may seek to raise capital in the future, including to take advantage of favorable opportunities in the capital markets. Additional funding, whether through additional sales of equity or debt securities, collaborative or other arrangements with corporate partners or from other sources, including governmental agencies in general and existing government contracts specifically, may not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative arrangements may require us to transfer certain material rights to such corporate partners. Insufficient funds may require us to delay, scale back or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eliminate certain of our research and development programs. Our future working capital requirements, including the need for additional working capital, will be largely determined by the advancement of our portfolio of product candidates and the commercialization of ORLADEYO, as well as any future decisions regarding the future of the RAPIVAB and galidesivir programs, including those relating to stockpiling procurement. More specifically, our working capital requirements will be dependent on the number, magnitude, scope and timing of our development programs; regulatory approval of our product candidates; obtaining funding from collaborative partners; the cost, timing and outcome of regulatory reviews, regulatory investigations, and changes in regulatory requirements; the costs of obtaining patent protection for our product candidates; the timing and terms of business development activities; the rate of technological advances relevant to our operations; the efficiency of manufacturing processes developed on our behalf by third parties; the timing, scope and magnitude of commercial spending; and the level of required administrative support for our daily operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restrictive covenants contained in our Credit Agreement could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial without the lenders&#8217; permission or without repaying all obligations outstanding under the Credit Agreement. These covenants limit our ability to, among other things, grant certain types of liens on our assets; make certain investments; incur or assume certain debt; engage in certain mergers, acquisitions, and similar transactions; dispose of assets; license certain property; distribute dividends; make certain restricted payments; change the nature of our business; engage in transactions with affiliates and insiders; prepay other indebtedness; or engage in sale and leaseback transactions. A breach of any of these covenants could result in an event of default under the Credit Agreement. As of September&#160;30, 2022, we were in compliance with the covenants under the Credit Agreement.</span></div><div id="ia4cd069c56504e93a883c91651012280_91"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Outlook for 2022</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the reduced spending on the BCX9930 program in the first three quarters of the year, and lower than projected spending on the program for the remainder of the year, we now expect operating expenses for full year 2022, not including non-cash stock compensation, to be between $365 million and $370 million.</span></div><div id="ia4cd069c56504e93a883c91651012280_94"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established various accounting policies that govern the application of U.S. GAAP, which were utilized in the preparation of our consolidated financial statements. Certain accounting policies involve significant judgments and assumptions by management that have a material impact on the carrying value of certain assets and liabilities. Management considers such accounting policies to be critical accounting policies. The judgments and assumptions used by management are based on historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the nature of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which could have a material impact on the carrying values of assets and liabilities and the results of operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are more fully described in &#8220;Note 1&#8212;Significant Accounting Policies and Concentrations of Risk&#8221; in the Notes to Consolidated Financial Statements in Part I, Item 1 of this report, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, we recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, we identify the goods or services promised within each contract, assess whether each promised good or service is distinct, and determine those that are performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales, Net</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal sources of product sales are sales of ORLADEYO, which we began shipping to patients in December 2020, sales of peramivir to our licensing partners and sales of RAPIVAB to HHS under our procurement contract. In the United States, we ship ORLADEYO directly to patients through a single specialty pharmacy, which is considered our customer. In the European Union, United Kingdom and elsewhere, we sell ORLADEYO to specialty distributors as well as hospitals and pharmacies, which collectively are considered our customers.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue for sales when our customers obtain control of the product, which generally occurs upon delivery. For ORLADEYO, we classify payments to our specialty pharmacy customer for certain services provided by our customer as selling, general and administrative expenses to the extent such services provided are determined to be distinct from the sale of our product.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or as a current liability. Overall, these reserves reflect our best estimates of the amount of consideration to which the Company is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from estimates, we adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government and Managed Care Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We contract with government agencies and managed care organizations or, collectively, third-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. We estimate the rebates we will provide to third-party payors and deduct these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. We estimate the rebates that we will provide to third-party payors based upon (i) our contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) product distribution information obtained from our specialty pharmacy.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from our specialty pharmacy. These customers purchase our products under contracts negotiated between them and our specialty pharmacy. The specialty pharmacy, in turn, charges back to us the difference between the price the specialty pharmacy paid and the negotiated price paid by the contracted customers, which may be higher or lower than the specialty pharmacy purchase price with us. We estimate chargebacks and adjust gross product revenues and accounts receivable based on the estimates at the time revenues are recognized.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance and patient assistance programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, we are able to estimate the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. We also offer a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#8217;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, we record gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We do not provide contractual return rights to our customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Research and Development Arrangements and Royalties</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when we satisfy a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that we expect to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will not occur.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have collaboration and license agreements with a number of third parties as well as research and development agreements with certain government entities.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and we have no further continuing performance obligations or we have completed the performance obligations under the terms of the agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by us represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, we measure progress using an input method based on the effort we expend or costs we incur toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which we separately sell the products or services. If a standalone selling price is not directly observable, then we estimate the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that we believe the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not probable at the inception of the agreement and (ii) we have a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under our contracts with BARDA/HHS and NIAID/HHS, revenue is recognized as reimbursable direct and indirect costs are incurred.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of our license agreements, we receive royalty payments based upon our licensees&#8217; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs; or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue and billings in excess of revenue recognized (contract liabilities) on the Consolidated Balance Sheets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of certain milestones. Often this results in billing occurring </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to revenue recognition, resulting in contract assets. Contract assets are generally classified as current assets in the Consolidated Balance Sheets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We often receive cash payments from customers in advance of our performance, resulting in contract liabilities. These contract liabilities are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">classified as either current or long-term in the Consolidated Balance Sheets based on the timing of when we expect to recognize the revenue.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Costs</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may incur direct and indirect costs associated with obtaining a contract. Incremental contract costs that we expect to recover are capitalized and amortized over the expected term of the contract. Non-incremental contract costs and costs that we expect to recover are expensed as incurred.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inventories primarily relate to ORLADEYO. Additionally, our inventory includes RAPIVAB and peramivir.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value our inventories at the lower of cost or estimated net realizable value. We determine the cost of our inventories, which includes amounts related to materials, labor, manufacturing overhead and shipping and handling costs on a first-in, first-out (FIFO) basis. Raw materials and work-in-process includes all inventory costs prior to packaging and labeling, including raw material, active product ingredient, and drug product. Finished goods include packaged and labeled products.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inventories are subject to expiration dating. We regularly evaluate the carrying value of our inventories and provide valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, we may experience spoilage of our raw materials and supplies. Our determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires us to utilize significant judgment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is upon receipt of regulatory approval. Upon regulatory approval, we capitalize subsequent costs related to the production of inventories.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contractual agreements with third-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. We record liabilities under these contractual commitments when we determine an obligation has been incurred. This accrual process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed and estimating the level of service performed and the associated cost when we have not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued expenses as of each balance sheet date based on the facts and circumstances known to us. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of our raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our expenses related to clinical trials on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of these costs, our actual expenses could differ from our estimates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development costs are charged to expense when incurred. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of our manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by us over the service periods specified in the contracts and estimates are adjusted, if required, based upon our ongoing review of the level of services actually performed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;), and the University of Alabama (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance fees. We expense sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. We expense maintenance payments as incurred.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred collaboration expenses represent sublicense payments paid to our academic partners upon receipt of consideration from various commercial partners, and other consideration to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from our commercial partners and are being expensed in proportion to the related revenue being recognized. We believe that this accounting treatment appropriately matches expenses with the associated revenue.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We group our R&amp;D expenses into two major categories: direct external expenses and indirect expenses. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials, as well as other costs related to our clinical and preclinical studies. These costs are accumulated and tracked by active program. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our research and development efforts. These costs apply to work on non-active product candidates and our discovery research efforts.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in our Consolidated Statements of Comprehensive Loss based on their fair values. Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related assumptions for the model requires judgment, including estimating the life of an award, the stock price volatility, and the expected term. We utilize the Black-Scholes option-pricing model to value our stock option awards and recognize compensation expense on a straight-line basis over the vesting periods. The estimation of share-based payment awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. In addition, we have outstanding performance-based stock options and restricted stock units for which no compensation expense is recognized until &#8220;performance&#8221; has occurred. Significant management judgment is also required in determining estimates of future stock price volatility and forfeitures to be used in the valuation of the options. Actual results, and future changes in estimates, may differ substantially from our current estimates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Royalty Financing Obligations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO, BCX9930, and another earlier stage Factor D inhibitor (BCX10013). Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires us to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. We impute interest on the carrying value of each of the royalty financing obligations and record interest expense using an imputed effective interest rate. We reassess the expected royalty payments each reporting period and account for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions in accordance with U.S. GAAP. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. We have recorded a valuation allowance against substantially all potential tax assets, due to uncertainties in our ability to utilize deferred tax assets, primarily consisting of certain net operating losses carried forward, before they expire. The valuation allowance is based on estimates of taxable income in each of the jurisdictions in which we operate and the period over which our deferred tax assets will be recoverable.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in fiscal year 2021, we began accruing foreign income taxes as a result of increased nexus in foreign jurisdictions where historically we had no presence.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, starting in 2022, amendments to Section 174 of the Internal Revenue Code of 1986, as amended (&#8220;IRC&#8221;), will no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil. As a result of this tax law change, we have recorded a U.S. state tax provision for the nine months ended September 30, 2022.</span></div><div id="ia4cd069c56504e93a883c91651012280_97"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Note 1&#8212;Significant Accounting Policies and Concentrations of Risk&#8221; in the Notes to Consolidated Financial Statements included in Part I, Item 1 of this report discusses accounting pronouncements recently issued or proposed but not yet required to be adopted.</span></div><div id="ia4cd069c56504e93a883c91651012280_100"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to interest rate risk on our investment portfolio and borrowings under our Credit Agreement. The Term Loans under the Credit Agreement bear interest each quarter at a rate equal to the three-month LIBOR rate, which is capped to be no less than 1.75% and no more than 3.50% (&#8220;LIBOR&#8221;), plus 8.25% or, for each quarterly interest period in which a PIK Interest Payment is made, LIBOR plus 10.25%. Accordingly, increases in interest rates could increase the associated interest payments that we are required to make on the Term Loans. As of September&#160;30, 2022, interest was accrued at an effective rate of 12.68% on the $200.0 million borrowings under the Credit Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-month LIBOR was 3.67% as of September 28, 2022, the LIBOR measurement date for the three-month interest period beginning October 1, 2022.  As the LIBOR rate exceeds the LIBOR cap of 3.50%, the 3.50% cap plus 10.25% will be used to record interest expense for the three-month interest period beginning October 1, 2022.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in marketable securities in accordance with our investment policy. The primary objectives of our investment policy are to preserve capital, maintain proper liquidity to meet operating needs and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. We place our excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of credit exposure. Some of the securities we invest in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment exposure to market risk for changes in interest rates relates to the increase or decrease in the amount of interest income we can earn on our portfolio, changes in the market value due to changes in interest rates and other market factors as well as the increase or decrease in any realized gains and losses. Our investment portfolio includes only marketable securities and instruments with active secondary or resale markets to help ensure portfolio liquidity. A hypothetical 100 basis point increase or decrease in interest rates along the entire interest rate yield curve would not significantly affect the fair value of our interest sensitive financial instruments, including our borrowings, but may affect our future earnings and cash flows. We generally have the ability to hold our fixed-income investments to maturity and, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therefore, do not expect that our operating results, financial position or cash flows will be materially impacted due to a sudden change in interest rates. However, our future investment income may fall short of expectations due to changes in interest rates, or we may suffer losses in principal if forced to sell securities which have declined in market value due to changes in interest rates or other factors, such as changes in credit risk related to the securities&#8217; issuers. To minimize this risk, we schedule our investments to have maturities that coincide with our expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, we do not believe that we have material exposure to interest rate risk arising from our investments. Generally, our investments are not collateralized. We have not realized any significant losses from our investments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use interest rate derivative instruments to manage exposure to interest rate changes. We ensure the safety and preservation of invested principal funds by limiting default risk, market risk and reinvestment risk. We reduce default risk by investing in investment grade securities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our revenues and expenses are denominated in U.S. dollars, and as a result, we have not experienced significant foreign currency transaction gains and losses to date. Our commercial sales in Europe are primarily denominated in Euros and the British Pound. We also had other transactions denominated in foreign currencies during the nine months ended September 30, 2022, primarily related to operations in Europe, contract manufacturing and ex-U.S. clinical trial activities, and we expect to continue to do so. Our royalties from Torii are derived from Torii&#8217;s sales of ORLADEYO in Japan. Those sales are denominated in Japanese yen and converted into U.S. dollars for purposes of determining the royalty owed to us. Our limited foreign currency exposure relative to our European operations is to fluctuations in the Euro, British Pound, Swiss Franc, Danish Krone, and Swedish Krona. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not anticipate that foreign currency transaction gains or losses will be significant at our current level of operations. However, transaction gains or losses may become significant in the future as we continue to expand our operations internationally. We have not engaged in foreign currency hedging during the nine months ended September 30, 2022; however, we may do so in the future. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation Risk</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally impacts us by potentially increasing our operating expenses, including clinical trial costs and selling activities. We do not believe that inflation has had a material impact on our business or results of operations during the periods for which the condensed consolidated financial statements are presented in this report. Significant adverse changes in inflation could negatively impact our future results of operations.</span></div><div id="ia4cd069c56504e93a883c91651012280_103"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a set of disclosure controls and procedures that are designed to ensure that information relating to the Company required to be disclosed in our periodic filings under the Exchange Act is recorded, processed, summarized and reported in a timely manner under the Exchange Act. We carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of September&#160;30, 2022, the Company&#8217;s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted by it under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and include controls and procedures designed to ensure that information required to be disclosed by the Company in such reports is accumulated and communicated to the Company&#8217;s management, including the Chief Executive Officer and Chief Financial Officer of the Company, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting that occurred during the quarter ended September&#160;30, 2022 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><div id="ia4cd069c56504e93a883c91651012280_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="ia4cd069c56504e93a883c91651012280_109"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RISK FACTORS</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An investment in our stock involves risks. You should carefully read this entire report and consider the following uncertainties and risks, which may adversely affect our business, financial condition or results of operations, along with all of the other information included in our other filings with the SEC, before making an investment decision regarding our common stock.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Business</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Relating to COVID-19</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, operations, clinical development or commercialization plans and timelines, and access to capital could be adversely affected by the effects of the ongoing COVID-19 pandemic on us or on third parties with whom we conduct business, including without limitation our development partners, manufacturers, CROs, and others, as well as on the regulatory and government agencies with whom we work.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic continues to affect the United States and global economies, and could cause disruptions to our business, operations, and clinical development or commercialization plans and timelines, as well as the business and operations of third parties with whom we conduct business. For example, government orders and evolving business policies and procedures have impacted and may continue to impact, among other things: (1) our personnel and those of third parties on whom we rely, including our development partners (such as Torii), manufacturers, CROs, and others; (2) the conduct of our current and future clinical trials and commercial interactions; and (3) the operations of the FDA, European Medicines Agency (&#8220;EMA&#8221;), Japanese Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;), and other health and governmental authorities, which could result in delays of reviews and approvals.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations or those of third parties with whom we conduct business are impaired or curtailed as a result of these events, the development and commercialization of our products and product candidates could be stopped or delayed, or the costs of such development and commercialization activities could increase, any of which could have a material adverse impact on our business. For example, our suppliers or other vendors may be unable to meet their obligations to us or perform their services as expected as a result of the COVID-19 pandemic or other health epidemics. In such circumstances, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Such delays could adversely impact our ability to meet our desired clinical development and any commercialization timelines. Although we carefully manage our relationships with our suppliers and vendors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our clinical trials have been and may continue to be affected by the COVID-19 pandemic. For example, the acceleration of COVID-19 slowed startup of the inadequate C5 responder cohorts in our complement oral Factor D program and, as a result, delayed the reporting of related data in 2020. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic or concerns among patients about participating in clinical trials during a pandemic. Some patients may have difficulty following certain aspects of clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our inability to successfully recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 or experience additional restrictions by their institutions, city, or state could adversely impact our clinical trial operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If global health concerns prevent the FDA, EMA, PMDA or other regulatory authorities from conducting their inspections, reviews, or other regulatory activities, it could significantly impact the ability of such authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business and clinical development and commercialization plans and timelines.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where possible and practical, we continue to provide work-from-home flexibility for our employees, which could negatively impact productivity, disrupt our business and delay our clinical programs and timelines. In addition, we are a government contractor, and as such, we are subject to the federal COVID-19 safety protocols. We cannot accurately predict the impact on operations of any return-to-the-office plan, nor of the federal COVID-19 safety protocols on our business or on third parties with whom we conduct business. Our business may be negatively impacted in the event that large numbers of employees or key employees do not comply with these protocols. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, could also materially affect our access to capital. While the future economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, the pandemic could result in further significant disruption of global financial markets, reducing our ability to access the equity or debt capital markets or obtain other sources of capital, which could negatively affect our liquidity. In addition, a recession or market correction resulting from the continued spread of COVID-19 variants and related responses could materially affect our business and the value of our common stock.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global pandemic continues to evolve, with the ultimate impact of the COVID-19 pandemic or a similar health epidemic being uncertain and subject to change. These effects could be material, and we will continue to monitor the COVID-19 situation closely. We do not yet know the full extent and magnitude of the impacts that COVID-19 has had or will have on our business, on the healthcare system, or on the global economy. In addition, the COVID-19 pandemic could have the effect of heightening many of the other risks described below.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial and Liquidity Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred losses since our inception, expect to continue to incur such losses, and may never be profitable.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have not achieved sustained profitability. We expect to incur additional losses for the foreseeable future, and our losses could increase as our research and development efforts and commercial activities progress. We expect that such losses will fluctuate from quarter to quarter and that losses and fluctuations may be substantial. To become profitable, we, or our collaborative partners, must successfully manufacture and develop products and product candidates, receive regulatory approval, and successfully commercialize our products and/or enter into profitable commercialization arrangements with other parties. It could take longer than expected before we receive, or we may never receive, significant revenue from any current or future license agreements or significant revenues directly from product sales. Even if we are able to successfully commercialize our existing products, or to develop or otherwise acquire new commercially viable products, certain obligations we have to third parties, including, without limitation, our obligation to pay RPI and OMERS, as applicable, royalties on certain revenues from ORLADEYO, BCX9930, and another earlier stage Factor D inhibitor (BCX10013) under the Royalty Purchase Agreements, may reduce the profitability of such products.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with developing our product candidates, launching new products, and their potential for commercialization, we are unable to predict the extent of any future losses. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are unable to achieve and sustain profitability, the market value of our common stock will likely decline.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to raise additional capital in the future. If we are unable to raise capital when needed, we may need to adjust our operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have sustained operating losses for the majority of our corporate history and expect that our 2022 expenses will exceed our 2022 revenues. We expect to continue to incur operating losses and negative cash flows unless and until revenues reach a level sufficient to support ongoing operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity needs will be largely determined by the success of operations in regard to the commercialization of our products and the progression of our product candidates in the future. Our plans for managing our liquidity needs primarily include controlling the timing and spending on our research and development programs, raising additional funds through equity and/or debt financings, and commercializing our approved products. We regularly evaluate other opportunities to fund operations including: (1) securing or increasing U.S. Government funding of our programs, including obtaining additional and delivering on procurement contracts; (2) out-licensing rights to certain of our products or product candidates, pursuant to which we would receive cash milestone payments and/or royalties; (3) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (4) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (5) reducing spending on research and development programs, including by discontinuing and suspending development; and/or (6) restructuring operations to change our overhead structure.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that any of our plans will be successful or that additional capital will be available to us on reasonable terms, or at all, when needed. If we are unable to obtain sufficient additional capital, we may be forced to adjust or curtail our operations; delay, reduce, or stop ongoing clinical trials or commercialization efforts; cease operations altogether; or file for bankruptcy.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Relating to Drug Development and Commercialization</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends upon our ability to manage our product candidate pipeline, advance our product candidates through the various stages of development, especially through the clinical trial process, and to receive regulatory approval for the commercial sale of our product candidates.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends upon our ability to manage our product candidate pipeline, including through expanding the pipeline, as appropriate, through our internal identification and discovery of product candidates or otherwise in-licensing or acquiring products or product candidates and integrating them into our business effectively and efficiently, advancing our product candidates through the various stages of development, and receiving regulatory approval for the commercial sale of our product candidates.  Identifying, selecting, and in-licensing or acquiring products and product candidates requires substantial expense and technical and financial expertise, and if we are unable to effectively manage our pipeline and integrate viable products or product candidates into our business on acceptable terms, or at all, our business and drug development efforts would suffer.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To receive the regulatory approvals necessary for the commercial sale of our product candidates, we or our partners must demonstrate through preclinical studies and clinical trials that each product candidate is safe and effective. The development process and related regulatory process are complex and uncertain. The preclinical and clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of drug development, including failure to demonstrate efficacy and safety, failure to demonstrate adequate benefit-risk balance, failure to achieve a commercially attractive and competitive product label, failure to achieve approval in commercially attractive indications, the occurrence of adverse events that are severe or medically or commercially unacceptable, our or our partners&#8217; failure to comply with trial protocols, applicable regulatory requirements, and industry standards, or a determination by the FDA or any comparable foreign regulatory authority that a product candidate may not continue development or be approved in accordance with our development plans or at all. We cannot guarantee that any preclinical studies and clinical trials will be conducted as planned or completed on schedule, if at all, or that the results of such trials will be sufficient to support regulatory approval for our product candidates.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progression of our product candidates through the clinical development process is dependent upon our trials indicating that our product candidates have adequate safety and efficacy in the patients being treated by achieving pre-determined safety and efficacy endpoints according to the clinical trial protocols, and adequate benefit-risk profile. Failure to achieve any of these endpoints or to show adequate benefit-risk profile in any of our programs, including our Factor D program (inclusive of BCX9930 and BCX10013) and our other rare disease product candidates could result in delays in or modifications to our trials or require the performance of additional unplanned trials. If any of our product candidates is associated with adverse events or undesirable side effects or has properties that are unexpected, we may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Product candidates that initially show promise in clinical or preclinical testing could later be found to be associated with or to cause undesirable or unexpected side effects that could result in substantial modifications and delays in the development plans for our product candidates, significant unexpected costs, or the termination of programs. For example, in April 2022, we voluntarily paused enrollment of our BCX9930 clinical trials due to observed elevations in serum creatinine seen in some patients, indicating drug-related kidney injury. The FDA subsequently placed the program on a partial clinical hold. On August 4, 2022, we announced that the FDA lifted its partial clinical hold with respect to BCX9930 and that we plan to resume enrollment under revised protocols which include a number of additional requirements and restrictions (e.g., a dose reduction, recommended hydration, and increased monitoring). The elevated serum creatinine signal and revisions to the BCX9930 development program create additional risk to the successful development of BCX9930, and the timelines for the BCX9930 program are uncertain. Specifically, the revised BCX9930 studies may not address the elevated serum creatinine issue, we may not be able to execute the BCX9930 clinical studies in a timely fashion or at all, we may not be able to recruit enough patients for the clinical studies, our hypothesis may not be correct or our data may be inconclusive, the lower dose of BCX9930 may not be effective, and the additional requirements and restrictions that have been imposed, or that may be imposed in the future, by regulatory authorities and others may impede development or commercialization. In addition, the development plans for our product candidates, including our clinical trials (including for BCX9930), may not be adequately designed or executed, which could negatively affect the outcome and analysis of study results. Because of the cost and duration of clinical trials, we have decided in the past, and may in the future decide, to discontinue development of product candidates for various reasons, including, but not limited to, they are unlikely to show favorable results in clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have reasonable commercial potential.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable or inconclusive data in our preclinical studies and clinical trials or side effects in humans could result in the FDA or foreign regulatory authorities (including, e.g., the EMA, the Ministry of Health, Labor and Welfare (&#8220;MHLW&#8221;) in Japan or the United Kingdom&#8217;s Medicines and Healthcare Regulatory Agency (&#8220;MHRA&#8221;)) refusing to approve a product candidate for any targeted indications or imposing restrictions or warnings that could impact development or the ultimate commercial viability of a product candidate. In addition, the FDA or foreign regulatory authorities may determine that study data from our product candidates necessitates additional studies or study designs which differ from our planned development strategy, and such regulatory authorities may also require patient monitoring and testing or may implement restrictions or other conditions on our development activities, any of which could materially impact the cost and timing of our planned development strategy. We, our partners, the FDA, or foreign regulatory authorities have previously, and may again in the future, pause enrollment in, suspend or terminate clinical trials at any time if we or they believe the trial participants face unacceptable health risks.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully complete the clinical development process is dependent upon many factors, including, but not limited to:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our or our partners&#8217; ability to secure suitable clinical sites and investigators and to enroll and maintain an adequate number of patients on a timely basis or at all;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients that enroll in a clinical trial may not comply with the clinical trial protocol or maintain contact with investigators to provide complete data during and after treatment;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may not prove to be either safe or effective or may produce unfavorable or inconclusive results;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may decide, or be required by regulatory authorities, to pause enrollment in, suspend or terminate clinical research for various reasons, including a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate, noncompliance with regulatory requirements or their standards of conduct, or findings of undesirable effects caused by a chemically or mechanistically similar product or product candidate;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may disagree with our or our partners&#8217; clinical trial protocols or our or their interpretation of data from preclinical studies and clinical trials;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical protocols or study procedures may not be adequately designed or followed by the investigators;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">formulation improvements may not work as expected, which could negatively impact commercial demand for our product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or facilities of third-party manufacturers with which we or our partners enter into agreements for clinical and commercial supplies;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quantity of raw materials or manufactured product candidates or other materials necessary to conduct development activities may be insufficient, inadequate, or unavailable at an acceptable cost, and we or our partners may experience interruptions in supply;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our or our partners&#8217; development plans may be delayed or changed as a result of changes in development strategy, the impact of new or different regulations, requirements, and guidelines, or other unexpected events or conditions;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of preclinical studies and clinical trials may be greater than we anticipate;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our third-party contractors, including those manufacturing our product candidates or components or ingredients thereof, or conducting clinical trials or laboratory testing on our or our partners&#8217; behalf, may fail to comply with regulatory requirements and industry standards or meet contractual obligations in a timely manner or at all; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the ongoing COVID-19 pandemic on one or more of the foregoing factors.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are lengthy and expensive. Many of the factors listed above could result in increased clinical development costs or longer clinical development times for any of our programs. We and our partners incur substantial expense for, and devote significant time to, preclinical testing and clinical trials, yet we cannot be certain that the tests and trials will ever result in the commercial sale of a product. Even if we or our partners successfully complete clinical trials for our product candidates, we or our partners might not file the required regulatory submissions in a timely manner or may not receive regulatory approval for the product candidates, which in either case would adversely impact or preclude our ability to generate any revenues from product sales or licensing arrangements. In addition, any product candidate, if approved, may be subject to restrictions on labeling, marketing, distribution, prescribing, and use, which could adversely impact the sales of such product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our development collaborations with third parties, such as our development partners, contractors and contract research organizations, fail, the development of our product candidates will be delayed or stopped.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely heavily upon third parties for many important stages of our product candidate development, including, but not limited to:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discovery of natural proteins that cause or enable biological reactions necessary for the progression of the disease or disorder, called enzyme targets;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">execution of certain pharmacology preclinical studies and late-stage development for our compounds and product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">management of our phase 1, 2 and 3 clinical trials, including medical monitoring, laboratory testing, and data management;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">execution of toxicology studies that may be required to obtain approval for our product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">formulation improvement strategies and methods;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing the starting materials and drug substance required to formulate our products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">management of certain regulatory interactions outside of the United States.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to engage in successful collaborations at any one of these stages would greatly impact our business. If we do not license enzyme targets or inhibitors from academic institutions or from other biotechnology companies on acceptable terms, our drug development efforts would suffer. Similarly, if the contract research organizations or third-party contractors that conduct our initial or late-stage clinical trials, conduct our toxicology or other studies, manufacture our starting materials, drug substance and product candidates, provide laboratory testing or other services in connection with our clinical trials, or assist with our regulatory function breach their obligations to us, perform their services inconsistent with industry standards, or fail to comply with regulatory requirements, this would delay or prevent both the development of our product candidates and the availability of any potential commercial product.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we lose our relationship with any one or more of these parties, we could experience a significant delay in both identifying another comparable provider and then contracting for its services. We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service as the original provider. In addition, any provider that we retain will be subject to applicable FDA current Good Laboratory Practices, current Good Manufacturing Practices (&#8220;cGMP&#8221;) and current Good Clinical Practices, and comparable foreign standards. We do not have control over compliance with these regulations by these providers. Consequently, if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates could be delayed. If any of the foregoing risks are realized, our business, financial condition and results of operations could be materially adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain additional financing or acceptable partnership arrangements as and when needed, we may be unable to complete the development and commercialization of our products and product candidates or continue operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our programs advance, our costs are likely to increase. Our current and planned discovery, development, approval, and commercialization efforts will require significant capital. Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including: our ability to effectively manage our product candidate pipeline; our ability to obtain regulatory approval for our product candidates, including BCX9930 and BCX10013; our ability to maintain regulatory approval for, successfully commercialize, and achieve market acceptance of our products, including ORLADEYO; our ability to raise additional capital; the amount of funding we receive from partnerships with third parties for the development and commercialization of our products and product candidates (including our collaborations with Torii, BARDA/HHS, and NIAID/HHS); the commercial success of our products achieved by our partners; the amount or profitability of any orders for peramivir by any government agency or other party; the progress and results of our current and proposed clinical trials for our product candidates; and the progress made in the manufacture of our lead products and the progression of our other programs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue future operations, progress our drug discovery and development programs, and commercialize our current products and product candidates, we will be required to raise additional capital. In addition to seeking strategic partnerships, transactions and government funding, we may access the equity or debt markets, incur additional borrowings, or seek other sources of funding to meet liquidity needs at any time, including to take advantage of attractive opportunities in the capital markets. Additional funding, whether through additional sales of securities, additional borrowings, royalty or other monetization transactions, collaborative arrangements with partners, including corporate partners such as Torii and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">governmental agencies such as BARDA/HHS or NIAID/HHS, or from other sources, may not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable than those of our currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights of our existing stockholders. Additional borrowings may subject us to more restrictive covenants than are currently applicable to us under our Credit Agreement. In addition, collaborative arrangements may require us to transfer certain material rights to such corporate partners. Insufficient funds or lack of an acceptable partnership may require us to delay, scale-back or eliminate certain of our research and development programs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to raise additional capital when needed or at all may be limited and may greatly depend upon our success in commercializing and achieving market acceptance of ORLADEYO and the success of our current drug development programs, including the progress, timeline and ultimate outcome of the development programs (including, but not limited to, formulation progress, long-term human safety studies, clinical trial investigations, and carcinogenicity, drug-drug interaction, toxicity, or other required studies) for our Factor D program (including BCX9930 and BCX10013) for diseases of the complement system and other rare disease product candidates, as well as any post-approval studies for our products. In addition, constriction and volatility in the equity and debt markets, including as a result of the impacts of COVID-19, rising inflation or increased interest rates, may restrict our future flexibility to raise capital when such needs arise. Furthermore, we have exposure to many different industries, financing partners and counterparties, including commercial banks, investment banks and partners (which include investors, licensing partners, and the U.S. Government), which may be unstable or may become unstable in the current economic and political environment, including as a result of the impacts of COVID-19, rising inflation, increased interest rates, or the conflict in Ukraine. Any such instability may impact these parties&#8217; ability to fulfill contractual obligations to us, or it might limit or place burdensome conditions upon future transactions with us. Also, it is possible that suppliers may be negatively impacted. Any such unfavorable outcomes in our current programs or unfavorable economic conditions have in the past and could again place severe downward pressure on the price of our common stock and may decrease opportunities to raise capital in the capital or credit markets, and further could reduce the return available on invested corporate cash, which, if severe and sustained, could have a material and adverse impact on our results of operations and cash flows and limit our ability to continue development and commercialization of our products and product candidates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners do not obtain governmental approval for our product candidates or maintain governmental approval for our products, we or our partners will not be able to commercialize and sell these products and potential products, which would significantly harm our business because we will receive no revenue.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners must obtain regulatory approval before marketing or selling our products. If the FDA or a comparable foreign regulatory authority delays or denies regulatory approval of one of our product candidates, or revokes approval of a previously approved product, we would be unable to market or sell the product in the applicable jurisdiction and would not receive revenue from sales or licensing arrangements related thereto, which could have a material and adverse impact on our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of preparing for and obtaining regulatory approval in any jurisdiction may be lengthy and expensive, and approval is never certain. Because of the risks and uncertainties inherent to the development process, including risks and uncertainties related to the impact of COVID-19, our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval. As discussed under &#8220;Risk Factors&#8212;Risks Relating to Our Business&#8212;Risks Relating to Drug Development and Commercialization&#8212;Our success depends upon our ability to manage our product candidate pipeline, advance our product candidates through the various stages of development, especially through the clinical trial process, and to receive regulatory approval for the commercial sale of our product candidates,&#8221; we or our partners have experienced, and may again in the future</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience, any number of unfavorable outcomes during or as a result of preclinical studies and clinical trials that could delay or prevent regulatory approval of our product candidates, or negatively impact our management&#8217;s credibility, our value and our operating results.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA or foreign regulatory authorities approve a product candidate, the approval may limit the indicated uses for a product candidate, impose other restrictions on the product candidate, and/or may require post-approval studies that could impair the commercial viability of a product candidate. Even upon any approval to market our potential products, whether in the United States or internationally, we will continue to be subject to extensive regulatory requirements. These requirements are wide ranging and govern, among other things:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse drug experience reporting regulations;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product promotion;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product manufacturing, including good manufacturing practice requirements; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product changes or modifications.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to comply with existing or future regulatory requirements for regulatory approval, or our loss of, or changes to, previously obtained approvals, could impair our ability to generate any revenues from product sales or licensing arrangements, which could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We focus on rare diseases, which may create additional risks and challenges.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we focus on developing drugs as treatments for rare diseases, we may seek orphan drug, breakthrough therapy or fast track designations for our product candidates in the United States or the equivalent designations elsewhere in the world. Often, regulatory authorities have broad discretion in determining whether or not to grant such designations. We cannot guarantee that our product candidates will receive orphan drug status from the FDA or equivalent designations from other regulatory authorities. We also cannot guarantee that we will receive breakthrough therapy, fast track, or equivalent designations, which provide certain potential benefits such as more frequent meetings with the applicable regulatory authorities to discuss development plans, intensive guidance on efficient drug development programs, and potential eligibility for rolling review or priority review. Even if we are successful in obtaining any such designations for our product candidates, such designations may not lead to faster development or regulatory review or approval and do not increase the likelihood that our product candidates will receive marketing approval. For instance, although BCX9930 for PNH has received Fast Track and Orphan Drug designations from the FDA, we may not experience a faster development, review or approval process compared to the conventional process. We may not be able to obtain or maintain these designations for BCX9930 or other product candidates that receive them, and our competitors may obtain these designations for their product candidates, which could impact our ability to develop and commercialize our products and product candidates or compete with such competitors, which may adversely impact our business, financial condition or results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial viability of any approved product could be compromised if the product is less effective than expected, causes undesirable side effects that were not previously identified, or fails to achieve market acceptance within the medical community.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, after obtaining regulatory approval of a product, we or others discover that it is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of, or impose marketing or manufacturing restrictions on, the product, or require us or our partners to create a medication guide outlining the risks of unidentified side effects for distribution to patients;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may be required to recall the product, change the way the product is administered, conduct additional clinical trials, or be subject to civil or criminal penalties; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive and our reputation may suffer.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after receiving regulatory approval, any product could fail to gain sufficient, or even any, market acceptance by physicians, patients, third-party payors, health authorities and others in the medical community. For example, physicians are often reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies. If an approved product does not achieve an adequate level of market acceptance, it may not generate significant revenues. The occurrence of any of the foregoing could have a material and adverse impact on our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to successfully commercialize or establish collaborative relationships to commercialize certain of our products and product candidates, or if any partner terminates or fails to perform its obligations under agreements with us, potential revenues from commercialization of our products and product candidates could be reduced, delayed or eliminated.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy includes increasing the asset value of our product and product candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative arrangements with third parties as appropriate. As needed, potential third-party relationships could include preclinical development, clinical development, regulatory approval, marketing, sales, and distribution of our products and product candidates.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we have established collaborative relationships, including with Torii for the commercialization of ORLADEYO in Japan and with each of Shionogi and Green Cross for the development and commercialization of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">peramivir. The process of establishing and implementing collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may seek to renegotiate or terminate our relationships due to unsatisfactory commercial, regulatory or clinical results, including post-approval clinical commitments, a change in business strategy, a change of control or other reasons;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contracts for collaborative arrangements may expire;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility that expiration or termination of collaborative relationships, such as those with certain of our distribution partners, may trigger repurchase obligations of the Company for unsold product held by our partners;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our partners may choose to pursue alternative technologies, including those of our competitors;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have had in the past, and in the future may have, disputes with a partner that could lead to litigation or arbitration, which could result in substantial costs and divert the attention of our management;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we do not have day-to-day control over the activities of our partners and have limited control over their decisions;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may not devote sufficient capital or resources toward our products and product candidates; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may not comply with applicable government regulatory requirements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our partners fail to fulfill our responsibilities in a timely manner, or at all, our development and commercialization efforts related to that collaboration could be reduced, delayed or terminated, or it may be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our partner. If we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue further development or commercialization of one or more of our products or product candidates, undertake commercialization activities at our own expense or find alternative sources of funding. Any delay in the development or commercialization of our products and product candidates would severely affect our business, because if our product candidates do not progress through the development process or reach the market in a timely manner, or at all, or if our products do not achieve market success, we may not receive any revenues from product sales or licensing arrangements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of our partnership with Torii may not meet our current expectations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an agreement with Torii for the development and commercialization of ORLADEYO in Japan. Our ability to realize the expected benefits of this collaboration, including with respect to the receipt or amounts of royalty payments, is subject to a number of risks, including that the commercial potential of ORLADEYO may not meet our current expectations, we or Torii may fail to comply with our respective obligations under the Torii Agreement, and third parties may fail to perform their obligations to us on a timely basis or at all.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Torii Agreement provides that we are entitled to receive tiered royalty payments, the amounts of which will depend upon the amount of annual net sales of ORLADEYO in Japan during each calendar year and other factors. We currently remain responsible for regulatory activities with respect to ORLADEYO in Japan, and we continue to use third parties to satisfy many of our obligations under the Torii Agreement, including, but not limited to, our regulatory and other responsibilities in Japan. If our interactions, or those of our third-party agents, are unsuccessful, we could fail to meet our obligations under the Torii Agreement, which could negatively impact the commercial success and the partnership, impact the economic benefit expected or require additional development of ORLADEYO.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Torii may terminate the Torii Agreement under certain limited circumstances, including upon one year&#8217;s written notice after the sixth anniversary of the first commercial sale of ORLADEYO in Japan. If the Torii Agreement is terminated in connection with these provisions, or at all, we will no longer be entitled to receive any milestone or royalty payments thereunder, which could have a material adverse impact on our business and results of operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Torii has sole control over, and decision-making authority with respect to, commercialization activities for ORLADEYO for the prevention of HAE attacks in Japan, subject to oversight from a joint steering committee. Therefore, our receipt, and the amounts, of any royalty payments under the Torii Agreement are dependent upon Torii&#8217;s successful </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance of such commercialization activities. In addition, competitive products and variations in patient demand, prescription levels, reimbursement determinations or other factors may limit the commercial potential of ORLADEYO in Japan, which could materially reduce the amount of any royalties we are entitled to receive under the Torii Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Torii Agreement, we are responsible for supplying Torii with its required amounts of ORLADEYO for commercial sale. If, due to the failure of our third-party contract manufacturers to produce sufficient drug product, we fail to supply to Torii the required amounts of ORLADEYO, then Torii&#8217;s ability to successfully commercialize ORLADEYO in Japan could be materially impaired, and we may receive less royalty income under the Torii Agreement, or none at all.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing risks could materially adversely impact our ability to perform our obligations under the Torii Agreement, which could materially reduce the economic benefits of the Torii Agreement to us and impair or result in the termination of our collaboration with Torii.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that our or our partners&#8217; commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that our and our partners&#8217; commercialization efforts, methods and strategies will succeed. We may be unable to establish or sufficiently increase our sales, marketing and distribution capabilities for products we currently, or plan to, commercialize. Our ability to receive revenue from products we or our partners commercialize is subject to several risks, including:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may fail to successfully complete clinical trials, or satisfy post-marketing commitments, sufficient to obtain and keep regulatory agency marketing approval;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">many competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our products and product candidates;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company, our products and product candidates, or royalties associated with such products (e.g., the loss of the peramivir patent in Korea, which may result in a reduced royalty from Green Cross);</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our and our partners&#8217; ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue from product sales depends on our ability to obtain and maintain favorable pricing;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reimbursement is constantly changing, which could greatly affect usage of our products;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future revenue from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market, distribute and commercialize our approved drugs; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on us or our partners.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future revenue from sales of ORLADEYO is subject to uncertainties and will depend on several factors, including the success of our and our partners&#8217; commercialization efforts in the United States and elsewhere, the number of new patients switching to ORLADEYO, patient retention and demand, the number of physicians prescribing ORLADEYO, the rate of monthly prescriptions, reimbursement from third-party and government payors, the conversion of patients from our clinical trials and early access programs to commercial customers, our pricing strategy, and market trends.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to successfully commercialize our existing products, or to develop new commercially viable products, certain obligations we have to third parties, including, without limitation, our obligations to pay royalties on certain revenues from ORLADEYO, BCX9930, and another earlier stage Factor D inhibitor (BCX10013) under the Royalty Purchase Agreements, may reduce the profitability of such products.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue expanding our development and regulatory capabilities and implementing sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue experiencing significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs, sales, marketing, and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. For example, we expanded </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our internal commercial team in 2020 in preparation for the commercial launch of ORLADEYO, and we have continued to add additional headcount throughout 2021 and 2022. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit, train, and retain additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. In addition, if a commercial launch for any product or product candidate for which we recruit a commercial team and establish marketing capabilities in any region is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third-party vendors in the manufacture and distribution of our products, product candidates and the materials for our products and product candidates. If we cannot rely on existing third-party vendors, we will be required to incur significant costs and potential delays in finding new third-party vendors, which could adversely impact the development and commercialization timeframes for our products and product candidates.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on third-party vendors, including third-party manufacturers, distributors, and specialty pharmacies, in the manufacture and distribution of our products, product candidates, and the materials for our products and product candidates. Often, especially in the early development and commercialization process, we have only one or limited sources for a particular product or service, such as manufacturing and/or distribution. We depend on these third-party vendors to perform their obligations in a timely manner and in accordance with applicable governmental regulations. Our third-party vendors, particularly our third-party manufacturers and distributors, which may be the only vendor we have engaged for a particular product, product candidate, or service or in a particular region, may encounter difficulties with meeting our requirements, including, but not limited to, problems involving, as applicable:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">insufficient resources being devoted in the manner necessary to satisfy our requirements within expected timeframes;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inconsistent production yields;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product liability claims or recalls of commercial product;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in scaling production to commercial and validation sizes;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of the delivery of materials required for the manufacturing process;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to distribute commercial supplies of our products to commercial vendors or end users in a timely manner;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scheduling of plant time with other vendors or unexpected equipment failure;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential catastrophes that could strike their facilities or have an effect on infrastructure;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">poor quality control and assurance or inadequate process controls;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to provide us with accurate or timely information regarding inventories, the number of patients who are using our products, or serious adverse events and/or product complaints regarding our products;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability of third parties to satisfy their financial obligations to us or to others;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential breach of the manufacturing or distribution agreement by the third party;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible termination or nonrenewal of a critical agreement by the third party at a time that is costly or inconvenient to us; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA or other foreign regulatory agencies or local customs, particularly associated with ORLADEYO, BCX9930, BCX10013, peramivir and our early-stage compounds.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many additional factors could cause production or distribution interruptions with the manufacture and distribution of any of our products and product candidates, including human error, natural disasters, pandemics, labor disputes, acts of terrorism or war, equipment malfunctions, or raw material shortages. If our commercial distribution partners are not able to satisfy our requirements within the expected timeframe, or are unable to provide us with accurate or timely information and data, including inventories and sales, serious adverse events, and/or product complaints, our business, including our commercial launch and sales of ORLADEYO may be at risk. In addition, if specialty pharmacy services, including our third-party call center services, which provide patient support and financial services, prescription intake and distribution, reimbursement adjudication, and ongoing compliance support, are not effectively managed, the continuance of our commercial launch and sales of ORLADEYO may be delayed or compromised.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our contract manufacturers may not be able to manufacture the materials required for our products or product candidates at a cost or in quantities necessary to make them commercially viable. Our raw materials, drug </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substances, products, and product candidates are manufactured by a limited group of suppliers, including some at a single facility. If any of these suppliers were unable to produce these items, this could significantly impact our supply of products and product candidate material for further preclinical testing and clinical trials. Our third-party manufacturers also may not meet our manufacturing requirements. Furthermore, changes in the manufacturing process or procedure, including a change in the location where the drug is manufactured or a change of a third-party manufacturer, may require prior review and approval in accordance with the FDA&#8217;s cGMP and comparable foreign requirements. This review may be costly and time-consuming and could delay or prevent the launch of a product. The FDA or foreign regulatory authorities may at any time implement new standards, or change their interpretation and enforcement of existing standards, for manufacture, packaging or testing of products. If we or our contract manufacturers are unable to comply, we or they may be subject to regulatory action, civil actions or penalties, any of which could be costly to us and could result in a delay or shortage of product.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to maintain current third-party relationships, or enter into new agreements with additional third parties on commercially reasonable terms, or if there is poor manufacturing or distribution performance or failure to comply with any regulatory agency on the part of any of our third-party vendors, we may not be able to complete development of, obtain timely approval of, or commercialize our products and product candidates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercialization of our products by us and our partners is subject to the potential commercialization risks described herein and numerous additional risks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any potential revenue benefits to us, including in the form of milestone payments, royalties or other consideration are highly speculative.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial success of our products is uncertain and is subject to all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization. In addition, commercialization of our products is subject to further risks and may be negatively impacted by a number of factors, including, but not limited to, the following:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our products may not prove to be adequately safe and effective for market approval in markets other than the markets in which they are currently approved;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">necessary funding for post-marketing commitments and further development of our products may not be available timely, at all, or in sufficient amounts;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advances in competing products could substantially replace potential demand for our products;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government and third-party payors may not provide sufficient coverage or reimbursement, which would negatively impact the demand for our products;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to supply commercial material to our partners and our partners may not be able to maintain or establish sufficient and acceptable commercial manufacturing, either directly or through third-party manufacturers;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial demand and acceptance for our products by healthcare providers and by patients may not be sufficient to result in substantial product revenues to us or to our partners and may result in little to no revenue, milestone payments, or royalties to us;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectiveness of marketing and commercialization efforts for our products by us or our partners;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market satisfaction with existing alternative therapies;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived efficacy relative to other available therapies;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disease prevalence;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost of treatment;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our pricing strategy may not be effective;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and availability of imports or alternative products;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">marketing and sales activities of competitors;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shifts in the medical community to new treatment paradigms or standards of care; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Relating to Competing in Our Industry</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are highly competitive and subject to rapid and substantial technological change. There are many companies seeking to develop products for the same indications that we currently target. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors have greater resources than we do, including greater financial resources, larger research and development staffs and more experienced manufacturing, marketing, and sales organizations. In addition, most of our competitors have greater experience than we do in conducting clinical trials and obtaining FDA and other regulatory approvals. Accordingly, our competitors may succeed </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in obtaining FDA or other regulatory approvals of product candidates more rapidly than we do or for products that compete with our products. Companies that complete clinical trials, obtain required regulatory approvals, and commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including patent and FDA exclusivity rights that would delay our ability to market products. We face, and will continue to face, competition in the commercialization of our products, licensing of potential product candidates for desirable disease targets, licensing of desirable product candidates, and development and marketing of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. Competition may also arise from, among other things:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other drug development technologies;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">methods of preventing or reducing the incidence of disease, including vaccines; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new small molecule or other classes of therapeutic agents.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Developments by others may render our products, product candidates, or technologies obsolete or noncompetitive.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received FDA approval of ORLADEYO, an oral, once-daily therapy for the prevention of HAE attacks in adults and pediatric patients 12 years and older, in December 2020. We subsequently received regulatory approvals for ORLADEYO in multiple global markets. In addition, we are performing research on or developing products for the treatment of several other rare diseases, including diseases of the complement system, as well as developing broad spectrum antivirals for use as medical countermeasures. We expect to encounter significant competition for our pharmaceutical products and product candidates. Companies that complete clinical trials, obtain required funding or government support, obtain required regulatory approvals and commence commercial sales or stockpiling orders of their products before their competitors may achieve a significant competitive advantage. There are licensed therapies for HAE (including Berinert&#174;, Haegarda&#174;, Cinryze&#174;, Kalbitor&#174;, Takhzyro&#174;, Firazyr&#174; (icatibant), generic icatibant, and Ruconest&#174;), therapies for certain complement-mediated diseases such as PNH, aHUS, myasthenia gravis, and neuromyelitis optica spectrum disorder (Soliris&#174;, Ultomiris&#174;, and Empaveli&#174;), products for the prevention or treatment of influenza (seasonal flu vaccines, Tamiflu&#174; (oseltamivir), generic oseltamivir, Relenza&#174;, and Inavir&#174;, favipiravir, and Xofluza&#174;), and a number of additional products in clinical development in these therapeutic areas. In addition, various government entities throughout the world may offer incentives, grants and contracts to encourage additional investment into preventative and therapeutic agents against viruses such as influenza, coronavirus, Ebola, and others, which may have the effect of further increasing the number of our competitors and/or providing advantages to certain competitors. See &#8220;Business&#8212;Competition&#8221; in Part I, Item 1 of our most recent Annual Report on Form 10-K for further discussion of our competitors, competitive products or programs, and the competitive conditions in these and other therapeutic areas.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one or more of our competitors&#8217; products or programs, including potential competitors not currently identified, are successful, the market for our products may be reduced or eliminated.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared to us, many of our competitors and potential competitors have substantially greater:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capital resources;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">research and development resources, including personnel and technology;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory experience;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical study and clinical testing experience;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing, marketing, and sales experience; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production facilities.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these competitive factors could impede our funding efforts, render our products, product candidates, or technologies noncompetitive or eliminate or reduce demand for our products and product candidates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal and Regulatory Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to various laws and regulations related to our products and product candidates, and if we or our partners do not comply with these laws and regulations, we could face substantial penalties.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our partners&#8217; activities related to approved products or, following their regulatory approval (if applicable), any of our product candidates under development, such as BCX9930 and BCX10013, are subject to regulatory and law enforcement authorities in the United States (including the FDA, the Federal Trade Commission, the Department of Justice (&#8220;DOJ&#8221;), and state and local governments) and their foreign equivalents (including the EMA, MHLW, MHRA, and others).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for reporting adverse drug experiences, have responsibility for certain post-approval studies, and may have responsibilities and costs related to a recall or withdrawal of our products from sale in the jurisdictions in which they are approved. We may also incur liability associated with product manufacturing contracted by us or in support of any of our partners. We are required to maintain records and provide data and reports to regulatory agencies related to our products (e.g. risk evaluation and mitigation strategies, track and trace requirements, and adverse events), and we may incur certain promotional regulatory and government pricing risks, all of which could have a material adverse impact on our operations and financial condition. Similar responsibilities would apply upon regulatory approval of any of our other product candidates currently under development.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are subject to the federal physician sunshine act and certain similar physician payment and drug pricing transparency legislation in various states. We are also subject to various federal and state laws pertaining to healthcare &#8220;fraud and abuse,&#8221; including both federal and state anti-kickback and false claims laws. Outside of the United States, we may be subject to analogous foreign laws and regulations in the various jurisdictions in which we operate. These laws and regulations apply to our and our partners&#8217; operations, sales and marketing practices, price reporting, and relationships with physicians and other customers and third-party payors. Anti-kickback laws generally prohibit a manufacturer from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may be no regulations, guidance or court decisions that clarify how the laws apply to particular industry practices. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented, for payment to third-party payors (including Medicare and Medicaid) claims for reimbursement or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. The sunshine provisions apply to manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government certain payments made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as, ownership and investment interests held by physicians (as defined above) and their immediate family members. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures. Although we seek to comply with these statutes, it is possible that our practices, or those of our partners, might be challenged under healthcare fraud and abuse, anti-kickback, false claims or similar laws. Violations of the physician sunshine act and similar legislation or the fraud and abuse laws may be punishable by civil or criminal sanctions, including fines and civil monetary penalties, and future exclusion from participation in government healthcare programs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to certain regulatory authorities, including the FDA and comparable foreign regulatory authorities. Consequently, the FDA or other regulatory authority may conclude that a financial relationship between us and a principal investigator creates a conflict of interest or otherwise affects interpretation of the study. In the event of a conflict of interest with respect to a study, the integrity of the data generated at the applicable clinical trial site may be questioned or the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and foreign regulatory authorities may also impose post-approval commitments on us for approved products, which we may not complete successfully or on time for any number of reasons, including, but not limited to, lack of funds to complete the studies and insufficient interest by appropriate sites, investigators or study subjects. We are currently subject to certain post-approval commitments. If we fail to comply with post-approval legal and regulatory requirements, we could be subject to penalties, and our products could be subject to continual recordkeeping and reporting requirements, review and periodic inspections by the FDA and other regulatory bodies. Regulatory approval of a product may be subject to limitations on the indicated uses for which the product may be marketed or to the other restrictive conditions of approval that limit our ability to promote, sell or distribute a product. Furthermore, the approval of our products and any other future product candidates may be subject to requirements for costly post-approval testing and surveillance to monitor their safety or efficacy.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising and promotion are subject to stringent FDA rules and oversight, and as an NDA holder, we may be held responsible for any advertising and promotion that is not in compliance with the rules and regulations. In particular, the claims in all promotional materials and activities must be consistent with the FDA approvals for approved products and must be appropriately substantiated and fairly balanced with information on the safety risks and limitations of the products. We are also required to engage in appropriate truthful, non-misleading, and non-promotional scientific exchange concerning our products, and applicable regulatory authorities, competitors, and other third parties may take the position that we are not in compliance with such regulations. In addition to medical education efforts, we may offer patient support </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services to assist patients receiving treatment with our commercially approved products which have increasingly become the focus of government investigation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse event information concerning approved products must be reviewed, and as an NDA holder, we are required to make expedited and periodic adverse event reports to the FDA and other regulatory authorities. In addition, the research, manufacturing, distribution, sale and promotion of products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the HHS, the DOJ and individual U.S. Attorney offices within the DOJ, state and local governments, and foreign equivalents of the foregoing. All of these activities are also potentially subject to healthcare false claims and fraud and abuse laws, as well as consumer protection and unfair competition laws.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations with respect to our products that are subject to healthcare laws and regulations are found to be in violation of any of the healthcare fraud and abuse laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with all applicable fraud and abuse laws may be costly.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the risk of fraud or other misconduct by our employees and consultants, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee and consultant misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee and consultant misconduct, whether intentional, reckless, negligent, or unintentional, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our partners may be subject to new legislation, regulatory proposals and healthcare payor initiatives that may increase our costs of compliance and adversely affect our or our partners</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ability to market and develop our products and product candidates, obtain collaborators and raise capital.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act (&#8220;PPACA&#8221;) made extensive changes to the delivery of healthcare in the United States. The PPACA included numerous provisions that affect pharmaceutical companies, some of which became effective immediately and others of which have taken effect over the past several years. For example, the PPACA expanded healthcare coverage to the uninsured through private health insurance reforms and an expansion of Medicaid. The PPACA also imposed substantial costs on pharmaceutical manufacturers, such as an increase in liability for rebates paid to Medicaid, new drug discounts that must be offered to certain enrollees in the Medicare prescription drug benefit, an annual fee imposed on all manufacturers of brand prescription drugs in the United States, and an expansion of an existing program requiring pharmaceutical discounts to certain types of hospitals and federally subsidized clinics. The PPACA also contains cost containment measures that could reduce reimbursement levels for healthcare items and services generally, including pharmaceuticals. It also required reporting and public disclosure of payments and other transfers of value provided by pharmaceutical companies to physicians and teaching hospitals.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare could result in decreased net revenues from our pharmaceutical products and decrease potential returns from our development efforts. In addition, pharmaceutical and device manufacturers are also required to report and disclose certain payments and transfers of value to, and investment interests held by, physicians and their immediate family members during the preceding calendar year. Failure to submit required </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information may result in civil monetary penalties for payments, transfers of value, or ownership or investment interests not reported in an annual submission. Compliance with the PPACA and state laws with similar provisions is difficult and time consuming, and companies that do not comply with these state laws face civil penalties. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there have been a number of other legislative and regulatory proposals aimed at changing the pharmaceutical industry. For example, legislation has been enacted in certain states and at a federal level that requires development of an electronic pedigree to track and trace each prescription drug at the saleable unit level through the distribution system. Compliance with these electronic pedigree requirements may increase our operational expenses and impose significant administrative burdens. In addition, our compliance may be deemed insufficient and we could face a material adverse effect on our business, financial condition, results of operations and growth prospects. As a result of these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adequate coverage and reimbursement in the United States and other markets is critical to the commercial success of our approved products. Recently in the United States, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement methodologies and establish certain government negotiated drug prices. Individual states in the United States have been increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Third-party payors are increasingly challenging the prices charged for medical products and services and, in some cases, imposing restrictions on the coverage of particular drugs. Many third-party payors negotiate the price of medical services and products and develop formularies which establish pricing and reimbursement levels. Exclusion of a product from a formulary can lead to its sharply reduced usage in the third-party payor&#8217;s patient population. The process for obtaining coverage can be lengthy and costly, and we expect that it could take several months before a particular payor initially reviews a product and makes a decision with respect to coverage. For example, third-party payors may require cost-benefit analysis data from us in order to demonstrate the cost-effectiveness of our products or any other product we might bring to market. For any individual third-party payor, we may not be able to provide data sufficient to gain reimbursement on a similar or preferred basis to competitive products, or at all, which may have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to data security and privacy risks, and our actual or perceived failure to comply with regulations and other legal obligations related to privacy and data protection could harm our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to legal obligations related to privacy and data protection. Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use, and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. For example, we may be subject to the California Consumer Privacy Act, which gives California residents expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. We also may be subject to the General Data Protection Regulation (&#8220;GDPR&#8221;) in the European Economic Area (&#8220;EEA&#8221;) and similar legislation in the United Kingdom and Switzerland. See &#8220;Risks Relating to Our Business&#8212;Risks Relating to International Operations&#8212;Our actual or perceived failure to comply with European governmental laws and regulations and other legal obligations related to privacy, data protection and information security could harm our business&#8221; in this section for additional discussion of international privacy laws and regulations. Failure to comply with these laws and regulations could result in government enforcement actions, private litigation, or harm to our reputation and our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If, because of our use of hazardous materials, we violate any environmental controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development involves the controlled use of hazardous materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing the use, storage, handling and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disposal of these materials and some waste products. Accidental contamination or injury from these materials could occur. In the event of an accident, we could be liable for any damages that result, and any liabilities could exceed our resources. Compliance with environmental laws and regulations or a violation of such environmental laws and regulations could require us to incur substantial unexpected costs, which would materially and adversely affect our results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of those rights would diminish.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part on our ability and the abilities of our partners to obtain, protect and enforce viable intellectual property rights including, but not limited to, trade name, trademark and patent protection for our Company and its products, methods, processes and other technologies we may license or develop, to preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both domestically and abroad. The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves complex legal and factual questions and has recently been the subject of much litigation. Neither the United States Patent and Trademark Office (&#8220;USPTO&#8221;), the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions have consistent policies nor predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology and pharmaceutical patents. Further, we may not have worldwide patent protection for all of our product candidates and our intellectual property rights may not be legally protected or enforceable in all countries throughout the world. In some jurisdictions, some of our product candidates in certain programs, including our HAE program, may have short or no composition of matter patent life and we may therefore rely on orphan drug exclusivity or data exclusivity. There can be no assurance that we will obtain orphan drug exclusivity or data exclusivity in every jurisdiction. Further, in some jurisdictions, we may rely on formulation patents or method of use patents. Both the ability to achieve issuance and the enforcement of formulation and method of use patents can be highly uncertain and can vary from jurisdiction to jurisdiction, and such patents may therefore not adequately prevent competitors and potential infringers in some jurisdictions. The validity, scope, enforceability and commercial value of the rights protected by such patents, therefore, is highly uncertain.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secrets to protect technology in cases when we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborators and advisors, our ability to receive patent protection or protect our proprietary information may be imperiled.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in legal proceedings to protect or enforce our patents, the patents of our partners or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive, time-consuming, and unsuccessful. An adverse result in any legal proceeding could put one or more of our patents at risk. Our success depends in part on avoiding the infringement of other parties&#8217; patents and other intellectual property rights as well as avoiding the breach of any licenses relating to our technologies and products. In the United States, patent applications filed in recent years are confidential for 18 months, while older applications are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, our partners or our licensors, we or they could be forced to stop or delay research, development, manufacturing or sales of any infringing product in the country or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. Such a license may not be available on acceptable terms, or at all, particularly if the third party is developing or marketing a product competitive with the infringing product. Even if we, our partners or our licensors were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our partners are unable or fail to adequately initiate, protect, defend or enforce our intellectual property rights in any area of commercial interest or in any part of the world where we wish to seek regulatory approval for our products, methods, processes and other technologies, the value of our products and product candidates to produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies or our commercial use of such products, processes, and other technologies, including, but not limited to, any trade name, trademark or commercial strategy infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent offices </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of other jurisdictions have issued to us a number of patents for our various inventions, and we have in-licensed several patents from various institutions. We have filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding foreign patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We have also filed certain trademark and trade name applications worldwide. We cannot assure you as to:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree and range of protection any patents will afford against competitors with similar products;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if and when patents will issue;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if patents do issue, we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents; or</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the USPTO or other foreign patent office upholds patents issued to others or if the USPTO grants patent applications filed by others, we may have to:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain licenses or redesign our products or processes to avoid infringement;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stop using the subject matter claimed in those patents; or</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay damages.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may initiate, or others may bring against us, litigation or administrative proceedings related to intellectual property rights, including proceedings before the USPTO or other foreign patent office. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent application could materially and adversely affect our business, financial condition and results of operations. In addition, the costs of any litigation or administrative proceeding may be substantial whether or not we are successful.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is also dependent upon the skills, knowledge and experience, none of which is patentable, of our scientific and technical personnel. To help protect our rights, we require all employees, consultants, advisors and partners to enter into confidentiality agreements that prohibit the disclosure of confidential information to anyone outside of our Company and require disclosure and assignment to us of their ideas, developments, discoveries and inventions. These agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information, and if any of our proprietary information is disclosed, our business will suffer because our revenues depend upon our ability to license or commercialize our products and product candidates and any such events would significantly impair the value of such products and product candidates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Liability Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face an inherent risk of liability in the event that the use or misuse of our products or product candidates results in personal injury or death and our product liability insurance coverage may be insufficient.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the use or misuse of any products we sell, or a partner sells, harms people, we may be subject to costly and damaging product liability claims brought against us by consumers, healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product candidates in clinical trials, including post-marketing clinical studies, could also expose us to product liability claims. We cannot predict all of the possible harms or side effects that may result from the use of our products or the testing of product candidates, and therefore, the amount of insurance coverage we currently have may not be adequate to cover all liabilities or defense costs we might incur. A product liability claim or series of claims brought against us could give rise to a substantial liability that could exceed our resources. Even if claims are not successful, the costs of defending such claims and potential adverse publicity could be harmful to our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and face even greater risks upon commercialization by us of our products or product candidates. We have product liability insurance covering our clinical trials. Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance or increase our existing coverage at a reasonable cost to protect us against losses that could have a material adverse effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates causes, or is claimed to have caused, an </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">injury or is found to be unsuitable for consumer use. Any product liability claim brought against us, with or without merit, could result in:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial volunteers or patients;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage to our reputation and the reputation of our products, resulting in lower sales;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory investigations that could require costly recalls or product modifications;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation costs; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the diversion of management&#8217;s attention from managing our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Relating to Contractual Arrangements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks related to our government-funded programs and are subject to various U.S. Government contract requirements, which may create a disadvantage and additional risks to us.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have contracts with BARDA/HHS and NIAID/HHS for the development of galidesivir as a treatment for diseases caused by RNA pathogens, including Marburg virus disease, Yellow Fever and Ebola virus disease. In contracting with these government agencies, we are subject to various U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which may limit our reimbursement or, if we are found to be in violation, could result in contract termination. We expect the funding under our government contracts to expire in 2022.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government contracts typically contain a number of extraordinary provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to us as compared to competitors that do not rely on U.S. Government contracts. These risks include the ability of the U.S. Government to unilaterally:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terminate or reduce the scope of our contract with or without cause;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interpret relevant regulations (federal acquisition regulation clauses);</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require performance under circumstances which may not be favorable to us;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require an in-process review where the U.S. Government will review the project and its options under the contract;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">control the timing and amount of funding, which impacts the development progress of our programs; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">audit and object to our contract-related costs and fees, including allocated indirect costs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Government may terminate its contracts with us either for its convenience or if we default by failing to perform in accordance with the contract schedule and terms. Termination for convenience provisions generally enable us to recover only our costs incurred or committed, and settlement expenses and profit on the work completed prior to termination. Termination does not permit these recoveries under default provisions. In the event of termination or upon expiration of a contract, the U.S. Government may dispute wind-down and termination costs and may question prior expenses under the contract and deny payment of those expenses. Should we choose to challenge the U.S. Government for denying certain payments under a contract, such a challenge could subject us to substantial additional expenses which we may or may not recover. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a U.S. Government contractor, we are required to comply with applicable laws, regulations and standards relating to our accounting practices and are subject to periodic audits and reviews. As part of any such audit or review, the U.S. Government may review the adequacy of, and our compliance with, our internal control systems and policies, including those relating to our purchasing, property, estimating, compensation and management information systems. Audits under the active BARDA/HHS and NIAID/HHS galidesivir contracts may occur at the election of the U.S. Government and have been concluded through fiscal 2019; all subsequent fiscal years are still open and auditable. Based on the results of its audits, the U.S. Government may adjust our contract-related costs and fees, including allocated indirect costs. This adjustment could impact the amount of revenues reported on a historic basis. In addition, in the event BARDA/HHS or NIAID/HHS determines that certain costs and fees were unallowable or determines that the allocated indirect cost rate was higher than the actual indirect cost rate, BARDA/HHS or NIAID/HHS would be entitled to recoup any overpayment from us as a result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension of payments, fines and suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm to our reputation if allegations of impropriety were made against us. In addition, under U.S. Government purchasing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations, some of our costs may not be reimbursable or allowed under our contracts. Further, as a U.S. Government contractor, we are subject to an increased risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared to private sector commercial companies.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There are risks related to the potential government use or sale of our antivirals.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government use or sale, in emergency situations or otherwise, of our antivirals (including peramivir for the treatment of influenza) may result in risks to us or our collaborative partners. There can be no assurance that government use of our antivirals (whether as indicated or outside of their current indications) will prove to be generally safe, well-tolerated and effective. Any government sale or use (on an emergency basis or otherwise) of our antivirals in any country may create liabilities for us or our partners.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we entered into a contract with the U.S. Government for the procurement of up to 50,000 doses of RAPIVAB (peramivir injection) over a five-year period. There can be no assurance that we or our manufacturers will be able to fully meet the demand for our antivirals with respect to this or any future arrangements. Further, we may not receive a favorable purchase price for future orders, if any, of our antivirals by governmental entities. Our competitors may develop products that could compete with or replace any antivirals selected for government sale or use. We may face competition in markets where we have no existing intellectual property protection or are unable to successfully enforce our intellectual property rights.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the non-U.S. partnerships that we have entered into for peramivir will result in any order for peramivir in those countries or that peramivir will be approved for any use or will achieve market approval in additional countries. In the event that any emergency use or market approval is granted in any country, there can be no assurance that any government order or commercialization of the applicable product or product candidate in such countries will be substantial or will be profitable to us.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to reach milestones or to make annual minimum payments or otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional remedies.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable or fail to meet payment obligations, performance milestones relating to the timing of regulatory filings, product supply obligations, post-approval commitments, or development and commercial diligence obligations; are unable or fail to make milestone payments or material data use payments in accordance with applicable provisions; or fail to pay the minimum annual payments under any of our in-licenses relating to our products or product candidates, our licensors may terminate the applicable license or seek other available remedies. As a result, our development of the respective product candidate or commercialization of the product would cease.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties and milestone payments, if any, from Shionogi under the Shionogi Agreement are required to be used by Royalty Sub to satisfy its obligations under its PhaRMA Notes, and generally will not be available to us for other purposes unless and until Royalty Sub has repaid in full its obligations under the PhaRMA Notes.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2011, our wholly-owned subsidiary, Royalty Sub, issued $30.0 million in aggregate principal amount of PhaRMA Notes. The PhaRMA Notes are secured principally by (i) certain royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from us the rights to market peramivir in Japan and Taiwan and (ii) the pledge by us of our equity interest in Royalty Sub. Payments, if any, from Shionogi to us on non-governmental sales under the Shionogi Agreement will generally not be available to us for other purposes unless and until Royalty Sub has repaid in full its obligations under the PhaRMA Notes. Accordingly, these funds have been and will continue to be required to be dedicated to Royalty Sub&#8217;s debt service and not available to us for product development or other purposes. Since September 1, 2014, payments from Shionogi have been insufficient for Royalty Sub to service its obligations under the PhaRMA Notes, resulting in a continuing event of default with respect to the PhaRMA Notes since that time. As a result of the continuing event of default, the holders of the PhaRMA Notes may be able to foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may exercise other remedies available to them under the indenture or other documents related to the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments, if any, that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs, and we might otherwise be adversely affected.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PhaRMA Notes had a final legal maturity date of December 1, 2020, at which time the outstanding principal amount of the PhaRMA Notes of $30.0 million, together with accrued and unpaid interest of $20.6 million, was due in full. The failure by Royalty Sub to repay in full the outstanding principal amount of the PhaRMA Notes, together with any accrued and unpaid interest, at the December 1, 2020 final maturity date constituted an additional event of default under the PhaRMA Notes. We cannot predict whether holders of PhaRMA Notes will seek to pursue any remedies as a result of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continuing events of default with respect to the PhaRMA Notes. The PhaRMA Notes are the obligation of Royalty Sub. As a result, we do not currently expect the continuing events of default on the PhaRMA Notes to have a significant impact on our future results of operations or cash flows. However, we cannot assure you that this will be the case or that we will not otherwise be adversely affected as a result of the continuing events of default under the PhaRMA Notes or the failure by Royalty Sub to repay the PhaRMA Notes at maturity.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We wrote off the balance due under the PhaRMA Notes to other income as a debt extinguishment as of December 31, 2021. See &#8220;Note 6&#8212;Royalty Monetizations&#8212;RAPIACTA&#8212;Non-Recourse Notes Payable&#8722;Debt Extinguishment&#8221; in the Notes to Consolidated Financial Statements in Part I, Item 1 of this report for additional information about the write-off.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because continuing events of default exist under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub. As a result, we may not realize the benefit of future royalty payments, if any, that might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely affected.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As Royalty Sub has been unable to service its obligations under the PhaRMA Notes and continuing events of default exist under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may exercise other remedies available to them under the indenture or other documents related to the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments, if any, that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs, and we might otherwise be adversely affected. In addition, the PhaRMA Notes had a final legal maturity date of December 1, 2020, at which time the outstanding principal amount of the PhaRMA Notes of $30.0 million, together with accrued and unpaid interest of $20.6 million, was due in full. The failure by Royalty Sub to repay in full the outstanding principal amount of the PhaRMA Notes, together with any accrued and unpaid interest, at the December 1, 2020 final maturity date constituted an additional event of default under the PhaRMA Notes. We cannot predict whether holders of PhaRMA Notes will seek to pursue any remedies as a result of the continuing events of default with respect to the PhaRMA Notes. The PhaRMA Notes are the obligation of Royalty Sub. As a result, we do not currently expect the continuing events of default on the PhaRMA Notes to have a significant impact on our future results of operations or cash flows. However, we cannot assure you that this will be the case or that we will not otherwise be adversely affected as a result of the continuing events of default under the PhaRMA Notes or the failure by Royalty Sub to repay the PhaRMA Notes at maturity.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We wrote off the balance due under the PhaRMA Notes to other income as a debt extinguishment as of December 31, 2021. See &#8220;Note 6&#8212;Royalty Monetizations&#8212;RAPIACTA&#8212;Non-Recourse Notes Payable&#8722;Debt Extinguishment&#8221; in the Notes to Consolidated Financial Statements in Part I, Item 1 of this report for additional information about the write-off.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant indebtedness, which could adversely affect our business. Additionally, our Credit Agreement contains conditions and restrictions that limit our flexibility in operating our business. We may be required to make a prepayment or repay our outstanding indebtedness earlier than we expect if a prepayment event or an event of default occurs, including a material adverse change with respect to us, which could have a material adverse effect on our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we had an outstanding principal balance under our Credit Agreement of $232.4 million, inclusive of the quarterly PIK Interest Payments. We will be required to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that we prepay or repay, or are required to prepay or repay, voluntarily or pursuant to a mandatory prepayment obligation under the Credit Agreement (e.g., with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions), all of the then-outstanding Term Loans under the Credit Agreement, in each case, subject to certain exceptions set forth in the Credit Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness could have important consequences to our stockholders. For example, it:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases our vulnerability to adverse general economic or industry conditions;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limits our flexibility in planning for, or reacting to, changes in our business or the industry in which we operate;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">makes us more vulnerable to increases in interest rates, as borrowings under our Credit Agreement are at variable rates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requires us to dedicate a portion of our cash flow from operations to interest payments, limiting the availability of cash for other purposes;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limits our ability to obtain additional financing or refinancing in the future for working capital or other purposes; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">places us at a competitive disadvantage compared to our competitors that have less indebtedness.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our Credit Agreement contains various covenants that limit our ability to engage in specified types of transactions. Subject to certain exceptions, these covenants limit our ability to, among other things, grant certain types of liens on our assets; make certain investments; incur or assume certain debt; engage in certain mergers, acquisitions, and similar transactions; dispose of assets; license certain property; distribute dividends; make certain restricted payments; change the nature of our business; engage in transactions with affiliates and insiders; prepay other indebtedness; or engage in sale and leaseback transactions.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement also contains certain financial covenants, including a minimum liquidity covenant that requires us to maintain at all times at least $15.0 million (or, in certain circumstances, $20.0 million) of unrestricted cash and cash equivalents, subject to certain exceptions. In addition, as a result of drawing upon the Term C Loan, we are required to achieve certain minimum targets for consolidated net revenues from ORLADEYO sales in the United States.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The covenants contained in the Credit Agreement could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial without the lenders&#8217; permission or without repaying all outstanding obligations under the Credit Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A breach of any of these covenants could result in an event of default under the Credit Agreement. An event of default will also occur if, among other things, we fail to pay amounts due under the Credit Agreement, we fail to repay certain other indebtedness having an aggregate principal amount in excess of one percent of our borrowings under the Credit Agreement, a material adverse change in our business, assets, properties, liabilities, or condition occurs, or a material impairment of our ability to perform our obligations under the Credit Agreement occurs, we experience a change of control, certain negative regulatory events occur, including without limitation the loss of a required permit or a recall of a product, or we fail to make required payments under our Royalty Purchase Agreements. In the case of a continuing event of default under the Credit Agreement, the lenders under the Credit Agreement could elect to declare all amounts outstanding to be immediately due and payable, proceed against the collateral in which we granted to the lenders a security interest, or otherwise exercise the rights of a secured creditor. Amounts outstanding under the Credit Agreement are secured by a security interest in, subject to certain exceptions, substantially all of our assets. Because substantially all of our assets are pledged to secure the Credit Agreement obligations, our ability to incur additional secured indebtedness or to sell or dispose of assets to raise capital may be impaired, which could have an adverse effect on our financial flexibility.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Relating to International Operations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International expansion of our business exposes us to business, legal, regulatory, political, operational, financial, and economic risks.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy includes international expansion, including the commercialization of products outside of the United States. In addition, we currently conduct clinical studies and regulatory activities and have hired, and expect to continue hiring, employees outside of the United States. Doing business internationally involves a number of risks, including, but not limited to:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple, conflicting, and changing laws and regulations such as privacy and data regulations, transparency regulations, tax laws, export and import restrictions, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new health authority requirements and/or changes in health authority expectations;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by us or our partners to obtain and maintain regulatory approvals for the use of our products in various countries;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities and difficulties in obtaining and maintaining protection for, and enforcing, our intellectual property;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in staffing and managing foreign operations;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limits on our ability to penetrate international markets;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations, which have been increasingly prevalent alongside a strengthening U.S. dollar;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters and political and economic instability, including wars (e.g., the conflict in Ukraine), terrorism, political unrest, results of certain elections and votes, actual or threatened public health emergencies and outbreak of disease (e.g., the ongoing COVID-19 pandemic), boycotts, adoption or expansion of government trade restrictions, and other business restrictions;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain expenses including, among others, expenses for travel, translation, and insurance;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory and compliance risks that relate to maintaining accurate information and control over commercial operations and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, including its books and records provisions or anti-bribery provisions, or the U.K. Bribery Act and similar foreign laws and regulations; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory and compliance risks relating to doing business with any entity that is subject to sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could significantly harm our future international expansion of operations and adversely affect our business and results of operations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in some countries, such as Japan and the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we or our partners may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our actual or perceived failure to comply with European governmental laws and regulations and other legal obligations related to privacy, data protection and information security could harm our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EU member states, the United Kingdom, Switzerland and other countries have adopted data protection laws and regulations, which impose significant compliance obligations. For example, the GDPR imposes strict requirements on controllers and processors of personal data, including special protections for &#8220;special category data,&#8221; which includes health, biometric and genetic information of data subjects located in the EEA and, through incorporation in national legislation, the United Kingdom. Further, the GDPR provides a broad right for EU member states to create supplemental national laws, for example relating to the processing of health, genetic and biometric data, which could further limit our ability to use and share such data or could cause our costs to increase and harm our business and financial condition. The GDPR and similar national legislation grant individuals the opportunity to object to the processing of their personal information, allows them to request deletion of personal information in certain circumstances, and provides the individual with an express right to seek legal remedies in the event the individual believes his or her rights have been violated. Further, the GDPR and similar national legislation impose strict rules on the transfer of personal data out of the EEA, the United Kingdom, Switzerland, and other countries to the United States or other regions that have not been deemed to offer &#8220;adequate&#8221; privacy protections.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with the requirements of the GDPR or related national data protection laws, which may deviate from the GDPR, may result in significant fines of up to 4% of global revenues, or &#8364;20.0 million, whichever is greater, and in addition to such fines, our failure to comply with the requirements of GDPR or similar national legislation may subject us to litigation and/or adverse publicity, which could have material adverse effects on our reputation and business. As a result of the implementation of the GDPR, we are required to put in place additional mechanisms to ensure compliance with the data protection rules. For example, the GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process personal data, makes it harder for us to obtain valid consent for processing, requires the appointment of a data protection officer where sensitive personal data (i.e., health data) is processed on a large scale, introduces mandatory data breach notification throughout the European Union, imposes additional obligations on us when we are contracting with service providers and requires us to adopt appropriate privacy governance including policies, procedures, training and data audit.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the supervision of local data protection authorities in those jurisdictions where we undertake clinical trials. We depend on a number of third parties in relation to the provision of our services, a number of which process personal data of EU individuals on our behalf. With each such provider we are required to enter into contractual arrangements under which they are contractually obligated to only process personal data according to our instructions, and conduct diligence to ensure that they have sufficient technical and organizational security measures in place.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the European Union adopted the EU Clinical Trials Regulation, which came into effect on January 31, 2022. This regulation imposes new obligations to make publicly available certain information generated from clinical trials. Only very limited information is exempted from disclosure, i.e. commercially confidential information (which is construed increasingly narrowly) and protected personal data. It may be possible for others to use this data (for example, competitors who may use this data in their own research and development programs anywhere in the world) once this data is in the public domain.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to evolving European privacy laws on electronic marketing and cookies. The European Union is in the process of replacing the e-Privacy Directive (2002/58/EC) with a new set of rules taking the form of a regulation that will be directly implemented in the laws of each EU member state. While this e-Privacy Regulation was originally intended to be adopted on May 25, 2018, it is still going through the European legislative process and the timing of its adoption remains unclear.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">s decision to withdraw from the European Union could result in increased regulatory and legal complexity, which may make it more difficult for us to do business in Europe and impose additional challenges in securing regulatory approval of our product candidates in Europe.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom&#8217;s exit from the European Union, or Brexit, has caused political and economic uncertainty, including in the regulatory framework applicable to our operations and product candidates, and this uncertainty may persist for years. Brexit could, among other outcomes, disrupt the free movement of goods, services and people between the United Kingdom and the European Union, and result in increased legal and regulatory complexities, as well as potential higher costs of conducting business in Europe. The long-term effects of Brexit will depend in part on how the current and future trade agreements between the United Kingdom and the European Union take effect in practice. Changes in United Kingdom or EU regulations may cause disruption or delays in granting clinical trial authorization or opinions for marketing authorization, disruption of importation and export of active substance and other components of new drug formulations, and disruption of the supply chain for clinical trial product and final authorized formulations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effects of the disruption to the regulatory framework may add considerably to the development lead time to marketing authorization and commercialization of products in the European Union and/or the United Kingdom. It is possible that there will be increased regulatory complexities, which can disrupt the timing of our clinical trials and regulatory approvals. In addition, changes in, and legal uncertainty with regard to, national and international laws and regulations may present difficulties for our clinical and regulatory strategy. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenues and achieve and sustain profitability.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of Brexit, other European countries may seek to conduct referenda with respect to their continuing membership with the European Union. Given these possibilities and others we may not anticipate, as well as the absence of comparable precedent, it is unclear what financial, regulatory and legal implications the withdrawal of the United Kingdom from the European Union will have and how such withdrawal will affect us, and the full extent to which our business could be adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Relating to Technology</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our facilities, or the facilities of our third-party vendors, incur damage or power is lost for a significant length of time, our business will suffer.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our third-party vendors store commercial product, clinical and stability samples at our facilities that could be damaged if the facilities incur physical damage or in the event of an extended power failure. We have backup power systems in addition to backup generators to maintain power to all critical functions, but any loss of these products or samples could result in significant delays in our commercialization or drug development process.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we store most of our preclinical and clinical data at our facilities. Duplicate copies of most critical data are secured off-site. Any significant degradation or failure of our computer systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant delays in our drug development process, and any system failure could harm our business and operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant disruption in our information technology systems or a cybersecurity breach could adversely affect our business.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on information technology systems to operate our business. In addition, the FDA and comparable foreign regulatory authorities regulate, among other things, the record keeping and storage of data pertaining to potential pharmaceutical products. We currently store most of our preclinical research data, our clinical data and our manufacturing data at our facilities. While we do store duplicate copies of most of our clinical data offsite and a significant portion of our data is included in regular backups of our systems, we could lose important data if our facilities incur damage, or if our vendor data systems fail, suffer damage or are destroyed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks or intrusions, including by computer hackers, foreign governments, foreign companies, or competitors, or may be breached by employee error, malfeasance or other disruption. A breakdown, invasion, corruption, destruction, or interruption of critical information technology systems could negatively impact operations. If our systems are damaged, fail to function properly or otherwise become unavailable, we may incur substantial costs to repair or replace them, and we may experience loss of critical data and interruptions or delays in our ability to perform critical functions, which could adversely affect our business, financial condition or results of operations. Any compromise of our data security could also result in a violation of applicable privacy and other laws, significant legal and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our data security measures, which could harm our business. There can be no assurance that our efforts to protect our data and information technology systems will prevent breakdowns or breaches in our systems, or those of third parties with which we do business, and any such events could adversely affect our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Investing in Our Common Stock</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing principal stockholders hold a substantial amount of our common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our stockholders own greater than 5% of our outstanding common stock. Our top ten stockholders own close to 50% of our common stock and can individually, and as a group, influence our operations based upon their concentrated ownership and may also be able to influence the outcome of matters requiring approval of the stockholders, including the election of our directors and other corporate actions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been, and is likely to continue to be, highly volatile, which could cause the value of an investment in our common stock to decline significantly.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of biotechnology companies in general have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price has fluctuated frequently, and these fluctuations are often not related to our financial results. For the twelve months ended September&#160;30, 2022, the 52-week range of the market price of our stock was from $7.61 to $19.99 per share. The following factors, in addition to other risk factors described in this section, may have, and in some cases have had, a significant impact on the market price of our common stock:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations or new products by us or our competitors;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patents or proprietary rights;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional dilution through sales of our common stock or other derivative securities;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">status of new or existing licensing or collaborative agreements and government contracts;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements relating to the status of our programs;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments and announcements regarding new and virulent strains of influenza;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners achieving or failing to achieve development milestones;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publicity regarding actual or potential medical results relating to products under development by us or our competitors;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publicity regarding certain public health concerns for which we are or may be developing treatments;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in both the United States and foreign countries;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of pharmaceutical products;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated fluctuations in our operating results;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial estimates or recommendations by securities analysts and the comparison of such estimates to our actual results;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our public guidance;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems, including developments in price control legislation;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel or members of our board of directors;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic and other external factors or other disasters or crises; and</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial results.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This volatility could cause the value of an investment in our common stock to decline significantly. In addition, companies that have experienced volatility in the market price of their stock in the past have been subject to securities class action litigation. Securities litigation, and any other type of litigation, brought against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business and adversely affect our results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of securities may dilute the ownership interests of our current stockholders and cause our stock price to decline.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future sales of our common stock by us or our current stockholders into the public market could cause the market price of our stock to fall. As of October&#160;31, 2022, there were 186,423,835 shares of our common stock outstanding. We may from time to time issue securities in relation to a license arrangement, collaboration, merger or acquisition. We may also sell, for our own account, shares of common stock or other equity securities, from time to time at prices and on terms to be determined at the time of sale.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;31, 2022, there were 29,514,511 stock options and restricted stock units outstanding and 11,346,721 shares available for issuance under our Amended and Restated Stock Incentive Plan, 5,769,450 stock options and restricted stock units outstanding and 1,269,508 shares available for issuance under our Amended and Restated Inducement Equity Incentive Plan, and 5,792,461 shares available for issuance under our Amended and Restated Employee Stock Purchase Plan. In addition, we could also make equity grants outside of our Amended and Restated Stock Incentive Plan or Amended and Restated Inducement Equity Incentive Plan. The shares underlying existing stock options, restricted stock units and possible future stock options, stock appreciation rights and stock awards have been registered pursuant to registration statements on Form S-8.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If some or all of such shares are sold or otherwise issued into the public market over a short period of time, our current stockholders&#8217; ownership interests may be diluted and the value of all publicly traded shares is likely to decline, as the market may not be able to absorb those shares at then-current market prices. Additionally, such sales and issuances may make it more difficult for us to sell equity securities or equity-related securities in the future at a time and price that our management deems acceptable, or at all.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, we entered into a Registration Rights Agreement with entities affiliated with Baker Bros. Advisors LP (the &#8220;Baker Entities&#8221;) to provide that, if requested, we will register the shares of our common stock beneficially owned by the Baker Entities for resale under the Securities Act of 1993, as amended (the &#8220;Securities Act&#8221;). Our registration obligations pursuant to the Registration Rights Agreement cover all shares then held or thereafter acquired by the Baker Entities, for up to ten years, and include our obligation to facilitate certain underwritten public offerings of our common stock by the Baker Entities in the future. On May 10, 2017, we filed a registration statement on Form S-3 with respect to 11,710,951 shares of common stock held by the Baker Entities. Subsequently, on November 21, 2019, certain of the Baker Entities acquired pre-funded warrants to purchase 11,764,706 shares of our common stock at a price of $1.69 per warrant, of which warrants to purchase 11,511,472 shares of our common stock remain outstanding. In addition, on June 1, 2020, we issued to certain of the Baker Entities pre-funded warrants to purchase 3,511,111 shares of our common stock at a price of $4.49 per warrant. Each warrant has an exercise price of $0.01 per share. If the Baker Entities, by exercising their underwriting rights or otherwise, sell a large number of our shares, or the market perceives that the Baker Entities intend to sell a large number of our shares, this could adversely affect the market price of our common stock.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have anti-takeover provisions in our corporate charter documents that may result in outcomes with which you do not agree.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has the authority to issue up to 5,000,000 shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without further vote or action by our stockholders. The rights of the holders of any preferred stock that may be issued in the future may adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third parties to acquire a majority of our outstanding voting stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our Certificate of Incorporation provides for staggered terms for the members of the board of directors and supermajority approval of the removal of any member of the board of directors and prevents our stockholders from acting by written consent. Our Certificate of Incorporation also requires supermajority approval of any amendment of these provisions. These provisions and other provisions of our Amended and Restated Bylaws and of Delaware law applicable to us could delay or make more difficult a merger, tender offer or proxy contest involving us.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid dividends on our common stock and do not anticipate doing so in the foreseeable future.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our stock. We currently intend to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do not anticipate paying cash dividends on our common stock in the foreseeable future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Amended and Restated Bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain litigation that may be initiated by our stockholders, which may limit a stockholder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">s ability to obtain a favorable judicial forum for such disputes with us or our directors, officers or employees.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended and Restated Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, stockholders, employees or agents to us or our stockholders, (iii) any action asserting a claim against us or any of our directors, officers, stockholders, employees or agents arising out of or relating to any provision of the General Corporation Law of Delaware or our Certificate of Incorporation or Amended and Restated Bylaws, or (iv) any action against us or any of our directors, officers, stockholders, employees or agents governed by the internal affairs doctrine of the State of Delaware. This exclusive forum provision does not apply to establish the Delaware Court of Chancery as the forum for actions or proceedings brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This exclusive forum provision may limit a stockholder&#8217;s ability to choose its preferred judicial forum for disputes with us or our directors, officers, employees or agents, which may discourage the filing of lawsuits with respect to such claims. If a court were to find this exclusive forum provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in another jurisdiction, which could adversely affect our business and financial condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Natural disasters, epidemic or pandemic disease outbreaks, trade wars, armed conflicts, political unrest or other events could disrupt our business or operations or those of our development partners, manufacturers, regulators or other third parties with whom we conduct business now or in the future.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A wide variety of events beyond our control, including natural disasters, epidemic or pandemic disease outbreaks (such as the ongoing COVID-19 pandemic), trade wars, armed conflicts, political unrest or other events could disrupt our business or operations or those of our development partners (such as Torii), manufacturers, regulatory authorities, or other third parties with whom we conduct business. These events may cause businesses and government agencies to be shut down, supply chains to be interrupted, slowed, or rendered inoperable, and individuals to become ill, quarantined, or otherwise unable to work and/or travel due to health reasons or governmental restrictions. If our operations or those of third parties with whom we conduct business are impaired or curtailed as a result of these events, the development and commercialization of our products and product candidates could be impaired or halted, which could have a material adverse impact on our business. See &#8220;Risk Factors&#8212;Risks Relating to Our Business&#8212;Risks Relating to COVID-19.&#8221; In addition, other events, such as the armed conflict between Russia and Ukraine, could adversely impact our business. Furthermore, the conflict could lead to sanctions, embargoes, supply shortages, regional instability, geopolitical shifts, cyberattacks, other retaliatory actions, and adverse effects on macroeconomic conditions, currency exchange rates, and financial markets, which could adversely impact our operations and financial results, as well as those of third parties with whom we conduct business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to legal proceedings, which could harm our reputation or result in other losses or unexpected expenditure of time and resources.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in disputes, including, without limitation, disputes with our employees, collaborative partners, and third-party vendors. We may be called upon to initiate legal proceedings or to defend ourselves in such legal proceedings relating to our relationships with these parties, our decisions and actions or omissions with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respect thereto, and our business. In addition, if our stock price is volatile, we may become involved in securities class action lawsuits in the future. Due to the inherent uncertainties in legal proceedings, we cannot accurately predict the ultimate outcome of any such proceedings. An unfavorable outcome in any such proceedings could have an adverse impact on our business, financial condition and results of operations. Any current or future dispute resolution or legal proceeding, regardless of the merits of any such proceeding, could harm our reputation and result in substantial costs and a diversion of management&#8217;s attention and resources that are needed to successfully run our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance coverage is increasingly more costly and difficult to obtain or maintain.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we currently have insurance for our business, property, directors and officers, and our products, insurance is increasingly more costly and narrower in scope, and we may be required to assume more risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage, we will be required to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage that is outside of our insurance coverage, we may incur significant uninsured costs associated with loss or damage that could have an adverse effect on our operations and financial position. Furthermore, any claims made on our insurance policies may impact our ability to obtain or maintain insurance coverage at reasonable costs or at all.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development of our product candidates, the commercialization of our products, and the related expansion of our business will be delayed or stopped.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon our senior management and scientific team, the unexpected loss of whose services might impede the achievement of our development and commercial objectives. This risk has been heightened in the current environment as a result of the ongoing COVID-19 pandemic. Competition for key personnel with the experience that we require is intense and is expected to continue to increase. Our inability to attract and retain the required number of skilled and experienced management, commercial, operational and scientific personnel would harm our business because we rely upon these personnel for many critical functions of our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><div id="ia4cd069c56504e93a883c91651012280_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;Exhibits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000103570406000836/d42297exv3w1.htm">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000103570406000836/d42297exv3w1.htm">Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed December 22, 2006.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000136231007001386/c70813exv3w1.htm">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000136231007001386/c70813exv3w1.htm">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the&#160;Company&#8217;s Form 8-K filed July 24, 2007.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex31.htm">3.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex31.htm">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the&#160;Company&#8217;s Form 8-K filed May 7, 2014.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_31.htm">3.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_31.htm">Certificate of Elimination of the Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed May 13, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_32.htm">0.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_32.htm">3.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_32.htm">Certificate of Amendment to the Third Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.2 to the Company&#8217;s Form 8-K filed May 13, 2020.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w2.htm">3.6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w2.htm">Amended and Restated Bylaws of Registrant effective October 29, 2008. Incorporated by reference to Exhibit 3.2 to the Company&#8217;s Form 8-K filed November 4, 2008.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000110465918003194/a18-3548_1ex3d1.htm#Exhibit3_1_084143">3.7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882796/000110465918003194/a18-3548_1ex3d1.htm#Exhibit3_1_084143">Amendment to Amended and Restated By-Laws of BioCryst Pharmaceuticals, Inc., dated January 21, 2018. Incorporated by reference to&#160;Exhibit 3.1 to the Company&#8217;s Form 8-K filed January 22, 2018.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101-biocrystxbcx993.htm">(10.1)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit101-biocrystxbcx993.htm">Waiver to Credit Agreement, dated as of July 14, 2022, by and among BioCryst Pharmaceuticals, Inc., as borrower, the guarantors listed on the signature pages thereto, the lenders listed on the signature pages thereto, and Athyrium Opportunities III Co-Invest 1 LP, as administrative agent for the lenders. </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102-biocrystxamendm.htm">(10.2)#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit102-biocrystxamendm.htm">Amendment Number Two to Credit Agreement, dated as of August 3, 2022, by and among BioCryst Pharmaceuticals, Inc., as borrower, the guarantors listed on the signature pages thereto, the lenders listed on the signature pages thereto, and Athyrium Opportunities III Co-Invest 1 LP, as administrative agent for the lenders.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000117184322005818/exh_101.htm">10.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000117184322005818/exh_101.htm">Amendment #5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000117184322005818/exh_101.htm">, dated August 10, 2022, to the Contract dated September 1, 2018 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000117184322005818/exh_101.htm">between BioCryst Pharmaceuticals, Inc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000117184322005818/exh_101.htm">. and the U.S. Department of Health and Human Services. Incorporated by reference to Exhibit 10.1 to the C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000117184322005818/exh_101.htm">ompany</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000117184322005818/exh_101.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000117184322005818/exh_101.htm">s Form 8-K filed August 25, 2022.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882796/000117184322005818/exh_101.htm"> </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bcrx-20220930xexhibit104.htm">(10.4)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bcrx-20220930xexhibit104.htm">Amendment No. 1 to the Amended and Restated Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and William P. Sheridan, dated September 15, 2022.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bcrx-20220930xexx311.htm">(31.1)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bcrx-20220930xexx311.htm">Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="bcrx-20220930xexx312.htm">(31.2)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bcrx-20220930xexx312.htm">Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="bcrx-20220930xexx321.htm">(32.1)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="bcrx-20220930xexx321.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="bcrx-20220930xexx322.htm">(32.2)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="bcrx-20220930xexx322.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statements from the Quarterly Report on Form 10-Q of BioCryst Pharmaceuticals, Inc. for the three and nine months ended September 30, 2022, formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File &#8211;&#160;The cover page from this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 is formatted in Inline XBRL (contained in Exhibit 101).</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">( )</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed or furnished herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contract.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because it is both not material and would likely cause competitive harm to the Company if publicly disclosed.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72</span></div></div></div><div id="ia4cd069c56504e93a883c91651012280_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ia4cd069c56504e93a883c91651012280_7">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 4th day of November, 2022.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">BIOCRYST PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Jon P. Stonehouse</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Jon P. Stonehouse</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Anthony Doyle</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Anthony Doyle</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Financial Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Michael L. Jones</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Michael L. Jones</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Executive Director, Finance and Principal Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Accounting Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-biocrystxbcx993.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i30932357bcc84ca3b990135aed181921_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WAIVER </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THIS WAIVER </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), dated as of July 14, 2022, is entered into by and among BIOCRYST PHARMACEUTICALS, INC., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the guarantors listed on the signature pages hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Guarantors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the lenders listed on the signature pages hereto (such lenders, and the other lenders party to the Credit Agreement (as defined below), together with their respective successors and permitted assigns, each individually, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP, a Delaware limited partnership, as administrative agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and in light of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">W I T N E S S E T H</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Borrower, the Guarantors, the Lenders and the Administrative Agent are parties to that certain Credit Agreement, dated as of December 7, 2020 (as supplemented by that certain (i) Joinder Agreement, dated as of December 31, 2020, by and between BioCryst US Sales Co., LLC, a Delaware limited liability company, and the Administrative Agent, (ii) Joinder Agreement, dated as of February 8, 2021, by and between BioCryst UK Limited, a private limited company incorporated in England and Wales (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">BioCryst UK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and the Administrative Agent, (iii) Joinder Agreement, dated as of May 5, 2022, by and among BioCryst Espa&#241;a, S.L., a Spanish private limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Sociedad de Responsabilidad Limitada</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">BioCryst Spain</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), BioCryst Italia, S.r.l., an Italian limited liability company (societ&#224; a responsabilit&#224; limitata) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">BioCryst Italy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and as amended by that certain (i) Amendment Number One to Credit Agreement, dated as of November 19, 2021 by and among the Borrower, the Guarantors, the Lenders and the Administrative Agent and (ii) this Waiver, and as further amended, restated, supplemented, or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Borrower has (i) voluntarily paused enrollment in clinical trials with BCX9930 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Voluntary Pause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) while it investigates elevated serum creatinine levels seen in some patients, as disclosed by Borrower on April 8, 2022 pursuant to an 8-K filing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">April 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Elevated Serum Creatinine Levels</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)  and (ii) subsequently received written notice by the FDA informing Borrower that the FDA has placed the clinical program for BCX9930 on a partial clinical hold, as disclosed by Borrower on May 5, 2022 pursuant to an 8-K filing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">FDA Partial Clinical Hold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and together with the Voluntary Pause, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Partial Clinical Hold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Borrower has informed the Administrative Agent of the Partial Clinical Hold and discussed with the Administrative Agent whether, prior to the date of this Waiver, the Partial Clinical Hold gave rise to one or more Events of Default under the Credit Agreement including, but not limited to, with respect to any related notices required to be delivered by Borrower (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Prior Potential BCX9930 Events of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Borrower cannot predict the likelihood of any potential outcomes, including, but not limited to, the potential modification and subsequent re-initiation of the BCX9930 clinical trial program, or a potential decision not to continue the program&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Borrower has requested that the Administrative Agent and the Lenders waive the Prior Potential BCX9930 Events of Default and future and potential Events of Default that may arise as a direct result of the Loan Parties&#8217; ongoing non-compliance with certain provisions of the Loan Documents as they solely relate to BCX9930, and solely to the extent such Events of Default arise directly from the April 2022 Elevated Serum Creatinine Levels, as described in Section 2(a) below (such </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">future and potential Events of Default, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Future Potential BCX9930 Events of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and together with the Prior Potential BCX9930 Events of Default, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Potential BCX9930 Events of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, upon the terms and conditions set forth herein, the Administrative Agent and the undersigned Lenders, which constitute Required Lenders, are willing to waive the Potential BCX9930 Events of Default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in consideration of the foregoing and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  All initially capitalized terms used herein (including the preamble and recitals hereof) without definition shall have the meanings ascribed thereto in the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Waivers of Potential BCX9930 Events of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.7pt">Notwithstanding anything to the contrary in any Loan Document, the placement of a voluntary pause or hold or FDA-imposed clinical hold (whether partial or full), the issuance of a Safety Notice, the voluntary or involuntary limitation, modification or withdrawal of any Material Required Permit, or the suspension or discontinuation of research, design or development, in each case, in respect solely of BCX9930, and solely to the extent such events or actions are the direct results of the April 2022 Elevated Serum Creatinine Levels, either prior to, on, or after the date hereof, shall not be deemed to violate or cause a Default or Event of Default under, cause a material inaccuracy of any representation or warranty under, or to cause any non-compliance with any term or condition under, any Loan Document, so long as (i) BCX9930 is not being marketed, sold or commercialized at the time of such clinical hold, issuance of a Safety Notice, limitation, modification or withdrawal, or suspension or discontinuation, as applicable and (ii) such clinical hold, issuance of a Safety Notice, limitation, modification or withdrawal, or suspension or discontinuation, as applicable, does not result directly or indirectly from the fraud, gross negligence or willful misconduct of any of the Loan Parties and their respective Related Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.02pt">The provisions of the Credit Agreement and the other Loan Documents to the contrary notwithstanding, the Administrative Agent and Required Lenders hereby waive the Potential BCX9930 Events of Default so long as such Potential BCX9930 Events of Default do not arise directly or indirectly from the fraud, gross negligence, or willful misconduct of any of the Loan Parties and their respective Related Parties.  The foregoing waiver is limited in nature and nothing contained herein is intended, or shall be deemed or construed (i) to constitute a waiver of any existing or future Defaults or Events of Default or compliance with any term or provision of the Loan Documents or applicable Law (other than Potential BCX9930 Events of Default as expressly provided herein) or (ii) to establish a custom or course of dealing between the Loan Parties, on the one hand, and the Administrative Agent and&#47;or any Lender, on the other hand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or to otherwise obligate, in any respect, the Agent or any Lender to grant any waivers under the same or similar or other circumstances in the future.  The Loan Parties acknowledge and agree that, except as expressly set forth in this Waiver, the Administrative Agent and the </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:95%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lenders expressly reserve all rights and remedies that they now or may in the future have under any or all of the Loan Documents and applicable Law in connection with all Defaults or Events of Default (other than the Potential BCX9930 Events of Default, only as and to the extent provided herein).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Condition Precedent to Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The effectiveness of this Waiver is conditioned on the satisfaction in full, in a manner satisfactory to the Administrative Agent and the Required Lenders, or waiver, of the following conditions precedent&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Executed Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Administrative Agent shall have received this Waiver, duly executed and delivered by the parties hereto, and the same shall be in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">No Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Since December 31, 2021, except as otherwise specified herein, there shall not have occurred any event or condition that has had or could reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  There shall not exist any action, suit, investigation or proceeding pending or threatened in any court or before an arbitrator or Governmental Authority that could reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Governmental and Third Party Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Borrower and its Subsidiaries shall have received all material governmental, shareholder and third-party consents and approvals necessary in connection with the transactions contemplated by this Waiver and the other transactions contemplated hereby and all applicable waiting periods shall have expired without any action being taken by any Person that could reasonably be expected to restrain, prevent or impose any material adverse conditions on Borrower or any of its Subsidiaries or such other transactions or that could seek to threaten any of the foregoing, and no law or regulation shall be applicable which could reasonably be expected to have such effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each of Borrower and each Guarantor hereby represents and warrants to the Administrative Agent and the Lenders as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The execution, delivery and performance of this Waiver and such Loan Party&#8217;s obligations hereunder have been duly authorized by all necessary corporate or other similar action.  This Waiver has been duly executed and delivered by each Loan Party that is party thereto.  Each of this Waiver and the Credit Agreement (for the avoidance of doubt, as amended by this Waiver) constitutes a legal, valid and binding obligation of each Loan Party that is party thereto, enforceable against each such Loan Party, subject to applicable Debtor Relief Laws or other Laws affecting creditors&#8217; rights generally and subject to general principles of equity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">After giving effect to this Waiver, no Default or Event of Default has occurred and is continuing as of the date of the effectiveness of this Waiver, and no condition exists which constitutes a Default or an Event of Default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">After giving effect to this Waiver, the representations and warranties of the Borrower and each other Loan Party contained in Article VI of the Credit Agreement or any other Loan Document, or which are contained in any document furnished at any time under or in connection herewith or therewith, shall be true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) on and as of the </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:95%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) as of such earlier date, and except that for purposes of this Section 4(c), the representations and warranties contained in subsections (a) and (b) of Section 6.05 of the Credit Agreement shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 7.01 of the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">GOVERNING LAW&#59; JURISDICTION&#59; ETC.&#59; WAIVER OF RIGHT TO JURY TRIAL&#59; AND JUDGMENT CURRENCY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.  THIS WAIVER SHALL BE SUBJECT TO THE PROVISIONS REGARDING GOVERNING LAW&#59; SUBMISSION TO JURISDICTION, WAIVER OF VENUE, SERVICE OF PROCESS&#59; WAIVER OF RIGHT TO TRIAL BY JURY&#59; AND JUDGMENT CURRENCY SET FORTH IN SECTIONS 12.14, 12.15 AND 12.16 OF THE CREDIT AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">MUTATIS MUTANDIS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Counterpart Execution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Waiver may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Waiver.  Delivery of an executed counterpart of this Waiver by telefacsimile or other electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this Waiver.  Any party delivering an executed counterpart of this Waiver by telefacsimile or other electronic method of transmission also shall deliver an original executed counterpart of this Waiver, but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Waiver.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Each of the Loan Parties hereby releases and forever discharges the Administrative Agent, the Lenders and their respective predecessors, successors, assigns, officers, managers, directors, employees, agents, attorneys, representatives, and affiliates (hereinafter all of the above collectively referred to as, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lender Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), from any and all claims, counterclaims, demands, damages, debts, suits, liabilities, actions and causes of action of any nature whatsoever, in each case to the extent arising in connection with the Loan Documents or any of the negotiations, activities, events or circumstances arising out of or related to the Loan Documents through the date of this Waiver, whether arising at law or in equity, whether known or unknown, whether liability be direct or indirect, liquidated or unliquidated, whether absolute or contingent, foreseen or unforeseen, and whether or not heretofore asserted, which any of the Loan Parties may have or claim to have against any entity within the Lender Group.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Acknowledgment and Reaffirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  By its execution hereof, each of the Loan Parties hereby expressly (a) acknowledges and agrees to the terms and conditions of this Waiver, (b) except as otherwise amended hereby, reaffirms all of its respective covenants and other obligations set forth in the Credit Agreement and the other Loan Documents to which it is a party, (c) ratifies and confirms all security interests previously granted by it to the Administrative Agent for the benefit of the Secured Parties under the Loan Documents, as amended hereby, and (d) acknowledges that its respective covenants and other obligations set forth in the Credit Agreement and the other Loan Documents to which it is a party remain in full force and effect as amended hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Waiver, and the terms and provisions hereof, the Credit Agreement and the other Loan Documents constitute the entire understanding and agreement between the </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:95%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">parties hereto with respect to the subject matter hereof and supersede any and all prior or contemporaneous Waivers or understandings with respect to the subject matter hereof, whether express or implied, oral or written.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Waiver, together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto with respect to the subject matter hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In case any provision in this Waiver shall be invalid, illegal or unenforceable, such provision shall be severable from the remainder of this Waiver and the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Costs and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  As an inducement to the Administrative Agent and the Lenders entering into this Waiver and as otherwise required under the Loan Documents, the Borrower hereby agrees to pay pursuant to Section 12.04 of the Credit Agreement, following execution and delivery of this Waiver, all reasonable out-of-pocket cost and expenses of the Administrative Agent and the Lenders incurred in connection with this Waiver and the matters contemplated herein, including all reasonable attorney&#8217;s fees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Loan Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Waiver shall constitute a Loan Document for all purposes of the Credit Agreement and the other Loan Documents. The occurrence and continuation of any Event of Default under this Waiver shall entitle the Administrative Agent and the Lenders to exercise all rights and remedies available to them under Section 9.02 of the Credit Agreement. Each reference in the Credit Agreement to &#8220;this Agreement&#8221;, &#8220;hereunder&#8221;, &#8220;hereof&#8221;, &#8220;herein&#8221;, or words of like import, and each reference to the Credit Agreement in any other Loan Document shall be deemed a reference to the Credit Agreement as amended hereby. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Signature pages follow&#93;</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:95%">5</font></div></div></div><div id="i30932357bcc84ca3b990135aed181921_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have entered into this Waiver as of the date first above written.</font></div><div><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:2.16pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:2.16pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BORROWER&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BIOCRYST PHARMACEUTICALS, INC.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Alane Barnes&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Alane Barnes<br>Title&#58; Chief Legal Officer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:2.16pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GUARANTORS&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BIOCRYST IRELAND LIMITED</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incorporated under the laws of Ireland</font></div><div style="margin-bottom:0.12pt;padding-left:2.16pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Kevin Greaney&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Kevin Greaney<br>Title&#58; Director</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BIOCRYST UK LIMITED<br>incorporated under the laws of England</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Luke Robinson&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Luke Robinson<br>Title&#58; Director</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BIOCRYST US Sales Co., LLC<br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Alane Barnes&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Alane Barnes<br>Title&#58; Chief Legal Officer</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BioCryst Espa&#241;a, S.L.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by&#58; SG Corporate Support, S.L., its sole director<br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Leonardo Jose Britto Leon&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Leonardo Jose Britto Leon<br>Title&#58; Individual Representative</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">&#91;Signature Page to Waiver to Credit Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BioCryst Italia, S.r.l.<br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Michele Bignami&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Michele Bignami<br>Title&#58; Director</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:24pt;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">&#91;Signature Page to Waiver to Credit Agreement&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font></div></div></div><div id="i30932357bcc84ca3b990135aed181921_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADMINISTRATIVE AGENT&#58;&#160;&#160;&#160;&#160;ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP,</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Administrative Agent</font></div><div style="margin-bottom:12pt;padding-left:202.5pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ATHYRIUM OPPORTUNITIES ASSOCIATES CO-INVEST LLC, its General Partner</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Rashida Adams&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Rashida Adams</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Authorized Signatory</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-180pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:2.16pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LENDER&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP</font></div><div style="margin-bottom:0.12pt;padding-left:2.16pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ATHYRIUM OPPORTUNITIES ASSOCIATES CO-INVEST LLC, its General Partner</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Rashida Adams&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Rashida Adams</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Authorized Signatory</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">&#91;Signature Page to Waiver to Credit Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102-biocrystxamendm.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1ed95cd196cf47cb917b98c41e43b844_1"></div><div style="min-height:120.96pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 10.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Certain information has been omitted from this exhibit in places marked &#8220;&#91;***&#93;&#8221; because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDMENT NUMBER TWO TO CREDIT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIS AMENDMENT NUMBER TWO TO CREDIT AGREEMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), dated as of August 3, 2022, is entered into by and among BIOCRYST PHARMACEUTICALS, INC., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the guarantors listed on the signature pages hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Guarantors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the lenders listed on the signature pages hereto (such lenders, and the other lenders party to the Credit Agreement (as defined below), together with their respective successors and permitted assigns, each individually, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP, a Delaware limited partnership, as administrative agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and in light of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">W I T N E S S E T H</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Borrower, the Guarantors, the Lenders and the Administrative Agent are parties to that certain Credit Agreement, dated as of December 7, 2020 (as supplemented by that certain (i) Joinder Agreement, dated as of December 31, 2020, by and between BioCryst US Sales Co., LLC, a Delaware limited liability company, and the Administrative Agent, (ii) Joinder Agreement, dated as of February 8, 2021, by and between BioCryst UK Limited, a private limited company incorporated in England and Wales, and the Administrative Agent, and (iii) Joinder Agreement, dated as of May 5, 2022, by and among BioCryst Espa&#241;a, S.L., a Spanish private limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Sociedad de Responsabilidad Limitada</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), BioCryst Italia, S.r.l., an Italian limited liability company (societ&#224; a responsabilit&#224; limitata), and the Administrative Agent, and as amended or modified by that certain (i) Amendment Number One to Credit Agreement, dated as of November 19, 2021 by and among the Borrower, the Guarantors party thereto, the Lenders and the Administrative Agent, (ii) the Waiver, dated as of July 14, 2022 by and among the Borrower, the Guarantors, the Lenders and the Administrative Agent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (iii) this Amendment, and as further amended, restated, supplemented, or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Borrower has requested that the Administrative Agent and the Lenders amend the Credit Agreement to allow for the entering into by the Loan Parties of certain corporate credit programs&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, upon the terms and conditions set forth herein, the Administrative Agent and the undersigned Lenders, which constitute Required Lenders, are willing to amend the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in consideration of the foregoing and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All initially capitalized terms used herein (including the preamble and recitals hereof) without definition shall have the meanings ascribed thereto in the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Amendments to Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the satisfaction (or waiver in writing by the Required Lenders) of the conditions precedent set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, the Credit Agreement is hereby amended as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Section 8.03(i) of the Credit Agreement is hereby amended by deleting the word &#8220;and&#8221; at the end thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Section 8.03(j) of the Credit Agreement is hereby amended by deleting the period at the end thereof and substituting &#8220;&#59; and&#8221; in lieu thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:120.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Section 8.03 of the Credit Agreement is hereby amended to add the following new clause (k) at the end thereof&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;(k)&#160;&#160;&#160;&#160;unsecured (other than Liens described in Section 8.01(l), excluding, for the avoidance of doubt, cash collateral) Indebtedness incurred in the ordinary course of business under a commercial credit card program in an aggregate amount not to exceed $&#91;***&#93; at any one time outstanding.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Section 8.11 of the Credit Agreement is hereby amended and restated in its entirety as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;8.11&#160;&#160;&#160;&#160;Prepayment of Other Indebtedness. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Make (or give any notice with respect thereto) any voluntary or optional payment or prepayment or voluntary or optional redemption or acquisition for value of (including without limitation, by way of depositing money or securities with the trustee with respect thereto before due for the purpose of paying when due), refund, refinance or exchange of any Indebtedness of any Loan Party or any Subsidiary that is (or is required to be) (a) subordinated in right of payment to the Obligations, (b) unsecured Indebtedness or (c) Indebtedness secured by Liens which are junior to the Liens securing the Obligations, in the case of each of the foregoing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> except for (i) any settlement or conversion of Convertible Bond Indebtedness solely with or into common stock of the Borrower, (ii) any payment of cash in lieu of a fractional share in accordance with the terms of any indenture governing Convertible Bond Indebtedness in connection with the settlement or conversion of Convertible Bond Indebtedness permitted by clause (i) above of this Section 8.11 and (iii) any payment in the ordinary course of business in respect of unsecured Indebtedness under a commercial credit card program permitted by clause (k) above of Section 8.03.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Condition Precedent to Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The effectiveness of this Amendment is conditioned on the satisfaction in full, in a manner satisfactory to the Administrative Agent and the Required Lenders, or waiver, of the following conditions precedent&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Executed Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Administrative Agent shall have received this Amendment, duly executed and delivered by the parties hereto, and the same shall be in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">No Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Since December 31, 2021, except as otherwise specified in the Waiver, there shall not have occurred any event or condition that has had or could reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  There shall not exist any action, suit, investigation or proceeding pending or threatened in any court or before an arbitrator or Governmental Authority that could reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Governmental and Third Party Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Borrower and its Subsidiaries shall have received all material governmental, shareholder and third-party consents and approvals necessary in connection with the transactions contemplated by this Amendment, the other Loan Documents, and the other transactions contemplated hereby and all applicable waiting periods shall have expired without any action being taken by any Person that could reasonably be expected to restrain, prevent or impose any material adverse conditions on the Borrower or any of its Subsidiaries or such other transactions or that could seek to threaten any of the foregoing, and no law or regulation shall be applicable which could reasonably be expected to have such effect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:120.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each of the Borrower and each Guarantor hereby represents and warrants to the Administrative Agent and the Lenders as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The execution, delivery and performance of this Amendment and such Loan Party&#8217;s obligations hereunder have been duly authorized by all necessary corporate or other similar action.  This Amendment has been duly executed and delivered by each Loan Party that is party thereto.  Each of this Amendment and the Credit Agreement (for the avoidance of doubt, as amended by this Amendment) constitutes a legal, valid and binding obligation of each Loan Party that is party thereto, enforceable against each such Loan Party, subject to applicable Debtor Relief Laws or other Laws affecting creditors&#8217; rights generally and subject to general principles of equity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">No Default or Event of Default has occurred and is continuing as of the date of the effectiveness of this Amendment, and no condition exists which constitutes a Default or an Event of Default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">After giving effect to this Amendment, the representations and warranties of the Borrower and each other Loan Party contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement or any other Loan Document, or which are contained in any document furnished at any time under or in connection herewith or therewith, shall be true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) on and as of the date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) as of such earlier date, and except that for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the representations and warranties contained in subsections (a) and (b) of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">GOVERNING LAW&#59; JURISDICTION&#59; ETC.&#59; WAIVER OF RIGHT TO JURY TRIAL&#59; AND JUDGMENT CURRENCY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.  THIS AMENDMENT SHALL BE SUBJECT TO THE PROVISIONS REGARDING GOVERNING LAW&#59; SUBMISSION TO JURISDICTION, WAIVER OF VENUE, SERVICE OF PROCESS&#59; WAIVER OF RIGHT TO TRIAL BY JURY&#59; AND JUDGMENT CURRENCY SET FORTH IN SECTIONS 12.14, 12.15 AND 12.16 OF THE CREDIT AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">MUTATIS MUTANDIS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Counterpart Execution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Amendment.  Delivery of an executed counterpart of this Amendment by telefacsimile or other electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this Amendment.  Any party delivering an executed counterpart of this Amendment by telefacsimile or other electronic method of transmission also shall deliver an original executed counterpart of this Amendment, but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each of the Loan Parties hereby releases and forever discharges the Administrative Agent, the Lenders and their respective predecessors, successors, assigns, officers, managers, directors, employees, agents, attorneys, representatives, and affiliates (hereinafter all of the above collectively referred to as, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lender Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), from any and all claims, counterclaims, demands, damages, debts, suits, liabilities, actions and causes of action of any nature whatsoever, in each case to the extent arising in connection with the Loan Documents or any of the negotiations, activities, events or circumstances arising out of or related to the Loan Documents through the date of this Amendment, whether arising at law or in equity, whether known or unknown, whether liability be direct or indirect, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:120.96pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">liquidated or unliquidated, whether absolute or contingent, foreseen or unforeseen, and whether or not heretofore asserted, which any of the Loan Parties may have or claim to have against any entity within the Lender Group.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Acknowledgment and Reaffirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  By its execution hereof, each of the Loan Parties hereby expressly (a) acknowledges and agrees to the terms and conditions of this Amendment, (b) except as otherwise amended hereby, reaffirms all of its respective covenants and other obligations set forth in the Credit Agreement and the other Loan Documents to which it is a party, (c) ratifies and confirms all security interests previously granted by it to the Administrative Agent for the benefit of the Secured Parties under the Loan Documents, as amended hereby, and (d) acknowledges that its respective covenants and other obligations set forth in the Credit Agreement and the other Loan Documents to which it is a party remain in full force and effect as amended hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Amendment, and the terms and provisions hereof, the Credit Agreement and the other Loan Documents constitute the entire understanding and agreement between the parties hereto with respect to the subject matter hereof and supersede any and all prior or contemporaneous amendments or understandings with respect to the subject matter hereof, whether express or implied, oral or written.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Amendment, together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the subject matter hereof and is the final expression and agreement of the parties hereto with respect to the subject matter hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In case any provision in this Amendment shall be invalid, illegal or unenforceable, such provision shall be severable from the remainder of this Amendment and the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Costs and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As an inducement to the Administrative Agent and the Lenders entering into this Amendment and as otherwise required under the Loan Documents, the Borrower hereby agrees to pay pursuant to Section 12.04 of the Credit Agreement, following execution and delivery of this Amendment, all reasonable out-of-pocket cost and expenses of the Administrative Agent and the Lenders incurred in connection with this Amendment and the matters contemplated herein, including all reasonable attorney&#8217;s fees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Loan Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Amendment shall constitute a Loan Document for all purposes of the Credit Agreement and the other Loan Documents. The occurrence and continuation of any Event of Default under this Amendment shall entitle the Administrative Agent and the Lenders to exercise all rights and remedies available to them under Section 9.02 of the Credit Agreement. Each reference in the Credit Agreement to &#8220;this Agreement&#8221;, &#8220;hereunder&#8221;, &#8220;hereof&#8221;, &#8220;herein&#8221;, or words of like import, and each reference to the Credit Agreement in any other Loan Document shall be deemed a reference to the Credit Agreement as amended hereby. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#91;Signature pages follow&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1ed95cd196cf47cb917b98c41e43b844_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have entered into this Amendment as of the date first above written.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BORROWER&#58;&#160;&#160;&#160;&#160;BIOCRYST PHARMACEUTICALS, INC. </font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Alane Barnes&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Alane Barnes<br>Title&#58; Chief Legal Officer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GUARANTORS&#58;&#160;&#160;&#160;&#160;BIOCRYST IRELAND LIMITED<br>incorporated under the laws of Ireland</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Brian McInerney&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Brian McInerney<br>Title&#58; Director</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BIOCRYST UK LIMITED<br>incorporated under the laws of England</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Luke Robinson&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Luke Robinson<br>Title&#58; Director</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BIOCRYST US Sales Co., LLC<br></font></div><div style="text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Alane Barnes&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Alane Barnes<br>Title&#58; Chief Legal Officer</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-180pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:2.16pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:2.16pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:2.16pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:2.16pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">&#91;Signature Page to Amendment Number Two to Credit Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BioCryst Espa&#241;a, S.L.<br>by&#58; SG Corporate Support, S.L., its sole director<br><br></font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Leonardo Jose Britto&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Leonardo Jose Britto<br>Title&#58; Individual Representative</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BioCryst Italia, S.r.l.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Michele Bignami&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Michele Bignami<br>Title&#58; Director</font></div><div style="margin-bottom:24pt;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">&#91;Signature Page to Amendment Number Two to Credit Agreement&#93;</font></div></div></div><div id="i1ed95cd196cf47cb917b98c41e43b844_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-right:18pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADMINISTRATIVE AGENT&#58;&#160;&#160;&#160;&#160;ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP, as Administrative Agent</font></div><div style="margin-bottom:12pt;padding-left:202.5pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ATHYRIUM OPPORTUNITIES ASSOCIATES CO-INVEST LLC, its General Partner</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Rashida Adams&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Rashida Adams</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Authorized Signatory</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-180pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-144pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LENDER&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; ATHYRIUM OPPORTUNITIES ASSOCIATES CO-INVEST LLC, its General Partner</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Rashida Adams&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Rashida Adams</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Authorized Signatory</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">&#91;Signature Page to Amendment Number Two to Credit Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>bcrx-20220930xexhibit104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia08aa7ccc36d4ff6b543cdf17e4f0468_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.4</font></div></div><div style="margin-top:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%;text-decoration:underline">FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT</font></div><div style="margin-top:9.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">This First Amendment to Amended and Restated Employment Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8221;), dated this 15th day of September 2022 (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#34;), is entered into by and between BioCryst Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8221;) and Dr. William Sheridan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8221;).</font></div><div style="margin-top:12.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%;text-decoration:underline">RECITALS</font></div><div style="margin-top:9.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">, the Company and Employee are parties to that Amended and Restated Employment Agreement, dated as of August 4, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8221;)&#59; and </font></div><div style="margin-top:9.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">the parties wish to amend the terms of the Employment Agreement, as set forth herein, effective as of the date hereof.</font></div><div style="margin-top:9.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">Section 1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">.  Section 1(a) is hereby amended by replacing the reference to &#8220;Chief Medical Officer&#8221; with &#8220;Chief Development Officer&#8221;. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">Continuation of Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">.  Except as otherwise expressly provided herein, all of the terms and provisions of the Employment Agreement shall remain in full force and effect and this Employment Amendment shall not amend or modify any other rights, powers, duties, or obligations of any party to the Employment Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">Complete Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">. This Amendment and the Employment Agreement contain the entire agreement between the parties hereto with respect to the matters contained herein and supersedes and replaces any prior agreement between the parties with respect to the matters set forth in this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">. This Amendment may be executed in any number of counterparts, and any such counterparts may be transmitted by electronic transmission, and each of such counterparts, whether an original or an electronic or &#34;.pdf&#34; of an original, shall be deemed to be an original and all of such counterparts together shall constitute a single agreement.</font></div><div style="margin-top:9.2pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">, the parties hereto have executed this Amendment, on the date first set forth above.</font></div><div style="margin-top:15.95pt;padding-left:3.6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYEE</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BIOCRYST PHARMACEUTICALS, INC.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-top:15.95pt;padding-left:3.6pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:15.95pt;padding-left:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">&#47;s&#47; William Sheridan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">____________</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:15.95pt;padding-left:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">&#47;s&#47; Jon Stonehouse&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">William Sheridan, MB BS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Jon Stonehouse</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Chief Executive Officer</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:219.6pt;text-align:justify;text-indent:32.4pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>bcrx-20220930xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i69c8d10e2c044ecdad51e3e6012ccac0_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jon P. Stonehouse, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:99pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:99pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:99pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:99pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:99pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:99pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jon P. Stonehouse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jon P. Stonehouse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>bcrx-20220930xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id191747584304123adbecb1c83dc4dd8_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Anthony Doyle, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:99pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:99pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:99pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:99pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:99pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:99pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anthony Doyle</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthony Doyle</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>bcrx-20220930xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idb55a4e639054097a1a19779409f1c3e_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jon P. Stonehouse, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Jon P. Stonehouse</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jon P. Stonehouse</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">President and Chief Executive Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date&#58; November 4, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>bcrx-20220930xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibaa7ec5eb9b746fc8645b9f75f4542c2_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Anthony Doyle, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Anthony Doyle</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Anthony Doyle</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date&#58; November 4, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>bcrx-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f6ec4fab-a519-489e-b421-6c7ee3322750,g:f7084e6e-47c2-4faa-aed0-8ba33c516e4f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bcrx="http://www.biocryst.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biocryst.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.biocryst.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.biocryst.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.biocryst.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000004 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersDeficit" roleURI="http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit">
        <link:definition>0000006 - Statement - Consolidated Statements of Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersDeficitParenthetical" roleURI="http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders' Deficit (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesandConcentrationsofRisk" roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRisk">
        <link:definition>0000008 - Disclosure - Significant Accounting Policies and Concentrations of Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.biocryst.com/role/Revenue">
        <link:definition>0000009 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.biocryst.com/role/Investments">
        <link:definition>0000010 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradeReceivables" roleURI="http://www.biocryst.com/role/TradeReceivables">
        <link:definition>0000011 - Disclosure - Trade Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biocryst.com/role/Inventory">
        <link:definition>0000012 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyMonetizations" roleURI="http://www.biocryst.com/role/RoyaltyMonetizations">
        <link:definition>0000013 - Disclosure - Royalty Monetizations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.biocryst.com/role/Debt">
        <link:definition>0000014 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligations" roleURI="http://www.biocryst.com/role/LeaseObligations">
        <link:definition>0000015 - Disclosure - Lease Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.biocryst.com/role/StockholdersEquity">
        <link:definition>0000016 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://www.biocryst.com/role/StockbasedCompensation">
        <link:definition>0000017 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationships" roleURI="http://www.biocryst.com/role/CollaborativeandOtherRelationships">
        <link:definition>0000018 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesandConcentrationsofRiskPolicies" roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies">
        <link:definition>0000019 - Disclosure - Significant Accounting Policies and Concentrations of Risk (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.biocryst.com/role/RevenueTables">
        <link:definition>0000020 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.biocryst.com/role/InvestmentsTables">
        <link:definition>0000021 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradeReceivablesTables" roleURI="http://www.biocryst.com/role/TradeReceivablesTables">
        <link:definition>0000022 - Disclosure - Trade Receivables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biocryst.com/role/InventoryTables">
        <link:definition>0000023 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyMonetizationsTables" roleURI="http://www.biocryst.com/role/RoyaltyMonetizationsTables">
        <link:definition>0000024 - Disclosure - Royalty Monetizations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsTables" roleURI="http://www.biocryst.com/role/LeaseObligationsTables">
        <link:definition>0000025 - Disclosure - Lease Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://www.biocryst.com/role/StockbasedCompensationTables">
        <link:definition>0000026 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesandConcentrationsofRiskDetails" roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails">
        <link:definition>0000027 - Disclosure - Significant Accounting Policies and Concentrations of Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDetails" roleURI="http://www.biocryst.com/role/RevenueDetails">
        <link:definition>0000028 - Disclosure - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails" roleURI="http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails">
        <link:definition>0000029 - Disclosure - Investments- Fair Value of the Company's Investments by Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofMaturityofInvestmentsDetails" roleURI="http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails">
        <link:definition>0000030 - Disclosure - Investments - Schedule of Maturity of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradeReceivablesDetailsTextual" roleURI="http://www.biocryst.com/role/TradeReceivablesDetailsTextual">
        <link:definition>0000031 - Disclosure - Trade Receivables (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradeReceivablesSummaryofReceivablesDetails" roleURI="http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails">
        <link:definition>0000032 - Disclosure - Trade Receivables - Summary of Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biocryst.com/role/InventoryDetails">
        <link:definition>0000033 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyMonetizationsDetailsTextual" roleURI="http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual">
        <link:definition>0000034 - Disclosure - Royalty Monetizations (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails" roleURI="http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails">
        <link:definition>0000035 - Disclosure - Royalty Monetizations - Schedule of Royalty Financing Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://www.biocryst.com/role/DebtDetails">
        <link:definition>0000036 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsDetailsTextual" roleURI="http://www.biocryst.com/role/LeaseObligationsDetailsTextual">
        <link:definition>0000037 - Disclosure - Lease Obligations (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails" roleURI="http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails">
        <link:definition>0000038 - Disclosure - Lease Obligations - Aggregate Lease Expense Under Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails" roleURI="http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails">
        <link:definition>0000039 - Disclosure - Lease Obligations - Other Supplemental Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails" roleURI="http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails">
        <link:definition>0000040 - Disclosure - Lease Obligations -Balance Sheets of the Company's Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>0000041 - Disclosure - Lease Obligations - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.biocryst.com/role/StockholdersEquityDetails">
        <link:definition>0000042 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationDetailsTextual" roleURI="http://www.biocryst.com/role/StockbasedCompensationDetailsTextual">
        <link:definition>0000043 - Disclosure - Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockPlanActivitiesDetails" roleURI="http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails">
        <link:definition>0000044 - Disclosure - Stock-based Compensation - Stock Plan Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails" roleURI="http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails">
        <link:definition>0000045 - Disclosure - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsDetails" roleURI="http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails">
        <link:definition>0000046 - Disclosure - Collaborative and Other Relationships (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bcrx_RoyaltiesRevenuesPaidAndPayable" abstract="false" name="RoyaltiesRevenuesPaidAndPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_OMERSCapitalMarketsMember" abstract="true" name="OMERSCapitalMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AnnualNetSalesOver230000Member" abstract="true" name="AnnualNetSalesOver230000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_PERAMIVIRMember" abstract="true" name="PERAMIVIRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_BCX9930Member" abstract="true" name="BCX9930Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AECOMAndIRLMember" abstract="true" name="AECOMAndIRLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" abstract="false" name="ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_InterestReserve" abstract="false" name="InterestReserve" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_AggregateLeaseExpense" abstract="false" name="AggregateLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_PercentageOfCommonStockSharesBeginning" abstract="false" name="PercentageOfCommonStockSharesBeginning" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_IncentivePlanAndInducementPlanMember" abstract="true" name="IncentivePlanAndInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" abstract="false" name="NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_AnnualNetSalesBetween15And3BillionsMember" abstract="true" name="AnnualNetSalesBetween15And3BillionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_LongTermInvestmentMaturityMinimum" abstract="false" name="LongTermInvestmentMaturityMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" abstract="false" name="AverageMaturityPeriodOfHighQualityMarketableSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bcrx_RPI2019IntermediateFinanceTrustMember" abstract="true" name="RPI2019IntermediateFinanceTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" abstract="true" name="VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_RoyaltyReceivableMember" abstract="true" name="RoyaltyReceivableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" abstract="false" name="PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_RoyaltyExpenseReversalOfExpense" abstract="false" name="RoyaltyExpenseReversalOfExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_ASPRBARDAContractMember" abstract="true" name="ASPRBARDAContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" abstract="false" name="RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_BetweenTheSecondAndThirdAnniversariesMember" abstract="true" name="BetweenTheSecondAndThirdAnniversariesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_DebtCovenantTermsAxis" abstract="true" name="DebtCovenantTermsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_DebtCovenantTermsDomain" abstract="true" name="DebtCovenantTermsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_MaturityPeriodOfHighQualityMarketableSecurities" abstract="false" name="MaturityPeriodOfHighQualityMarketableSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bcrx_RoyaltyFinancingObligationsTableTextBlock" abstract="false" name="RoyaltyFinancingObligationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_RoyaltyMonetizationsLineItems" abstract="true" name="RoyaltyMonetizationsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_JPRRoyaltySubLLCMember" abstract="true" name="JPRRoyaltySubLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_BaseContractMember" abstract="true" name="BaseContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AnnualNetSalesRangeDomain" abstract="true" name="AnnualNetSalesRangeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_TermLoanAAndBDrawnMember" abstract="true" name="TermLoanAAndBDrawnMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_RPI2021And2020IntermediateFinanceTrustMember" abstract="true" name="RPI2021And2020IntermediateFinanceTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_MaximumAggregateOfferingPrice" abstract="false" name="MaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_TermBLoanMember" abstract="true" name="TermBLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_TransactionCosts" abstract="false" name="TransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_AfterFourthAnniversaryMember" abstract="true" name="AfterFourthAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_FutureRoyaltiesPayable" abstract="false" name="FutureRoyaltiesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_AnnualNetSalesUnder350000Member" abstract="true" name="AnnualNetSalesUnder350000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_CommonStockPurchaseAgreementWithRPIMember" abstract="true" name="CommonStockPurchaseAgreementWithRPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" abstract="false" name="ScheduleOfReceivablesFromCollaborationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" abstract="false" name="NonCashInterestExpenseOnRoyaltyFinancingObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_AnnualNetSalesRangeAxis" abstract="true" name="AnnualNetSalesRangeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_TermCLoanMember" abstract="true" name="TermCLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AnnualNetSalesOver550000Member" abstract="true" name="AnnualNetSalesOver550000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_TradeReceivablesTextBlock" abstract="false" name="TradeReceivablesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_SharesIssuedCommonStockPremium" abstract="false" name="SharesIssuedCommonStockPremium" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_TermALoanMember" abstract="true" name="TermALoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_SharesIssuedPricePerSharePremium" abstract="false" name="SharesIssuedPricePerSharePremium" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bcrx_MilestonePaymentMaximum" abstract="false" name="MilestonePaymentMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" abstract="false" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_ThirtysixEqualMonthlyInstallmentsMember" abstract="true" name="ThirtysixEqualMonthlyInstallmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_RoyaltyMontizationsRollForward" abstract="true" name="RoyaltyMontizationsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization" abstract="false" name="OperatingLeaseRightOfUseAssetAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_FutureRoyaltiesPayableMember" abstract="true" name="FutureRoyaltiesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_TermLoanADrawnMember" abstract="true" name="TermLoanADrawnMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_ORLADEYOMember" abstract="true" name="ORLADEYOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_CollateralForCreditMember" abstract="true" name="CollateralForCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_BetweenTheThirdAndFourthAnniversariesMember" abstract="true" name="BetweenTheThirdAndFourthAnniversariesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_InterestAndOtherIncomeLoss" abstract="false" name="InterestAndOtherIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" abstract="false" name="DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_DebtInstrumentLiborCap" abstract="false" name="DebtInstrumentLiborCap" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" abstract="false" name="InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_The2021RPIRoyaltyPurchaseAgreementMember" abstract="true" name="The2021RPIRoyaltyPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_InducementPlanMember" abstract="true" name="InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_DescriptionOfCompanyPolicyTextBlock" abstract="false" name="DescriptionOfCompanyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable" abstract="true" name="SignificantAccountingPoliciesAndConcentrationsOfRiskTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" abstract="false" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" abstract="false" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_ShionogiCoLtdMember" abstract="true" name="ShionogiCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_MilestoneRevenueMember" abstract="true" name="MilestoneRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_TermLoansABAndCDrawnMember" abstract="true" name="TermLoansABAndCDrawnMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AnnualNetSalesBetween150000And230000Member" abstract="true" name="AnnualNetSalesBetween150000And230000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" abstract="true" name="LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" abstract="false" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" abstract="false" name="AmortizationOfDiscountAndPremiumOnInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_SharesIssuedPricePerShareClosingPrice" abstract="false" name="SharesIssuedPricePerShareClosingPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bcrx_CollaborativeAgreementContractValue" abstract="false" name="CollaborativeAgreementContractValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_GreenCrossCorporationMember" abstract="true" name="GreenCrossCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" abstract="false" name="AvailableForSaleDebtSecuritiesAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_PeriodOfAgreement" abstract="false" name="PeriodOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bcrx_DebtInstrumentLiborFloor" abstract="false" name="DebtInstrumentLiborFloor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_RenewablePeriodOfAgreement" abstract="false" name="RenewablePeriodOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" abstract="false" name="LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_AthyriumMember" abstract="true" name="AthyriumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_RoyaltyMonetizationMember" abstract="true" name="RoyaltyMonetizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_MaximumCustomaryReductionOnRoyaltyRate" abstract="false" name="MaximumCustomaryReductionOnRoyaltyRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" abstract="false" name="MaximumNumberOfProductsPermittedToBeObtainedDoses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" abstract="true" name="SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_DebtInstrumentExitFeePercentageOfPrincipal" abstract="false" name="DebtInstrumentExitFeePercentageOfPrincipal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_AnnualNetSalesUnder15BillionMember" abstract="true" name="AnnualNetSalesUnder15BillionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" abstract="false" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_TwentyTwentyRPIRoyaltyAgreementMember" abstract="true" name="TwentyTwentyRPIRoyaltyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AnnualNetSalesUnder150000Member" abstract="true" name="AnnualNetSalesUnder150000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_MilestonePaymentMinimum" abstract="false" name="MilestonePaymentMinimum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_AdditionalDevelopmentOptionsMember" abstract="true" name="AdditionalDevelopmentOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_UABMember" abstract="true" name="UABMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_DebtInstrumentCommitmentFeePercentage" abstract="false" name="DebtInstrumentCommitmentFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" abstract="true" name="CollaborativeAndOtherResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" abstract="false" name="CollaborativeAgreementContractCovenantMaximumAmountOfFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" abstract="false" name="ConcentrationOfMarketRiskPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_AnnualNetSalesBetween350000And550000Member" abstract="true" name="AnnualNetSalesBetween350000And550000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_RoyaltyMonetizationTextBlock" abstract="false" name="RoyaltyMonetizationTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_AccruedExpensesPolicyTextBlock" abstract="false" name="AccruedExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" abstract="true" name="TwentyTwentyOneRPIRoyaltyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_OMERSRoyaltyAgreementMember" abstract="true" name="OMERSRoyaltyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" abstract="true" name="TermLoansABAndCDrawnAndCureRightExercisedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_SeniorCreditFacilityMember" abstract="true" name="SeniorCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bcrx_AnnualLicenseFeeMaximum" abstract="false" name="AnnualLicenseFeeMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" abstract="false" name="AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_BCX9930BCX10013Member" abstract="true" name="BCX9930BCX10013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_TermBAndCLoanMember" abstract="true" name="TermBAndCLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" abstract="false" name="DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_OperatingLeaseAssets" abstract="true" name="OperatingLeaseAssets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_RAPIVABMember" abstract="true" name="RAPIVABMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_ToriiPharmaceuticalCoMember" abstract="true" name="ToriiPharmaceuticalCoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_PerformancebasedRestrictedStockUnitsMember" abstract="true" name="PerformancebasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock" abstract="false" name="OtherSupplementalInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_MidCapFinancialServicesLLCMember" abstract="true" name="MidCapFinancialServicesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_NumberOfProductsObtainedDoses" abstract="false" name="NumberOfProductsObtainedDoses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" abstract="false" name="InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bcrx_RoyaltiesMonetizationsTable" abstract="true" name="RoyaltiesMonetizationsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bcrx_PercentageOfCommonStockSharesEnding" abstract="false" name="PercentageOfCommonStockSharesEnding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_MaturityPeriodOfShortTermInvestment" abstract="false" name="MaturityPeriodOfShortTermInvestment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" abstract="false" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" abstract="false" name="RoyaltyRateIfMaintainsSakigakeDesignation" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_USDepartmentOfHealthAndHumanServicesMember" abstract="true" name="USDepartmentOfHealthAndHumanServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_AnnualNetSalesOver3BillionsMember" abstract="true" name="AnnualNetSalesOver3BillionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" abstract="false" name="PercentageOfSalaryToPurchaseCommonStockMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bcrx_Vest25PercentEachYearUntilFullyVestedMember" abstract="true" name="Vest25PercentEachYearUntilFullyVestedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_PikInterestPaymentIsMadeMember" abstract="true" name="PikInterestPaymentIsMadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_PriorToTheSecondAnniversaryMember" abstract="true" name="PriorToTheSecondAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_NonEmployeeDirectorsMember" abstract="true" name="NonEmployeeDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bcrx_AnnualLicenseFeeMinimum" abstract="false" name="AnnualLicenseFeeMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bcrx_RoyaltyReceivablesFromPartnersMember" abstract="true" name="RoyaltyReceivablesFromPartnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_ShareBasedPaymentArrangementNumberOfPlans" abstract="false" name="ShareBasedPaymentArrangementNumberOfPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" abstract="false" name="DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_PhaRMANotesMember" abstract="true" name="PhaRMANotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" abstract="false" name="ProceedsFromAwardsForResearchAndDevelopmentContracts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_PrivatePlacementOfSeniorSecuredNotes" abstract="false" name="PrivatePlacementOfSeniorSecuredNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_IncentivePlanMember" abstract="true" name="IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bcrx_ContractTerm" abstract="false" name="ContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" abstract="false" name="DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>bcrx-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f6ec4fab-a519-489e-b421-6c7ee3322750,g:f7084e6e-47c2-4faa-aed0-8ba33c516e4f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="bcrx-20220930.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_acd4acc7-c8cc-4fbd-89fb-1fb756349ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a15bee86-aa6a-4440-b8ba-6218842c82f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_acd4acc7-c8cc-4fbd-89fb-1fb756349ed6" xlink:to="loc_us-gaap_AccountsPayableCurrent_a15bee86-aa6a-4440-b8ba-6218842c82f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3a948646-df19-458d-81b1-1d947e8a5144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_acd4acc7-c8cc-4fbd-89fb-1fb756349ed6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3a948646-df19-458d-81b1-1d947e8a5144" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_642a67e0-8905-4b37-9ecc-f9fc60f19b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_acd4acc7-c8cc-4fbd-89fb-1fb756349ed6" xlink:to="loc_us-gaap_DeferredRevenueCurrent_642a67e0-8905-4b37-9ecc-f9fc60f19b3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d4ab2802-9208-4ec5-8ed1-120e1ef9f0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_acd4acc7-c8cc-4fbd-89fb-1fb756349ed6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d4ab2802-9208-4ec5-8ed1-120e1ef9f0f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3ad4abc8-fc05-4568-bf1e-a5454e0e346a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e94faf1a-1281-474a-b528-77c0917a42e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3ad4abc8-fc05-4568-bf1e-a5454e0e346a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e94faf1a-1281-474a-b528-77c0917a42e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_38b06a9c-c809-4400-b040-f35518237eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3ad4abc8-fc05-4568-bf1e-a5454e0e346a" xlink:to="loc_us-gaap_LiabilitiesCurrent_38b06a9c-c809-4400-b040-f35518237eb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3fafb860-0265-48b6-a14d-849979053eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3ad4abc8-fc05-4568-bf1e-a5454e0e346a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3fafb860-0265-48b6-a14d-849979053eaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FutureRoyaltiesPayable_6272f930-09b2-493e-bb7b-f68d57df3a51" xlink:href="bcrx-20220930.xsd#bcrx_FutureRoyaltiesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3ad4abc8-fc05-4568-bf1e-a5454e0e346a" xlink:to="loc_bcrx_FutureRoyaltiesPayable_6272f930-09b2-493e-bb7b-f68d57df3a51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6474a66c-60eb-43de-be4f-514e6bea3a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3ad4abc8-fc05-4568-bf1e-a5454e0e346a" xlink:to="loc_us-gaap_StockholdersEquity_6474a66c-60eb-43de-be4f-514e6bea3a57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_662a4520-e2e0-4c1b-8293-66155fb3b221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_721633c0-8ff9-4d83-8ba2-dc35adcf9d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_662a4520-e2e0-4c1b-8293-66155fb3b221" xlink:to="loc_us-gaap_AssetsCurrent_721633c0-8ff9-4d83-8ba2-dc35adcf9d8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c7ededf4-fa78-4c14-8c09-ffd9b74a2576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_662a4520-e2e0-4c1b-8293-66155fb3b221" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c7ededf4-fa78-4c14-8c09-ffd9b74a2576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_4441a37c-6ac6-4ec4-96da-4fee75cfdd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_662a4520-e2e0-4c1b-8293-66155fb3b221" xlink:to="loc_us-gaap_LongTermInvestments_4441a37c-6ac6-4ec4-96da-4fee75cfdd7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fb0756a5-ebcc-49c2-a5b6-468c53ec8108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_662a4520-e2e0-4c1b-8293-66155fb3b221" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fb0756a5-ebcc-49c2-a5b6-468c53ec8108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_50b816d5-43f7-4d27-9842-abf030d7acc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_95e3da21-cb89-4c93-989e-b4cbe43bda09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_50b816d5-43f7-4d27-9842-abf030d7acc6" xlink:to="loc_us-gaap_PreferredStockValue_95e3da21-cb89-4c93-989e-b4cbe43bda09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_eb593522-28dc-4503-b82f-6d137bf91a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_50b816d5-43f7-4d27-9842-abf030d7acc6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_eb593522-28dc-4503-b82f-6d137bf91a58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_de35e9a4-8fbc-449c-99e4-b562b6640ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_50b816d5-43f7-4d27-9842-abf030d7acc6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_de35e9a4-8fbc-449c-99e4-b562b6640ab0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0ff225a-682e-4215-ae62-b059072bd9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_50b816d5-43f7-4d27-9842-abf030d7acc6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0ff225a-682e-4215-ae62-b059072bd9c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6ee430a8-59cf-4c5d-b73b-7cef69fdfaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_50b816d5-43f7-4d27-9842-abf030d7acc6" xlink:to="loc_us-gaap_CommonStockValue_6ee430a8-59cf-4c5d-b73b-7cef69fdfaef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1400b1c4-e176-430b-8112-32754d7445b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d9cbe464-5c67-4878-8858-6fdaaa2a7787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1400b1c4-e176-430b-8112-32754d7445b0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d9cbe464-5c67-4878-8858-6fdaaa2a7787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0b5b4fce-b7e1-4e2b-9f7a-f2b555db5598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1400b1c4-e176-430b-8112-32754d7445b0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0b5b4fce-b7e1-4e2b-9f7a-f2b555db5598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5a0d8b9f-4596-4f30-9d4f-1ffa27f4aafd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1400b1c4-e176-430b-8112-32754d7445b0" xlink:to="loc_us-gaap_InventoryNet_5a0d8b9f-4596-4f30-9d4f-1ffa27f4aafd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b0057cab-dbc2-4ea8-ad4d-051b328faae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1400b1c4-e176-430b-8112-32754d7445b0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b0057cab-dbc2-4ea8-ad4d-051b328faae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24e52d76-a19c-4609-b2ec-aff85126ad3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1400b1c4-e176-430b-8112-32754d7445b0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24e52d76-a19c-4609-b2ec-aff85126ad3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_367e8fd2-d8b7-48e0-96df-b928b1d72906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1400b1c4-e176-430b-8112-32754d7445b0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_367e8fd2-d8b7-48e0-96df-b928b1d72906" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="bcrx-20220930.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6a32270f-78a2-4424-b964-f108240a3509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a46ce82f-2f8d-4995-8a92-cab586511a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6a32270f-78a2-4424-b964-f108240a3509" xlink:to="loc_us-gaap_NetIncomeLoss_a46ce82f-2f8d-4995-8a92-cab586511a4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_87ba4652-d48d-4c74-9312-f8c1fdb07109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6a32270f-78a2-4424-b964-f108240a3509" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_87ba4652-d48d-4c74-9312-f8c1fdb07109" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9ce39578-d177-4d0a-80c7-750ab6a5bddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6a32270f-78a2-4424-b964-f108240a3509" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9ce39578-d177-4d0a-80c7-750ab6a5bddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef29f75c-bc0c-48f7-bb68-77e7db382cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c2be7dbf-ed78-4b52-bad4-0054f5498e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef29f75c-bc0c-48f7-bb68-77e7db382cfa" xlink:to="loc_us-gaap_OperatingIncomeLoss_c2be7dbf-ed78-4b52-bad4-0054f5498e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestAndOtherIncomeLoss_fb889f43-fec2-4685-b7a3-6524ce8fcfa5" xlink:href="bcrx-20220930.xsd#bcrx_InterestAndOtherIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef29f75c-bc0c-48f7-bb68-77e7db382cfa" xlink:to="loc_bcrx_InterestAndOtherIncomeLoss_fb889f43-fec2-4685-b7a3-6524ce8fcfa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2fba80b0-62b0-4947-b2b3-2ba2ac6c7426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef29f75c-bc0c-48f7-bb68-77e7db382cfa" xlink:to="loc_us-gaap_InterestExpense_2fba80b0-62b0-4947-b2b3-2ba2ac6c7426" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_271e24df-7188-48be-9a82-61a1fa054ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef29f75c-bc0c-48f7-bb68-77e7db382cfa" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_271e24df-7188-48be-9a82-61a1fa054ed3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c37e546c-1f49-4b9c-9742-153fa8478a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8e7e7c87-455f-4121-b6c1-1a9bc5cfce1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c37e546c-1f49-4b9c-9742-153fa8478a85" xlink:to="loc_us-gaap_CostsAndExpenses_8e7e7c87-455f-4121-b6c1-1a9bc5cfce1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_223ca4c8-62fd-4867-b70b-f8c3de02a2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c37e546c-1f49-4b9c-9742-153fa8478a85" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_223ca4c8-62fd-4867-b70b-f8c3de02a2ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a659306a-57bf-4d5f-b415-cb830e2bdcba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4c69b63d-40a1-444f-93d2-4092a1dc7e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a659306a-57bf-4d5f-b415-cb830e2bdcba" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4c69b63d-40a1-444f-93d2-4092a1dc7e8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7c93239d-ef95-42fc-9738-ad271cf7a1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a659306a-57bf-4d5f-b415-cb830e2bdcba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7c93239d-ef95-42fc-9738-ad271cf7a1f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_66b87cf9-ff0c-47c0-8e8b-5e60850c08c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fe47893d-e490-4b92-9f3b-829921addea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_66b87cf9-ff0c-47c0-8e8b-5e60850c08c8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fe47893d-e490-4b92-9f3b-829921addea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyExpenseReversalOfExpense_26cb4abc-c501-425f-a71d-d0f5cf882679" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyExpenseReversalOfExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_66b87cf9-ff0c-47c0-8e8b-5e60850c08c8" xlink:to="loc_bcrx_RoyaltyExpenseReversalOfExpense_26cb4abc-c501-425f-a71d-d0f5cf882679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4662daa0-516c-4d6e-aad2-6268e3ceb632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_66b87cf9-ff0c-47c0-8e8b-5e60850c08c8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4662daa0-516c-4d6e-aad2-6268e3ceb632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5e18dee1-53de-4e61-8a57-d11596dbbbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_66b87cf9-ff0c-47c0-8e8b-5e60850c08c8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5e18dee1-53de-4e61-8a57-d11596dbbbd1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="bcrx-20220930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6f8b7467-1cf2-4656-ad7c-c704d704e1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a78cf5fa-17fb-40e7-9f37-1577f8747d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6f8b7467-1cf2-4656-ad7c-c704d704e1dd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a78cf5fa-17fb-40e7-9f37-1577f8747d9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_555001db-b6c7-4099-8aea-b359f5a182b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6f8b7467-1cf2-4656-ad7c-c704d704e1dd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_555001db-b6c7-4099-8aea-b359f5a182b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_acae622c-25d2-41c4-a85e-81a9bf8a5b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6f8b7467-1cf2-4656-ad7c-c704d704e1dd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_acae622c-25d2-41c4-a85e-81a9bf8a5b75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33ed6003-ab3d-44fe-9d77-085797c76cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6f8b7467-1cf2-4656-ad7c-c704d704e1dd" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33ed6003-ab3d-44fe-9d77-085797c76cf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74ba8b9f-2c1f-4e41-8d0b-087a660965c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_1c6bc2ec-1e89-42e1-8419-17887d82cee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74ba8b9f-2c1f-4e41-8d0b-087a660965c7" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_1c6bc2ec-1e89-42e1-8419-17887d82cee3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5b107309-c892-4420-af80-c89c3dbaf75d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74ba8b9f-2c1f-4e41-8d0b-087a660965c7" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5b107309-c892-4420-af80-c89c3dbaf75d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b13d1761-e0cb-4d97-971b-205147696e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_ff94daac-091e-446b-a4f3-1c9869d09d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b13d1761-e0cb-4d97-971b-205147696e08" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_ff94daac-091e-446b-a4f3-1c9869d09d4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_26cd9499-b3df-4148-89a5-daa0c7754238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b13d1761-e0cb-4d97-971b-205147696e08" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_26cd9499-b3df-4148-89a5-daa0c7754238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_487c2c44-af6a-4172-88b9-3ce5e8f87b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b13d1761-e0cb-4d97-971b-205147696e08" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_487c2c44-af6a-4172-88b9-3ce5e8f87b8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb3ca6ed-602a-43c3-95b3-13e77c804d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_49ee5967-a6ed-407d-8b20-d96fb2a830c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb3ca6ed-602a-43c3-95b3-13e77c804d99" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_49ee5967-a6ed-407d-8b20-d96fb2a830c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_ed0e298b-c25a-4c43-8891-87f9e8e22e52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb3ca6ed-602a-43c3-95b3-13e77c804d99" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_ed0e298b-c25a-4c43-8891-87f9e8e22e52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_33afcd9f-9237-4845-9723-0078e4c5f7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb3ca6ed-602a-43c3-95b3-13e77c804d99" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_33afcd9f-9237-4845-9723-0078e4c5f7a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b3f469c4-29b5-4b5d-a3f4-4420378a9aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb3ca6ed-602a-43c3-95b3-13e77c804d99" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b3f469c4-29b5-4b5d-a3f4-4420378a9aa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ff623ab9-4d94-40b0-aab2-7a2ac03c8ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb3ca6ed-602a-43c3-95b3-13e77c804d99" xlink:to="loc_us-gaap_ShareBasedCompensation_ff623ab9-4d94-40b0-aab2-7a2ac03c8ad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts_9973a90d-47f6-4ec6-b777-c06e53a6685d" xlink:href="bcrx-20220930.xsd#bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb3ca6ed-602a-43c3-95b3-13e77c804d99" xlink:to="loc_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts_9973a90d-47f6-4ec6-b777-c06e53a6685d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AmortizationOfDiscountAndPremiumOnInvestments_e029165d-d868-47e2-89fd-67fa7a5d816a" xlink:href="bcrx-20220930.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb3ca6ed-602a-43c3-95b3-13e77c804d99" xlink:to="loc_bcrx_AmortizationOfDiscountAndPremiumOnInvestments_e029165d-d868-47e2-89fd-67fa7a5d816a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_0bc7c927-2730-4339-a297-6145c92deb82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb3ca6ed-602a-43c3-95b3-13e77c804d99" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_0bc7c927-2730-4339-a297-6145c92deb82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_204d6c3d-1efd-43d0-902b-a20b431ac2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb3ca6ed-602a-43c3-95b3-13e77c804d99" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_204d6c3d-1efd-43d0-902b-a20b431ac2ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0cc934e6-593b-48f6-8377-8de493d67434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb3ca6ed-602a-43c3-95b3-13e77c804d99" xlink:to="loc_us-gaap_NetIncomeLoss_0cc934e6-593b-48f6-8377-8de493d67434" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d159fcfe-81f7-473a-b2db-af4a657bf806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb3ca6ed-602a-43c3-95b3-13e77c804d99" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d159fcfe-81f7-473a-b2db-af4a657bf806" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#InvestmentsScheduleofMaturityofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dcd0f432-b526-4366-9556-6a6b52266b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0bb5a88b-4e46-4e3a-8a15-8fd94a749320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dcd0f432-b526-4366-9556-6a6b52266b79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0bb5a88b-4e46-4e3a-8a15-8fd94a749320" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_6ef51534-2f27-43ac-ba95-814e6bb90400" xlink:href="bcrx-20220930.xsd#bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dcd0f432-b526-4366-9556-6a6b52266b79" xlink:to="loc_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_6ef51534-2f27-43ac-ba95-814e6bb90400" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InventoryDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_72a2af4f-22f6-4d69-a55b-04eac24bd17f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_c5c513da-0c0e-4783-a3d4-93b669e7e9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_72a2af4f-22f6-4d69-a55b-04eac24bd17f" xlink:to="loc_us-gaap_InventoryFinishedGoods_c5c513da-0c0e-4783-a3d4-93b669e7e9b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_9a3019f4-9b4e-4186-948f-52ac29ef6512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_72a2af4f-22f6-4d69-a55b-04eac24bd17f" xlink:to="loc_us-gaap_InventoryRawMaterials_9a3019f4-9b4e-4186-948f-52ac29ef6512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_f7bd923d-9c7c-4aa1-a5bd-682bb055cf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_72a2af4f-22f6-4d69-a55b-04eac24bd17f" xlink:to="loc_us-gaap_InventoryWorkInProcess_f7bd923d-9c7c-4aa1-a5bd-682bb055cf13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1b407786-bd96-4496-bcc2-3d8134c3d038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_e03f4a6a-9ced-490c-b391-7f2257002a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_1b407786-bd96-4496-bcc2-3d8134c3d038" xlink:to="loc_us-gaap_InventoryGross_e03f4a6a-9ced-490c-b391-7f2257002a7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_8772d01b-f735-46b3-ad5c-5813a50eec39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_1b407786-bd96-4496-bcc2-3d8134c3d038" xlink:to="loc_us-gaap_InventoryValuationReserves_8772d01b-f735-46b3-ad5c-5813a50eec39" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_aaf09f0d-f5ef-4a8c-9dc1-46b3315c3c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9db38486-3f01-4e08-9bf9-546e03f59c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_aaf09f0d-f5ef-4a8c-9dc1-46b3315c3c49" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9db38486-3f01-4e08-9bf9-546e03f59c59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_209b60c4-907a-4b60-a8e0-35a93315d7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_aaf09f0d-f5ef-4a8c-9dc1-46b3315c3c49" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_209b60c4-907a-4b60-a8e0-35a93315d7ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_56966327-b074-4f06-ac1f-72444fff0ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f609a744-14a6-45f9-a3f7-202fe0d70223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_56966327-b074-4f06-ac1f-72444fff0ea3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f609a744-14a6-45f9-a3f7-202fe0d70223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_36f53881-8f92-4909-9b7e-561bc43fd723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_56966327-b074-4f06-ac1f-72444fff0ea3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_36f53881-8f92-4909-9b7e-561bc43fd723" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8bb6fac4-2f97-43aa-8a31-d73a6db540c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_56966327-b074-4f06-ac1f-72444fff0ea3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8bb6fac4-2f97-43aa-8a31-d73a6db540c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_10524ed7-c36c-4c0a-a5bc-af8de4a1780b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_56966327-b074-4f06-ac1f-72444fff0ea3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_10524ed7-c36c-4c0a-a5bc-af8de4a1780b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_766292c9-7a72-43ab-b993-f516abf3793c" xlink:href="bcrx-20220930.xsd#bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_56966327-b074-4f06-ac1f-72444fff0ea3" xlink:to="loc_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_766292c9-7a72-43ab-b993-f516abf3793c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_50153782-4500-46db-b4d6-e2506d775e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_56966327-b074-4f06-ac1f-72444fff0ea3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_50153782-4500-46db-b4d6-e2506d775e45" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>bcrx-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f6ec4fab-a519-489e-b421-6c7ee3322750,g:f7084e6e-47c2-4faa-aed0-8ba33c516e4f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="bcrx-20220930.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="i38dd20caacb24856bc67547169a480d6_ConsolidatedStatementsofComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ea666e7e-9fe7-4671-9e8e-b9b6c06ab120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_RevenuesAbstract_ea666e7e-9fe7-4671-9e8e-b9b6c06ab120" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5e87b493-f9bb-4e9a-8b9b-0aefa2494a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_ea666e7e-9fe7-4671-9e8e-b9b6c06ab120" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5e87b493-f9bb-4e9a-8b9b-0aefa2494a2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b4193b6c-06ac-4072-8c1a-88c23a0c98b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b4193b6c-06ac-4072-8c1a-88c23a0c98b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_be0d1366-8de6-4c05-876c-220714f6529e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b4193b6c-06ac-4072-8c1a-88c23a0c98b9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_be0d1366-8de6-4c05-876c-220714f6529e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_298b5617-d137-449f-9a0d-f2eca01f7604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b4193b6c-06ac-4072-8c1a-88c23a0c98b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_298b5617-d137-449f-9a0d-f2eca01f7604" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7d641fc3-4292-42d6-97d7-eeccf522f176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b4193b6c-06ac-4072-8c1a-88c23a0c98b9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7d641fc3-4292-42d6-97d7-eeccf522f176" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyExpenseReversalOfExpense_b23fcbf8-3c72-4231-9876-d9136285ef49" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyExpenseReversalOfExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b4193b6c-06ac-4072-8c1a-88c23a0c98b9" xlink:to="loc_bcrx_RoyaltyExpenseReversalOfExpense_b23fcbf8-3c72-4231-9876-d9136285ef49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7d768db7-f035-48f8-8800-e857b543f238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b4193b6c-06ac-4072-8c1a-88c23a0c98b9" xlink:to="loc_us-gaap_CostsAndExpenses_7d768db7-f035-48f8-8800-e857b543f238" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0e518bf1-2a42-4f97-9718-dccafdfd19e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_OperatingIncomeLoss_0e518bf1-2a42-4f97-9718-dccafdfd19e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestAndOtherIncomeLoss_d299d8ff-d16a-403b-a1c0-2d7e66772d2b" xlink:href="bcrx-20220930.xsd#bcrx_InterestAndOtherIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_bcrx_InterestAndOtherIncomeLoss_d299d8ff-d16a-403b-a1c0-2d7e66772d2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_947a7e62-cd50-47fd-af3e-dfb2794b776c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_InterestExpense_947a7e62-cd50-47fd-af3e-dfb2794b776c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_fe3480ec-dafe-45c9-95f0-ad4126ee059c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_fe3480ec-dafe-45c9-95f0-ad4126ee059c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5be28deb-ee69-43f3-b746-e4b2c932e27e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5be28deb-ee69-43f3-b746-e4b2c932e27e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e3eb901c-db15-4815-a6c5-643a3beb40c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e3eb901c-db15-4815-a6c5-643a3beb40c6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bcd471af-6062-4b96-8b71-3c68af6a1e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_NetIncomeLoss_bcd471af-6062-4b96-8b71-3c68af6a1e85" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4a1c15e2-9d4d-47ee-be6d-8d2270d7b447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4a1c15e2-9d4d-47ee-be6d-8d2270d7b447" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3965294e-ac6f-40aa-ab14-1f1d9ae0a851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3965294e-ac6f-40aa-ab14-1f1d9ae0a851" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6e143a56-5ed7-4f54-9975-c2e61f71a780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6e143a56-5ed7-4f54-9975-c2e61f71a780" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_55657e72-8965-47a5-8904-79fcabfee3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_EarningsPerShareBasic_55657e72-8965-47a5-8904-79fcabfee3c8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f6be2df6-65bf-4254-b91e-c861ec9b10b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f6be2df6-65bf-4254-b91e-c861ec9b10b3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5eeb1d40-0ce3-42a9-974b-0305ed0a10d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5eeb1d40-0ce3-42a9-974b-0305ed0a10d5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cbbe148b-9847-4b17-b52b-cb83cbda7010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cbbe148b-9847-4b17-b52b-cb83cbda7010" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0ec6abfb-ecdd-44e9-addc-796d0315a1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_StatementTable_0ec6abfb-ecdd-44e9-addc-796d0315a1ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_65201625-992c-4b7a-b8eb-147a669c5bab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0ec6abfb-ecdd-44e9-addc-796d0315a1ea" xlink:to="loc_srt_ProductOrServiceAxis_65201625-992c-4b7a-b8eb-147a669c5bab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_65201625-992c-4b7a-b8eb-147a669c5bab_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_65201625-992c-4b7a-b8eb-147a669c5bab" xlink:to="loc_srt_ProductsAndServicesDomain_65201625-992c-4b7a-b8eb-147a669c5bab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c572ede4-68e0-4233-a81a-3adf5f6c9dbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_65201625-992c-4b7a-b8eb-147a669c5bab" xlink:to="loc_srt_ProductsAndServicesDomain_c572ede4-68e0-4233-a81a-3adf5f6c9dbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_06a1f7d7-f93c-4db8-9106-e3447d6aa3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c572ede4-68e0-4233-a81a-3adf5f6c9dbb" xlink:to="loc_us-gaap_ProductMember_06a1f7d7-f93c-4db8-9106-e3447d6aa3a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_404885b7-b023-4972-b2eb-d2ad21596933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c572ede4-68e0-4233-a81a-3adf5f6c9dbb" xlink:to="loc_us-gaap_RoyaltyMember_404885b7-b023-4972-b2eb-d2ad21596933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MilestoneRevenueMember_ed9b4cf1-842b-423a-a1c3-b2f150cc71c2" xlink:href="bcrx-20220930.xsd#bcrx_MilestoneRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c572ede4-68e0-4233-a81a-3adf5f6c9dbb" xlink:to="loc_bcrx_MilestoneRevenueMember_ed9b4cf1-842b-423a-a1c3-b2f150cc71c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_ffc7af89-c73f-4595-bfad-cbd0226a16d7" xlink:href="bcrx-20220930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c572ede4-68e0-4233-a81a-3adf5f6c9dbb" xlink:to="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_ffc7af89-c73f-4595-bfad-cbd0226a16d7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit" xlink:type="simple" xlink:href="bcrx-20220930.xsd#ConsolidatedStatementsofStockholdersDeficit"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit" xlink:type="extended" id="id19abe702c6e46569422834c46947eaf_ConsolidatedStatementsofStockholdersDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3f363f5e-30ac-4154-9883-c7ef2eec1b72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f363f5e-30ac-4154-9883-c7ef2eec1b72" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bbcaa615-b3c1-4499-89c2-9a4c1079f12d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:to="loc_us-gaap_StockholdersEquity_bbcaa615-b3c1-4499-89c2-9a4c1079f12d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5f3c0a32-6eac-4ef5-905c-240e7c7b095e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:to="loc_us-gaap_NetIncomeLoss_5f3c0a32-6eac-4ef5-905c-240e7c7b095e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cea00248-9c57-49a9-8873-a1a27da93ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cea00248-9c57-49a9-8873-a1a27da93ad2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_StockIssuedDuringPeriodValueWarrantsExercised_9409ca27-d129-4c4a-b719-26c64cb37c41" xlink:href="bcrx-20220930.xsd#bcrx_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:to="loc_bcrx_StockIssuedDuringPeriodValueWarrantsExercised_9409ca27-d129-4c4a-b719-26c64cb37c41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6afd0d75-c006-49af-a06d-06feb2f66852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6afd0d75-c006-49af-a06d-06feb2f66852" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_613ca156-789b-4e9a-9635-ecb03721fe76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_613ca156-789b-4e9a-9635-ecb03721fe76" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_016dded5-e573-4449-a7bd-deb19f37a2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_016dded5-e573-4449-a7bd-deb19f37a2ab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f5c0d73f-7387-4d0d-ad65-ebcd3eff0bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_23b50f50-5205-46d1-aa69-e4659a64b494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3f363f5e-30ac-4154-9883-c7ef2eec1b72" xlink:to="loc_us-gaap_StatementTable_23b50f50-5205-46d1-aa69-e4659a64b494" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4f641724-7964-4016-8fd2-79e896ecc011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_23b50f50-5205-46d1-aa69-e4659a64b494" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4f641724-7964-4016-8fd2-79e896ecc011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4f641724-7964-4016-8fd2-79e896ecc011_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4f641724-7964-4016-8fd2-79e896ecc011" xlink:to="loc_us-gaap_EquityComponentDomain_4f641724-7964-4016-8fd2-79e896ecc011_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b6877c37-fc8b-48d3-8d36-283636715d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4f641724-7964-4016-8fd2-79e896ecc011" xlink:to="loc_us-gaap_EquityComponentDomain_b6877c37-fc8b-48d3-8d36-283636715d90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9bd14ef4-025e-4356-8125-32083331957c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b6877c37-fc8b-48d3-8d36-283636715d90" xlink:to="loc_us-gaap_CommonStockMember_9bd14ef4-025e-4356-8125-32083331957c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_73fc2c1d-14a1-4b24-b494-8e605ccb011a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b6877c37-fc8b-48d3-8d36-283636715d90" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_73fc2c1d-14a1-4b24-b494-8e605ccb011a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6776052-a4bb-4652-ba73-b7e8e6ae3985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b6877c37-fc8b-48d3-8d36-283636715d90" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6776052-a4bb-4652-ba73-b7e8e6ae3985" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_82369e92-cc03-480d-9754-914ec7318740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b6877c37-fc8b-48d3-8d36-283636715d90" xlink:to="loc_us-gaap_RetainedEarningsMember_82369e92-cc03-480d-9754-914ec7318740" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#SignificantAccountingPoliciesandConcentrationsofRiskDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails" xlink:type="extended" id="ib9f142f5811a4436b5bbdb719c32282b_SignificantAccountingPoliciesandConcentrationsofRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:href="bcrx-20220930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_cbf9f6e0-13df-4dc9-83b8-340a8bedbeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_cbf9f6e0-13df-4dc9-83b8-340a8bedbeeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaturityPeriodOfHighQualityMarketableSecurities_12d94947-f131-4130-aa01-3c8e644f5aa2" xlink:href="bcrx-20220930.xsd#bcrx_MaturityPeriodOfHighQualityMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_bcrx_MaturityPeriodOfHighQualityMarketableSecurities_12d94947-f131-4130-aa01-3c8e644f5aa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_efe91de0-9878-4100-9f3e-54b8cbd988f8" xlink:href="bcrx-20220930.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_efe91de0-9878-4100-9f3e-54b8cbd988f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaturityPeriodOfShortTermInvestment_64eb2653-95b6-41f1-a894-a814375fd646" xlink:href="bcrx-20220930.xsd#bcrx_MaturityPeriodOfShortTermInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_bcrx_MaturityPeriodOfShortTermInvestment_64eb2653-95b6-41f1-a894-a814375fd646" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LongTermInvestmentMaturityMinimum_c27da899-1721-4f74-9a25-18282b401fe5" xlink:href="bcrx-20220930.xsd#bcrx_LongTermInvestmentMaturityMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_bcrx_LongTermInvestmentMaturityMinimum_c27da899-1721-4f74-9a25-18282b401fe5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_480fef97-beeb-4bfc-9d6e-1a12d80d600e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_480fef97-beeb-4bfc-9d6e-1a12d80d600e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_2456bd53-cda8-436c-a42b-1fe1780223b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_us-gaap_AdvertisingExpense_2456bd53-cda8-436c-a42b-1fe1780223b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_9c832577-169a-4185-9203-55f3b17fd409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_us-gaap_InterestExpenseDebt_9c832577-169a-4185-9203-55f3b17fd409" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts_a76c4832-0b72-4069-9502-9d57d1be0e46" xlink:href="bcrx-20220930.xsd#bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts_a76c4832-0b72-4069-9502-9d57d1be0e46" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ea4aeb72-0104-4bb0-adfd-8ba65587e9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ea4aeb72-0104-4bb0-adfd-8ba65587e9a4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_c0a4afd7-cf32-4f79-801a-9b78f23821d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_c0a4afd7-cf32-4f79-801a-9b78f23821d9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_665df6e4-e954-4044-ab00-dfdde748a3a1" xlink:href="bcrx-20220930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_665df6e4-e954-4044-ab00-dfdde748a3a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_e2e0df02-e04c-4079-9ab2-da94bf6c6c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_665df6e4-e954-4044-ab00-dfdde748a3a1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_e2e0df02-e04c-4079-9ab2-da94bf6c6c9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e2e0df02-e04c-4079-9ab2-da94bf6c6c9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_e2e0df02-e04c-4079-9ab2-da94bf6c6c9e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e2e0df02-e04c-4079-9ab2-da94bf6c6c9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2b87d856-4643-4dda-838e-8b52cd6b63ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_e2e0df02-e04c-4079-9ab2-da94bf6c6c9e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2b87d856-4643-4dda-838e-8b52cd6b63ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyReceivableMember_70093473-f3d0-4135-b96e-1bebc20760a7" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2b87d856-4643-4dda-838e-8b52cd6b63ef" xlink:to="loc_bcrx_RoyaltyReceivableMember_70093473-f3d0-4135-b96e-1bebc20760a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollateralForCreditMember_66d735ff-bbc3-449f-8fac-ab21665812f7" xlink:href="bcrx-20220930.xsd#bcrx_CollateralForCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2b87d856-4643-4dda-838e-8b52cd6b63ef" xlink:to="loc_bcrx_CollateralForCreditMember_66d735ff-bbc3-449f-8fac-ab21665812f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0f16d1a8-f9be-4123-9f88-3d5aa309caf4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_665df6e4-e954-4044-ab00-dfdde748a3a1" xlink:to="loc_srt_RangeAxis_0f16d1a8-f9be-4123-9f88-3d5aa309caf4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0f16d1a8-f9be-4123-9f88-3d5aa309caf4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0f16d1a8-f9be-4123-9f88-3d5aa309caf4" xlink:to="loc_srt_RangeMember_0f16d1a8-f9be-4123-9f88-3d5aa309caf4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e52606c-8246-47e6-b421-35e8cecbb1f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0f16d1a8-f9be-4123-9f88-3d5aa309caf4" xlink:to="loc_srt_RangeMember_6e52606c-8246-47e6-b421-35e8cecbb1f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_03d01bde-0c16-48b6-b381-61f85077cb5a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6e52606c-8246-47e6-b421-35e8cecbb1f8" xlink:to="loc_srt_MaximumMember_03d01bde-0c16-48b6-b381-61f85077cb5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7484457a-3253-4397-b88b-6cc6bfe383e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_665df6e4-e954-4044-ab00-dfdde748a3a1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7484457a-3253-4397-b88b-6cc6bfe383e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7484457a-3253-4397-b88b-6cc6bfe383e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7484457a-3253-4397-b88b-6cc6bfe383e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7484457a-3253-4397-b88b-6cc6bfe383e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19749b37-60f7-4033-b68b-7da06e979685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7484457a-3253-4397-b88b-6cc6bfe383e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19749b37-60f7-4033-b68b-7da06e979685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_b27beffd-c2c7-4510-bd97-5a8291f8aaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19749b37-60f7-4033-b68b-7da06e979685" xlink:to="loc_us-gaap_ComputerEquipmentMember_b27beffd-c2c7-4510-bd97-5a8291f8aaf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember_d3857916-8a13-4d33-b00c-3699817cbee5" xlink:href="bcrx-20220930.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19749b37-60f7-4033-b68b-7da06e979685" xlink:to="loc_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember_d3857916-8a13-4d33-b00c-3699817cbee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f9ffccd6-94bb-419f-b048-b7b28070e0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19749b37-60f7-4033-b68b-7da06e979685" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f9ffccd6-94bb-419f-b048-b7b28070e0ac" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RevenueDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#RevenueDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/RevenueDetails" xlink:type="extended" id="iba71da33690b4956b9d3cdb22e0bc9cc_RevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_61d4e62d-1ec3-42a0-9f7c-3500d71b4a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3caa8a4a-b510-42aa-831e-68eeeb301195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_61d4e62d-1ec3-42a0-9f7c-3500d71b4a0d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3caa8a4a-b510-42aa-831e-68eeeb301195" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_482baa8e-2d80-4b1e-bb17-1ab207ce8b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_61d4e62d-1ec3-42a0-9f7c-3500d71b4a0d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_482baa8e-2d80-4b1e-bb17-1ab207ce8b7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6c0d7c2b-f594-4bd6-9a51-df5e2b669af1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_482baa8e-2d80-4b1e-bb17-1ab207ce8b7f" xlink:to="loc_srt_ProductOrServiceAxis_6c0d7c2b-f594-4bd6-9a51-df5e2b669af1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6c0d7c2b-f594-4bd6-9a51-df5e2b669af1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6c0d7c2b-f594-4bd6-9a51-df5e2b669af1" xlink:to="loc_srt_ProductsAndServicesDomain_6c0d7c2b-f594-4bd6-9a51-df5e2b669af1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_74b99c51-fdc5-4b25-b5c7-d7c805354413" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6c0d7c2b-f594-4bd6-9a51-df5e2b669af1" xlink:to="loc_srt_ProductsAndServicesDomain_74b99c51-fdc5-4b25-b5c7-d7c805354413" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_42304a45-828f-4f3a-9639-247ffd5682ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_74b99c51-fdc5-4b25-b5c7-d7c805354413" xlink:to="loc_us-gaap_ProductMember_42304a45-828f-4f3a-9639-247ffd5682ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_ef41189d-98f5-4bdd-b2ca-92a85043cfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_74b99c51-fdc5-4b25-b5c7-d7c805354413" xlink:to="loc_us-gaap_RoyaltyMember_ef41189d-98f5-4bdd-b2ca-92a85043cfb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MilestoneRevenueMember_b67962d6-ec9c-4441-8659-a0c25cc3e8ed" xlink:href="bcrx-20220930.xsd#bcrx_MilestoneRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_74b99c51-fdc5-4b25-b5c7-d7c805354413" xlink:to="loc_bcrx_MilestoneRevenueMember_b67962d6-ec9c-4441-8659-a0c25cc3e8ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_6fffebaa-48f7-4572-8c0e-587aa0969aaf" xlink:href="bcrx-20220930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_74b99c51-fdc5-4b25-b5c7-d7c805354413" xlink:to="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_6fffebaa-48f7-4572-8c0e-587aa0969aaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c809c2d2-0aca-42ef-a31e-50041aa36fca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_482baa8e-2d80-4b1e-bb17-1ab207ce8b7f" xlink:to="loc_srt_CounterpartyNameAxis_c809c2d2-0aca-42ef-a31e-50041aa36fca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c809c2d2-0aca-42ef-a31e-50041aa36fca_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c809c2d2-0aca-42ef-a31e-50041aa36fca" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c809c2d2-0aca-42ef-a31e-50041aa36fca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_384baa86-25a0-45c0-aa67-857f6889264e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c809c2d2-0aca-42ef-a31e-50041aa36fca" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_384baa86-25a0-45c0-aa67-857f6889264e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember_c777d878-5830-4bae-9025-313fee0b5c49" xlink:href="bcrx-20220930.xsd#bcrx_ORLADEYOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_384baa86-25a0-45c0-aa67-857f6889264e" xlink:to="loc_bcrx_ORLADEYOMember_c777d878-5830-4bae-9025-313fee0b5c49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RAPIVABMember_0054770a-cc6a-41ef-81d8-a43ee7874819" xlink:href="bcrx-20220930.xsd#bcrx_RAPIVABMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_384baa86-25a0-45c0-aa67-857f6889264e" xlink:to="loc_bcrx_RAPIVABMember_0054770a-cc6a-41ef-81d8-a43ee7874819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PERAMIVIRMember_cba73fef-da95-45a0-b74a-a1002d5ba008" xlink:href="bcrx-20220930.xsd#bcrx_PERAMIVIRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_384baa86-25a0-45c0-aa67-857f6889264e" xlink:to="loc_bcrx_PERAMIVIRMember_cba73fef-da95-45a0-b74a-a1002d5ba008" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_USDepartmentOfHealthAndHumanServicesMember_dcc07179-470e-4541-92a3-ff7f5502600e" xlink:href="bcrx-20220930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_384baa86-25a0-45c0-aa67-857f6889264e" xlink:to="loc_bcrx_USDepartmentOfHealthAndHumanServicesMember_dcc07179-470e-4541-92a3-ff7f5502600e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails" xlink:type="extended" id="i967a3b35c54041e998808d21dbace6e3_InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_8a6f63c9-89e0-4144-8c4e-c580210e11e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_02da0544-8702-4783-871f-fc634b1040be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8a6f63c9-89e0-4144-8c4e-c580210e11e3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_02da0544-8702-4783-871f-fc634b1040be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest_3a32152e-2c3b-4586-9e40-bc8faf6b5678" xlink:href="bcrx-20220930.xsd#bcrx_AvailableForSaleDebtSecuritiesAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8a6f63c9-89e0-4144-8c4e-c580210e11e3" xlink:to="loc_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest_3a32152e-2c3b-4586-9e40-bc8faf6b5678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b4a9f501-fb91-49c6-afb5-14afb6ae4f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8a6f63c9-89e0-4144-8c4e-c580210e11e3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b4a9f501-fb91-49c6-afb5-14afb6ae4f9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_725fc74d-7293-43fc-a1a8-f44bf51cbe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8a6f63c9-89e0-4144-8c4e-c580210e11e3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_725fc74d-7293-43fc-a1a8-f44bf51cbe2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0d258c41-f18d-4320-92a4-f3848b333e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8a6f63c9-89e0-4144-8c4e-c580210e11e3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0d258c41-f18d-4320-92a4-f3848b333e33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_496d250a-5c12-47ba-9fa6-e22ad6b9e226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8a6f63c9-89e0-4144-8c4e-c580210e11e3" xlink:to="loc_us-gaap_MarketableSecuritiesTable_496d250a-5c12-47ba-9fa6-e22ad6b9e226" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_75d9e895-5f76-40b7-898b-126316426e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_496d250a-5c12-47ba-9fa6-e22ad6b9e226" xlink:to="loc_us-gaap_FinancialInstrumentAxis_75d9e895-5f76-40b7-898b-126316426e66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75d9e895-5f76-40b7-898b-126316426e66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_75d9e895-5f76-40b7-898b-126316426e66" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75d9e895-5f76-40b7-898b-126316426e66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d95cf0a9-1a10-45f8-90aa-36f4a5d81d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_75d9e895-5f76-40b7-898b-126316426e66" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d95cf0a9-1a10-45f8-90aa-36f4a5d81d73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f9aa717b-f7a6-4e4a-9382-0aae4b83f549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d95cf0a9-1a10-45f8-90aa-36f4a5d81d73" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f9aa717b-f7a6-4e4a-9382-0aae4b83f549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_787f27d3-9e65-4702-a81c-15ecb22df9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d95cf0a9-1a10-45f8-90aa-36f4a5d81d73" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_787f27d3-9e65-4702-a81c-15ecb22df9e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_3752b079-3251-4551-9814-a7c3edf2aa09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d95cf0a9-1a10-45f8-90aa-36f4a5d81d73" xlink:to="loc_us-gaap_CertificatesOfDepositMember_3752b079-3251-4551-9814-a7c3edf2aa09" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/TradeReceivablesDetailsTextual" xlink:type="simple" xlink:href="bcrx-20220930.xsd#TradeReceivablesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/TradeReceivablesDetailsTextual" xlink:type="extended" id="i2484dbdaba464d0daefca257df24130b_TradeReceivablesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d8bbfeea-85e9-4216-b7f3-6cfbe438cac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_26498e50-09d2-4146-822f-fa2b2ee24d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d8bbfeea-85e9-4216-b7f3-6cfbe438cac8" xlink:to="loc_us-gaap_AccountsReceivableNet_26498e50-09d2-4146-822f-fa2b2ee24d3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c7624aac-cc72-478e-8629-7004dd9259a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d8bbfeea-85e9-4216-b7f3-6cfbe438cac8" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c7624aac-cc72-478e-8629-7004dd9259a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_277d02ea-003f-4002-96b6-6cb8a133c073" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c7624aac-cc72-478e-8629-7004dd9259a0" xlink:to="loc_srt_ProductOrServiceAxis_277d02ea-003f-4002-96b6-6cb8a133c073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_277d02ea-003f-4002-96b6-6cb8a133c073_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_277d02ea-003f-4002-96b6-6cb8a133c073" xlink:to="loc_srt_ProductsAndServicesDomain_277d02ea-003f-4002-96b6-6cb8a133c073_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0972ccd5-be56-4aec-b75a-6bae11d6d635" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_277d02ea-003f-4002-96b6-6cb8a133c073" xlink:to="loc_srt_ProductsAndServicesDomain_0972ccd5-be56-4aec-b75a-6bae11d6d635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember_83ce40d0-5350-4aef-8818-c092a4ad7883" xlink:href="bcrx-20220930.xsd#bcrx_ORLADEYOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0972ccd5-be56-4aec-b75a-6bae11d6d635" xlink:to="loc_bcrx_ORLADEYOMember_83ce40d0-5350-4aef-8818-c092a4ad7883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RAPIVABMember_e422f823-6a80-480f-96e0-9b727343da0c" xlink:href="bcrx-20220930.xsd#bcrx_RAPIVABMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0972ccd5-be56-4aec-b75a-6bae11d6d635" xlink:to="loc_bcrx_RAPIVABMember_e422f823-6a80-480f-96e0-9b727343da0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_GreenCrossCorporationMember_b49b00c0-91ab-40eb-ba68-c14167dacb6a" xlink:href="bcrx-20220930.xsd#bcrx_GreenCrossCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0972ccd5-be56-4aec-b75a-6bae11d6d635" xlink:to="loc_bcrx_GreenCrossCorporationMember_b49b00c0-91ab-40eb-ba68-c14167dacb6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b55ef89f-f52e-4acd-a7b7-b16b1d4d98ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c7624aac-cc72-478e-8629-7004dd9259a0" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b55ef89f-f52e-4acd-a7b7-b16b1d4d98ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_b55ef89f-f52e-4acd-a7b7-b16b1d4d98ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b55ef89f-f52e-4acd-a7b7-b16b1d4d98ef" xlink:to="loc_us-gaap_ReceivableTypeDomain_b55ef89f-f52e-4acd-a7b7-b16b1d4d98ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_47b909e1-4e88-4858-9e20-5b1d3b7559fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b55ef89f-f52e-4acd-a7b7-b16b1d4d98ef" xlink:to="loc_us-gaap_ReceivableTypeDomain_47b909e1-4e88-4858-9e20-5b1d3b7559fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_d02ca6fe-b982-474d-aba3-2bdbcd673862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_47b909e1-4e88-4858-9e20-5b1d3b7559fd" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_d02ca6fe-b982-474d-aba3-2bdbcd673862" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#TradeReceivablesSummaryofReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails" xlink:type="extended" id="i8c70bba0a00843daadc4515245577e5b_TradeReceivablesSummaryofReceivablesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bed052ef-ec52-4f47-a9b1-d203d6d10f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_78d7baf0-f6bb-457f-be47-ad2cb5ea76e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bed052ef-ec52-4f47-a9b1-d203d6d10f33" xlink:to="loc_us-gaap_ReceivablesNetCurrent_78d7baf0-f6bb-457f-be47-ad2cb5ea76e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_043e1611-8e15-4b58-b805-ab014aea3dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bed052ef-ec52-4f47-a9b1-d203d6d10f33" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_043e1611-8e15-4b58-b805-ab014aea3dce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_feb546b8-8313-48ec-800d-0815e73101bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_043e1611-8e15-4b58-b805-ab014aea3dce" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_feb546b8-8313-48ec-800d-0815e73101bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_feb546b8-8313-48ec-800d-0815e73101bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_feb546b8-8313-48ec-800d-0815e73101bf" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_feb546b8-8313-48ec-800d-0815e73101bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_2df7d58a-3f88-4ede-9453-4734e59c5a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_feb546b8-8313-48ec-800d-0815e73101bf" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_2df7d58a-3f88-4ede-9453-4734e59c5a17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_USDepartmentOfHealthAndHumanServicesMember_63bc3269-8a55-46c4-b1ee-b8f9703c3f97" xlink:href="bcrx-20220930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_2df7d58a-3f88-4ede-9453-4734e59c5a17" xlink:to="loc_bcrx_USDepartmentOfHealthAndHumanServicesMember_63bc3269-8a55-46c4-b1ee-b8f9703c3f97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShionogiCoLtdMember_6c1709b9-9f32-4aaf-89a6-337f18087515" xlink:href="bcrx-20220930.xsd#bcrx_ShionogiCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_2df7d58a-3f88-4ede-9453-4734e59c5a17" xlink:to="loc_bcrx_ShionogiCoLtdMember_6c1709b9-9f32-4aaf-89a6-337f18087515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyReceivablesFromPartnersMember_36809b99-bf8f-4fb6-b350-31127602a185" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyReceivablesFromPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_2df7d58a-3f88-4ede-9453-4734e59c5a17" xlink:to="loc_bcrx_RoyaltyReceivablesFromPartnersMember_36809b99-bf8f-4fb6-b350-31127602a185" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_c2ce0276-f31f-460f-ba42-4e60ee7f32ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_043e1611-8e15-4b58-b805-ab014aea3dce" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_c2ce0276-f31f-460f-ba42-4e60ee7f32ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesBillingStatusDomain_c2ce0276-f31f-460f-ba42-4e60ee7f32ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_c2ce0276-f31f-460f-ba42-4e60ee7f32ca" xlink:to="loc_us-gaap_ReceivablesBillingStatusDomain_c2ce0276-f31f-460f-ba42-4e60ee7f32ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesBillingStatusDomain_6d392581-8bf1-466b-b5ec-4cd958b43ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_c2ce0276-f31f-460f-ba42-4e60ee7f32ca" xlink:to="loc_us-gaap_ReceivablesBillingStatusDomain_6d392581-8bf1-466b-b5ec-4cd958b43ae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledRevenuesMember_c3dda8c9-d107-4c0b-bb6f-8a89b75f2599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivablesBillingStatusDomain_6d392581-8bf1-466b-b5ec-4cd958b43ae5" xlink:to="loc_us-gaap_BilledRevenuesMember_c3dda8c9-d107-4c0b-bb6f-8a89b75f2599" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledRevenuesMember_2448a0f7-420f-487a-88f5-ea9a49956cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivablesBillingStatusDomain_6d392581-8bf1-466b-b5ec-4cd958b43ae5" xlink:to="loc_us-gaap_UnbilledRevenuesMember_2448a0f7-420f-487a-88f5-ea9a49956cca" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual" xlink:type="simple" xlink:href="bcrx-20220930.xsd#RoyaltyMonetizationsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual" xlink:type="extended" id="i8a0b8a0ecc9144d894599aeb5b31df12_RoyaltyMonetizationsDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyMonetizationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8a3be7e1-aaf3-4cef-bf1a-b715146b1bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8a3be7e1-aaf3-4cef-bf1a-b715146b1bcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_7e72ef51-22d1-44f3-8673-3d17d7b3cc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_7e72ef51-22d1-44f3-8673-3d17d7b3cc3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TransactionCosts_b4eed3c6-7cb9-4016-8994-6214ee51955b" xlink:href="bcrx-20220930.xsd#bcrx_TransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_TransactionCosts_b4eed3c6-7cb9-4016-8994-6214ee51955b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestReserve_97966c1d-df1b-4774-af1f-cdd2ea43422b" xlink:href="bcrx-20220930.xsd#bcrx_InterestReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_InterestReserve_97966c1d-df1b-4774-af1f-cdd2ea43422b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PrivatePlacementOfSeniorSecuredNotes_0fa7df88-7229-4fbd-bf33-2836e5b479ec" xlink:href="bcrx-20220930.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_PrivatePlacementOfSeniorSecuredNotes_0fa7df88-7229-4fbd-bf33-2836e5b479ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_95f3cf8e-5490-4d3f-97a6-90afa558c188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_95f3cf8e-5490-4d3f-97a6-90afa558c188" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_524db925-2f39-4395-927e-3165abb3f082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_SecuredDebt_524db925-2f39-4395-927e-3165abb3f082" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_c21394c3-2629-41f9-8adb-c340bd475153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_c21394c3-2629-41f9-8adb-c340bd475153" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_99b0a752-603e-4f57-ba8a-3778840d621c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_99b0a752-603e-4f57-ba8a-3778840d621c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ceb87e60-70f8-4d50-9aa7-ceb1bdee6a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ceb87e60-70f8-4d50-9aa7-ceb1bdee6a3c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_f195a396-0418-4f23-872b-2f6f1097c615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_f195a396-0418-4f23-872b-2f6f1097c615" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories_5898e222-e2d1-4fa2-8302-a7212786c571" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories_5898e222-e2d1-4fa2-8302-a7212786c571" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales_7bf75bf1-14cc-49d1-a05b-2764e69d29cc" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales_7bf75bf1-14cc-49d1-a05b-2764e69d29cc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets_5d2619aa-ebaf-4661-91e0-c7662b6ca176" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets_5d2619aa-ebaf-4661-91e0-c7662b6ca176" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets_7073395c-1468-4a7d-b7ee-e2eeda62db97" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets_7073395c-1468-4a7d-b7ee-e2eeda62db97" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold_c8959fdb-13d7-492c-8bf1-1204387f93ac" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold_c8959fdb-13d7-492c-8bf1-1204387f93ac" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets_b1fb4ed9-58be-4056-9bf1-8d0477bd4fe7" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets_b1fb4ed9-58be-4056-9bf1-8d0477bd4fe7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales_cfcda91a-a403-4a64-9d42-4a592d65fc24" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales_cfcda91a-a403-4a64-9d42-4a592d65fc24" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales_20173912-a9c6-4579-901d-cbf69bc017d5" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales_20173912-a9c6-4579-901d-cbf69bc017d5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice_33b2a03a-5676-4af9-b2f6-e4405ff6eca7" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice_33b2a03a-5676-4af9-b2f6-e4405ff6eca7" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount_941d8dc0-fdbf-4b6b-b916-e708ec4d2c8e" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount_941d8dc0-fdbf-4b6b-b916-e708ec4d2c8e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_71972a73-8e42-4cc0-85b7-7cacdd074964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_71972a73-8e42-4cc0-85b7-7cacdd074964" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharesIssuedCommonStockPremium_26e7069d-38e8-4fc1-beed-71702ad5fd0b" xlink:href="bcrx-20220930.xsd#bcrx_SharesIssuedCommonStockPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_SharesIssuedCommonStockPremium_26e7069d-38e8-4fc1-beed-71702ad5fd0b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltiesMonetizationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8e957f6d-518f-45fe-9e5f-d26e9899e4e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_dei_LegalEntityAxis_8e957f6d-518f-45fe-9e5f-d26e9899e4e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8e957f6d-518f-45fe-9e5f-d26e9899e4e5_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8e957f6d-518f-45fe-9e5f-d26e9899e4e5" xlink:to="loc_dei_EntityDomain_8e957f6d-518f-45fe-9e5f-d26e9899e4e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e76fdf47-7399-46d4-8ae8-f532071c86d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8e957f6d-518f-45fe-9e5f-d26e9899e4e5" xlink:to="loc_dei_EntityDomain_e76fdf47-7399-46d4-8ae8-f532071c86d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_JPRRoyaltySubLLCMember_98607343-77ba-41e7-bfd0-2fb6eddd2088" xlink:href="bcrx-20220930.xsd#bcrx_JPRRoyaltySubLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e76fdf47-7399-46d4-8ae8-f532071c86d2" xlink:to="loc_bcrx_JPRRoyaltySubLLCMember_98607343-77ba-41e7-bfd0-2fb6eddd2088" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_3ff3d7f7-7797-414c-9f7c-19319d420c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_us-gaap_OtherCommitmentsAxis_3ff3d7f7-7797-414c-9f7c-19319d420c8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_3ff3d7f7-7797-414c-9f7c-19319d420c8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_3ff3d7f7-7797-414c-9f7c-19319d420c8f" xlink:to="loc_us-gaap_OtherCommitmentsDomain_3ff3d7f7-7797-414c-9f7c-19319d420c8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_9a87f6f1-81f5-483c-99e4-6d7112abe864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_3ff3d7f7-7797-414c-9f7c-19319d420c8f" xlink:to="loc_us-gaap_OtherCommitmentsDomain_9a87f6f1-81f5-483c-99e4-6d7112abe864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMonetizationMember_796b49c7-8207-4a91-b8f0-1d79663bd09d" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyMonetizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_9a87f6f1-81f5-483c-99e4-6d7112abe864" xlink:to="loc_bcrx_RoyaltyMonetizationMember_796b49c7-8207-4a91-b8f0-1d79663bd09d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7dd84c6f-d419-4743-bfe7-afb10187a4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_us-gaap_DebtInstrumentAxis_7dd84c6f-d419-4743-bfe7-afb10187a4a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7dd84c6f-d419-4743-bfe7-afb10187a4a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7dd84c6f-d419-4743-bfe7-afb10187a4a2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7dd84c6f-d419-4743-bfe7-afb10187a4a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3490f5b9-ffeb-441f-8cac-5da0be32add7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7dd84c6f-d419-4743-bfe7-afb10187a4a2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3490f5b9-ffeb-441f-8cac-5da0be32add7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PhaRMANotesMember_bcc4b5b9-0cdb-4471-a398-2dc1b787e473" xlink:href="bcrx-20220930.xsd#bcrx_PhaRMANotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3490f5b9-ffeb-441f-8cac-5da0be32add7" xlink:to="loc_bcrx_PhaRMANotesMember_bcc4b5b9-0cdb-4471-a398-2dc1b787e473" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d9515b0f-8913-4f80-862d-41d4999e6f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d9515b0f-8913-4f80-862d-41d4999e6f06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d9515b0f-8913-4f80-862d-41d4999e6f06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d9515b0f-8913-4f80-862d-41d4999e6f06" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d9515b0f-8913-4f80-862d-41d4999e6f06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a4c84b1f-211f-43c8-b44b-017411cf1843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d9515b0f-8913-4f80-862d-41d4999e6f06" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a4c84b1f-211f-43c8-b44b-017411cf1843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bf998b68-2b6d-4f75-baa3-ab7718bacc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a4c84b1f-211f-43c8-b44b-017411cf1843" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bf998b68-2b6d-4f75-baa3-ab7718bacc2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e7b91622-0ba7-4336-8e6b-d20677342d2c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_srt_CounterpartyNameAxis_e7b91622-0ba7-4336-8e6b-d20677342d2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7b91622-0ba7-4336-8e6b-d20677342d2c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e7b91622-0ba7-4336-8e6b-d20677342d2c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7b91622-0ba7-4336-8e6b-d20677342d2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_964136bd-38b2-41af-832a-daf1781c7223" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e7b91622-0ba7-4336-8e6b-d20677342d2c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_964136bd-38b2-41af-832a-daf1781c7223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RPI2019IntermediateFinanceTrustMember_d603c281-8d1a-4187-8183-03ec651d473f" xlink:href="bcrx-20220930.xsd#bcrx_RPI2019IntermediateFinanceTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_964136bd-38b2-41af-832a-daf1781c7223" xlink:to="loc_bcrx_RPI2019IntermediateFinanceTrustMember_d603c281-8d1a-4187-8183-03ec651d473f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RPI2021And2020IntermediateFinanceTrustMember_b7a25855-ecfc-4b10-b5cc-a536ed73f580" xlink:href="bcrx-20220930.xsd#bcrx_RPI2021And2020IntermediateFinanceTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_964136bd-38b2-41af-832a-daf1781c7223" xlink:to="loc_bcrx_RPI2021And2020IntermediateFinanceTrustMember_b7a25855-ecfc-4b10-b5cc-a536ed73f580" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_The2021RPIRoyaltyPurchaseAgreementMember_e115af11-6907-47bd-bf30-349ef9333d95" xlink:href="bcrx-20220930.xsd#bcrx_The2021RPIRoyaltyPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_964136bd-38b2-41af-832a-daf1781c7223" xlink:to="loc_bcrx_The2021RPIRoyaltyPurchaseAgreementMember_e115af11-6907-47bd-bf30-349ef9333d95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OMERSCapitalMarketsMember_02005dc4-54ab-42ae-af81-c1470a01ce93" xlink:href="bcrx-20220930.xsd#bcrx_OMERSCapitalMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_964136bd-38b2-41af-832a-daf1781c7223" xlink:to="loc_bcrx_OMERSCapitalMarketsMember_02005dc4-54ab-42ae-af81-c1470a01ce93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cc5e5193-16fb-4df0-a44f-66e8fad187f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cc5e5193-16fb-4df0-a44f-66e8fad187f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cc5e5193-16fb-4df0-a44f-66e8fad187f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cc5e5193-16fb-4df0-a44f-66e8fad187f0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cc5e5193-16fb-4df0-a44f-66e8fad187f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0c47794c-0eae-43dd-b7d5-67be979c2968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cc5e5193-16fb-4df0-a44f-66e8fad187f0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0c47794c-0eae-43dd-b7d5-67be979c2968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FutureRoyaltiesPayableMember_841eb079-86f8-4533-ac59-935a40903967" xlink:href="bcrx-20220930.xsd#bcrx_FutureRoyaltiesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0c47794c-0eae-43dd-b7d5-67be979c2968" xlink:to="loc_bcrx_FutureRoyaltiesPayableMember_841eb079-86f8-4533-ac59-935a40903967" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_22202dc9-fb05-49df-ab2e-a5928382424a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_srt_ProductOrServiceAxis_22202dc9-fb05-49df-ab2e-a5928382424a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_22202dc9-fb05-49df-ab2e-a5928382424a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_22202dc9-fb05-49df-ab2e-a5928382424a" xlink:to="loc_srt_ProductsAndServicesDomain_22202dc9-fb05-49df-ab2e-a5928382424a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_887d148f-cf9f-4de3-a4ef-36cb9e0c2d29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_22202dc9-fb05-49df-ab2e-a5928382424a" xlink:to="loc_srt_ProductsAndServicesDomain_887d148f-cf9f-4de3-a4ef-36cb9e0c2d29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember_49757da6-981a-4e43-bd15-028e070128fd" xlink:href="bcrx-20220930.xsd#bcrx_ORLADEYOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_887d148f-cf9f-4de3-a4ef-36cb9e0c2d29" xlink:to="loc_bcrx_ORLADEYOMember_49757da6-981a-4e43-bd15-028e070128fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BCX9930Member_a1c93f8e-9bce-4957-96a0-8728feb71700" xlink:href="bcrx-20220930.xsd#bcrx_BCX9930Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_887d148f-cf9f-4de3-a4ef-36cb9e0c2d29" xlink:to="loc_bcrx_BCX9930Member_a1c93f8e-9bce-4957-96a0-8728feb71700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BCX9930BCX10013Member_139916ba-98cf-4c32-9de1-7521f366ef7e" xlink:href="bcrx-20220930.xsd#bcrx_BCX9930BCX10013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_887d148f-cf9f-4de3-a4ef-36cb9e0c2d29" xlink:to="loc_bcrx_BCX9930BCX10013Member_139916ba-98cf-4c32-9de1-7521f366ef7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeAxis_59c8fa55-79fa-4af3-a819-80b6bbf36bfc" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_bcrx_AnnualNetSalesRangeAxis_59c8fa55-79fa-4af3-a819-80b6bbf36bfc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeDomain_59c8fa55-79fa-4af3-a819-80b6bbf36bfc_default" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bcrx_AnnualNetSalesRangeAxis_59c8fa55-79fa-4af3-a819-80b6bbf36bfc" xlink:to="loc_bcrx_AnnualNetSalesRangeDomain_59c8fa55-79fa-4af3-a819-80b6bbf36bfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bcrx_AnnualNetSalesRangeAxis_59c8fa55-79fa-4af3-a819-80b6bbf36bfc" xlink:to="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesUnder350000Member_1c65adac-60d2-4e32-beb2-43a2ff541e4a" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesUnder350000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesUnder350000Member_1c65adac-60d2-4e32-beb2-43a2ff541e4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesBetween350000And550000Member_decd2844-492c-498e-9b41-69305f4c69bf" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesBetween350000And550000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesBetween350000And550000Member_decd2844-492c-498e-9b41-69305f4c69bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOver550000Member_3ffc650a-9fc1-4372-a6f5-5ab59e1a312e" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesOver550000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesOver550000Member_3ffc650a-9fc1-4372-a6f5-5ab59e1a312e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesUnder150000Member_96bacf16-c7e2-4da2-af29-f615097a9524" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesUnder150000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesUnder150000Member_96bacf16-c7e2-4da2-af29-f615097a9524" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesBetween150000And230000Member_7cf3fc7c-34c2-4438-b61b-699135f0f85a" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesBetween150000And230000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesBetween150000And230000Member_7cf3fc7c-34c2-4438-b61b-699135f0f85a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOver230000Member_78562d70-7360-4072-8c6a-ca97f390abf6" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesOver230000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesOver230000Member_78562d70-7360-4072-8c6a-ca97f390abf6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesUnder15BillionMember_8d2201e3-b026-4067-af4e-0acd718830e0" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesUnder15BillionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesUnder15BillionMember_8d2201e3-b026-4067-af4e-0acd718830e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesBetween15And3BillionsMember_460e6bf6-333e-4d8d-b527-1ec5908bc167" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesBetween15And3BillionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesBetween15And3BillionsMember_460e6bf6-333e-4d8d-b527-1ec5908bc167" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOver3BillionsMember_5cb6c88d-be93-4874-ba9f-e94f27ee2943" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesOver3BillionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesOver3BillionsMember_5cb6c88d-be93-4874-ba9f-e94f27ee2943" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_996e1b5c-f1a6-4340-b492-536bb028368e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_srt_RangeAxis_996e1b5c-f1a6-4340-b492-536bb028368e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_996e1b5c-f1a6-4340-b492-536bb028368e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_996e1b5c-f1a6-4340-b492-536bb028368e" xlink:to="loc_srt_RangeMember_996e1b5c-f1a6-4340-b492-536bb028368e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5674736-6fb8-4592-826c-3af41f31d7a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_996e1b5c-f1a6-4340-b492-536bb028368e" xlink:to="loc_srt_RangeMember_a5674736-6fb8-4592-826c-3af41f31d7a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_88f241c6-5aa7-49f3-b320-f279501798a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a5674736-6fb8-4592-826c-3af41f31d7a5" xlink:to="loc_srt_MinimumMember_88f241c6-5aa7-49f3-b320-f279501798a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_feffa3ef-4abe-4f6c-a585-68fbcd4ef36d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a5674736-6fb8-4592-826c-3af41f31d7a5" xlink:to="loc_srt_MaximumMember_feffa3ef-4abe-4f6c-a585-68fbcd4ef36d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails" xlink:type="extended" id="if8394f0f43c046dcb55dad6986e0c80f_RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMonetizationsLineItems_2ac737ca-c73d-4020-b41a-ab0fc997e171" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyMonetizationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMontizationsRollForward_4b8695c3-672d-415d-956d-07a6248bd0b9" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyMontizationsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_2ac737ca-c73d-4020-b41a-ab0fc997e171" xlink:to="loc_bcrx_RoyaltyMontizationsRollForward_4b8695c3-672d-415d-956d-07a6248bd0b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FutureRoyaltiesPayable_2ed8c769-d275-4559-84e5-57e9490d0eb5" xlink:href="bcrx-20220930.xsd#bcrx_FutureRoyaltiesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b8695c3-672d-415d-956d-07a6248bd0b9" xlink:to="loc_bcrx_FutureRoyaltiesPayable_2ed8c769-d275-4559-84e5-57e9490d0eb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_5b730492-eba9-4988-b1d6-dfb183f6e1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b8695c3-672d-415d-956d-07a6248bd0b9" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_5b730492-eba9-4988-b1d6-dfb183f6e1fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation_c67df09e-f866-4918-8c15-2d10e0a1e58a" xlink:href="bcrx-20220930.xsd#bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b8695c3-672d-415d-956d-07a6248bd0b9" xlink:to="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation_c67df09e-f866-4918-8c15-2d10e0a1e58a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltiesRevenuesPaidAndPayable_32fb89f6-077d-46bc-80d2-ceda557f2ca1" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltiesRevenuesPaidAndPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b8695c3-672d-415d-956d-07a6248bd0b9" xlink:to="loc_bcrx_RoyaltiesRevenuesPaidAndPayable_32fb89f6-077d-46bc-80d2-ceda557f2ca1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FutureRoyaltiesPayable_0af31dc0-bcc4-4817-8913-299ac7f6c144" xlink:href="bcrx-20220930.xsd#bcrx_FutureRoyaltiesPayable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ee9d31ec-7148-41fd-b335-07ab4a08fe22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b8695c3-672d-415d-956d-07a6248bd0b9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ee9d31ec-7148-41fd-b335-07ab4a08fe22" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltiesMonetizationsTable_d0c248e3-5f90-4ecc-899e-2b6054ff9169" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltiesMonetizationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_2ac737ca-c73d-4020-b41a-ab0fc997e171" xlink:to="loc_bcrx_RoyaltiesMonetizationsTable_d0c248e3-5f90-4ecc-899e-2b6054ff9169" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fbf24708-d334-49d0-84b5-ec2232b3d353" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_d0c248e3-5f90-4ecc-899e-2b6054ff9169" xlink:to="loc_srt_CounterpartyNameAxis_fbf24708-d334-49d0-84b5-ec2232b3d353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fbf24708-d334-49d0-84b5-ec2232b3d353_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fbf24708-d334-49d0-84b5-ec2232b3d353" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fbf24708-d334-49d0-84b5-ec2232b3d353_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a190c189-9ab1-469d-86e3-4ba30e8f8738" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fbf24708-d334-49d0-84b5-ec2232b3d353" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a190c189-9ab1-469d-86e3-4ba30e8f8738" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TwentyTwentyRPIRoyaltyAgreementMember_b6be750f-6a41-44bf-a5f4-83393ed9aa17" xlink:href="bcrx-20220930.xsd#bcrx_TwentyTwentyRPIRoyaltyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a190c189-9ab1-469d-86e3-4ba30e8f8738" xlink:to="loc_bcrx_TwentyTwentyRPIRoyaltyAgreementMember_b6be750f-6a41-44bf-a5f4-83393ed9aa17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember_3bd24ffb-8f25-47d2-a2fa-d37b489f0591" xlink:href="bcrx-20220930.xsd#bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a190c189-9ab1-469d-86e3-4ba30e8f8738" xlink:to="loc_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember_3bd24ffb-8f25-47d2-a2fa-d37b489f0591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OMERSRoyaltyAgreementMember_d0d826f6-5252-4f63-9bad-5850a0dc88fe" xlink:href="bcrx-20220930.xsd#bcrx_OMERSRoyaltyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a190c189-9ab1-469d-86e3-4ba30e8f8738" xlink:to="loc_bcrx_OMERSRoyaltyAgreementMember_d0d826f6-5252-4f63-9bad-5850a0dc88fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ce1cf9b4-19d1-42df-945d-225294ec2c80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_d0c248e3-5f90-4ecc-899e-2b6054ff9169" xlink:to="loc_srt_RangeAxis_ce1cf9b4-19d1-42df-945d-225294ec2c80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ce1cf9b4-19d1-42df-945d-225294ec2c80_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ce1cf9b4-19d1-42df-945d-225294ec2c80" xlink:to="loc_srt_RangeMember_ce1cf9b4-19d1-42df-945d-225294ec2c80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_684e3195-5d9a-45a1-96f5-05f59ee74b88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ce1cf9b4-19d1-42df-945d-225294ec2c80" xlink:to="loc_srt_RangeMember_684e3195-5d9a-45a1-96f5-05f59ee74b88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a01a7637-abf8-4831-90f3-46fd614657d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_684e3195-5d9a-45a1-96f5-05f59ee74b88" xlink:to="loc_srt_MaximumMember_a01a7637-abf8-4831-90f3-46fd614657d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_be6ea88c-0f3c-4b65-8345-e9571f34dd12" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_684e3195-5d9a-45a1-96f5-05f59ee74b88" xlink:to="loc_srt_MinimumMember_be6ea88c-0f3c-4b65-8345-e9571f34dd12" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/DebtDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#DebtDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/DebtDetails" xlink:type="extended" id="i64d0dce473204852859dd8cea8eb89fd_DebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c96a1193-fbd3-44ab-a352-2cf1cbc11c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c96a1193-fbd3-44ab-a352-2cf1cbc11c8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7a335bca-020e-4009-8c0c-bdc82ab2d814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7a335bca-020e-4009-8c0c-bdc82ab2d814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_d76a0c30-721b-4dc4-aa7f-deae36bb2242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_d76a0c30-721b-4dc4-aa7f-deae36bb2242" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentLiborFloor_6d637861-1999-45be-9cdb-8ab4f346a6d2" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentLiborFloor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_bcrx_DebtInstrumentLiborFloor_6d637861-1999-45be-9cdb-8ab4f346a6d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentLiborCap_bfda690d-fdf6-465b-a737-a1cad3d0ecd1" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentLiborCap"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_bcrx_DebtInstrumentLiborCap_bfda690d-fdf6-465b-a737-a1cad3d0ecd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ea2cb046-ed69-48b8-8796-3f38a0da504f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ea2cb046-ed69-48b8-8796-3f38a0da504f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments_20727c30-460c-44c0-afe5-e57672815696" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments_20727c30-460c-44c0-afe5-e57672815696" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest_67eecbbc-bc10-482f-8123-a9c3048ffc59" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest_67eecbbc-bc10-482f-8123-a9c3048ffc59" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentExitFeePercentageOfPrincipal_4b3dabfd-1b63-44e0-b80e-2b0d66c33fff" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentExitFeePercentageOfPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_bcrx_DebtInstrumentExitFeePercentageOfPrincipal_4b3dabfd-1b63-44e0-b80e-2b0d66c33fff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentCommitmentFeePercentage_448addac-79d2-421d-98cb-018f421cd2d6" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_bcrx_DebtInstrumentCommitmentFeePercentage_448addac-79d2-421d-98cb-018f421cd2d6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents_1664d2e9-e18a-4aa2-8cfb-33f1fef2dc85" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents_1664d2e9-e18a-4aa2-8cfb-33f1fef2dc85" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_26ecc9c2-c59e-4515-b754-25a5bb39e383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_26ecc9c2-c59e-4515-b754-25a5bb39e383" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_46717632-fe3b-4fb6-ac59-66b7ff270be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_PaidInKindInterest_46717632-fe3b-4fb6-ac59-66b7ff270be0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_726e56b1-2c46-407e-adf9-66e20c7bf055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_LongTermDebt_726e56b1-2c46-407e-adf9-66e20c7bf055" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a2a871e7-5814-4160-b01b-82c15b86e39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a2a871e7-5814-4160-b01b-82c15b86e39c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_25db6288-5f55-44a4-9d0e-7686b0f3939c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_25db6288-5f55-44a4-9d0e-7686b0f3939c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b0a7e513-1b2a-4c57-ab91-400f84f9a836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b0a7e513-1b2a-4c57-ab91-400f84f9a836" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4e705315-b613-45e2-9025-43e3184d6e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:to="loc_us-gaap_DebtInstrumentAxis_4e705315-b613-45e2-9025-43e3184d6e97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4e705315-b613-45e2-9025-43e3184d6e97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4e705315-b613-45e2-9025-43e3184d6e97" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4e705315-b613-45e2-9025-43e3184d6e97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_46363050-0f03-420c-904f-d399f3c5072d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4e705315-b613-45e2-9025-43e3184d6e97" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_46363050-0f03-420c-904f-d399f3c5072d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CreditAgreementMember_bc461ac7-87f5-4290-994d-9a919f47c8e0" xlink:href="bcrx-20220930.xsd#bcrx_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46363050-0f03-420c-904f-d399f3c5072d" xlink:to="loc_bcrx_CreditAgreementMember_bc461ac7-87f5-4290-994d-9a919f47c8e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_df1eb3f4-34aa-458d-a6b8-d769822fecfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_df1eb3f4-34aa-458d-a6b8-d769822fecfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_df1eb3f4-34aa-458d-a6b8-d769822fecfb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_df1eb3f4-34aa-458d-a6b8-d769822fecfb" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_df1eb3f4-34aa-458d-a6b8-d769822fecfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_67fba284-b4ca-430e-9b3f-41b2d3246c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_df1eb3f4-34aa-458d-a6b8-d769822fecfb" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_67fba284-b4ca-430e-9b3f-41b2d3246c2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AthyriumMember_6482e203-19e1-4df6-ad97-aa4f76cf6142" xlink:href="bcrx-20220930.xsd#bcrx_AthyriumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_67fba284-b4ca-430e-9b3f-41b2d3246c2c" xlink:to="loc_bcrx_AthyriumMember_6482e203-19e1-4df6-ad97-aa4f76cf6142" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MidCapFinancialServicesLLCMember_e23103b4-8842-4805-8487-e36cca9a4ee8" xlink:href="bcrx-20220930.xsd#bcrx_MidCapFinancialServicesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_67fba284-b4ca-430e-9b3f-41b2d3246c2c" xlink:to="loc_bcrx_MidCapFinancialServicesLLCMember_e23103b4-8842-4805-8487-e36cca9a4ee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e7004351-28bb-4b49-b618-5397b0945755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e7004351-28bb-4b49-b618-5397b0945755" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e7004351-28bb-4b49-b618-5397b0945755_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e7004351-28bb-4b49-b618-5397b0945755" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e7004351-28bb-4b49-b618-5397b0945755_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_847d4500-cb34-4fa4-90cc-d7017736c063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e7004351-28bb-4b49-b618-5397b0945755" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_847d4500-cb34-4fa4-90cc-d7017736c063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermALoanMember_06e45344-3770-45da-bebc-4bcaf04993b0" xlink:href="bcrx-20220930.xsd#bcrx_TermALoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_847d4500-cb34-4fa4-90cc-d7017736c063" xlink:to="loc_bcrx_TermALoanMember_06e45344-3770-45da-bebc-4bcaf04993b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermBLoanMember_48b01f01-3447-471e-8634-f523b39ef5e7" xlink:href="bcrx-20220930.xsd#bcrx_TermBLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_847d4500-cb34-4fa4-90cc-d7017736c063" xlink:to="loc_bcrx_TermBLoanMember_48b01f01-3447-471e-8634-f523b39ef5e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermCLoanMember_e7d7eccf-9253-4156-aff1-206f21947734" xlink:href="bcrx-20220930.xsd#bcrx_TermCLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_847d4500-cb34-4fa4-90cc-d7017736c063" xlink:to="loc_bcrx_TermCLoanMember_e7d7eccf-9253-4156-aff1-206f21947734" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermBAndCLoanMember_54cb1968-e703-4197-9eca-248baf7bb4c9" xlink:href="bcrx-20220930.xsd#bcrx_TermBAndCLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_847d4500-cb34-4fa4-90cc-d7017736c063" xlink:to="loc_bcrx_TermBAndCLoanMember_54cb1968-e703-4197-9eca-248baf7bb4c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_0e1af7fd-ea8e-4e29-9973-cd720267d273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:to="loc_us-gaap_CreditFacilityAxis_0e1af7fd-ea8e-4e29-9973-cd720267d273" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0e1af7fd-ea8e-4e29-9973-cd720267d273_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_0e1af7fd-ea8e-4e29-9973-cd720267d273" xlink:to="loc_us-gaap_CreditFacilityDomain_0e1af7fd-ea8e-4e29-9973-cd720267d273_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5fb83774-18f3-4384-9801-e90f9159c398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_0e1af7fd-ea8e-4e29-9973-cd720267d273" xlink:to="loc_us-gaap_CreditFacilityDomain_5fb83774-18f3-4384-9801-e90f9159c398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SeniorCreditFacilityMember_b565b3dc-f9ae-4ddf-8cfc-abc74ed42978" xlink:href="bcrx-20220930.xsd#bcrx_SeniorCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5fb83774-18f3-4384-9801-e90f9159c398" xlink:to="loc_bcrx_SeniorCreditFacilityMember_b565b3dc-f9ae-4ddf-8cfc-abc74ed42978" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_4d4dbf39-2195-42fc-bef1-01f6bdb000b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:to="loc_us-gaap_VariableRateAxis_4d4dbf39-2195-42fc-bef1-01f6bdb000b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4d4dbf39-2195-42fc-bef1-01f6bdb000b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_4d4dbf39-2195-42fc-bef1-01f6bdb000b2" xlink:to="loc_us-gaap_VariableRateDomain_4d4dbf39-2195-42fc-bef1-01f6bdb000b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f6637017-08c0-4e9e-9cf3-8d45aee72835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_4d4dbf39-2195-42fc-bef1-01f6bdb000b2" xlink:to="loc_us-gaap_VariableRateDomain_f6637017-08c0-4e9e-9cf3-8d45aee72835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a5f9ab42-7e06-4057-ac61-9a75f5043dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_f6637017-08c0-4e9e-9cf3-8d45aee72835" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a5f9ab42-7e06-4057-ac61-9a75f5043dec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtCovenantTermsAxis_d74781aa-ef69-4dd8-ae49-a3a2366dfbde" xlink:href="bcrx-20220930.xsd#bcrx_DebtCovenantTermsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:to="loc_bcrx_DebtCovenantTermsAxis_d74781aa-ef69-4dd8-ae49-a3a2366dfbde" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtCovenantTermsDomain_d74781aa-ef69-4dd8-ae49-a3a2366dfbde_default" xlink:href="bcrx-20220930.xsd#bcrx_DebtCovenantTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bcrx_DebtCovenantTermsAxis_d74781aa-ef69-4dd8-ae49-a3a2366dfbde" xlink:to="loc_bcrx_DebtCovenantTermsDomain_d74781aa-ef69-4dd8-ae49-a3a2366dfbde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:href="bcrx-20220930.xsd#bcrx_DebtCovenantTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bcrx_DebtCovenantTermsAxis_d74781aa-ef69-4dd8-ae49-a3a2366dfbde" xlink:to="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PikInterestPaymentIsMadeMember_538cd664-f750-4256-a692-73a27caff5f6" xlink:href="bcrx-20220930.xsd#bcrx_PikInterestPaymentIsMadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_PikInterestPaymentIsMadeMember_538cd664-f750-4256-a692-73a27caff5f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PriorToTheSecondAnniversaryMember_4142efaa-ea0d-4f01-8dfe-4acf3baeb27a" xlink:href="bcrx-20220930.xsd#bcrx_PriorToTheSecondAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_PriorToTheSecondAnniversaryMember_4142efaa-ea0d-4f01-8dfe-4acf3baeb27a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BetweenTheSecondAndThirdAnniversariesMember_89f1b34a-2490-412e-8fba-470dedae9668" xlink:href="bcrx-20220930.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_BetweenTheSecondAndThirdAnniversariesMember_89f1b34a-2490-412e-8fba-470dedae9668" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BetweenTheThirdAndFourthAnniversariesMember_68fb44c3-62d9-4f98-bb7d-ecd6fa9fe25e" xlink:href="bcrx-20220930.xsd#bcrx_BetweenTheThirdAndFourthAnniversariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_BetweenTheThirdAndFourthAnniversariesMember_68fb44c3-62d9-4f98-bb7d-ecd6fa9fe25e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AfterFourthAnniversaryMember_65a52114-2fea-4375-b3d7-1c3c9c4781cf" xlink:href="bcrx-20220930.xsd#bcrx_AfterFourthAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_AfterFourthAnniversaryMember_65a52114-2fea-4375-b3d7-1c3c9c4781cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanADrawnMember_45ec2c08-8fa6-4b48-990e-b8968c70dd9c" xlink:href="bcrx-20220930.xsd#bcrx_TermLoanADrawnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_TermLoanADrawnMember_45ec2c08-8fa6-4b48-990e-b8968c70dd9c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanAAndBDrawnMember_871f869a-aac3-48d9-a80d-fc5cbaeead54" xlink:href="bcrx-20220930.xsd#bcrx_TermLoanAAndBDrawnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_TermLoanAAndBDrawnMember_871f869a-aac3-48d9-a80d-fc5cbaeead54" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoansABAndCDrawnMember_18179d1a-81fa-4bac-9715-8566092cc32a" xlink:href="bcrx-20220930.xsd#bcrx_TermLoansABAndCDrawnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_TermLoansABAndCDrawnMember_18179d1a-81fa-4bac-9715-8566092cc32a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember_c59e9ccc-46de-48f3-aa7f-d0fa1a3e751a" xlink:href="bcrx-20220930.xsd#bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember_c59e9ccc-46de-48f3-aa7f-d0fa1a3e751a" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsDetailsTextual" xlink:type="simple" xlink:href="bcrx-20220930.xsd#LeaseObligationsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/LeaseObligationsDetailsTextual" xlink:type="extended" id="i18cdd1fe4a4c47ed9d204a24a07ea40f_LeaseObligationsDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4763c864-71d1-4883-b05b-ce5ce7a108e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_58138ea6-5957-4a2c-a354-f9d4147337ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4763c864-71d1-4883-b05b-ce5ce7a108e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_58138ea6-5957-4a2c-a354-f9d4147337ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_311b3d99-c405-4da4-bef2-090067a78ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4763c864-71d1-4883-b05b-ce5ce7a108e9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_311b3d99-c405-4da4-bef2-090067a78ce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_571bee16-0e9b-4b1a-acdf-ddd7cabadeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4763c864-71d1-4883-b05b-ce5ce7a108e9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_571bee16-0e9b-4b1a-acdf-ddd7cabadeb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization_7b081cc2-323c-4201-a1d7-6812b9ef8b9f" xlink:href="bcrx-20220930.xsd#bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4763c864-71d1-4883-b05b-ce5ce7a108e9" xlink:to="loc_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization_7b081cc2-323c-4201-a1d7-6812b9ef8b9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_f765658b-a2bc-4ecf-bbb3-ba6d0fa9fa65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4763c864-71d1-4883-b05b-ce5ce7a108e9" xlink:to="loc_us-gaap_OperatingLeasePayments_f765658b-a2bc-4ecf-bbb3-ba6d0fa9fa65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_aff042da-7a1c-430c-887a-38ea4ebc275f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4763c864-71d1-4883-b05b-ce5ce7a108e9" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_aff042da-7a1c-430c-887a-38ea4ebc275f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b61498ef-4514-4c71-8234-2466391b9635" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aff042da-7a1c-430c-887a-38ea4ebc275f" xlink:to="loc_srt_RangeAxis_b61498ef-4514-4c71-8234-2466391b9635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b61498ef-4514-4c71-8234-2466391b9635_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b61498ef-4514-4c71-8234-2466391b9635" xlink:to="loc_srt_RangeMember_b61498ef-4514-4c71-8234-2466391b9635_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1d910d6-2c56-4022-86d2-d0e62a1aac86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b61498ef-4514-4c71-8234-2466391b9635" xlink:to="loc_srt_RangeMember_b1d910d6-2c56-4022-86d2-d0e62a1aac86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a2fd9f2-f051-4deb-8f42-9478d4591883" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b1d910d6-2c56-4022-86d2-d0e62a1aac86" xlink:to="loc_srt_MinimumMember_6a2fd9f2-f051-4deb-8f42-9478d4591883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_15fe61a9-f1c2-4f6b-b20a-880db3b2c7a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b1d910d6-2c56-4022-86d2-d0e62a1aac86" xlink:to="loc_srt_MaximumMember_15fe61a9-f1c2-4f6b-b20a-880db3b2c7a4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/StockholdersEquityDetails" xlink:type="extended" id="i6ec90281dd5948c4be45f4d7b5300420_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaximumAggregateOfferingPrice_9cda05fd-336a-4b75-8607-504e2c28df22" xlink:href="bcrx-20220930.xsd#bcrx_MaximumAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:to="loc_bcrx_MaximumAggregateOfferingPrice_9cda05fd-336a-4b75-8607-504e2c28df22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8bbb3704-b0a5-457c-be61-c510be195e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8bbb3704-b0a5-457c-be61-c510be195e03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_daad3fef-1353-48e2-a270-060655c18cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_daad3fef-1353-48e2-a270-060655c18cbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_2b567e0f-b57f-442c-8ff3-4341ee67218e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_2b567e0f-b57f-442c-8ff3-4341ee67218e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharesIssuedPricePerSharePremium_6ab26e24-3399-4468-8c01-5c1e78b86cf5" xlink:href="bcrx-20220930.xsd#bcrx_SharesIssuedPricePerSharePremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:to="loc_bcrx_SharesIssuedPricePerSharePremium_6ab26e24-3399-4468-8c01-5c1e78b86cf5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharesIssuedPricePerShareClosingPrice_2225a961-ce03-41fb-89e7-318d19716f18" xlink:href="bcrx-20220930.xsd#bcrx_SharesIssuedPricePerShareClosingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:to="loc_bcrx_SharesIssuedPricePerShareClosingPrice_2225a961-ce03-41fb-89e7-318d19716f18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharesIssuedCommonStockPremium_716e6a60-187a-4a40-89cb-b2bc2d75e004" xlink:href="bcrx-20220930.xsd#bcrx_SharesIssuedCommonStockPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:to="loc_bcrx_SharesIssuedCommonStockPremium_716e6a60-187a-4a40-89cb-b2bc2d75e004" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_befb9441-f43c-4fc1-8671-b60f2d3c4f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_befb9441-f43c-4fc1-8671-b60f2d3c4f69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7701357a-ebe1-41f5-a69c-45a9b491ec13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_befb9441-f43c-4fc1-8671-b60f2d3c4f69" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7701357a-ebe1-41f5-a69c-45a9b491ec13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7701357a-ebe1-41f5-a69c-45a9b491ec13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7701357a-ebe1-41f5-a69c-45a9b491ec13" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7701357a-ebe1-41f5-a69c-45a9b491ec13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3adfeff0-47c7-4cb2-804d-366ba3b56d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7701357a-ebe1-41f5-a69c-45a9b491ec13" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3adfeff0-47c7-4cb2-804d-366ba3b56d67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CommonStockPurchaseAgreementWithRPIMember_11d8b12f-f8d7-4f64-a80b-c85f9a8cecfd" xlink:href="bcrx-20220930.xsd#bcrx_CommonStockPurchaseAgreementWithRPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3adfeff0-47c7-4cb2-804d-366ba3b56d67" xlink:to="loc_bcrx_CommonStockPurchaseAgreementWithRPIMember_11d8b12f-f8d7-4f64-a80b-c85f9a8cecfd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationDetailsTextual" xlink:type="simple" xlink:href="bcrx-20220930.xsd#StockbasedCompensationDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationDetailsTextual" xlink:type="extended" id="ida6a7596f505407a870db363ed584811_StockbasedCompensationDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShareBasedPaymentArrangementNumberOfPlans_575f9c95-9fea-443c-97f5-85bb28ea8bd0" xlink:href="bcrx-20220930.xsd#bcrx_ShareBasedPaymentArrangementNumberOfPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_ShareBasedPaymentArrangementNumberOfPlans_575f9c95-9fea-443c-97f5-85bb28ea8bd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9fe29d73-59f4-4718-947c-1bba7eeeb7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9fe29d73-59f4-4718-947c-1bba7eeeb7b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d62ca596-988f-42ee-a757-32e579809e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d62ca596-988f-42ee-a757-32e579809e6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear_214a7816-1532-4e75-80da-ba55981b6fc2" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear_214a7816-1532-4e75-80da-ba55981b6fc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear_8a84914b-6682-4d06-a967-7e92ff8a4c91" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear_8a84914b-6682-4d06-a967-7e92ff8a4c91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo_e6010a48-94a5-4c75-af59-bd22fe79370a" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo_e6010a48-94a5-4c75-af59-bd22fe79370a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree_677a7ddd-c858-4485-a58d-4ed8cdde63ce" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree_677a7ddd-c858-4485-a58d-4ed8cdde63ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour_728c45e3-0fd9-4dca-9a5f-b89608f30e47" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour_728c45e3-0fd9-4dca-9a5f-b89608f30e47" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dc8b56b8-3dc2-4246-9675-77a3515f9947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dc8b56b8-3dc2-4246-9675-77a3515f9947" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d75a92ca-7f5c-49bc-b4f7-f104fe10b41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d75a92ca-7f5c-49bc-b4f7-f104fe10b41d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_608b5df2-4e09-4265-b3d6-2fe4c82242c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_608b5df2-4e09-4265-b3d6-2fe4c82242c6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_306e45b7-0b39-4fa9-91f5-871d3029d18b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_306e45b7-0b39-4fa9-91f5-871d3029d18b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_aeb6e5b0-ca9c-40d0-a5d4-a998b1372b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_aeb6e5b0-ca9c-40d0-a5d4-a998b1372b01" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a49de71e-e562-43c8-a567-8d9a0731f6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a49de71e-e562-43c8-a567-8d9a0731f6a5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7fff0da9-1078-48d8-b973-b00d5b74407f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7fff0da9-1078-48d8-b973-b00d5b74407f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c3f445b9-3a44-43bc-9898-ea9b3fabedba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c3f445b9-3a44-43bc-9898-ea9b3fabedba" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3741c865-0d51-41a3-9b22-c7549fea621f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3741c865-0d51-41a3-9b22-c7549fea621f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9e87b737-9396-4b6c-af9e-1c79adc432ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9e87b737-9396-4b6c-af9e-1c79adc432ed" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_16a220ae-667a-43ab-a810-642d4b0e5af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_16a220ae-667a-43ab-a810-642d4b0e5af3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum_6303dea1-7b84-4fdf-af89-b7e01721ce24" xlink:href="bcrx-20220930.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum_6303dea1-7b84-4fdf-af89-b7e01721ce24" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PercentageOfCommonStockSharesBeginning_f0e35059-329f-4c01-b304-44929665b3c7" xlink:href="bcrx-20220930.xsd#bcrx_PercentageOfCommonStockSharesBeginning"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_PercentageOfCommonStockSharesBeginning_f0e35059-329f-4c01-b304-44929665b3c7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PercentageOfCommonStockSharesEnding_a25138ad-4385-45c2-a878-c1d56bbcfbdc" xlink:href="bcrx-20220930.xsd#bcrx_PercentageOfCommonStockSharesEnding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_PercentageOfCommonStockSharesEnding_a25138ad-4385-45c2-a878-c1d56bbcfbdc" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_83c7437e-c045-440b-8540-69a1547b28b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_83c7437e-c045-440b-8540-69a1547b28b5" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount_081fe1dc-5f5b-49c9-9d07-3eb612d69bfc" xlink:href="bcrx-20220930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount_081fe1dc-5f5b-49c9-9d07-3eb612d69bfc" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0c6a264b-1b15-4f8e-9071-d53c0d0b574d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0c6a264b-1b15-4f8e-9071-d53c0d0b574d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a75eda43-0da2-4e24-aaaa-3cdc703c1de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a75eda43-0da2-4e24-aaaa-3cdc703c1de1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_47d43e4f-6233-4e7d-919d-f2612a9f4d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a75eda43-0da2-4e24-aaaa-3cdc703c1de1" xlink:to="loc_us-gaap_PlanNameAxis_47d43e4f-6233-4e7d-919d-f2612a9f4d8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_47d43e4f-6233-4e7d-919d-f2612a9f4d8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_47d43e4f-6233-4e7d-919d-f2612a9f4d8b" xlink:to="loc_us-gaap_PlanNameDomain_47d43e4f-6233-4e7d-919d-f2612a9f4d8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c4b376dd-a021-4e5b-a05e-0efbfc136311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_47d43e4f-6233-4e7d-919d-f2612a9f4d8b" xlink:to="loc_us-gaap_PlanNameDomain_c4b376dd-a021-4e5b-a05e-0efbfc136311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_5f1697b7-7b9f-474a-ae7a-edaa6b0a0be8" xlink:href="bcrx-20220930.xsd#bcrx_IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c4b376dd-a021-4e5b-a05e-0efbfc136311" xlink:to="loc_bcrx_IncentivePlanMember_5f1697b7-7b9f-474a-ae7a-edaa6b0a0be8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_fd04debd-6fad-49c5-9131-542b1f682699" xlink:href="bcrx-20220930.xsd#bcrx_InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c4b376dd-a021-4e5b-a05e-0efbfc136311" xlink:to="loc_bcrx_InducementPlanMember_fd04debd-6fad-49c5-9131-542b1f682699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeStockPurchasePlanMember_657e96a0-7dce-4cc4-8c86-ba8aa990f5a2" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c4b376dd-a021-4e5b-a05e-0efbfc136311" xlink:to="loc_bcrx_EmployeeStockPurchasePlanMember_657e96a0-7dce-4cc4-8c86-ba8aa990f5a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2620a9b0-f555-40d7-8950-a9841be42188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a75eda43-0da2-4e24-aaaa-3cdc703c1de1" xlink:to="loc_us-gaap_AwardTypeAxis_2620a9b0-f555-40d7-8950-a9841be42188" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2620a9b0-f555-40d7-8950-a9841be42188_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2620a9b0-f555-40d7-8950-a9841be42188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2620a9b0-f555-40d7-8950-a9841be42188_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a18b372-2036-4150-97b1-93c6143f96a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2620a9b0-f555-40d7-8950-a9841be42188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a18b372-2036-4150-97b1-93c6143f96a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_812eb369-2912-4e68-821b-64f7a109fc45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a18b372-2036-4150-97b1-93c6143f96a3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_812eb369-2912-4e68-821b-64f7a109fc45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7e3d8ebb-6590-4d12-a0b9-5d16774bcc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a18b372-2036-4150-97b1-93c6143f96a3" xlink:to="loc_us-gaap_PerformanceSharesMember_7e3d8ebb-6590-4d12-a0b9-5d16774bcc2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PerformancebasedRestrictedStockUnitsMember_9e21da00-02f6-4430-94a3-6af372ba3786" xlink:href="bcrx-20220930.xsd#bcrx_PerformancebasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a18b372-2036-4150-97b1-93c6143f96a3" xlink:to="loc_bcrx_PerformancebasedRestrictedStockUnitsMember_9e21da00-02f6-4430-94a3-6af372ba3786" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_33564f6e-d0e1-4de8-97a4-875ccf0feb10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a18b372-2036-4150-97b1-93c6143f96a3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_33564f6e-d0e1-4de8-97a4-875ccf0feb10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_b1fb761d-8fb4-4d49-83b4-425724c3e0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a75eda43-0da2-4e24-aaaa-3cdc703c1de1" xlink:to="loc_us-gaap_VestingAxis_b1fb761d-8fb4-4d49-83b4-425724c3e0e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b1fb761d-8fb4-4d49-83b4-425724c3e0e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_b1fb761d-8fb4-4d49-83b4-425724c3e0e0" xlink:to="loc_us-gaap_VestingDomain_b1fb761d-8fb4-4d49-83b4-425724c3e0e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_20031e8d-320c-4db4-8469-6da8135ad82b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_b1fb761d-8fb4-4d49-83b4-425724c3e0e0" xlink:to="loc_us-gaap_VestingDomain_20031e8d-320c-4db4-8469-6da8135ad82b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_Vest25PercentEachYearUntilFullyVestedMember_5cf5eda2-998d-49f8-a5a7-d3364120ff84" xlink:href="bcrx-20220930.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_20031e8d-320c-4db4-8469-6da8135ad82b" xlink:to="loc_bcrx_Vest25PercentEachYearUntilFullyVestedMember_5cf5eda2-998d-49f8-a5a7-d3364120ff84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember_e7368a84-b9f1-4161-96ca-9d8b6dc38e50" xlink:href="bcrx-20220930.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_20031e8d-320c-4db4-8469-6da8135ad82b" xlink:to="loc_bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember_e7368a84-b9f1-4161-96ca-9d8b6dc38e50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2566e4cc-4272-4902-b929-ef6fc9b00f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_20031e8d-320c-4db4-8469-6da8135ad82b" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2566e4cc-4272-4902-b929-ef6fc9b00f70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ThirtysixEqualMonthlyInstallmentsMember_a877d96e-742d-45a7-8aec-e3161b9f158b" xlink:href="bcrx-20220930.xsd#bcrx_ThirtysixEqualMonthlyInstallmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_20031e8d-320c-4db4-8469-6da8135ad82b" xlink:to="loc_bcrx_ThirtysixEqualMonthlyInstallmentsMember_a877d96e-742d-45a7-8aec-e3161b9f158b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_378319b4-f972-44a4-a58c-ac79ef4f9267" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a75eda43-0da2-4e24-aaaa-3cdc703c1de1" xlink:to="loc_srt_TitleOfIndividualAxis_378319b4-f972-44a4-a58c-ac79ef4f9267" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_378319b4-f972-44a4-a58c-ac79ef4f9267_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_378319b4-f972-44a4-a58c-ac79ef4f9267" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_378319b4-f972-44a4-a58c-ac79ef4f9267_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e4535ff3-a098-48cb-a6ec-400c3a4c89e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_378319b4-f972-44a4-a58c-ac79ef4f9267" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e4535ff3-a098-48cb-a6ec-400c3a4c89e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonEmployeeDirectorsMember_f7d895fd-3a6b-4da4-b5d5-f0635b74c4f7" xlink:href="bcrx-20220930.xsd#bcrx_NonEmployeeDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e4535ff3-a098-48cb-a6ec-400c3a4c89e5" xlink:to="loc_bcrx_NonEmployeeDirectorsMember_f7d895fd-3a6b-4da4-b5d5-f0635b74c4f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3a015522-b493-4bc2-b68e-aa7d7b7bdded" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a75eda43-0da2-4e24-aaaa-3cdc703c1de1" xlink:to="loc_srt_RangeAxis_3a015522-b493-4bc2-b68e-aa7d7b7bdded" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3a015522-b493-4bc2-b68e-aa7d7b7bdded_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3a015522-b493-4bc2-b68e-aa7d7b7bdded" xlink:to="loc_srt_RangeMember_3a015522-b493-4bc2-b68e-aa7d7b7bdded_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f70dc3b-d3ee-4814-9215-1a2ca6375437" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3a015522-b493-4bc2-b68e-aa7d7b7bdded" xlink:to="loc_srt_RangeMember_1f70dc3b-d3ee-4814-9215-1a2ca6375437" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3506b42c-2bb4-4129-aacc-454c121027ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1f70dc3b-d3ee-4814-9215-1a2ca6375437" xlink:to="loc_srt_MaximumMember_3506b42c-2bb4-4129-aacc-454c121027ae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#StockbasedCompensationStockPlanActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails" xlink:type="extended" id="ia5505ad5722b4cb4be813f4c0e2baaf6_StockbasedCompensationStockPlanActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0df26004-1b91-4235-88f9-0b12fc9ce4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0df26004-1b91-4235-88f9-0b12fc9ce4f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e14fb474-321b-4e05-8719-00d7cbd24c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e14fb474-321b-4e05-8719-00d7cbd24c41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares_60efb7a9-2f1f-40b6-bf78-6af2061b9c3b" xlink:href="bcrx-20220930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:to="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares_60efb7a9-2f1f-40b6-bf78-6af2061b9c3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4008510a-c4f9-4909-8bb5-f0d4ff348f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4008510a-c4f9-4909-8bb5-f0d4ff348f1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e667a5e3-f69b-4e78-b01e-cd5f256f0850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e667a5e3-f69b-4e78-b01e-cd5f256f0850" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable_35d69600-eb63-4910-a599-c3731df4d051" xlink:href="bcrx-20220930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:to="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable_35d69600-eb63-4910-a599-c3731df4d051" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable_d03fdf2b-93ab-46ea-a115-435102abada3" xlink:href="bcrx-20220930.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:to="loc_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable_d03fdf2b-93ab-46ea-a115-435102abada3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_644bf056-3a7e-4989-98a1-571dbe98d597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa94229d-b470-4a00-a1c6-a615f2f04d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0df26004-1b91-4235-88f9-0b12fc9ce4f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa94229d-b470-4a00-a1c6-a615f2f04d2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_32b147f7-5542-4cab-88e2-80d8d8c9a33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa94229d-b470-4a00-a1c6-a615f2f04d2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_32b147f7-5542-4cab-88e2-80d8d8c9a33e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f9c0dc63-f99d-4a8d-9c7a-748bab9889e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa94229d-b470-4a00-a1c6-a615f2f04d2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f9c0dc63-f99d-4a8d-9c7a-748bab9889e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7bd3a1d5-9773-4897-b612-bf7e4e0cf7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa94229d-b470-4a00-a1c6-a615f2f04d2e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7bd3a1d5-9773-4897-b612-bf7e4e0cf7fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_fd063132-b802-40cb-80b5-19ab5c75cf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa94229d-b470-4a00-a1c6-a615f2f04d2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_fd063132-b802-40cb-80b5-19ab5c75cf3a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bc24b592-85d1-44de-9ecb-6289dcd1b482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2f12f093-b614-4493-984a-7bbffe8fc1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0df26004-1b91-4235-88f9-0b12fc9ce4f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2f12f093-b614-4493-984a-7bbffe8fc1de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7e044850-9710-4510-a25d-22c0546a1657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2f12f093-b614-4493-984a-7bbffe8fc1de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7e044850-9710-4510-a25d-22c0546a1657" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0c3efd8e-f4dd-4338-9821-ca3ca5339adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2f12f093-b614-4493-984a-7bbffe8fc1de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0c3efd8e-f4dd-4338-9821-ca3ca5339adb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_66d7d6ef-7f1e-49d0-8578-b5ac58b99163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2f12f093-b614-4493-984a-7bbffe8fc1de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_66d7d6ef-7f1e-49d0-8578-b5ac58b99163" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c29e05b8-05af-4cd1-8b42-afa4572d6a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2f12f093-b614-4493-984a-7bbffe8fc1de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c29e05b8-05af-4cd1-8b42-afa4572d6a78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8dfa78d0-40f7-4262-8992-136d509c832d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e438690a-8dd2-42fa-a37a-b53c7ccba293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0df26004-1b91-4235-88f9-0b12fc9ce4f1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e438690a-8dd2-42fa-a37a-b53c7ccba293" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_91b3ab2a-9323-4d03-9427-d794805b6751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e438690a-8dd2-42fa-a37a-b53c7ccba293" xlink:to="loc_us-gaap_PlanNameAxis_91b3ab2a-9323-4d03-9427-d794805b6751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_91b3ab2a-9323-4d03-9427-d794805b6751_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_91b3ab2a-9323-4d03-9427-d794805b6751" xlink:to="loc_us-gaap_PlanNameDomain_91b3ab2a-9323-4d03-9427-d794805b6751_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f98f3b8e-6e96-4109-a071-b84e3ef3cf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_91b3ab2a-9323-4d03-9427-d794805b6751" xlink:to="loc_us-gaap_PlanNameDomain_f98f3b8e-6e96-4109-a071-b84e3ef3cf7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_0ea2e824-801d-4ac1-98f0-f2b04cc3bfc2" xlink:href="bcrx-20220930.xsd#bcrx_IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f98f3b8e-6e96-4109-a071-b84e3ef3cf7e" xlink:to="loc_bcrx_IncentivePlanMember_0ea2e824-801d-4ac1-98f0-f2b04cc3bfc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_4191e4a1-b755-4e36-8aca-11eb61c22a87" xlink:href="bcrx-20220930.xsd#bcrx_InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f98f3b8e-6e96-4109-a071-b84e3ef3cf7e" xlink:to="loc_bcrx_InducementPlanMember_4191e4a1-b755-4e36-8aca-11eb61c22a87" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails" xlink:type="extended" id="i6fea45fa05de454c88f78c45fa9e92e7_StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91f904da-abb2-4be1-a703-1c5fa064f76a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_37f026c5-3d67-409c-ab7c-303eeae90f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91f904da-abb2-4be1-a703-1c5fa064f76a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_37f026c5-3d67-409c-ab7c-303eeae90f46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7648d052-9426-4fe5-a07c-7de81a8960c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91f904da-abb2-4be1-a703-1c5fa064f76a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7648d052-9426-4fe5-a07c-7de81a8960c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0d1c6072-c328-4014-b621-22e14e7b13a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91f904da-abb2-4be1-a703-1c5fa064f76a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0d1c6072-c328-4014-b621-22e14e7b13a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_aa6477bb-6e37-491c-94c0-c99ba344d5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91f904da-abb2-4be1-a703-1c5fa064f76a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_aa6477bb-6e37-491c-94c0-c99ba344d5e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6bb816be-f74c-494b-9952-8a8e0d041ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91f904da-abb2-4be1-a703-1c5fa064f76a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6bb816be-f74c-494b-9952-8a8e0d041ec1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e55f85a0-100f-4c25-b315-5530af544a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6bb816be-f74c-494b-9952-8a8e0d041ec1" xlink:to="loc_us-gaap_PlanNameAxis_e55f85a0-100f-4c25-b315-5530af544a43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e55f85a0-100f-4c25-b315-5530af544a43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e55f85a0-100f-4c25-b315-5530af544a43" xlink:to="loc_us-gaap_PlanNameDomain_e55f85a0-100f-4c25-b315-5530af544a43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fce7d0f5-3674-4004-8263-3103437a734d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e55f85a0-100f-4c25-b315-5530af544a43" xlink:to="loc_us-gaap_PlanNameDomain_fce7d0f5-3674-4004-8263-3103437a734d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanAndInducementPlanMember_6f372b95-f1f1-4608-8cbf-f04685728bb9" xlink:href="bcrx-20220930.xsd#bcrx_IncentivePlanAndInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fce7d0f5-3674-4004-8263-3103437a734d" xlink:to="loc_bcrx_IncentivePlanAndInducementPlanMember_6f372b95-f1f1-4608-8cbf-f04685728bb9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#CollaborativeandOtherRelationshipsDetails"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails" xlink:type="extended" id="i5a7fb96e930f403285934026715acd2b_CollaborativeandOtherRelationshipsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts_518b7775-a263-4c2f-b6aa-5906f4baa44b" xlink:href="bcrx-20220930.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts_518b7775-a263-4c2f-b6aa-5906f4baa44b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding_4052dd3d-01df-468d-9e75-044bd49b06b4" xlink:href="bcrx-20220930.xsd#bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding_4052dd3d-01df-468d-9e75-044bd49b06b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAgreementContractValue_f9ba83a3-e76f-450e-b517-2ca7ff19f07c" xlink:href="bcrx-20220930.xsd#bcrx_CollaborativeAgreementContractValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_CollaborativeAgreementContractValue_f9ba83a3-e76f-450e-b517-2ca7ff19f07c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractReceivable_03ed14b1-5ca8-4921-9738-c00ca9c0617d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_us-gaap_GovernmentContractReceivable_03ed14b1-5ca8-4921-9738-c00ca9c0617d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts_ee044f47-51d4-4107-b2f2-90646a7a986b" xlink:href="bcrx-20220930.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts_ee044f47-51d4-4107-b2f2-90646a7a986b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses_0f12c569-c0c3-4aa4-9722-0e072384d0fc" xlink:href="bcrx-20220930.xsd#bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses_0f12c569-c0c3-4aa4-9722-0e072384d0fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NumberOfProductsObtainedDoses_aed9fc07-9447-4289-a97d-c78077e42b0f" xlink:href="bcrx-20220930.xsd#bcrx_NumberOfProductsObtainedDoses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_NumberOfProductsObtainedDoses_aed9fc07-9447-4289-a97d-c78077e42b0f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ContractTerm_fe5bff1c-980a-4162-9f9c-7948dc232243" xlink:href="bcrx-20220930.xsd#bcrx_ContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_ContractTerm_fe5bff1c-980a-4162-9f9c-7948dc232243" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_7c70c8a4-ac1d-4ea9-a4f9-a5a6d25ef4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_us-gaap_ProceedsFromCollaborators_7c70c8a4-ac1d-4ea9-a4f9-a5a6d25ef4a8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_08f9a4f2-d7ae-40e0-a1e9-dea2322a2add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_08f9a4f2-d7ae-40e0-a1e9-dea2322a2add" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone_ca182020-3a40-49fb-83a6-48e0d1312621" xlink:href="bcrx-20220930.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone_ca182020-3a40-49fb-83a6-48e0d1312621" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation_496080e9-c3e1-47d8-9665-3b345dea3ca1" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyRateIfMaintainsSakigakeDesignation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation_496080e9-c3e1-47d8-9665-3b345dea3ca1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaximumCustomaryReductionOnRoyaltyRate_43d25527-c4e0-4f5c-a3a6-e4d8bc67cacd" xlink:href="bcrx-20220930.xsd#bcrx_MaximumCustomaryReductionOnRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_MaximumCustomaryReductionOnRoyaltyRate_43d25527-c4e0-4f5c-a3a6-e4d8bc67cacd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial_efcfd237-eebb-4b68-86da-f801263d3942" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial_efcfd237-eebb-4b68-86da-f801263d3942" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MilestonePaymentMinimum_384fbdbe-f4d0-46d6-bb39-00ba69322e14" xlink:href="bcrx-20220930.xsd#bcrx_MilestonePaymentMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_MilestonePaymentMinimum_384fbdbe-f4d0-46d6-bb39-00ba69322e14" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MilestonePaymentMaximum_2cce2a98-0bfa-4072-b5c0-4d41f81f6fb9" xlink:href="bcrx-20220930.xsd#bcrx_MilestonePaymentMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_MilestonePaymentMaximum_2cce2a98-0bfa-4072-b5c0-4d41f81f6fb9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualLicenseFeeMinimum_9a597029-feba-4d31-b1f2-910243bef264" xlink:href="bcrx-20220930.xsd#bcrx_AnnualLicenseFeeMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_AnnualLicenseFeeMinimum_9a597029-feba-4d31-b1f2-910243bef264" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualLicenseFeeMaximum_e058715f-43d2-434b-ae24-a89642626efa" xlink:href="bcrx-20220930.xsd#bcrx_AnnualLicenseFeeMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_AnnualLicenseFeeMaximum_e058715f-43d2-434b-ae24-a89642626efa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PeriodOfAgreement_45714209-3e8e-436a-98a1-a0fbf52703e8" xlink:href="bcrx-20220930.xsd#bcrx_PeriodOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_PeriodOfAgreement_45714209-3e8e-436a-98a1-a0fbf52703e8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RenewablePeriodOfAgreement_3d1d28fd-5f56-4a46-9e11-8bb80c97bc77" xlink:href="bcrx-20220930.xsd#bcrx_RenewablePeriodOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_RenewablePeriodOfAgreement_3d1d28fd-5f56-4a46-9e11-8bb80c97bc77" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2051724d-1899-45ee-a3e3-ff5cc6e495b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2051724d-1899-45ee-a3e3-ff5cc6e495b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9c814e58-a043-4ef7-a93f-a6e52fecd5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2051724d-1899-45ee-a3e3-ff5cc6e495b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9c814e58-a043-4ef7-a93f-a6e52fecd5c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c814e58-a043-4ef7-a93f-a6e52fecd5c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9c814e58-a043-4ef7-a93f-a6e52fecd5c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c814e58-a043-4ef7-a93f-a6e52fecd5c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_140e9d38-79c2-4136-996b-6040bf1b1bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9c814e58-a043-4ef7-a93f-a6e52fecd5c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_140e9d38-79c2-4136-996b-6040bf1b1bd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_b8121800-cac2-43d6-9b4d-43a901a28cdd" xlink:href="bcrx-20220930.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_140e9d38-79c2-4136-996b-6040bf1b1bd9" xlink:to="loc_bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_b8121800-cac2-43d6-9b4d-43a901a28cdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_UABMember_4535ab85-238e-4b21-a7a3-d0b36139349a" xlink:href="bcrx-20220930.xsd#bcrx_UABMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_140e9d38-79c2-4136-996b-6040bf1b1bd9" xlink:to="loc_bcrx_UABMember_4535ab85-238e-4b21-a7a3-d0b36139349a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6806b090-60c5-4c77-88c6-ae1aa0f7d864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2051724d-1899-45ee-a3e3-ff5cc6e495b9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6806b090-60c5-4c77-88c6-ae1aa0f7d864" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6806b090-60c5-4c77-88c6-ae1aa0f7d864_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6806b090-60c5-4c77-88c6-ae1aa0f7d864" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6806b090-60c5-4c77-88c6-ae1aa0f7d864_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_369b6cb6-4482-475e-9ffb-90168bb0a965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6806b090-60c5-4c77-88c6-ae1aa0f7d864" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_369b6cb6-4482-475e-9ffb-90168bb0a965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BaseContractMember_e1ee616b-d2ff-46ac-84ff-9342a8de897d" xlink:href="bcrx-20220930.xsd#bcrx_BaseContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_369b6cb6-4482-475e-9ffb-90168bb0a965" xlink:to="loc_bcrx_BaseContractMember_e1ee616b-d2ff-46ac-84ff-9342a8de897d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AdditionalDevelopmentOptionsMember_99f500cb-c787-400d-8bb3-2b843c330d5c" xlink:href="bcrx-20220930.xsd#bcrx_AdditionalDevelopmentOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_369b6cb6-4482-475e-9ffb-90168bb0a965" xlink:to="loc_bcrx_AdditionalDevelopmentOptionsMember_99f500cb-c787-400d-8bb3-2b843c330d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ASPRBARDAContractMember_d881a3fa-96a4-43f1-b549-226a6a5560c1" xlink:href="bcrx-20220930.xsd#bcrx_ASPRBARDAContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_369b6cb6-4482-475e-9ffb-90168bb0a965" xlink:to="loc_bcrx_ASPRBARDAContractMember_d881a3fa-96a4-43f1-b549-226a6a5560c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AECOMAndIRLMember_b5c762a0-4809-43d2-a53c-2ef3257d1c0c" xlink:href="bcrx-20220930.xsd#bcrx_AECOMAndIRLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_369b6cb6-4482-475e-9ffb-90168bb0a965" xlink:to="loc_bcrx_AECOMAndIRLMember_b5c762a0-4809-43d2-a53c-2ef3257d1c0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b894e983-fc7c-402b-a50f-d41f47da76c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2051724d-1899-45ee-a3e3-ff5cc6e495b9" xlink:to="loc_srt_CounterpartyNameAxis_b894e983-fc7c-402b-a50f-d41f47da76c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b894e983-fc7c-402b-a50f-d41f47da76c4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b894e983-fc7c-402b-a50f-d41f47da76c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b894e983-fc7c-402b-a50f-d41f47da76c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32937a1f-7fd7-46fc-a35a-155bf135039e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b894e983-fc7c-402b-a50f-d41f47da76c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32937a1f-7fd7-46fc-a35a-155bf135039e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_USDepartmentOfHealthAndHumanServicesMember_ca1b3150-ed90-4813-8deb-a87439c1bdc7" xlink:href="bcrx-20220930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32937a1f-7fd7-46fc-a35a-155bf135039e" xlink:to="loc_bcrx_USDepartmentOfHealthAndHumanServicesMember_ca1b3150-ed90-4813-8deb-a87439c1bdc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ToriiPharmaceuticalCoMember_f81944ad-e892-4fb4-acae-9fd08eff710d" xlink:href="bcrx-20220930.xsd#bcrx_ToriiPharmaceuticalCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32937a1f-7fd7-46fc-a35a-155bf135039e" xlink:to="loc_bcrx_ToriiPharmaceuticalCoMember_f81944ad-e892-4fb4-acae-9fd08eff710d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9529642e-df1a-4046-8ea2-a7ba2c2f3456" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2051724d-1899-45ee-a3e3-ff5cc6e495b9" xlink:to="loc_srt_ProductOrServiceAxis_9529642e-df1a-4046-8ea2-a7ba2c2f3456" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9529642e-df1a-4046-8ea2-a7ba2c2f3456_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9529642e-df1a-4046-8ea2-a7ba2c2f3456" xlink:to="loc_srt_ProductsAndServicesDomain_9529642e-df1a-4046-8ea2-a7ba2c2f3456_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d6818e00-2e4f-4734-bddf-fe7ae78e8035" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9529642e-df1a-4046-8ea2-a7ba2c2f3456" xlink:to="loc_srt_ProductsAndServicesDomain_d6818e00-2e4f-4734-bddf-fe7ae78e8035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RAPIVABMember_2ee436af-0c64-4ffc-b081-dce1a2fadfae" xlink:href="bcrx-20220930.xsd#bcrx_RAPIVABMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d6818e00-2e4f-4734-bddf-fe7ae78e8035" xlink:to="loc_bcrx_RAPIVABMember_2ee436af-0c64-4ffc-b081-dce1a2fadfae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a76811cd-d179-45da-8d0d-05c1df07f01c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2051724d-1899-45ee-a3e3-ff5cc6e495b9" xlink:to="loc_srt_RangeAxis_a76811cd-d179-45da-8d0d-05c1df07f01c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a76811cd-d179-45da-8d0d-05c1df07f01c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a76811cd-d179-45da-8d0d-05c1df07f01c" xlink:to="loc_srt_RangeMember_a76811cd-d179-45da-8d0d-05c1df07f01c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_830f2664-65c6-41ff-9c6b-c685861e0374" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a76811cd-d179-45da-8d0d-05c1df07f01c" xlink:to="loc_srt_RangeMember_830f2664-65c6-41ff-9c6b-c685861e0374" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6bc98784-5cd8-4396-ae22-97bcb2bb49e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_830f2664-65c6-41ff-9c6b-c685861e0374" xlink:to="loc_srt_MinimumMember_6bc98784-5cd8-4396-ae22-97bcb2bb49e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fbd6bd69-74b4-4672-a536-f5f70a635df1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_830f2664-65c6-41ff-9c6b-c685861e0374" xlink:to="loc_srt_MaximumMember_fbd6bd69-74b4-4672-a536-f5f70a635df1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>bcrx-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f6ec4fab-a519-489e-b421-6c7ee3322750,g:f7084e6e-47c2-4faa-aed0-8ba33c516e4f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_eec2a6c0-8f9a-4769-bb6d-f87920df5da1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_InterestAndOtherIncomeLoss_48860b51-183a-4861-bfbf-0379842968b5_terseLabel_en-US" xlink:label="lab_bcrx_InterestAndOtherIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income</link:label>
    <link:label id="lab_bcrx_InterestAndOtherIncomeLoss_label_en-US" xlink:label="lab_bcrx_InterestAndOtherIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income</link:label>
    <link:label id="lab_bcrx_InterestAndOtherIncomeLoss_documentation_en-US" xlink:label="lab_bcrx_InterestAndOtherIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of interest income and other income (loss) recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income (loss) from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestAndOtherIncomeLoss" xlink:href="bcrx-20220930.xsd#bcrx_InterestAndOtherIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_InterestAndOtherIncomeLoss" xlink:to="lab_bcrx_InterestAndOtherIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TermBAndCLoanMember_2b8ec4f2-b0c2-4bd3-9657-5354d1e07f21_terseLabel_en-US" xlink:label="lab_bcrx_TermBAndCLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B And C Loan</link:label>
    <link:label id="lab_bcrx_TermBAndCLoanMember_label_en-US" xlink:label="lab_bcrx_TermBAndCLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B And C Loan [Member]</link:label>
    <link:label id="lab_bcrx_TermBAndCLoanMember_documentation_en-US" xlink:label="lab_bcrx_TermBAndCLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B And C Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermBAndCLoanMember" xlink:href="bcrx-20220930.xsd#bcrx_TermBAndCLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TermBAndCLoanMember" xlink:to="lab_bcrx_TermBAndCLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c17275cc-6ef1-4f61-847d-39dcd88b41b9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ec09f553-e77a-499a-8e7a-172a59a0b6ca_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_7c162bd1-dce7-42b8-b005-254a82645726_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts_9e579e55-c9b1-4876-a8a3-8d69004c2331_terseLabel_en-US" xlink:label="lab_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs</link:label>
    <link:label id="lab_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts_label_en-US" xlink:label="lab_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs</link:label>
    <link:label id="lab_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts_documentation_en-US" xlink:label="lab_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of noncash interest expense and amortization of debt issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:href="bcrx-20220930.xsd#bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:to="lab_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f6e37954-d5f8-4e8e-96ba-d2bf9371f19e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8dd86b1b-f24d-4e0b-b2fa-f361a4bd7586_verboseLabel_en-US" xlink:label="lab_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability To Be Paid After Year Four</link:label>
    <link:label id="lab_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="bcrx-20220930.xsd#bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_70f2e1d8-9ca5-48ff-8500-e31166e419b2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_ab3f68e3-2ad4-4434-b929-cd5928502a0c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_IncentivePlanMember_868aa033-b537-4a40-9b50-d2ff33061007_terseLabel_en-US" xlink:label="lab_bcrx_IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Plan</link:label>
    <link:label id="lab_bcrx_IncentivePlanMember_label_en-US" xlink:label="lab_bcrx_IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Plan [Member]</link:label>
    <link:label id="lab_bcrx_IncentivePlanMember_documentation_en-US" xlink:label="lab_bcrx_IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember" xlink:href="bcrx-20220930.xsd#bcrx_IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_IncentivePlanMember" xlink:to="lab_bcrx_IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_MidCapFinancialServicesLLCMember_e236002d-da2a-4ddc-96c8-b8a7335b43fc_terseLabel_en-US" xlink:label="lab_bcrx_MidCapFinancialServicesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Financial Services, LLC</link:label>
    <link:label id="lab_bcrx_MidCapFinancialServicesLLCMember_label_en-US" xlink:label="lab_bcrx_MidCapFinancialServicesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Financial Services, LLC [Member]</link:label>
    <link:label id="lab_bcrx_MidCapFinancialServicesLLCMember_documentation_en-US" xlink:label="lab_bcrx_MidCapFinancialServicesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents MidCap Financial Services, LLC entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MidCapFinancialServicesLLCMember" xlink:href="bcrx-20220930.xsd#bcrx_MidCapFinancialServicesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_MidCapFinancialServicesLLCMember" xlink:to="lab_bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_e173e538-aa70-4ce9-b2e8-1cd05f56b217_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_8c47c336-7ea3-4b9d-ade1-ea3e3c05fc39_terseLabel_en-US" xlink:label="lab_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and other research and development</link:label>
    <link:label id="lab_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_label_en-US" xlink:label="lab_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Research and Development [Member]</link:label>
    <link:label id="lab_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information pertaining to Collaborative and other research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:href="bcrx-20220930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:to="lab_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_6debd944-6a2b-427e-8058-ab5fa3269d62_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_44f2c064-6868-475c-a084-19cea709cd14_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_UABMember_1657536f-cd10-43db-8e61-bdc9dacb01e9_terseLabel_en-US" xlink:label="lab_bcrx_UABMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UAB</link:label>
    <link:label id="lab_bcrx_UABMember_label_en-US" xlink:label="lab_bcrx_UABMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UAB [Member]</link:label>
    <link:label id="lab_bcrx_UABMember_documentation_en-US" xlink:label="lab_bcrx_UABMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UAB</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_UABMember" xlink:href="bcrx-20220930.xsd#bcrx_UABMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_UABMember" xlink:to="lab_bcrx_UABMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6e5a971e-7fda-496f-a8ae-878712bd0939_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4318cf9b-0899-452d-b8e8-bfab27fc7c5b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_3b0f67f2-113c-48df-89e5-2112dbd84057_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8db50262-5938-4ae8-a8c8-1c32bdbee2ba_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0f453640-e913-4a55-87b5-7491a41007dc_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, stock option awards exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtInstrumentLiborCap_94fd9340-d102-4956-a607-f4cc58ef7759_terseLabel_en-US" xlink:label="lab_bcrx_DebtInstrumentLiborCap" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, LIBOR cap</link:label>
    <link:label id="lab_bcrx_DebtInstrumentLiborCap_label_en-US" xlink:label="lab_bcrx_DebtInstrumentLiborCap" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Libor Cap</link:label>
    <link:label id="lab_bcrx_DebtInstrumentLiborCap_documentation_en-US" xlink:label="lab_bcrx_DebtInstrumentLiborCap" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum LIBOR interest rate for debt instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentLiborCap" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentLiborCap"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtInstrumentLiborCap" xlink:to="lab_bcrx_DebtInstrumentLiborCap" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_EmployeeStockPurchasePlanMember_b167dee5-707f-4949-88bb-8156e4c87f26_terseLabel_en-US" xlink:label="lab_bcrx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_bcrx_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_bcrx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_bcrx_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_bcrx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan, (ESPP).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeStockPurchasePlanMember" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_EmployeeStockPurchasePlanMember" xlink:to="lab_bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5f041e6b-501f-45e5-a064-f7f6abb61414_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_34449946-de8b-4520-bb9f-b2b23a61b575_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesOver550000Member_1ee74acb-f978-4814-9c5e-a21b32d2036a_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesOver550000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Over $550,000</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesOver550000Member_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesOver550000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Over $550,000 [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesOver550000Member_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesOver550000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents annual net sales over $550,000.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOver550000Member" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesOver550000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesOver550000Member" xlink:to="lab_bcrx_AnnualNetSalesOver550000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount_7056b755-f92c-407d-ad54-0e1d74a0f09d_terseLabel_en-US" xlink:label="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares per employee, amount</link:label>
    <link:label id="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount_label_en-US" xlink:label="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee Amount</link:label>
    <link:label id="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount_documentation_en-US" xlink:label="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:href="bcrx-20220930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:to="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AthyriumMember_ee39af35-d011-46c0-ba71-e63571214086_terseLabel_en-US" xlink:label="lab_bcrx_AthyriumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Athyrium</link:label>
    <link:label id="lab_bcrx_AthyriumMember_label_en-US" xlink:label="lab_bcrx_AthyriumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Athyrium [Member]</link:label>
    <link:label id="lab_bcrx_AthyriumMember_documentation_en-US" xlink:label="lab_bcrx_AthyriumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Athyrium Opportunities III Co-Invest 1 LP (&#8220;Athyrium&#8221;).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AthyriumMember" xlink:href="bcrx-20220930.xsd#bcrx_AthyriumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AthyriumMember" xlink:to="lab_bcrx_AthyriumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_cfea2902-663d-401c-80c9-bd38b4d753ec_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_398b023c-7a8e-4ca0-a393-fad7c5b4e33c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_10bf7bd3-366a-410f-a807-8cd3b4acb4d7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4d845ce9-42a4-4ca2-b86b-0512315286a9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice_ea63ca11-7340-45f2-9530-0d4914caf0af_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty purchase agreement, royalties, percentage of purchase price</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Royalties Percentage Of Purchase Price</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of the purchase price under the royalty purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RAPIVABMember_ad288689-e77f-4fa7-8cb9-3cae8e9faaf3_terseLabel_en-US" xlink:label="lab_bcrx_RAPIVABMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RAPIVAB</link:label>
    <link:label id="lab_bcrx_RAPIVABMember_label_en-US" xlink:label="lab_bcrx_RAPIVABMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RAPIVAB [Member]</link:label>
    <link:label id="lab_bcrx_RAPIVABMember_documentation_en-US" xlink:label="lab_bcrx_RAPIVABMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents RAPIVAB product.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RAPIVABMember" xlink:href="bcrx-20220930.xsd#bcrx_RAPIVABMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RAPIVABMember" xlink:to="lab_bcrx_RAPIVABMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebt_646e5a91-35de-40da-9a55-5dbd2119028b_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured debt, total</link:label>
    <link:label id="lab_us-gaap_SecuredDebt_label_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebt" xlink:to="lab_us-gaap_SecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_2ceea02d-ad36-4b14-9ac9-75d280ed763f_terseLabel_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_label_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_7107f9d6-928d-4a25-9505-21f9de2d9b77_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesRangeDomain_5cde09c9-c247-44b3-a2f7-589e963d8a3f_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Range [Domain]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesRangeDomain_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Range [Domain]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesRangeDomain_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesRangeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Range</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeDomain" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain" xlink:to="lab_bcrx_AnnualNetSalesRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_JPRRoyaltySubLLCMember_0ae2c70a-82b5-4ef6-9864-ed3c59e2f266_terseLabel_en-US" xlink:label="lab_bcrx_JPRRoyaltySubLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JPR Royalty Sub LLC</link:label>
    <link:label id="lab_bcrx_JPRRoyaltySubLLCMember_label_en-US" xlink:label="lab_bcrx_JPRRoyaltySubLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JPR Royalty Sub LLC [Member]</link:label>
    <link:label id="lab_bcrx_JPRRoyaltySubLLCMember_documentation_en-US" xlink:label="lab_bcrx_JPRRoyaltySubLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents JPR Royalty Sub LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_JPRRoyaltySubLLCMember" xlink:href="bcrx-20220930.xsd#bcrx_JPRRoyaltySubLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_JPRRoyaltySubLLCMember" xlink:to="lab_bcrx_JPRRoyaltySubLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TermLoanAAndBDrawnMember_a586b4fc-856a-448d-a7af-c3ae53ba06e0_terseLabel_en-US" xlink:label="lab_bcrx_TermLoanAAndBDrawnMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A and B Drawn</link:label>
    <link:label id="lab_bcrx_TermLoanAAndBDrawnMember_label_en-US" xlink:label="lab_bcrx_TermLoanAAndBDrawnMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A and B Drawn [Member]</link:label>
    <link:label id="lab_bcrx_TermLoanAAndBDrawnMember_documentation_en-US" xlink:label="lab_bcrx_TermLoanAAndBDrawnMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents term loan A and B drawn.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanAAndBDrawnMember" xlink:href="bcrx-20220930.xsd#bcrx_TermLoanAAndBDrawnMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TermLoanAAndBDrawnMember" xlink:to="lab_bcrx_TermLoanAAndBDrawnMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_3ab52985-02de-4917-9109-4778d52fd3a9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_6537c992-c7ef-4227-b495-342997e195d8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Obligations</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_2508aa0a-badd-4faa-99b3-f1adb2c5603e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable_a6298718-a663-49ee-800d-52c833fb001e_terseLabel_en-US" xlink:label="lab_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards available, stock option awards cancelled (in shares)</link:label>
    <link:label id="lab_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable_label_en-US" xlink:label="lab_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards available, stock option awards cancelled (in shares)</link:label>
    <link:label id="lab_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable_documentation_en-US" xlink:label="lab_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options forfeitures in period awards available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:href="bcrx-20220930.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:to="lab_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_fdb9366f-ed6a-4992-a7b6-d4aa2cdb91a6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BilledRevenuesMember_74cdf30b-4dee-4fe7-9baa-16e4045f4293_terseLabel_en-US" xlink:label="lab_us-gaap_BilledRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed</link:label>
    <link:label id="lab_us-gaap_BilledRevenuesMember_label_en-US" xlink:label="lab_us-gaap_BilledRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledRevenuesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledRevenuesMember" xlink:to="lab_us-gaap_BilledRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_526ebb6b-f8de-4153-9792-ae8e536ffeb5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fc61652c-da44-40dc-a388-254482c5c38c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_668e0e00-512c-4009-abe0-54ae64594a6b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_e3411d0f-9401-455d-8ff8-cf9e29e2ddaa_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e0726063-900d-44e4-ab58-3df6081279ad_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remaining)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_63e55b0b-7e29-417d-8681-eeef5413ac56_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_db9eb9a2-01e8-472b-8954-55edc7f98c77_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_a23fceeb-88cf-43ca-bbd5-66b89e00b028_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_66e31960-ef72-413e-b253-4496777bc503_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount_4b372d14-6391-4b49-8152-30d119663d04_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty purchase agreement, royalties, purchase price, amount</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Royalties Purchase Price Amount</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of the purchase price under the royalty purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PikInterestPaymentIsMadeMember_8c7079ba-0db8-4963-97e8-b4577ddb2327_terseLabel_en-US" xlink:label="lab_bcrx_PikInterestPaymentIsMadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PIK Interest Payment is Made</link:label>
    <link:label id="lab_bcrx_PikInterestPaymentIsMadeMember_label_en-US" xlink:label="lab_bcrx_PikInterestPaymentIsMadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PIK Interest Payment is Made [Member]</link:label>
    <link:label id="lab_bcrx_PikInterestPaymentIsMadeMember_documentation_en-US" xlink:label="lab_bcrx_PikInterestPaymentIsMadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents PIK interest payment is made.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PikInterestPaymentIsMadeMember" xlink:href="bcrx-20220930.xsd#bcrx_PikInterestPaymentIsMadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PikInterestPaymentIsMadeMember" xlink:to="lab_bcrx_PikInterestPaymentIsMadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f72fb1b0-0bd3-46f4-914a-7da196f71c1a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_41cc74a3-8349-4e33-899a-1479daa79d16_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease financing obligation</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtInstrumentLiborFloor_78418644-c69a-4640-a378-4ae5d0f5d46b_terseLabel_en-US" xlink:label="lab_bcrx_DebtInstrumentLiborFloor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, LIBOR floor</link:label>
    <link:label id="lab_bcrx_DebtInstrumentLiborFloor_label_en-US" xlink:label="lab_bcrx_DebtInstrumentLiborFloor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Libor Floor</link:label>
    <link:label id="lab_bcrx_DebtInstrumentLiborFloor_documentation_en-US" xlink:label="lab_bcrx_DebtInstrumentLiborFloor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum LIBOR interest rate for debt instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentLiborFloor" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentLiborFloor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtInstrumentLiborFloor" xlink:to="lab_bcrx_DebtInstrumentLiborFloor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_75e27e07-e3a4-4b32-b584-d0da12e9f3e4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_e7302aa6-9fb5-4654-a991-7c541b5a99fe_terseLabel_en-US" xlink:label="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies and Concentrations of Risk [Table]</link:label>
    <link:label id="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_label_en-US" xlink:label="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies and Concentrations of Risk [Table]</link:label>
    <link:label id="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_documentation_en-US" xlink:label="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies and Concentrations of Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable" xlink:href="bcrx-20220930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable" xlink:to="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_54c7fc80-4c43-4f5b-a98b-a8785fa9aae0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of the Company's Investments by Type</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PERAMIVIRMember_136ae15a-e854-4fbe-ba28-7233cab0cfb1_terseLabel_en-US" xlink:label="lab_bcrx_PERAMIVIRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peramivir</link:label>
    <link:label id="lab_bcrx_PERAMIVIRMember_label_en-US" xlink:label="lab_bcrx_PERAMIVIRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PERAMIVIR [Member]</link:label>
    <link:label id="lab_bcrx_PERAMIVIRMember_documentation_en-US" xlink:label="lab_bcrx_PERAMIVIRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information pertaining to Peramivir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PERAMIVIRMember" xlink:href="bcrx-20220930.xsd#bcrx_PERAMIVIRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PERAMIVIRMember" xlink:to="lab_bcrx_PERAMIVIRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_LongTermInvestmentMaturityMinimum_59fd13a0-b22f-4a8c-b8ad-03f12b08797f_terseLabel_en-US" xlink:label="lab_bcrx_LongTermInvestmentMaturityMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investment maturity, minimum (in years)</link:label>
    <link:label id="lab_bcrx_LongTermInvestmentMaturityMinimum_label_en-US" xlink:label="lab_bcrx_LongTermInvestmentMaturityMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term Investment Maturity Minimum</link:label>
    <link:label id="lab_bcrx_LongTermInvestmentMaturityMinimum_documentation_en-US" xlink:label="lab_bcrx_LongTermInvestmentMaturityMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents long term investment maturity minimum.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LongTermInvestmentMaturityMinimum" xlink:href="bcrx-20220930.xsd#bcrx_LongTermInvestmentMaturityMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_LongTermInvestmentMaturityMinimum" xlink:to="lab_bcrx_LongTermInvestmentMaturityMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_2b4931e3-9c97-4152-ac64-db0a9054cfd1_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_41f535b2-e044-4e15-9f98-cbd7774f2cf0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_41e11828-697a-4d97-b523-7827d698f58d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TransactionCosts_9bdc0ffa-6277-477f-a659-2dd8c855dce3_terseLabel_en-US" xlink:label="lab_bcrx_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_bcrx_TransactionCosts_label_en-US" xlink:label="lab_bcrx_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs</link:label>
    <link:label id="lab_bcrx_TransactionCosts_documentation_en-US" xlink:label="lab_bcrx_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents transaction costs associated with royalty monetization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TransactionCosts" xlink:href="bcrx-20220930.xsd#bcrx_TransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TransactionCosts" xlink:to="lab_bcrx_TransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_473446e5-8eec-46f2-9a9e-6369c9089d3c_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_bb34522f-b7b8-4182-9316-f442eb6996af_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured term loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_25658a0a-942b-466f-ba71-a148c37da5c3_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6c04feb2-a187-4294-95ca-fde18e49db93_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50dfcd8e-bbbc-4bf4-8a78-b011b9e3def5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310b630c-ddf2-49bc-9a38-c31fd759f393_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales_b9dc07a8-19ca-4a23-9353-8609642bd117_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty purchase agreement, royalties, percentage of annual net sales, based on reduction in sales</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales Based On Reduction In Sales</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">he percentage of annual net sales of royalties to be paid under the royalty purchase agreement if sales are less than specified.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales_b498a1f7-7285-4af7-a8c6-53e590e4ca3d_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty purchase agreement, royalties, percentage of global annual net sales</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Royalties Percentage of Global Annual Net Sales</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of global annual net sales of royalties to be paid under the royalty purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_aea518b4-d041-4beb-afa4-eb8f8ecd7da9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d048093e-fd27-4277-b2b7-61851cce4f9d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ShionogiCoLtdMember_fa512aae-f71c-482b-9cc0-148699452cb9_terseLabel_en-US" xlink:label="lab_bcrx_ShionogiCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shionogi &amp; Co. Ltd.</link:label>
    <link:label id="lab_bcrx_ShionogiCoLtdMember_label_en-US" xlink:label="lab_bcrx_ShionogiCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shionogi &amp; Co. Ltd. [Member]</link:label>
    <link:label id="lab_bcrx_ShionogiCoLtdMember_documentation_en-US" xlink:label="lab_bcrx_ShionogiCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shionogi &amp; Co. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShionogiCoLtdMember" xlink:href="bcrx-20220930.xsd#bcrx_ShionogiCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ShionogiCoLtdMember" xlink:to="lab_bcrx_ShionogiCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_MilestoneRevenueMember_e1c37c56-03f1-44e3-b61e-aa030a318655_terseLabel_en-US" xlink:label="lab_bcrx_MilestoneRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue</link:label>
    <link:label id="lab_bcrx_MilestoneRevenueMember_label_en-US" xlink:label="lab_bcrx_MilestoneRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Revenue [Member]</link:label>
    <link:label id="lab_bcrx_MilestoneRevenueMember_documentation_en-US" xlink:label="lab_bcrx_MilestoneRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MilestoneRevenueMember" xlink:href="bcrx-20220930.xsd#bcrx_MilestoneRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_MilestoneRevenueMember" xlink:to="lab_bcrx_MilestoneRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e06b3a6c-d131-4923-9611-0983f1f61520_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6975b08c-03f2-4324-ac61-e5321ef931c7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_aa5e8002-67bd-4a0a-a25c-bbfb0427fc28_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_959dd766-3570-42df-97e6-9230455c49b9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_13d60116-fa63-49e1-a78a-1d2627c0b51d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, stock option awards cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_7dee46db-4f3a-4527-a5f3-fdd80f257c01_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_4c567557-8e32-4a23-8571-8ded5ba50f97_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesBetween150000And230000Member_9574acfd-e0c4-4e78-b719-c340b18c4be0_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesBetween150000And230000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Between $150,000 and $230,000</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesBetween150000And230000Member_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesBetween150000And230000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Between $150,000 and $230,000 [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesBetween150000And230000Member_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesBetween150000And230000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents annual net sales between $150,000 and $230,000.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesBetween150000And230000Member" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesBetween150000And230000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesBetween150000And230000Member" xlink:to="lab_bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_68cea97d-f41f-449b-bd85-2db3882671d0_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_CollateralForCreditMember_c89568ac-d291-4a7b-8ff7-fba804ea51e6_terseLabel_en-US" xlink:label="lab_bcrx_CollateralForCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral for Credit</link:label>
    <link:label id="lab_bcrx_CollateralForCreditMember_label_en-US" xlink:label="lab_bcrx_CollateralForCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral for Credit [Member]</link:label>
    <link:label id="lab_bcrx_CollateralForCreditMember_documentation_en-US" xlink:label="lab_bcrx_CollateralForCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollateralForCreditMember" xlink:href="bcrx-20220930.xsd#bcrx_CollateralForCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_CollateralForCreditMember" xlink:to="lab_bcrx_CollateralForCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_af6ed7cd-aa4e-4939-bae4-6bfa52adf53a_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b4a23a6a-986c-4556-937a-89345ec83a7f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtInstrumentExitFeePercentageOfPrincipal_0586dedc-dca8-4500-9143-1bb54474fc82_terseLabel_en-US" xlink:label="lab_bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, exit fee, percentage of principal</link:label>
    <link:label id="lab_bcrx_DebtInstrumentExitFeePercentageOfPrincipal_label_en-US" xlink:label="lab_bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Exit Fee Percentage of Principal</link:label>
    <link:label id="lab_bcrx_DebtInstrumentExitFeePercentageOfPrincipal_documentation_en-US" xlink:label="lab_bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of principal for exit fee of the debt instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentExitFeePercentageOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:to="lab_bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo_965aeebd-a3d3-4aac-b711-826a684161b9_terseLabel_en-US" xlink:label="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost expected to be recognized year two</link:label>
    <link:label id="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo_label_en-US" xlink:label="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Year Two</link:label>
    <link:label id="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo_documentation_en-US" xlink:label="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:to="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ec358ecb-afb5-4cca-867a-27c161978ed9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b9e8cc3d-7821-464c-b65f-dcf1c5a7af90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DescriptionOfCompanyPolicyTextBlock_9d4d6395-d4a8-49c9-ae00-821e0b184329_terseLabel_en-US" xlink:label="lab_bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company</link:label>
    <link:label id="lab_bcrx_DescriptionOfCompanyPolicyTextBlock_label_en-US" xlink:label="lab_bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Company [Policy Text Block]</link:label>
    <link:label id="lab_bcrx_DescriptionOfCompanyPolicyTextBlock_documentation_en-US" xlink:label="lab_bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The description of company policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:href="bcrx-20220930.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:to="lab_bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TermBLoanMember_b89436ab-d01a-44ce-bc0e-f9d11c53f294_terseLabel_en-US" xlink:label="lab_bcrx_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan</link:label>
    <link:label id="lab_bcrx_TermBLoanMember_label_en-US" xlink:label="lab_bcrx_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan [Member]</link:label>
    <link:label id="lab_bcrx_TermBLoanMember_documentation_en-US" xlink:label="lab_bcrx_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents term B loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermBLoanMember" xlink:href="bcrx-20220930.xsd#bcrx_TermBLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TermBLoanMember" xlink:to="lab_bcrx_TermBLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TradeReceivablesTextBlock_614b9c7b-c27f-45d2-b4e5-35fa48490c5d_terseLabel_en-US" xlink:label="lab_bcrx_TradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Receivables</link:label>
    <link:label id="lab_bcrx_TradeReceivablesTextBlock_label_en-US" xlink:label="lab_bcrx_TradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Receivables [Text Block]</link:label>
    <link:label id="lab_bcrx_TradeReceivablesTextBlock_documentation_en-US" xlink:label="lab_bcrx_TradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TradeReceivablesTextBlock" xlink:href="bcrx-20220930.xsd#bcrx_TradeReceivablesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TradeReceivablesTextBlock" xlink:to="lab_bcrx_TradeReceivablesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_66bda596-5c4f-42d4-bcd3-4dec6a4bf195_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_82d491ab-91fe-4dc8-b8fb-c8590a03a542_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Maturity of Investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear_8631fd2d-cc33-494a-8a7f-30618f82061f_terseLabel_en-US" xlink:label="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost expected to be recognized next year</link:label>
    <link:label id="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear_label_en-US" xlink:label="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Next Year</link:label>
    <link:label id="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear_documentation_en-US" xlink:label="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service share-based compensation nonvested awards compensation cost expected to be recognized next year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:to="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_ac8e8589-efe3-499c-a345-00efc362b5e8_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_fd6d7345-1a1a-4e7b-8ddd-248a50376db2_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAccountsReceivableMember" xlink:to="lab_us-gaap_TradeAccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock_b28919b3-6c65-44d8-86a7-0a6def8cff94_terseLabel_en-US" xlink:label="lab_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Receivables</link:label>
    <link:label id="lab_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock_label_en-US" xlink:label="lab_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Receivables from Collaborations [Table Text Block]</link:label>
    <link:label id="lab_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock_documentation_en-US" xlink:label="lab_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure representing receivables from collaborations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:href="bcrx-20220930.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:to="lab_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e48aaf2b-20ba-44c5-a10a-5f6d34699839_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_109cd286-8426-4f38-87b1-9a4af8314e9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of stock option awards exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a3108721-b6f3-420b-b950-f93b59a9202b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_16646094-5a5d-42d1-91a2-48bacd25b598_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_3cf48a07-55da-4455-a786-dc88b994be20_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_4346a08e-695a-4cf7-a284-1c97bbec818d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, debt, total</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_b790bf57-b9c2-4cc9-b965-2f023361f610_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts_723f74e2-949d-4401-a4cd-c6259125497a_terseLabel_en-US" xlink:label="lab_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt financing costs and original issue discounts</link:label>
    <link:label id="lab_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts_label_en-US" xlink:label="lab_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Debt Financing Costs And Original Issue Discounts</link:label>
    <link:label id="lab_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts_documentation_en-US" xlink:label="lab_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of amortization of debt financing costs and original issue discounts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:href="bcrx-20220930.xsd#bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:to="lab_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RenewablePeriodOfAgreement_d3f1aeb6-dcba-4d9f-bbca-5f4e9932cd89_terseLabel_en-US" xlink:label="lab_bcrx_RenewablePeriodOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewable period of agreement (in years)</link:label>
    <link:label id="lab_bcrx_RenewablePeriodOfAgreement_label_en-US" xlink:label="lab_bcrx_RenewablePeriodOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewable Period Of Agreement</link:label>
    <link:label id="lab_bcrx_RenewablePeriodOfAgreement_documentation_en-US" xlink:label="lab_bcrx_RenewablePeriodOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents renewable period of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RenewablePeriodOfAgreement" xlink:href="bcrx-20220930.xsd#bcrx_RenewablePeriodOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RenewablePeriodOfAgreement" xlink:to="lab_bcrx_RenewablePeriodOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f48e38cb-9a72-471e-80dc-bfbc6e14f9d3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a1ab230a-e320-4091-ac0b-171550a5664f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_38725f36-1928-4a61-9a61-1fdadcf9e128_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PerformancebasedRestrictedStockUnitsMember_cce0f6cd-4218-493f-8609-0a45efac7796_terseLabel_en-US" xlink:label="lab_bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based Restricted Stock Units</link:label>
    <link:label id="lab_bcrx_PerformancebasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bcrx_PerformancebasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents performance-based restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:href="bcrx-20220930.xsd#bcrx_PerformancebasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:to="lab_bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_550bdc35-4b51-4afa-b278-bb61f2351946_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency losses, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_af7897e8-b115-4a7f-85ae-ea7511c97810_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7309fa92-441a-425f-89da-b9f17c957d1c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_644e5ced-55d7-4791-be2a-26d7432fedcb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_24bf445d-fbbe-46ad-9ba8-e7faca1ef2f4_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt, total</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b4eb8a33-4df5-4d87-ae81-9958ab766fa6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option awards remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_a2160d63-5cbe-4e36-bc49-d4e133a035c4_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_fc72929a-9128-4aa5-a709-c8ff96c7b64f_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_c1a309f6-8a4e-480b-a7b2-f8eccd78964f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares_09e84802-a477-4727-8847-decb989641e4_terseLabel_en-US" xlink:label="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan amendment (in shares)</link:label>
    <link:label id="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares_label_en-US" xlink:label="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Plan Amendment, Awards In Shares</link:label>
    <link:label id="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares_documentation_en-US" xlink:label="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Plan Amendment, Awards In Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares" xlink:href="bcrx-20220930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares" xlink:to="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5213a488-3935-407f-9be4-f286d41d9c4a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_af931487-37ee-4ce0-88c5-0609fc34d0f0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_259714e3-5ee4-4c1b-b604-1dadb26149d2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period, shares, new issues (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember_3e758c8a-0e6f-4d71-806d-59d43043d948_terseLabel_en-US" xlink:label="lab_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 RPI Royalty Agreement</link:label>
    <link:label id="lab_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember_label_en-US" xlink:label="lab_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 RPI Royalty Agreement [Member]</link:label>
    <link:label id="lab_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember_documentation_en-US" xlink:label="lab_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on 2021 RPI Royalty Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:href="bcrx-20220930.xsd#bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:to="lab_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest_9f25c639-03e8-4418-9953-4c35803f5410_terseLabel_en-US" xlink:label="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, prepayment fee, percentage of accrued interest</link:label>
    <link:label id="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest_label_en-US" xlink:label="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Fee Percentage of Accrued Interest</link:label>
    <link:label id="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest_documentation_en-US" xlink:label="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of interest that would have accrued on principal voluntary paid for prepayment fee of the debt instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:to="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_7ae52125-fc80-4406-af81-18e146a10fb2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Relationships [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_702bf499-22a2-43a2-b944-7bd3910a5c5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses_a1299535-9ed9-4c6c-86de-c69d6f3bfc22_terseLabel_en-US" xlink:label="lab_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of products, doses</link:label>
    <link:label id="lab_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses_label_en-US" xlink:label="lab_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Number Of Products Permitted To Be Obtained Doses</link:label>
    <link:label id="lab_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses_documentation_en-US" xlink:label="lab_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on the maximum number of doses of RAPIVAB permitted under the contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:href="bcrx-20220930.xsd#bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:to="lab_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_07b0b372-c7a6-4b6e-8802-1e87956d85b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Dividend Yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a404e66d-c39a-43f0-ad65-15b51ffc970b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e19d1668-667e-4d6c-84f5-96de1494b171_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_BaseContractMember_91aaea6f-695f-4924-97b2-eb7a32165e87_terseLabel_en-US" xlink:label="lab_bcrx_BaseContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Contract</link:label>
    <link:label id="lab_bcrx_BaseContractMember_label_en-US" xlink:label="lab_bcrx_BaseContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Contract [Member]</link:label>
    <link:label id="lab_bcrx_BaseContractMember_documentation_en-US" xlink:label="lab_bcrx_BaseContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The base contract of ASPR/BARDA to support BCX4430 drug manufacturing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BaseContractMember" xlink:href="bcrx-20220930.xsd#bcrx_BaseContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_BaseContractMember" xlink:to="lab_bcrx_BaseContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltiesRevenuesPaidAndPayable_322224e2-220c-4848-beb8-5492179d8336_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltiesRevenuesPaidAndPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenues paid and payable</link:label>
    <link:label id="lab_bcrx_RoyaltiesRevenuesPaidAndPayable_label_en-US" xlink:label="lab_bcrx_RoyaltiesRevenuesPaidAndPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenues paid and payable</link:label>
    <link:label id="lab_bcrx_RoyaltiesRevenuesPaidAndPayable_documentation_en-US" xlink:label="lab_bcrx_RoyaltiesRevenuesPaidAndPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents royalties revenues paid and payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltiesRevenuesPaidAndPayable" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltiesRevenuesPaidAndPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltiesRevenuesPaidAndPayable" xlink:to="lab_bcrx_RoyaltiesRevenuesPaidAndPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesOver3BillionsMember_04b81d81-04ea-45f7-936b-c280a1ec0084_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesOver3BillionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Over $3 Billions</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesOver3BillionsMember_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesOver3BillionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Over $3 Billions [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesOver3BillionsMember_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesOver3BillionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents annual net sales over $3 billions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOver3BillionsMember" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesOver3BillionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesOver3BillionsMember" xlink:to="lab_bcrx_AnnualNetSalesOver3BillionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents_6c92fde2-11ce-4bef-9b14-db4f63da92e4_terseLabel_en-US" xlink:label="lab_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, minimum unrestricted cash and cash equivalents</link:label>
    <link:label id="lab_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Covenant Minimum Unrestricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents_documentation_en-US" xlink:label="lab_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum amount of unrestricted cash and cash equivalents required under the covenant of the debt instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:to="lab_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesBetween350000And550000Member_7541a9a9-b837-4016-8464-d3de607d3a5c_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesBetween350000And550000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Between $350,000 and $550,000</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesBetween350000And550000Member_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesBetween350000And550000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Between $350,000 and $550,000 [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesBetween350000And550000Member_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesBetween350000And550000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents annual net sales between $350,000 and $550,000.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesBetween350000And550000Member" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesBetween350000And550000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesBetween350000And550000Member" xlink:to="lab_bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_MilestonePaymentMinimum_36efaf41-a281-4c49-a0c8-99bb68fb537a_terseLabel_en-US" xlink:label="lab_bcrx_MilestonePaymentMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment minimum</link:label>
    <link:label id="lab_bcrx_MilestonePaymentMinimum_label_en-US" xlink:label="lab_bcrx_MilestonePaymentMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Minimum</link:label>
    <link:label id="lab_bcrx_MilestonePaymentMinimum_documentation_en-US" xlink:label="lab_bcrx_MilestonePaymentMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents milestone payment minimum.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MilestonePaymentMinimum" xlink:href="bcrx-20220930.xsd#bcrx_MilestonePaymentMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_MilestonePaymentMinimum" xlink:to="lab_bcrx_MilestonePaymentMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1e512a1f-c9a5-4006-82aa-e72ee5567131_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_5cf0375c-dd60-4556-addf-859ddd7de70c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1f4704a4-16eb-41bc-9fdc-6fc25d5d8cac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1462a0d6-7be5-4930-89d3-840089fa6ed1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_13a8aa50-daf2-4629-b061-b3ad659391ac_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_28e1a36c-962d-4cf2-8c74-ec806b71ba76_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_616ebb26-0ca2-4ec0-ae97-38f5f7497ccd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of secured debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AfterFourthAnniversaryMember_b47e0882-725a-457d-91d9-867e113807e8_terseLabel_en-US" xlink:label="lab_bcrx_AfterFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After Fourth Anniversary</link:label>
    <link:label id="lab_bcrx_AfterFourthAnniversaryMember_label_en-US" xlink:label="lab_bcrx_AfterFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After Fourth Anniversary [Member]</link:label>
    <link:label id="lab_bcrx_AfterFourthAnniversaryMember_documentation_en-US" xlink:label="lab_bcrx_AfterFourthAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents after the fourth anniversary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AfterFourthAnniversaryMember" xlink:href="bcrx-20220930.xsd#bcrx_AfterFourthAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AfterFourthAnniversaryMember" xlink:to="lab_bcrx_AfterFourthAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_InterestReserve_09c8f7f4-82b4-4181-a3fd-eebcd62abf12_terseLabel_en-US" xlink:label="lab_bcrx_InterestReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest reserve</link:label>
    <link:label id="lab_bcrx_InterestReserve_label_en-US" xlink:label="lab_bcrx_InterestReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Reserve</link:label>
    <link:label id="lab_bcrx_InterestReserve_documentation_en-US" xlink:label="lab_bcrx_InterestReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents interest reserve established as part of the royalty monetization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestReserve" xlink:href="bcrx-20220930.xsd#bcrx_InterestReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_InterestReserve" xlink:to="lab_bcrx_InterestReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_290f2727-4e03-45d4-98f6-e80da09d093d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, net, total</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ToriiPharmaceuticalCoMember_46993d9b-1523-4799-9fdc-af6bf04ab1aa_terseLabel_en-US" xlink:label="lab_bcrx_ToriiPharmaceuticalCoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Torii Pharmaceutical Co. [Member]</link:label>
    <link:label id="lab_bcrx_ToriiPharmaceuticalCoMember_label_en-US" xlink:label="lab_bcrx_ToriiPharmaceuticalCoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Torii Pharmaceutical Co. [Member]</link:label>
    <link:label id="lab_bcrx_ToriiPharmaceuticalCoMember_documentation_en-US" xlink:label="lab_bcrx_ToriiPharmaceuticalCoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to Torii Pharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ToriiPharmaceuticalCoMember" xlink:href="bcrx-20220930.xsd#bcrx_ToriiPharmaceuticalCoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ToriiPharmaceuticalCoMember" xlink:to="lab_bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_76f61aab-9f2d-488e-a8d0-c6fe8bfcd24d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d1ecb0df-fa03-475d-a696-a569c6e46deb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a60a8d45-2a6f-42c6-a0f9-540422ca7777_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesUnder350000Member_6298b896-85ef-4d46-8d2b-25060645b950_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesUnder350000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Under $350,000</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesUnder350000Member_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesUnder350000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Under $350,000 [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesUnder350000Member_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesUnder350000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents annual net sales under $350,000.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesUnder350000Member" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesUnder350000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesUnder350000Member" xlink:to="lab_bcrx_AnnualNetSalesUnder350000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_ae775344-6a9d-4be6-a085-48db64f43ccb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PercentageOfCommonStockSharesEnding_734366af-214b-4fb9-8826-ebe29b6ba545_terseLabel_en-US" xlink:label="lab_bcrx_PercentageOfCommonStockSharesEnding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of common stock shares, ending</link:label>
    <link:label id="lab_bcrx_PercentageOfCommonStockSharesEnding_label_en-US" xlink:label="lab_bcrx_PercentageOfCommonStockSharesEnding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Common Stock Shares Ending</link:label>
    <link:label id="lab_bcrx_PercentageOfCommonStockSharesEnding_documentation_en-US" xlink:label="lab_bcrx_PercentageOfCommonStockSharesEnding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of common stock shares ending.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PercentageOfCommonStockSharesEnding" xlink:href="bcrx-20220930.xsd#bcrx_PercentageOfCommonStockSharesEnding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PercentageOfCommonStockSharesEnding" xlink:to="lab_bcrx_PercentageOfCommonStockSharesEnding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_fb29f75f-9827-4446-a61b-03c26f9dab91_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales_fb8aba9e-5a9d-4dbd-ab5d-91a08ef07983_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty purchase agreement, royalties, percentage of annual net sales</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of annual net sales for royalties to be paid under the royalty purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_365ae4cb-df13-4c56-9c58-d262339a95e1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_644cf53c-0f54-4209-a5ad-e041b6e90eed_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards available, restricted stock awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_2bd17b9e-b83a-440e-9e89-c6f97efeda55_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_6151db65-457e-4a21-adb6-8455423735a9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from secured term loans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_fecbe091-e2f3-4d58-a5ae-4c8b4907f682_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ThirtysixEqualMonthlyInstallmentsMember_b71a793b-f5a2-4ef1-bf31-30a29226d440_terseLabel_en-US" xlink:label="lab_bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thirty-six Equal Monthly Installments</link:label>
    <link:label id="lab_bcrx_ThirtysixEqualMonthlyInstallmentsMember_label_en-US" xlink:label="lab_bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thirty-six Equal Monthly Installments [Member]</link:label>
    <link:label id="lab_bcrx_ThirtysixEqualMonthlyInstallmentsMember_documentation_en-US" xlink:label="lab_bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on the vesting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:href="bcrx-20220930.xsd#bcrx_ThirtysixEqualMonthlyInstallmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:to="lab_bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_7be69a6c-86b5-43fb-9e7b-8c566d0cc010_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_06f1577a-3ed9-4e55-9582-090c2e765b54_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_349705f6-fbff-465a-89e8-c0c0e8e0c589_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_ebf878d9-b89c-40c5-9257-a0bf0a033ccd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Other Noncurrent Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:to="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_NonEmployeeDirectorsMember_824d9f7e-6fec-41fe-a14e-e338e3435e17_terseLabel_en-US" xlink:label="lab_bcrx_NonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee Directors</link:label>
    <link:label id="lab_bcrx_NonEmployeeDirectorsMember_label_en-US" xlink:label="lab_bcrx_NonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee Directors [Member]</link:label>
    <link:label id="lab_bcrx_NonEmployeeDirectorsMember_documentation_en-US" xlink:label="lab_bcrx_NonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents non-employee directors of the company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonEmployeeDirectorsMember" xlink:href="bcrx-20220930.xsd#bcrx_NonEmployeeDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_NonEmployeeDirectorsMember" xlink:to="lab_bcrx_NonEmployeeDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_73329fac-d1d9-45fd-8d11-f9d4e2d5d9be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based restricted stock unit awards issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_b64df9fc-ef0a-4c9b-8271-28f42d5ac67f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyExpenseReversalOfExpense_3d0f56fd-eb58-41f0-84f2-b10b40933aee_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyExpenseReversalOfExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_bcrx_RoyaltyExpenseReversalOfExpense_label_en-US" xlink:label="lab_bcrx_RoyaltyExpenseReversalOfExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_bcrx_RoyaltyExpenseReversalOfExpense_documentation_en-US" xlink:label="lab_bcrx_RoyaltyExpenseReversalOfExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of royalty expense (reversal of expense) during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyExpenseReversalOfExpense" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyExpenseReversalOfExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyExpenseReversalOfExpense" xlink:to="lab_bcrx_RoyaltyExpenseReversalOfExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6b455320-f600-480f-ac5e-2e990df9f9e6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear_17b19d6c-bb76-43c1-98ef-67eafe1fdca7_terseLabel_en-US" xlink:label="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost expected to be recognized for remainder of fiscal year</link:label>
    <link:label id="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear_label_en-US" xlink:label="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized for Remainder of Fiscal Year</link:label>
    <link:label id="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear_documentation_en-US" xlink:label="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:to="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_34bc4a8a-c622-4bce-941c-4e1989b1a353_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesBetween15And3BillionsMember_e9d5ad44-99d7-45b8-8c39-ae194b1090b5_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Between $1.5 and $3 Billions</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesBetween15And3BillionsMember_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Between $1.5 and $3 Billions [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesBetween15And3BillionsMember_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents annual net sales between $1.5 and $3 billions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesBetween15And3BillionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:to="lab_bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_bc0410bb-6f1a-4194-bbe8-29562d72f56c_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from accumulated other comprehensive income, current period, before tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_3ae714d3-63e5-4761-96b6-bd7150a3584c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_54a9c2ac-c20b-4fc0-af92-6a7b46da78d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Receivables [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_31e66fa8-470c-421d-8a6c-aad92a9bc3f9_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_07278ccc-97fa-4b9a-ac73-91f2bd543bd4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e3fd21d8-00a5-4416-befc-84ddd7acf6c4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2cf987e7-cd73-43bd-85fa-23e408412c2c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_4ea7a868-9181-4614-bbf3-77f13ee6eb48_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_8c2102b2-48aa-4581-be75-dc380bf925e9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_079c6175-379d-46ed-b35a-beb68e2bc697_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_0085b73e-8388-4018-9a4f-d68be279a8c2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_615845f8-01b3-4ab9-b8c8-c2991db5f590_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8e32e15d-42b1-4e32-ba99-8ff2bbb1de37_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2e90aa5a-73bb-45ea-ac99-dcf285ec8be8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_06ff8d8a-2b17-40fa-988e-5d481a483a13_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_d1ba694e-f3f9-4941-a332-bd18d1835c48_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Lease Expense Under Operating Leases</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b9a0b884-3bf0-4fb7-9ff7-602380fad809_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares available for purchase (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8cf74c55-c418-42f3-b144-b18b727b9d3b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards available, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cfca8417-3889-418e-8ed7-0595c231e5ff_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards available, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_9d58ca35-ba78-4f65-8116-fe8da1b33806_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_bffcb3f8-67e8-498a-aac8-3c1029c5d203_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ea3bd572-4bff-450c-b659-4fef25ae6e9a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_48ae7f65-57d9-49c6-9f05-5b0af9c843d0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_c6d75343-21d9-48fe-a024-7d15ca520c8a_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_fb9eef05-9b53-4d33-8bdf-aeb4b3a6c353_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_d1bcdfd7-b4fd-4596-a3de-8658cb6330d9_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_bd2a1095-ec20-48b0-80a3-21700ee16609_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_f84accdf-44e4-4b48-af44-8a51fb770510_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease financing obligation</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_f77ae1fd-ebb0-4a6e-938f-69c2b1d102da_terseLabel_en-US" xlink:label="lab_bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Institute of Allergy and Infectious Diseases</link:label>
    <link:label id="lab_bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_label_en-US" xlink:label="lab_bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label id="lab_bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents National Institute of Allergy and Infectious Diseases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="bcrx-20220930.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="lab_bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_060a14e3-f959-4a59-991e-1f03011f2bb5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_a51b183a-0e8f-4ea0-abf9-0a0777dd7407_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_01a3aaaf-da5b-4c85-b0a1-f6345eeabfca_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e8360461-8b3a-4fb1-abab-2b0064db03e5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_85b4cb32-672c-4e9c-b0b2-e0fbacde8d12_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AggregateLeaseExpense_b816e79c-58bd-42d6-8ee0-f9bcc713f224_terseLabel_en-US" xlink:label="lab_bcrx_AggregateLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate lease expense</link:label>
    <link:label id="lab_bcrx_AggregateLeaseExpense_label_en-US" xlink:label="lab_bcrx_AggregateLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Lease Expense</link:label>
    <link:label id="lab_bcrx_AggregateLeaseExpense_documentation_en-US" xlink:label="lab_bcrx_AggregateLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AggregateLeaseExpense" xlink:href="bcrx-20220930.xsd#bcrx_AggregateLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AggregateLeaseExpense" xlink:to="lab_bcrx_AggregateLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_GreenCrossCorporationMember_da9cf811-9962-4cda-a0f6-4095e53059cd_terseLabel_en-US" xlink:label="lab_bcrx_GreenCrossCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Green Cross Corporation</link:label>
    <link:label id="lab_bcrx_GreenCrossCorporationMember_label_en-US" xlink:label="lab_bcrx_GreenCrossCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Green Cross Corporation [Member]</link:label>
    <link:label id="lab_bcrx_GreenCrossCorporationMember_documentation_en-US" xlink:label="lab_bcrx_GreenCrossCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Green Cross Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_GreenCrossCorporationMember" xlink:href="bcrx-20220930.xsd#bcrx_GreenCrossCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_GreenCrossCorporationMember" xlink:to="lab_bcrx_GreenCrossCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtInstrumentCommitmentFeePercentage_ce0266cd-3cea-4ccd-9d8d-8e11a33ae366_terseLabel_en-US" xlink:label="lab_bcrx_DebtInstrumentCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, commitment fee percentage</link:label>
    <link:label id="lab_bcrx_DebtInstrumentCommitmentFeePercentage_label_en-US" xlink:label="lab_bcrx_DebtInstrumentCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Commitment Fee Percentage</link:label>
    <link:label id="lab_bcrx_DebtInstrumentCommitmentFeePercentage_documentation_en-US" xlink:label="lab_bcrx_DebtInstrumentCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The commitment fee percentage of the debt instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentCommitmentFeePercentage" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtInstrumentCommitmentFeePercentage" xlink:to="lab_bcrx_DebtInstrumentCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2eb5a4a2-6e63-448c-af2d-f2cad1dc3717_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_efb48e6b-e127-4900-a234-05d842426612_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_149a2d4c-700f-4565-b5f9-0fa731e573ac_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3d77bd1b-29b3-4eea-8901-0756726dc8cb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation_2f8aab03-a2a3-4cd8-b541-2b9f21b83d0e_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate if maintains sakigake designation</link:label>
    <link:label id="lab_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation_label_en-US" xlink:label="lab_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate If Maintains Sakigake Designation</link:label>
    <link:label id="lab_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation_documentation_en-US" xlink:label="lab_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyRateIfMaintainsSakigakeDesignation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:to="lab_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_BetweenTheThirdAndFourthAnniversariesMember_448de50d-0148-437c-bc53-04c18cf5ad80_terseLabel_en-US" xlink:label="lab_bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Between the Third and Fourth Anniversaries</link:label>
    <link:label id="lab_bcrx_BetweenTheThirdAndFourthAnniversariesMember_label_en-US" xlink:label="lab_bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Between the Third and Fourth Anniversaries [Member]</link:label>
    <link:label id="lab_bcrx_BetweenTheThirdAndFourthAnniversariesMember_documentation_en-US" xlink:label="lab_bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents after the third anniversary and before the fourth anniversary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:href="bcrx-20220930.xsd#bcrx_BetweenTheThirdAndFourthAnniversariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:to="lab_bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_02608af3-be2a-4d2d-a50c-ca89fef72537_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_eeebe480-7fb3-414f-979d-44d91ea0045b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_304bb6ab-beed-4aaa-ac64-46f3b68ae542_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_09601bcb-872d-4372-bcc8-ddec6a92b578_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9dd4725e-727f-47d9-9c37-2ae0edd9d770_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_dfa08346-252c-450b-b254-aadf83d52e7b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9304f594-746e-4775-97d9-ab49d4776138_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_4fcf65a0-2df2-4024-aaff-90d78d3d14af_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_cd1e1a80-e9c1-4a8a-89fa-f543fa56347f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_201216dc-c7a4-4e9f-a64e-2f11390ada7e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_InducementPlanMember_a4d836cd-a9c0-4dfe-b513-c68c61dde589_terseLabel_en-US" xlink:label="lab_bcrx_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Plan</link:label>
    <link:label id="lab_bcrx_InducementPlanMember_label_en-US" xlink:label="lab_bcrx_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Plan [Member]</link:label>
    <link:label id="lab_bcrx_InducementPlanMember_documentation_en-US" xlink:label="lab_bcrx_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related to the Inducement Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember" xlink:href="bcrx-20220930.xsd#bcrx_InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_InducementPlanMember" xlink:to="lab_bcrx_InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c8e667cd-4e6a-4320-8509-6664d1a469dd_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_3cb2ecbf-44ea-4a46-b426-ab37fb2c8c91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Plan Activities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_b481f5c3-0b54-484d-a57c-efd8452a033a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_21b66b01-84a6-446f-ab9a-1ec10abe5382_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_20f99a10-250e-4bdb-99b3-6358b687096e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9ca922e1-3da3-42cf-aa6d-c987ef1dbf63_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f9360965-3330-43a6-bc91-c4940c25fe18_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_a3e098f0-30d8-4c76-b89c-80742ebbe8cd_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9c8a9b05-80d8-442d-85f8-cb29d3e32f45_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyFinancingObligationsTableTextBlock_9f02cd9e-e0fb-4f5c-b071-e3de0d6f7d99_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyFinancingObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Royalty Financing Obligations</link:label>
    <link:label id="lab_bcrx_RoyaltyFinancingObligationsTableTextBlock_label_en-US" xlink:label="lab_bcrx_RoyaltyFinancingObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Financing Obligations [Table Text Block]</link:label>
    <link:label id="lab_bcrx_RoyaltyFinancingObligationsTableTextBlock_documentation_en-US" xlink:label="lab_bcrx_RoyaltyFinancingObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure for royalty financing obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingObligationsTableTextBlock" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyFinancingObligationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyFinancingObligationsTableTextBlock" xlink:to="lab_bcrx_RoyaltyFinancingObligationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization_c0a70efa-9dd7-40c9-9108-9afcbf5c1ab4_terseLabel_en-US" xlink:label="lab_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, right-of-use asset, accumulated amortization</link:label>
    <link:label id="lab_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Right of use Asset Accumulated Amortization</link:label>
    <link:label id="lab_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization_documentation_en-US" xlink:label="lab_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accumulated amortization on lessee's right to use underlying asset under operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="bcrx-20220930.xsd#bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7968f9d9-30dd-4dec-9ac7-036ffa65985f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_91439054-cab7-4cc7-a7cc-e04b6154ce6c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_063a1317-c074-47be-bbc6-64470d0a2074_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Disclosure [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d48a8929-cdb3-4870-905a-cc17790229ee_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable_c1f2de5d-c8c9-422c-adf1-5b6ad0057628_negatedLabel_en-US" xlink:label="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards available, stock option awards granted (in shares)</link:label>
    <link:label id="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable_label_en-US" xlink:label="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Awards Available</link:label>
    <link:label id="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable_documentation_en-US" xlink:label="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents share based compensation arrangement by share based payment award options grants in period awards available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:href="bcrx-20220930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:to="lab_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_StockIssuedDuringPeriodSharesWarrantsExercised_6262c1d3-bddc-4d20-8583-b835993679b3_terseLabel_en-US" xlink:label="lab_bcrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:label id="lab_bcrx_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_bcrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_bcrx_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_bcrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="bcrx-20220930.xsd#bcrx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_bcrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_23d331fc-6ca9-4438-9fb0-9580254583d6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_576e0a06-7772-4990-ab59-eb2d37135270_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_a6e77a7b-da21-4de5-aa56-ccc6a7cec1c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AECOMAndIRLMember_63896411-85a0-4c8a-b17e-451bc6c16a89_terseLabel_en-US" xlink:label="lab_bcrx_AECOMAndIRLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AECOM and IRL</link:label>
    <link:label id="lab_bcrx_AECOMAndIRLMember_label_en-US" xlink:label="lab_bcrx_AECOMAndIRLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AECOM and IRL [Member]</link:label>
    <link:label id="lab_bcrx_AECOMAndIRLMember_documentation_en-US" xlink:label="lab_bcrx_AECOMAndIRLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AECOM and IRL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AECOMAndIRLMember" xlink:href="bcrx-20220930.xsd#bcrx_AECOMAndIRLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AECOMAndIRLMember" xlink:to="lab_bcrx_AECOMAndIRLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_18352b1d-26c2-496a-beed-51c83f89b565_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based stock options issued in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a2506ec3-987e-4589-b322-32b56f323c9c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_853d1c0d-8967-4cef-9b66-9b62d35baa38_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest_3bfc6b34-8186-4266-b730-5badb9bfb02c_terseLabel_en-US" xlink:label="lab_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest</link:label>
    <link:label id="lab_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest_label_en-US" xlink:label="lab_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest</link:label>
    <link:label id="lab_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest_documentation_en-US" xlink:label="lab_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of accrued interest in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:href="bcrx-20220930.xsd#bcrx_AvailableForSaleDebtSecuritiesAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:to="lab_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_5e0d45cd-9857-4a33-a58f-e4fa3c645831_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd3e9738-c749-4561-a2d7-d19f6dd91332_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_eca1ba02-772c-408e-9369-f41abfdd4ad4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_bb24f64e-2acf-4e15-90c2-e7a4a2a56c53_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Life in Years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_8ae68890-60d6-45bb-bec4-b9c023e4427c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares per employee (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_63cb5994-f54a-4efd-87ed-7143a6ddee35_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_2c92f9ac-351d-4be4-8492-864b1daf5897_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_87d41e1f-5ec5-4d16-a8d6-9c171f1ab71b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding &#8211; 186,411 as of September&#160;30, 2022 and 184,350 as of December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_72183756-a3bb-4276-9f40-4aa6ae907661_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_MaximumCustomaryReductionOnRoyaltyRate_4151a3f6-515b-449e-b343-b9ed7eb736d4_terseLabel_en-US" xlink:label="lab_bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum customary reduction on royalty rate</link:label>
    <link:label id="lab_bcrx_MaximumCustomaryReductionOnRoyaltyRate_label_en-US" xlink:label="lab_bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Customary Reduction On Royalty Rate</link:label>
    <link:label id="lab_bcrx_MaximumCustomaryReductionOnRoyaltyRate_documentation_en-US" xlink:label="lab_bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The maximum percentage of customary reductions allowed on royalty rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:href="bcrx-20220930.xsd#bcrx_MaximumCustomaryReductionOnRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:to="lab_bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_CollaborativeAgreementContractValue_fcd1a746-882c-4905-b81d-d76e93f35911_terseLabel_en-US" xlink:label="lab_bcrx_CollaborativeAgreementContractValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement contract value</link:label>
    <link:label id="lab_bcrx_CollaborativeAgreementContractValue_label_en-US" xlink:label="lab_bcrx_CollaborativeAgreementContractValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Contract Value</link:label>
    <link:label id="lab_bcrx_CollaborativeAgreementContractValue_documentation_en-US" xlink:label="lab_bcrx_CollaborativeAgreementContractValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents collaborative agreement contract value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAgreementContractValue" xlink:href="bcrx-20220930.xsd#bcrx_CollaborativeAgreementContractValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_CollaborativeAgreementContractValue" xlink:to="lab_bcrx_CollaborativeAgreementContractValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_df601a18-46ca-4b12-8ce0-dafe2b03e622_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock_6c366400-cb0d-4166-85c6-c282782c1a18_terseLabel_en-US" xlink:label="lab_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheets of the Company's Operating Leases</link:label>
    <link:label id="lab_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Assets and Liabilities [Table Text Block]</link:label>
    <link:label id="lab_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the assets and liabilities of the lessee's operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:href="bcrx-20220930.xsd#bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TermALoanMember_e763bb75-c80f-460b-92a2-65c71c0ecc2a_terseLabel_en-US" xlink:label="lab_bcrx_TermALoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Loan</link:label>
    <link:label id="lab_bcrx_TermALoanMember_label_en-US" xlink:label="lab_bcrx_TermALoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Loan [Member]</link:label>
    <link:label id="lab_bcrx_TermALoanMember_documentation_en-US" xlink:label="lab_bcrx_TermALoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents term A loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermALoanMember" xlink:href="bcrx-20220930.xsd#bcrx_TermALoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TermALoanMember" xlink:to="lab_bcrx_TermALoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember_b9d0db79-19cb-47e6-8184-4d8fe3a9c07e_terseLabel_en-US" xlink:label="lab_bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans A, B and C Drawn and Cure Right Exercised</link:label>
    <link:label id="lab_bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember_label_en-US" xlink:label="lab_bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans A, B and C Drawn and Cure Right Exercised [Member]</link:label>
    <link:label id="lab_bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember_documentation_en-US" xlink:label="lab_bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents term loans A, B and C drawn and the Cure Right has been exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:href="bcrx-20220930.xsd#bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:to="lab_bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ca696546-ce31-4898-91dd-0358935ee999_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TermCLoanMember_f1091c20-6dcd-4609-9298-28b8356b5801_terseLabel_en-US" xlink:label="lab_bcrx_TermCLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term C Loan</link:label>
    <link:label id="lab_bcrx_TermCLoanMember_label_en-US" xlink:label="lab_bcrx_TermCLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term C Loan [Member]</link:label>
    <link:label id="lab_bcrx_TermCLoanMember_documentation_en-US" xlink:label="lab_bcrx_TermCLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents term C loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermCLoanMember" xlink:href="bcrx-20220930.xsd#bcrx_TermCLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TermCLoanMember" xlink:to="lab_bcrx_TermCLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_MaturityPeriodOfShortTermInvestment_434bdda6-7a5d-4ff4-8b51-b8bffc59025f_terseLabel_en-US" xlink:label="lab_bcrx_MaturityPeriodOfShortTermInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period of short term investment (in months)</link:label>
    <link:label id="lab_bcrx_MaturityPeriodOfShortTermInvestment_label_en-US" xlink:label="lab_bcrx_MaturityPeriodOfShortTermInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Period Of Short Term Investment</link:label>
    <link:label id="lab_bcrx_MaturityPeriodOfShortTermInvestment_documentation_en-US" xlink:label="lab_bcrx_MaturityPeriodOfShortTermInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period of short term investment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaturityPeriodOfShortTermInvestment" xlink:href="bcrx-20220930.xsd#bcrx_MaturityPeriodOfShortTermInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_MaturityPeriodOfShortTermInvestment" xlink:to="lab_bcrx_MaturityPeriodOfShortTermInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_441b70aa-c2e7-407d-9a04-b96e26229107_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt, total</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_44a89c9a-2997-4490-a5a6-1260813398e0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from common stock issued under stock-based compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0cb0a20e-e382-49ca-9003-0b0dd622299b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding_a0b86206-0e8a-451d-af86-8f59366f412c_terseLabel_en-US" xlink:label="lab_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential aggregate maximum amount of funding</link:label>
    <link:label id="lab_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding_label_en-US" xlink:label="lab_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Contract Covenant Maximum Amount of Funding</link:label>
    <link:label id="lab_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding_documentation_en-US" xlink:label="lab_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents collaborative agreement contract maximum amount if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of product.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:href="bcrx-20220930.xsd#bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:to="lab_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_StockIssuedDuringPeriodValueWarrantsExercised_cc4679d9-3946-4e11-a155-84ba12e7e9bf_terseLabel_en-US" xlink:label="lab_bcrx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants</link:label>
    <link:label id="lab_bcrx_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_bcrx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_bcrx_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_bcrx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="bcrx-20220930.xsd#bcrx_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_bcrx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1ef5b171-8e4c-4eb3-88db-d61bc15e7d67_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3c9ae159-121b-40dd-bd26-2c0706cf03ef_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_19ec8115-dafb-4a72-9ed5-f48e88bfef50_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_The2021RPIRoyaltyPurchaseAgreementMember_b5a1b59b-5ff7-43dc-92fc-2852737a261d_terseLabel_en-US" xlink:label="lab_bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2021 RPI Royalty Purchase Agreement</link:label>
    <link:label id="lab_bcrx_The2021RPIRoyaltyPurchaseAgreementMember_label_en-US" xlink:label="lab_bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2021 RPI Royalty Purchase Agreement [Member]</link:label>
    <link:label id="lab_bcrx_The2021RPIRoyaltyPurchaseAgreementMember_documentation_en-US" xlink:label="lab_bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the 2021 RPI Royalty Purchase Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:href="bcrx-20220930.xsd#bcrx_The2021RPIRoyaltyPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:to="lab_bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_912079a4-1055-444d-8bb2-ca5cb8657516_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6058b678-fa82-4f25-92ea-ed329dee242f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_OMERSRoyaltyAgreementMember_3f59c032-3335-4470-9d6e-acfc3a272dab_terseLabel_en-US" xlink:label="lab_bcrx_OMERSRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OMERS Royalty Agreement</link:label>
    <link:label id="lab_bcrx_OMERSRoyaltyAgreementMember_label_en-US" xlink:label="lab_bcrx_OMERSRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OMERS Royalty Agreement [Member]</link:label>
    <link:label id="lab_bcrx_OMERSRoyaltyAgreementMember_documentation_en-US" xlink:label="lab_bcrx_OMERSRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on OMERS Royalty Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OMERSRoyaltyAgreementMember" xlink:href="bcrx-20220930.xsd#bcrx_OMERSRoyaltyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_OMERSRoyaltyAgreementMember" xlink:to="lab_bcrx_OMERSRoyaltyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_340788d0-1f85-4f34-a177-9bcf2edad4fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan sales, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_dfb8440c-a20d-42ab-a4aa-c0c6a7b6917a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyMonetizationsLineItems_3828dfb9-7357-4c60-8bbc-d6b19023582c_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyMonetizationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Monetizations [Line Items]</link:label>
    <link:label id="lab_bcrx_RoyaltyMonetizationsLineItems_label_en-US" xlink:label="lab_bcrx_RoyaltyMonetizationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Monetizations [Line Items]</link:label>
    <link:label id="lab_bcrx_RoyaltyMonetizationsLineItems_documentation_en-US" xlink:label="lab_bcrx_RoyaltyMonetizationsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Monetizations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMonetizationsLineItems" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyMonetizationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems" xlink:to="lab_bcrx_RoyaltyMonetizationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesRangeAxis_b4007688-a91e-41c4-9d9a-111e68afcd42_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Range [Axis]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesRangeAxis_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Range [Axis]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesRangeAxis_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesRangeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Range</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeAxis" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesRangeAxis" xlink:to="lab_bcrx_AnnualNetSalesRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d0254505-954f-4f74-abd1-2d49c73f4acd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a0683c6a-cd47-4ff4-9191-5b86fa66b37e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PrivatePlacementOfSeniorSecuredNotes_56e9d920-deda-48df-b26c-941c7e4ba5ce_terseLabel_en-US" xlink:label="lab_bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private placement of senior secured notes</link:label>
    <link:label id="lab_bcrx_PrivatePlacementOfSeniorSecuredNotes_label_en-US" xlink:label="lab_bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement Of Senior Secured Notes</link:label>
    <link:label id="lab_bcrx_PrivatePlacementOfSeniorSecuredNotes_documentation_en-US" xlink:label="lab_bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents private placement of senior secured notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:href="bcrx-20220930.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:to="lab_bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_28a4dade-e9d9-4300-b017-6902603f4085_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesUnder150000Member_308b3a68-022b-4c37-ac32-c89df4761b6c_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesUnder150000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Under $150,000</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesUnder150000Member_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesUnder150000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Under $150,000 [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesUnder150000Member_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesUnder150000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents annual net sales under $150,000.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesUnder150000Member" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesUnder150000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesUnder150000Member" xlink:to="lab_bcrx_AnnualNetSalesUnder150000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_94d3bfa6-0fc2-4b96-8e75-d5434981d0ba_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_cddd7ca7-757e-4f1c-a4bb-e9afb9a5dfb8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PhaRMANotesMember_af7cab29-b934-41e7-a737-805744de6a30_terseLabel_en-US" xlink:label="lab_bcrx_PhaRMANotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PhaRMA Notes</link:label>
    <link:label id="lab_bcrx_PhaRMANotesMember_label_en-US" xlink:label="lab_bcrx_PhaRMANotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PhaRMA Notes Member]</link:label>
    <link:label id="lab_bcrx_PhaRMANotesMember_documentation_en-US" xlink:label="lab_bcrx_PhaRMANotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents PhaRMA notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PhaRMANotesMember" xlink:href="bcrx-20220930.xsd#bcrx_PhaRMANotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PhaRMANotesMember" xlink:to="lab_bcrx_PhaRMANotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1ef50dce-668e-498f-805e-c1ec2e86dca0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, term of contract (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_USDepartmentOfHealthAndHumanServicesMember_d4f1b02e-44a3-42d6-83f8-5ab7f30bd5cc_terseLabel_en-US" xlink:label="lab_bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Department of Health and Human Services</link:label>
    <link:label id="lab_bcrx_USDepartmentOfHealthAndHumanServicesMember_label_en-US" xlink:label="lab_bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Health and Human Services [Member]</link:label>
    <link:label id="lab_bcrx_USDepartmentOfHealthAndHumanServicesMember_documentation_en-US" xlink:label="lab_bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States department of health and human services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:href="bcrx-20220930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:to="lab_bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ad759912-94bc-45bf-a502-31b0c9906362_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan sales, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_24a96206-3d3c-4e78-a866-6413715e5d5f_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2f916d99-bc0b-4d3d-af5b-b0bac29fd139_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7a85898c-0f1b-4b1c-887b-4175b3c0c53d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0d3e44a1-afd5-4f75-8a86-e88878ecf61d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, unamortized discount (premium) and debt issuance costs, net, total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentContractReceivable_d09a7ceb-bf97-430f-8812-13cc1dc096c6_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentContractReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government contract receivable</link:label>
    <link:label id="lab_us-gaap_GovernmentContractReceivable_label_en-US" xlink:label="lab_us-gaap_GovernmentContractReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Contract Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentContractReceivable" xlink:to="lab_us-gaap_GovernmentContractReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_BCX9930BCX10013Member_e139558c-fdf9-48b9-897c-dc35b341effe_terseLabel_en-US" xlink:label="lab_bcrx_BCX9930BCX10013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BCX9930 &amp; BCX10013</link:label>
    <link:label id="lab_bcrx_BCX9930BCX10013Member_label_en-US" xlink:label="lab_bcrx_BCX9930BCX10013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BCX9930 &amp; BCX10013 [Member]</link:label>
    <link:label id="lab_bcrx_BCX9930BCX10013Member_documentation_en-US" xlink:label="lab_bcrx_BCX9930BCX10013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BCX9930 &amp; BCX10013</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BCX9930BCX10013Member" xlink:href="bcrx-20220930.xsd#bcrx_BCX9930BCX10013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_BCX9930BCX10013Member" xlink:to="lab_bcrx_BCX9930BCX10013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_79cd5db6-be4e-4d9b-8a9f-e1fa92c79cb7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0d37151b-ac6c-4f21-a537-d9289a53a8c5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_06927f08-2747-48cd-87c1-68e8a58d740e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e7095bab-bf26-41c4-b10b-0fc8f99c2e63_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_b66080f2-840a-42cd-a118-9333699541fb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets_0c557242-3a11-4c6a-8bff-dae78660cd72_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Royalties Percentage of Sublicense Revenue In Other Markets</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of sublicense revenue in other markets of royalties to be paid under the royalty purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree_55628dea-7ed9-43cf-860d-a2408aea2467_terseLabel_en-US" xlink:label="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost expected to be recognized year three</link:label>
    <link:label id="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree_label_en-US" xlink:label="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Year Three</link:label>
    <link:label id="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree_documentation_en-US" xlink:label="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:to="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ac65fb7b-b8c5-47bb-9664-ef38969c522b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_715165ce-875d-4240-ad52-e0633d0280a0_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bcd53a8d-7314-4c09-8db9-f4dbe5b2ac82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f43889f6-7fa0-40f2-98e3-0dfa73bfe4dc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_31ccbb8b-777e-4626-8ad4-eae55c87bf19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards available, restricted stock awards cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_465453a0-0814-40fb-8057-81399c4b5d69_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_1ad0d140-afe1-4c8c-8f28-49a0f9cdac36_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ORLADEYOMember_8386ed74-8a56-4d82-9e76-776821b04a9d_terseLabel_en-US" xlink:label="lab_bcrx_ORLADEYOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORLADEYO</link:label>
    <link:label id="lab_bcrx_ORLADEYOMember_label_en-US" xlink:label="lab_bcrx_ORLADEYOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORLADEYO [Member]</link:label>
    <link:label id="lab_bcrx_ORLADEYOMember_documentation_en-US" xlink:label="lab_bcrx_ORLADEYOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents ORLADEYO.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember" xlink:href="bcrx-20220930.xsd#bcrx_ORLADEYOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ORLADEYOMember" xlink:to="lab_bcrx_ORLADEYOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_NumberOfProductsObtainedDoses_e259f6c0-c55d-4d99-8729-5ebc69acaab4_terseLabel_en-US" xlink:label="lab_bcrx_NumberOfProductsObtainedDoses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of doses delivered, doses</link:label>
    <link:label id="lab_bcrx_NumberOfProductsObtainedDoses_label_en-US" xlink:label="lab_bcrx_NumberOfProductsObtainedDoses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Products Obtained Doses</link:label>
    <link:label id="lab_bcrx_NumberOfProductsObtainedDoses_documentation_en-US" xlink:label="lab_bcrx_NumberOfProductsObtainedDoses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Products Obtained Doses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NumberOfProductsObtainedDoses" xlink:href="bcrx-20220930.xsd#bcrx_NumberOfProductsObtainedDoses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_NumberOfProductsObtainedDoses" xlink:to="lab_bcrx_NumberOfProductsObtainedDoses" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation_49d5cf07-2c0a-4b4f-adf8-570f23ad5dd6_terseLabel_en-US" xlink:label="lab_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Interest expense on Royalty financing obligations</link:label>
    <link:label id="lab_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation_label_en-US" xlink:label="lab_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Interest expense on Royalty financing obligations</link:label>
    <link:label id="lab_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation_documentation_en-US" xlink:label="lab_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of non-cash interest expense on royalty financing obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" xlink:href="bcrx-20220930.xsd#bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" xlink:to="lab_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_aaae67b6-ee2b-4007-a9db-b6bf8eb8dbbd_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4d3f6d83-5bf4-4493-ab74-6181ec718c9c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0fb213cb-89ee-400b-86ea-0ca9bce776be_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyReceivablesFromPartnersMember_b3a3cf79-b69c-4348-902f-d5a17abf8779_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyReceivablesFromPartnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty receivables from partners</link:label>
    <link:label id="lab_bcrx_RoyaltyReceivablesFromPartnersMember_label_en-US" xlink:label="lab_bcrx_RoyaltyReceivablesFromPartnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Receivables from Partners [Member]</link:label>
    <link:label id="lab_bcrx_RoyaltyReceivablesFromPartnersMember_documentation_en-US" xlink:label="lab_bcrx_RoyaltyReceivablesFromPartnersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to royalty receivables from partners.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyReceivablesFromPartnersMember" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyReceivablesFromPartnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyReceivablesFromPartnersMember" xlink:to="lab_bcrx_RoyaltyReceivablesFromPartnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8d7b2825-ca0c-425b-9577-07d025005d4b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_9644e72d-53d2-42b9-8599-b01e7672beac_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_57896e9f-6b39-49a6-b803-28b5922b0183_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_586996cb-1991-43b4-b466-1fbc0bb82d82_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_IncentivePlanAndInducementPlanMember_9e57b676-5f92-4d51-a55e-0abd39557587_terseLabel_en-US" xlink:label="lab_bcrx_IncentivePlanAndInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Plan and Inducement Plan</link:label>
    <link:label id="lab_bcrx_IncentivePlanAndInducementPlanMember_label_en-US" xlink:label="lab_bcrx_IncentivePlanAndInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Plan and Inducement Plan [Member]</link:label>
    <link:label id="lab_bcrx_IncentivePlanAndInducementPlanMember_documentation_en-US" xlink:label="lab_bcrx_IncentivePlanAndInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the incentive and inducement plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanAndInducementPlanMember" xlink:href="bcrx-20220930.xsd#bcrx_IncentivePlanAndInducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_IncentivePlanAndInducementPlanMember" xlink:to="lab_bcrx_IncentivePlanAndInducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyMonetizationMember_6d8e49e9-3c78-4e19-b43e-81e1d45d8975_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyMonetizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Monetization</link:label>
    <link:label id="lab_bcrx_RoyaltyMonetizationMember_label_en-US" xlink:label="lab_bcrx_RoyaltyMonetizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Monetization [Member]</link:label>
    <link:label id="lab_bcrx_RoyaltyMonetizationMember_documentation_en-US" xlink:label="lab_bcrx_RoyaltyMonetizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the royalty monetization transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMonetizationMember" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyMonetizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyMonetizationMember" xlink:to="lab_bcrx_RoyaltyMonetizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5ec0d622-f949-4eea-b779-b9d15d4303c8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_173b905a-255b-473e-83e9-b4e012a10937_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets [extensible enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_SeniorCreditFacilityMember_37906dda-2825-4c2d-9ac4-908e261ed983_terseLabel_en-US" xlink:label="lab_bcrx_SeniorCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facility</link:label>
    <link:label id="lab_bcrx_SeniorCreditFacilityMember_label_en-US" xlink:label="lab_bcrx_SeniorCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facility [Member]</link:label>
    <link:label id="lab_bcrx_SeniorCreditFacilityMember_documentation_en-US" xlink:label="lab_bcrx_SeniorCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents senior credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SeniorCreditFacilityMember" xlink:href="bcrx-20220930.xsd#bcrx_SeniorCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_SeniorCreditFacilityMember" xlink:to="lab_bcrx_SeniorCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_MaturityPeriodOfHighQualityMarketableSecurities_28084a31-89e4-49fb-be5b-f24a95dd98bd_terseLabel_en-US" xlink:label="lab_bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period of high quality marketable securities (in years)</link:label>
    <link:label id="lab_bcrx_MaturityPeriodOfHighQualityMarketableSecurities_label_en-US" xlink:label="lab_bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Period Of High Quality Marketable Securities</link:label>
    <link:label id="lab_bcrx_MaturityPeriodOfHighQualityMarketableSecurities_documentation_en-US" xlink:label="lab_bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents maturity period of high quality marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:href="bcrx-20220930.xsd#bcrx_MaturityPeriodOfHighQualityMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:to="lab_bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_05f33b3b-3a57-4637-b132-a92511e6ed09_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4f2e287a-273f-48cc-8a81-2227a7dbe700_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_f981d90c-2e1e-43f5-9182-a9015ce8de98_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_MilestonePaymentMaximum_0dd3e7ed-4687-4520-89b8-77cfb26a0817_terseLabel_en-US" xlink:label="lab_bcrx_MilestonePaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment maximum</link:label>
    <link:label id="lab_bcrx_MilestonePaymentMaximum_label_en-US" xlink:label="lab_bcrx_MilestonePaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Maximum</link:label>
    <link:label id="lab_bcrx_MilestonePaymentMaximum_documentation_en-US" xlink:label="lab_bcrx_MilestonePaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents milestone payment maximum.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MilestonePaymentMaximum" xlink:href="bcrx-20220930.xsd#bcrx_MilestonePaymentMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_MilestonePaymentMaximum" xlink:to="lab_bcrx_MilestonePaymentMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_24033b7a-e181-48e1-aecb-c5630df30826_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_f8126508-7259-416b-9e93-f519f4f538b2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Product Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_4a9c0ce2-bfa3-4996-8a2c-c6da2fe2c0d3_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies and Concentrations of Risk</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_98619724-ba11-47a6-a9db-99c35d067cf9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation expense related to non-vested stock options and RSU awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a217d022-9a4a-4966-a9d8-df3f3b51bc77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_54ffcc3e-9c0a-46c1-a8ab-262333927000_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-kind interest</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts_9e95c083-a4e6-4255-a7e6-0153b8a3aab8_terseLabel_en-US" xlink:label="lab_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected receivable from awards for research and development contracts</link:label>
    <link:label id="lab_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts_label_en-US" xlink:label="lab_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Receivable From Awards For Research and Development Contracts</link:label>
    <link:label id="lab_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts_documentation_en-US" xlink:label="lab_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents expected receivable from awards for research and development contracts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:href="bcrx-20220930.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:to="lab_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_f918ed87-ddd4-4ae3-a4c0-22e1057d73b6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_14bbeb8c-3480-40f6-ba56-c1001a129267_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_6c052fdd-50e6-4c3f-adf2-3a469b15039b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_0454608c-f26b-468b-bdaf-757ee6cd21bd_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8dafda08-c382-4ddc-a2da-5d7cc9926f8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, stock option awards granted ( in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_9cf8b74c-1c34-46fe-bb57-73a48c12de64_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts_223713ec-39b0-49d0-8350-1cc7d3fdacd8_terseLabel_en-US" xlink:label="lab_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from awards for research and development contracts</link:label>
    <link:label id="lab_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts_label_en-US" xlink:label="lab_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Awards For Research And Development Contracts</link:label>
    <link:label id="lab_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts_documentation_en-US" xlink:label="lab_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents proceeds from awards for research and development contracts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:href="bcrx-20220930.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:to="lab_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_c882f61d-3c0a-47c3-8470-ac3e39a1a3d0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_6cd0ed2b-c48c-4a12-bb18-765e59082725_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_FutureRoyaltiesPayable_3f491922-5ad4-4da6-a95e-e4c50b47ad0f_terseLabel_en-US" xlink:label="lab_bcrx_FutureRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty financing obligations</link:label>
    <link:label id="lab_bcrx_FutureRoyaltiesPayable_a4730364-c3fc-4af1-a88e-7abeef33f32a_periodStartLabel_en-US" xlink:label="lab_bcrx_FutureRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_bcrx_FutureRoyaltiesPayable_8fa2837a-0779-43de-9a9c-e72c000a0ead_periodEndLabel_en-US" xlink:label="lab_bcrx_FutureRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_bcrx_FutureRoyaltiesPayable_label_en-US" xlink:label="lab_bcrx_FutureRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty financing obligations</link:label>
    <link:label id="lab_bcrx_FutureRoyaltiesPayable_documentation_en-US" xlink:label="lab_bcrx_FutureRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount as of the balance sheet date of obligations for future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FutureRoyaltiesPayable" xlink:href="bcrx-20220930.xsd#bcrx_FutureRoyaltiesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_FutureRoyaltiesPayable" xlink:to="lab_bcrx_FutureRoyaltiesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualLicenseFeeMinimum_05d7b92c-dd69-484f-92da-110b677a6b98_terseLabel_en-US" xlink:label="lab_bcrx_AnnualLicenseFeeMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license fee minimum</link:label>
    <link:label id="lab_bcrx_AnnualLicenseFeeMinimum_label_en-US" xlink:label="lab_bcrx_AnnualLicenseFeeMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual License Fee Minimum</link:label>
    <link:label id="lab_bcrx_AnnualLicenseFeeMinimum_documentation_en-US" xlink:label="lab_bcrx_AnnualLicenseFeeMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represent minimum annual license fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualLicenseFeeMinimum" xlink:href="bcrx-20220930.xsd#bcrx_AnnualLicenseFeeMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualLicenseFeeMinimum" xlink:to="lab_bcrx_AnnualLicenseFeeMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_db53eca6-3159-480b-86e4-a92f0f26f671_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_2e7c94b3-2cc4-43f6-a5d7-f236266b949a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c9df1205-5e14-41c3-9743-2d0454704a85_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations of U.S. Government and its agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltiesMonetizationsTable_388d75e5-98d6-4fc3-a326-d749cfcc8a6e_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltiesMonetizationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Monetizations [Table]</link:label>
    <link:label id="lab_bcrx_RoyaltiesMonetizationsTable_label_en-US" xlink:label="lab_bcrx_RoyaltiesMonetizationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Monetizations [Table]</link:label>
    <link:label id="lab_bcrx_RoyaltiesMonetizationsTable_documentation_en-US" xlink:label="lab_bcrx_RoyaltiesMonetizationsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Monetizations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltiesMonetizationsTable" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltiesMonetizationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable" xlink:to="lab_bcrx_RoyaltiesMonetizationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6d1c2e7d-08fc-459e-bd40-ff3d093dac22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_OperatingLeaseAssets_9e0469c6-b228-4bbd-bb6f-3db9b88df421_terseLabel_en-US" xlink:label="lab_bcrx_OperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_bcrx_OperatingLeaseAssets_label_en-US" xlink:label="lab_bcrx_OperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_bcrx_OperatingLeaseAssets_documentation_en-US" xlink:label="lab_bcrx_OperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on operating lease right-of-use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OperatingLeaseAssets" xlink:href="bcrx-20220930.xsd#bcrx_OperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_OperatingLeaseAssets" xlink:to="lab_bcrx_OperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_af28a985-1386-4033-abf7-53527831603c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5699eda3-f685-4c8e-a49b-e698397d7204_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets_6d70ce86-d358-4026-be10-4312b10f460c_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty purchase agreement, royalties, percentage of annual net sales in other markets</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales In Other Markets</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of annual net sales in other markets of royalties to be paid under the royalty purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_62a79ab9-3ba8-4d52-95f2-3765a505373c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of stock option awards granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_aa563430-6243-4d99-9a25-30d3a0f8f198_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_89601d97-e7af-4223-b61c-138e7928eddb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of stock option awards cancelled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyMontizationsRollForward_03ea5502-8557-42df-8087-38b846627e08_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyMontizationsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Montizations [Roll Forward]</link:label>
    <link:label id="lab_bcrx_RoyaltyMontizationsRollForward_label_en-US" xlink:label="lab_bcrx_RoyaltyMontizationsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Montizations [Roll Forward]</link:label>
    <link:label id="lab_bcrx_RoyaltyMontizationsRollForward_documentation_en-US" xlink:label="lab_bcrx_RoyaltyMontizationsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Montizations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMontizationsRollForward" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyMontizationsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward" xlink:to="lab_bcrx_RoyaltyMontizationsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_4055679e-0425-4dd8-bb94-4fce5a1661f4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_ee9526ff-f0f8-4066-9358-81d86547a9d5_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_fc04b7bb-7492-4142-9925-10861f90ae82_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_FutureRoyaltiesPayableMember_de5a044b-6e71-4a30-b030-a403a53979ea_terseLabel_en-US" xlink:label="lab_bcrx_FutureRoyaltiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Royalties Payable</link:label>
    <link:label id="lab_bcrx_FutureRoyaltiesPayableMember_label_en-US" xlink:label="lab_bcrx_FutureRoyaltiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Royalties Payable [Member]</link:label>
    <link:label id="lab_bcrx_FutureRoyaltiesPayableMember_documentation_en-US" xlink:label="lab_bcrx_FutureRoyaltiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents future royalties payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FutureRoyaltiesPayableMember" xlink:href="bcrx-20220930.xsd#bcrx_FutureRoyaltiesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_FutureRoyaltiesPayableMember" xlink:to="lab_bcrx_FutureRoyaltiesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_bb151e91-6d10-45c2-8ecb-4d47b68c447e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2e123065-45d5-484a-a441-7b5e431c6b7b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_87730f50-2adb-4f51-b84b-37fd5552f4ab_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_9f32d05a-84ff-4661-a071-a6f124a06185_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_23ecca03-6e62-4572-8719-116f03fce34c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangement, expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial_3e7459d1-e794-49e8-80c0-9b03fa1d01e8_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payments receivable, expiration term from first commercial (in years)</link:label>
    <link:label id="lab_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial_label_en-US" xlink:label="lab_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payments Receivable Expiration Term From First Commercial</link:label>
    <link:label id="lab_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expiration term of the royalty payments from first commercial date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:to="lab_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_64a0516b-c6ee-4952-a0ee-73e2d601a246_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_db6aca31-d521-467f-bc66-958b40b27569_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_05aac11f-f2d1-486f-82c4-48aabe3f2da3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_6b70fb7d-6ca9-4f47-b43c-1a925f27087d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, after allowance for credit loss, total</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_866a3abb-3c98-474d-9d8f-f66eca553668_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_d1195f90-82e6-416a-8bcb-6efed3ee6ca6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_SharesIssuedPricePerShareClosingPrice_05305e56-d2bd-44fb-9758-e1184b35b8e4_terseLabel_en-US" xlink:label="lab_bcrx_SharesIssuedPricePerShareClosingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, price per share, closing price (in usd per share)</link:label>
    <link:label id="lab_bcrx_SharesIssuedPricePerShareClosingPrice_label_en-US" xlink:label="lab_bcrx_SharesIssuedPricePerShareClosingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Price Per Share Closing Price</link:label>
    <link:label id="lab_bcrx_SharesIssuedPricePerShareClosingPrice_documentation_en-US" xlink:label="lab_bcrx_SharesIssuedPricePerShareClosingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on the closing price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharesIssuedPricePerShareClosingPrice" xlink:href="bcrx-20220930.xsd#bcrx_SharesIssuedPricePerShareClosingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_SharesIssuedPricePerShareClosingPrice" xlink:to="lab_bcrx_SharesIssuedPricePerShareClosingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RPI2021And2020IntermediateFinanceTrustMember_746796cd-f395-4e8e-b519-6b977105281c_terseLabel_en-US" xlink:label="lab_bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI 2021 and 2020 Intermediate Finance Trust</link:label>
    <link:label id="lab_bcrx_RPI2021And2020IntermediateFinanceTrustMember_label_en-US" xlink:label="lab_bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI 2021 and 2020 Intermediate Finance Trust [Member]</link:label>
    <link:label id="lab_bcrx_RPI2021And2020IntermediateFinanceTrustMember_documentation_en-US" xlink:label="lab_bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents RPI 2021 and 2020 Intermediate Finance Trust (RPI).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:href="bcrx-20220930.xsd#bcrx_RPI2021And2020IntermediateFinanceTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:to="lab_bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AdditionalDevelopmentOptionsMember_a6a9d1e8-863c-4737-9d43-9af6f0795e01_terseLabel_en-US" xlink:label="lab_bcrx_AdditionalDevelopmentOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Development Options</link:label>
    <link:label id="lab_bcrx_AdditionalDevelopmentOptionsMember_label_en-US" xlink:label="lab_bcrx_AdditionalDevelopmentOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Development Options [Member]</link:label>
    <link:label id="lab_bcrx_AdditionalDevelopmentOptionsMember_documentation_en-US" xlink:label="lab_bcrx_AdditionalDevelopmentOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The additional development options that can be exercised by the Government.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AdditionalDevelopmentOptionsMember" xlink:href="bcrx-20220930.xsd#bcrx_AdditionalDevelopmentOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AdditionalDevelopmentOptionsMember" xlink:to="lab_bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_MaximumAggregateOfferingPrice_7c1960f4-d7cf-426f-a7f0-c500c60f0e2d_terseLabel_en-US" xlink:label="lab_bcrx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price</link:label>
    <link:label id="lab_bcrx_MaximumAggregateOfferingPrice_label_en-US" xlink:label="lab_bcrx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label id="lab_bcrx_MaximumAggregateOfferingPrice_documentation_en-US" xlink:label="lab_bcrx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaximumAggregateOfferingPrice" xlink:href="bcrx-20220930.xsd#bcrx_MaximumAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_MaximumAggregateOfferingPrice" xlink:to="lab_bcrx_MaximumAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_OMERSCapitalMarketsMember_f9725d8f-12b8-468d-905c-64e58e74ff99_terseLabel_en-US" xlink:label="lab_bcrx_OMERSCapitalMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OMERS Capital Markets</link:label>
    <link:label id="lab_bcrx_OMERSCapitalMarketsMember_label_en-US" xlink:label="lab_bcrx_OMERSCapitalMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OMERS Capital Markets [Member]</link:label>
    <link:label id="lab_bcrx_OMERSCapitalMarketsMember_documentation_en-US" xlink:label="lab_bcrx_OMERSCapitalMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on the rights of OMERS Capital Markets to receive certain royalty payments under the OMERS Royalty Purchase Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OMERSCapitalMarketsMember" xlink:href="bcrx-20220930.xsd#bcrx_OMERSCapitalMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_OMERSCapitalMarketsMember" xlink:to="lab_bcrx_OMERSCapitalMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ShareBasedPaymentArrangementNumberOfPlans_fccb9fc4-5b42-4770-814e-dda10fadd5da_terseLabel_en-US" xlink:label="lab_bcrx_ShareBasedPaymentArrangementNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plans</link:label>
    <link:label id="lab_bcrx_ShareBasedPaymentArrangementNumberOfPlans_label_en-US" xlink:label="lab_bcrx_ShareBasedPaymentArrangementNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Number of Plans</link:label>
    <link:label id="lab_bcrx_ShareBasedPaymentArrangementNumberOfPlans_documentation_en-US" xlink:label="lab_bcrx_ShareBasedPaymentArrangementNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Number of Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShareBasedPaymentArrangementNumberOfPlans" xlink:href="bcrx-20220930.xsd#bcrx_ShareBasedPaymentArrangementNumberOfPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ShareBasedPaymentArrangementNumberOfPlans" xlink:to="lab_bcrx_ShareBasedPaymentArrangementNumberOfPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RPI2019IntermediateFinanceTrustMember_1f070a12-73de-4ac8-b745-5f948136d39c_terseLabel_en-US" xlink:label="lab_bcrx_RPI2019IntermediateFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI 2019 Intermediate Finance Trust</link:label>
    <link:label id="lab_bcrx_RPI2019IntermediateFinanceTrustMember_label_en-US" xlink:label="lab_bcrx_RPI2019IntermediateFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI 2019 Intermediate Finance Trust [Member]</link:label>
    <link:label id="lab_bcrx_RPI2019IntermediateFinanceTrustMember_documentation_en-US" xlink:label="lab_bcrx_RPI2019IntermediateFinanceTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents RPI 2019 Intermediate Finance Trust (RPI)..</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RPI2019IntermediateFinanceTrustMember" xlink:href="bcrx-20220930.xsd#bcrx_RPI2019IntermediateFinanceTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RPI2019IntermediateFinanceTrustMember" xlink:to="lab_bcrx_RPI2019IntermediateFinanceTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PeriodOfAgreement_1c3783a4-b7db-48d1-add9-73d840de47e3_terseLabel_en-US" xlink:label="lab_bcrx_PeriodOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of agreement (in years)</link:label>
    <link:label id="lab_bcrx_PeriodOfAgreement_label_en-US" xlink:label="lab_bcrx_PeriodOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Agreement</link:label>
    <link:label id="lab_bcrx_PeriodOfAgreement_documentation_en-US" xlink:label="lab_bcrx_PeriodOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents period of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PeriodOfAgreement" xlink:href="bcrx-20220930.xsd#bcrx_PeriodOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PeriodOfAgreement" xlink:to="lab_bcrx_PeriodOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_617dc277-f8ee-40f1-ba3e-18244c435307_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_3feb8899-b0fe-4161-a0bd-2f285a497443_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone_4134d756-83b8-4e87-ad86-65374154c412_terseLabel_en-US" xlink:label="lab_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments receivable if regulatory approval before specified date</link:label>
    <link:label id="lab_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone_label_en-US" xlink:label="lab_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments Receivable If Regulatory Approval Before Milestone</link:label>
    <link:label id="lab_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone_documentation_en-US" xlink:label="lab_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of potential milestone payments receivable if regulatory approval is granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" xlink:href="bcrx-20220930.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" xlink:to="lab_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_4a8fd803-7d07-416c-813e-540c2194e429_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability, statement of financial position [extensible enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ConcentrationOfMarketRiskPolicyTextBlock_4980d4cb-7211-4f7a-886b-9fdfbeb2a07c_terseLabel_en-US" xlink:label="lab_bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Customers and Other Risks</link:label>
    <link:label id="lab_bcrx_ConcentrationOfMarketRiskPolicyTextBlock_label_en-US" xlink:label="lab_bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Market Risk [Policy Text Block]</link:label>
    <link:label id="lab_bcrx_ConcentrationOfMarketRiskPolicyTextBlock_documentation_en-US" xlink:label="lab_bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents concentration of market risk policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:href="bcrx-20220930.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:to="lab_bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ContractTerm_49952857-3482-4223-a69a-2f3b8679f1a4_terseLabel_en-US" xlink:label="lab_bcrx_ContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term (in years)</link:label>
    <link:label id="lab_bcrx_ContractTerm_label_en-US" xlink:label="lab_bcrx_ContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Term</link:label>
    <link:label id="lab_bcrx_ContractTerm_documentation_en-US" xlink:label="lab_bcrx_ContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of time between the contract date and its expiration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ContractTerm" xlink:href="bcrx-20220930.xsd#bcrx_ContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ContractTerm" xlink:to="lab_bcrx_ContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8335164b-4e14-4838-9ae1-014c8dc957e7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_454d2d0d-0313-440f-a015-60cc26e5b0f4_terseLabel_en-US" xlink:label="lab_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity period of high quality marketable securities (in months)</link:label>
    <link:label id="lab_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_label_en-US" xlink:label="lab_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Maturity Period Of High Quality Marketable Securities</link:label>
    <link:label id="lab_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_documentation_en-US" xlink:label="lab_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity period of high quality marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:href="bcrx-20220930.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:to="lab_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock_aa030f7e-aeec-4900-b9e5-2fbc9d6213cc_terseLabel_en-US" xlink:label="lab_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Supplemental Information Related to Leases</link:label>
    <link:label id="lab_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock_label_en-US" xlink:label="lab_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Supplemental Information Related to Leases [Table Text Block]</link:label>
    <link:label id="lab_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock_documentation_en-US" xlink:label="lab_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Supplemental Information Related to Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock" xlink:href="bcrx-20220930.xsd#bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock" xlink:to="lab_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_945d85be-1ea2-4eaf-9656-6b96a13ba0fb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold_2780dc74-3704-40f4-b256-b47d838d7cad_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty purchase agreement, royalties, annual net sales payment threshold</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Royalties Annual Net Sales Payment Threshold</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on the maximum dollar amount of net sales allowed for royalty payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_SharesIssuedCommonStockPremium_ec7eb3bb-26e2-4f18-ae81-6dbc87837672_terseLabel_en-US" xlink:label="lab_bcrx_SharesIssuedCommonStockPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, common stock, premium</link:label>
    <link:label id="lab_bcrx_SharesIssuedCommonStockPremium_label_en-US" xlink:label="lab_bcrx_SharesIssuedCommonStockPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Common Stock Premium</link:label>
    <link:label id="lab_bcrx_SharesIssuedCommonStockPremium_documentation_en-US" xlink:label="lab_bcrx_SharesIssuedCommonStockPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on the amount of the common stock premium.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharesIssuedCommonStockPremium" xlink:href="bcrx-20220930.xsd#bcrx_SharesIssuedCommonStockPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_SharesIssuedCommonStockPremium" xlink:to="lab_bcrx_SharesIssuedCommonStockPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesOver230000Member_b8e7a0e0-6ca8-40a5-9a8c-b5a14d25f922_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesOver230000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Over $230,000</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesOver230000Member_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesOver230000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Over $230,000 [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesOver230000Member_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesOver230000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents annual net sales over $230,000.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOver230000Member" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesOver230000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesOver230000Member" xlink:to="lab_bcrx_AnnualNetSalesOver230000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember_11620f71-e4f3-40c9-9908-4d72ba845b34_terseLabel_en-US" xlink:label="lab_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment, Office Equipment and Software</link:label>
    <link:label id="lab_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment, Office Equipment and Software [Member]</link:label>
    <link:label id="lab_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information pertaining to laboratory equipment, office equipment and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:href="bcrx-20220930.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:to="lab_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_931bfee0-fe31-450c-9163-cd701780888c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments_59e30df0-1b8e-4feb-a555-275c3585924b_terseLabel_en-US" xlink:label="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, prepayment fee, percentage of principal voluntary payments</link:label>
    <link:label id="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments_label_en-US" xlink:label="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Fee Percentage of Principal Voluntary Payments</link:label>
    <link:label id="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments_documentation_en-US" xlink:label="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of principal paid voluntarily for prepayment fee of the debt instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:to="lab_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f79088d9-b96e-4fb4-9ce7-a3372c85d24e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_5d2cff1f-41ea-49fc-aefa-70482119a897_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TwentyTwentyRPIRoyaltyAgreementMember_272af2fc-4c9e-4b29-8849-bca3a21bf4c5_terseLabel_en-US" xlink:label="lab_bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 RPI Royalty Agreement</link:label>
    <link:label id="lab_bcrx_TwentyTwentyRPIRoyaltyAgreementMember_label_en-US" xlink:label="lab_bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 RPI Royalty Agreement [Member]</link:label>
    <link:label id="lab_bcrx_TwentyTwentyRPIRoyaltyAgreementMember_documentation_en-US" xlink:label="lab_bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on 2020 RPI Royalty agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:href="bcrx-20220930.xsd#bcrx_TwentyTwentyRPIRoyaltyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:to="lab_bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_9cf27adf-e481-4496-80ce-157fd9f41459_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_2ce8f374-c982-42a7-b2d8-d84b42d9a796_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AmortizationOfDiscountAndPremiumOnInvestments_c3e4128c-cfb4-47b5-a390-f20124f3e534_terseLabel_en-US" xlink:label="lab_bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium/discount on investments</link:label>
    <link:label id="lab_bcrx_AmortizationOfDiscountAndPremiumOnInvestments_label_en-US" xlink:label="lab_bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium/discount on investments</link:label>
    <link:label id="lab_bcrx_AmortizationOfDiscountAndPremiumOnInvestments_documentation_en-US" xlink:label="lab_bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of amortization expense attributable to the discount and premium on investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:href="bcrx-20220930.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:to="lab_bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_ccdfbddb-6039-4a2d-9849-84fdcefda1ad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e69896d4-e224-46f7-9613-eadab5458db5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_feceabae-649d-4af9-ad72-c5c3fa219aab_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cc6ddb93-4ae5-4d0e-a699-0ec94412896a_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_e2871a33-fd40-4eaf-9950-1f26d8265e55_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_637b7a68-8093-4a78-94e0-a4ed01479da1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_63db3683-fb10-4d62-9b03-39fd79fd3a11_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvanceRoyaltiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdvanceRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Royalties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract" xlink:to="lab_us-gaap_AdvanceRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a60c10f2-8e05-4f4d-bc6a-fa746565059b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories_eed6c4ee-26a6-4710-bf80-a276c390c47b_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty purchase agreement, royalties, percentage of annual net sales in key territories</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales In Key Territories</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of net sales in key territories for royalties to be paid under the royalty purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock_522279f7-3975-40ce-ab52-3a88f1643318_terseLabel_en-US" xlink:label="lab_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense and Royalty Financing Obligations</link:label>
    <link:label id="lab_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock_label_en-US" xlink:label="lab_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense and Royalty Financing Obligation [Policy Text Block]</link:label>
    <link:label id="lab_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock_documentation_en-US" xlink:label="lab_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for interest expense and royalty financing obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:href="bcrx-20220930.xsd#bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:to="lab_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_12d76f41-d297-4ffc-a1ba-37c6fe4789df_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_ASPRBARDAContractMember_c7403c6a-6f57-4775-9ae9-b71d1e39a001_terseLabel_en-US" xlink:label="lab_bcrx_ASPRBARDAContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASPRBARDA Contract</link:label>
    <link:label id="lab_bcrx_ASPRBARDAContractMember_label_en-US" xlink:label="lab_bcrx_ASPRBARDAContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASPRBARDA Contract [Member]</link:label>
    <link:label id="lab_bcrx_ASPRBARDAContractMember_documentation_en-US" xlink:label="lab_bcrx_ASPRBARDAContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The potential value of the ASPR/BARDA Contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ASPRBARDAContractMember" xlink:href="bcrx-20220930.xsd#bcrx_ASPRBARDAContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_ASPRBARDAContractMember" xlink:to="lab_bcrx_ASPRBARDAContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5a1ba7ac-a70b-406b-afa6-b526421172e8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_63bf1ba3-35fa-4121-983a-9e45c4223d74_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_65bc2098-4a22-4a09-b02b-cfd369e09d34_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesBillingStatusDomain_f456d2b1-a334-485f-8f68-b3c80c580703_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesBillingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivablesBillingStatusDomain_label_en-US" xlink:label="lab_us-gaap_ReceivablesBillingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesBillingStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesBillingStatusDomain" xlink:to="lab_us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock_bf0d8a78-9039-4c22-a679-75e5c252e5aa_terseLabel_en-US" xlink:label="lab_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense and Deferred Financing Costs</link:label>
    <link:label id="lab_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock_label_en-US" xlink:label="lab_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense and Deferred Financing Costs [Policy Text Block]</link:label>
    <link:label id="lab_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock_documentation_en-US" xlink:label="lab_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents interest expense and deferred financing costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:href="bcrx-20220930.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:to="lab_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_79c40e77-dd27-41b0-8330-6a149fd1237c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember_9ae891f4-8eed-40eb-90f8-99396c978ab2_terseLabel_en-US" xlink:label="lab_bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest Upon Successful Completion of Specific Development Milestones</link:label>
    <link:label id="lab_bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember_label_en-US" xlink:label="lab_bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest Upon Successful Completion of Specific Development Milestones [Member]</link:label>
    <link:label id="lab_bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents vesting upon successful completion of specific development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:href="bcrx-20220930.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:to="lab_bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_45cfbcfb-e640-4aad-8a7d-65af0ee70581_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour_ef61a704-5d11-447d-996c-4df3a879b264_terseLabel_en-US" xlink:label="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost expected to be recognized year four</link:label>
    <link:label id="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour_label_en-US" xlink:label="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Year Four</link:label>
    <link:label id="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour_documentation_en-US" xlink:label="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:to="lab_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_50e34cd5-a440-4221-89da-0e1e23775f47_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a07b5ad9-97d2-43b7-9a17-75d932b35f60_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledRevenuesMember_aefa2888-1925-432f-a1f3-c37fbbc5476c_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled</link:label>
    <link:label id="lab_us-gaap_UnbilledRevenuesMember_label_en-US" xlink:label="lab_us-gaap_UnbilledRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledRevenuesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledRevenuesMember" xlink:to="lab_us-gaap_UnbilledRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b1988a32-330a-4be3-9d9e-4da716716a04_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets_6a8ea775-1c0b-4db9-9a05-0e93fc5eb104_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty purchase agreement, royalties, maximum tiered profit share percentage on permitted sales in other markets</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets_label_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Royalties Maximum Tiered Profit Share Percentage On Permitted Sales In Other Markets</link:label>
    <link:label id="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets_documentation_en-US" xlink:label="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of net sales in certain markets for royalties to be paid under the royalty purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" xlink:to="lab_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyReceivableMember_42b817ab-31bd-4af5-b5da-c5cee5981adf_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Receivable</link:label>
    <link:label id="lab_bcrx_RoyaltyReceivableMember_label_en-US" xlink:label="lab_bcrx_RoyaltyReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Receivable [Member]</link:label>
    <link:label id="lab_bcrx_RoyaltyReceivableMember_documentation_en-US" xlink:label="lab_bcrx_RoyaltyReceivableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents royalty receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyReceivableMember" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyReceivableMember" xlink:to="lab_bcrx_RoyaltyReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_RoyaltyMonetizationTextBlock_bb875a8d-37fa-4f9a-9963-9716a20a24b3_terseLabel_en-US" xlink:label="lab_bcrx_RoyaltyMonetizationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Monetizations</link:label>
    <link:label id="lab_bcrx_RoyaltyMonetizationTextBlock_label_en-US" xlink:label="lab_bcrx_RoyaltyMonetizationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Monetization [Text Block]</link:label>
    <link:label id="lab_bcrx_RoyaltyMonetizationTextBlock_documentation_en-US" xlink:label="lab_bcrx_RoyaltyMonetizationTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty monetization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMonetizationTextBlock" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyMonetizationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_RoyaltyMonetizationTextBlock" xlink:to="lab_bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtCovenantTermsDomain_439b0a21-ff67-4b51-9654-d6f2ab11d60e_terseLabel_en-US" xlink:label="lab_bcrx_DebtCovenantTermsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Terms [Domain]</link:label>
    <link:label id="lab_bcrx_DebtCovenantTermsDomain_label_en-US" xlink:label="lab_bcrx_DebtCovenantTermsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Terms [Domain]</link:label>
    <link:label id="lab_bcrx_DebtCovenantTermsDomain_documentation_en-US" xlink:label="lab_bcrx_DebtCovenantTermsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtCovenantTermsDomain" xlink:href="bcrx-20220930.xsd#bcrx_DebtCovenantTermsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtCovenantTermsDomain" xlink:to="lab_bcrx_DebtCovenantTermsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_dd52bc23-de2a-42fd-a37f-017f85c195e9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_89751d9b-2c11-47a9-9ccd-5da391296428_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum_b77e399a-32ec-4d8f-90f4-dd91c2c56bdb_terseLabel_en-US" xlink:label="lab_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of salary to purchase common stock, maximum</link:label>
    <link:label id="lab_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum_label_en-US" xlink:label="lab_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Salary To Purchase Common Stock Maximum</link:label>
    <link:label id="lab_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum_documentation_en-US" xlink:label="lab_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of salary to purchase common stock maximum.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:href="bcrx-20220930.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:to="lab_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_db751907-482e-4e23-ac47-6df87d5cb5ab_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_48beeff5-5587-4890-a412-e3ee4429580f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3d019fc7-07b8-49af-b56c-c71d65cedc78_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available for sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_7b3ffa07-5340-44c8-b99d-acdf7b993769_terseLabel_en-US" xlink:label="lab_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through two years</link:label>
    <link:label id="lab_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_label_en-US" xlink:label="lab_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through two years</link:label>
    <link:label id="lab_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_documentation_en-US" xlink:label="lab_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of investment in debt securities maturing after one year through two years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:href="bcrx-20220930.xsd#bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:to="lab_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_899330e1-9aed-4850-b28e-664ac6b3aa11_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_8c2f0871-ca1b-4a66-bed9-c95f51c2df26_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_4bdae854-97ba-4853-b44b-933f20a5f367_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_CommonStockPurchaseAgreementWithRPIMember_2d758dc3-9308-44c6-ab7d-1e9f1e09e0f2_terseLabel_en-US" xlink:label="lab_bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement with RPI</link:label>
    <link:label id="lab_bcrx_CommonStockPurchaseAgreementWithRPIMember_label_en-US" xlink:label="lab_bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement with RPI [Member]</link:label>
    <link:label id="lab_bcrx_CommonStockPurchaseAgreementWithRPIMember_documentation_en-US" xlink:label="lab_bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on the Common Stock Purchase Agreement with RPI.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:href="bcrx-20220930.xsd#bcrx_CommonStockPurchaseAgreementWithRPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:to="lab_bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e30c3a23-7556-47e6-bdff-52d4feb3772d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_d54b4ddb-4772-46a7-b7b0-7caa218c195e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Available</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ab69cf32-d194-4098-87ee-e536574b8996_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ba280f6d-f0d8-4c25-a5a3-ecd5bef20a10_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock authorized to be purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_SharesIssuedPricePerSharePremium_9f10c08d-1e73-486d-8fac-fa3719e37258_terseLabel_en-US" xlink:label="lab_bcrx_SharesIssuedPricePerSharePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, price per share, premium (in usd per share)</link:label>
    <link:label id="lab_bcrx_SharesIssuedPricePerSharePremium_label_en-US" xlink:label="lab_bcrx_SharesIssuedPricePerSharePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Price Per Share Premium</link:label>
    <link:label id="lab_bcrx_SharesIssuedPricePerSharePremium_documentation_en-US" xlink:label="lab_bcrx_SharesIssuedPricePerSharePremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">information on the premium over the closing price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharesIssuedPricePerSharePremium" xlink:href="bcrx-20220930.xsd#bcrx_SharesIssuedPricePerSharePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_SharesIssuedPricePerSharePremium" xlink:to="lab_bcrx_SharesIssuedPricePerSharePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_6a598310-8485-4919-b5e8-92a0cc28d193_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_2a8a7a8b-d8ee-4878-a34a-e74b4dd1725d_terseLabel_en-US" xlink:label="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies and Concentration of Risk [Line Items]</link:label>
    <link:label id="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_label_en-US" xlink:label="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies and Concentrations of Risk [Line Items]</link:label>
    <link:label id="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_documentation_en-US" xlink:label="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies and Concentrations of Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" xlink:href="bcrx-20220930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" xlink:to="lab_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_ac689fa2-383f-4ea2-ba3d-08687798ede6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TermLoanADrawnMember_ab916d45-9891-47cc-bf6a-c30443799ee9_terseLabel_en-US" xlink:label="lab_bcrx_TermLoanADrawnMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Drawn</link:label>
    <link:label id="lab_bcrx_TermLoanADrawnMember_label_en-US" xlink:label="lab_bcrx_TermLoanADrawnMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Drawn [Member]</link:label>
    <link:label id="lab_bcrx_TermLoanADrawnMember_documentation_en-US" xlink:label="lab_bcrx_TermLoanADrawnMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents term loan A drawn.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanADrawnMember" xlink:href="bcrx-20220930.xsd#bcrx_TermLoanADrawnMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TermLoanADrawnMember" xlink:to="lab_bcrx_TermLoanADrawnMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_93cee32c-351c-4a39-9f84-ead80025ba02_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_TermLoansABAndCDrawnMember_17a3a562-9847-4046-9d65-03d06aeb6cf4_terseLabel_en-US" xlink:label="lab_bcrx_TermLoansABAndCDrawnMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans A, B and C Drawn</link:label>
    <link:label id="lab_bcrx_TermLoansABAndCDrawnMember_label_en-US" xlink:label="lab_bcrx_TermLoansABAndCDrawnMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans A, B and C Drawn [Member]</link:label>
    <link:label id="lab_bcrx_TermLoansABAndCDrawnMember_documentation_en-US" xlink:label="lab_bcrx_TermLoansABAndCDrawnMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents term loans A, B and C drawn.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoansABAndCDrawnMember" xlink:href="bcrx-20220930.xsd#bcrx_TermLoansABAndCDrawnMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_TermLoansABAndCDrawnMember" xlink:to="lab_bcrx_TermLoansABAndCDrawnMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_DebtCovenantTermsAxis_9e232078-74c6-429e-9c8a-bc77e3fa9895_terseLabel_en-US" xlink:label="lab_bcrx_DebtCovenantTermsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Terms [Axis]</link:label>
    <link:label id="lab_bcrx_DebtCovenantTermsAxis_label_en-US" xlink:label="lab_bcrx_DebtCovenantTermsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Terms [Axis]</link:label>
    <link:label id="lab_bcrx_DebtCovenantTermsAxis_documentation_en-US" xlink:label="lab_bcrx_DebtCovenantTermsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtCovenantTermsAxis" xlink:href="bcrx-20220930.xsd#bcrx_DebtCovenantTermsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_DebtCovenantTermsAxis" xlink:to="lab_bcrx_DebtCovenantTermsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_418e8be9-f075-49d8-91ff-a6ebe11d22f7_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_4f6f3dc6-b9f2-48c1-a14e-9d7f590e65dd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AccruedExpensesPolicyTextBlock_c5352c27-520f-4b33-bf6d-ea43cf45f063_terseLabel_en-US" xlink:label="lab_bcrx_AccruedExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_bcrx_AccruedExpensesPolicyTextBlock_label_en-US" xlink:label="lab_bcrx_AccruedExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses [Policy Text Block]</link:label>
    <link:label id="lab_bcrx_AccruedExpensesPolicyTextBlock_documentation_en-US" xlink:label="lab_bcrx_AccruedExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents accrued expenses policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AccruedExpensesPolicyTextBlock" xlink:href="bcrx-20220930.xsd#bcrx_AccruedExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AccruedExpensesPolicyTextBlock" xlink:to="lab_bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05d1ab06-9f39-473c-a89b-deedd8f2e695_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_b107543e-90df-498e-869b-0d84638a08db_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_f871986a-def1-40d7-ae27-0f739a57caee_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_da2b5602-0486-49c6-b75b-638fa28f3cec_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_Vest25PercentEachYearUntilFullyVestedMember_c7784366-af84-47c7-a777-e75a171d9626_terseLabel_en-US" xlink:label="lab_bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest 25% Each Year Until Fully Vested</link:label>
    <link:label id="lab_bcrx_Vest25PercentEachYearUntilFullyVestedMember_label_en-US" xlink:label="lab_bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest 25% Each Year Until Fully Vested [Member]</link:label>
    <link:label id="lab_bcrx_Vest25PercentEachYearUntilFullyVestedMember_documentation_en-US" xlink:label="lab_bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents vest 25% each year until fully vested.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:href="bcrx-20220930.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:to="lab_bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5629e9ef-ea93-4309-b9aa-e4d6a20d05a7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_62e7e5e9-329b-40b6-9990-39a5eed159fd_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_225cdc6e-0351-41c3-ad93-463f0d6a7a3d_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_0cbdce96-2fcb-4990-b99b-2237be0f6702_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_5cb75b36-41d8-4ce7-af7e-ca67da290526_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28e54989-aeff-401c-9480-aa93cec5428d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_2a003384-ad4f-49a5-b1af-7d67d752a4aa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualNetSalesUnder15BillionMember_9974e8a0-63ce-435d-9bdf-16c59c9201f1_terseLabel_en-US" xlink:label="lab_bcrx_AnnualNetSalesUnder15BillionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Under $1.5 Billion</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesUnder15BillionMember_label_en-US" xlink:label="lab_bcrx_AnnualNetSalesUnder15BillionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Under $1.5 Billion [Member]</link:label>
    <link:label id="lab_bcrx_AnnualNetSalesUnder15BillionMember_documentation_en-US" xlink:label="lab_bcrx_AnnualNetSalesUnder15BillionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents annual net sales under $1.5 billions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesUnder15BillionMember" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesUnder15BillionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualNetSalesUnder15BillionMember" xlink:to="lab_bcrx_AnnualNetSalesUnder15BillionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9983529b-bc54-4da1-a4dd-aa3a172aae05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a5ad9877-52fc-4497-8200-98db95798230_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value stock option awards (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_a5c349a1-3c52-4bbc-80dc-07516041526a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PriorToTheSecondAnniversaryMember_35331ba1-6673-4d47-91d6-c38ec0c152c3_terseLabel_en-US" xlink:label="lab_bcrx_PriorToTheSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to the Second Anniversary</link:label>
    <link:label id="lab_bcrx_PriorToTheSecondAnniversaryMember_label_en-US" xlink:label="lab_bcrx_PriorToTheSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to the Second Anniversary [Member]</link:label>
    <link:label id="lab_bcrx_PriorToTheSecondAnniversaryMember_documentation_en-US" xlink:label="lab_bcrx_PriorToTheSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents prior to the second anniversary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PriorToTheSecondAnniversaryMember" xlink:href="bcrx-20220930.xsd#bcrx_PriorToTheSecondAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PriorToTheSecondAnniversaryMember" xlink:to="lab_bcrx_PriorToTheSecondAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_ab74affb-4a96-445b-bdef-19caffacacb7_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_PercentageOfCommonStockSharesBeginning_d3139f85-c9d8-48ac-b2ad-9d72c5f95f42_terseLabel_en-US" xlink:label="lab_bcrx_PercentageOfCommonStockSharesBeginning" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of common stock shares, beginning</link:label>
    <link:label id="lab_bcrx_PercentageOfCommonStockSharesBeginning_label_en-US" xlink:label="lab_bcrx_PercentageOfCommonStockSharesBeginning" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Common Stock Shares Beginning</link:label>
    <link:label id="lab_bcrx_PercentageOfCommonStockSharesBeginning_documentation_en-US" xlink:label="lab_bcrx_PercentageOfCommonStockSharesBeginning" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of common stock shares beginning.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PercentageOfCommonStockSharesBeginning" xlink:href="bcrx-20220930.xsd#bcrx_PercentageOfCommonStockSharesBeginning"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_PercentageOfCommonStockSharesBeginning" xlink:to="lab_bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_3be1a679-bcf2-487f-bf14-f8fc1f95c103_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_BCX9930Member_fca556c2-af27-422f-97c7-d2d29bccc0b7_terseLabel_en-US" xlink:label="lab_bcrx_BCX9930Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BCX9930</link:label>
    <link:label id="lab_bcrx_BCX9930Member_label_en-US" xlink:label="lab_bcrx_BCX9930Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BCX9930 [Member]</link:label>
    <link:label id="lab_bcrx_BCX9930Member_documentation_en-US" xlink:label="lab_bcrx_BCX9930Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents BCX9930.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BCX9930Member" xlink:href="bcrx-20220930.xsd#bcrx_BCX9930Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_BCX9930Member" xlink:to="lab_bcrx_BCX9930Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_CreditAgreementMember_206f6ddc-cc09-4860-92c5-69a6ab9e1314_terseLabel_en-US" xlink:label="lab_bcrx_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_bcrx_CreditAgreementMember_label_en-US" xlink:label="lab_bcrx_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_bcrx_CreditAgreementMember_documentation_en-US" xlink:label="lab_bcrx_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the credit agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CreditAgreementMember" xlink:href="bcrx-20220930.xsd#bcrx_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_CreditAgreementMember" xlink:to="lab_bcrx_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_AnnualLicenseFeeMaximum_a3545e0e-698f-4252-a704-b6088396c6a7_terseLabel_en-US" xlink:label="lab_bcrx_AnnualLicenseFeeMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license fee maximum</link:label>
    <link:label id="lab_bcrx_AnnualLicenseFeeMaximum_label_en-US" xlink:label="lab_bcrx_AnnualLicenseFeeMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual License Fee Maximum</link:label>
    <link:label id="lab_bcrx_AnnualLicenseFeeMaximum_documentation_en-US" xlink:label="lab_bcrx_AnnualLicenseFeeMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents annual maximum license fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualLicenseFeeMaximum" xlink:href="bcrx-20220930.xsd#bcrx_AnnualLicenseFeeMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_AnnualLicenseFeeMaximum" xlink:to="lab_bcrx_AnnualLicenseFeeMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_bcrx_BetweenTheSecondAndThirdAnniversariesMember_39b1b3b0-bcc5-4574-ae61-b9d5b6ca6653_terseLabel_en-US" xlink:label="lab_bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Between the Second and Third Anniversaries</link:label>
    <link:label id="lab_bcrx_BetweenTheSecondAndThirdAnniversariesMember_label_en-US" xlink:label="lab_bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Between the Second and Third Anniversaries [Member]</link:label>
    <link:label id="lab_bcrx_BetweenTheSecondAndThirdAnniversariesMember_documentation_en-US" xlink:label="lab_bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents between the second and third anniversaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:href="bcrx-20220930.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:to="lab_bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>bcrx-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f6ec4fab-a519-489e-b421-6c7ee3322750,g:f7084e6e-47c2-4faa-aed0-8ba33c516e4f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/role/Cover" xlink:type="simple" xlink:href="bcrx-20220930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e24c305e-bb30-45b1-a578-7294aa0f5576" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_DocumentType_e24c305e-bb30-45b1-a578-7294aa0f5576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_4972f23a-7735-452d-943d-ffe3e5b56816" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_DocumentQuarterlyReport_4972f23a-7735-452d-943d-ffe3e5b56816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3316bddf-f583-4815-8b2a-a4070e28a7dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_DocumentPeriodEndDate_3316bddf-f583-4815-8b2a-a4070e28a7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0e5dcb40-9952-4330-8ea4-2032a6756202" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_DocumentTransitionReport_0e5dcb40-9952-4330-8ea4-2032a6756202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6ada14ec-c53c-4b67-af8f-2f2e67854e3c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntityFileNumber_6ada14ec-c53c-4b67-af8f-2f2e67854e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_639c7a53-528e-4e63-af7a-ea923c868df5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntityRegistrantName_639c7a53-528e-4e63-af7a-ea923c868df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5c650378-4138-4d86-95df-ea577d13a34f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5c650378-4138-4d86-95df-ea577d13a34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4b99cf79-c1c6-4192-bc2a-5ae377475cf7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntityTaxIdentificationNumber_4b99cf79-c1c6-4192-bc2a-5ae377475cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7988d32d-b7e4-4ecb-bf3b-eed28043576b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntityAddressAddressLine1_7988d32d-b7e4-4ecb-bf3b-eed28043576b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5f926871-7665-442f-ad45-9f72d9c7fd35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntityAddressCityOrTown_5f926871-7665-442f-ad45-9f72d9c7fd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c90611b3-69bf-47f0-81b9-a5803388043a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntityAddressStateOrProvince_c90611b3-69bf-47f0-81b9-a5803388043a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c188b8ca-9bfd-4fbe-9d24-9d84c6ee3437" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntityAddressPostalZipCode_c188b8ca-9bfd-4fbe-9d24-9d84c6ee3437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9d18d0b0-698e-43d4-9122-79a9aaf181f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_CityAreaCode_9d18d0b0-698e-43d4-9122-79a9aaf181f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e26d07fd-693e-496b-9b10-c105347feff0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_LocalPhoneNumber_e26d07fd-693e-496b-9b10-c105347feff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_04551e07-7f02-41dd-9b62-a5661028170e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_Security12bTitle_04551e07-7f02-41dd-9b62-a5661028170e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c4489f63-7c06-4a4d-9d9a-8d94b9d71137" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_TradingSymbol_c4489f63-7c06-4a4d-9d9a-8d94b9d71137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_35ef4ac9-354f-476b-a0e4-43562b527933" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_SecurityExchangeName_35ef4ac9-354f-476b-a0e4-43562b527933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_cc7dd939-6361-49c5-b23f-849a36f65542" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntityCurrentReportingStatus_cc7dd939-6361-49c5-b23f-849a36f65542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_710ac1d0-5afa-4086-93c4-4e0c11f1180c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntityInteractiveDataCurrent_710ac1d0-5afa-4086-93c4-4e0c11f1180c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_93e84d31-797e-49cd-9bc3-38041320921d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntityFilerCategory_93e84d31-797e-49cd-9bc3-38041320921d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2e93cc82-9003-4fc0-91c0-56bd2913a3f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntitySmallBusiness_2e93cc82-9003-4fc0-91c0-56bd2913a3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ba0337c3-fc74-40ca-89c6-bc5482880801" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntityEmergingGrowthCompany_ba0337c3-fc74-40ca-89c6-bc5482880801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5f2f0a6a-5dfc-4b8a-8e41-866869199cba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntityShellCompany_5f2f0a6a-5dfc-4b8a-8e41-866869199cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_920a32b4-501c-4fb9-a0d4-627d0cc400e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_920a32b4-501c-4fb9-a0d4-627d0cc400e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_50a5b3bb-55c2-4acf-adb7-5d7a6f36d1ab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_EntityCentralIndexKey_50a5b3bb-55c2-4acf-adb7-5d7a6f36d1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5c052076-3f12-4110-8756-3a3755f6383a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_CurrentFiscalYearEndDate_5c052076-3f12-4110-8756-3a3755f6383a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_58e5b4b8-8594-47a2-95bb-300826a9deab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_DocumentFiscalYearFocus_58e5b4b8-8594-47a2-95bb-300826a9deab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4319327a-f78e-4f86-9d92-7b5665498685" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4319327a-f78e-4f86-9d92-7b5665498685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0388d383-44d3-4475-8ebd-320479274c96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a6ae9b7a-b073-48b1-90ec-c67a9f82fba3" xlink:to="loc_dei_AmendmentFlag_0388d383-44d3-4475-8ebd-320479274c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="bcrx-20220930.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e3f09b24-b30a-4fd5-9e13-6a01a5f40b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_cbbeac1d-7e1d-4f06-b409-c0b0913aaa41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e3f09b24-b30a-4fd5-9e13-6a01a5f40b12" xlink:to="loc_us-gaap_AssetsAbstract_cbbeac1d-7e1d-4f06-b409-c0b0913aaa41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_052b294a-ead7-40e7-9933-5a322a220b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbeac1d-7e1d-4f06-b409-c0b0913aaa41" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_052b294a-ead7-40e7-9933-5a322a220b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3093d479-01e8-4123-8201-8e048b102730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbeac1d-7e1d-4f06-b409-c0b0913aaa41" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3093d479-01e8-4123-8201-8e048b102730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d2dd2a74-fbb0-4cc3-b96c-aa79b3d06afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbeac1d-7e1d-4f06-b409-c0b0913aaa41" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d2dd2a74-fbb0-4cc3-b96c-aa79b3d06afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_05e2b9a0-791b-4aeb-bd23-db92f9fb4da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbeac1d-7e1d-4f06-b409-c0b0913aaa41" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_05e2b9a0-791b-4aeb-bd23-db92f9fb4da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ab49ae65-714c-4a8f-accf-2866933e2da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbeac1d-7e1d-4f06-b409-c0b0913aaa41" xlink:to="loc_us-gaap_InventoryNet_ab49ae65-714c-4a8f-accf-2866933e2da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f8313659-e3d6-4ced-a17a-f14b70c53519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbeac1d-7e1d-4f06-b409-c0b0913aaa41" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f8313659-e3d6-4ced-a17a-f14b70c53519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_094d5497-652c-4425-8e8f-571245b6bb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbeac1d-7e1d-4f06-b409-c0b0913aaa41" xlink:to="loc_us-gaap_AssetsCurrent_094d5497-652c-4425-8e8f-571245b6bb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_aa3aedb1-d2fd-4fd9-9695-fc630966c656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbeac1d-7e1d-4f06-b409-c0b0913aaa41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_aa3aedb1-d2fd-4fd9-9695-fc630966c656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_6dfdcea4-e376-482b-b2ef-df30393ee646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbeac1d-7e1d-4f06-b409-c0b0913aaa41" xlink:to="loc_us-gaap_LongTermInvestments_6dfdcea4-e376-482b-b2ef-df30393ee646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_922010ec-a2cc-47c5-be65-1c5d5188f9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbeac1d-7e1d-4f06-b409-c0b0913aaa41" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_922010ec-a2cc-47c5-be65-1c5d5188f9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b3f1b07c-3c6f-4eee-a72e-a23a847c8520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbeac1d-7e1d-4f06-b409-c0b0913aaa41" xlink:to="loc_us-gaap_Assets_b3f1b07c-3c6f-4eee-a72e-a23a847c8520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bda0dabb-f0e3-437b-acb3-a41f89cb7b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e3f09b24-b30a-4fd5-9e13-6a01a5f40b12" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bda0dabb-f0e3-437b-acb3-a41f89cb7b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b06bc1e6-55be-4fdf-83d7-b7f2124e1932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bda0dabb-f0e3-437b-acb3-a41f89cb7b21" xlink:to="loc_us-gaap_AccountsPayableCurrent_b06bc1e6-55be-4fdf-83d7-b7f2124e1932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_916a553f-7cc0-477c-9371-b7b5da9cb885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bda0dabb-f0e3-437b-acb3-a41f89cb7b21" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_916a553f-7cc0-477c-9371-b7b5da9cb885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_b5d18dcb-7d75-4e98-b600-3242d2f8929f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bda0dabb-f0e3-437b-acb3-a41f89cb7b21" xlink:to="loc_us-gaap_DeferredRevenueCurrent_b5d18dcb-7d75-4e98-b600-3242d2f8929f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7e3210eb-2de0-456f-bffb-bc5983bae6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bda0dabb-f0e3-437b-acb3-a41f89cb7b21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7e3210eb-2de0-456f-bffb-bc5983bae6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_08bd845f-a07b-4623-bf4d-6a16805fec4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bda0dabb-f0e3-437b-acb3-a41f89cb7b21" xlink:to="loc_us-gaap_LiabilitiesCurrent_08bd845f-a07b-4623-bf4d-6a16805fec4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a9fee7e2-33cf-403c-b53e-165e57e0f7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bda0dabb-f0e3-437b-acb3-a41f89cb7b21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a9fee7e2-33cf-403c-b53e-165e57e0f7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FutureRoyaltiesPayable_26989210-12aa-403f-8604-77f9c32ee9db" xlink:href="bcrx-20220930.xsd#bcrx_FutureRoyaltiesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bda0dabb-f0e3-437b-acb3-a41f89cb7b21" xlink:to="loc_bcrx_FutureRoyaltiesPayable_26989210-12aa-403f-8604-77f9c32ee9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9b0e3e2c-a7e4-41fd-a8ae-40d56d40585c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bda0dabb-f0e3-437b-acb3-a41f89cb7b21" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9b0e3e2c-a7e4-41fd-a8ae-40d56d40585c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_afc217b4-2da8-43b6-aac9-05a3a40214a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bda0dabb-f0e3-437b-acb3-a41f89cb7b21" xlink:to="loc_us-gaap_StockholdersEquityAbstract_afc217b4-2da8-43b6-aac9-05a3a40214a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_602d92fb-4119-496a-acd6-dd1f081e3c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_afc217b4-2da8-43b6-aac9-05a3a40214a3" xlink:to="loc_us-gaap_PreferredStockValue_602d92fb-4119-496a-acd6-dd1f081e3c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8e1086b9-8ca7-40fd-8993-bf54ed39cae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_afc217b4-2da8-43b6-aac9-05a3a40214a3" xlink:to="loc_us-gaap_CommonStockValue_8e1086b9-8ca7-40fd-8993-bf54ed39cae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_10a9522b-5897-4b1c-89b3-8f4e788b72fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_afc217b4-2da8-43b6-aac9-05a3a40214a3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_10a9522b-5897-4b1c-89b3-8f4e788b72fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_eabc4fc4-92ba-4159-b58a-8d2bbb04febc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_afc217b4-2da8-43b6-aac9-05a3a40214a3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_eabc4fc4-92ba-4159-b58a-8d2bbb04febc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a721a576-594d-4b78-a0f1-d8325436249c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_afc217b4-2da8-43b6-aac9-05a3a40214a3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a721a576-594d-4b78-a0f1-d8325436249c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9e4ac1ea-3f1d-44af-9baf-babec49a7c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_afc217b4-2da8-43b6-aac9-05a3a40214a3" xlink:to="loc_us-gaap_StockholdersEquity_9e4ac1ea-3f1d-44af-9baf-babec49a7c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_de778293-a5d2-4006-82c7-cfbd8b227be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bda0dabb-f0e3-437b-acb3-a41f89cb7b21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_de778293-a5d2-4006-82c7-cfbd8b227be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="bcrx-20220930.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_413f9bf2-ce2f-4331-8b2e-4e51798c2b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_917aaf1a-a7fd-43b6-9d72-cce7f7061bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_413f9bf2-ce2f-4331-8b2e-4e51798c2b87" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_917aaf1a-a7fd-43b6-9d72-cce7f7061bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0f3cf530-42c9-4395-b616-ec44a7bc2901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_413f9bf2-ce2f-4331-8b2e-4e51798c2b87" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0f3cf530-42c9-4395-b616-ec44a7bc2901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1c0d0753-f77e-442f-9ee5-bdef271915fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_413f9bf2-ce2f-4331-8b2e-4e51798c2b87" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1c0d0753-f77e-442f-9ee5-bdef271915fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d3666728-80b4-4f02-bf39-2f2a1c07edd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_413f9bf2-ce2f-4331-8b2e-4e51798c2b87" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d3666728-80b4-4f02-bf39-2f2a1c07edd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e08e743c-2364-496b-9641-673d12321b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_413f9bf2-ce2f-4331-8b2e-4e51798c2b87" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e08e743c-2364-496b-9641-673d12321b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7aa2196c-6d62-4230-8407-a9cda5078cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_413f9bf2-ce2f-4331-8b2e-4e51798c2b87" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7aa2196c-6d62-4230-8407-a9cda5078cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_be75f86e-ad04-40b1-ace0-577ddf4c8f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_413f9bf2-ce2f-4331-8b2e-4e51798c2b87" xlink:to="loc_us-gaap_CommonStockSharesIssued_be75f86e-ad04-40b1-ace0-577ddf4c8f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_aac08b8c-00b9-45aa-8733-2f22d2c1d8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_413f9bf2-ce2f-4331-8b2e-4e51798c2b87" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_aac08b8c-00b9-45aa-8733-2f22d2c1d8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="bcrx-20220930.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fe1b2496-ceef-43d9-98bb-7f1460165a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0ec6abfb-ecdd-44e9-addc-796d0315a1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fe1b2496-ceef-43d9-98bb-7f1460165a1d" xlink:to="loc_us-gaap_StatementTable_0ec6abfb-ecdd-44e9-addc-796d0315a1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_65201625-992c-4b7a-b8eb-147a669c5bab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0ec6abfb-ecdd-44e9-addc-796d0315a1ea" xlink:to="loc_srt_ProductOrServiceAxis_65201625-992c-4b7a-b8eb-147a669c5bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c572ede4-68e0-4233-a81a-3adf5f6c9dbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_65201625-992c-4b7a-b8eb-147a669c5bab" xlink:to="loc_srt_ProductsAndServicesDomain_c572ede4-68e0-4233-a81a-3adf5f6c9dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_06a1f7d7-f93c-4db8-9106-e3447d6aa3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c572ede4-68e0-4233-a81a-3adf5f6c9dbb" xlink:to="loc_us-gaap_ProductMember_06a1f7d7-f93c-4db8-9106-e3447d6aa3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_404885b7-b023-4972-b2eb-d2ad21596933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c572ede4-68e0-4233-a81a-3adf5f6c9dbb" xlink:to="loc_us-gaap_RoyaltyMember_404885b7-b023-4972-b2eb-d2ad21596933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MilestoneRevenueMember_ed9b4cf1-842b-423a-a1c3-b2f150cc71c2" xlink:href="bcrx-20220930.xsd#bcrx_MilestoneRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c572ede4-68e0-4233-a81a-3adf5f6c9dbb" xlink:to="loc_bcrx_MilestoneRevenueMember_ed9b4cf1-842b-423a-a1c3-b2f150cc71c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_ffc7af89-c73f-4595-bfad-cbd0226a16d7" xlink:href="bcrx-20220930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c572ede4-68e0-4233-a81a-3adf5f6c9dbb" xlink:to="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_ffc7af89-c73f-4595-bfad-cbd0226a16d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0ec6abfb-ecdd-44e9-addc-796d0315a1ea" xlink:to="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ea666e7e-9fe7-4671-9e8e-b9b6c06ab120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_RevenuesAbstract_ea666e7e-9fe7-4671-9e8e-b9b6c06ab120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5e87b493-f9bb-4e9a-8b9b-0aefa2494a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_ea666e7e-9fe7-4671-9e8e-b9b6c06ab120" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5e87b493-f9bb-4e9a-8b9b-0aefa2494a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b4193b6c-06ac-4072-8c1a-88c23a0c98b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b4193b6c-06ac-4072-8c1a-88c23a0c98b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_be0d1366-8de6-4c05-876c-220714f6529e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b4193b6c-06ac-4072-8c1a-88c23a0c98b9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_be0d1366-8de6-4c05-876c-220714f6529e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_298b5617-d137-449f-9a0d-f2eca01f7604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b4193b6c-06ac-4072-8c1a-88c23a0c98b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_298b5617-d137-449f-9a0d-f2eca01f7604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7d641fc3-4292-42d6-97d7-eeccf522f176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b4193b6c-06ac-4072-8c1a-88c23a0c98b9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7d641fc3-4292-42d6-97d7-eeccf522f176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyExpenseReversalOfExpense_b23fcbf8-3c72-4231-9876-d9136285ef49" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyExpenseReversalOfExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b4193b6c-06ac-4072-8c1a-88c23a0c98b9" xlink:to="loc_bcrx_RoyaltyExpenseReversalOfExpense_b23fcbf8-3c72-4231-9876-d9136285ef49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7d768db7-f035-48f8-8800-e857b543f238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b4193b6c-06ac-4072-8c1a-88c23a0c98b9" xlink:to="loc_us-gaap_CostsAndExpenses_7d768db7-f035-48f8-8800-e857b543f238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0e518bf1-2a42-4f97-9718-dccafdfd19e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_OperatingIncomeLoss_0e518bf1-2a42-4f97-9718-dccafdfd19e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestAndOtherIncomeLoss_d299d8ff-d16a-403b-a1c0-2d7e66772d2b" xlink:href="bcrx-20220930.xsd#bcrx_InterestAndOtherIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_bcrx_InterestAndOtherIncomeLoss_d299d8ff-d16a-403b-a1c0-2d7e66772d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_947a7e62-cd50-47fd-af3e-dfb2794b776c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_InterestExpense_947a7e62-cd50-47fd-af3e-dfb2794b776c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_fe3480ec-dafe-45c9-95f0-ad4126ee059c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_fe3480ec-dafe-45c9-95f0-ad4126ee059c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5be28deb-ee69-43f3-b746-e4b2c932e27e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5be28deb-ee69-43f3-b746-e4b2c932e27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e3eb901c-db15-4815-a6c5-643a3beb40c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e3eb901c-db15-4815-a6c5-643a3beb40c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bcd471af-6062-4b96-8b71-3c68af6a1e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_NetIncomeLoss_bcd471af-6062-4b96-8b71-3c68af6a1e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4a1c15e2-9d4d-47ee-be6d-8d2270d7b447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4a1c15e2-9d4d-47ee-be6d-8d2270d7b447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3965294e-ac6f-40aa-ab14-1f1d9ae0a851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3965294e-ac6f-40aa-ab14-1f1d9ae0a851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6e143a56-5ed7-4f54-9975-c2e61f71a780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6e143a56-5ed7-4f54-9975-c2e61f71a780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_55657e72-8965-47a5-8904-79fcabfee3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_EarningsPerShareBasic_55657e72-8965-47a5-8904-79fcabfee3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f6be2df6-65bf-4254-b91e-c861ec9b10b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f6be2df6-65bf-4254-b91e-c861ec9b10b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5eeb1d40-0ce3-42a9-974b-0305ed0a10d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5eeb1d40-0ce3-42a9-974b-0305ed0a10d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cbbe148b-9847-4b17-b52b-cb83cbda7010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8f68a12c-5a7c-4f0f-8a22-5d2417f8626c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cbbe148b-9847-4b17-b52b-cb83cbda7010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="bcrx-20220930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_030cd9bc-8359-4de7-8c98-f1e67d480827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a44471b0-db83-474e-875b-9210aa9a4ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_030cd9bc-8359-4de7-8c98-f1e67d480827" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a44471b0-db83-474e-875b-9210aa9a4ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9c75b2ea-4026-41bd-8764-fa6e3402eb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a44471b0-db83-474e-875b-9210aa9a4ba5" xlink:to="loc_us-gaap_NetIncomeLoss_9c75b2ea-4026-41bd-8764-fa6e3402eb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c4f6216-63a9-4acf-97b0-7a922073833a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a44471b0-db83-474e-875b-9210aa9a4ba5" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c4f6216-63a9-4acf-97b0-7a922073833a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f6874f3d-2f1a-4db6-ae65-d038050a5f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c4f6216-63a9-4acf-97b0-7a922073833a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f6874f3d-2f1a-4db6-ae65-d038050a5f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d1d44661-6e9d-4d5e-9a53-426201e1261c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c4f6216-63a9-4acf-97b0-7a922073833a" xlink:to="loc_us-gaap_ShareBasedCompensation_d1d44661-6e9d-4d5e-9a53-426201e1261c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts_740c102e-0b17-4dbe-b428-5cb90d3afbae" xlink:href="bcrx-20220930.xsd#bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c4f6216-63a9-4acf-97b0-7a922073833a" xlink:to="loc_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts_740c102e-0b17-4dbe-b428-5cb90d3afbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AmortizationOfDiscountAndPremiumOnInvestments_b9cc3ed5-8ef0-4240-966a-36f1988d4484" xlink:href="bcrx-20220930.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c4f6216-63a9-4acf-97b0-7a922073833a" xlink:to="loc_bcrx_AmortizationOfDiscountAndPremiumOnInvestments_b9cc3ed5-8ef0-4240-966a-36f1988d4484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b0a476d-36f2-49db-b7f6-ed1aa526481f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a44471b0-db83-474e-875b-9210aa9a4ba5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b0a476d-36f2-49db-b7f6-ed1aa526481f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_f35abf63-8d79-40b4-9b54-f39704f40dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b0a476d-36f2-49db-b7f6-ed1aa526481f" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_f35abf63-8d79-40b4-9b54-f39704f40dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6d31169a-0f7d-4e05-9435-90bdb70ada07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b0a476d-36f2-49db-b7f6-ed1aa526481f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6d31169a-0f7d-4e05-9435-90bdb70ada07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b2c02e7c-6114-4d0e-b0e4-09ca09fcbbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b0a476d-36f2-49db-b7f6-ed1aa526481f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b2c02e7c-6114-4d0e-b0e4-09ca09fcbbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ed98a2eb-3f51-4a18-85e4-e93770db8182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b0a476d-36f2-49db-b7f6-ed1aa526481f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ed98a2eb-3f51-4a18-85e4-e93770db8182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_ce04b2bf-e53a-45ff-9ef4-9370cf4274b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b0a476d-36f2-49db-b7f6-ed1aa526481f" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_ce04b2bf-e53a-45ff-9ef4-9370cf4274b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6c672063-1edd-4f45-8a9f-b6375c9b82a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b0a476d-36f2-49db-b7f6-ed1aa526481f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6c672063-1edd-4f45-8a9f-b6375c9b82a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fc46df98-f5a5-4b02-9914-63b03f7f9bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a44471b0-db83-474e-875b-9210aa9a4ba5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fc46df98-f5a5-4b02-9914-63b03f7f9bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1a8767c8-619d-481d-b9fb-1ad792ff0617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_030cd9bc-8359-4de7-8c98-f1e67d480827" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1a8767c8-619d-481d-b9fb-1ad792ff0617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_432de48b-b3e2-487a-b8cb-1ee1c13d8f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1a8767c8-619d-481d-b9fb-1ad792ff0617" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_432de48b-b3e2-487a-b8cb-1ee1c13d8f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_96b279a3-1588-4615-a107-cb79fe734507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1a8767c8-619d-481d-b9fb-1ad792ff0617" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_96b279a3-1588-4615-a107-cb79fe734507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7c799aa7-9502-4983-9cdb-1c9189ed41b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1a8767c8-619d-481d-b9fb-1ad792ff0617" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7c799aa7-9502-4983-9cdb-1c9189ed41b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_33edbce9-5614-430b-882f-ca7e08a40728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1a8767c8-619d-481d-b9fb-1ad792ff0617" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_33edbce9-5614-430b-882f-ca7e08a40728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_419ad680-631f-4f5f-b38a-6b5457412d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_030cd9bc-8359-4de7-8c98-f1e67d480827" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_419ad680-631f-4f5f-b38a-6b5457412d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3adc947e-eae6-4141-a665-23ea105a4b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_419ad680-631f-4f5f-b38a-6b5457412d18" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3adc947e-eae6-4141-a665-23ea105a4b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_77721099-73c8-4dfa-b533-f5d5af31bc87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_419ad680-631f-4f5f-b38a-6b5457412d18" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_77721099-73c8-4dfa-b533-f5d5af31bc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0f3037b-99a7-429e-8871-1432a233012c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_419ad680-631f-4f5f-b38a-6b5457412d18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0f3037b-99a7-429e-8871-1432a233012c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1869f7f7-df08-488a-8019-a08125b19fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_030cd9bc-8359-4de7-8c98-f1e67d480827" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1869f7f7-df08-488a-8019-a08125b19fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7734e366-68fc-4e46-9ff9-f218dc684af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_030cd9bc-8359-4de7-8c98-f1e67d480827" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7734e366-68fc-4e46-9ff9-f218dc684af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5e57dee7-832c-49a6-9767-44bbe0b2ea48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_030cd9bc-8359-4de7-8c98-f1e67d480827" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5e57dee7-832c-49a6-9767-44bbe0b2ea48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1dcf53bf-a399-4a57-b032-c83448846a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_030cd9bc-8359-4de7-8c98-f1e67d480827" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1dcf53bf-a399-4a57-b032-c83448846a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit" xlink:type="simple" xlink:href="bcrx-20220930.xsd#ConsolidatedStatementsofStockholdersDeficit"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b5b9947b-050f-427f-9e5b-da3f8d37cf84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_23b50f50-5205-46d1-aa69-e4659a64b494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b5b9947b-050f-427f-9e5b-da3f8d37cf84" xlink:to="loc_us-gaap_StatementTable_23b50f50-5205-46d1-aa69-e4659a64b494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4f641724-7964-4016-8fd2-79e896ecc011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_23b50f50-5205-46d1-aa69-e4659a64b494" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4f641724-7964-4016-8fd2-79e896ecc011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b6877c37-fc8b-48d3-8d36-283636715d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4f641724-7964-4016-8fd2-79e896ecc011" xlink:to="loc_us-gaap_EquityComponentDomain_b6877c37-fc8b-48d3-8d36-283636715d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9bd14ef4-025e-4356-8125-32083331957c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b6877c37-fc8b-48d3-8d36-283636715d90" xlink:to="loc_us-gaap_CommonStockMember_9bd14ef4-025e-4356-8125-32083331957c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_73fc2c1d-14a1-4b24-b494-8e605ccb011a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b6877c37-fc8b-48d3-8d36-283636715d90" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_73fc2c1d-14a1-4b24-b494-8e605ccb011a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6776052-a4bb-4652-ba73-b7e8e6ae3985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b6877c37-fc8b-48d3-8d36-283636715d90" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b6776052-a4bb-4652-ba73-b7e8e6ae3985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_82369e92-cc03-480d-9754-914ec7318740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b6877c37-fc8b-48d3-8d36-283636715d90" xlink:to="loc_us-gaap_RetainedEarningsMember_82369e92-cc03-480d-9754-914ec7318740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3f363f5e-30ac-4154-9883-c7ef2eec1b72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_23b50f50-5205-46d1-aa69-e4659a64b494" xlink:to="loc_us-gaap_StatementLineItems_3f363f5e-30ac-4154-9883-c7ef2eec1b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f363f5e-30ac-4154-9883-c7ef2eec1b72" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bbcaa615-b3c1-4499-89c2-9a4c1079f12d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:to="loc_us-gaap_StockholdersEquity_bbcaa615-b3c1-4499-89c2-9a4c1079f12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5f3c0a32-6eac-4ef5-905c-240e7c7b095e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:to="loc_us-gaap_NetIncomeLoss_5f3c0a32-6eac-4ef5-905c-240e7c7b095e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cea00248-9c57-49a9-8873-a1a27da93ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cea00248-9c57-49a9-8873-a1a27da93ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_StockIssuedDuringPeriodValueWarrantsExercised_9409ca27-d129-4c4a-b719-26c64cb37c41" xlink:href="bcrx-20220930.xsd#bcrx_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:to="loc_bcrx_StockIssuedDuringPeriodValueWarrantsExercised_9409ca27-d129-4c4a-b719-26c64cb37c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6afd0d75-c006-49af-a06d-06feb2f66852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6afd0d75-c006-49af-a06d-06feb2f66852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_613ca156-789b-4e9a-9635-ecb03721fe76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_613ca156-789b-4e9a-9635-ecb03721fe76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_016dded5-e573-4449-a7bd-deb19f37a2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_016dded5-e573-4449-a7bd-deb19f37a2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f5c0d73f-7387-4d0d-ad65-ebcd3eff0bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4de9bde5-0f2d-4aa9-a9a7-a62d806beb6d" xlink:to="loc_us-gaap_StockholdersEquity_f5c0d73f-7387-4d0d-ad65-ebcd3eff0bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical" xlink:type="simple" xlink:href="bcrx-20220930.xsd#ConsolidatedStatementsofStockholdersDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_fc06d142-04cc-407a-9cab-440a7c6d40d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_845caa09-bca0-4439-9116-b15da13a8d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fc06d142-04cc-407a-9cab-440a7c6d40d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_845caa09-bca0-4439-9116-b15da13a8d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_77642cdc-6286-42d0-a626-913313b2f4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fc06d142-04cc-407a-9cab-440a7c6d40d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_77642cdc-6286-42d0-a626-913313b2f4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_StockIssuedDuringPeriodSharesWarrantsExercised_74a011ce-3434-4d35-a2ab-a2f93842829b" xlink:href="bcrx-20220930.xsd#bcrx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fc06d142-04cc-407a-9cab-440a7c6d40d8" xlink:to="loc_bcrx_StockIssuedDuringPeriodSharesWarrantsExercised_74a011ce-3434-4d35-a2ab-a2f93842829b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRisk" xlink:type="simple" xlink:href="bcrx-20220930.xsd#SignificantAccountingPoliciesandConcentrationsofRisk"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRisk" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_039925ba-f4fd-49bb-a9b8-cf3068588b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c7bb9cb7-a173-4e2c-b865-5ab776eb48da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_039925ba-f4fd-49bb-a9b8-cf3068588b16" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c7bb9cb7-a173-4e2c-b865-5ab776eb48da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/Revenue" xlink:type="simple" xlink:href="bcrx-20220930.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_441c5bfb-abea-49ce-9827-6e1737158b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_818531c8-ad6d-4259-87fb-e278ab3431cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_441c5bfb-abea-49ce-9827-6e1737158b50" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_818531c8-ad6d-4259-87fb-e278ab3431cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/Investments" xlink:type="simple" xlink:href="bcrx-20220930.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_a4d4602f-1f95-4fb8-9db1-d8a6c616d036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_cbe98060-8dae-4674-a957-2ea052ee68d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_a4d4602f-1f95-4fb8-9db1-d8a6c616d036" xlink:to="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_cbe98060-8dae-4674-a957-2ea052ee68d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/TradeReceivables" xlink:type="simple" xlink:href="bcrx-20220930.xsd#TradeReceivables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/TradeReceivables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_6714b661-2795-4de5-bd03-6e2eb640c301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TradeReceivablesTextBlock_dc633ef6-3042-4870-8f7c-7f3e8239e1db" xlink:href="bcrx-20220930.xsd#bcrx_TradeReceivablesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_6714b661-2795-4de5-bd03-6e2eb640c301" xlink:to="loc_bcrx_TradeReceivablesTextBlock_dc633ef6-3042-4870-8f7c-7f3e8239e1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/Inventory" xlink:type="simple" xlink:href="bcrx-20220930.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a28a95ff-edcf-4843-b9aa-a81875b451e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_6438fadd-8941-4aaf-a958-4860520ab2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a28a95ff-edcf-4843-b9aa-a81875b451e8" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_6438fadd-8941-4aaf-a958-4860520ab2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RoyaltyMonetizations" xlink:type="simple" xlink:href="bcrx-20220930.xsd#RoyaltyMonetizations"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/RoyaltyMonetizations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract_ec84ead6-0beb-4c56-9eb3-438476b4cfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMonetizationTextBlock_8fcac205-316b-440b-98c5-ffc305651ca8" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyMonetizationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_ec84ead6-0beb-4c56-9eb3-438476b4cfcc" xlink:to="loc_bcrx_RoyaltyMonetizationTextBlock_8fcac205-316b-440b-98c5-ffc305651ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/Debt" xlink:type="simple" xlink:href="bcrx-20220930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_78c0c53e-baa7-41df-9d3e-0effbd1251d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_6493eff7-82c5-4c54-a9e0-c414f9c92041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_78c0c53e-baa7-41df-9d3e-0effbd1251d2" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_6493eff7-82c5-4c54-a9e0-c414f9c92041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligations" xlink:type="simple" xlink:href="bcrx-20220930.xsd#LeaseObligations"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_17d10c04-c963-4a55-b74f-18d20b5724a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1ebb1d15-4dfa-4900-b32d-6f82b139bb87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_17d10c04-c963-4a55-b74f-18d20b5724a2" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1ebb1d15-4dfa-4900-b32d-6f82b139bb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockholdersEquity" xlink:type="simple" xlink:href="bcrx-20220930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_de345beb-4636-4e70-83b5-3b95b7900acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_de423712-77c9-436c-bbc5-25f4f06d0244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_de345beb-4636-4e70-83b5-3b95b7900acb" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_de423712-77c9-436c-bbc5-25f4f06d0244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="bcrx-20220930.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c694318c-8edf-4073-875f-40eecae3ab7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4ddcebcd-5e82-4837-ae21-79d971962515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c694318c-8edf-4073-875f-40eecae3ab7f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4ddcebcd-5e82-4837-ae21-79d971962515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="bcrx-20220930.xsd#CollaborativeandOtherRelationships"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/CollaborativeandOtherRelationships" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aae6a104-d989-45a2-a88d-efc0886709c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6e06f13b-48b8-4a72-8603-1493253d4bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aae6a104-d989-45a2-a88d-efc0886709c7" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6e06f13b-48b8-4a72-8603-1493253d4bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies" xlink:type="simple" xlink:href="bcrx-20220930.xsd#SignificantAccountingPoliciesandConcentrationsofRiskPolicies"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DescriptionOfCompanyPolicyTextBlock_49cc0c15-a5f8-4134-afa4-72ef413fb699" xlink:href="bcrx-20220930.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_bcrx_DescriptionOfCompanyPolicyTextBlock_49cc0c15-a5f8-4134-afa4-72ef413fb699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c5d97a31-39ec-470d-affa-d4e07034499f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c5d97a31-39ec-470d-affa-d4e07034499f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_3a785473-68cd-40f2-b13f-c52cd0ff592a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_UseOfEstimates_3a785473-68cd-40f2-b13f-c52cd0ff592a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ecc7c1ad-a9c8-4954-a58c-47aa83fc6c78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ecc7c1ad-a9c8-4954-a58c-47aa83fc6c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_507d1b35-3e07-4b43-910d-c7140ee9aadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_507d1b35-3e07-4b43-910d-c7140ee9aadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_74d53090-b473-42ce-ba90-142d495e7d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_74d53090-b473-42ce-ba90-142d495e7d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_e8741e89-289a-40e8-8173-3ba69013b7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_e8741e89-289a-40e8-8173-3ba69013b7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_370e4845-7707-421a-ad98-20dba5bd4299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_370e4845-7707-421a-ad98-20dba5bd4299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_bdd07dab-b734-4b26-8927-f1604c099ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_bdd07dab-b734-4b26-8927-f1604c099ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_cb2b994c-b334-433f-af06-6cc733600a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_cb2b994c-b334-433f-af06-6cc733600a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AccruedExpensesPolicyTextBlock_60430995-c2df-4f1b-8eab-7fb37e956117" xlink:href="bcrx-20220930.xsd#bcrx_AccruedExpensesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_bcrx_AccruedExpensesPolicyTextBlock_60430995-c2df-4f1b-8eab-7fb37e956117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_c06f9832-24d3-42eb-beb9-758aec4b3087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_c06f9832-24d3-42eb-beb9-758aec4b3087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1355663b-65e8-419d-8923-c8d1ecccb2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1355663b-65e8-419d-8923-c8d1ecccb2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_5e24900e-b171-48da-a946-1d6ac940f611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_5e24900e-b171-48da-a946-1d6ac940f611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_4ec68c81-8e95-4337-9c40-c6d1b26625f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_4ec68c81-8e95-4337-9c40-c6d1b26625f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8ec3d4c2-5ab3-4f7f-90d6-aec1d14a099d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8ec3d4c2-5ab3-4f7f-90d6-aec1d14a099d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock_eb7424d2-faee-441e-8d33-7a7013d7e21d" xlink:href="bcrx-20220930.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock_eb7424d2-faee-441e-8d33-7a7013d7e21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock_75ed048e-21cf-4cdf-9e9f-001cdbc0f7b2" xlink:href="bcrx-20220930.xsd#bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock_75ed048e-21cf-4cdf-9e9f-001cdbc0f7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_29900895-b420-4686-9324-08decfeda51c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_29900895-b420-4686-9324-08decfeda51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_56cdbfb7-eb1f-4e3d-835a-262aa34e0608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_56cdbfb7-eb1f-4e3d-835a-262aa34e0608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c871f08e-3cca-4016-bfe0-5d9624eb65a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c871f08e-3cca-4016-bfe0-5d9624eb65a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ConcentrationOfMarketRiskPolicyTextBlock_823ef7f4-7ed9-4d03-b304-372a81ee77c4" xlink:href="bcrx-20220930.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_bcrx_ConcentrationOfMarketRiskPolicyTextBlock_823ef7f4-7ed9-4d03-b304-372a81ee77c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cbc3f454-52fc-4c74-ad99-bc5b1637c6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1482f3c9-64e3-4802-b11c-5bd59a4f28d1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cbc3f454-52fc-4c74-ad99-bc5b1637c6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RevenueTables" xlink:type="simple" xlink:href="bcrx-20220930.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f8c0cb39-a55e-4e64-a2a8-36c7ec24413f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_82f95ba6-5995-4eab-81e4-0e7f946b3f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f8c0cb39-a55e-4e64-a2a8-36c7ec24413f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_82f95ba6-5995-4eab-81e4-0e7f946b3f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InvestmentsTables" xlink:type="simple" xlink:href="bcrx-20220930.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_78ef4f54-7d57-4a73-babf-74c9543822eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_706bfc48-c334-4b5a-97ef-923fd3a749b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_78ef4f54-7d57-4a73-babf-74c9543822eb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_706bfc48-c334-4b5a-97ef-923fd3a749b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_32b1867b-15f9-4eb3-8821-bef11d598225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_78ef4f54-7d57-4a73-babf-74c9543822eb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_32b1867b-15f9-4eb3-8821-bef11d598225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/TradeReceivablesTables" xlink:type="simple" xlink:href="bcrx-20220930.xsd#TradeReceivablesTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/TradeReceivablesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_68f1824b-ddcd-4e37-817c-c21a192dbf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock_9bb9c13c-99bf-4309-ac76-68ba3bb7d9e1" xlink:href="bcrx-20220930.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_68f1824b-ddcd-4e37-817c-c21a192dbf5c" xlink:to="loc_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock_9bb9c13c-99bf-4309-ac76-68ba3bb7d9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InventoryTables" xlink:type="simple" xlink:href="bcrx-20220930.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0882733c-ebae-4b43-a00d-a01ec15af460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4f78d441-7084-403a-96f0-63292ad4f833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0882733c-ebae-4b43-a00d-a01ec15af460" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4f78d441-7084-403a-96f0-63292ad4f833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RoyaltyMonetizationsTables" xlink:type="simple" xlink:href="bcrx-20220930.xsd#RoyaltyMonetizationsTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/RoyaltyMonetizationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract_80a8693a-4625-42b8-a252-2d2071846941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyFinancingObligationsTableTextBlock_70ad01ea-768a-4f2a-9990-5ab029dee8bb" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyFinancingObligationsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_80a8693a-4625-42b8-a252-2d2071846941" xlink:to="loc_bcrx_RoyaltyFinancingObligationsTableTextBlock_70ad01ea-768a-4f2a-9990-5ab029dee8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsTables" xlink:type="simple" xlink:href="bcrx-20220930.xsd#LeaseObligationsTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cd54aa31-fde5-4131-8b3e-9bebc9a7ae27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_01c6d2e2-5902-4952-ab96-8a2c175da047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd54aa31-fde5-4131-8b3e-9bebc9a7ae27" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_01c6d2e2-5902-4952-ab96-8a2c175da047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock_e339e9ae-097b-431d-89ca-de8a9476215e" xlink:href="bcrx-20220930.xsd#bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd54aa31-fde5-4131-8b3e-9bebc9a7ae27" xlink:to="loc_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock_e339e9ae-097b-431d-89ca-de8a9476215e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock_30a16aa2-1e60-4427-8ce7-ffd4cac33e67" xlink:href="bcrx-20220930.xsd#bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd54aa31-fde5-4131-8b3e-9bebc9a7ae27" xlink:to="loc_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock_30a16aa2-1e60-4427-8ce7-ffd4cac33e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ceb65e55-3441-480f-9e0f-b45ef379b726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd54aa31-fde5-4131-8b3e-9bebc9a7ae27" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ceb65e55-3441-480f-9e0f-b45ef379b726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="bcrx-20220930.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d7281230-d378-48d1-a6e4-f0f28cfb5067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_3fa48493-443a-485d-af93-aed362c7d157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d7281230-d378-48d1-a6e4-f0f28cfb5067" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_3fa48493-443a-485d-af93-aed362c7d157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2c0e936f-86a8-472b-8134-191b578a4d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d7281230-d378-48d1-a6e4-f0f28cfb5067" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2c0e936f-86a8-472b-8134-191b578a4d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#SignificantAccountingPoliciesandConcentrationsofRiskDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0151a7b5-eb64-4de0-8712-144c37644ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_665df6e4-e954-4044-ab00-dfdde748a3a1" xlink:href="bcrx-20220930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0151a7b5-eb64-4de0-8712-144c37644ad2" xlink:to="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_665df6e4-e954-4044-ab00-dfdde748a3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_e2e0df02-e04c-4079-9ab2-da94bf6c6c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_665df6e4-e954-4044-ab00-dfdde748a3a1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_e2e0df02-e04c-4079-9ab2-da94bf6c6c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2b87d856-4643-4dda-838e-8b52cd6b63ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_e2e0df02-e04c-4079-9ab2-da94bf6c6c9e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2b87d856-4643-4dda-838e-8b52cd6b63ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyReceivableMember_70093473-f3d0-4135-b96e-1bebc20760a7" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2b87d856-4643-4dda-838e-8b52cd6b63ef" xlink:to="loc_bcrx_RoyaltyReceivableMember_70093473-f3d0-4135-b96e-1bebc20760a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollateralForCreditMember_66d735ff-bbc3-449f-8fac-ab21665812f7" xlink:href="bcrx-20220930.xsd#bcrx_CollateralForCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2b87d856-4643-4dda-838e-8b52cd6b63ef" xlink:to="loc_bcrx_CollateralForCreditMember_66d735ff-bbc3-449f-8fac-ab21665812f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0f16d1a8-f9be-4123-9f88-3d5aa309caf4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_665df6e4-e954-4044-ab00-dfdde748a3a1" xlink:to="loc_srt_RangeAxis_0f16d1a8-f9be-4123-9f88-3d5aa309caf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e52606c-8246-47e6-b421-35e8cecbb1f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0f16d1a8-f9be-4123-9f88-3d5aa309caf4" xlink:to="loc_srt_RangeMember_6e52606c-8246-47e6-b421-35e8cecbb1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_03d01bde-0c16-48b6-b381-61f85077cb5a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6e52606c-8246-47e6-b421-35e8cecbb1f8" xlink:to="loc_srt_MaximumMember_03d01bde-0c16-48b6-b381-61f85077cb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7484457a-3253-4397-b88b-6cc6bfe383e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_665df6e4-e954-4044-ab00-dfdde748a3a1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7484457a-3253-4397-b88b-6cc6bfe383e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19749b37-60f7-4033-b68b-7da06e979685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7484457a-3253-4397-b88b-6cc6bfe383e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19749b37-60f7-4033-b68b-7da06e979685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_b27beffd-c2c7-4510-bd97-5a8291f8aaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19749b37-60f7-4033-b68b-7da06e979685" xlink:to="loc_us-gaap_ComputerEquipmentMember_b27beffd-c2c7-4510-bd97-5a8291f8aaf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember_d3857916-8a13-4d33-b00c-3699817cbee5" xlink:href="bcrx-20220930.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19749b37-60f7-4033-b68b-7da06e979685" xlink:to="loc_bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember_d3857916-8a13-4d33-b00c-3699817cbee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f9ffccd6-94bb-419f-b048-b7b28070e0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19749b37-60f7-4033-b68b-7da06e979685" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f9ffccd6-94bb-419f-b048-b7b28070e0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:href="bcrx-20220930.xsd#bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable_665df6e4-e954-4044-ab00-dfdde748a3a1" xlink:to="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_cbf9f6e0-13df-4dc9-83b8-340a8bedbeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_cbf9f6e0-13df-4dc9-83b8-340a8bedbeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaturityPeriodOfHighQualityMarketableSecurities_12d94947-f131-4130-aa01-3c8e644f5aa2" xlink:href="bcrx-20220930.xsd#bcrx_MaturityPeriodOfHighQualityMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_bcrx_MaturityPeriodOfHighQualityMarketableSecurities_12d94947-f131-4130-aa01-3c8e644f5aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_efe91de0-9878-4100-9f3e-54b8cbd988f8" xlink:href="bcrx-20220930.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_efe91de0-9878-4100-9f3e-54b8cbd988f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaturityPeriodOfShortTermInvestment_64eb2653-95b6-41f1-a894-a814375fd646" xlink:href="bcrx-20220930.xsd#bcrx_MaturityPeriodOfShortTermInvestment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_bcrx_MaturityPeriodOfShortTermInvestment_64eb2653-95b6-41f1-a894-a814375fd646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LongTermInvestmentMaturityMinimum_c27da899-1721-4f74-9a25-18282b401fe5" xlink:href="bcrx-20220930.xsd#bcrx_LongTermInvestmentMaturityMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_bcrx_LongTermInvestmentMaturityMinimum_c27da899-1721-4f74-9a25-18282b401fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_480fef97-beeb-4bfc-9d6e-1a12d80d600e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_480fef97-beeb-4bfc-9d6e-1a12d80d600e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_2456bd53-cda8-436c-a42b-1fe1780223b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_us-gaap_AdvertisingExpense_2456bd53-cda8-436c-a42b-1fe1780223b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_9c832577-169a-4185-9203-55f3b17fd409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_us-gaap_InterestExpenseDebt_9c832577-169a-4185-9203-55f3b17fd409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts_a76c4832-0b72-4069-9502-9d57d1be0e46" xlink:href="bcrx-20220930.xsd#bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts_a76c4832-0b72-4069-9502-9d57d1be0e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ea4aeb72-0104-4bb0-adfd-8ba65587e9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ea4aeb72-0104-4bb0-adfd-8ba65587e9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_c0a4afd7-cf32-4f79-801a-9b78f23821d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems_8691289b-c081-4ac2-8a87-f83bc5420b5d" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_c0a4afd7-cf32-4f79-801a-9b78f23821d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RevenueDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#RevenueDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/RevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2948b81b-7056-4077-985a-135ad5fbc826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_482baa8e-2d80-4b1e-bb17-1ab207ce8b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2948b81b-7056-4077-985a-135ad5fbc826" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_482baa8e-2d80-4b1e-bb17-1ab207ce8b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6c0d7c2b-f594-4bd6-9a51-df5e2b669af1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_482baa8e-2d80-4b1e-bb17-1ab207ce8b7f" xlink:to="loc_srt_ProductOrServiceAxis_6c0d7c2b-f594-4bd6-9a51-df5e2b669af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_74b99c51-fdc5-4b25-b5c7-d7c805354413" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6c0d7c2b-f594-4bd6-9a51-df5e2b669af1" xlink:to="loc_srt_ProductsAndServicesDomain_74b99c51-fdc5-4b25-b5c7-d7c805354413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_42304a45-828f-4f3a-9639-247ffd5682ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_74b99c51-fdc5-4b25-b5c7-d7c805354413" xlink:to="loc_us-gaap_ProductMember_42304a45-828f-4f3a-9639-247ffd5682ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_ef41189d-98f5-4bdd-b2ca-92a85043cfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_74b99c51-fdc5-4b25-b5c7-d7c805354413" xlink:to="loc_us-gaap_RoyaltyMember_ef41189d-98f5-4bdd-b2ca-92a85043cfb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MilestoneRevenueMember_b67962d6-ec9c-4441-8659-a0c25cc3e8ed" xlink:href="bcrx-20220930.xsd#bcrx_MilestoneRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_74b99c51-fdc5-4b25-b5c7-d7c805354413" xlink:to="loc_bcrx_MilestoneRevenueMember_b67962d6-ec9c-4441-8659-a0c25cc3e8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_6fffebaa-48f7-4572-8c0e-587aa0969aaf" xlink:href="bcrx-20220930.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_74b99c51-fdc5-4b25-b5c7-d7c805354413" xlink:to="loc_bcrx_CollaborativeAndOtherResearchAndDevelopmentMember_6fffebaa-48f7-4572-8c0e-587aa0969aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c809c2d2-0aca-42ef-a31e-50041aa36fca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_482baa8e-2d80-4b1e-bb17-1ab207ce8b7f" xlink:to="loc_srt_CounterpartyNameAxis_c809c2d2-0aca-42ef-a31e-50041aa36fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_384baa86-25a0-45c0-aa67-857f6889264e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c809c2d2-0aca-42ef-a31e-50041aa36fca" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_384baa86-25a0-45c0-aa67-857f6889264e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember_c777d878-5830-4bae-9025-313fee0b5c49" xlink:href="bcrx-20220930.xsd#bcrx_ORLADEYOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_384baa86-25a0-45c0-aa67-857f6889264e" xlink:to="loc_bcrx_ORLADEYOMember_c777d878-5830-4bae-9025-313fee0b5c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RAPIVABMember_0054770a-cc6a-41ef-81d8-a43ee7874819" xlink:href="bcrx-20220930.xsd#bcrx_RAPIVABMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_384baa86-25a0-45c0-aa67-857f6889264e" xlink:to="loc_bcrx_RAPIVABMember_0054770a-cc6a-41ef-81d8-a43ee7874819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PERAMIVIRMember_cba73fef-da95-45a0-b74a-a1002d5ba008" xlink:href="bcrx-20220930.xsd#bcrx_PERAMIVIRMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_384baa86-25a0-45c0-aa67-857f6889264e" xlink:to="loc_bcrx_PERAMIVIRMember_cba73fef-da95-45a0-b74a-a1002d5ba008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_USDepartmentOfHealthAndHumanServicesMember_dcc07179-470e-4541-92a3-ff7f5502600e" xlink:href="bcrx-20220930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_384baa86-25a0-45c0-aa67-857f6889264e" xlink:to="loc_bcrx_USDepartmentOfHealthAndHumanServicesMember_dcc07179-470e-4541-92a3-ff7f5502600e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_61d4e62d-1ec3-42a0-9f7c-3500d71b4a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_482baa8e-2d80-4b1e-bb17-1ab207ce8b7f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_61d4e62d-1ec3-42a0-9f7c-3500d71b4a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3caa8a4a-b510-42aa-831e-68eeeb301195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_61d4e62d-1ec3-42a0-9f7c-3500d71b4a0d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3caa8a4a-b510-42aa-831e-68eeeb301195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_fe661a51-e3d5-446d-add0-f078860e9e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_496d250a-5c12-47ba-9fa6-e22ad6b9e226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_fe661a51-e3d5-446d-add0-f078860e9e9f" xlink:to="loc_us-gaap_MarketableSecuritiesTable_496d250a-5c12-47ba-9fa6-e22ad6b9e226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_75d9e895-5f76-40b7-898b-126316426e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_496d250a-5c12-47ba-9fa6-e22ad6b9e226" xlink:to="loc_us-gaap_FinancialInstrumentAxis_75d9e895-5f76-40b7-898b-126316426e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d95cf0a9-1a10-45f8-90aa-36f4a5d81d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_75d9e895-5f76-40b7-898b-126316426e66" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d95cf0a9-1a10-45f8-90aa-36f4a5d81d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f9aa717b-f7a6-4e4a-9382-0aae4b83f549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d95cf0a9-1a10-45f8-90aa-36f4a5d81d73" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f9aa717b-f7a6-4e4a-9382-0aae4b83f549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_787f27d3-9e65-4702-a81c-15ecb22df9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d95cf0a9-1a10-45f8-90aa-36f4a5d81d73" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_787f27d3-9e65-4702-a81c-15ecb22df9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_3752b079-3251-4551-9814-a7c3edf2aa09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d95cf0a9-1a10-45f8-90aa-36f4a5d81d73" xlink:to="loc_us-gaap_CertificatesOfDepositMember_3752b079-3251-4551-9814-a7c3edf2aa09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_8a6f63c9-89e0-4144-8c4e-c580210e11e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_496d250a-5c12-47ba-9fa6-e22ad6b9e226" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_8a6f63c9-89e0-4144-8c4e-c580210e11e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_02da0544-8702-4783-871f-fc634b1040be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8a6f63c9-89e0-4144-8c4e-c580210e11e3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_02da0544-8702-4783-871f-fc634b1040be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest_3a32152e-2c3b-4586-9e40-bc8faf6b5678" xlink:href="bcrx-20220930.xsd#bcrx_AvailableForSaleDebtSecuritiesAccruedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8a6f63c9-89e0-4144-8c4e-c580210e11e3" xlink:to="loc_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest_3a32152e-2c3b-4586-9e40-bc8faf6b5678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b4a9f501-fb91-49c6-afb5-14afb6ae4f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8a6f63c9-89e0-4144-8c4e-c580210e11e3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b4a9f501-fb91-49c6-afb5-14afb6ae4f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_725fc74d-7293-43fc-a1a8-f44bf51cbe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8a6f63c9-89e0-4144-8c4e-c580210e11e3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_725fc74d-7293-43fc-a1a8-f44bf51cbe2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0d258c41-f18d-4320-92a4-f3848b333e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8a6f63c9-89e0-4144-8c4e-c580210e11e3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0d258c41-f18d-4320-92a4-f3848b333e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#InvestmentsScheduleofMaturityofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_9afbc7ff-f17b-49f8-915c-68c6d1661854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7c5d1851-e34c-4122-b87f-5bac724bd80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_9afbc7ff-f17b-49f8-915c-68c6d1661854" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7c5d1851-e34c-4122-b87f-5bac724bd80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_23302b87-0838-4b28-ad89-eebd5a4c5bde" xlink:href="bcrx-20220930.xsd#bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_9afbc7ff-f17b-49f8-915c-68c6d1661854" xlink:to="loc_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_23302b87-0838-4b28-ad89-eebd5a4c5bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fb625004-a1d5-4887-95d4-8443974ce699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_9afbc7ff-f17b-49f8-915c-68c6d1661854" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fb625004-a1d5-4887-95d4-8443974ce699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/TradeReceivablesDetailsTextual" xlink:type="simple" xlink:href="bcrx-20220930.xsd#TradeReceivablesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/TradeReceivablesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_1daa9ce2-07c2-48ee-9247-3952f3e69a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c7624aac-cc72-478e-8629-7004dd9259a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_1daa9ce2-07c2-48ee-9247-3952f3e69a29" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c7624aac-cc72-478e-8629-7004dd9259a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_277d02ea-003f-4002-96b6-6cb8a133c073" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c7624aac-cc72-478e-8629-7004dd9259a0" xlink:to="loc_srt_ProductOrServiceAxis_277d02ea-003f-4002-96b6-6cb8a133c073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0972ccd5-be56-4aec-b75a-6bae11d6d635" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_277d02ea-003f-4002-96b6-6cb8a133c073" xlink:to="loc_srt_ProductsAndServicesDomain_0972ccd5-be56-4aec-b75a-6bae11d6d635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember_83ce40d0-5350-4aef-8818-c092a4ad7883" xlink:href="bcrx-20220930.xsd#bcrx_ORLADEYOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0972ccd5-be56-4aec-b75a-6bae11d6d635" xlink:to="loc_bcrx_ORLADEYOMember_83ce40d0-5350-4aef-8818-c092a4ad7883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RAPIVABMember_e422f823-6a80-480f-96e0-9b727343da0c" xlink:href="bcrx-20220930.xsd#bcrx_RAPIVABMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0972ccd5-be56-4aec-b75a-6bae11d6d635" xlink:to="loc_bcrx_RAPIVABMember_e422f823-6a80-480f-96e0-9b727343da0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_GreenCrossCorporationMember_b49b00c0-91ab-40eb-ba68-c14167dacb6a" xlink:href="bcrx-20220930.xsd#bcrx_GreenCrossCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0972ccd5-be56-4aec-b75a-6bae11d6d635" xlink:to="loc_bcrx_GreenCrossCorporationMember_b49b00c0-91ab-40eb-ba68-c14167dacb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b55ef89f-f52e-4acd-a7b7-b16b1d4d98ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c7624aac-cc72-478e-8629-7004dd9259a0" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b55ef89f-f52e-4acd-a7b7-b16b1d4d98ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_47b909e1-4e88-4858-9e20-5b1d3b7559fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b55ef89f-f52e-4acd-a7b7-b16b1d4d98ef" xlink:to="loc_us-gaap_ReceivableTypeDomain_47b909e1-4e88-4858-9e20-5b1d3b7559fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_d02ca6fe-b982-474d-aba3-2bdbcd673862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_47b909e1-4e88-4858-9e20-5b1d3b7559fd" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_d02ca6fe-b982-474d-aba3-2bdbcd673862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d8bbfeea-85e9-4216-b7f3-6cfbe438cac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_c7624aac-cc72-478e-8629-7004dd9259a0" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d8bbfeea-85e9-4216-b7f3-6cfbe438cac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_26498e50-09d2-4146-822f-fa2b2ee24d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d8bbfeea-85e9-4216-b7f3-6cfbe438cac8" xlink:to="loc_us-gaap_AccountsReceivableNet_26498e50-09d2-4146-822f-fa2b2ee24d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#TradeReceivablesSummaryofReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_4d8dde87-798e-4b8f-b1c2-e963362c4619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_043e1611-8e15-4b58-b805-ab014aea3dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_4d8dde87-798e-4b8f-b1c2-e963362c4619" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_043e1611-8e15-4b58-b805-ab014aea3dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_feb546b8-8313-48ec-800d-0815e73101bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_043e1611-8e15-4b58-b805-ab014aea3dce" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_feb546b8-8313-48ec-800d-0815e73101bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_2df7d58a-3f88-4ede-9453-4734e59c5a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_feb546b8-8313-48ec-800d-0815e73101bf" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_2df7d58a-3f88-4ede-9453-4734e59c5a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_USDepartmentOfHealthAndHumanServicesMember_63bc3269-8a55-46c4-b1ee-b8f9703c3f97" xlink:href="bcrx-20220930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_2df7d58a-3f88-4ede-9453-4734e59c5a17" xlink:to="loc_bcrx_USDepartmentOfHealthAndHumanServicesMember_63bc3269-8a55-46c4-b1ee-b8f9703c3f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShionogiCoLtdMember_6c1709b9-9f32-4aaf-89a6-337f18087515" xlink:href="bcrx-20220930.xsd#bcrx_ShionogiCoLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_2df7d58a-3f88-4ede-9453-4734e59c5a17" xlink:to="loc_bcrx_ShionogiCoLtdMember_6c1709b9-9f32-4aaf-89a6-337f18087515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyReceivablesFromPartnersMember_36809b99-bf8f-4fb6-b350-31127602a185" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyReceivablesFromPartnersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_2df7d58a-3f88-4ede-9453-4734e59c5a17" xlink:to="loc_bcrx_RoyaltyReceivablesFromPartnersMember_36809b99-bf8f-4fb6-b350-31127602a185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_c2ce0276-f31f-460f-ba42-4e60ee7f32ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_043e1611-8e15-4b58-b805-ab014aea3dce" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_c2ce0276-f31f-460f-ba42-4e60ee7f32ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesBillingStatusDomain_6d392581-8bf1-466b-b5ec-4cd958b43ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_c2ce0276-f31f-460f-ba42-4e60ee7f32ca" xlink:to="loc_us-gaap_ReceivablesBillingStatusDomain_6d392581-8bf1-466b-b5ec-4cd958b43ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledRevenuesMember_c3dda8c9-d107-4c0b-bb6f-8a89b75f2599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledRevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesBillingStatusDomain_6d392581-8bf1-466b-b5ec-4cd958b43ae5" xlink:to="loc_us-gaap_BilledRevenuesMember_c3dda8c9-d107-4c0b-bb6f-8a89b75f2599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledRevenuesMember_2448a0f7-420f-487a-88f5-ea9a49956cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledRevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesBillingStatusDomain_6d392581-8bf1-466b-b5ec-4cd958b43ae5" xlink:to="loc_us-gaap_UnbilledRevenuesMember_2448a0f7-420f-487a-88f5-ea9a49956cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bed052ef-ec52-4f47-a9b1-d203d6d10f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_043e1611-8e15-4b58-b805-ab014aea3dce" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bed052ef-ec52-4f47-a9b1-d203d6d10f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_78d7baf0-f6bb-457f-be47-ad2cb5ea76e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bed052ef-ec52-4f47-a9b1-d203d6d10f33" xlink:to="loc_us-gaap_ReceivablesNetCurrent_78d7baf0-f6bb-457f-be47-ad2cb5ea76e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/InventoryDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e6fda2cc-4d1b-431c-8c68-cac3664ed9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_026f9251-c5f0-482d-bc35-ac940dd583ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e6fda2cc-4d1b-431c-8c68-cac3664ed9c6" xlink:to="loc_us-gaap_InventoryRawMaterials_026f9251-c5f0-482d-bc35-ac940dd583ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_0dc92fa6-c69c-4838-b9d7-a109ceb0fad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e6fda2cc-4d1b-431c-8c68-cac3664ed9c6" xlink:to="loc_us-gaap_InventoryWorkInProcess_0dc92fa6-c69c-4838-b9d7-a109ceb0fad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_af891ba3-f2db-47bd-8a80-45bdeaf395ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e6fda2cc-4d1b-431c-8c68-cac3664ed9c6" xlink:to="loc_us-gaap_InventoryFinishedGoods_af891ba3-f2db-47bd-8a80-45bdeaf395ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_5dc9ebf2-6af8-4245-bbf4-3bf31ae0c324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e6fda2cc-4d1b-431c-8c68-cac3664ed9c6" xlink:to="loc_us-gaap_InventoryGross_5dc9ebf2-6af8-4245-bbf4-3bf31ae0c324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_c44d1b77-beec-4a1e-b15b-29492f45b5da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e6fda2cc-4d1b-431c-8c68-cac3664ed9c6" xlink:to="loc_us-gaap_InventoryValuationReserves_c44d1b77-beec-4a1e-b15b-29492f45b5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8fda405f-9d4f-4733-83c6-20da8b98c2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e6fda2cc-4d1b-431c-8c68-cac3664ed9c6" xlink:to="loc_us-gaap_InventoryNet_8fda405f-9d4f-4733-83c6-20da8b98c2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual" xlink:type="simple" xlink:href="bcrx-20220930.xsd#RoyaltyMonetizationsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract_dfdefa7a-efe6-4b8e-a6f8-63864f92b9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltiesMonetizationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_dfdefa7a-efe6-4b8e-a6f8-63864f92b9d9" xlink:to="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8e957f6d-518f-45fe-9e5f-d26e9899e4e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_dei_LegalEntityAxis_8e957f6d-518f-45fe-9e5f-d26e9899e4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e76fdf47-7399-46d4-8ae8-f532071c86d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_8e957f6d-518f-45fe-9e5f-d26e9899e4e5" xlink:to="loc_dei_EntityDomain_e76fdf47-7399-46d4-8ae8-f532071c86d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_JPRRoyaltySubLLCMember_98607343-77ba-41e7-bfd0-2fb6eddd2088" xlink:href="bcrx-20220930.xsd#bcrx_JPRRoyaltySubLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e76fdf47-7399-46d4-8ae8-f532071c86d2" xlink:to="loc_bcrx_JPRRoyaltySubLLCMember_98607343-77ba-41e7-bfd0-2fb6eddd2088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_3ff3d7f7-7797-414c-9f7c-19319d420c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_us-gaap_OtherCommitmentsAxis_3ff3d7f7-7797-414c-9f7c-19319d420c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_9a87f6f1-81f5-483c-99e4-6d7112abe864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_3ff3d7f7-7797-414c-9f7c-19319d420c8f" xlink:to="loc_us-gaap_OtherCommitmentsDomain_9a87f6f1-81f5-483c-99e4-6d7112abe864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMonetizationMember_796b49c7-8207-4a91-b8f0-1d79663bd09d" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyMonetizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_9a87f6f1-81f5-483c-99e4-6d7112abe864" xlink:to="loc_bcrx_RoyaltyMonetizationMember_796b49c7-8207-4a91-b8f0-1d79663bd09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7dd84c6f-d419-4743-bfe7-afb10187a4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_us-gaap_DebtInstrumentAxis_7dd84c6f-d419-4743-bfe7-afb10187a4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3490f5b9-ffeb-441f-8cac-5da0be32add7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7dd84c6f-d419-4743-bfe7-afb10187a4a2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3490f5b9-ffeb-441f-8cac-5da0be32add7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PhaRMANotesMember_bcc4b5b9-0cdb-4471-a398-2dc1b787e473" xlink:href="bcrx-20220930.xsd#bcrx_PhaRMANotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3490f5b9-ffeb-441f-8cac-5da0be32add7" xlink:to="loc_bcrx_PhaRMANotesMember_bcc4b5b9-0cdb-4471-a398-2dc1b787e473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d9515b0f-8913-4f80-862d-41d4999e6f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d9515b0f-8913-4f80-862d-41d4999e6f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a4c84b1f-211f-43c8-b44b-017411cf1843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d9515b0f-8913-4f80-862d-41d4999e6f06" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a4c84b1f-211f-43c8-b44b-017411cf1843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_bf998b68-2b6d-4f75-baa3-ab7718bacc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a4c84b1f-211f-43c8-b44b-017411cf1843" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_bf998b68-2b6d-4f75-baa3-ab7718bacc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e7b91622-0ba7-4336-8e6b-d20677342d2c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_srt_CounterpartyNameAxis_e7b91622-0ba7-4336-8e6b-d20677342d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_964136bd-38b2-41af-832a-daf1781c7223" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e7b91622-0ba7-4336-8e6b-d20677342d2c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_964136bd-38b2-41af-832a-daf1781c7223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RPI2019IntermediateFinanceTrustMember_d603c281-8d1a-4187-8183-03ec651d473f" xlink:href="bcrx-20220930.xsd#bcrx_RPI2019IntermediateFinanceTrustMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_964136bd-38b2-41af-832a-daf1781c7223" xlink:to="loc_bcrx_RPI2019IntermediateFinanceTrustMember_d603c281-8d1a-4187-8183-03ec651d473f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RPI2021And2020IntermediateFinanceTrustMember_b7a25855-ecfc-4b10-b5cc-a536ed73f580" xlink:href="bcrx-20220930.xsd#bcrx_RPI2021And2020IntermediateFinanceTrustMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_964136bd-38b2-41af-832a-daf1781c7223" xlink:to="loc_bcrx_RPI2021And2020IntermediateFinanceTrustMember_b7a25855-ecfc-4b10-b5cc-a536ed73f580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_The2021RPIRoyaltyPurchaseAgreementMember_e115af11-6907-47bd-bf30-349ef9333d95" xlink:href="bcrx-20220930.xsd#bcrx_The2021RPIRoyaltyPurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_964136bd-38b2-41af-832a-daf1781c7223" xlink:to="loc_bcrx_The2021RPIRoyaltyPurchaseAgreementMember_e115af11-6907-47bd-bf30-349ef9333d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OMERSCapitalMarketsMember_02005dc4-54ab-42ae-af81-c1470a01ce93" xlink:href="bcrx-20220930.xsd#bcrx_OMERSCapitalMarketsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_964136bd-38b2-41af-832a-daf1781c7223" xlink:to="loc_bcrx_OMERSCapitalMarketsMember_02005dc4-54ab-42ae-af81-c1470a01ce93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cc5e5193-16fb-4df0-a44f-66e8fad187f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cc5e5193-16fb-4df0-a44f-66e8fad187f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0c47794c-0eae-43dd-b7d5-67be979c2968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cc5e5193-16fb-4df0-a44f-66e8fad187f0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0c47794c-0eae-43dd-b7d5-67be979c2968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FutureRoyaltiesPayableMember_841eb079-86f8-4533-ac59-935a40903967" xlink:href="bcrx-20220930.xsd#bcrx_FutureRoyaltiesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0c47794c-0eae-43dd-b7d5-67be979c2968" xlink:to="loc_bcrx_FutureRoyaltiesPayableMember_841eb079-86f8-4533-ac59-935a40903967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_22202dc9-fb05-49df-ab2e-a5928382424a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_srt_ProductOrServiceAxis_22202dc9-fb05-49df-ab2e-a5928382424a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_887d148f-cf9f-4de3-a4ef-36cb9e0c2d29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_22202dc9-fb05-49df-ab2e-a5928382424a" xlink:to="loc_srt_ProductsAndServicesDomain_887d148f-cf9f-4de3-a4ef-36cb9e0c2d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ORLADEYOMember_49757da6-981a-4e43-bd15-028e070128fd" xlink:href="bcrx-20220930.xsd#bcrx_ORLADEYOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_887d148f-cf9f-4de3-a4ef-36cb9e0c2d29" xlink:to="loc_bcrx_ORLADEYOMember_49757da6-981a-4e43-bd15-028e070128fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BCX9930Member_a1c93f8e-9bce-4957-96a0-8728feb71700" xlink:href="bcrx-20220930.xsd#bcrx_BCX9930Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_887d148f-cf9f-4de3-a4ef-36cb9e0c2d29" xlink:to="loc_bcrx_BCX9930Member_a1c93f8e-9bce-4957-96a0-8728feb71700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BCX9930BCX10013Member_139916ba-98cf-4c32-9de1-7521f366ef7e" xlink:href="bcrx-20220930.xsd#bcrx_BCX9930BCX10013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_887d148f-cf9f-4de3-a4ef-36cb9e0c2d29" xlink:to="loc_bcrx_BCX9930BCX10013Member_139916ba-98cf-4c32-9de1-7521f366ef7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeAxis_59c8fa55-79fa-4af3-a819-80b6bbf36bfc" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesRangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_bcrx_AnnualNetSalesRangeAxis_59c8fa55-79fa-4af3-a819-80b6bbf36bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeAxis_59c8fa55-79fa-4af3-a819-80b6bbf36bfc" xlink:to="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesUnder350000Member_1c65adac-60d2-4e32-beb2-43a2ff541e4a" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesUnder350000Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesUnder350000Member_1c65adac-60d2-4e32-beb2-43a2ff541e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesBetween350000And550000Member_decd2844-492c-498e-9b41-69305f4c69bf" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesBetween350000And550000Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesBetween350000And550000Member_decd2844-492c-498e-9b41-69305f4c69bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOver550000Member_3ffc650a-9fc1-4372-a6f5-5ab59e1a312e" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesOver550000Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesOver550000Member_3ffc650a-9fc1-4372-a6f5-5ab59e1a312e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesUnder150000Member_96bacf16-c7e2-4da2-af29-f615097a9524" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesUnder150000Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesUnder150000Member_96bacf16-c7e2-4da2-af29-f615097a9524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesBetween150000And230000Member_7cf3fc7c-34c2-4438-b61b-699135f0f85a" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesBetween150000And230000Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesBetween150000And230000Member_7cf3fc7c-34c2-4438-b61b-699135f0f85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOver230000Member_78562d70-7360-4072-8c6a-ca97f390abf6" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesOver230000Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesOver230000Member_78562d70-7360-4072-8c6a-ca97f390abf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesUnder15BillionMember_8d2201e3-b026-4067-af4e-0acd718830e0" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesUnder15BillionMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesUnder15BillionMember_8d2201e3-b026-4067-af4e-0acd718830e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesBetween15And3BillionsMember_460e6bf6-333e-4d8d-b527-1ec5908bc167" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesBetween15And3BillionsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesBetween15And3BillionsMember_460e6bf6-333e-4d8d-b527-1ec5908bc167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualNetSalesOver3BillionsMember_5cb6c88d-be93-4874-ba9f-e94f27ee2943" xlink:href="bcrx-20220930.xsd#bcrx_AnnualNetSalesOver3BillionsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_AnnualNetSalesRangeDomain_e970e54d-193b-48e6-856f-5949ee5c27ce" xlink:to="loc_bcrx_AnnualNetSalesOver3BillionsMember_5cb6c88d-be93-4874-ba9f-e94f27ee2943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_996e1b5c-f1a6-4340-b492-536bb028368e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_srt_RangeAxis_996e1b5c-f1a6-4340-b492-536bb028368e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5674736-6fb8-4592-826c-3af41f31d7a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_996e1b5c-f1a6-4340-b492-536bb028368e" xlink:to="loc_srt_RangeMember_a5674736-6fb8-4592-826c-3af41f31d7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_88f241c6-5aa7-49f3-b320-f279501798a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a5674736-6fb8-4592-826c-3af41f31d7a5" xlink:to="loc_srt_MinimumMember_88f241c6-5aa7-49f3-b320-f279501798a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_feffa3ef-4abe-4f6c-a585-68fbcd4ef36d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a5674736-6fb8-4592-826c-3af41f31d7a5" xlink:to="loc_srt_MaximumMember_feffa3ef-4abe-4f6c-a585-68fbcd4ef36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyMonetizationsLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_b0e57339-aa8d-4701-a93c-7190b8c8c86c" xlink:to="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8a3be7e1-aaf3-4cef-bf1a-b715146b1bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8a3be7e1-aaf3-4cef-bf1a-b715146b1bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_7e72ef51-22d1-44f3-8673-3d17d7b3cc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_7e72ef51-22d1-44f3-8673-3d17d7b3cc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TransactionCosts_b4eed3c6-7cb9-4016-8994-6214ee51955b" xlink:href="bcrx-20220930.xsd#bcrx_TransactionCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_TransactionCosts_b4eed3c6-7cb9-4016-8994-6214ee51955b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InterestReserve_97966c1d-df1b-4774-af1f-cdd2ea43422b" xlink:href="bcrx-20220930.xsd#bcrx_InterestReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_InterestReserve_97966c1d-df1b-4774-af1f-cdd2ea43422b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PrivatePlacementOfSeniorSecuredNotes_0fa7df88-7229-4fbd-bf33-2836e5b479ec" xlink:href="bcrx-20220930.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_PrivatePlacementOfSeniorSecuredNotes_0fa7df88-7229-4fbd-bf33-2836e5b479ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_95f3cf8e-5490-4d3f-97a6-90afa558c188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_95f3cf8e-5490-4d3f-97a6-90afa558c188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_524db925-2f39-4395-927e-3165abb3f082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_SecuredDebt_524db925-2f39-4395-927e-3165abb3f082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_c21394c3-2629-41f9-8adb-c340bd475153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_c21394c3-2629-41f9-8adb-c340bd475153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_99b0a752-603e-4f57-ba8a-3778840d621c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_99b0a752-603e-4f57-ba8a-3778840d621c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ceb87e60-70f8-4d50-9aa7-ceb1bdee6a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ceb87e60-70f8-4d50-9aa7-ceb1bdee6a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_f195a396-0418-4f23-872b-2f6f1097c615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_f195a396-0418-4f23-872b-2f6f1097c615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories_5898e222-e2d1-4fa2-8302-a7212786c571" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories_5898e222-e2d1-4fa2-8302-a7212786c571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales_7bf75bf1-14cc-49d1-a05b-2764e69d29cc" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales_7bf75bf1-14cc-49d1-a05b-2764e69d29cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets_5d2619aa-ebaf-4661-91e0-c7662b6ca176" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets_5d2619aa-ebaf-4661-91e0-c7662b6ca176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets_7073395c-1468-4a7d-b7ee-e2eeda62db97" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets_7073395c-1468-4a7d-b7ee-e2eeda62db97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold_c8959fdb-13d7-492c-8bf1-1204387f93ac" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold_c8959fdb-13d7-492c-8bf1-1204387f93ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets_b1fb4ed9-58be-4056-9bf1-8d0477bd4fe7" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets_b1fb4ed9-58be-4056-9bf1-8d0477bd4fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales_cfcda91a-a403-4a64-9d42-4a592d65fc24" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales_cfcda91a-a403-4a64-9d42-4a592d65fc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales_20173912-a9c6-4579-901d-cbf69bc017d5" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales_20173912-a9c6-4579-901d-cbf69bc017d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice_33b2a03a-5676-4af9-b2f6-e4405ff6eca7" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice_33b2a03a-5676-4af9-b2f6-e4405ff6eca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount_941d8dc0-fdbf-4b6b-b916-e708ec4d2c8e" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount_941d8dc0-fdbf-4b6b-b916-e708ec4d2c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_71972a73-8e42-4cc0-85b7-7cacdd074964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_71972a73-8e42-4cc0-85b7-7cacdd074964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharesIssuedCommonStockPremium_26e7069d-38e8-4fc1-beed-71702ad5fd0b" xlink:href="bcrx-20220930.xsd#bcrx_SharesIssuedCommonStockPremium"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_0666817a-286f-4b1a-9db3-942a7d9793cf" xlink:to="loc_bcrx_SharesIssuedCommonStockPremium_26e7069d-38e8-4fc1-beed-71702ad5fd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract_2b4544bb-0d29-47b9-8f14-119542f02393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltiesMonetizationsTable_d0c248e3-5f90-4ecc-899e-2b6054ff9169" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltiesMonetizationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_2b4544bb-0d29-47b9-8f14-119542f02393" xlink:to="loc_bcrx_RoyaltiesMonetizationsTable_d0c248e3-5f90-4ecc-899e-2b6054ff9169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fbf24708-d334-49d0-84b5-ec2232b3d353" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_d0c248e3-5f90-4ecc-899e-2b6054ff9169" xlink:to="loc_srt_CounterpartyNameAxis_fbf24708-d334-49d0-84b5-ec2232b3d353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a190c189-9ab1-469d-86e3-4ba30e8f8738" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fbf24708-d334-49d0-84b5-ec2232b3d353" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a190c189-9ab1-469d-86e3-4ba30e8f8738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TwentyTwentyRPIRoyaltyAgreementMember_b6be750f-6a41-44bf-a5f4-83393ed9aa17" xlink:href="bcrx-20220930.xsd#bcrx_TwentyTwentyRPIRoyaltyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a190c189-9ab1-469d-86e3-4ba30e8f8738" xlink:to="loc_bcrx_TwentyTwentyRPIRoyaltyAgreementMember_b6be750f-6a41-44bf-a5f4-83393ed9aa17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember_3bd24ffb-8f25-47d2-a2fa-d37b489f0591" xlink:href="bcrx-20220930.xsd#bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a190c189-9ab1-469d-86e3-4ba30e8f8738" xlink:to="loc_bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember_3bd24ffb-8f25-47d2-a2fa-d37b489f0591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OMERSRoyaltyAgreementMember_d0d826f6-5252-4f63-9bad-5850a0dc88fe" xlink:href="bcrx-20220930.xsd#bcrx_OMERSRoyaltyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a190c189-9ab1-469d-86e3-4ba30e8f8738" xlink:to="loc_bcrx_OMERSRoyaltyAgreementMember_d0d826f6-5252-4f63-9bad-5850a0dc88fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ce1cf9b4-19d1-42df-945d-225294ec2c80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_d0c248e3-5f90-4ecc-899e-2b6054ff9169" xlink:to="loc_srt_RangeAxis_ce1cf9b4-19d1-42df-945d-225294ec2c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_684e3195-5d9a-45a1-96f5-05f59ee74b88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ce1cf9b4-19d1-42df-945d-225294ec2c80" xlink:to="loc_srt_RangeMember_684e3195-5d9a-45a1-96f5-05f59ee74b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a01a7637-abf8-4831-90f3-46fd614657d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_684e3195-5d9a-45a1-96f5-05f59ee74b88" xlink:to="loc_srt_MaximumMember_a01a7637-abf8-4831-90f3-46fd614657d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_be6ea88c-0f3c-4b65-8345-e9571f34dd12" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_684e3195-5d9a-45a1-96f5-05f59ee74b88" xlink:to="loc_srt_MinimumMember_be6ea88c-0f3c-4b65-8345-e9571f34dd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMonetizationsLineItems_2ac737ca-c73d-4020-b41a-ab0fc997e171" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyMonetizationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltiesMonetizationsTable_d0c248e3-5f90-4ecc-899e-2b6054ff9169" xlink:to="loc_bcrx_RoyaltyMonetizationsLineItems_2ac737ca-c73d-4020-b41a-ab0fc997e171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyMontizationsRollForward_4b8695c3-672d-415d-956d-07a6248bd0b9" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyMontizationsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMonetizationsLineItems_2ac737ca-c73d-4020-b41a-ab0fc997e171" xlink:to="loc_bcrx_RoyaltyMontizationsRollForward_4b8695c3-672d-415d-956d-07a6248bd0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FutureRoyaltiesPayable_2ed8c769-d275-4559-84e5-57e9490d0eb5" xlink:href="bcrx-20220930.xsd#bcrx_FutureRoyaltiesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b8695c3-672d-415d-956d-07a6248bd0b9" xlink:to="loc_bcrx_FutureRoyaltiesPayable_2ed8c769-d275-4559-84e5-57e9490d0eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_5b730492-eba9-4988-b1d6-dfb183f6e1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b8695c3-672d-415d-956d-07a6248bd0b9" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_5b730492-eba9-4988-b1d6-dfb183f6e1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation_c67df09e-f866-4918-8c15-2d10e0a1e58a" xlink:href="bcrx-20220930.xsd#bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b8695c3-672d-415d-956d-07a6248bd0b9" xlink:to="loc_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation_c67df09e-f866-4918-8c15-2d10e0a1e58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltiesRevenuesPaidAndPayable_32fb89f6-077d-46bc-80d2-ceda557f2ca1" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltiesRevenuesPaidAndPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b8695c3-672d-415d-956d-07a6248bd0b9" xlink:to="loc_bcrx_RoyaltiesRevenuesPaidAndPayable_32fb89f6-077d-46bc-80d2-ceda557f2ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_FutureRoyaltiesPayable_0af31dc0-bcc4-4817-8913-299ac7f6c144" xlink:href="bcrx-20220930.xsd#bcrx_FutureRoyaltiesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b8695c3-672d-415d-956d-07a6248bd0b9" xlink:to="loc_bcrx_FutureRoyaltiesPayable_0af31dc0-bcc4-4817-8913-299ac7f6c144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ee9d31ec-7148-41fd-b335-07ab4a08fe22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_RoyaltyMontizationsRollForward_4b8695c3-672d-415d-956d-07a6248bd0b9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ee9d31ec-7148-41fd-b335-07ab4a08fe22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/DebtDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#DebtDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d9d77997-4e66-4b18-8baa-6ba40359ae82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d9d77997-4e66-4b18-8baa-6ba40359ae82" xlink:to="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4e705315-b613-45e2-9025-43e3184d6e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:to="loc_us-gaap_DebtInstrumentAxis_4e705315-b613-45e2-9025-43e3184d6e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_46363050-0f03-420c-904f-d399f3c5072d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4e705315-b613-45e2-9025-43e3184d6e97" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_46363050-0f03-420c-904f-d399f3c5072d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CreditAgreementMember_bc461ac7-87f5-4290-994d-9a919f47c8e0" xlink:href="bcrx-20220930.xsd#bcrx_CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46363050-0f03-420c-904f-d399f3c5072d" xlink:to="loc_bcrx_CreditAgreementMember_bc461ac7-87f5-4290-994d-9a919f47c8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_df1eb3f4-34aa-458d-a6b8-d769822fecfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_df1eb3f4-34aa-458d-a6b8-d769822fecfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_67fba284-b4ca-430e-9b3f-41b2d3246c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_df1eb3f4-34aa-458d-a6b8-d769822fecfb" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_67fba284-b4ca-430e-9b3f-41b2d3246c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AthyriumMember_6482e203-19e1-4df6-ad97-aa4f76cf6142" xlink:href="bcrx-20220930.xsd#bcrx_AthyriumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_67fba284-b4ca-430e-9b3f-41b2d3246c2c" xlink:to="loc_bcrx_AthyriumMember_6482e203-19e1-4df6-ad97-aa4f76cf6142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MidCapFinancialServicesLLCMember_e23103b4-8842-4805-8487-e36cca9a4ee8" xlink:href="bcrx-20220930.xsd#bcrx_MidCapFinancialServicesLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_67fba284-b4ca-430e-9b3f-41b2d3246c2c" xlink:to="loc_bcrx_MidCapFinancialServicesLLCMember_e23103b4-8842-4805-8487-e36cca9a4ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e7004351-28bb-4b49-b618-5397b0945755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e7004351-28bb-4b49-b618-5397b0945755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_847d4500-cb34-4fa4-90cc-d7017736c063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e7004351-28bb-4b49-b618-5397b0945755" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_847d4500-cb34-4fa4-90cc-d7017736c063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermALoanMember_06e45344-3770-45da-bebc-4bcaf04993b0" xlink:href="bcrx-20220930.xsd#bcrx_TermALoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_847d4500-cb34-4fa4-90cc-d7017736c063" xlink:to="loc_bcrx_TermALoanMember_06e45344-3770-45da-bebc-4bcaf04993b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermBLoanMember_48b01f01-3447-471e-8634-f523b39ef5e7" xlink:href="bcrx-20220930.xsd#bcrx_TermBLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_847d4500-cb34-4fa4-90cc-d7017736c063" xlink:to="loc_bcrx_TermBLoanMember_48b01f01-3447-471e-8634-f523b39ef5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermCLoanMember_e7d7eccf-9253-4156-aff1-206f21947734" xlink:href="bcrx-20220930.xsd#bcrx_TermCLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_847d4500-cb34-4fa4-90cc-d7017736c063" xlink:to="loc_bcrx_TermCLoanMember_e7d7eccf-9253-4156-aff1-206f21947734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermBAndCLoanMember_54cb1968-e703-4197-9eca-248baf7bb4c9" xlink:href="bcrx-20220930.xsd#bcrx_TermBAndCLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_847d4500-cb34-4fa4-90cc-d7017736c063" xlink:to="loc_bcrx_TermBAndCLoanMember_54cb1968-e703-4197-9eca-248baf7bb4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_0e1af7fd-ea8e-4e29-9973-cd720267d273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:to="loc_us-gaap_CreditFacilityAxis_0e1af7fd-ea8e-4e29-9973-cd720267d273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5fb83774-18f3-4384-9801-e90f9159c398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_0e1af7fd-ea8e-4e29-9973-cd720267d273" xlink:to="loc_us-gaap_CreditFacilityDomain_5fb83774-18f3-4384-9801-e90f9159c398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SeniorCreditFacilityMember_b565b3dc-f9ae-4ddf-8cfc-abc74ed42978" xlink:href="bcrx-20220930.xsd#bcrx_SeniorCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5fb83774-18f3-4384-9801-e90f9159c398" xlink:to="loc_bcrx_SeniorCreditFacilityMember_b565b3dc-f9ae-4ddf-8cfc-abc74ed42978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_4d4dbf39-2195-42fc-bef1-01f6bdb000b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:to="loc_us-gaap_VariableRateAxis_4d4dbf39-2195-42fc-bef1-01f6bdb000b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f6637017-08c0-4e9e-9cf3-8d45aee72835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_4d4dbf39-2195-42fc-bef1-01f6bdb000b2" xlink:to="loc_us-gaap_VariableRateDomain_f6637017-08c0-4e9e-9cf3-8d45aee72835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a5f9ab42-7e06-4057-ac61-9a75f5043dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_f6637017-08c0-4e9e-9cf3-8d45aee72835" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a5f9ab42-7e06-4057-ac61-9a75f5043dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtCovenantTermsAxis_d74781aa-ef69-4dd8-ae49-a3a2366dfbde" xlink:href="bcrx-20220930.xsd#bcrx_DebtCovenantTermsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:to="loc_bcrx_DebtCovenantTermsAxis_d74781aa-ef69-4dd8-ae49-a3a2366dfbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:href="bcrx-20220930.xsd#bcrx_DebtCovenantTermsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_DebtCovenantTermsAxis_d74781aa-ef69-4dd8-ae49-a3a2366dfbde" xlink:to="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PikInterestPaymentIsMadeMember_538cd664-f750-4256-a692-73a27caff5f6" xlink:href="bcrx-20220930.xsd#bcrx_PikInterestPaymentIsMadeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_PikInterestPaymentIsMadeMember_538cd664-f750-4256-a692-73a27caff5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PriorToTheSecondAnniversaryMember_4142efaa-ea0d-4f01-8dfe-4acf3baeb27a" xlink:href="bcrx-20220930.xsd#bcrx_PriorToTheSecondAnniversaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_PriorToTheSecondAnniversaryMember_4142efaa-ea0d-4f01-8dfe-4acf3baeb27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BetweenTheSecondAndThirdAnniversariesMember_89f1b34a-2490-412e-8fba-470dedae9668" xlink:href="bcrx-20220930.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_BetweenTheSecondAndThirdAnniversariesMember_89f1b34a-2490-412e-8fba-470dedae9668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BetweenTheThirdAndFourthAnniversariesMember_68fb44c3-62d9-4f98-bb7d-ecd6fa9fe25e" xlink:href="bcrx-20220930.xsd#bcrx_BetweenTheThirdAndFourthAnniversariesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_BetweenTheThirdAndFourthAnniversariesMember_68fb44c3-62d9-4f98-bb7d-ecd6fa9fe25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AfterFourthAnniversaryMember_65a52114-2fea-4375-b3d7-1c3c9c4781cf" xlink:href="bcrx-20220930.xsd#bcrx_AfterFourthAnniversaryMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_AfterFourthAnniversaryMember_65a52114-2fea-4375-b3d7-1c3c9c4781cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanADrawnMember_45ec2c08-8fa6-4b48-990e-b8968c70dd9c" xlink:href="bcrx-20220930.xsd#bcrx_TermLoanADrawnMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_TermLoanADrawnMember_45ec2c08-8fa6-4b48-990e-b8968c70dd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoanAAndBDrawnMember_871f869a-aac3-48d9-a80d-fc5cbaeead54" xlink:href="bcrx-20220930.xsd#bcrx_TermLoanAAndBDrawnMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_TermLoanAAndBDrawnMember_871f869a-aac3-48d9-a80d-fc5cbaeead54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoansABAndCDrawnMember_18179d1a-81fa-4bac-9715-8566092cc32a" xlink:href="bcrx-20220930.xsd#bcrx_TermLoansABAndCDrawnMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_TermLoansABAndCDrawnMember_18179d1a-81fa-4bac-9715-8566092cc32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember_c59e9ccc-46de-48f3-aa7f-d0fa1a3e751a" xlink:href="bcrx-20220930.xsd#bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_DebtCovenantTermsDomain_4972c3a4-e9ff-4f06-8a7f-2ee82cf39594" xlink:to="loc_bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember_c59e9ccc-46de-48f3-aa7f-d0fa1a3e751a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d5d57552-37f6-4e10-b682-691975496d50" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c96a1193-fbd3-44ab-a352-2cf1cbc11c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c96a1193-fbd3-44ab-a352-2cf1cbc11c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7a335bca-020e-4009-8c0c-bdc82ab2d814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7a335bca-020e-4009-8c0c-bdc82ab2d814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_d76a0c30-721b-4dc4-aa7f-deae36bb2242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_d76a0c30-721b-4dc4-aa7f-deae36bb2242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentLiborFloor_6d637861-1999-45be-9cdb-8ab4f346a6d2" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentLiborFloor"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_bcrx_DebtInstrumentLiborFloor_6d637861-1999-45be-9cdb-8ab4f346a6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentLiborCap_bfda690d-fdf6-465b-a737-a1cad3d0ecd1" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentLiborCap"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_bcrx_DebtInstrumentLiborCap_bfda690d-fdf6-465b-a737-a1cad3d0ecd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ea2cb046-ed69-48b8-8796-3f38a0da504f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ea2cb046-ed69-48b8-8796-3f38a0da504f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments_20727c30-460c-44c0-afe5-e57672815696" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments_20727c30-460c-44c0-afe5-e57672815696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest_67eecbbc-bc10-482f-8123-a9c3048ffc59" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest_67eecbbc-bc10-482f-8123-a9c3048ffc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentExitFeePercentageOfPrincipal_4b3dabfd-1b63-44e0-b80e-2b0d66c33fff" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentExitFeePercentageOfPrincipal"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_bcrx_DebtInstrumentExitFeePercentageOfPrincipal_4b3dabfd-1b63-44e0-b80e-2b0d66c33fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentCommitmentFeePercentage_448addac-79d2-421d-98cb-018f421cd2d6" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentCommitmentFeePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_bcrx_DebtInstrumentCommitmentFeePercentage_448addac-79d2-421d-98cb-018f421cd2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents_1664d2e9-e18a-4aa2-8cfb-33f1fef2dc85" xlink:href="bcrx-20220930.xsd#bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents_1664d2e9-e18a-4aa2-8cfb-33f1fef2dc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_26ecc9c2-c59e-4515-b754-25a5bb39e383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_26ecc9c2-c59e-4515-b754-25a5bb39e383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_46717632-fe3b-4fb6-ac59-66b7ff270be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_PaidInKindInterest_46717632-fe3b-4fb6-ac59-66b7ff270be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_726e56b1-2c46-407e-adf9-66e20c7bf055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_LongTermDebt_726e56b1-2c46-407e-adf9-66e20c7bf055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a2a871e7-5814-4160-b01b-82c15b86e39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a2a871e7-5814-4160-b01b-82c15b86e39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_25db6288-5f55-44a4-9d0e-7686b0f3939c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_25db6288-5f55-44a4-9d0e-7686b0f3939c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b0a7e513-1b2a-4c57-ab91-400f84f9a836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3b6aa8-107f-440a-8def-b64139375454" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b0a7e513-1b2a-4c57-ab91-400f84f9a836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsDetailsTextual" xlink:type="simple" xlink:href="bcrx-20220930.xsd#LeaseObligationsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c4290e24-9e4b-4d24-b162-ea12bf3a5439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_aff042da-7a1c-430c-887a-38ea4ebc275f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c4290e24-9e4b-4d24-b162-ea12bf3a5439" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_aff042da-7a1c-430c-887a-38ea4ebc275f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b61498ef-4514-4c71-8234-2466391b9635" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aff042da-7a1c-430c-887a-38ea4ebc275f" xlink:to="loc_srt_RangeAxis_b61498ef-4514-4c71-8234-2466391b9635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1d910d6-2c56-4022-86d2-d0e62a1aac86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b61498ef-4514-4c71-8234-2466391b9635" xlink:to="loc_srt_RangeMember_b1d910d6-2c56-4022-86d2-d0e62a1aac86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a2fd9f2-f051-4deb-8f42-9478d4591883" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b1d910d6-2c56-4022-86d2-d0e62a1aac86" xlink:to="loc_srt_MinimumMember_6a2fd9f2-f051-4deb-8f42-9478d4591883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_15fe61a9-f1c2-4f6b-b20a-880db3b2c7a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b1d910d6-2c56-4022-86d2-d0e62a1aac86" xlink:to="loc_srt_MaximumMember_15fe61a9-f1c2-4f6b-b20a-880db3b2c7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4763c864-71d1-4883-b05b-ce5ce7a108e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aff042da-7a1c-430c-887a-38ea4ebc275f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_4763c864-71d1-4883-b05b-ce5ce7a108e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_58138ea6-5957-4a2c-a354-f9d4147337ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4763c864-71d1-4883-b05b-ce5ce7a108e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_58138ea6-5957-4a2c-a354-f9d4147337ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_311b3d99-c405-4da4-bef2-090067a78ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4763c864-71d1-4883-b05b-ce5ce7a108e9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_311b3d99-c405-4da4-bef2-090067a78ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_571bee16-0e9b-4b1a-acdf-ddd7cabadeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4763c864-71d1-4883-b05b-ce5ce7a108e9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_571bee16-0e9b-4b1a-acdf-ddd7cabadeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization_7b081cc2-323c-4201-a1d7-6812b9ef8b9f" xlink:href="bcrx-20220930.xsd#bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4763c864-71d1-4883-b05b-ce5ce7a108e9" xlink:to="loc_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization_7b081cc2-323c-4201-a1d7-6812b9ef8b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_f765658b-a2bc-4ecf-bbb3-ba6d0fa9fa65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4763c864-71d1-4883-b05b-ce5ce7a108e9" xlink:to="loc_us-gaap_OperatingLeasePayments_f765658b-a2bc-4ecf-bbb3-ba6d0fa9fa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_81098b49-4b83-4ade-94d4-d9f037aba0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AggregateLeaseExpense_92c6ba75-7cf1-4e92-a9c8-2ae68c752b2e" xlink:href="bcrx-20220930.xsd#bcrx_AggregateLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_81098b49-4b83-4ade-94d4-d9f037aba0c4" xlink:to="loc_bcrx_AggregateLeaseExpense_92c6ba75-7cf1-4e92-a9c8-2ae68c752b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9c4375f2-108b-44da-ba32-b10fcbdecb19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_483cc6cd-e3cf-402d-8504-d84c0e00d3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9c4375f2-108b-44da-ba32-b10fcbdecb19" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_483cc6cd-e3cf-402d-8504-d84c0e00d3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_adf2eee1-af8d-41e2-ae8f-461570f95b11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9c4375f2-108b-44da-ba32-b10fcbdecb19" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_adf2eee1-af8d-41e2-ae8f-461570f95b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_46ab9748-1245-4f1c-80e2-a339c0f707af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_OperatingLeaseAssets_60f000f0-8a64-4979-ab1e-a5ab0d55af0e" xlink:href="bcrx-20220930.xsd#bcrx_OperatingLeaseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_46ab9748-1245-4f1c-80e2-a339c0f707af" xlink:to="loc_bcrx_OperatingLeaseAssets_60f000f0-8a64-4979-ab1e-a5ab0d55af0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b8f5e68-17d8-4130-a905-b36360569ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_OperatingLeaseAssets_60f000f0-8a64-4979-ab1e-a5ab0d55af0e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b8f5e68-17d8-4130-a905-b36360569ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6b1fcc64-4744-4ec8-9918-abad879aa870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bcrx_OperatingLeaseAssets_60f000f0-8a64-4979-ab1e-a5ab0d55af0e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6b1fcc64-4744-4ec8-9918-abad879aa870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_85c57bc2-f4f3-4ccb-9145-942360993d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_46ab9748-1245-4f1c-80e2-a339c0f707af" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_85c57bc2-f4f3-4ccb-9145-942360993d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bc76ed09-5890-4da7-b5d9-f4c13349f309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_85c57bc2-f4f3-4ccb-9145-942360993d9f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bc76ed09-5890-4da7-b5d9-f4c13349f309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_be7e2d14-04b1-4bee-8bb0-bfffece62a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_85c57bc2-f4f3-4ccb-9145-942360993d9f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_be7e2d14-04b1-4bee-8bb0-bfffece62a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_479ea482-4f6f-4852-92e2-3fcb51a7f1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_85c57bc2-f4f3-4ccb-9145-942360993d9f" xlink:to="loc_us-gaap_OperatingLeaseLiability_479ea482-4f6f-4852-92e2-3fcb51a7f1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1ac05a16-8423-429d-a76c-376cf84e190a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f4bbecc4-38c9-4156-b0a5-eba67a3396ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ac05a16-8423-429d-a76c-376cf84e190a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f4bbecc4-38c9-4156-b0a5-eba67a3396ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9406e913-e6f3-4ae3-a530-afee996521e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ac05a16-8423-429d-a76c-376cf84e190a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9406e913-e6f3-4ae3-a530-afee996521e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_40cb4d92-922a-45d3-b158-1886124af4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ac05a16-8423-429d-a76c-376cf84e190a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_40cb4d92-922a-45d3-b158-1886124af4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d19a200b-e688-4a2d-ad48-58c872fb6f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ac05a16-8423-429d-a76c-376cf84e190a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d19a200b-e688-4a2d-ad48-58c872fb6f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ff7306c1-899a-4f00-bb0f-cfb0c3cc98a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ac05a16-8423-429d-a76c-376cf84e190a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ff7306c1-899a-4f00-bb0f-cfb0c3cc98a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_d692b6f1-3564-45fa-b512-6022d2f011df" xlink:href="bcrx-20220930.xsd#bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ac05a16-8423-429d-a76c-376cf84e190a" xlink:to="loc_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_d692b6f1-3564-45fa-b512-6022d2f011df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_26502302-d30a-4328-8b55-5b8c48d848c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ac05a16-8423-429d-a76c-376cf84e190a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_26502302-d30a-4328-8b55-5b8c48d848c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ec397de7-6659-4c21-bfe5-710b4d07ff96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ac05a16-8423-429d-a76c-376cf84e190a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ec397de7-6659-4c21-bfe5-710b4d07ff96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_17531a11-de3b-4fca-a732-befd7c6739f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ac05a16-8423-429d-a76c-376cf84e190a" xlink:to="loc_us-gaap_OperatingLeaseLiability_17531a11-de3b-4fca-a732-befd7c6739f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_85225dc3-1998-4a37-8aee-657598fa94a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1ac05a16-8423-429d-a76c-376cf84e190a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_85225dc3-1998-4a37-8aee-657598fa94a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_bef4cc26-c4ab-497f-8c55-34312bc47a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_befb9441-f43c-4fc1-8671-b60f2d3c4f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_bef4cc26-c4ab-497f-8c55-34312bc47a06" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_befb9441-f43c-4fc1-8671-b60f2d3c4f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7701357a-ebe1-41f5-a69c-45a9b491ec13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_befb9441-f43c-4fc1-8671-b60f2d3c4f69" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7701357a-ebe1-41f5-a69c-45a9b491ec13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3adfeff0-47c7-4cb2-804d-366ba3b56d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7701357a-ebe1-41f5-a69c-45a9b491ec13" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3adfeff0-47c7-4cb2-804d-366ba3b56d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CommonStockPurchaseAgreementWithRPIMember_11d8b12f-f8d7-4f64-a80b-c85f9a8cecfd" xlink:href="bcrx-20220930.xsd#bcrx_CommonStockPurchaseAgreementWithRPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3adfeff0-47c7-4cb2-804d-366ba3b56d67" xlink:to="loc_bcrx_CommonStockPurchaseAgreementWithRPIMember_11d8b12f-f8d7-4f64-a80b-c85f9a8cecfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_befb9441-f43c-4fc1-8671-b60f2d3c4f69" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaximumAggregateOfferingPrice_9cda05fd-336a-4b75-8607-504e2c28df22" xlink:href="bcrx-20220930.xsd#bcrx_MaximumAggregateOfferingPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:to="loc_bcrx_MaximumAggregateOfferingPrice_9cda05fd-336a-4b75-8607-504e2c28df22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8bbb3704-b0a5-457c-be61-c510be195e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8bbb3704-b0a5-457c-be61-c510be195e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_daad3fef-1353-48e2-a270-060655c18cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_daad3fef-1353-48e2-a270-060655c18cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_2b567e0f-b57f-442c-8ff3-4341ee67218e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_2b567e0f-b57f-442c-8ff3-4341ee67218e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharesIssuedPricePerSharePremium_6ab26e24-3399-4468-8c01-5c1e78b86cf5" xlink:href="bcrx-20220930.xsd#bcrx_SharesIssuedPricePerSharePremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:to="loc_bcrx_SharesIssuedPricePerSharePremium_6ab26e24-3399-4468-8c01-5c1e78b86cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharesIssuedPricePerShareClosingPrice_2225a961-ce03-41fb-89e7-318d19716f18" xlink:href="bcrx-20220930.xsd#bcrx_SharesIssuedPricePerShareClosingPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:to="loc_bcrx_SharesIssuedPricePerShareClosingPrice_2225a961-ce03-41fb-89e7-318d19716f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharesIssuedCommonStockPremium_716e6a60-187a-4a40-89cb-b2bc2d75e004" xlink:href="bcrx-20220930.xsd#bcrx_SharesIssuedCommonStockPremium"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6db4ba28-457c-4f65-87ec-e5e234abc9ec" xlink:to="loc_bcrx_SharesIssuedCommonStockPremium_716e6a60-187a-4a40-89cb-b2bc2d75e004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationDetailsTextual" xlink:type="simple" xlink:href="bcrx-20220930.xsd#StockbasedCompensationDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_417c2cb7-e505-4835-9631-ee06f2d3fa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a75eda43-0da2-4e24-aaaa-3cdc703c1de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_417c2cb7-e505-4835-9631-ee06f2d3fa1b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a75eda43-0da2-4e24-aaaa-3cdc703c1de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_47d43e4f-6233-4e7d-919d-f2612a9f4d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a75eda43-0da2-4e24-aaaa-3cdc703c1de1" xlink:to="loc_us-gaap_PlanNameAxis_47d43e4f-6233-4e7d-919d-f2612a9f4d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c4b376dd-a021-4e5b-a05e-0efbfc136311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_47d43e4f-6233-4e7d-919d-f2612a9f4d8b" xlink:to="loc_us-gaap_PlanNameDomain_c4b376dd-a021-4e5b-a05e-0efbfc136311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_5f1697b7-7b9f-474a-ae7a-edaa6b0a0be8" xlink:href="bcrx-20220930.xsd#bcrx_IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c4b376dd-a021-4e5b-a05e-0efbfc136311" xlink:to="loc_bcrx_IncentivePlanMember_5f1697b7-7b9f-474a-ae7a-edaa6b0a0be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_fd04debd-6fad-49c5-9131-542b1f682699" xlink:href="bcrx-20220930.xsd#bcrx_InducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c4b376dd-a021-4e5b-a05e-0efbfc136311" xlink:to="loc_bcrx_InducementPlanMember_fd04debd-6fad-49c5-9131-542b1f682699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeStockPurchasePlanMember_657e96a0-7dce-4cc4-8c86-ba8aa990f5a2" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c4b376dd-a021-4e5b-a05e-0efbfc136311" xlink:to="loc_bcrx_EmployeeStockPurchasePlanMember_657e96a0-7dce-4cc4-8c86-ba8aa990f5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2620a9b0-f555-40d7-8950-a9841be42188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a75eda43-0da2-4e24-aaaa-3cdc703c1de1" xlink:to="loc_us-gaap_AwardTypeAxis_2620a9b0-f555-40d7-8950-a9841be42188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a18b372-2036-4150-97b1-93c6143f96a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2620a9b0-f555-40d7-8950-a9841be42188" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a18b372-2036-4150-97b1-93c6143f96a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_812eb369-2912-4e68-821b-64f7a109fc45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a18b372-2036-4150-97b1-93c6143f96a3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_812eb369-2912-4e68-821b-64f7a109fc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7e3d8ebb-6590-4d12-a0b9-5d16774bcc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a18b372-2036-4150-97b1-93c6143f96a3" xlink:to="loc_us-gaap_PerformanceSharesMember_7e3d8ebb-6590-4d12-a0b9-5d16774bcc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PerformancebasedRestrictedStockUnitsMember_9e21da00-02f6-4430-94a3-6af372ba3786" xlink:href="bcrx-20220930.xsd#bcrx_PerformancebasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a18b372-2036-4150-97b1-93c6143f96a3" xlink:to="loc_bcrx_PerformancebasedRestrictedStockUnitsMember_9e21da00-02f6-4430-94a3-6af372ba3786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_33564f6e-d0e1-4de8-97a4-875ccf0feb10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a18b372-2036-4150-97b1-93c6143f96a3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_33564f6e-d0e1-4de8-97a4-875ccf0feb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_b1fb761d-8fb4-4d49-83b4-425724c3e0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a75eda43-0da2-4e24-aaaa-3cdc703c1de1" xlink:to="loc_us-gaap_VestingAxis_b1fb761d-8fb4-4d49-83b4-425724c3e0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_20031e8d-320c-4db4-8469-6da8135ad82b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_b1fb761d-8fb4-4d49-83b4-425724c3e0e0" xlink:to="loc_us-gaap_VestingDomain_20031e8d-320c-4db4-8469-6da8135ad82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_Vest25PercentEachYearUntilFullyVestedMember_5cf5eda2-998d-49f8-a5a7-d3364120ff84" xlink:href="bcrx-20220930.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_20031e8d-320c-4db4-8469-6da8135ad82b" xlink:to="loc_bcrx_Vest25PercentEachYearUntilFullyVestedMember_5cf5eda2-998d-49f8-a5a7-d3364120ff84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember_e7368a84-b9f1-4161-96ca-9d8b6dc38e50" xlink:href="bcrx-20220930.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_20031e8d-320c-4db4-8469-6da8135ad82b" xlink:to="loc_bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember_e7368a84-b9f1-4161-96ca-9d8b6dc38e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2566e4cc-4272-4902-b929-ef6fc9b00f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_20031e8d-320c-4db4-8469-6da8135ad82b" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2566e4cc-4272-4902-b929-ef6fc9b00f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ThirtysixEqualMonthlyInstallmentsMember_a877d96e-742d-45a7-8aec-e3161b9f158b" xlink:href="bcrx-20220930.xsd#bcrx_ThirtysixEqualMonthlyInstallmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_20031e8d-320c-4db4-8469-6da8135ad82b" xlink:to="loc_bcrx_ThirtysixEqualMonthlyInstallmentsMember_a877d96e-742d-45a7-8aec-e3161b9f158b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_378319b4-f972-44a4-a58c-ac79ef4f9267" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a75eda43-0da2-4e24-aaaa-3cdc703c1de1" xlink:to="loc_srt_TitleOfIndividualAxis_378319b4-f972-44a4-a58c-ac79ef4f9267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e4535ff3-a098-48cb-a6ec-400c3a4c89e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_378319b4-f972-44a4-a58c-ac79ef4f9267" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e4535ff3-a098-48cb-a6ec-400c3a4c89e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NonEmployeeDirectorsMember_f7d895fd-3a6b-4da4-b5d5-f0635b74c4f7" xlink:href="bcrx-20220930.xsd#bcrx_NonEmployeeDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e4535ff3-a098-48cb-a6ec-400c3a4c89e5" xlink:to="loc_bcrx_NonEmployeeDirectorsMember_f7d895fd-3a6b-4da4-b5d5-f0635b74c4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3a015522-b493-4bc2-b68e-aa7d7b7bdded" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a75eda43-0da2-4e24-aaaa-3cdc703c1de1" xlink:to="loc_srt_RangeAxis_3a015522-b493-4bc2-b68e-aa7d7b7bdded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f70dc3b-d3ee-4814-9215-1a2ca6375437" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3a015522-b493-4bc2-b68e-aa7d7b7bdded" xlink:to="loc_srt_RangeMember_1f70dc3b-d3ee-4814-9215-1a2ca6375437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3506b42c-2bb4-4129-aacc-454c121027ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1f70dc3b-d3ee-4814-9215-1a2ca6375437" xlink:to="loc_srt_MaximumMember_3506b42c-2bb4-4129-aacc-454c121027ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a75eda43-0da2-4e24-aaaa-3cdc703c1de1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShareBasedPaymentArrangementNumberOfPlans_575f9c95-9fea-443c-97f5-85bb28ea8bd0" xlink:href="bcrx-20220930.xsd#bcrx_ShareBasedPaymentArrangementNumberOfPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_ShareBasedPaymentArrangementNumberOfPlans_575f9c95-9fea-443c-97f5-85bb28ea8bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9fe29d73-59f4-4718-947c-1bba7eeeb7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9fe29d73-59f4-4718-947c-1bba7eeeb7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d62ca596-988f-42ee-a757-32e579809e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d62ca596-988f-42ee-a757-32e579809e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear_214a7816-1532-4e75-80da-ba55981b6fc2" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear_214a7816-1532-4e75-80da-ba55981b6fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear_8a84914b-6682-4d06-a967-7e92ff8a4c91" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear_8a84914b-6682-4d06-a967-7e92ff8a4c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo_e6010a48-94a5-4c75-af59-bd22fe79370a" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo_e6010a48-94a5-4c75-af59-bd22fe79370a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree_677a7ddd-c858-4485-a58d-4ed8cdde63ce" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree_677a7ddd-c858-4485-a58d-4ed8cdde63ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour_728c45e3-0fd9-4dca-9a5f-b89608f30e47" xlink:href="bcrx-20220930.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour_728c45e3-0fd9-4dca-9a5f-b89608f30e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dc8b56b8-3dc2-4246-9675-77a3515f9947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dc8b56b8-3dc2-4246-9675-77a3515f9947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d75a92ca-7f5c-49bc-b4f7-f104fe10b41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d75a92ca-7f5c-49bc-b4f7-f104fe10b41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_608b5df2-4e09-4265-b3d6-2fe4c82242c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_608b5df2-4e09-4265-b3d6-2fe4c82242c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_306e45b7-0b39-4fa9-91f5-871d3029d18b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_306e45b7-0b39-4fa9-91f5-871d3029d18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_aeb6e5b0-ca9c-40d0-a5d4-a998b1372b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_aeb6e5b0-ca9c-40d0-a5d4-a998b1372b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a49de71e-e562-43c8-a567-8d9a0731f6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a49de71e-e562-43c8-a567-8d9a0731f6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7fff0da9-1078-48d8-b973-b00d5b74407f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7fff0da9-1078-48d8-b973-b00d5b74407f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c3f445b9-3a44-43bc-9898-ea9b3fabedba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c3f445b9-3a44-43bc-9898-ea9b3fabedba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3741c865-0d51-41a3-9b22-c7549fea621f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3741c865-0d51-41a3-9b22-c7549fea621f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9e87b737-9396-4b6c-af9e-1c79adc432ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9e87b737-9396-4b6c-af9e-1c79adc432ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_16a220ae-667a-43ab-a810-642d4b0e5af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_16a220ae-667a-43ab-a810-642d4b0e5af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum_6303dea1-7b84-4fdf-af89-b7e01721ce24" xlink:href="bcrx-20220930.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum_6303dea1-7b84-4fdf-af89-b7e01721ce24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PercentageOfCommonStockSharesBeginning_f0e35059-329f-4c01-b304-44929665b3c7" xlink:href="bcrx-20220930.xsd#bcrx_PercentageOfCommonStockSharesBeginning"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_PercentageOfCommonStockSharesBeginning_f0e35059-329f-4c01-b304-44929665b3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PercentageOfCommonStockSharesEnding_a25138ad-4385-45c2-a878-c1d56bbcfbdc" xlink:href="bcrx-20220930.xsd#bcrx_PercentageOfCommonStockSharesEnding"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_PercentageOfCommonStockSharesEnding_a25138ad-4385-45c2-a878-c1d56bbcfbdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_83c7437e-c045-440b-8540-69a1547b28b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_83c7437e-c045-440b-8540-69a1547b28b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount_081fe1dc-5f5b-49c9-9d07-3eb612d69bfc" xlink:href="bcrx-20220930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount_081fe1dc-5f5b-49c9-9d07-3eb612d69bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0c6a264b-1b15-4f8e-9071-d53c0d0b574d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b3246cd-ae0c-409b-9da1-2f437ea0f264" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0c6a264b-1b15-4f8e-9071-d53c0d0b574d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#StockbasedCompensationStockPlanActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_de02b347-1c77-4c8b-bf07-ac1e178eb7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e438690a-8dd2-42fa-a37a-b53c7ccba293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_de02b347-1c77-4c8b-bf07-ac1e178eb7ec" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e438690a-8dd2-42fa-a37a-b53c7ccba293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_91b3ab2a-9323-4d03-9427-d794805b6751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e438690a-8dd2-42fa-a37a-b53c7ccba293" xlink:to="loc_us-gaap_PlanNameAxis_91b3ab2a-9323-4d03-9427-d794805b6751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f98f3b8e-6e96-4109-a071-b84e3ef3cf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_91b3ab2a-9323-4d03-9427-d794805b6751" xlink:to="loc_us-gaap_PlanNameDomain_f98f3b8e-6e96-4109-a071-b84e3ef3cf7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanMember_0ea2e824-801d-4ac1-98f0-f2b04cc3bfc2" xlink:href="bcrx-20220930.xsd#bcrx_IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f98f3b8e-6e96-4109-a071-b84e3ef3cf7e" xlink:to="loc_bcrx_IncentivePlanMember_0ea2e824-801d-4ac1-98f0-f2b04cc3bfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_InducementPlanMember_4191e4a1-b755-4e36-8aca-11eb61c22a87" xlink:href="bcrx-20220930.xsd#bcrx_InducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f98f3b8e-6e96-4109-a071-b84e3ef3cf7e" xlink:to="loc_bcrx_InducementPlanMember_4191e4a1-b755-4e36-8aca-11eb61c22a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0df26004-1b91-4235-88f9-0b12fc9ce4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e438690a-8dd2-42fa-a37a-b53c7ccba293" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0df26004-1b91-4235-88f9-0b12fc9ce4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0df26004-1b91-4235-88f9-0b12fc9ce4f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e14fb474-321b-4e05-8719-00d7cbd24c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e14fb474-321b-4e05-8719-00d7cbd24c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares_60efb7a9-2f1f-40b6-bf78-6af2061b9c3b" xlink:href="bcrx-20220930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:to="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares_60efb7a9-2f1f-40b6-bf78-6af2061b9c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4008510a-c4f9-4909-8bb5-f0d4ff348f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4008510a-c4f9-4909-8bb5-f0d4ff348f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e667a5e3-f69b-4e78-b01e-cd5f256f0850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e667a5e3-f69b-4e78-b01e-cd5f256f0850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable_35d69600-eb63-4910-a599-c3731df4d051" xlink:href="bcrx-20220930.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:to="loc_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable_35d69600-eb63-4910-a599-c3731df4d051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable_d03fdf2b-93ab-46ea-a115-435102abada3" xlink:href="bcrx-20220930.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:to="loc_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable_d03fdf2b-93ab-46ea-a115-435102abada3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_644bf056-3a7e-4989-98a1-571dbe98d597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_b191ae88-10f1-4095-bd01-1200d87bcf2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_644bf056-3a7e-4989-98a1-571dbe98d597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa94229d-b470-4a00-a1c6-a615f2f04d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0df26004-1b91-4235-88f9-0b12fc9ce4f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa94229d-b470-4a00-a1c6-a615f2f04d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_32b147f7-5542-4cab-88e2-80d8d8c9a33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa94229d-b470-4a00-a1c6-a615f2f04d2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_32b147f7-5542-4cab-88e2-80d8d8c9a33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f9c0dc63-f99d-4a8d-9c7a-748bab9889e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa94229d-b470-4a00-a1c6-a615f2f04d2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f9c0dc63-f99d-4a8d-9c7a-748bab9889e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7bd3a1d5-9773-4897-b612-bf7e4e0cf7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa94229d-b470-4a00-a1c6-a615f2f04d2e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7bd3a1d5-9773-4897-b612-bf7e4e0cf7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_fd063132-b802-40cb-80b5-19ab5c75cf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa94229d-b470-4a00-a1c6-a615f2f04d2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_fd063132-b802-40cb-80b5-19ab5c75cf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bc24b592-85d1-44de-9ecb-6289dcd1b482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa94229d-b470-4a00-a1c6-a615f2f04d2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bc24b592-85d1-44de-9ecb-6289dcd1b482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2f12f093-b614-4493-984a-7bbffe8fc1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0df26004-1b91-4235-88f9-0b12fc9ce4f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2f12f093-b614-4493-984a-7bbffe8fc1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7e044850-9710-4510-a25d-22c0546a1657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2f12f093-b614-4493-984a-7bbffe8fc1de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7e044850-9710-4510-a25d-22c0546a1657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0c3efd8e-f4dd-4338-9821-ca3ca5339adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2f12f093-b614-4493-984a-7bbffe8fc1de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0c3efd8e-f4dd-4338-9821-ca3ca5339adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_66d7d6ef-7f1e-49d0-8578-b5ac58b99163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2f12f093-b614-4493-984a-7bbffe8fc1de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_66d7d6ef-7f1e-49d0-8578-b5ac58b99163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c29e05b8-05af-4cd1-8b42-afa4572d6a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2f12f093-b614-4493-984a-7bbffe8fc1de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c29e05b8-05af-4cd1-8b42-afa4572d6a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8dfa78d0-40f7-4262-8992-136d509c832d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_2f12f093-b614-4493-984a-7bbffe8fc1de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8dfa78d0-40f7-4262-8992-136d509c832d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5746737-8b9d-44a2-bcae-d3394d967687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6bb816be-f74c-494b-9952-8a8e0d041ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5746737-8b9d-44a2-bcae-d3394d967687" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6bb816be-f74c-494b-9952-8a8e0d041ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e55f85a0-100f-4c25-b315-5530af544a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6bb816be-f74c-494b-9952-8a8e0d041ec1" xlink:to="loc_us-gaap_PlanNameAxis_e55f85a0-100f-4c25-b315-5530af544a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fce7d0f5-3674-4004-8263-3103437a734d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e55f85a0-100f-4c25-b315-5530af544a43" xlink:to="loc_us-gaap_PlanNameDomain_fce7d0f5-3674-4004-8263-3103437a734d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_IncentivePlanAndInducementPlanMember_6f372b95-f1f1-4608-8cbf-f04685728bb9" xlink:href="bcrx-20220930.xsd#bcrx_IncentivePlanAndInducementPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fce7d0f5-3674-4004-8263-3103437a734d" xlink:to="loc_bcrx_IncentivePlanAndInducementPlanMember_6f372b95-f1f1-4608-8cbf-f04685728bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91f904da-abb2-4be1-a703-1c5fa064f76a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6bb816be-f74c-494b-9952-8a8e0d041ec1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91f904da-abb2-4be1-a703-1c5fa064f76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_37f026c5-3d67-409c-ab7c-303eeae90f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91f904da-abb2-4be1-a703-1c5fa064f76a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_37f026c5-3d67-409c-ab7c-303eeae90f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7648d052-9426-4fe5-a07c-7de81a8960c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91f904da-abb2-4be1-a703-1c5fa064f76a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7648d052-9426-4fe5-a07c-7de81a8960c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0d1c6072-c328-4014-b621-22e14e7b13a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91f904da-abb2-4be1-a703-1c5fa064f76a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0d1c6072-c328-4014-b621-22e14e7b13a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_aa6477bb-6e37-491c-94c0-c99ba344d5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91f904da-abb2-4be1-a703-1c5fa064f76a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_aa6477bb-6e37-491c-94c0-c99ba344d5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails" xlink:type="simple" xlink:href="bcrx-20220930.xsd#CollaborativeandOtherRelationshipsDetails"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f98f56d9-95e7-4c5c-95e9-fb0574956dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2051724d-1899-45ee-a3e3-ff5cc6e495b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f98f56d9-95e7-4c5c-95e9-fb0574956dfc" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2051724d-1899-45ee-a3e3-ff5cc6e495b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9c814e58-a043-4ef7-a93f-a6e52fecd5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2051724d-1899-45ee-a3e3-ff5cc6e495b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9c814e58-a043-4ef7-a93f-a6e52fecd5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_140e9d38-79c2-4136-996b-6040bf1b1bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9c814e58-a043-4ef7-a93f-a6e52fecd5c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_140e9d38-79c2-4136-996b-6040bf1b1bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_b8121800-cac2-43d6-9b4d-43a901a28cdd" xlink:href="bcrx-20220930.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_140e9d38-79c2-4136-996b-6040bf1b1bd9" xlink:to="loc_bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_b8121800-cac2-43d6-9b4d-43a901a28cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_UABMember_4535ab85-238e-4b21-a7a3-d0b36139349a" xlink:href="bcrx-20220930.xsd#bcrx_UABMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_140e9d38-79c2-4136-996b-6040bf1b1bd9" xlink:to="loc_bcrx_UABMember_4535ab85-238e-4b21-a7a3-d0b36139349a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6806b090-60c5-4c77-88c6-ae1aa0f7d864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2051724d-1899-45ee-a3e3-ff5cc6e495b9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6806b090-60c5-4c77-88c6-ae1aa0f7d864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_369b6cb6-4482-475e-9ffb-90168bb0a965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6806b090-60c5-4c77-88c6-ae1aa0f7d864" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_369b6cb6-4482-475e-9ffb-90168bb0a965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_BaseContractMember_e1ee616b-d2ff-46ac-84ff-9342a8de897d" xlink:href="bcrx-20220930.xsd#bcrx_BaseContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_369b6cb6-4482-475e-9ffb-90168bb0a965" xlink:to="loc_bcrx_BaseContractMember_e1ee616b-d2ff-46ac-84ff-9342a8de897d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AdditionalDevelopmentOptionsMember_99f500cb-c787-400d-8bb3-2b843c330d5c" xlink:href="bcrx-20220930.xsd#bcrx_AdditionalDevelopmentOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_369b6cb6-4482-475e-9ffb-90168bb0a965" xlink:to="loc_bcrx_AdditionalDevelopmentOptionsMember_99f500cb-c787-400d-8bb3-2b843c330d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ASPRBARDAContractMember_d881a3fa-96a4-43f1-b549-226a6a5560c1" xlink:href="bcrx-20220930.xsd#bcrx_ASPRBARDAContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_369b6cb6-4482-475e-9ffb-90168bb0a965" xlink:to="loc_bcrx_ASPRBARDAContractMember_d881a3fa-96a4-43f1-b549-226a6a5560c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AECOMAndIRLMember_b5c762a0-4809-43d2-a53c-2ef3257d1c0c" xlink:href="bcrx-20220930.xsd#bcrx_AECOMAndIRLMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_369b6cb6-4482-475e-9ffb-90168bb0a965" xlink:to="loc_bcrx_AECOMAndIRLMember_b5c762a0-4809-43d2-a53c-2ef3257d1c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b894e983-fc7c-402b-a50f-d41f47da76c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2051724d-1899-45ee-a3e3-ff5cc6e495b9" xlink:to="loc_srt_CounterpartyNameAxis_b894e983-fc7c-402b-a50f-d41f47da76c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32937a1f-7fd7-46fc-a35a-155bf135039e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b894e983-fc7c-402b-a50f-d41f47da76c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32937a1f-7fd7-46fc-a35a-155bf135039e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_USDepartmentOfHealthAndHumanServicesMember_ca1b3150-ed90-4813-8deb-a87439c1bdc7" xlink:href="bcrx-20220930.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32937a1f-7fd7-46fc-a35a-155bf135039e" xlink:to="loc_bcrx_USDepartmentOfHealthAndHumanServicesMember_ca1b3150-ed90-4813-8deb-a87439c1bdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ToriiPharmaceuticalCoMember_f81944ad-e892-4fb4-acae-9fd08eff710d" xlink:href="bcrx-20220930.xsd#bcrx_ToriiPharmaceuticalCoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32937a1f-7fd7-46fc-a35a-155bf135039e" xlink:to="loc_bcrx_ToriiPharmaceuticalCoMember_f81944ad-e892-4fb4-acae-9fd08eff710d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9529642e-df1a-4046-8ea2-a7ba2c2f3456" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2051724d-1899-45ee-a3e3-ff5cc6e495b9" xlink:to="loc_srt_ProductOrServiceAxis_9529642e-df1a-4046-8ea2-a7ba2c2f3456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d6818e00-2e4f-4734-bddf-fe7ae78e8035" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9529642e-df1a-4046-8ea2-a7ba2c2f3456" xlink:to="loc_srt_ProductsAndServicesDomain_d6818e00-2e4f-4734-bddf-fe7ae78e8035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RAPIVABMember_2ee436af-0c64-4ffc-b081-dce1a2fadfae" xlink:href="bcrx-20220930.xsd#bcrx_RAPIVABMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d6818e00-2e4f-4734-bddf-fe7ae78e8035" xlink:to="loc_bcrx_RAPIVABMember_2ee436af-0c64-4ffc-b081-dce1a2fadfae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a76811cd-d179-45da-8d0d-05c1df07f01c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2051724d-1899-45ee-a3e3-ff5cc6e495b9" xlink:to="loc_srt_RangeAxis_a76811cd-d179-45da-8d0d-05c1df07f01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_830f2664-65c6-41ff-9c6b-c685861e0374" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a76811cd-d179-45da-8d0d-05c1df07f01c" xlink:to="loc_srt_RangeMember_830f2664-65c6-41ff-9c6b-c685861e0374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6bc98784-5cd8-4396-ae22-97bcb2bb49e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_830f2664-65c6-41ff-9c6b-c685861e0374" xlink:to="loc_srt_MinimumMember_6bc98784-5cd8-4396-ae22-97bcb2bb49e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fbd6bd69-74b4-4672-a536-f5f70a635df1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_830f2664-65c6-41ff-9c6b-c685861e0374" xlink:to="loc_srt_MaximumMember_fbd6bd69-74b4-4672-a536-f5f70a635df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2051724d-1899-45ee-a3e3-ff5cc6e495b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts_518b7775-a263-4c2f-b6aa-5906f4baa44b" xlink:href="bcrx-20220930.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts_518b7775-a263-4c2f-b6aa-5906f4baa44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding_4052dd3d-01df-468d-9e75-044bd49b06b4" xlink:href="bcrx-20220930.xsd#bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding_4052dd3d-01df-468d-9e75-044bd49b06b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_CollaborativeAgreementContractValue_f9ba83a3-e76f-450e-b517-2ca7ff19f07c" xlink:href="bcrx-20220930.xsd#bcrx_CollaborativeAgreementContractValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_CollaborativeAgreementContractValue_f9ba83a3-e76f-450e-b517-2ca7ff19f07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractReceivable_03ed14b1-5ca8-4921-9738-c00ca9c0617d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_us-gaap_GovernmentContractReceivable_03ed14b1-5ca8-4921-9738-c00ca9c0617d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts_ee044f47-51d4-4107-b2f2-90646a7a986b" xlink:href="bcrx-20220930.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts_ee044f47-51d4-4107-b2f2-90646a7a986b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses_0f12c569-c0c3-4aa4-9722-0e072384d0fc" xlink:href="bcrx-20220930.xsd#bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses_0f12c569-c0c3-4aa4-9722-0e072384d0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_NumberOfProductsObtainedDoses_aed9fc07-9447-4289-a97d-c78077e42b0f" xlink:href="bcrx-20220930.xsd#bcrx_NumberOfProductsObtainedDoses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_NumberOfProductsObtainedDoses_aed9fc07-9447-4289-a97d-c78077e42b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_ContractTerm_fe5bff1c-980a-4162-9f9c-7948dc232243" xlink:href="bcrx-20220930.xsd#bcrx_ContractTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_ContractTerm_fe5bff1c-980a-4162-9f9c-7948dc232243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_7c70c8a4-ac1d-4ea9-a4f9-a5a6d25ef4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_us-gaap_ProceedsFromCollaborators_7c70c8a4-ac1d-4ea9-a4f9-a5a6d25ef4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_08f9a4f2-d7ae-40e0-a1e9-dea2322a2add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_08f9a4f2-d7ae-40e0-a1e9-dea2322a2add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone_ca182020-3a40-49fb-83a6-48e0d1312621" xlink:href="bcrx-20220930.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone_ca182020-3a40-49fb-83a6-48e0d1312621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation_496080e9-c3e1-47d8-9665-3b345dea3ca1" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyRateIfMaintainsSakigakeDesignation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation_496080e9-c3e1-47d8-9665-3b345dea3ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MaximumCustomaryReductionOnRoyaltyRate_43d25527-c4e0-4f5c-a3a6-e4d8bc67cacd" xlink:href="bcrx-20220930.xsd#bcrx_MaximumCustomaryReductionOnRoyaltyRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_MaximumCustomaryReductionOnRoyaltyRate_43d25527-c4e0-4f5c-a3a6-e4d8bc67cacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial_efcfd237-eebb-4b68-86da-f801263d3942" xlink:href="bcrx-20220930.xsd#bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial_efcfd237-eebb-4b68-86da-f801263d3942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MilestonePaymentMinimum_384fbdbe-f4d0-46d6-bb39-00ba69322e14" xlink:href="bcrx-20220930.xsd#bcrx_MilestonePaymentMinimum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_MilestonePaymentMinimum_384fbdbe-f4d0-46d6-bb39-00ba69322e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_MilestonePaymentMaximum_2cce2a98-0bfa-4072-b5c0-4d41f81f6fb9" xlink:href="bcrx-20220930.xsd#bcrx_MilestonePaymentMaximum"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_MilestonePaymentMaximum_2cce2a98-0bfa-4072-b5c0-4d41f81f6fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualLicenseFeeMinimum_9a597029-feba-4d31-b1f2-910243bef264" xlink:href="bcrx-20220930.xsd#bcrx_AnnualLicenseFeeMinimum"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_AnnualLicenseFeeMinimum_9a597029-feba-4d31-b1f2-910243bef264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_AnnualLicenseFeeMaximum_e058715f-43d2-434b-ae24-a89642626efa" xlink:href="bcrx-20220930.xsd#bcrx_AnnualLicenseFeeMaximum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_AnnualLicenseFeeMaximum_e058715f-43d2-434b-ae24-a89642626efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_PeriodOfAgreement_45714209-3e8e-436a-98a1-a0fbf52703e8" xlink:href="bcrx-20220930.xsd#bcrx_PeriodOfAgreement"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_PeriodOfAgreement_45714209-3e8e-436a-98a1-a0fbf52703e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bcrx_RenewablePeriodOfAgreement_3d1d28fd-5f56-4a46-9e11-8bb80c97bc77" xlink:href="bcrx-20220930.xsd#bcrx_RenewablePeriodOfAgreement"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_84ab1115-18fd-482a-ad95-e4a2fb05bb45" xlink:to="loc_bcrx_RenewablePeriodOfAgreement_3d1d28fd-5f56-4a46-9e11-8bb80c97bc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953851375744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOCRYST PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1413174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4505 Emperor Blvd., Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">859-1302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,423,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953852387184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 246,899<span></span>
</td>
<td class="nump">$ 504,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">1,444<span></span>
</td>
<td class="nump">3,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">179,959<span></span>
</td>
<td class="nump">3,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables</a></td>
<td class="nump">42,610<span></span>
</td>
<td class="nump">29,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">27,019<span></span>
</td>
<td class="nump">15,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,070<span></span>
</td>
<td class="nump">9,986<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">509,001<span></span>
</td>
<td class="nump">566,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,464<span></span>
</td>
<td class="nump">8,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">34,332<span></span>
</td>
<td class="nump">6,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,797<span></span>
</td>
<td class="nump">6,472<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">558,594<span></span>
</td>
<td class="nump">588,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,622<span></span>
</td>
<td class="nump">27,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">69,265<span></span>
</td>
<td class="nump">72,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,554<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease financing obligation</a></td>
<td class="nump">2,196<span></span>
</td>
<td class="nump">1,819<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">81,637<span></span>
</td>
<td class="nump">103,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease financing obligation</a></td>
<td class="nump">5,968<span></span>
</td>
<td class="nump">5,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Royalty financing obligations</a></td>
<td class="nump">489,781<span></span>
</td>
<td class="nump">449,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Secured term loan</a></td>
<td class="nump">223,867<span></span>
</td>
<td class="nump">136,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding &#8211; 186,411 as of September&#160;30, 2022 and 184,350 as of December&#160;31, 2021</a></td>
<td class="nump">1,864<span></span>
</td>
<td class="nump">1,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,138,654<span></span>
</td>
<td class="nump">1,098,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(98)<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,383,079)<span></span>
</td>
<td class="num">(1,207,504)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(242,659)<span></span>
</td>
<td class="num">(106,986)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 558,594<span></span>
</td>
<td class="nump">$ 588,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_FutureRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations for future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_FutureRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953851154112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">450,000,000<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">186,411,000<span></span>
</td>
<td class="nump">184,350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">186,411,000<span></span>
</td>
<td class="nump">184,350,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953849524768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 75,827<span></span>
</td>
<td class="nump">$ 40,994<span></span>
</td>
<td class="nump">$ 191,282<span></span>
</td>
<td class="nump">$ 110,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">3,543<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="nump">4,025<span></span>
</td>
<td class="nump">6,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">52,740<span></span>
</td>
<td class="nump">49,971<span></span>
</td>
<td class="nump">180,090<span></span>
</td>
<td class="nump">145,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">36,919<span></span>
</td>
<td class="nump">34,992<span></span>
</td>
<td class="nump">109,218<span></span>
</td>
<td class="nump">83,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyExpenseReversalOfExpense', window );">Royalty</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">93,272<span></span>
</td>
<td class="nump">85,578<span></span>
</td>
<td class="nump">293,406<span></span>
</td>
<td class="nump">235,555<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(17,445)<span></span>
</td>
<td class="num">(44,584)<span></span>
</td>
<td class="num">(102,124)<span></span>
</td>
<td class="num">(125,543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_InterestAndOtherIncomeLoss', window );">Interest and other income</a></td>
<td class="nump">1,760<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">2,423<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(24,775)<span></span>
</td>
<td class="num">(14,115)<span></span>
</td>
<td class="num">(72,634)<span></span>
</td>
<td class="num">(40,514)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Foreign currency losses, net</a></td>
<td class="num">(538)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="num">(583)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(40,998)<span></span>
</td>
<td class="num">(58,801)<span></span>
</td>
<td class="num">(172,918)<span></span>
</td>
<td class="num">(166,283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">1,522<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,657<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(42,520)<span></span>
</td>
<td class="num">(58,801)<span></span>
</td>
<td class="num">(175,575)<span></span>
</td>
<td class="num">(166,283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">695<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">877<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available for sale investments</a></td>
<td class="num">(808)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1,152)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (42,633)<span></span>
</td>
<td class="num">$ (58,774)<span></span>
</td>
<td class="num">$ (175,850)<span></span>
</td>
<td class="num">$ (166,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in usd per share)</a></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in usd per share)</a></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (in shares)</a></td>
<td class="nump">186,180<span></span>
</td>
<td class="nump">179,106<span></span>
</td>
<td class="nump">185,566<span></span>
</td>
<td class="nump">178,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (in shares)</a></td>
<td class="nump">186,180<span></span>
</td>
<td class="nump">179,106<span></span>
</td>
<td class="nump">185,566<span></span>
</td>
<td class="nump">178,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 75,213<span></span>
</td>
<td class="nump">$ 39,141<span></span>
</td>
<td class="nump">$ 189,647<span></span>
</td>
<td class="nump">$ 90,442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
<td class="num">(447)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_MilestoneRevenueMember', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and other research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 1,531<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 5,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestAndOtherIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income (loss) recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income (loss) from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestAndOtherIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyExpenseReversalOfExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of royalty expense (reversal of expense) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyExpenseReversalOfExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_MilestoneRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_MilestoneRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953852311792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (175,575)<span></span>
</td>
<td class="num">$ (166,283)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">29,419<span></span>
</td>
<td class="nump">26,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts', window );">Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs</a></td>
<td class="nump">55,119<span></span>
</td>
<td class="nump">36,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_AmortizationOfDiscountAndPremiumOnInvestments', window );">Amortization of premium/discount on investments</a></td>
<td class="num">(818)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(13,827)<span></span>
</td>
<td class="num">(17,579)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(11,263)<span></span>
</td>
<td class="num">(6,630)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(1,132)<span></span>
</td>
<td class="num">(3,460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(27,639)<span></span>
</td>
<td class="nump">16,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Interest payable</a></td>
<td class="nump">6,345<span></span>
</td>
<td class="nump">3,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">457<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(138,001)<span></span>
</td>
<td class="num">(109,698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisitions of property and equipment</a></td>
<td class="num">(825)<span></span>
</td>
<td class="num">(1,277)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of investments</a></td>
<td class="num">(244,283)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">39,655<span></span>
</td>
<td class="nump">28,201<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(205,453)<span></span>
</td>
<td class="nump">26,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from common stock issued under stock-based compensation plans</a></td>
<td class="nump">10,756<span></span>
</td>
<td class="nump">12,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Net proceeds from secured term loans</a></td>
<td class="nump">73,072<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">83,828<span></span>
</td>
<td class="nump">12,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(259,391)<span></span>
</td>
<td class="num">(70,455)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">507,734<span></span>
</td>
<td class="nump">274,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">$ 248,343<span></span>
</td>
<td class="nump">$ 203,893<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AmortizationOfDiscountAndPremiumOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to the discount and premium on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AmortizationOfDiscountAndPremiumOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of noncash interest expense and amortization of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953849180192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Deficit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">$ (19,262)<span></span>
</td>
<td class="nump">$ 1,769<span></span>
</td>
<td class="nump">$ 1,002,408<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (1,023,442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(64,284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales, net</a></td>
<td class="nump">723<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net</a></td>
<td class="nump">2,177<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">2,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="num">(74,988)<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">1,010,779<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="num">(1,087,726)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">(19,262)<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">1,002,408<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(1,023,442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(166,283)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="num">(147,044)<span></span>
</td>
<td class="nump">1,798<span></span>
</td>
<td class="nump">1,040,769<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="num">(1,189,725)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="num">(74,988)<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">1,010,779<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="num">(1,087,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(43,198)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,198)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(95)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net</a></td>
<td class="nump">4,574<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">4,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="num">(106,075)<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
<td class="nump">1,022,975<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="num">(1,130,924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(58,801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,801)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales, net</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net</a></td>
<td class="nump">3,535<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">3,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">13,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="num">(147,044)<span></span>
</td>
<td class="nump">1,798<span></span>
</td>
<td class="nump">1,040,769<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="num">(1,189,725)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="num">(106,986)<span></span>
</td>
<td class="nump">1,843<span></span>
</td>
<td class="nump">1,098,498<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="num">(1,207,504)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(74,196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales, net</a></td>
<td class="nump">1,504<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net</a></td>
<td class="nump">5,853<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">5,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">9,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="num">(164,215)<span></span>
</td>
<td class="nump">1,856<span></span>
</td>
<td class="nump">1,115,443<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="num">(1,281,700)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="num">(106,986)<span></span>
</td>
<td class="nump">1,843<span></span>
</td>
<td class="nump">1,098,498<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="num">(1,207,504)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(175,575)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="num">(242,659)<span></span>
</td>
<td class="nump">1,864<span></span>
</td>
<td class="nump">1,138,654<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="num">(1,383,079)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="num">(164,215)<span></span>
</td>
<td class="nump">1,856<span></span>
</td>
<td class="nump">1,115,443<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="num">(1,281,700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(58,859)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,859)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">9,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="num">(213,232)<span></span>
</td>
<td class="nump">1,859<span></span>
</td>
<td class="nump">1,125,453<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(1,340,559)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(42,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales, net</a></td>
<td class="nump">1,357<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net</a></td>
<td class="nump">1,896<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">9,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="num">$ (242,659)<span></span>
</td>
<td class="nump">$ 1,864<span></span>
</td>
<td class="nump">$ 1,138,654<span></span>
</td>
<td class="num">$ (98)<span></span>
</td>
<td class="num">$ (1,383,079)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953852909664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Deficit (Parenthetical)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, net (in shares)</a></td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953857023760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies and Concentrations of Risk<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies and Concentrations of Risk</a></td>
<td class="text">Significant Accounting Policies and Concentrations of Risk<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in 1986 and incorporated in Delaware in 1991, and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketed products include oral, once-daily ORLADEYO&#174; for the prevention of hereditary angioedema (&#8220;HAE&#8221;) attacks and RAPIVAB&#174; (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. ORLADEYO received regulatory approval in the United States in December 2020. ORLADEYO has also received regulatory approvals in multiple global markets. The Company is commercializing ORLADEYO in each of these territories directly or through distributors, except in Japan where Torii Pharmaceutical Co., Ltd., the Company&#8217;s collaborative partner, has the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in exchange for certain milestone and royalty payments to the Company. In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada, Australia, Japan, Taiwan and Korea. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s expectations for revenue and operating expenses, the Company believes its financial resources available at September&#160;30, 2022 will be sufficient to fund its operations for at least the next 12 months. The Company has sustained operating losses for the majority of its corporate history and expects that its 2022 expenses will exceed its 2022 revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#8217;s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company regularly evaluates other opportunities to fund future operations, including: (1) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (2) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestone payments; (3) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (4) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (5) reducing spending on one or more research and development programs, including by discontinuing development; and/or (6) restructuring operations to change its overhead structure. The Company may issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#8217;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events and its decisions in the future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the financial statements for the year ended December&#160;31, 2021 and the notes thereto included in the Company&#8217;s 2021 Annual Report on Form 10-K. Interim operating </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results are not necessarily indicative of operating results for the full year. The balance sheet as of December&#160;31, 2021 has been derived from the audited consolidated financial statements included in the Company&#8217;s most recent Annual Report on Form 10-K.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the valuation of stock options, the ORLADEYO and Factor D inhibitors royalty financing obligations and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales, Net</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in December 2020, sales of peramivir to the Company&#8217;s licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) under the Company&#8217;s procurement contract. In the United States, the Company ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. In the European Union, United Kingdom and elsewhere, the Company sells ORLADEYO to specialty distributors as well as hospitals and pharmacies, which collectively are considered its customers.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue for sales when its customers obtain control of the product, which generally occurs upon delivery. For ORLADEYO, the Company classifies payments to its specialty pharmacy customer for certain services provided by its customer as selling, general and administrative expenses to the extent such services provided are determined to be distinct from the sale of its product.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or as a current liability. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government and Managed Care Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company contracts with government agencies and managed care organizations or, collectively, third-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">establishment of a current liability. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) product distribution information obtained from the Company's specialty pharmacy.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company&#8217;s specialty pharmacy. These customers purchase the Company&#8217;s product under contracts negotiated between them and the Company&#8217;s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price the specialty pharmacy paid and the negotiated price paid by the contracted customers, which may be higher or lower than the specialty pharmacy&#8217;s purchase price from the Company. The Company estimates chargebacks and adjusts gross product revenues and accounts receivable based on the estimates at the time revenues are recognized.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance and patient assistance programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company is able to estimate the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#8217;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company does not provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Research and Development Arrangements and Royalties</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has collaboration and license agreements with a number of third parties, as well as research and development agreements with certain government entities. The Company&#8217;s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not probable at the inception of the agreement </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within the HHS (&#8220;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of the Company&#8217;s license agreements, the Company receives royalty payments based upon its licensees&#8217; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash of $21 and $1,924 as of September&#160;30, 2022 and December&#160;31, 2021, respectively, reflects royalty revenue paid by Shionogi designated for interest on the PhaRMA Notes (defined in Note 6). Additionally, restricted cash of $1,423 and $1,421 as of September&#160;30, 2022 and December&#160;31, 2021, respectively, reflects collateral for a letter of credit the Company is required to maintain associated with the lease execution and build-out of its Birmingham research facilities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, certificates of deposits, municipal and corporate notes and bonds, and commercial paper, among others. The Company&#8217;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 12 months. Some of the securities in which the Company invests may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#8217;s investments are not collateralized. The Company has not realized any significant losses from its investments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At September&#160;30, 2022, the Company believes that the cost of its investments is recoverable in all material respects.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other third-party distributors, hospitals and pharmacies in the European Union, United Kingdom and elsewhere and have standard payment terms that generally require payment within 30 to 90 days.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the HHS, and royalty receivables from the Company&#8217;s partners, including Shionogi, Green Cross, and Torii.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monthly invoices are submitted to HHS related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not adjust its receivables for the effects of a significant financing component at contract inception if it expects to collect the receivables in one year or less from the time of sale.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides reserves against trade receivables for estimated losses that may result from a customer's inability to pay. Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company&#8217;s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, labor, manufacturing overhead and shipping and handling costs on a first-in, first-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labelled products.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventories are subject to expiration dating. The Company regularly evaluates the carrying value of its inventories and provides valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, the Company may experience spoilage of its raw materials and supplies. The Company&#8217;s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company&#8217;s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of September&#160;30, 2022 and December&#160;31, 2021, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including freight. In addition, shipping and handling costs for product shipments are recorded as incurred. Finally, cost of product sales may also include costs related to excess or obsolete inventory adjustment charges.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts, and estimates are adjusted, if required, based upon the Company&#8217;s ongoing review of the level of services actually performed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;), and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred collaboration expenses represent sublicense payments, paid to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#8217;s academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense is primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other general and administrative costs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expenses related to ORLADEYO were $3,476 and $11,555 for the three and nine months ended September&#160;30, 2022, respectively, and $1,492 and $4,696 for the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of September&#160;30, 2022. The Company accounts for lease obligations in accordance with ASU 2016-02: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most operating leases.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#8217;s Consolidated Balance Sheets represent payments over the lease term, which includes renewal options for certain real estate leases that the Company is likely to exercise. As part of the Company&#8217;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of twelve months or less was not material.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used in the calculation of the Company&#8217;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#8217;s collateralized borrowing rate from lending institutions.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not made any residual value guarantees related to its operating leases; therefore, the Company has no corresponding liability recorded on its Consolidated Balance Sheets.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, the Company has outstanding performance-based stock options and restricted stock units for which no compensation expense is recognized until &#8220;performance&#8221; is deemed to have occurred.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Deferred Financing Costs</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three and nine months ended September&#160;30, 2022 was $24,775 and $72,634, respectively, and $14,115 and $40,514 for the three and nine months ended September&#160;30, 2021, respectively, and primarily relates to the royalty financing obligations (Note 6), the secured term loan borrowing from the Credit Agreement (Note 7) and the PhaRMA Notes (Note 6). Costs directly associated with the borrowings have been capitalized and are netted against the corresponding debt liabilities on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $(258) and $(597) for the three and nine months ended September&#160;30, 2022, respectively, and $(158) and $(369) for the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the PhaRMA Notes and associated accrued interest payable was written-off into other income as a debt extinguishment (Refer to &#8220;Note 6&#8212;Royalty Monetizations&#8212;RAPIACTA&#8212;Non-Recourse Notes Payable &#8211; Debt Extinguishment&#8221; for additional information regarding the debt extinguishment).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Royalty Financing Obligations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO, BCX9930, and another earlier stage Factor D inhibitor (BCX10013). Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability method is used in the Company&#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in fiscal year 2021, the Company began accruing foreign income taxes as a result of increased nexus in foreign jurisdictions where historically the Company had no presence.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, starting in 2022, amendments to Section 174 of the Internal Revenue Code of 1986, as amended (&#8220;IRC&#8221;), will no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil. As a result of this tax law change, the Company has recorded a U.S. state tax provision for the nine months ended September 30, 2022.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company&#8217;s equity compensation plans were anti-dilutive. The calculation of diluted earnings per share does not include 26,236 and 25,918 shares of potential common stock for the three and nine months ended September&#160;30, 2022, respectively, and 28,472 and 26,131 shares of potential common stock for the three and nine months ended September&#160;30, 2021, respectively, as their impact would be anti-dilutive.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income and recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. There were no realized gains or losses reclassified out of accumulated other comprehensive income for the nine months ended September 30, 2022.  For the nine months ended September 30, 2021, realized gains of $1 were reclassified out of accumulated other comprehensive loss.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers and Other Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Customers</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary sources of revenue and cash flow are the sales of ORLADEYO in the United States and other global markets as well as sales of RAPIVAB (peramivir injection) under the Company's procurement contract with the Assistant Secretary for Preparedness and Response within HHS. Additionally, the Company receives reimbursement of </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">galidesivir (formerly BCX4430) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ORLADEYO is distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. The specialty pharmacy&#8217;s inability or unwillingness to continue these distribution activities could adversely impact the Company&#8217;s business, results of operations and financial condition.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company is distributing ORLADEYO in other global markets directly or through distributors, except in Japan where Torii, the Company&#8217;s collaborative partner, has the exclusive right to commercialize ORLADEYO.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses has represented a significant portion of the Company&#8217;s collaborative and other research and development revenues. All government funding for galidesivir is expected to expire in 2022. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, HHS is the primary customer for RAPIVAB, and it has exercised the remaining option for the purchase of RAPIVAB under the procurement contract with the Company.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Company&#8217;s drug development activities are performed by a limited group of third-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks from Third-Party Manufacturing and Distribution Concentration</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays or disruption in the manufacture or distribution of any product could adversely impact the future procurement stockpiling of the Company&#8217;s product candidates and commercial revenue, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 12 months or less.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables from sales of ORLADEYO are primarily due from one customer, resulting in a concentration of credit risk. Sales of ORLADEYO from the Company to the specialty pharmacy only occur once an order of product has been received by the specialty pharmacy from one of its customers, which include pharmacy benefit managers, insurance companies, government programs and group purchasing organizations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div>There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the nine months ended September 30, 2022, as compared to the recent accounting pronouncements described in Note 1 of the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, that the Company believes are of s<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953853689056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following revenues (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORLADEYO</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RAPIVAB</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peramivir</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other research and development revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Health and Human Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaborative and other research and development revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,017&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75,827</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">191,282</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110,012</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953939406928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the fair value of the Company&#8217;s investments by type. The estimated fair values of the Company&#8217;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued<br/>Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,074)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,125&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,170)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,291&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued<br/>Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,041&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the scheduled maturity for the Company&#8217;s investments at September&#160;30, 2022 and December&#160;31, 2021:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,041&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953851364368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Receivables<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_TradeReceivablesTextBlock', window );">Trade Receivables</a></td>
<td class="text">Trade Receivables<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO and RAPIVAB. At September&#160;30, 2022 and December&#160;31, 2021, receivables related to sales of ORLADEYO were $39,565 and $27,384, respectively. At September&#160;30, 2022 and December&#160;31, 2021, receivables related to sales of RAPIVAB were $28 and $49, respectively. No reserve or allowance amounts were recorded as of both September&#160;30, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from collaborations were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Billed</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unbilled</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Health and Human Services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shionogi &amp; Co. Ltd.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty receivables from partners</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total receivables</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Billed</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unbilled</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Health and Human Services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty receivables from partners</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total receivables</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>As of both September&#160;30, 2022 and December&#160;31, 2021, the Company maintained a reserve of $701 related to royalties associated with Green Cross.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_TradeReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_TradeReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953939406928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022 and December&#160;31, 2021, the Company&#8217;s inventory primarily related to ORLADEYO. Additionally, inventory included RAPIVAB and peramivir, which is manufactured for the Company&#8217;s partners.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventories consisted of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,264&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,036&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,019&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953939406928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Monetizations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvanceRoyaltiesAbstract', window );"><strong>Advance Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationTextBlock', window );">Royalty Monetizations</a></td>
<td class="text">Royalty Monetizations<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RAPIACTA </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;9, 2011, the Company completed a $30,000 financing transaction to monetize certain future royalty and milestone payments under the Company&#8217;s agreement with Shionogi (the &#8220;Shionogi Agreement&#8221;), pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of $22,691 from the transaction after transaction costs of $4,309 and the establishment of a $3,000 interest reserve account by JPR Royalty Sub LLC, a wholly-owned subsidiary of the Company (&#8220;Royalty Sub&#8221;), available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, the Company entered into a purchase and sale agreement dated as of March 9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement and (ii) the right to receive payments under a Japanese yen/U.S. dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency Hedge Agreement&#8221;) put into place by the Company in connection with the transaction. Royalty payments are paid by Shionogi in Japanese yen, and any milestone payments will be paid in U.S. dollars. The Company&#8217;s collaboration with Shionogi was not impacted as a result of this transaction.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Recourse Notes Payable</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due on December 1, 2020 (the &#8220;PhaRMA Notes&#8221;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March 9, 2011 (the &#8220;Indenture&#8221;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14% per annum, payable annually in arrears on September 1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty Sub&#8217;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#8217;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2014, Royalty Sub was unable to pay the accrued interest obligation due September 3, 2013. Under the terms of the Indenture, Royalty Sub&#8217;s inability to pay the full amount of interest payable in September 2013 by the next succeeding payment date for the PhaRMA Notes, which was September 1, 2014, constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the December 31, 2014 balance sheet and thereafter. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential foreclosure, the primary impact to the Company would be the loss of future royalty payments, if any, from Shionogi and legal costs associated with retiring the PhaRMA Notes. The PhaRMA Notes had a final legal maturity date of December&#160;1, 2020, at which time the outstanding principal amount of the PhaRMA Notes of $30,000, together with accrued and unpaid interest of $20,614, was due in full.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Recourse Notes Payable &#8211; Debt Extinguishment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the royalty-bearing patents associated with RAPIACTA in Japan expired. Accordingly, the Company evaluated the current circumstances of the PhaRMA Notes, including (i) their non-recourse nature relative to the Company, (ii) the current state of default since September 1, 2014 and the legal maturity on December 1, 2020 and (iii) the loss of patent protection relative to RAPIACTA in Japan, upon which any significant repayment of the PhaRMA Notes is </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">predicated. As a result, the Company determined that it was no longer the financial obligor, and as a result, the principal balance of $30,000 and associated accrued interest payable balance of $25,838 were written off, resulting in a gain on extinguishment recorded in other income (expense) for the year ended December&#160;31, 2021.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ORLADEYO and Factor D Inhibitors</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;7, 2020, the Company and RPI 2019 Intermediate Finance Trust (&#8220;RPI&#8221;) entered into a Purchase and Sale Agreement (the &#8220;2020 RPI Royalty Purchase Agreement&#8221;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $125,000 in cash (the &#8220;2020 RPI Royalty Sale&#8221;). Under the 2020 RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the United States and certain key European markets (collectively, the &#8220;Key Territories&#8221;), and other markets where the Company sells ORLADEYO directly or through distributors (collectively, the &#8220;Direct Sales&#8221;) in an amount equal to: (i) 8.75% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 2.75% of annual net sales for annual net sales between $350,000 and $550,000. No royalty payments are payable on annual Direct Sales over $550,000. In addition, RPI will be entitled to receive 1.0% of global net sales, if any, of BCX9930.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2020 RPI Royalty Purchase Agreement, RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories (the &#8220;Other Markets&#8221;) equal to: (i) 20% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets; (ii) 20% of proceeds received on annual net sales of up to $150,000 in the Other Markets; and (iii) 10% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company and RPI entered into (i) a Purchase and Sale Agreement (the &#8220;2021 RPI Royalty Purchase Agreement&#8221; and together with the 2020 RPI Royalty Purchase Agreement, the &#8220;RPI Royalty Purchase Agreements&#8221;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $150,000 in cash, and (ii) a Purchase and Sale Agreement with OCM IP Healthcare Holdings Limited, an affiliate of OMERS Capital Markets (&#8220;OMERS&#8221;) (the &#8220;OMERS Royalty Purchase Agreement&#8221; and collectively with the RPI Royalty Purchase Agreements, the &#8220;Royalty Purchase Agreements&#8221;), pursuant to which the Company sold to OMERS the right to receive certain royalty payments from the Company for a purchase price of an additional $150,000 in cash.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2021 RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) 0.75% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 1.75% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000. No royalty payments are payable on Direct Sales over $550,000. RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to 3.0% of proceeds received by the Company on annual net sales of up to $150,000 in the Other Markets, and (iii) 2.0% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2021 RPI Royalty Purchase Agreement, RPI is also entitled to receive tiered, sales-based royalties on net product sales of BCX9930 and another earlier stage Factor D inhibitor (BCX10013) in an amount equal to: (i) 3.0% of worldwide aggregate annual net sales up to $1,500,000 and (ii) 2.0% of worldwide aggregate annual net sales between $1,500,000 and $3,000,000. No royalty payments are payable on annual net sales above $3,000,000. RPI is also entitled to receive tiered profit share amounts of up to 3.0% from certain other permitted sales in certain other markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalties payable under the 2021 RPI Royalty Purchase Agreement are in addition to the royalties payable to RPI under the 2020 RPI Royalty Purchase Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the OMERS Royalty Purchase Agreement, commencing with the calendar quarter beginning October 1, 2023, OMERS will be entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) 7.5% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 6.0% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000 (with no royalty payments payable on annual Direct Sales over $550,000) (the &#8220;Regime A Royalty Rate&#8221;). If annual Direct Sales for calendar year 2023 reach a specified amount set forth in the OMERS Royalty Purchase Agreement, then for each calendar quarter beginning on or after January 1, 2024, OMERS will be entitled to receive the Regime A Royalty Rate. If annual Direct Sales for calendar year 2023 are less than the specified amount, OMERS will be entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) 10.0% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 3.0% of annual net sales of </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ORLADEYO for annual net sales between $350,000 and $550,000 (with no royalty payments payable on annual Direct Sales over $550,000) (the &#8220;Regime B Royalty Rate&#8221;).</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the OMERS Royalty Purchase Agreement, OMERS is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to: (i) 20.0% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets, (ii) 20.0% of proceeds received by the Company on annual net sales of up to $150,000 in the Other Markets, and (iii) 10.0% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets. OMERS is also entitled to receive profit share amounts of up to 10% from certain other permitted sales in certain other markets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2020 RPI Royalty Purchase Agreement, the Company is required to make royalty payments of amounts owed to RPI each calendar quarter following the first commercial sale of ORLADEYO in any country. Under the 2021 RPI Royalty Purchase Agreement, the Company is required to make payments to RPI in respect of net sales or sublicense revenue in each calendar quarter from and after October 1, 2021. Under the OMERS Royalty Purchase Agreement, the Company will be required to make payments to OMERS is respect of net sales or sublicense revenue in each calendar quarter from and after October 1, 2023. OMERS will no longer be entitled to receive any payments on the date in which aggregate payments actually received by OMERS equals either 142.5% or 155.0% of the $150,000 purchase price, depending on sales levels in calendar year 2023.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the &#8220;Royalty Sales&#8221;.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Royalty Purchase Agreements, the Company has agreed to specified affirmative and negative covenants, including covenants regarding periodic reporting of information by the Company to RPI and OMERS, third-party audits of royalties paid under the Royalty Purchase Agreements, and restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness other than certain royalty sales and as is permitted to be incurred under the terms of the Company&#8217;s Credit Agreement with Athyrium Opportunities III Co-Invest 1 LP. Refer to Note 7 for further details on the Credit Agreement. The restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness are eliminated after the achievement of certain specified milestones in the Royalty Purchase Agreements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash consideration obtained pursuant to the Royalty Purchase Agreements is recorded in &#8220;Royalty financing obligations&#8221; on the Company&#8217;s Consolidated Balance Sheets. The fair value for the royalty financing obligations at the time of the transactions was based on the Company&#8217;s estimates of future royalties expected to be paid to the counterparty over the life of the arrangement. The Company subsequently records the obligations at its carrying value using the effective interest method. In order to amortize the royalty financing obligations, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. The Company periodically assesses the amount and timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success, and sales price, among others. To the extent such payments are greater or less than the Company&#8217;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, the Company adjusted its forecasts related to its R&amp;D programs and ORLADEYO sales. Accordingly, this impacted the amount and timing of expected royalties to be made under the RPI Royalty Purchase Agreements. As a result, the effective interest rate related to the 2020 RPI Royalty Purchase Agreement decreased from 25.5% to 23.1%, and the effective interest rate related to the 2021 RPI Royalty Purchase Agreement decreased from 12.1% to 11.0%. Additionally, the effective interest rate related to the OMERS Agreement increased from 8.5% to 10.6%.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the Royalty financing obligations account (in thousands) as well as the effective interest rate as of September&#160;30, 2022: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 RPI<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 RPI<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OMERS<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash Interest expense on Royalty financing obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues paid and payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,385)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,004&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash Interest expense on Royalty financing obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,462&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,020&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues paid and payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,702&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,155&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477,666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash Interest expense on Royalty financing obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues paid and payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred issuance costs pursuant to the Royalty financing obligations, which consist primarily of advisory and legal fees, totaled $8,531 as of September&#160;30, 2022. The Royalty financing obligations liabilities and the associated deferred issuance costs are amortized using the effective interest method over the term of the arrangement, in accordance with the respective guidance.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with entering into the 2021 RPI Royalty Purchase Agreement, the Company and RPI entered into a Common Stock Purchase Agreement (the &#8220;Common Stock Purchase Agreement&#8221;), pursuant to which the Company sold common stock to RPI for a premium of $4,269. This premium has been deferred and is being amortized through interest expense using the effective interest method over the term of the applicable arrangement. Refer to Note 9 for further details on the common stock sale premium.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMonetizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyMonetizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvanceRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvanceRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953857047968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;7, 2020, the Company entered into a $200,000 Credit Agreement (the &#8220;Credit Agreement&#8221;) with Athyrium Opportunities III Co-Invest 1 LP (&#8220;Athyrium&#8221;), as lender and as administrative agent for the lenders. Certain of the Company&#8217;s direct and indirect subsidiaries are guarantors to the Credit Agreement. The Credit Agreement provides for an initial term loan in the principal amount of $125,000 (the &#8220;Term A Loan&#8221;), which was received by the Company on December&#160;7, 2020 and is recorded in &#8220;Secured term loan&#8221; on the Company&#8217;s balance sheet as of September&#160;30, 2022. The Company used a portion of the proceeds from the Term A Loan to repay $43,298 of outstanding indebtedness, including accrued interest, under its prior credit facility with MidCap Financial Trust. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement also provided for two additional term loans, at the Company&#8217;s option, in the respective principal amounts of $25,000 (the &#8220;Term B Loan&#8221;) and $50,000 (the &#8220;Term C Loan&#8221; and, collectively with the Term A Loan and the Term B Loan, the &#8220;Term Loans&#8221;). Having achieved all required revenue-based milestones, the Company exercised its option to draw upon the additional funding available under the Credit Agreement, borrowing the principal amounts of $25,000 under the Term B Loan and $50,000 under the Term C Loan. Both the Term B Loan and the Term C Loan were funded on July 29, 2022 in the aggregate principal amount of $75,000. The Term B Loan and the Term C Loan are subject to all the provisions under the Credit Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, the Company entered into an amendment to the Credit Agreement (i) to permit the Company to enter into the 2021 RPI Royalty Purchase Agreement, the OMERS Royalty Purchase Agreement, and the </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other definitive documentation related thereto and to perform its obligations thereunder; (ii) to require the Company to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that the Company did not draw the Term B Loan or the Term C Loan, as applicable, by the end of the applicable period available to draw the Term B Loan or the Term C Loan, subject to certain exceptions set forth in the Credit Agreement; and (iii) to require the Company to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that the Company either (x) terminated the commitments in respect of the Term B Loan or the Term C Loan, as applicable, on or prior to the end of the applicable period available to draw the Term B Loan or the Term C Loan, or (y) prepays or repays, or is required to prepay or repay, voluntarily or pursuant to mandatory prepayment obligations under the Credit Agreement (e.g., with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions), all of the then-outstanding Term Loans, in each case, subject to certain exceptions set forth in the Credit Agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for quarterly interest-only payments until the maturity date, with the unpaid principal amount of the outstanding Term Loans due and payable on the maturity date. For each of the first eight full fiscal quarters following December 7, 2020, the Company has the option to make the applicable interest payment in-kind (a &#8220;PIK Interest Payment&#8221;) by capitalizing the entire amount of interest accrued during the applicable interest period with the unpaid original principal amount outstanding on the last day of such period. The Term Loans will bear interest at a rate equal to the three-month LIBOR rate, which shall be no less than 1.75% and no more than 3.50% (&#8220;LIBOR&#8221;), plus 8.25%, or for each interest period in which a PIK Interest Payment is made, LIBOR plus 10.25%.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-month LIBOR was 2.31% as of June 28, 2022, the LIBOR measurement date for the three-month interest period beginning July 1, 2022. Accordingly, this LIBOR rate plus 10.25% was used to record interest expense for the three months ended September 30, 2022. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-month LIBOR was 3.67% as of September 28, 2022, the LIBOR measurement date for the three-month interest period beginning October 1, 2022.  As the LIBOR rate exceeds the LIBOR cap of 3.50%, the 3.50% cap plus 10.25% will be used to record interest expense for the three-month interest period beginning October 1, 2022. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions, the Company is required to make mandatory prepayments of the Term Loans with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events. The Company may make voluntary prepayments in whole or in part. Prepayments are subject to a premium equal to, (i) with respect to any voluntary prepayment and certain mandatory prepayments paid on or prior to the second anniversary of the applicable Term Loan borrowing date, the amount, if any, by which (a) the sum of (1) 102.00% of the principal amount of the Term Loan being prepaid plus (2) the present value of all interest that would have accrued on the principal amount of the Term Loan being prepaid through and including the second anniversary of the date of the borrowing of such Term Loan, plus 0.50%, exceeds (b) the principal amount of the Term Loan being prepaid; (ii) with respect to any prepayment made between the second and third anniversaries of the applicable Term Loan borrowing date, 2.00% of the principal amount of the Term Loan being prepaid; (iii) with respect to any prepayment made between the third and fourth anniversaries of the applicable Term Loan borrowing date, 1.00% of the principal amount of the Term Loan being prepaid; and (iv) with respect to any prepayment made after the fourth anniversary of the applicable Term Loan borrowing date, 0.00% of the principal amount of the Term Loan being prepaid. Upon the prepayment or repayment, including at maturity, of all or any of the Term Loans, the Company is obligated to pay an exit fee in an amount equal to 2.00% of the principal amount of the Term Loans prepaid or repaid. In addition, each Term Loan is subject to a 1.00% commitment fee at its respective borrowing date.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement also contains representations and warranties and affirmative and negative covenants customary for financings of this type, as well as customary events of default. Certain of the customary negative covenants limit the ability of the Company and certain of its subsidiaries to, among other things, grant liens, make investments, incur additional indebtedness, engage in mergers, acquisitions, and similar transactions, dispose of assets, license certain property, distribute dividends, make certain restricted payments, change the nature of the Company&#8217;s business, engage in transactions with affiliates and insiders, prepay other indebtedness, or engage in sale and leaseback transactions, subject to certain exceptions. Additionally, as of the last day of each fiscal quarter (a &#8220;Test Date&#8221;), beginning with the first Test Date occurring immediately after the Term C Loan is drawn, if applicable, the Company may not permit consolidated net revenues from ORLADEYO sales in the United States for the four-fiscal quarter period ending on such Test Date to be less than the specified amounts set forth in the Credit Agreement (collectively, the &#8220;Revenue Tests&#8221;). If the Company fails to satisfy the Revenue Tests as of any Test Date, it will have a one-time right (the &#8220;Cure Right&#8221;) to repay in full the entire </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount of the Term C Loan outstanding at such time together with all accrued and unpaid interest thereon plus the prepayment premium, exit fee, and any other fees or amounts payable under the Credit Agreement at such time. In addition, the Credit Agreement contains a minimum liquidity covenant requiring the Company to maintain at all times, as applicable, at least $15,000 of unrestricted cash and cash equivalents if only the Term A Loan has been drawn; at least $20,000 of unrestricted cash and cash equivalents if the Term B Loan has been drawn but the Term C Loan has not been drawn; and at least $15,000 (or, if the Cure Right has been exercised, $20,000) of unrestricted cash and cash equivalents if the Term C Loan has been drawn, subject to certain exceptions.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A failure to comply with the covenants in the Credit Agreement could permit the lenders under the Credit Agreement to declare the outstanding principal as well as accrued interest and fees, to be immediately due and payable.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's obligations under the Credit Agreement are secured by a security interest in, subject to certain exceptions, substantially all of the Company's assets.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had total borrowings of $200,000 under the Credit Agreement. Quarterly interest payments under the Credit Agreement for the nine months ended September 30, 2022 and 2021 totaled $15,311 and $11,815, respectively, and have been designated and accounted for as PIK Interest Payments and added to the outstanding principal balance of the borrowing. As of September&#160;30, 2022, borrowings, including the PIK Interest Payments, totaled $232,376. The principal balance of the borrowings, including PIK amounts, is accruing interest at an effective rate of 12.68%. The fair value of the debt approximates its carrying value based on prevailing interest rates as of the balance sheet date and is considered as Level 2 in the fair value hierarchy.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, the Company incurred deferred debt fees and issuance costs associated with the Term B and Term C Loans of $3,428. As of September&#160;30, 2022, deferred debt fees and issuance costs associated with all Term Loans under the Credit Agreement totaled $12,509 and are being amortized as interest expense on an effective interest rate method over the remaining term of the Term Loans. When utilizing the effective interest method, in periods in which PIK interest is designated and those amounts are added to the outstanding principal balance of the borrowing, the amortization of the deferred debt fees and issuance costs is accretive. Deferred financing amortization of $(597) and $(369), was recognized for the nine months ended September 30, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains two provisions that, if deemed probable, would create the recognition of an embedded feature; however, at this time, the Company does not believe either provision is probable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953852872608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lease Obligations</a></td>
<td class="text">Lease Obligations <div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of September&#160;30, 2022. Renewal options for the Company's leases range from 1 to 5 years in length and begin from 2023 through 2026. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate lease expense under operating leases was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental information related to leases was as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s leases qualify as operating leases. The following table summarizes the presentation in the Consolidated Balance Sheets of the Company&#8217;s operating leases: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfMi0xLTEtMS05MzYw_842fa9e2-603a-4d76-932f-26e9d70fccbc">Other Assets</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lease financing obligation &#8211; current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lease financing obligation &#8211; long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,781&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets are recorded net of accumulated amortization of $3,874 and $2,626 as of September&#160;30, 2022 and December&#160;31, 2021, respectively. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities was $615 and $1,796 for the three and nine months ended September&#160;30, 2022, respectively, and $306 and $1,125 for the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of September&#160;30, 2022, are as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953853827136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Equity</span><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of Common Stock</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;24, 2020, the Company filed a shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective on May 14, 2020 and allows the Company to sell up to $500,000 in securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2021, the Company filed an automatic shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective automatically upon filing and allows the Company to sell an indeterminate number of securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, concurrent with the Company entering into the 2021 RPI Royalty Purchase Agreement, the Company and RPI entered into the Common Stock Purchase Agreement, pursuant to which the Company issued 3,846,154 </span></div>shares of the Company&#8217;s common stock to RPI for an aggregate purchase price of $50,000, at a price of $13.00 per share, calculated based on the 20-day volume weighted average price. The $13.00 per share price represents a premium of $1.11 over the closing price of $11.89 of the Company&#8217;s common stock on November&#160;17, 2021, the last trading day prior to the execution of the Common Stock Purchase Agreement. The premium of $4,269 paid by RPI on the purchase of the Company&#8217;s common stock has been deferred and is being amortized as a component of interest expense of the 2021 RPI royalty financing obligation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953852675680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had three stock-based employee compensation plans: the Amended and Restated Stock Incentive Plan (&#8220;Incentive Plan&#8221;), the Amended and Restated Inducement Equity Incentive Plan (&#8220;Inducement Plan&#8221;) and the Amended and Restated Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The Incentive Plan was most recently amended and restated on April 18, 2022 and approved by the Company&#8217;s stockholders on June 7, 2022. The Inducement Plan was most recently amended and restated by the Board of Directors on August 26, 2022. The ESPP was most recently amended and restated on April 1, 2021 and approved by the Company&#8217;s stockholders on May 25, 2021.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense of $29,421 ($23,687 of expense related to the Incentive Plan, $4,604 of expense related to the Inducement Plan, and $1,130 of expense related to the ESPP) was recognized during the nine months ended September 30, 2022, while $26,140 ($19,973 of expense related to the Incentive Plan, $5,025 of expense related to the Inducement Plan and $1,142 of expense related to the ESPP) was recognized during the nine months ended September 30, 2021.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was approximately $100,171 of total unrecognized compensation expense related to non-vested stock option and restricted stock unit awards granted by the Company as of September&#160;30, 2022. As of September&#160;30, 2022, the Company expected to recognize that expense as follows: $10,707 during the remainder of 2022, $35,987 in 2023, $31,537 in 2024, $19,524 in 2025 and $2,416 in 2026. In addition, the Company has outstanding performance-based stock options and restricted stock unit awards for which no compensation expense is recognized until &#8220;performance&#8221; has occurred and the award vests.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plan</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants stock option awards, restricted stock and restricted stock units to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#8217;s common stock at the date of grant. Commencing March 1, 2011, stock option awards and restricted stock units granted to employees generally vest 25% each year until fully vested after four years.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2014, the Company issued 1,250 performance-based stock options. These awards vest upon successful completion of specific development milestones. As of September&#160;30, 2022, 85% of these grants have vested.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company issued 221 performance-based restricted stock unit awards. Contingent upon successful achievement of specific commercial or operational objectives in 2022, the awards become eligible for vesting at 50% on the first anniversary of the grant date and 25% on each of the second and third anniversaries of the grant date, until fully vested after three years.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards and restricted stock unit awards granted to non-employee directors of the Company generally vest over one year. Stock option awards granted to new non-employee directors when they first join the Company&#8217;s Board of Directors generally vest, subject to the terms of the Incentive Plan, in 36 equal monthly installments over a three-year period measured from the grant date. All stock option awards have contractual terms of 10 years. Restricted stock unit awards granted to new non-employee directors when they first join the Company's Board of Directors generally vest, subject to the terms of the Incentive Plan, in three equal annual installments beginning on the first anniversary of the grant date. The vesting and exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related activity under the Incentive Plan is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Awards<br/>Available</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(681)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(813)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(787)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,162&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,377&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For stock option awards granted under the Incentive Plan during the first nine months of 2022 and 2021, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table following the next subsection. The weighted average grant date fair value of these awards granted during the first nine months of 2022 and 2021 was $7.78 and $8.11, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. For restricted stock units granted under the Incentive Plan, the fair value of the awards was determined based on the market value of the Company&#8217;s shares on the grant date. The weighted average grant date fair value of these awards granted during the first nine months of 2022 and 2021 was $13.18 and $10.17, respectively. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement Equity Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the ability to grant stock option and restricted stock unit awards to newly-hired employees as inducements material to each employee entering employment with the Company. Awards granted to newly hired employees generally vest 25% each year until fully vested after four years and are subject to the terms and conditions of the Inducement Plan. Each stock option has a term of 10 years. The vesting and exercise provisions of all awards granted under the Inducement Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Inducement Plan.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related activity under the Inducement Plan is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Awards<br/>Available</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For stock option awards granted under the Inducement Plan during the first nine months of 2022 and 2021, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during the first nine months of 2022 and 2021 was $9.72 and $9.74, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. For restricted stock units granted under the Inducement Plan, the </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair value of the awards was determined based on the market value of the Company&#8217;s shares on the grant date. The weighted average grant date fair value of these awards granted during the first nine months of 2022 was $13.38. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method. No restricted stock unit awards were granted under the Inducement Plan during the first nine months of 2021.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the key assumptions used by the Company to value the stock option awards granted under all plans during the first nine months of 2022 and 2021, respectively. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#8217;s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining term equal to the expected term.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Assumptions for Stock Option Awards Granted to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Directors under the Plans</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:71.889%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected Life in Years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected Dividend Yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-Free Interest Rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved a total of 7,975 shares of common stock to be purchased under the ESPP, of which 5,792 shares remain available for purchase as of September&#160;30, 2022. Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates, and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. During the nine months ended September&#160;30, 2022, and 2021, the Company issued 260 and 316 shares under the ESPP, respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#8220;look-back&#8221; option were determined using a Black-Scholes option pricing model.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953939406928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text">Collaborative and Other Relationships<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">National Institute of Allergy and Infectious Diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2013, NIAID/HHS contracted with the Company for the development of galidesivir as a treatment for Marburg virus disease and subsequently, Yellow Fever and Ebola virus disease. On September&#160;15, 2021, the Company entered into an amendment to pay for certain additional costs, including additional manufacturing development costs and overhead, and to change the total value of the contract, as amended, to $47,315 from $45,931. This is the commencement of closing out the contract. All options under the contract have been awarded.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, NIAID/HHS awarded the Company a contract, with potential aggregate funding of up to $43,908 if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir. NIAID/HHS made an initial award of $6,326 to the Company under this contract.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biomedical Advanced Research and Development Authority</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In March 2015, BARDA/HHS awarded the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract includes a base contract of $16,265 to support galidesivir drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $39,120. As of September&#160;30, 2022, a total of $20,574 has been awarded under exercised options within this contract. The most recent development option was completed as of September&#160;30, 2022.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contracts with NIAID/HHS and BARDA/HHS are cost-plus-fixed-fee contracts. The Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress, and </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the continuation of the contracts is based on the Company&#8217;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects all government funding for its galidesivir program to expire in 2022.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Department of Health and Human Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2018, HHS awarded the Company a $34,660 contract for the procurement of up to 50,000 doses of RAPIVAB (peramivir injection) over a five-year period. On August 25, 2022, the Company announced that HHS had exercised its remaining option under the contract to purchase 10,000 doses of RAPIVAB for $6,932. As of September&#160;30, 2022, the Company has delivered a total of 39,980 RAPIVAB doses of the 50,000 RAPIVAB doses available under the contract with HHS for a total of $27,714.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Torii Pharmaceutical Co., Ltd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On November&#160;5, 2019, the Company entered into a Commercialization and License Agreement with Torii (the &#8220;Torii Agreement&#8221;), granting Torii the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in Japan.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Torii Agreement, the Company received an upfront, non-refundable payment of $22,000. The Japanese National Health Insurance System&#8217;s (&#8220;NHI&#8221;) approval of the addition of ORLADEYO to the NHI drug price list in April 2021 triggered a $15,000 milestone payment from Torii to the Company, which was received in May 2021.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Torii Agreement, the Company is entitled to receive tiered royalty payments, ranging from 20% to 40% of annual net sales of ORLADEYO in Japan during each calendar year. Torii&#8217;s royalty payment obligations are subject to customary reductions in certain circumstances, but may not be reduced by more than 50% of the amount that otherwise would have been payable to the Company in the applicable calendar quarter. Torii&#8217;s royalty payment obligations commenced upon the first commercial sale of ORLADEYO in Japan and expire upon the later of (i) the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMzYzNw_a3daa0dc-7723-4501-842e-5ed805a38078">ten</span>th anniversary of the date of first commercial sale of ORLADEYO in Japan, (ii) the expiration of the Company&#8217;s patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. The Company is responsible for supplying Torii with its required amounts of ORLADEYO. The activities of the parties pursuant to the Torii Agreement are overseen by a joint steering committee, composed of an equal number of representatives from each party to coordinate the development and commercialization of ORLADEYO in Japan. Torii launched ORLADEYO in Japan on April 23, 2021.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified performance obligations related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the $22,000 upfront consideration to the identified performance obligations using estimation approaches to determine the standalone selling prices under ASC Topic 606. Specifically, in determining the value related to the license, a valuation approach utilizing risk adjusted discounted cash flow projections was used, and an expected cost plus margin approach was utilized for the other performance obligations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shionogi &amp; Co., Ltd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to UAB on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Green Cross Corporation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross is responsible for all development, regulatory, and commercialization costs in Korea and the Company is entitled to share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2000, the Company licensed a series of potent inhibitors of purine nucleoside phosphorylase from AECOM and IRL (together, the &#8220;Licensors&#8221;). The lead product candidate from this collaboration is forodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute this, or any other, product candidate that might arise from research on these inhibitors. The Company has the option to expand the agreement to include other inventions in the field made by the investigators or employees of the Licensors. Under this agreement, as amended and restated, the Company has agreed to </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use commercially reasonable efforts to develop these drugs, to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000 per indication) for future development and single digit royalties on net sales of any resulting product made by the Company, and to share a portion of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. The Licensors have also granted the Company an exclusive worldwide license of galidesivir for any antiviral use.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The University of Alabama at Birmingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed by UAB with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements each have an initial 25-year term, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon three months&#8217; notice and by UAB under certain circumstances. Upon termination, both parties shall cease using the other parties&#8217; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross collaborations, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts received.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953851211904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies and Concentrations of Risk (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DescriptionOfCompanyPolicyTextBlock', window );">The Company</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in 1986 and incorporated in Delaware in 1991, and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketed products include oral, once-daily ORLADEYO&#174; for the prevention of hereditary angioedema (&#8220;HAE&#8221;) attacks and RAPIVAB&#174; (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. ORLADEYO received regulatory approval in the United States in December 2020. ORLADEYO has also received regulatory approvals in multiple global markets. The Company is commercializing ORLADEYO in each of these territories directly or through distributors, except in Japan where Torii Pharmaceutical Co., Ltd., the Company&#8217;s collaborative partner, has the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in exchange for certain milestone and royalty payments to the Company. In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada, Australia, Japan, Taiwan and Korea. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s expectations for revenue and operating expenses, the Company believes its financial resources available at September&#160;30, 2022 will be sufficient to fund its operations for at least the next 12 months. The Company has sustained operating losses for the majority of its corporate history and expects that its 2022 expenses will exceed its 2022 revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#8217;s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company regularly evaluates other opportunities to fund future operations, including: (1) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (2) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestone payments; (3) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (4) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (5) reducing spending on one or more research and development programs, including by discontinuing development; and/or (6) restructuring operations to change its overhead structure. The Company may issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#8217;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events and its decisions in the future.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the financial statements for the year ended December&#160;31, 2021 and the notes thereto included in the Company&#8217;s 2021 Annual Report on Form 10-K. Interim operating </span></div>results are not necessarily indicative of operating results for the full year. The balance sheet as of December&#160;31, 2021 has been derived from the audited consolidated financial statements included in the Company&#8217;s most recent Annual Report on Form 10-K.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the valuation of stock options, the ORLADEYO and Factor D inhibitors royalty financing obligations and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales, Net</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in December 2020, sales of peramivir to the Company&#8217;s licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) under the Company&#8217;s procurement contract. In the United States, the Company ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. In the European Union, United Kingdom and elsewhere, the Company sells ORLADEYO to specialty distributors as well as hospitals and pharmacies, which collectively are considered its customers.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue for sales when its customers obtain control of the product, which generally occurs upon delivery. For ORLADEYO, the Company classifies payments to its specialty pharmacy customer for certain services provided by its customer as selling, general and administrative expenses to the extent such services provided are determined to be distinct from the sale of its product.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or as a current liability. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government and Managed Care Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company contracts with government agencies and managed care organizations or, collectively, third-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">establishment of a current liability. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) product distribution information obtained from the Company's specialty pharmacy.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company&#8217;s specialty pharmacy. These customers purchase the Company&#8217;s product under contracts negotiated between them and the Company&#8217;s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price the specialty pharmacy paid and the negotiated price paid by the contracted customers, which may be higher or lower than the specialty pharmacy&#8217;s purchase price from the Company. The Company estimates chargebacks and adjusts gross product revenues and accounts receivable based on the estimates at the time revenues are recognized.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance and patient assistance programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company is able to estimate the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#8217;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company does not provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Research and Development Arrangements and Royalties</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has collaboration and license agreements with a number of third parties, as well as research and development agreements with certain government entities. The Company&#8217;s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not probable at the inception of the agreement </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within the HHS (&#8220;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of the Company&#8217;s license agreements, the Company receives royalty payments based upon its licensees&#8217; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash of $21 and $1,924 as of September&#160;30, 2022 and December&#160;31, 2021, respectively, reflects royalty revenue paid by Shionogi designated for interest on the PhaRMA Notes (defined in Note 6). Additionally, restricted cash of $1,423 and $1,421 as of September&#160;30, 2022 and December&#160;31, 2021, respectively, reflects collateral for a letter of credit the Company is required to maintain associated with the lease execution and build-out of its Birmingham research facilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, certificates of deposits, municipal and corporate notes and bonds, and commercial paper, among others. The Company&#8217;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 12 months. Some of the securities in which the Company invests may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#8217;s investments are not collateralized. The Company has not realized any significant losses from its investments.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At September&#160;30, 2022, the Company believes that the cost of its investments is recoverable in all material respects.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Trade Receivables</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other third-party distributors, hospitals and pharmacies in the European Union, United Kingdom and elsewhere and have standard payment terms that generally require payment within 30 to 90 days.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the HHS, and royalty receivables from the Company&#8217;s partners, including Shionogi, Green Cross, and Torii.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monthly invoices are submitted to HHS related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not adjust its receivables for the effects of a significant financing component at contract inception if it expects to collect the receivables in one year or less from the time of sale.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides reserves against trade receivables for estimated losses that may result from a customer's inability to pay. Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company&#8217;s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, labor, manufacturing overhead and shipping and handling costs on a first-in, first-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labelled products.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventories are subject to expiration dating. The Company regularly evaluates the carrying value of its inventories and provides valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, the Company may experience spoilage of its raw materials and supplies. The Company&#8217;s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company&#8217;s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of September&#160;30, 2022 and December&#160;31, 2021, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Sales</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including freight. In addition, shipping and handling costs for product shipments are recorded as incurred. Finally, cost of product sales may also include costs related to excess or obsolete inventory adjustment charges.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts, and estimates are adjusted, if required, based upon the Company&#8217;s ongoing review of the level of services actually performed.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;), and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</span></div>Deferred collaboration expenses represent sublicense payments, paid to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#8217;s academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense is primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other general and administrative costs.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expenses related to ORLADEYO were $3,476 and $11,555 for the three and nine months ended September&#160;30, 2022, respectively, and $1,492 and $4,696 for the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of September&#160;30, 2022. The Company accounts for lease obligations in accordance with ASU 2016-02: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most operating leases.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#8217;s Consolidated Balance Sheets represent payments over the lease term, which includes renewal options for certain real estate leases that the Company is likely to exercise. As part of the Company&#8217;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of twelve months or less was not material.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used in the calculation of the Company&#8217;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#8217;s collateralized borrowing rate from lending institutions.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not made any residual value guarantees related to its operating leases; therefore, the Company has no corresponding liability recorded on its Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, the Company has outstanding performance-based stock options and restricted stock units for which no compensation expense is recognized until &#8220;performance&#8221; is deemed to have occurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock', window );">Interest Expense and Deferred Financing Costs</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Deferred Financing Costs</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three and nine months ended September&#160;30, 2022 was $24,775 and $72,634, respectively, and $14,115 and $40,514 for the three and nine months ended September&#160;30, 2021, respectively, and primarily relates to the royalty financing obligations (Note 6), the secured term loan borrowing from the Credit Agreement (Note 7) and the PhaRMA Notes (Note 6). Costs directly associated with the borrowings have been capitalized and are netted against the corresponding debt liabilities on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $(258) and $(597) for the three and nine months ended September&#160;30, 2022, respectively, and $(158) and $(369) for the three and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the PhaRMA Notes and associated accrued interest payable was written-off into other income as a debt extinguishment (Refer to &#8220;Note 6&#8212;Royalty Monetizations&#8212;RAPIACTA&#8212;Non-Recourse Notes Payable &#8211; Debt Extinguishment&#8221; for additional information regarding the debt extinguishment).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock', window );">Interest Expense and Royalty Financing Obligations</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Royalty Financing Obligations</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO, BCX9930, and another earlier stage Factor D inhibitor (BCX10013). Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability method is used in the Company&#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in fiscal year 2021, the Company began accruing foreign income taxes as a result of increased nexus in foreign jurisdictions where historically the Company had no presence.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, starting in 2022, amendments to Section 174 of the Internal Revenue Code of 1986, as amended (&#8220;IRC&#8221;), will no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil. As a result of this tax law change, the Company has recorded a U.S. state tax provision for the nine months ended September 30, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company&#8217;s equity compensation plans were anti-dilutive. The calculation of diluted earnings per share does not include 26,236 and 25,918 shares of potential common stock for the three and nine months ended September&#160;30, 2022, respectively, and 28,472 and 26,131 shares of potential common stock for the three and nine months ended September&#160;30, 2021, respectively, as their impact would be anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income and recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. There were no realized gains or losses reclassified out of accumulated other comprehensive income for the nine months ended September 30, 2022.  For the nine months ended September 30, 2021, realized gains of $1 were reclassified out of accumulated other comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock', window );">Significant Customers and Other Risks</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers and Other Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Customers</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary sources of revenue and cash flow are the sales of ORLADEYO in the United States and other global markets as well as sales of RAPIVAB (peramivir injection) under the Company's procurement contract with the Assistant Secretary for Preparedness and Response within HHS. Additionally, the Company receives reimbursement of </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">galidesivir (formerly BCX4430) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ORLADEYO is distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. The specialty pharmacy&#8217;s inability or unwillingness to continue these distribution activities could adversely impact the Company&#8217;s business, results of operations and financial condition.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company is distributing ORLADEYO in other global markets directly or through distributors, except in Japan where Torii, the Company&#8217;s collaborative partner, has the exclusive right to commercialize ORLADEYO.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses has represented a significant portion of the Company&#8217;s collaborative and other research and development revenues. All government funding for galidesivir is expected to expire in 2022. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, HHS is the primary customer for RAPIVAB, and it has exercised the remaining option for the purchase of RAPIVAB under the procurement contract with the Company.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Company&#8217;s drug development activities are performed by a limited group of third-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks from Third-Party Manufacturing and Distribution Concentration</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays or disruption in the manufacture or distribution of any product could adversely impact the future procurement stockpiling of the Company&#8217;s product candidates and commercial revenue, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 12 months or less.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables from sales of ORLADEYO are primarily due from one customer, resulting in a concentration of credit risk. Sales of ORLADEYO from the Company to the specialty pharmacy only occur once an order of product has been received by the specialty pharmacy from one of its customers, which include pharmacy benefit managers, insurance companies, government programs and group purchasing organizations.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text">Recently Adopted Accounting PronouncementsThere have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the nine months ended September 30, 2022, as compared to the recent accounting pronouncements described in Note 1 of the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, that the Company believes are of s<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents accrued expenses policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents concentration of market risk policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ConcentrationOfMarketRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DescriptionOfCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of company policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DescriptionOfCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents interest expense and deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interest expense and royalty financing obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953852711680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Revenues</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following revenues (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORLADEYO</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RAPIVAB</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peramivir</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other research and development revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Health and Human Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaborative and other research and development revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,017&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75,827</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">191,282</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110,012</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953852658784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Fair Value of the Company's Investments by Type</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the fair value of the Company&#8217;s investments by type. The estimated fair values of the Company&#8217;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued<br/>Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,074)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,125&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,170)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,291&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued<br/>Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. Government and its agencies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,041&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesTextBlock', window );">Schedule of the Maturity of Investments</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the scheduled maturity for the Company&#8217;s investments at September&#160;30, 2022 and December&#160;31, 2021:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,041&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269825-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953850956288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock', window );">Summary of Receivables</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from collaborations were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Billed</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unbilled</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Health and Human Services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shionogi &amp; Co. Ltd.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty receivables from partners</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total receivables</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Billed</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unbilled</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Health and Human Services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty receivables from partners</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total receivables</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure representing receivables from collaborations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953851114848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventories consisted of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,264&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,036&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,019&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953850956288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Monetizations (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvanceRoyaltiesAbstract', window );"><strong>Advance Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyFinancingObligationsTableTextBlock', window );">Schedule of Royalty Financing Obligations</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the Royalty financing obligations account (in thousands) as well as the effective interest rate as of September&#160;30, 2022: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 RPI<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 RPI<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OMERS<br/>Royalty<br/>Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash Interest expense on Royalty financing obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues paid and payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,385)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,004&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash Interest expense on Royalty financing obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,462&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,020&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues paid and payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,702&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,155&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477,666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash Interest expense on Royalty financing obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues paid and payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyFinancingObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for royalty financing obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyFinancingObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvanceRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvanceRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953852261792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Aggregate Lease Expense Under Operating Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate lease expense under operating leases was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock', window );">Other Supplemental Information Related to Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental information related to leases was as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock', window );">Balance Sheets of the Company's Operating Leases</a></td>
<td class="text">The following table summarizes the presentation in the Consolidated Balance Sheets of the Company&#8217;s operating leases: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfMi0xLTEtMS05MzYw_842fa9e2-603a-4d76-932f-26e9d70fccbc">Other Assets</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lease financing obligation &#8211; current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lease financing obligation &#8211; long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,781&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of September&#160;30, 2022, are as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assets and liabilities of the lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Supplemental Information Related to Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953852758816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Stock Plan Activities</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related activity under the Incentive Plan is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Awards<br/>Available</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(681)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(813)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(787)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,162&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,377&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related activity under the Inducement Plan is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Awards<br/>Available</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option awards cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans</a></td>
<td class="text"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Assumptions for Stock Option Awards Granted to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Directors under the Plans</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:71.889%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected Life in Years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected Dividend Yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-Free Interest Rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953849320848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies and Concentrations of Risk (Details) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">$ 1,444,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,444,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,345,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_LongTermInvestmentMaturityMinimum', window );">Long-term investment maturity, minimum (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">3,476,000<span></span>
</td>
<td class="nump">$ 1,492,000<span></span>
</td>
<td class="nump">$ 11,555,000<span></span>
</td>
<td class="nump">$ 4,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt, total</a></td>
<td class="nump">24,775,000<span></span>
</td>
<td class="nump">14,115,000<span></span>
</td>
<td class="nump">72,634,000<span></span>
</td>
<td class="nump">40,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts', window );">Amortization of debt financing costs and original issue discounts</a></td>
<td class="num">$ (258,000)<span></span>
</td>
<td class="num">$ (158,000)<span></span>
</td>
<td class="num">$ (597,000)<span></span>
</td>
<td class="num">$ (369,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">26,236<span></span>
</td>
<td class="nump">28,472<span></span>
</td>
<td class="nump">25,918<span></span>
</td>
<td class="nump">26,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification from accumulated other comprehensive income, current period, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember', window );">Laboratory Equipment, Office Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_MaturityPeriodOfHighQualityMarketableSecurities', window );">Maturity period of high quality marketable securities (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities', window );">Average maturity period of high quality marketable securities (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_MaturityPeriodOfShortTermInvestment', window );">Maturity period of short term investment (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember', window );">Royalty Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,924,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember', window );">Collateral for Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems', window );"><strong>Significant Accounting Policies and Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">$ 1,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,421,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization of debt financing costs and original issue discounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LongTermInvestmentMaturityMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents long term investment maturity minimum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LongTermInvestmentMaturityMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityPeriodOfHighQualityMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityPeriodOfHighQualityMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityPeriodOfShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity period of short term investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityPeriodOfShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies and Concentrations of Risk</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953850351712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 75,827<span></span>
</td>
<td class="nump">$ 40,994<span></span>
</td>
<td class="nump">$ 191,282<span></span>
</td>
<td class="nump">$ 110,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">75,213<span></span>
</td>
<td class="nump">39,141<span></span>
</td>
<td class="nump">189,647<span></span>
</td>
<td class="nump">90,442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net | ORLADEYO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">65,395<span></span>
</td>
<td class="nump">36,711<span></span>
</td>
<td class="nump">179,492<span></span>
</td>
<td class="nump">76,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net | RAPIVAB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,953<span></span>
</td>
<td class="nump">2,430<span></span>
</td>
<td class="nump">7,290<span></span>
</td>
<td class="nump">7,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net | Peramivir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,865<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,865<span></span>
</td>
<td class="nump">7,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
<td class="num">(447)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_MilestoneRevenueMember', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and other research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">1,531<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">5,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and other research and development | U.S. Department of Health and Human Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 1,531<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 5,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_ORLADEYOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_ORLADEYOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_RAPIVABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_RAPIVABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_PERAMIVIRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_PERAMIVIRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_MilestoneRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_MilestoneRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953850931456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments- Fair Value of the Company's Investments by Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 215,125<span></span>
</td>
<td class="nump">$ 9,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,170)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">214,291<span></span>
</td>
<td class="nump">10,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Obligations of U.S. Government and its agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">205,133<span></span>
</td>
<td class="nump">4,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,074)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">204,348<span></span>
</td>
<td class="nump">4,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">7,337<span></span>
</td>
<td class="nump">4,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">7,310<span></span>
</td>
<td class="nump">4,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,655<span></span>
</td>
<td class="nump">1,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 2,633<span></span>
</td>
<td class="nump">$ 1,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued interest in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleDebtSecuritiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953856288848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Maturity of Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 179,959<span></span>
</td>
<td class="nump">$ 3,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo', window );">Maturing after one year through two years</a></td>
<td class="nump">34,332<span></span>
</td>
<td class="nump">6,829<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments</a></td>
<td class="nump">$ 214,291<span></span>
</td>
<td class="nump">$ 10,041<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt securities maturing after one year through two years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953852334896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade Receivables (Details Textual) - Trade Accounts Receivable - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, after allowance for credit loss, total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_ORLADEYOMember', window );">ORLADEYO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, after allowance for credit loss, total</a></td>
<td class="nump">39,565<span></span>
</td>
<td class="nump">27,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_RAPIVABMember', window );">RAPIVAB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, after allowance for credit loss, total</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, after allowance for credit loss, total</a></td>
<td class="nump">$ 701<span></span>
</td>
<td class="nump">$ 701<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_ORLADEYOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_ORLADEYOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_RAPIVABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_RAPIVABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953850361456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade Receivables - Summary of Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">$ 3,017<span></span>
</td>
<td class="nump">$ 1,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">2,774<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">1,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">U.S. Department of Health and Human Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">1,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">U.S. Department of Health and Human Services | Billed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">U.S. Department of Health and Human Services | Unbilled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">1,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiCoLtdMember', window );">Shionogi &amp; Co. Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">1,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiCoLtdMember', window );">Shionogi &amp; Co. Ltd. | Billed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">1,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiCoLtdMember', window );">Shionogi &amp; Co. Ltd. | Unbilled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_RoyaltyReceivablesFromPartnersMember', window );">Royalty receivables from partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_RoyaltyReceivablesFromPartnersMember', window );">Royalty receivables from partners | Billed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_RoyaltyReceivablesFromPartnersMember', window );">Royalty receivables from partners | Unbilled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_RoyaltyReceivablesFromPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_RoyaltyReceivablesFromPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953845199088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 8,419<span></span>
</td>
<td class="nump">$ 5,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">15,364<span></span>
</td>
<td class="nump">9,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">3,481<span></span>
</td>
<td class="nump">709<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total inventory</a></td>
<td class="nump">27,264<span></span>
</td>
<td class="nump">16,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserves</a></td>
<td class="num">(245)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory, net</a></td>
<td class="nump">$ 27,019<span></span>
</td>
<td class="nump">$ 15,791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953842794512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Monetizations (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 19, 2021</div></th>
<th class="th"><div>Mar. 09, 2021</div></th>
<th class="th"><div>Dec. 07, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 01, 2020</div></th>
<th class="th"><div>Mar. 09, 2011</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SharesIssuedCommonStockPremium', window );">Shares issued, common stock, premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | ORLADEYO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | ORLADEYO | Annual Net Sales Under $350,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty purchase agreement, royalties, percentage of annual net sales in key territories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | ORLADEYO | Annual Net Sales Between $350,000 and $550,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty purchase agreement, royalties, percentage of annual net sales in key territories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | ORLADEYO | Annual Net Sales Over $550,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty purchase agreement, royalties, percentage of annual net sales in key territories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | ORLADEYO | Annual Net Sales Under $150,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of annual net sales in other markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | ORLADEYO | Annual Net Sales Between $150,000 and $230,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of annual net sales in other markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | ORLADEYO | Annual Net Sales Over $230,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of annual net sales in other markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | BCX9930</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales', window );">Royalty purchase agreement, royalties, percentage of global annual net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | BCX9930 &amp; BCX10013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets', window );">Royalty purchase agreement, royalties, maximum tiered profit share percentage on permitted sales in other markets</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | BCX9930 &amp; BCX10013 | Annual Net Sales Over $3 Billions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold', window );">Royalty purchase agreement, royalties, annual net sales payment threshold</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust | Future Royalties Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2021And2020IntermediateFinanceTrustMember', window );">RPI 2021 and 2020 Intermediate Finance Trust | Future Royalties Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement | Annual Net Sales Under $350,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty purchase agreement, royalties, percentage of annual net sales in key territories</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement | Annual Net Sales Between $350,000 and $550,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty purchase agreement, royalties, percentage of annual net sales in key territories</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of annual net sales in other markets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement | Annual Net Sales Under $150,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement | Annual Net Sales Between $150,000 and $230,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement | BCX9930 &amp; BCX10013 | Annual Net Sales Under $1.5 Billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty purchase agreement, royalties, percentage of annual net sales in key territories</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement | BCX9930 &amp; BCX10013 | Annual Net Sales Between $1.5 and $3 Billions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty purchase agreement, royalties, percentage of annual net sales in key territories</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement | BCX9930 &amp; BCX10013 | Annual Net Sales Over $3 Billions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of annual net sales in other markets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of annual net sales in other markets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount', window );">Royalty purchase agreement, royalties, purchase price, amount</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice', window );">Royalty purchase agreement, royalties, percentage of purchase price</a></td>
<td class="nump">142.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice', window );">Royalty purchase agreement, royalties, percentage of purchase price</a></td>
<td class="nump">155.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO | Annual Net Sales Under $350,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales', window );">Royalty purchase agreement, royalties, percentage of annual net sales</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales', window );">Royalty purchase agreement, royalties, percentage of annual net sales, based on reduction in sales</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO | Annual Net Sales Between $350,000 and $550,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales', window );">Royalty purchase agreement, royalties, percentage of annual net sales</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales', window );">Royalty purchase agreement, royalties, percentage of annual net sales, based on reduction in sales</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO | Annual Net Sales Over $550,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales', window );">Royalty purchase agreement, royalties, percentage of annual net sales</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales', window );">Royalty purchase agreement, royalties, percentage of annual net sales, based on reduction in sales</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO | Annual Net Sales Under $150,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO | Annual Net Sales Between $150,000 and $230,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets | ORLADEYO | Annual Net Sales Over $230,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC | PhaRMA Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_PrivatePlacementOfSeniorSecuredNotes', window );">Private placement of senior secured notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured debt, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC | PhaRMA Notes | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC | Royalty Monetization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationsLineItems', window );"><strong>Royalty Monetizations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of secured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_TransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_InterestReserve', window );">Interest reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents interest reserve established as part of the royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PrivatePlacementOfSeniorSecuredNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents private placement of senior secured notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PrivatePlacementOfSeniorSecuredNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMonetizationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Monetizations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyMonetizationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information on the maximum dollar amount of net sales allowed for royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of net sales in certain markets for royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of annual net sales for royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>he percentage of annual net sales of royalties to be paid under the royalty purchase agreement if sales are less than specified.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of net sales in key territories for royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of annual net sales in other markets of royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of global annual net sales of royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the purchase price under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of sublicense revenue in other markets of royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the purchase price under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharesIssuedCommonStockPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information on the amount of the common stock premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharesIssuedCommonStockPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents transaction costs associated with royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_ORLADEYOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_ORLADEYOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesUnder350000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesUnder350000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesBetween350000And550000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesBetween350000And550000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOver550000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOver550000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesUnder150000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesUnder150000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesBetween150000And230000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesBetween150000And230000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOver230000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOver230000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_BCX9930Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_BCX9930Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_BCX9930BCX10013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_BCX9930BCX10013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOver3BillionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOver3BillionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_FutureRoyaltiesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_FutureRoyaltiesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_RPI2021And2020IntermediateFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_RPI2021And2020IntermediateFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesUnder15BillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesUnder15BillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesBetween15And3BillionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesBetween15And3BillionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953850300640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Monetizations - Schedule of Royalty Financing Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMontizationsRollForward', window );"><strong>Royalty Montizations [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Balance</a></td>
<td class="nump">$ 477,666<span></span>
</td>
<td class="nump">$ 464,225<span></span>
</td>
<td class="nump">$ 449,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation', window );">Non-cash Interest expense on Royalty financing obligations</a></td>
<td class="nump">18,460<span></span>
</td>
<td class="nump">19,706<span></span>
</td>
<td class="nump">19,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltiesRevenuesPaidAndPayable', window );">Royalty revenues paid and payable</a></td>
<td class="num">(6,345)<span></span>
</td>
<td class="num">(6,265)<span></span>
</td>
<td class="num">(4,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Balance</a></td>
<td class="nump">489,781<span></span>
</td>
<td class="nump">477,666<span></span>
</td>
<td class="nump">464,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_TwentyTwentyRPIRoyaltyAgreementMember', window );">2020 RPI Royalty Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMontizationsRollForward', window );"><strong>Royalty Montizations [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Balance</a></td>
<td class="nump">157,702<span></span>
</td>
<td class="nump">153,004<span></span>
</td>
<td class="nump">147,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation', window );">Non-cash Interest expense on Royalty financing obligations</a></td>
<td class="nump">9,938<span></span>
</td>
<td class="nump">10,462<span></span>
</td>
<td class="nump">10,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltiesRevenuesPaidAndPayable', window );">Royalty revenues paid and payable</a></td>
<td class="num">(5,837)<span></span>
</td>
<td class="num">(5,764)<span></span>
</td>
<td class="num">(4,385)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Balance</a></td>
<td class="nump">$ 161,802<span></span>
</td>
<td class="nump">$ 157,702<span></span>
</td>
<td class="nump">153,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">23.10%<span></span>
</td>
<td class="nump">25.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember', window );">2021 RPI Royalty Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMontizationsRollForward', window );"><strong>Royalty Montizations [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Balance</a></td>
<td class="nump">$ 164,809<span></span>
</td>
<td class="nump">$ 159,290<span></span>
</td>
<td class="nump">153,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation', window );">Non-cash Interest expense on Royalty financing obligations</a></td>
<td class="nump">4,903<span></span>
</td>
<td class="nump">6,020<span></span>
</td>
<td class="nump">6,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltiesRevenuesPaidAndPayable', window );">Royalty revenues paid and payable</a></td>
<td class="num">(508)<span></span>
</td>
<td class="num">(501)<span></span>
</td>
<td class="num">(380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Balance</a></td>
<td class="nump">$ 169,204<span></span>
</td>
<td class="nump">$ 164,809<span></span>
</td>
<td class="nump">159,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSRoyaltyAgreementMember', window );">OMERS Royalty Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyMontizationsRollForward', window );"><strong>Royalty Montizations [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Balance</a></td>
<td class="nump">$ 155,155<span></span>
</td>
<td class="nump">$ 151,931<span></span>
</td>
<td class="nump">148,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation', window );">Non-cash Interest expense on Royalty financing obligations</a></td>
<td class="nump">3,619<span></span>
</td>
<td class="nump">3,224<span></span>
</td>
<td class="nump">3,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltiesRevenuesPaidAndPayable', window );">Royalty revenues paid and payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Balance</a></td>
<td class="nump">$ 158,774<span></span>
</td>
<td class="nump">$ 155,155<span></span>
</td>
<td class="nump">$ 151,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">10.60%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_FutureRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations for future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_FutureRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash interest expense on royalty financing obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltiesRevenuesPaidAndPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents royalties revenues paid and payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltiesRevenuesPaidAndPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMontizationsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Montizations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyMontizationsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_TwentyTwentyRPIRoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_TwentyTwentyRPIRoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_OMERSRoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_OMERSRoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953848050080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 28, 2022</div></th>
<th class="th"><div>Jun. 28, 2022</div></th>
<th class="th"><div>Dec. 07, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jul. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-kind interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,311,000<span></span>
</td>
<td class="nump">$ 11,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt instrument, unamortized discount (premium) and debt issuance costs, net, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,509,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(597,000)<span></span>
</td>
<td class="num">$ (369,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bcrx_TermBAndCLoanMember', window );">Term B And C Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt instrument, unamortized discount (premium) and debt issuance costs, net, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">MidCap Financial Services, LLC | Senior Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,298,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement | Athyrium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentLiborFloor', window );">Debt instrument, LIBOR floor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentLiborCap', window );">Debt instrument, LIBOR cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentExitFeePercentageOfPrincipal', window );">Debt instrument, exit fee, percentage of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentCommitmentFeePercentage', window );">Debt instrument, commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 232,376,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement | Athyrium | Prior to the Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt instrument, prepayment fee, percentage of principal voluntary payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest', window );">Debt instrument, prepayment fee, percentage of accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement | Athyrium | Between the Second and Third Anniversaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt instrument, prepayment fee, percentage of principal voluntary payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement | Athyrium | Between the Third and Fourth Anniversaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt instrument, prepayment fee, percentage of principal voluntary payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement | Athyrium | After Fourth Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt instrument, prepayment fee, percentage of principal voluntary payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement | Athyrium | Term Loan A Drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents', window );">Debt instrument, covenant, minimum unrestricted cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement | Athyrium | Term Loan A and B Drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents', window );">Debt instrument, covenant, minimum unrestricted cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement | Athyrium | Term Loans A, B and C Drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents', window );">Debt instrument, covenant, minimum unrestricted cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement | Athyrium | Term Loans A, B and C Drawn and Cure Right Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents', window );">Debt instrument, covenant, minimum unrestricted cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement | Athyrium | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement | Athyrium | London Interbank Offered Rate (LIBOR) | PIK Interest Payment is Made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">10.25%<span></span>
</td>
<td class="nump">10.25%<span></span>
</td>
<td class="nump">10.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement | Athyrium | Term A Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement | Athyrium | Term B Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement | Athyrium | Term C Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement | Athyrium | Term B And C Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The commitment fee percentage of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of unrestricted cash and cash equivalents required under the covenant of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentExitFeePercentageOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of principal for exit fee of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentExitFeePercentageOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentLiborCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum LIBOR interest rate for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentLiborCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentLiborFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum LIBOR interest rate for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentLiborFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of interest that would have accrued on principal voluntary paid for prepayment fee of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of principal paid voluntarily for prepayment fee of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_TermBAndCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_TermBAndCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_AthyriumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_AthyriumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtCovenantTermsAxis=bcrx_PriorToTheSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtCovenantTermsAxis=bcrx_PriorToTheSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtCovenantTermsAxis=bcrx_BetweenTheSecondAndThirdAnniversariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtCovenantTermsAxis=bcrx_BetweenTheSecondAndThirdAnniversariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtCovenantTermsAxis=bcrx_BetweenTheThirdAndFourthAnniversariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtCovenantTermsAxis=bcrx_BetweenTheThirdAndFourthAnniversariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtCovenantTermsAxis=bcrx_AfterFourthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtCovenantTermsAxis=bcrx_AfterFourthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtCovenantTermsAxis=bcrx_TermLoanADrawnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtCovenantTermsAxis=bcrx_TermLoanADrawnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtCovenantTermsAxis=bcrx_TermLoanAAndBDrawnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtCovenantTermsAxis=bcrx_TermLoanAAndBDrawnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtCovenantTermsAxis=bcrx_TermLoansABAndCDrawnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtCovenantTermsAxis=bcrx_TermLoansABAndCDrawnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtCovenantTermsAxis=bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtCovenantTermsAxis=bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtCovenantTermsAxis=bcrx_PikInterestPaymentIsMadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtCovenantTermsAxis=bcrx_PikInterestPaymentIsMadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_TermALoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_TermALoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_TermBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_TermBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_TermCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_TermCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953842668848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">10.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization', window );">Operating lease, right-of-use asset, accumulated amortization</a></td>
<td class="nump">$ 3,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="nump">$ 615<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">$ 1,796<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization on lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953848957776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations - Aggregate Lease Expense Under Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_AggregateLeaseExpense', window );">Aggregate lease expense</a></td>
<td class="nump">$ 634<span></span>
</td>
<td class="nump">$ 393<span></span>
</td>
<td class="nump">$ 1,854<span></span>
</td>
<td class="nump">$ 1,306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AggregateLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AggregateLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953857432992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligations - Other Supplemental Information Related to Leases (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">10.90%<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953856182736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligations -Balance Sheets of the Company's Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_OperatingLeaseAssets', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets, net</a></td>
<td class="nump">$ 6,797<span></span>
</td>
<td class="nump">$ 6,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Other assets [extensible enumeration]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease financing obligation</a></td>
<td class="nump">$ 2,196<span></span>
</td>
<td class="nump">1,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease financing obligation</a></td>
<td class="nump">5,968<span></span>
</td>
<td class="nump">5,962<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 8,164<span></span>
</td>
<td class="nump">$ 7,781<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_OperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information on operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_OperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953851154368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligations - Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (remaining)</a></td>
<td class="nump">$ 684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">2,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">6,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">13,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(5,465)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 8,164<span></span>
</td>
<td class="nump">$ 7,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating lease, liability, statement of financial position [extensible enumeration]</a></td>
<td class="text">Accrued expenses<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953852226512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 19, 2021</div></th>
<th class="th"><div>Nov. 17, 2021</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcrx_CommonStockPurchaseAgreementWithRPIMember', window );">Common Stock Purchase Agreement with RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues (in shares)</a></td>
<td class="nump">3,846,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in usd per share)</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SharesIssuedPricePerSharePremium', window );">Shares issued, price per share, premium (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SharesIssuedPricePerShareClosingPrice', window );">Shares issued, price per share, closing price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SharesIssuedCommonStockPremium', window );">Shares issued, common stock, premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharesIssuedCommonStockPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information on the amount of the common stock premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharesIssuedCommonStockPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharesIssuedPricePerShareClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information on the closing price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharesIssuedPricePerShareClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharesIssuedPricePerSharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>information on the premium over the closing price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharesIssuedPricePerSharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bcrx_CommonStockPurchaseAgreementWithRPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bcrx_CommonStockPurchaseAgreementWithRPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953841470896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Details Textual)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ShareBasedPaymentArrangementNumberOfPlans', window );">Number of plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,421<span></span>
</td>
<td class="nump">$ 26,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense related to non-vested stock options and RSU awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear', window );">Compensation cost expected to be recognized for remainder of fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear', window );">Compensation cost expected to be recognized next year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo', window );">Compensation cost expected to be recognized year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree', window );">Compensation cost expected to be recognized year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour', window );">Compensation cost expected to be recognized year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan sales, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option | Non-employee Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,687<span></span>
</td>
<td class="nump">$ 19,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock shares available for purchase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan | Share-Based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value stock option awards (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.78<span></span>
</td>
<td class="nump">$ 8.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan | Share-Based Payment Arrangement, Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option awards remaining contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan | Share-Based Payment Arrangement, Option | Vest 25% Each Year Until Fully Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan | Share-Based Payment Arrangement, Option | Thirty-six Equal Monthly Installments | Non-employee Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan | Performance Shares | Vest Upon Successful Completion of Specific Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Performance-based stock options issued in period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan | Performance-based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan | Performance-based Restricted Stock Units | Vest 25% Each Year Until Fully Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan | Performance-based Restricted Stock Units | Vest Upon Successful Completion of Specific Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Performance-based restricted stock unit awards issued (in shares) | shares</a></td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan | Performance-based Restricted Stock Units | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.18<span></span>
</td>
<td class="nump">$ 10.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,604<span></span>
</td>
<td class="nump">$ 5,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value stock option awards (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.72<span></span>
</td>
<td class="nump">$ 9.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock shares available for purchase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan | Vest 25% Each Year Until Fully Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan | Share-Based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,130<span></span>
</td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock authorized to be purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock shares available for purchase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum', window );">Percentage of salary to purchase common stock, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesBeginning', window );">Percentage of common stock shares, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesEnding', window );">Percentage of common stock shares, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares per employee (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount', window );">Maximum number of shares per employee, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share-based compensation nonvested awards compensation cost expected to be recognized next year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares beginning.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares ending.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of salary to purchase common stock maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedPaymentArrangementNumberOfPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Number of Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedPaymentArrangementNumberOfPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_ThirtysixEqualMonthlyInstallmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_ThirtysixEqualMonthlyInstallmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bcrx_PerformancebasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bcrx_PerformancebasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953847775008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Plan Activities (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options outstanding, stock option awards exercised (in shares)</a></td>
<td class="num">(390)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(1,108)<span></span>
</td>
<td class="num">(942)<span></span>
</td>
<td class="num">(1,056)<span></span>
</td>
<td class="num">(593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Awards Available</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares', window );">Plan amendment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards available, restricted stock awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards available, restricted stock awards cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable', window );">Awards available, stock option awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(813)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable', window );">Awards available, stock option awards cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, ending balance (in shares)</a></td>
<td class="nump">11,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options outstanding, stock option awards granted ( in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options outstanding, stock option awards exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options outstanding, stock option awards cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(787)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">27,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of stock option awards granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of stock option awards exercised (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of stock option awards cancelled (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in usd per share)</a></td>
<td class="nump">$ 8.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Awards Available</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares', window );">Plan amendment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards available, restricted stock awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards available, restricted stock awards cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable', window );">Awards available, stock option awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable', window );">Awards available, stock option awards cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, ending balance (in shares)</a></td>
<td class="nump">1,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options outstanding, stock option awards granted ( in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options outstanding, stock option awards exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options outstanding, stock option awards cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">5,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of stock option awards granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of stock option awards exercised (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of stock option awards cancelled (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in usd per share)</a></td>
<td class="nump">$ 8.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Plan Amendment, Awards In Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents share based compensation arrangement by share based payment award options grants in period awards available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options forfeitures in period awards available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953852899648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details) - Incentive Plan and Inducement Plan<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life in Years</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">84.10%<span></span>
</td>
<td class="nump">84.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-Free Interest Rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139953842345424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 25, 2022 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Sep. 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 05, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2018 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Sep. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2000 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,827<span></span>
</td>
<td class="nump">$ 40,994<span></span>
</td>
<td class="nump">$ 191,282<span></span>
</td>
<td class="nump">$ 110,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">U.S. Department of Health and Human Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractValue', window );">Collaborative agreement contract value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ContractTerm', window );">Contract term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">U.S. Department of Health and Human Services | RAPIVAB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses', window );">Maximum number of products, doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_NumberOfProductsObtainedDoses', window );">Number of doses delivered, doses | dose</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="nump">$ 6,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone', window );">Potential milestone payments receivable if regulatory approval before specified date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_MaximumCustomaryReductionOnRoyaltyRate', window );">Maximum customary reduction on royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial', window );">Royalty payments receivable, expiration term from first commercial (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation', window );">Royalty rate if maintains sakigake designation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation', window );">Royalty rate if maintains sakigake designation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember', window );">Base Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government contract receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember', window );">Additional Development Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government contract receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember', window );">ASPRBARDA Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government contract receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for research and development contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember', window );">AECOM and IRL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_MilestonePaymentMinimum', window );">Milestone payment minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone payment maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMinimum', window );">Annual license fee minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMaximum', window );">Annual license fee maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">National Institute of Allergy and Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts', window );">Expected receivable from awards for research and development contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding', window );">Potential aggregate maximum amount of funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractValue', window );">Collaborative agreement contract value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember', window );">UAB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Collaborative and Other Relationships [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_PeriodOfAgreement', window );">Period of agreement (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bcrx_RenewablePeriodOfAgreement', window );">Renewable period of agreement (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents annual maximum license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent minimum annual license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement contract maximum amount if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementContractValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement contract value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementContractValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between the contract date and its expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents expected receivable from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumCustomaryReductionOnRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of customary reductions allowed on royalty rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumCustomaryReductionOnRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information on the maximum number of doses of RAPIVAB permitted under the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment minimum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfProductsObtainedDoses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Products Obtained Doses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NumberOfProductsObtainedDoses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents period of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payments receivable if regulatory approval is granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents proceeds from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RenewablePeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents renewable period of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RenewablePeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expiration term of the royalty payments from first commercial date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyRateIfMaintainsSakigakeDesignation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables that are derived from government contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55295-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_RAPIVABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_RAPIVABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>bcrx-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bcrx="http://www.biocryst.com/20220930"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bcrx-20220930.xsd" xlink:type="simple"/>
    <context id="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib45ffcc775c34a8ebd2fcae622dd7ea1_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="idb265a8308724c57833eccc5d77be8aa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie20bac9cd8014f8cb989d999d452c248_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02cd59e16e0149199ce28d859c3ac6a8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i03da29ccbd9f4d09beeb6288fdf053b4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id38b2ee116544f90a76e9d8b6d33f39b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if885f6f8cf8d4e339f135dd75b604594_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9b2b8611a0384b2e8a19a43ecfab2135_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i06ca5f40fc4b4aa98634268fcf2525a0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie51f3d3839d1472ea8a99419a9e1d1dd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i69c7f898fb47496b80d856f7a82a5454_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7d334c267d664d22a3b7769ac993451a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:MilestoneRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8fa865c7a786428b8ce79ebf9351f4ad_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:MilestoneRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9dd8066819384bae8b29a1bc99808b48_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:MilestoneRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9435042756cd4d408e47bff42738cf8e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:MilestoneRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i67cf7bf22deb4aff91b49db594f6a877_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7382589fe0034462aa011f377b6998da_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6dde7334e062479ab641b4c89a0a55e4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i89dd57b2bc7948769d0753db905659dd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i41745e32b23b47e7a00caf0e1c1db339_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a3b74ad1e0f4442b522495e111be937_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i91882c79d9d24c96aa878de55cbae53b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95ba6a07e68a459195b3cded3ca6d43a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2765f24346841dfa50adf712fcd6e0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50edc98ace4c4817bc584c2cd01683db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1da831eb386440a9ae03883cb9de9c2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib2e88ed6e0ef4275a5cbc5b2259cb414_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib471f07fd4b04491b1575b8c3455d232_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if67232e493004bbe9a89d123b94f9781_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i15308f75ade643a5bd5c3c0ad201bd13_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2bbcac9495d54029ab8d5adb83847966_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if036eb5c6c274213bd73c03c974994a7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i153d098e317143b991cc8821cf708987_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i705ede78548e4661a484496cffb01473_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5b50a0d24e4a41a098b3d1ead84b5e3d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3fb8db5ef2e34b14ab9a1ba55b73c8cb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if913b8a18461412aaa90a9e59f28bbb9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0b867b6cc56641799cba16d11bfa60a4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i39c3785f664d490d93d4cc107acc6eab_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4a1c4dc78aff440ba2b7ae2d04ee9ebb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia81363840c6d47819c0a0300f9de63ea_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifc1eb8ebb6744a0a90475dfb612381f8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaaaa54dd893e44a9ba927dae3ebc58fc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7d973d539b60454bb3e347b4bb6c7431_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9896466435844fdaadb265c1f69482cc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia35fcc7c1df8404fa70855f6f2fe6cee_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib07b7833ec9c4f5ba79349d729d7e86a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifcb838f1aea441109992ece58d5d1419_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i41766aec3ee549cc9ffd2983c192fdc0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idf830df2b86a45cd9f92bf47fec71ee6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i29f30a466222458bb694b5b460e4b5fb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i17fd2b8b68ab41d29358bf85ce87dc12_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61c4036a23a640018a70d37f4b27fb0b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1588d8fa978d43ecbc8214f1b4283763_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id581e5368d914277ac0ce9fee558e4ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5d58b9fd63041f3bc17cf6fc173034b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if076f350ff45436996af2f05839c8882_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie9fa7ce59f8e428fba39af60c2c10e30_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i762c8172b9e54274a05337bb853015e5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4a9b9d93a9dc4310ae5a5a00e96b249e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7a3ae9e595754fd8b7b517f5d6502c61_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifdcafea902a94b74806fbbc66676de9b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7a87a730f5264586b524537e3168930d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2f09c79fd6f5409491477c45b1543e48_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9086f7c6548c4033b8ecf3a3a2cc454e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icb74c52ede444e4585f9077b04bd8f51_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ife6d0af669364983a00fd3d0254f171b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i99d7ba3d2a234849a4f237f0d5b55516_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7be39acc2a414f32b4108381b199c1d2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i00f4f783bc4640caa49ae534564dda62_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i49595be0c9ca44d8bdf145a82b2c37a0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5fffddbb207f442684761c141969e63e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifc7f6cadfe9a4eeab4afe3e1661f4099_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i766e3bef22c54ee3bdab656c940663e9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie4937c63164a42b3a6326fc7d4b4babe_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iec324695fb5c455faa27509e51bd78b4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaea012f1493f49fd8a6586b2899d6b3a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iac6aea1e78d3493ea6d07c8e22679e2e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic7b7c292e90941a398476976288e3ff4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic4fd1209b6f7440bb9686323eb1893fc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1c7532d73a584500bbd44288b8006073_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie5a7cdd440cf410c82c96bf461ca3e07_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ieb951a6478734d308e70fb7798d6529f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibc1913ba4028440697583a0160c2c9a9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2b656b9adf614afe8e4311bfc8c36b08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4bab20e161348dda0d3fc5277f3602c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iff682572ef0b4643862b85d792331a8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c206d1885894084b6b64b92557dff74_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i30f04607b9fd4fbd8d1e3b4e116511df_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4f4820f68b75491386429192e255c412_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iacbf3ec994f848c3afd3f6edf48b0963_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i01b1e25bb16a4e61b3726d6578c74362_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i085d63dc06a84f6ea9de568acc4df142_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i451dda4c3a8e4ccfad33168494bc9c9d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaae1596b0387405c82740b7390d33d38_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iadb0a3977d2e464381bb4a2a4912955b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i72fe97c0b03a4aefa6351d9bbfc48eb8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id2b500470aa1440998f2b21760e6893f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8d1a5d14f8b040478c08a0ed5704b783_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i20a97685da3b4dc781181f5228701bd4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:PERAMIVIRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i95e09ca159fe4d35ad4cf6c7111aadae_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:PERAMIVIRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6355a4b7fee3482482574de4cadc4f2c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:PERAMIVIRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i530113c61c0045f5a77ebf99982dd4cf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:PERAMIVIRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i300f876718414e03a6d92b6eef13452b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4a43835db50e40aa8dae8ed521e3d03c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibc7c54d81f614da2bf398d8589ddba3d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4ca21205297a4dce8632aec47144b369_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iae7bd5bdeed04eb0a29ec0c7ed2a15cd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9ae49712cd2e41b4952fd9e10638809f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id7cb4025c8734daeb09b21962b869678_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icba59a9ed8954f15bb323330c2072dc7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9834b9d88aa64e0e826bd49839d8f0a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i138269de9639423b9754ab90611310ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d5cc209df4b4f158f63ba78067df1d3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0bf1868a8c07401995c9209a9fed2a20_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i822a4f18efa9407ca27d5a5c54dbf5e2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i00f15b2faead42f68b751bfd1a5a76bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3fad271ec831459885eb81d1bf350ac2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1c255209851347d2823e94f1a619328e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i148b60adb92b488a9a9a9586b8ce630f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i39ef3ff428bf4f4891cb088a64691907_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i575f84670ae346f3b0aaf66dac4ce33a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i555cad33b5d44135b244268bf4d08939_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6909fce5d6ea480fb5472075566b87fa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib207348a887d4eac8ea660147a235790_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i30df1d46204d4ed3bcab448f681a0f99_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibe28a0b9ba504c29a6bbfb22a00d691b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9164b1431b374f07841c05f4d2661cf0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic5b5e996fc4f46a0bea68e7eae665edd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i527a858d3bdd48b4bbbc58eaa0c86127_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i61c931a38b8f4fb79cd7b1bfc15541af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifba625b9dbe14b648921db96471dc959_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib09e2423a7504296aafabf85a78b11e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06da809ae51d46f4a859c0e6d5105e1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie681521de8e8461695ee96dbd9571fcb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie154d98fc18c4a1bb3006dded763756f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97245d53c4b147daaf476637df025ab6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9144542bf0074b97b464b99a2e251ddb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ed0f773e01c46b0a1ec1a9b710e5c96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c2f2931216342fc952334687bc6784f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id71eb7a7f4934c329e8946aad8843f79_I20110309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-03-09</instant>
        </period>
    </context>
    <context id="i6cd2274f76d84f7d8aa1fecb06595801_D20210309-20210309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-09</startDate>
            <endDate>2021-03-09</endDate>
        </period>
    </context>
    <context id="ifa8c84cacb9b47f0858154719b4d86b1_D20210309-20210309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-09</startDate>
            <endDate>2021-03-09</endDate>
        </period>
    </context>
    <context id="i9da1b8e68e3943f4b431a7f4b8c6ddb6_I20110309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-03-09</instant>
        </period>
    </context>
    <context id="i6a9d2be26d104c7f88a240ce0bdae3b0_I20201201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-01</instant>
        </period>
    </context>
    <context id="ifc57076200334d0195d02ed18bd1d7f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3555a1cac734984b0bc78b41179373c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i40eed59cc9974d4da70c7edd9d0d8c82_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="i659ab2cd433f43e38df5288340793caf_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="id0d847dbf3cc433cb71781a71246c04d_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="i8229178c1776432b9a14327383dbd4e8_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="i6c43924485804171baf9b85f8c65941c_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="i8038e6b568aa4157a7628b82914dffe6_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="i3a1f4d036f7c4e5698e71c2f543364b0_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="i131aea96e86e4fbbbd650ebc98f6ffca_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="if618ed9fbfce4a02b7658195a856d8be_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="i67142cf4c13a4d68bc0ac1f76af05df3_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2021And2020IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i7f1b22877b3740e68dd9cfbae1ff0365_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i42c79576567c4b2bbc81a0de713c8389_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i1c82dcc5f02c4662947d1881f5cc203e_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="if9cf1579776d4680a6bf379ea0a42c2c_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="iab0a5cddb915447c9e805b68ffc9d835_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930BCX10013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder15BillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="ibeeda3897a624890bc65185aab3a382f_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930BCX10013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween15And3BillionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i43d710969d584356a886f1c9563fef66_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930BCX10013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver3BillionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="iea24828b86d54f41a2b4874e96d088f2_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930BCX10013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver3BillionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i7c6e9851b8104036bbcd12e9aa0bc4a8_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930BCX10013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i922a1d857b42485f92214971ed78a0da_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="ie7f72565b0f5439abca0ea90d3a6f24b_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i11b7628d9fda491980452daac486f097_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i1b2bc1c2bed841eb99664d403903ea7f_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i178ec38dd6014b1d9adf94656a10b03e_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i92914c34dfeb459cb7418faf28e8f5c5_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i782dba101c4049a68737ea34eaa114a0_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i96ce4725997d4522ab18ef4f78970321_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="ifd9066e5a18b494489a571f56afaf09a_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i4d5e09b3fd4d49c3acbe8c9499ec13f9_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:AnnualNetSalesRangeAxis">bcrx:AnnualNetSalesOver230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i0a099c2a65d543edbf8358cc0e472f2a_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i1a14b6aff29e4ab0899284236dbee713_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i3387c2eb985849859a399492ce421ce8_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="ib7810c48b6754267aa2a3f2a660bf13e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib01a977ea3bd4a78aca463e3dcbcae61_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id6782cfa98ec4a439c817a6ffa240688_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie0126a3e3d9242d79ce8101efe7c2a9f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib0dc4b1e9eb848818b47548abe6e3324_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i492a9e744ab44aecb99a707368b9137a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibede6ebb23bb41718df5c414f9e0d733_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7aa7623896fd466a8100ad400138b291_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3fe7ee6d739f433bac2aa26b00c08cb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic215859d996647a59c854764e5c698e1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia0a54a935fad483f8a7abc4b9481af07_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2a395490d1fb4b4a89833e1ca81fdd7b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3864fa52358945bfbd68481e97ea6545_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2633d031d70949ebac044dd59a84d949_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id7bfbb0963cd492f8cc0ff3fbce8c491_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i274b955cf1e1448988b54629cbefc21c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4b0b77fa77814d6686ce59c957db2ab2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i106ce134a512494ea43edc85bb29e49c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic550bdd44f464d7e8684a82d73605d43_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1fe7d973553d4d5abc3a63e8fec38c3a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i11cfeff79ad34520b776332a393c0b35_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i86233c8a15e74c029b96ae45ad9b3911_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i63012785f2d64008b6eb5c1c19199d9b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7b8c0ef1641d490bad48d0ce9744d424_I20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="i03bffbefba234cc0a1128fb5302a1f91_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermALoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="i7929cd2eb5634ff0ac5139d08ffc47a8_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="ice4776aac34540989938d21b8dfb4e97_I20220729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermBLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-29</instant>
        </period>
    </context>
    <context id="ia003b9df8396437497d66b989248c2b6_I20220729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermCLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-29</instant>
        </period>
    </context>
    <context id="i709dd3e270264784bde603419255d61f_I20220729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermBAndCLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-29</instant>
        </period>
    </context>
    <context id="i15ce1d8574044e7da22ce59b9f6dd167_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="ia232f6672e22447fb6af60f22e2ceb87_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="icf6c8a213e4c4e488e6eb643867a2197_D20220628-20220628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-28</startDate>
            <endDate>2022-06-28</endDate>
        </period>
    </context>
    <context id="icde5f4a46a1c4f8c83cf48af673b7a45_D20220928-20220928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-28</startDate>
            <endDate>2022-09-28</endDate>
        </period>
    </context>
    <context id="i89ce560e3ccb4a498fdff95231d6e1c9_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:PriorToTheSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="i74fcf15aaa914945ab7836b9ee0ad9e5_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:BetweenTheSecondAndThirdAnniversariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="iad2a1f48ddac433db045de7d1a2ebd84_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:BetweenTheThirdAndFourthAnniversariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="id4ae9ab1e00c4d9bbb0a43e40f958d82_D20201207-20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:AfterFourthAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="i48c8f87e596a4a9797c757c4107dca8e_I20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:TermLoanADrawnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="i029bc0b0132a43d3a133840d08bafae3_I20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:TermLoanAAndBDrawnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="i81bdcb366fcb440dac7cccb46bc6c432_I20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:TermLoansABAndCDrawnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="id1df07995b624c41ad1f4b2eb4c8b729_I20201207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bcrx:DebtCovenantTermsAxis">bcrx:TermLoansABAndCDrawnAndCureRightExercisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="i577b5813966249238ff1a37dcadb61ec_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iad15e5ebbe854d989fa28f085ec20706_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermBAndCLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7c80142b202447dcb8ead43698b1102f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i52f9872ea30d41b1879aa0576f67e92d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ief8dcbde5b0e41c3bb5a8ebe4a804426_I20200424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2020-04-24</instant>
        </period>
    </context>
    <context id="i8832490c13ad4270a151ea2cb8adc636_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcrx:CommonStockPurchaseAgreementWithRPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i85cc5e9604864268a804d5d399fb8420_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcrx:CommonStockPurchaseAgreementWithRPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="ic0f22034638c4665942e299d6fb219aa_I20211117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcrx:CommonStockPurchaseAgreementWithRPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-17</instant>
        </period>
    </context>
    <context id="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i13db33977a904b03be5d11e9b117d150_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibd71d21d51204504b4c1150f43b3bc59_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id57db78843ad455581cbbe07f42c6f48_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3c2fb0c425f946d798549cf02852e9ea_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i861f5991bef64ba4ae244c970bd11b45_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b5364d1d1904b7bb97eaee357c6a65b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3bf5349aab0e46d5b3e8bc79f32bc420_D20141201-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="i462f026921bb4afe83030f8fadf9da13_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="ib155b4c963014e029dd2f85fefc4a14e_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i67e8248b60f64ce28584296c7129913e_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="icacb2b425bc14f50b771626f8aa5b582_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcrx:NonEmployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:ThirtysixEqualMonthlyInstallmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia6112bb62bc84e76a366906fa6013306_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcrx:NonEmployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4e78b10dfe9d40829b789acc025a272e_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i597f21b52a2341598aca37ab541e979b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i33b8d296b67f42aa822d875c50677a2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f2ae249b8c14d8c879f0c3632532318_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5250a5d435e4416ea19390c093e8d969_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i91216e37813c427d9f33a23eb389ed62_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i41d42bfc79fc4caf8d758c368878895a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9c9a5b90264d44ee9f8599fe14b89e37_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if2932078af7f45c0bfcbbbc172f1e3f7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6e4a49026de84920a3819232a6a19cd9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d8b3a042362474cbb230d0362f4776c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibdd2f542ee4f472fbd033582bf493f66_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie6d5329452f640458e577180ba9077a1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1c0bfd7955ac4b51957fb2e28260133d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9b8f1d28ff564258a3694150b17ecfbc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i612bfa266c9d4fdaabd216b7743222f3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6962c7b3c532429d9dc533d16085a1be_D20210915-20210915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-15</startDate>
            <endDate>2021-09-15</endDate>
        </period>
    </context>
    <context id="i7e86c77b3f93473aba60a62ad6ac9c1a_D20130930-20130930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-09-30</startDate>
            <endDate>2013-09-30</endDate>
        </period>
    </context>
    <context id="i9fe0f9acd7e14572953ee3262d1924ec_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i939d2e62994c419ba66434c3debb0192_I20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:BaseContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="ie89d5e9da1fb4552906ccc29db0c6910_I20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AdditionalDevelopmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="i5578f786012042cb8b526aad1347720f_I20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="ic71ceab0e4b64e95b2df289f6f3faaec_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id43ef6e8fa364fd8b928caaf91fbd1a6_D20180906-20180906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-06</startDate>
            <endDate>2018-09-06</endDate>
        </period>
    </context>
    <context id="i535cf829316841bfa7015ff15880d35a_D20180906-20180906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-06</startDate>
            <endDate>2018-09-06</endDate>
        </period>
    </context>
    <context id="i285e93f7aad44dada9abb5c04565a489_D20220825-20220825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-25</startDate>
            <endDate>2022-08-25</endDate>
        </period>
    </context>
    <context id="ic103b1fd563c46dbb16e1ab091c2bc47_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i726cc8c2bd0b4ed78ad0a2c84ed2479c_D20191105-20191105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-05</startDate>
            <endDate>2019-11-05</endDate>
        </period>
    </context>
    <context id="i2fb11f122dad4dbb93a70888951bbc85_I20191105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="i4097a995127f49fa8ee4dd7b99237dda_I20191105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="iabfffedc39c340fabce60b94d0d32249_I20191105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="i90941783cef64f03915cc4e7222642e6_D20000601-20000630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2000-06-01</startDate>
            <endDate>2000-06-30</endDate>
        </period>
    </context>
    <context id="i8cba6072ef5b463d92db14b5c09be6b9_I20000630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2000-06-30</instant>
        </period>
    </context>
    <context id="ifba7c735102f46f692d875d1a37529f9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:UABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="plan">
        <measure>bcrx:plan</measure>
    </unit>
    <unit id="dose">
        <measure>bcrx:dose</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80L2ZyYWc6OWIxYjY5MWVkNzkxNDA2NjhlNzhkNWIwMGYxNTZmOWYvdGFibGU6ZGZkZDI5MTg0MmZkNDA5MzhmYjc4YzRlNDMwMzU2NTUvdGFibGVyYW5nZTpkZmRkMjkxODQyZmQ0MDkzOGZiNzhjNGU0MzAzNTY1NV8yLTEtMS0xLTkzNjA_fef75201-25a8-43ca-9d7e-f78b411aa010">0000882796</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80L2ZyYWc6OWIxYjY5MWVkNzkxNDA2NjhlNzhkNWIwMGYxNTZmOWYvdGFibGU6ZGZkZDI5MTg0MmZkNDA5MzhmYjc4YzRlNDMwMzU2NTUvdGFibGVyYW5nZTpkZmRkMjkxODQyZmQ0MDkzOGZiNzhjNGU0MzAzNTY1NV80LTEtMS0xLTkzNjA_f19a80c5-04cd-46d8-a15b-1141ee45cbdc">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80L2ZyYWc6OWIxYjY5MWVkNzkxNDA2NjhlNzhkNWIwMGYxNTZmOWYvdGFibGU6ZGZkZDI5MTg0MmZkNDA5MzhmYjc4YzRlNDMwMzU2NTUvdGFibGVyYW5nZTpkZmRkMjkxODQyZmQ0MDkzOGZiNzhjNGU0MzAzNTY1NV81LTEtMS0xLTkzNjA_fc4a3ed2-3056-4eb2-86e0-b6368bf661b8">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80L2ZyYWc6OWIxYjY5MWVkNzkxNDA2NjhlNzhkNWIwMGYxNTZmOWYvdGFibGU6ZGZkZDI5MTg0MmZkNDA5MzhmYjc4YzRlNDMwMzU2NTUvdGFibGVyYW5nZTpkZmRkMjkxODQyZmQ0MDkzOGZiNzhjNGU0MzAzNTY1NV82LTEtMS0xLTkzNjA_41d560ac-6bd5-418f-9ce6-69b8b071c012">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80L2ZyYWc6OWIxYjY5MWVkNzkxNDA2NjhlNzhkNWIwMGYxNTZmOWYvdGFibGU6ZGZkZDI5MTg0MmZkNDA5MzhmYjc4YzRlNDMwMzU2NTUvdGFibGVyYW5nZTpkZmRkMjkxODQyZmQ0MDkzOGZiNzhjNGU0MzAzNTY1NV83LTEtMS0xLTkzNjA_99559cc3-a113-4eff-8a81-c7015483ecb5">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfMi0xLTEtMS05MzYw_842fa9e2-603a-4d76-932f-26e9d70fccbc">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMTUvZnJhZzo0MjMxN2NhZjU4NDc0MTgwYjQ4NzczZTcwYWYyMjY4Yy90ZXh0cmVnaW9uOjQyMzE3Y2FmNTg0NzQxODBiNDg3NzNlNzBhZjIyNjhjXzEwOTk1MTE2Mjc5NjM_14196b86-b52b-4a5f-a62a-af498a366b99">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <bcrx:RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial
      contextRef="i726cc8c2bd0b4ed78ad0a2c84ed2479c_D20191105-20191105"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMzYzNw_a3daa0dc-7723-4501-842e-5ed805a38078">P10Y</bcrx:RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial>
    <dei:DocumentType
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTQ1_24694232-1591-4331-be92-dd1c0e51d702">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTQ2_0f873daf-2a6d-4368-8862-69ff5ec255d5">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTA_1b631481-1c2c-4a08-bedc-052b184aef5e">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTUy_1e181d0d-a1c1-438b-85ad-65fe947a4fa8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTQ3_4771dc9b-12d3-4f0b-ba3c-90012485f3f0">000-23186</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTQ4_47f8f985-db08-4fb5-9c45-ea3bef4eb334">BIOCRYST PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6NmQyYWEwMmU4N2MxNDIwODljMDkyZWE5MTJiMTQzZTQvdGFibGVyYW5nZTo2ZDJhYTAyZTg3YzE0MjA4OWMwOTJlYTkxMmIxNDNlNF8wLTAtMS0xLTkzNjA_fcaa8312-fa6c-4c4c-9ef1-3405a4960284">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6NmQyYWEwMmU4N2MxNDIwODljMDkyZWE5MTJiMTQzZTQvdGFibGVyYW5nZTo2ZDJhYTAyZTg3YzE0MjA4OWMwOTJlYTkxMmIxNDNlNF8wLTEtMS0xLTkzNjA_ab26b699-d154-4e26-9ed3-ff335b220dec">62-1413174</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6NmQyYWEwMmU4N2MxNDIwODljMDkyZWE5MTJiMTQzZTQvdGFibGVyYW5nZTo2ZDJhYTAyZTg3YzE0MjA4OWMwOTJlYTkxMmIxNDNlNF80LTAtMS0xLTkzNjA_6367c1d5-3938-43e9-8f8e-541a9e804d5e">4505 Emperor Blvd., Suite 200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6NmQyYWEwMmU4N2MxNDIwODljMDkyZWE5MTJiMTQzZTQvdGFibGVyYW5nZTo2ZDJhYTAyZTg3YzE0MjA4OWMwOTJlYTkxMmIxNDNlNF81LTAtMS0xLTkzNjAvdGV4dHJlZ2lvbjplZTA4ZjYzNDE5OGM0MGYxOTM1MDllYTAzOTAzZGY1NF80_bbead806-b86a-414b-abba-45ea8387662f">Durham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6NmQyYWEwMmU4N2MxNDIwODljMDkyZWE5MTJiMTQzZTQvdGFibGVyYW5nZTo2ZDJhYTAyZTg3YzE0MjA4OWMwOTJlYTkxMmIxNDNlNF81LTAtMS0xLTkzNjAvdGV4dHJlZ2lvbjplZTA4ZjYzNDE5OGM0MGYxOTM1MDllYTAzOTAzZGY1NF84_ce8a67f8-3410-4556-813a-00273f163fcb">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6NmQyYWEwMmU4N2MxNDIwODljMDkyZWE5MTJiMTQzZTQvdGFibGVyYW5nZTo2ZDJhYTAyZTg3YzE0MjA4OWMwOTJlYTkxMmIxNDNlNF81LTEtMS0xLTkzNjAvdGV4dHJlZ2lvbjpiODk0ZTA2MmQxNTc0NjhlOTRmYzI4ZmRiMWZlYzU2N180_36561f2a-538f-4b82-9c69-3cce5bcba237">27703</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTUz_72ba082e-9168-4794-9560-b4c2449533cf">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTU0_42ce0ed0-4849-4f78-b415-f28b923be4ce">859-1302</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6MWEzM2Q1ZjZhMTRlNDU0M2EzODMwYzc0M2ExMWNhOTIvdGFibGVyYW5nZToxYTMzZDVmNmExNGU0NTQzYTM4MzBjNzQzYTExY2E5Ml8xLTAtMS0xLTkzNjA_71a86ba1-5244-4839-b3bd-25881d523f7c">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6MWEzM2Q1ZjZhMTRlNDU0M2EzODMwYzc0M2ExMWNhOTIvdGFibGVyYW5nZToxYTMzZDVmNmExNGU0NTQzYTM4MzBjNzQzYTExY2E5Ml8xLTEtMS0xLTkzNjA_26db71fa-d420-451b-882d-e0318be72d56">BCRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6MWEzM2Q1ZjZhMTRlNDU0M2EzODMwYzc0M2ExMWNhOTIvdGFibGVyYW5nZToxYTMzZDVmNmExNGU0NTQzYTM4MzBjNzQzYTExY2E5Ml8xLTItMS0xLTkzNjA_bb847fdc-5fee-4873-8584-dd6b0df96675">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTU1_a23a9739-1eea-436b-8c89-cfc83510d6a7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTQ5_129c6f0e-4dc4-40f0-9a0a-7187e8b0d4cd">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6YzJiMmE3MjlmMWMyNDU3YWE2MWQ5NDQ3YzdhYzIyMzMvdGFibGVyYW5nZTpjMmIyYTcyOWYxYzI0NTdhYTYxZDk0NDdjN2FjMjIzM18wLTAtMS0xLTkzNjA_f67aaa12-8d31-4e9d-8e70-decd81aa00a9">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6YzJiMmE3MjlmMWMyNDU3YWE2MWQ5NDQ3YzdhYzIyMzMvdGFibGVyYW5nZTpjMmIyYTcyOWYxYzI0NTdhYTYxZDk0NDdjN2FjMjIzM18xLTMtMS0xLTkzNjA_9f6b630c-d56a-4ac4-ae7f-559fc60746ac">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGFibGU6YzJiMmE3MjlmMWMyNDU3YWE2MWQ5NDQ3YzdhYzIyMzMvdGFibGVyYW5nZTpjMmIyYTcyOWYxYzI0NTdhYTYxZDk0NDdjN2FjMjIzM18yLTMtMS0xLTkzNjA_3a58d9f1-0bde-47a6-814e-b81235397921">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTUx_9f63d6fa-e8aa-439a-a377-9cb8e8229b8c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib45ffcc775c34a8ebd2fcae622dd7ea1_I20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8xL2ZyYWc6ZjE4Yjc2ZDdhMzQyNGMyYjg3NTllNDNjOTNhNDQzYzYvdGV4dHJlZ2lvbjpmMThiNzZkN2EzNDI0YzJiODc1OWU0M2M5M2E0NDNjNl8yMTQw_376c83db-d4f7-45e8-ba52-ec368887a330"
      unitRef="shares">186423835</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMy0xLTEtMS05MzYw_2217d0a6-cd2e-4bf5-bf39-2f7c786479bb"
      unitRef="usd">246899000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMy0zLTEtMS05MzYw_10692ed0-d089-4b81-8715-4bcefde7a023"
      unitRef="usd">504389000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNC0xLTEtMS05MzYw_82625ec1-7d31-4060-bf34-2b64811ca178"
      unitRef="usd">1444000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNC0zLTEtMS05MzYw_867752e3-45ba-4fa0-8527-ad667bb67c11"
      unitRef="usd">3345000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNS0xLTEtMS05MzYw_39d3cc02-8474-4cb5-9003-254b19833f3e"
      unitRef="usd">179959000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNS0zLTEtMS05MzYw_f26d052c-7aed-4f55-b0a1-c6f54069409f"
      unitRef="usd">3212000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNi0xLTEtMS05MzYw_896137d8-b4c7-471c-aee4-ceab86a21067"
      unitRef="usd">42610000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNi0zLTEtMS05MzYw_9d9c0267-1653-4dd7-938c-feb19433ed39"
      unitRef="usd">29413000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNy0xLTEtMS05MzYw_39bdbf6a-bcb1-4fe0-a445-8c742310620f"
      unitRef="usd">27019000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfNy0zLTEtMS05MzYw_54c1b4f0-1ef2-4972-8308-51be51790043"
      unitRef="usd">15791000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfOC0xLTEtMS05MzYw_4d977bdd-51d9-45dd-9138-7ff0dfbaab70"
      unitRef="usd">11070000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfOC0zLTEtMS05MzYw_86adebbd-974d-46e8-8677-3bec7bb8383f"
      unitRef="usd">9986000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfOS0xLTEtMS05MzYw_797e7891-2dfc-4728-a06e-9a6bc003ae07"
      unitRef="usd">509001000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfOS0zLTEtMS05MzYw_07235982-6ef0-4660-9d81-40d77a5e0453"
      unitRef="usd">566136000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTAtMS0xLTEtOTM2MA_b5152f5f-2de0-4db1-ba57-e5c32f15b9a4"
      unitRef="usd">8464000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTAtMy0xLTEtOTM2MA_869d97e1-f745-4265-8514-34089cc6e84c"
      unitRef="usd">8714000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermInvestments
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTEtMS0xLTEtOTM2MA_876e8390-1898-43f7-a87b-1a307f3e30ff"
      unitRef="usd">34332000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTEtMy0xLTEtOTM2MA_7a0da62b-8e30-45e8-a486-a99997865630"
      unitRef="usd">6829000</us-gaap:LongTermInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTItMS0xLTEtOTM2MA_ad18e57d-a757-4e13-84dd-5179b20009b0"
      unitRef="usd">6797000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTItMy0xLTEtOTM2MA_23c69f1c-0726-4c2b-a3c5-f81e24fbee3a"
      unitRef="usd">6472000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTMtMS0xLTEtOTM2MA_48fcc069-fc15-4326-8541-4847d893cd08"
      unitRef="usd">558594000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTMtMy0xLTEtOTM2MA_db97eff1-eb80-4beb-95c6-25b558a1ba36"
      unitRef="usd">588151000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTYtMS0xLTEtOTM2MA_8c461c3b-2d0b-4c9a-8327-31d22f55dbfc"
      unitRef="usd">8622000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTYtMy0xLTEtOTM2MA_979b73f6-b7d6-42c3-b1d8-ee1e5639f42b"
      unitRef="usd">27808000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTctMS0xLTEtOTM2MA_147edd62-f417-40f2-a002-7d9eb8a95d46"
      unitRef="usd">69265000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTctMy0xLTEtOTM2MA_ffb3dfc1-867b-4048-a22d-23163ceeb6f8"
      unitRef="usd">72670000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTgtMS0xLTEtOTM2MA_35f31b36-176f-4dba-adda-a09e80c9e973"
      unitRef="usd">1554000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTgtMy0xLTEtOTM2MA_f4176efe-accd-4ed7-9b0c-10738e0a4cb5"
      unitRef="usd">1421000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTktMS0xLTEtOTM2MA_b5dfde4b-abd8-433b-891a-6ead7a567df3"
      unitRef="usd">2196000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMTktMy0xLTEtOTM2MA_01ab41fe-f219-490b-aeda-9394ea167109"
      unitRef="usd">1819000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjAtMS0xLTEtOTM2MA_d3998fef-f32f-475e-a1f4-507441662e81"
      unitRef="usd">81637000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjAtMy0xLTEtOTM2MA_ae1f5d88-231c-47fb-835e-5cd1f40055c7"
      unitRef="usd">103718000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjEtMS0xLTEtOTM2MA_91fdfe25-1931-457f-93c4-5e7d5f862251"
      unitRef="usd">5968000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjEtMy0xLTEtOTM2MA_cd1998ad-a3ea-46e3-b5b4-882602f744a4"
      unitRef="usd">5962000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <bcrx:FutureRoyaltiesPayable
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjItMS0xLTEtOTM2MA_f7a0aaa2-00f5-46b2-ba07-3763142ec176"
      unitRef="usd">489781000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjItMy0xLTEtOTM2MA_fbafdea5-7604-45f5-91cd-2b570d45d320"
      unitRef="usd">449375000</bcrx:FutureRoyaltiesPayable>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjMtMS0xLTEtOTM2MA_0685e379-3752-4c5e-acb7-817c2e633b76"
      unitRef="usd">223867000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjMtMy0xLTEtOTM2MA_4582e6eb-257a-4beb-9bcd-c69919d66009"
      unitRef="usd">136082000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzIx_3fa1f264-9183-4bd6-a657-a2b62a292fcd"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzIx_bd546421-3a7e-4192-b815-9e292217b4ce"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzU1_75757389-cb21-460b-bec8-5afea0fe8972"
      unitRef="shares">5000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzU1_95d9ed0a-639c-4406-b2c3-36e3bf283364"
      unitRef="shares">5000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzU5_74d57ed2-df9b-49a0-b875-24838a7d56d7"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzU5_ee3c95cb-f063-4d71-b31f-0ba16e614191"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzU5_f66e40da-2781-4adc-9b1e-2d4a457e957e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmUzODM4YmFhYzMyMDQzYThiNTJjOWJiNTM2YTFiMjc0XzU5_fb314b80-b730-4c59-99a2-7401d1a38fd3"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMS0xLTEtOTM2MA_14c5cf80-86f9-47da-88f0-2b778131e4b6"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjUtMy0xLTEtOTM2MA_3eed53dd-9d46-4af4-982d-63866681a06e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3XzE4_4b466f41-8eb5-45da-a8e4-b818740b17d7"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3XzE4_5313c748-87cd-4bbc-a2cd-c5a70fe5c055"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3XzUy_1c25e20f-01c4-4e64-9fa1-9c84d2c44639"
      unitRef="shares">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3XzUy_e9f81dfb-d587-4b13-82f4-46d566023117"
      unitRef="shares">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3Xzg4_80becb38-b037-4861-b266-9919d9331380"
      unitRef="shares">186411000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3Xzg4_a2c2326f-ac65-448f-ab9b-333cc1974f51"
      unitRef="shares">186411000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3XzEwNA_9c8817a4-5f8e-40e6-bf7a-1a4f3f33d6df"
      unitRef="shares">184350000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjIzOWNlYmE5NWMwNjQ4MzM4YjRiZDFkZWUwNmUzNGY3XzEwNA_e5f17ef2-40a7-4daf-b795-c052cd2afa99"
      unitRef="shares">184350000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMS0xLTEtOTM2MA_c20e4bde-fd58-41f1-b0df-ac466cb13b56"
      unitRef="usd">1864000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjYtMy0xLTEtOTM2MA_cd9fd33b-292f-48f5-9abd-9e5d339a70d5"
      unitRef="usd">1843000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjctMS0xLTEtOTM2MA_9d1a6884-a2c6-4fc3-adac-36ca4facb4a3"
      unitRef="usd">1138654000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjctMy0xLTEtOTM2MA_b88c904a-9798-4d0f-9886-3801495685a1"
      unitRef="usd">1098498000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjgtMS0xLTEtOTM2MA_c68c051b-ef7a-443d-be4f-621aa2109837"
      unitRef="usd">-98000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjgtMy0xLTEtOTM2MA_673f4f46-7b45-48d0-b950-1c65fd6377ff"
      unitRef="usd">177000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjktMS0xLTEtOTM2MA_7608fb56-eee1-4238-b827-25bdd456bab0"
      unitRef="usd">-1383079000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMjktMy0xLTEtOTM2MA_37b98674-d2da-4465-993c-44d40888a7a5"
      unitRef="usd">-1207504000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMzAtMS0xLTEtOTM2MA_ca07dc42-43d2-44d2-b640-be3363fd4e19"
      unitRef="usd">-242659000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMzAtMy0xLTEtOTM2MA_bb5aa3d4-f105-44f0-a8ac-a5546105f8f0"
      unitRef="usd">-106986000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMzEtMS0xLTEtOTM2MA_316051ed-fd67-4d3e-a97b-568823331c06"
      unitRef="usd">558594000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yMi9mcmFnOmRjMzY2ZWM0Yzc2NzQyZmRiNWMxY2UxODkyMmY1OWM1L3RhYmxlOjI5N2M0YmYyMDMzYzQ1MjQ4Mjg4NjRlMTBlNjVjMTVmL3RhYmxlcmFuZ2U6Mjk3YzRiZjIwMzNjNDUyNDgyODg2NGUxMGU2NWMxNWZfMzEtMy0xLTEtOTM2MA_b5e3186b-369f-4763-b691-7e6ab83c1625"
      unitRef="usd">588151000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i02cd59e16e0149199ce28d859c3ac6a8_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMy0xLTEtMS05MzYw_563ea358-6a11-4776-8556-4da4218971a5"
      unitRef="usd">75213000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i03da29ccbd9f4d09beeb6288fdf053b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMy0zLTEtMS05MzYw_aa74449b-248d-44e7-afda-14d8b70db439"
      unitRef="usd">39141000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id38b2ee116544f90a76e9d8b6d33f39b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMy01LTEtMS05MzYw_bc03ed02-e294-4ebb-9906-1cbb05bbe8a8"
      unitRef="usd">189647000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if885f6f8cf8d4e339f135dd75b604594_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMy03LTEtMS05MzYw_8b771fd3-e60e-4923-8821-2f429c587d1d"
      unitRef="usd">90442000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9b2b8611a0384b2e8a19a43ecfab2135_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNC0xLTEtMS05MzYw_8bc819bb-54a2-4d52-a330-b92e8345073c"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i06ca5f40fc4b4aa98634268fcf2525a0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNC0zLTEtMS05MzYw_71d4fcec-6703-4012-a5a5-268680830500"
      unitRef="usd">322000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie51f3d3839d1472ea8a99419a9e1d1dd_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNC01LTEtMS05MzYw_520a2000-a3f8-41a8-a7f6-39fde32fd5fc"
      unitRef="usd">1487000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i69c7f898fb47496b80d856f7a82a5454_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNC03LTEtMS05MzYw_4a638a27-754b-477b-afa4-bd5711fe5cd5"
      unitRef="usd">-447000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7d334c267d664d22a3b7769ac993451a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNS0xLTEtMS05MzYw_5532bd23-95e3-4219-a450-6f785b19f4af"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8fa865c7a786428b8ce79ebf9351f4ad_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNS0zLTEtMS05MzYw_7752c5b1-8378-43aa-8eae-ef88dece4842"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9dd8066819384bae8b29a1bc99808b48_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNS01LTEtMS05MzYw_c15cc77d-5ffe-4c92-8725-4d47ddf38a81"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9435042756cd4d408e47bff42738cf8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNS03LTEtMS05MzYw_84181fcf-4cba-4c1a-9bc0-b8e598083195"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i67cf7bf22deb4aff91b49db594f6a877_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNi0xLTEtMS05MzYw_87bdffc3-011e-47b5-b254-c77f0f3b0324"
      unitRef="usd">14000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7382589fe0034462aa011f377b6998da_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNi0zLTEtMS05MzYw_e2c8eceb-e10d-44eb-8c4a-4778a55b928e"
      unitRef="usd">1531000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6dde7334e062479ab641b4c89a0a55e4_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNi01LTEtMS05MzYw_3e6fe43f-b6c7-4474-a8ef-7d558825dae0"
      unitRef="usd">148000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i89dd57b2bc7948769d0753db905659dd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNi03LTEtMS05MzYw_45895912-d372-4d23-9129-af6617d0fbb1"
      unitRef="usd">5017000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNy0xLTEtMS05MzYw_8c176fc3-65eb-4cb5-a54a-99a8191a89bf"
      unitRef="usd">75827000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNy0zLTEtMS05MzYw_2ceebb7a-ac1a-401a-825b-6fbbc1aa978b"
      unitRef="usd">40994000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNy01LTEtMS05MzYw_3f747647-a01c-42cb-8e6f-50abc119ea59"
      unitRef="usd">191282000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfNy03LTEtMS05MzYw_bef2059d-618c-4065-93af-6e10980457bd"
      unitRef="usd">110012000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfOS0xLTEtMS05MzYw_1f93c0a3-bf98-40d1-9b48-8c80d78788ba"
      unitRef="usd">3543000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfOS0zLTEtMS05MzYw_736a5488-ef9d-4269-aa18-ea9c73e19f66"
      unitRef="usd">591000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfOS01LTEtMS05MzYw_81dadc5d-6975-4cbf-8383-615172b38e98"
      unitRef="usd">4025000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfOS03LTEtMS05MzYw_c88ac079-5a0f-4dc1-b591-102ca5c63b42"
      unitRef="usd">6811000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTAtMS0xLTEtOTM2MA_87371e60-7984-419a-8ab4-35dfd256edab"
      unitRef="usd">52740000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTAtMy0xLTEtOTM2MA_866a043f-077d-4cff-a434-3bc5845bc5aa"
      unitRef="usd">49971000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTAtNS0xLTEtOTM2MA_90d4cb67-7714-44d3-bf80-37c085aed2ca"
      unitRef="usd">180090000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTAtNy0xLTEtOTM2MA_0a56967c-e2a0-4914-8d02-d09827a4e582"
      unitRef="usd">145279000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTEtMS0xLTEtOTM2MA_54e6b77a-f20d-4492-a949-2eb2f4a164db"
      unitRef="usd">36919000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTEtMy0xLTEtOTM2MA_f3e15a23-3567-4453-b60c-b5341382f3e2"
      unitRef="usd">34992000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTEtNS0xLTEtOTM2MA_0cabf66c-1f0f-4cab-86e9-d7572aa1779d"
      unitRef="usd">109218000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTEtNy0xLTEtOTM2MA_ba215954-e18e-49c6-a71b-437ed8b35a12"
      unitRef="usd">83431000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <bcrx:RoyaltyExpenseReversalOfExpense
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTItMS0xLTEtOTM2MA_63e31086-fea2-42b4-bfc3-ec8a8450b1ab"
      unitRef="usd">70000</bcrx:RoyaltyExpenseReversalOfExpense>
    <bcrx:RoyaltyExpenseReversalOfExpense
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTItMy0xLTEtOTM2MA_4e5bdfd9-7e11-486d-8e32-c5dbba5b4f7b"
      unitRef="usd">24000</bcrx:RoyaltyExpenseReversalOfExpense>
    <bcrx:RoyaltyExpenseReversalOfExpense
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTItNS0xLTEtOTM2MA_255b8e67-a783-41ee-8672-037c90d6683b"
      unitRef="usd">73000</bcrx:RoyaltyExpenseReversalOfExpense>
    <bcrx:RoyaltyExpenseReversalOfExpense
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTItNy0xLTEtOTM2MA_2a288e67-fe06-46d1-8190-2572cfc608f7"
      unitRef="usd">34000</bcrx:RoyaltyExpenseReversalOfExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTMtMS0xLTEtOTM2MA_daa0add2-eebb-4fa6-a526-d90b5c3d8266"
      unitRef="usd">93272000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTMtMy0xLTEtOTM2MA_4df57592-0a3f-44a5-8d94-a1cc68feda9d"
      unitRef="usd">85578000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTMtNS0xLTEtOTM2MA_b1f63948-5686-44c0-bfa6-60dc4689863a"
      unitRef="usd">293406000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTMtNy0xLTEtOTM2MA_bc7b2cab-ae16-49b7-8e77-422d4a90ce97"
      unitRef="usd">235555000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTQtMS0xLTEtOTM2MA_727bf2ec-e343-494c-9d82-b97bd1164098"
      unitRef="usd">-17445000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTQtMy0xLTEtOTM2MA_5a4ff6ab-026e-446a-a496-cad20ba06d52"
      unitRef="usd">-44584000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTQtNS0xLTEtOTM2MA_e9b4c5a7-cfa1-4a93-9f10-500941397851"
      unitRef="usd">-102124000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTQtNy0xLTEtOTM2MA_095bdf0a-97a3-4f73-a8bc-aedbb0748319"
      unitRef="usd">-125543000</us-gaap:OperatingIncomeLoss>
    <bcrx:InterestAndOtherIncomeLoss
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTUtMS0xLTEtOTM2MA_00ccc231-02f1-46b8-9eb9-ec547db35c49"
      unitRef="usd">1760000</bcrx:InterestAndOtherIncomeLoss>
    <bcrx:InterestAndOtherIncomeLoss
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTUtMy0xLTEtOTM2MA_d753aa1e-f73e-4cdf-bce7-c559d9f0da96"
      unitRef="usd">9000</bcrx:InterestAndOtherIncomeLoss>
    <bcrx:InterestAndOtherIncomeLoss
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTUtNS0xLTEtOTM2MA_810671e8-863f-4e99-85bf-4e2778e91cb9"
      unitRef="usd">2423000</bcrx:InterestAndOtherIncomeLoss>
    <bcrx:InterestAndOtherIncomeLoss
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTUtNy0xLTEtOTM2MA_39f57ea9-48df-4c31-896f-9b63fc1ae4a5"
      unitRef="usd">48000</bcrx:InterestAndOtherIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTYtMS0xLTEtOTM2MA_f12328e2-1cba-4a19-b7e8-e1e5fe8c2fb3"
      unitRef="usd">24775000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTYtMy0xLTEtOTM2MA_05746e41-7604-431c-bacf-0369daa99646"
      unitRef="usd">14115000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTYtNS0xLTEtOTM2MA_0eb076bf-1795-4844-97d9-ca74efe13132"
      unitRef="usd">72634000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTYtNy0xLTEtOTM2MA_c690294b-5066-4722-9ad7-621b8d7a7d58"
      unitRef="usd">40514000</us-gaap:InterestExpense>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTctMS0xLTEtOTM2MA_483c648b-1688-44a1-ae42-c19729387fd2"
      unitRef="usd">-538000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTctMy0xLTEtOTM2MA_1c6f9039-fd61-4b07-8cb0-2669180a926d"
      unitRef="usd">-111000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTctNS0xLTEtOTM2MA_5bda41c6-bca4-477a-bbde-c6e31cd8510b"
      unitRef="usd">-583000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTctNy0xLTEtOTM2MA_21b4cfe4-8812-476b-8e03-f61ffa391a26"
      unitRef="usd">-274000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTgtMS0xLTEtOTM2MA_71c9a31e-245e-4849-8732-400b9bdcd9be"
      unitRef="usd">-40998000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTgtMy0xLTEtOTM2MA_d926a545-c27f-4ad1-96fd-a36695a37d98"
      unitRef="usd">-58801000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTgtNS0xLTEtOTM2MA_b489cca4-a01c-4e5b-b21a-d77582481600"
      unitRef="usd">-172918000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTgtNy0xLTEtOTM2MA_e371bf96-9956-4813-905c-ea3ffaabfb91"
      unitRef="usd">-166283000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTktMS0xLTEtOTM2MA_395c10e0-3dfb-4cf7-b7a6-564b492bc7e4"
      unitRef="usd">1522000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTktMy0xLTEtOTM2MA_e657ab6e-9cfd-4154-88ff-97619702ea8a"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTktNS0xLTEtOTM2MA_ce293273-e999-40d1-85e4-e099b7169424"
      unitRef="usd">2657000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMTktNy0xLTEtOTM2MA_25d0f90e-e094-4bdf-9123-fcef3004fcf0"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjAtMS0xLTEtOTM2MA_f8930804-3336-4d8f-a55e-8b598c882279"
      unitRef="usd">-42520000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjAtMy0xLTEtOTM2MA_884e881f-918b-4799-b0e2-a41216aebd4e"
      unitRef="usd">-58801000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjAtNS0xLTEtOTM2MA_e9796363-c667-4912-a55f-74761a59c749"
      unitRef="usd">-175575000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjAtNy0xLTEtOTM2MA_94f0857a-7ef6-4475-b04c-24d94652aa41"
      unitRef="usd">-166283000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjEtMS0xLTEtOTM2MA_eacacad2-d58c-4726-979e-ea91700a7ed2"
      unitRef="usd">695000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjEtMy0xLTEtOTM2MA_45314a2e-4b7f-48d7-96fe-e7211eb060e0"
      unitRef="usd">28000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjEtNS0xLTEtOTM2MA_6f0cd2c1-61f5-48a0-ad9c-96d75b7ac92e"
      unitRef="usd">877000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjEtNy0xLTEtOTM2MA_7f00ccb7-59cb-441b-a0e0-af7ceddd559e"
      unitRef="usd">114000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjItMS0xLTEtOTM2MA_289b9fb0-4fb0-40fb-8097-f36b874c64e6"
      unitRef="usd">-808000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjItMy0xLTEtOTM2MA_79de9c31-4193-4f2e-87b5-1ecddb51de8b"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjItNS0xLTEtOTM2MA_502b53eb-1af1-428c-ac51-df3e194a3c6b"
      unitRef="usd">-1152000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjItNy0xLTEtOTM2MA_d22580f5-208e-4075-83a8-3e4be99a6bb7"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjMtMS0xLTEtOTM2MA_15788a50-74f6-4fc3-9b17-55a74c1ce1a5"
      unitRef="usd">-42633000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjMtMy0xLTEtOTM2MA_20507142-4bcd-4271-ae7f-300b36f7c7a9"
      unitRef="usd">-58774000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjMtNS0xLTEtOTM2MA_412c49ba-c056-4c33-96b8-9b0398ae4666"
      unitRef="usd">-175850000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjMtNy0xLTEtOTM2MA_4744f84c-e22f-4bf2-9934-75d69beed769"
      unitRef="usd">-166172000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtMS0xLTEtOTM2MA_a205f0d6-f97e-438f-a8b1-06e694ac8e21"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtMS0xLTEtOTM2MA_be9f58b7-5ddf-49f3-958d-49fb1344d97a"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtMy0xLTEtOTM2MA_22a05470-5b12-4a97-ac00-97c917d436cd"
      unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtMy0xLTEtOTM2MA_f78f5783-847f-4759-9d57-b3ae8372eca6"
      unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtNS0xLTEtOTM2MA_94c4e9ef-627f-4724-8529-197fb3e37e45"
      unitRef="usdPerShare">-0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtNS0xLTEtOTM2MA_c0c33a74-9a1d-4608-a348-fad69ae51e4b"
      unitRef="usdPerShare">-0.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtNy0xLTEtOTM2MA_1964df01-addc-4b95-ba6a-1576ee3e562f"
      unitRef="usdPerShare">-0.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjUtNy0xLTEtOTM2MA_de981f0f-213e-4c82-ac7c-23d27a27b45a"
      unitRef="usdPerShare">-0.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtMS0xLTEtOTM2MA_47702e7b-d144-419e-b5bb-8802a89b403d"
      unitRef="shares">186180000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtMS0xLTEtOTM2MA_b1295ac6-de21-4c74-b5a6-1cd99f2548da"
      unitRef="shares">186180000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtMy0xLTEtOTM2MA_a7de8f20-a2e7-484c-9111-d634662a1422"
      unitRef="shares">179106000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtMy0xLTEtOTM2MA_e98ed4c5-f052-4d01-a187-107aaa125e86"
      unitRef="shares">179106000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtNS0xLTEtOTM2MA_0ffd1f08-5792-41ee-bccc-64e24d59ecda"
      unitRef="shares">185566000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtNS0xLTEtOTM2MA_da0e1e5c-6947-4220-9fcb-ca10b8d09c1d"
      unitRef="shares">185566000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtNy0xLTEtOTM2MA_7da750ee-84bc-4165-8efb-6453219d478f"
      unitRef="shares">178199000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yNS9mcmFnOjE0NTA0YmExYWRiNTQ0OGVhNWIyZjgwY2RjMmE3OGQyL3RhYmxlOmRjYmFmZGYxY2VhMzQ1YTg4OWRjNWQ3NDliNGY3OTk5L3RhYmxlcmFuZ2U6ZGNiYWZkZjFjZWEzNDVhODg5ZGM1ZDc0OWI0Zjc5OTlfMjYtNy0xLTEtOTM2MA_ce951d70-249e-41e3-a166-c185c0582f1e"
      unitRef="shares">178199000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMy0xLTEtMS05MzYw_48f4ed6b-0b02-4bf0-8aa9-c041a5589625"
      unitRef="usd">-175575000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMy0zLTEtMS05MzYw_3be52fbe-f043-491d-81b0-38765fb8bc71"
      unitRef="usd">-166283000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfNS0xLTEtMS05MzYw_9dfd7193-8768-4057-b75a-3684a807ee87"
      unitRef="usd">1041000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfNS0zLTEtMS05MzYw_a835646a-e75a-49b0-a25b-843c035a63c7"
      unitRef="usd">606000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfNi0xLTEtMS05MzYw_008039af-f6e8-4e2c-953a-285cf1a17d09"
      unitRef="usd">29419000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfNi0zLTEtMS05MzYw_4bf1d0f3-af71-4808-be00-d82094e79e5f"
      unitRef="usd">26140000</us-gaap:ShareBasedCompensation>
    <bcrx:NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfNy0xLTEtMS05MzYw_24f721d4-b86d-474c-bb6c-7d12835dd3eb"
      unitRef="usd">55119000</bcrx:NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts>
    <bcrx:NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfNy0zLTEtMS05MzYw_c7a7c2b4-e407-4b20-b7fa-dc699779b17e"
      unitRef="usd">36440000</bcrx:NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts>
    <bcrx:AmortizationOfDiscountAndPremiumOnInvestments
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfOC0xLTEtMS05MzYw_2d62fee9-fe15-4558-8e09-8a0fd14c093a"
      unitRef="usd">-818000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
    <bcrx:AmortizationOfDiscountAndPremiumOnInvestments
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfOC0zLTEtMS05MzYw_dc191bb2-963d-4e62-828f-ead115b0b803"
      unitRef="usd">35000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTAtMS0xLTEtOTM2MA_b4755114-6c54-4bca-b085-fcd1686eecc3"
      unitRef="usd">13827000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTAtMy0xLTEtOTM2MA_da631d73-2c94-4bc5-8eea-9fc3a327b6f5"
      unitRef="usd">17579000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTEtMS0xLTEtOTM2MA_1dd16f12-fcc8-4df0-93e0-e605eaecd031"
      unitRef="usd">11263000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTEtMy0xLTEtOTM2MA_134e7d8e-922d-4228-9968-f1dc9d42024c"
      unitRef="usd">6630000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTItMS0xLTEtOTM2MA_d1fde3fe-eef0-4617-8728-2b9563884dc7"
      unitRef="usd">1132000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTItMy0xLTEtOTM2MA_16e1cb8e-6833-4ff1-b672-1eaea407ef06"
      unitRef="usd">3460000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTMtMS0xLTEtOTM2MA_6723cbc8-886a-483b-b81f-31287d720801"
      unitRef="usd">-27639000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTMtMy0xLTEtOTM2MA_e72413ac-17e6-4064-9b2e-4b6e3f2c5f77"
      unitRef="usd">16692000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTQtMS0xLTEtOTM2MA_e75d45c7-c317-4b2f-8e2a-a5f687b4e64f"
      unitRef="usd">6345000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTQtMy0xLTEtOTM2MA_0bc71ebb-135d-4386-b396-158c9d19267a"
      unitRef="usd">3884000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTUtMS0xLTEtOTM2MA_04a51e83-2337-445c-9f40-aff1522f60a2"
      unitRef="usd">329000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTUtMy0xLTEtOTM2MA_71d2006a-bf7a-4b4f-8188-dcc211fb2410"
      unitRef="usd">457000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTYtMS0xLTEtOTM2MA_9690ae38-0bfd-4bc0-8b24-346f03c478b9"
      unitRef="usd">-138001000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTYtMy0xLTEtOTM2MA_43d78398-5a2c-4d4d-890b-815fb4210bd5"
      unitRef="usd">-109698000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTktMS0xLTEtOTM2MA_64b6b174-6993-48b5-857f-eae9f7fcc6c6"
      unitRef="usd">825000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMTktMy0xLTEtOTM2MA_04fc7e04-7e52-4f40-8a92-897c4986b98b"
      unitRef="usd">1277000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjAtMS0xLTEtOTM2MA_2b0d3759-610b-4c5b-9b3c-2007347b991f"
      unitRef="usd">244283000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjAtMy0xLTEtOTM2MA_9b2bfed6-d09f-460a-ad5c-104b3176d9f9"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjEtMS0xLTEtOTM2MA_51182d37-333c-4cb4-8997-f354e92d6a08"
      unitRef="usd">39655000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjEtMy0xLTEtOTM2MA_53216bad-fa31-4f1b-9bb6-348813c07679"
      unitRef="usd">28201000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjItMS0xLTEtOTM2MA_9738e853-0768-4447-bdc3-94e3c8eb0bc0"
      unitRef="usd">-205453000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjItMy0xLTEtOTM2MA_14e5e94e-65f3-4ba7-82c1-6e939aebec50"
      unitRef="usd">26924000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjUtMS0xLTEtOTM2MA_62f399d7-5344-4409-a1cc-7341a7a86032"
      unitRef="usd">10756000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjUtMy0xLTEtOTM2MA_f7cc51f0-ca44-4bce-af9c-112fb8865b18"
      unitRef="usd">12250000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjYtMS0xLTEtMTA3Nzc_f622cf7a-5792-4395-bac7-08b4cfbca045"
      unitRef="usd">73072000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjYtMy0xLTEtMTA3ODU_9a4780b3-1380-4374-8df8-8a05ebb44762"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjYtMS0xLTEtOTM2MA_6acd5d3d-6e1c-4efb-82fd-25aa1f7ec179"
      unitRef="usd">83828000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjYtMy0xLTEtOTM2MA_9b81aa57-31bd-40fe-945c-081b3f6f10a4"
      unitRef="usd">12250000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjctMS0xLTEtOTM2MA_a1bab8e0-8028-4dc2-8585-a7b83c9d8290"
      unitRef="usd">235000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjctMy0xLTEtOTM2MA_c2a141ad-613f-4281-b728-6cd0b1590f65"
      unitRef="usd">69000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjktMS0xLTEtOTM2MA_c96d5535-2f9e-4750-8c3b-38d523614d8a"
      unitRef="usd">-259391000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMjktMy0xLTEtOTM2MA_70b8ff86-76b2-4c63-80e9-4a1820c1d6e0"
      unitRef="usd">-70455000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMzAtMS0xLTEtOTM2MA_c263b696-ee76-425e-8e00-1273a902ec6d"
      unitRef="usd">507734000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i41745e32b23b47e7a00caf0e1c1db339_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMzAtMy0xLTEtOTM2MA_af6be929-d0fe-4118-aff4-399040035d63"
      unitRef="usd">274348000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMzEtMS0xLTEtOTM2MA_e8d60cc4-322b-4cbd-8483-eeb9db1b4940"
      unitRef="usd">248343000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i1a3b74ad1e0f4442b522495e111be937_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8yOC9mcmFnOmUzMWFjZmQzMDA5MjQ3ODliZjAwMjMyMzQ4ZTY1YjkyL3RhYmxlOjg0NzEzODdiMmM4NjRmYWQ5NDExYzQzM2FiNGFkZDVkL3RhYmxlcmFuZ2U6ODQ3MTM4N2IyYzg2NGZhZDk0MTFjNDMzYWI0YWRkNWRfMzEtMy0xLTEtOTM2MA_af2544ac-75d6-4f04-9cb3-72d886f54317"
      unitRef="usd">203893000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:StockholdersEquity
      contextRef="i91882c79d9d24c96aa878de55cbae53b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMS0xLTEtMS05MzYw_4e5319ab-997e-45f4-bd07-c44ba2896120"
      unitRef="usd">1843000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i95ba6a07e68a459195b3cded3ca6d43a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMS0zLTEtMS05MzYw_a22abe83-f88a-4471-bf31-8e2e4b748e35"
      unitRef="usd">1098498000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if2765f24346841dfa50adf712fcd6e0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMS01LTEtMS05MzYw_504eab6d-0954-4d05-aa15-1a8c1db5f3cb"
      unitRef="usd">177000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50edc98ace4c4817bc584c2cd01683db_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMS03LTEtMS05MzYw_bca2ccad-d14e-42b8-a738-39b700d72bdb"
      unitRef="usd">-1207504000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMS05LTEtMS05MzYw_c15c4a21-d297-40cb-9d04-ccd2eca2933b"
      unitRef="usd">-106986000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie1da831eb386440a9ae03883cb9de9c2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMi03LTEtMS05MzYw_91797f6e-efa6-41b8-ad45-142a354f4f91"
      unitRef="usd">-74196000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMi05LTEtMS05MzYw_16b5fc3f-e8be-4dc9-be81-1ac49cfbf4a5"
      unitRef="usd">-74196000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib2e88ed6e0ef4275a5cbc5b2259cb414_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMy01LTEtMS05MzYw_e28a36d3-a4fa-4d76-af0d-08271b0e4cc0"
      unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMy05LTEtMS05MzYw_32e6063f-a09b-4505-8021-81503423992b"
      unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNC0wLTEtMS05MzYwL3RleHRyZWdpb246NDAzMTgwZTM0NzA4NGYxNGIzMDQxMTUxZmU5YWZmN2RfNDA_c6f540b5-6fb7-442b-8598-4385b8abc333"
      unitRef="shares">115000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib471f07fd4b04491b1575b8c3455d232_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNC0xLTEtMS05MzYw_a4bd4b0c-32c5-45d2-abeb-324cf0cf4502"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if67232e493004bbe9a89d123b94f9781_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNC0zLTEtMS05MzYw_4172f4b3-815d-49c9-96c4-7eb8f7e7d8e6"
      unitRef="usd">1503000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNC05LTEtMS05MzYw_836f985b-d059-4aca-b2ad-fb865a99f56e"
      unitRef="usd">1504000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNS0wLTEtMS05MzYwL3RleHRyZWdpb246NGYyMTFjNzVjMzBlNDYwOWI2ZDk0N2Q4YjVmZmQ3MWZfMzE_98f4f906-0ec0-4ef0-8c07-07b7ac84080a"
      unitRef="shares">1108000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib471f07fd4b04491b1575b8c3455d232_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNS0xLTEtMS05MzYw_a7fbceb8-5566-4bc5-9c43-1ae82e5d7e64"
      unitRef="usd">12000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if67232e493004bbe9a89d123b94f9781_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNS0zLTEtMS05MzYw_9dbbaa4e-bebf-4cb7-a636-4303620b4eee"
      unitRef="usd">5841000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNS05LTEtMS05MzYw_c501a2e3-4ee0-4913-b84b-7876c66260b5"
      unitRef="usd">5853000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if67232e493004bbe9a89d123b94f9781_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNi0zLTEtMS05MzYw_1d6494ea-2e20-470e-9b1f-575257e97eec"
      unitRef="usd">9601000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNi05LTEtMS05MzYw_1fc79ee3-7d83-49ae-86f4-dcfe163b1a56"
      unitRef="usd">9601000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="i15308f75ade643a5bd5c3c0ad201bd13_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNy0xLTEtMS05MzYw_6355aad9-c1b8-4aa6-8177-d24312a442c2"
      unitRef="usd">1856000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2bbcac9495d54029ab8d5adb83847966_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNy0zLTEtMS05MzYw_782804d2-99c1-4a7f-83f1-6d4ebc67b65f"
      unitRef="usd">1115443000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if036eb5c6c274213bd73c03c974994a7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNy01LTEtMS05MzYw_dee31ce2-9a75-42ac-9569-f0622ec1eb89"
      unitRef="usd">186000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i153d098e317143b991cc8821cf708987_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNy03LTEtMS05MzYw_b44d5b06-bea5-4798-853a-a1d1c5f3f8bd"
      unitRef="usd">-1281700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i705ede78548e4661a484496cffb01473_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfNy05LTEtMS05MzYw_8661de5a-329a-4815-9600-2c9a1203c0a1"
      unitRef="usd">-164215000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i5b50a0d24e4a41a098b3d1ead84b5e3d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfOC03LTEtMS05MzYw_f2425817-0567-445e-9a93-80e6e094838f"
      unitRef="usd">-58859000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfOC05LTEtMS05MzYw_92c0a992-87fc-4428-bdeb-cc15dcd5db66"
      unitRef="usd">-58859000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3fb8db5ef2e34b14ab9a1ba55b73c8cb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfOS01LTEtMS05MzYw_337d5ec7-3511-4d9a-86e9-01255a0e485c"
      unitRef="usd">-171000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfOS05LTEtMS05MzYw_3d2e5c45-a41e-4549-be72-410afc61de2a"
      unitRef="usd">-171000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <bcrx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTAtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmM5NmM2YWY0ZWM2MTRmN2ViYjIzNWI2Mjg3OTE2YjJkXzI2_ca99b7a5-efcb-4b4a-8f86-3ffd89029a08"
      unitRef="shares">253000</bcrx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <bcrx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="if913b8a18461412aaa90a9e59f28bbb9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTAtMS0xLTEtOTM2MA_a86bc802-c140-4055-b2a4-c4bc2b9d5bbf"
      unitRef="usd">3000</bcrx:StockIssuedDuringPeriodValueWarrantsExercised>
    <bcrx:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTAtOS0xLTEtOTM2MA_2a10aa90-de33-4b4c-93a2-782f6f3ee628"
      unitRef="usd">3000</bcrx:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTEtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOjI1NTI0MDNjYTBjZTQwOGRhZGVlNjE4Y2ExNjE2NjFiXzMx_af197400-65b4-481a-aee1-b14649194172"
      unitRef="shares">51000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0b867b6cc56641799cba16d11bfa60a4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTEtMy0xLTEtOTM2MA_082b82d7-7935-45a6-94ee-e813271a48b6"
      unitRef="usd">145000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTEtOS0xLTEtOTM2MA_4ba77d46-b9da-45e7-a8cf-96d75052a7ef"
      unitRef="usd">145000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0b867b6cc56641799cba16d11bfa60a4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTItMy0xLTEtOTM2MA_f293efdc-a682-4891-bd20-9e14beb738a9"
      unitRef="usd">9865000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTItOS0xLTEtOTM2MA_4abe07fe-6d02-4f0a-88bd-fca4d14237c1"
      unitRef="usd">9865000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="i39c3785f664d490d93d4cc107acc6eab_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTMtMS0xLTEtOTM2MA_21869673-20f8-46a0-aa17-bbd4ff43f321"
      unitRef="usd">1859000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a1c4dc78aff440ba2b7ae2d04ee9ebb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTMtMy0xLTEtOTM2MA_25d82993-738d-4ab1-bd2b-3885ce7bc22a"
      unitRef="usd">1125453000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia81363840c6d47819c0a0300f9de63ea_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTMtNS0xLTEtOTM2MA_629b422c-6a5c-4a7c-aa0c-8898b44eafbf"
      unitRef="usd">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifc1eb8ebb6744a0a90475dfb612381f8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTMtNy0xLTEtOTM2MA_b1e8124f-ead1-4adc-b808-1c9b154b6f8c"
      unitRef="usd">-1340559000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaaaa54dd893e44a9ba927dae3ebc58fc_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTMtOS0xLTEtOTM2MA_7806d8af-24e4-4f90-bc04-46e01975d701"
      unitRef="usd">-213232000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i7d973d539b60454bb3e347b4bb6c7431_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTQtNy0xLTEtOTY2Mg_8343e8c5-899d-47c5-8605-7f688f1352df"
      unitRef="usd">-42520000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTQtOS0xLTEtOTY2OQ_235186d3-79a4-42bb-8979-7c4f3ca786ee"
      unitRef="usd">-42520000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9896466435844fdaadb265c1f69482cc_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTUtNS0xLTEtOTY0OA_4fd64e60-1d4d-4344-a940-a0eeea405f55"
      unitRef="usd">-113000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTUtOS0xLTEtOTY2OQ_2449f8b5-11b7-4dff-9856-487f91aaffa5"
      unitRef="usd">-113000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTYtMC0xLTEtOTYxOC90ZXh0cmVnaW9uOjY5ZWRiOWIzMDM0YjRlYTc5ZTM2Y2JjNTg1N2JkOWMyXzU0OTc1NTgxMzk1MQ_be549de2-8a3f-4872-abc3-a855087a3704"
      unitRef="shares">145000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia35fcc7c1df8404fa70855f6f2fe6cee_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTYtMS0xLTEtOTYyOA_ca48af75-85c1-4d13-bd3e-a9e264f8e61e"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib07b7833ec9c4f5ba79349d729d7e86a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTYtMy0xLTEtOTY1NQ_31a4a654-6c28-411a-b2b3-0248a9e25251"
      unitRef="usd">1356000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTYtOS0xLTEtOTY2OQ_999d9fe5-4943-42fa-a8cf-bf37855f3251"
      unitRef="usd">1357000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTctMC0xLTEtOTYxOC90ZXh0cmVnaW9uOjJmMWMxMmMyZTA3YTRkMzdiYjY1YmNmNjc1YmZjMzEyXzU0OTc1NTgxMzk0MQ_cb53f641-919c-403b-9f2f-10fc4f745dfc"
      unitRef="shares">390000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia35fcc7c1df8404fa70855f6f2fe6cee_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTctMS0xLTEtOTYyOA_42a4a2a3-dfb5-4edf-aae6-2c6d593a4618"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib07b7833ec9c4f5ba79349d729d7e86a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTctMy0xLTEtOTY1NQ_f849c24c-c52c-496a-af8d-b8266fde67cc"
      unitRef="usd">1892000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTctOS0xLTEtOTY2OQ_f06cc886-6538-4eda-8439-eb5d19873141"
      unitRef="usd">1896000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib07b7833ec9c4f5ba79349d729d7e86a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTgtMy0xLTEtOTY1NQ_e2f8c5ac-0218-4ba6-8ad5-8849ed3c6368"
      unitRef="usd">9953000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTgtOS0xLTEtOTY2OQ_d86785d1-f218-4f3a-b1c6-1dbbb9c75ba0"
      unitRef="usd">9953000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="ifcb838f1aea441109992ece58d5d1419_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTktMS0xLTEtOTYyOA_e47f842b-6e63-4871-a9e4-cb68116f0c66"
      unitRef="usd">1864000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i41766aec3ee549cc9ffd2983c192fdc0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTktMy0xLTEtOTYzNQ_d788e7f6-f2b0-432e-9994-465b2ad6e8c1"
      unitRef="usd">1138654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf830df2b86a45cd9f92bf47fec71ee6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTktNS0xLTEtOTY0Mg_ac6d4026-0494-4523-b1d9-35108623712c"
      unitRef="usd">-98000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i29f30a466222458bb694b5b460e4b5fb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTktNy0xLTEtOTY2Mg_7b166a3e-fa64-45f8-9d07-c255b75723cc"
      unitRef="usd">-1383079000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjNlOGE5ZTQ4NTI2YjQ0OWNiMjk4YmU0NGRhNDhlNzIzL3RhYmxlcmFuZ2U6M2U4YTllNDg1MjZiNDQ5Y2IyOThiZTQ0ZGE0OGU3MjNfMTktOS0xLTEtOTY2OQ_f3a81a9c-fb25-457d-b124-f913fb12cf04"
      unitRef="usd">-242659000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17fd2b8b68ab41d29358bf85ce87dc12_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMS0xLTEtMS05MzYw_fe79ead8-8a2b-43f2-abcd-fb1c842da995"
      unitRef="usd">1769000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i61c4036a23a640018a70d37f4b27fb0b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMS0zLTEtMS05MzYw_2406aa13-7df0-4407-b9e1-d5a701dff421"
      unitRef="usd">1002408000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1588d8fa978d43ecbc8214f1b4283763_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMS01LTEtMS05MzYw_ecfc2165-9928-49dc-852d-d86f9bda7e42"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id581e5368d914277ac0ce9fee558e4ea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMS03LTEtMS05MzYw_84d10b30-b183-4c5c-a32d-b9a01877da84"
      unitRef="usd">-1023442000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i41745e32b23b47e7a00caf0e1c1db339_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMS05LTEtMS05MzYw_b676fc18-230b-4993-8729-b2c2e9b1c197"
      unitRef="usd">-19262000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ib5d58b9fd63041f3bc17cf6fc173034b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMi03LTEtMS05MzYw_de715f01-cf0b-4e39-9199-ca787d1c363a"
      unitRef="usd">-64284000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if076f350ff45436996af2f05839c8882_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMi05LTEtMS05MzYw_89dc1edd-5e7d-4de7-9f53-240e3a44ce24"
      unitRef="usd">-64284000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie9fa7ce59f8e428fba39af60c2c10e30_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMy01LTEtMS05MzYw_c7cab485-e9be-4b64-9a29-30f6359ad1ad"
      unitRef="usd">179000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if076f350ff45436996af2f05839c8882_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMy05LTEtMS05MzYw_7ad1ab7e-54f7-4176-982e-6cadf5a9f4ef"
      unitRef="usd">179000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if076f350ff45436996af2f05839c8882_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNC0wLTEtMS05MzYwL3RleHRyZWdpb246MDkyNDYwMTEyYzk3NGI2ZGFmOGY2OGFjZjBlY2FlZjlfNDA_06a6d289-a364-462d-bb88-5c37e51b67ab"
      unitRef="shares">193000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i762c8172b9e54274a05337bb853015e5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNC0xLTEtMS05MzYw_850339fb-d00f-401e-ad63-0007dcee8770"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4a9b9d93a9dc4310ae5a5a00e96b249e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNC0zLTEtMS05MzYw_eb2590ab-2b85-41d7-a233-b0c697221af3"
      unitRef="usd">721000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if076f350ff45436996af2f05839c8882_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNC05LTEtMS05MzYw_554f3ce8-db4e-4b6b-8479-906a7250931d"
      unitRef="usd">723000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if076f350ff45436996af2f05839c8882_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNS0wLTEtMS05MzYwL3RleHRyZWdpb246NmE2NWRkMzQ1OWM0NGEwMGFhNjljZmIyMzM4NDc1ZDNfMzE_bef03b73-49de-4818-be79-d048c885cf4f"
      unitRef="shares">593000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i762c8172b9e54274a05337bb853015e5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNS0xLTEtMS05MzYw_05f75263-4ebd-43c9-ae41-dbcec2bbedb6"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4a9b9d93a9dc4310ae5a5a00e96b249e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNS0zLTEtMS05MzYw_0d701c31-ef14-481e-9297-42e235cbb47c"
      unitRef="usd">2171000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if076f350ff45436996af2f05839c8882_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNS05LTEtMS05MzYw_7bd932d6-cbe9-494d-8a61-fc39bdcd9051"
      unitRef="usd">2177000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4a9b9d93a9dc4310ae5a5a00e96b249e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNi0zLTEtMS05MzYw_9b57cd7d-dd5f-42cd-a154-2d1311077c37"
      unitRef="usd">5479000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if076f350ff45436996af2f05839c8882_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNi05LTEtMS05MzYw_c46c8b4c-1356-4139-a921-190ea47eea8a"
      unitRef="usd">5479000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="i7a3ae9e595754fd8b7b517f5d6502c61_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNy0xLTEtMS05MzYw_a6fdc4f7-700e-4eba-9049-2b7dc7f11ded"
      unitRef="usd">1777000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifdcafea902a94b74806fbbc66676de9b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNy0zLTEtMS05MzYw_2e21d664-7727-48aa-b0b9-dff5a464c08b"
      unitRef="usd">1010779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a87a730f5264586b524537e3168930d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNy01LTEtMS05MzYw_66a63f83-aedc-4ed1-b541-5d3ec5c59614"
      unitRef="usd">182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f09c79fd6f5409491477c45b1543e48_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNy03LTEtMS05MzYw_6ecb148e-57f6-4414-909b-e78f273fb171"
      unitRef="usd">-1087726000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9086f7c6548c4033b8ecf3a3a2cc454e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfNy05LTEtMS05MzYw_b85bde62-f843-4997-978b-db0a6768f068"
      unitRef="usd">-74988000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="icb74c52ede444e4585f9077b04bd8f51_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfOC03LTEtMS05MzYw_61eb92d6-21ee-4a30-8ea8-74604b804892"
      unitRef="usd">-43198000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ife6d0af669364983a00fd3d0254f171b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfOC05LTEtMS05MzYw_df844ea4-645a-4efc-b730-46f062733729"
      unitRef="usd">-43198000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i99d7ba3d2a234849a4f237f0d5b55516_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfOS01LTEtMS05MzYw_d14d9fab-29e3-4410-9dfb-3f9c59b587c5"
      unitRef="usd">-95000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ife6d0af669364983a00fd3d0254f171b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfOS05LTEtMS05MzYw_d144efee-30b6-4b47-8d1e-216c5f2e056b"
      unitRef="usd">-95000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ife6d0af669364983a00fd3d0254f171b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTAtMC0xLTEtOTM2MC90ZXh0cmVnaW9uOmExZjFiOWM0OTg2MzQ4MzFiMzI0YWE0MmYwZTRhN2ZiXzMx_aa100be0-948b-4608-8c20-8c18cfc2505e"
      unitRef="shares">1056000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7be39acc2a414f32b4108381b199c1d2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTAtMS0xLTEtOTM2MA_1383264a-d968-423c-b318-f9300bbe8683"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i00f4f783bc4640caa49ae534564dda62_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTAtMy0xLTEtOTM2MA_0b6507dc-7fb4-4948-a1c1-42ba890d9246"
      unitRef="usd">4564000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ife6d0af669364983a00fd3d0254f171b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTAtOS0xLTEtOTM2MA_9ec79dd5-8796-48f0-a798-6f582a81fb53"
      unitRef="usd">4574000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i00f4f783bc4640caa49ae534564dda62_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTEtMy0xLTEtOTM2MA_f47225fd-2845-423f-b40b-2b4cac20a0e1"
      unitRef="usd">7632000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ife6d0af669364983a00fd3d0254f171b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTEtOS0xLTEtOTM2MA_03b1be3e-346d-45b1-b6fa-2898af9924e6"
      unitRef="usd">7632000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="i49595be0c9ca44d8bdf145a82b2c37a0_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTItMS0xLTEtOTM2MA_73e43f1f-d819-4eb1-8a38-1b208ed3f8ba"
      unitRef="usd">1787000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5fffddbb207f442684761c141969e63e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTItMy0xLTEtOTM2MA_b82f91e2-571d-4cca-93a6-77fb693acf91"
      unitRef="usd">1022975000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifc7f6cadfe9a4eeab4afe3e1661f4099_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTItNS0xLTEtOTM2MA_316b9bb9-3168-4e55-8760-877877bfb71d"
      unitRef="usd">87000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i766e3bef22c54ee3bdab656c940663e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTItNy0xLTEtOTM2MA_861cd323-f68c-4729-a620-5c18f3674586"
      unitRef="usd">-1130924000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie4937c63164a42b3a6326fc7d4b4babe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTItOS0xLTEtOTM2MA_62424999-2091-45ae-8c6b-59586cd59879"
      unitRef="usd">-106075000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iec324695fb5c455faa27509e51bd78b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTMtNy0xLTEtOTYwMQ_96452d32-8456-4e37-bf09-a05f8211c11b"
      unitRef="usd">-58801000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTMtOS0xLTEtOTYwOQ_d8cadcff-6ca9-4afb-be78-25af9f74237d"
      unitRef="usd">-58801000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaea012f1493f49fd8a6586b2899d6b3a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTQtNS0xLTEtOTU4OA_8a5b91bb-da31-45d5-a9e2-c44fb5d84082"
      unitRef="usd">27000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTQtOS0xLTEtOTYwOQ_33cc961e-d2c3-4d7d-a6b4-94f59e727fdb"
      unitRef="usd">27000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTUtMC0xLTEtOTU0Mi90ZXh0cmVnaW9uOjEwNWQ3ZTQzN2QzOTQ5M2ZhYmFlZmQ4ZmZjMzA0Yjg5XzU0OTc1NTgxMzk0Ng_81efd32e-b975-4954-a3d5-8d2402b8d15f"
      unitRef="shares">123000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iac6aea1e78d3493ea6d07c8e22679e2e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTUtMS0xLTEtOTU0Mg_7072ff48-d180-429b-87d9-0821a1711f9b"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic7b7c292e90941a398476976288e3ff4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTUtMy0xLTEtOTU3MA_09308d4c-ef9f-40db-bcac-c7c8689494e2"
      unitRef="usd">1240000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTUtOS0xLTEtOTYwOQ_de89b243-8306-4718-a8e3-632520b20a28"
      unitRef="usd">1241000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTYtMC0xLTEtOTU0Mi90ZXh0cmVnaW9uOmZiZmU1ZDAwOWJmZjQ0OTdiNTAyMzQzYWNiNTMyOGVkXzU0OTc1NTgxMzkzNw_c8fd8e00-6fcf-458f-bf21-9dec6ae8f8c6"
      unitRef="shares">942000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iac6aea1e78d3493ea6d07c8e22679e2e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTYtMS0xLTEtOTU0Mg_7829df27-2ea6-4092-8809-5ce64c600a30"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic7b7c292e90941a398476976288e3ff4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTYtMy0xLTEtOTU3MA_2dfcaea6-a476-49a4-9dc4-f24b8afff408"
      unitRef="usd">3525000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTYtOS0xLTEtOTYwOQ_7c709653-4453-4d33-9df8-f8f479e69563"
      unitRef="usd">3535000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic7b7c292e90941a398476976288e3ff4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTctMy0xLTEtOTU3MA_873243b2-59a6-4bee-9645-b553ac6b65c3"
      unitRef="usd">13029000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTctOS0xLTEtOTYwOQ_b9b2118a-23fc-494c-982c-845431a62cfd"
      unitRef="usd">13029000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="ic4fd1209b6f7440bb9686323eb1893fc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTgtMS0xLTEtOTU0Mg_4e4d9691-ab20-4ac9-ab26-0022f1036af7"
      unitRef="usd">1798000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c7532d73a584500bbd44288b8006073_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTgtMy0xLTEtOTU3OA_3d4d8c22-46a2-4c71-8055-bc148c24b33a"
      unitRef="usd">1040769000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5a7cdd440cf410c82c96bf461ca3e07_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTgtNS0xLTEtOTU4OA_2321c8b5-e448-4eea-9d90-9bc4ee80ac7f"
      unitRef="usd">114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieb951a6478734d308e70fb7798d6529f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTgtNy0xLTEtOTYwMQ_0a89f254-3bf3-4020-ae85-c6aa9ce9f926"
      unitRef="usd">-1189725000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1a3b74ad1e0f4442b522495e111be937_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zMS9mcmFnOmZiN2EzYWIzMzUwZDRmMTFhNWQ2NjhmZTYwMTQ5NmMxL3RhYmxlOjk2ZTU2OWRhMzA2NzQ3MjZiMzVlMTY2NmQyNzJiZjRhL3RhYmxlcmFuZ2U6OTZlNTY5ZGEzMDY3NDcyNmIzNWUxNjY2ZDI3MmJmNGFfMTgtOS0xLTEtOTYwOQ_3e1b325a-11ee-43e0-96ca-7d744ac47baa"
      unitRef="usd">-147044000</us-gaap:StockholdersEquity>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMzI_ef2baa86-4b0b-4f66-b8da-1e3f7e04f893">Significant Accounting Policies and Concentrations of Risk&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in 1986 and incorporated in Delaware in 1991, and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s marketed products include oral, once-daily ORLADEYO&#xae; for the prevention of hereditary angioedema (&#x201c;HAE&#x201d;) attacks and RAPIVAB&#xae; (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. ORLADEYO received regulatory approval in the United States in December 2020. ORLADEYO has also received regulatory approvals in multiple global markets. The Company is commercializing ORLADEYO in each of these territories directly or through distributors, except in Japan where Torii Pharmaceutical Co., Ltd., the Company&#x2019;s collaborative partner, has the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in exchange for certain milestone and royalty payments to the Company. In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada, Australia, Japan, Taiwan and Korea. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company&#x2019;s expectations for revenue and operating expenses, the Company believes its financial resources available at September&#160;30, 2022 will be sufficient to fund its operations for at least the next 12 months. The Company has sustained operating losses for the majority of its corporate history and expects that its 2022 expenses will exceed its 2022 revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company regularly evaluates other opportunities to fund future operations, including: (1) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (2) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestone payments; (3) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (4) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (5) reducing spending on one or more research and development programs, including by discontinuing development; and/or (6) restructuring operations to change its overhead structure. The Company may issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events and its decisions in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements should be read in conjunction with the financial statements for the year ended December&#160;31, 2021 and the notes thereto included in the Company&#x2019;s 2021 Annual Report on Form 10-K. Interim operating &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;results are not necessarily indicative of operating results for the full year. The balance sheet as of December&#160;31, 2021 has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to the valuation of stock options, the ORLADEYO and Factor D inhibitors royalty financing obligations and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in December 2020, sales of peramivir to the Company&#x2019;s licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;) under the Company&#x2019;s procurement contract. In the United States, the Company ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. In the European Union, United Kingdom and elsewhere, the Company sells ORLADEYO to specialty distributors as well as hospitals and pharmacies, which collectively are considered its customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue for sales when its customers obtain control of the product, which generally occurs upon delivery. For ORLADEYO, the Company classifies payments to its specialty pharmacy customer for certain services provided by its customer as selling, general and administrative expenses to the extent such services provided are determined to be distinct from the sale of its product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or as a current liability. Overall, these reserves reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government and Managed Care Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company contracts with government agencies and managed care organizations or, collectively, third-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;establishment of a current liability. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) product distribution information obtained from the Company's specialty pharmacy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company&#x2019;s specialty pharmacy. These customers purchase the Company&#x2019;s product under contracts negotiated between them and the Company&#x2019;s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price the specialty pharmacy paid and the negotiated price paid by the contracted customers, which may be higher or lower than the specialty pharmacy&#x2019;s purchase price from the Company. The Company estimates chargebacks and adjusts gross product revenues and accounts receivable based on the estimates at the time revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment assistance and patient assistance programs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company is able to estimate the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#x2019;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product returns&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company does not provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has collaboration and license agreements with a number of third parties, as well as research and development agreements with certain government entities. The Company&#x2019;s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not probable at the inception of the agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the HHS (&#x201c;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash of $21 and $1,924 as of September&#160;30, 2022 and December&#160;31, 2021, respectively, reflects royalty revenue paid by Shionogi designated for interest on the PhaRMA Notes (defined in Note 6). Additionally, restricted cash of $1,423 and $1,421 as of September&#160;30, 2022 and December&#160;31, 2021, respectively, reflects collateral for a letter of credit the Company is required to maintain associated with the lease execution and build-out of its Birmingham research facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, certificates of deposits, municipal and corporate notes and bonds, and commercial paper, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 12 months. Some of the securities in which the Company invests may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At September&#160;30, 2022, the Company believes that the cost of its investments is recoverable in all material respects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other third-party distributors, hospitals and pharmacies in the European Union, United Kingdom and elsewhere and have standard payment terms that generally require payment within 30 to 90 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the HHS, and royalty receivables from the Company&#x2019;s partners, including Shionogi, Green Cross, and Torii.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monthly invoices are submitted to HHS related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not adjust its receivables for the effects of a significant financing component at contract inception if it expects to collect the receivables in one year or less from the time of sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides reserves against trade receivables for estimated losses that may result from a customer's inability to pay. Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company&#x2019;s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, labor, manufacturing overhead and shipping and handling costs on a first-in, first-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labelled products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s inventories are subject to expiration dating. The Company regularly evaluates the carrying value of its inventories and provides valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, the Company may experience spoilage of its raw materials and supplies. The Company&#x2019;s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of September&#160;30, 2022 and December&#160;31, 2021, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including freight. In addition, shipping and handling costs for product shipments are recorded as incurred. Finally, cost of product sales may also include costs related to excess or obsolete inventory adjustment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts, and estimates are adjusted, if required, based upon the Company&#x2019;s ongoing review of the level of services actually performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred collaboration expenses represent sublicense payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#x2019;s academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expense is primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other general and administrative costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising expenses related to ORLADEYO were $3,476 and $11,555 for the three and nine months ended September&#160;30, 2022, respectively, and $1,492 and $4,696 for the three and nine months ended September&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of September&#160;30, 2022. The Company accounts for lease obligations in accordance with ASU 2016-02: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#x2019;s Consolidated Balance Sheets represent payments over the lease term, which includes renewal options for certain real estate leases that the Company is likely to exercise. As part of the Company&#x2019;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of twelve months or less was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The discount rate used in the calculation of the Company&#x2019;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#x2019;s collateralized borrowing rate from lending institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not made any residual value guarantees related to its operating leases; therefore, the Company has no corresponding liability recorded on its Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, the Company has outstanding performance-based stock options and restricted stock units for which no compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Expense and Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the three and nine months ended September&#160;30, 2022 was $24,775 and $72,634, respectively, and $14,115 and $40,514 for the three and nine months ended September&#160;30, 2021, respectively, and primarily relates to the royalty financing obligations (Note 6), the secured term loan borrowing from the Credit Agreement (Note 7) and the PhaRMA Notes (Note 6). Costs directly associated with the borrowings have been capitalized and are netted against the corresponding debt liabilities on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $(258) and $(597) for the three and nine months ended September&#160;30, 2022, respectively, and $(158) and $(369) for the three and nine months ended September&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the PhaRMA Notes and associated accrued interest payable was written-off into other income as a debt extinguishment (Refer to &#x201c;Note 6&#x2014;Royalty Monetizations&#x2014;RAPIACTA&#x2014;Non-Recourse Notes Payable &#x2013; Debt Extinguishment&#x201d; for additional information regarding the debt extinguishment).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Expense and Royalty Financing Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO, BCX9930, and another earlier stage Factor D inhibitor (BCX10013). Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in fiscal year 2021, the Company began accruing foreign income taxes as a result of increased nexus in foreign jurisdictions where historically the Company had no presence.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, starting in 2022, amendments to Section 174 of the Internal Revenue Code of 1986, as amended (&#x201c;IRC&#x201d;), will no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil. As a result of this tax law change, the Company has recorded a U.S. state tax provision for the nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company&#x2019;s equity compensation plans were anti-dilutive. The calculation of diluted earnings per share does not include 26,236 and 25,918 shares of potential common stock for the three and nine months ended September&#160;30, 2022, respectively, and 28,472 and 26,131 shares of potential common stock for the three and nine months ended September&#160;30, 2021, respectively, as their impact would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income and recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. There were no realized gains or losses reclassified out of accumulated other comprehensive income for the nine months ended September 30, 2022.  For the nine months ended September 30, 2021, realized gains of $1 were reclassified out of accumulated other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Customers and Other Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s primary sources of revenue and cash flow are the sales of ORLADEYO in the United States and other global markets as well as sales of RAPIVAB (peramivir injection) under the Company's procurement contract with the Assistant Secretary for Preparedness and Response within HHS. Additionally, the Company receives reimbursement of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;galidesivir (formerly BCX4430) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ORLADEYO is distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. The specialty pharmacy&#x2019;s inability or unwillingness to continue these distribution activities could adversely impact the Company&#x2019;s business, results of operations and financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company is distributing ORLADEYO in other global markets directly or through distributors, except in Japan where Torii, the Company&#x2019;s collaborative partner, has the exclusive right to commercialize ORLADEYO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses has represented a significant portion of the Company&#x2019;s collaborative and other research and development revenues. All government funding for galidesivir is expected to expire in 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, HHS is the primary customer for RAPIVAB, and it has exercised the remaining option for the purchase of RAPIVAB under the procurement contract with the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, the Company&#x2019;s drug development activities are performed by a limited group of third-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks from Third-Party Manufacturing and Distribution Concentration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays or disruption in the manufacture or distribution of any product could adversely impact the future procurement stockpiling of the Company&#x2019;s product candidates and commercial revenue, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 12 months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables from sales of ORLADEYO are primarily due from one customer, resulting in a concentration of credit risk. Sales of ORLADEYO from the Company to the specialty pharmacy only occur once an order of product has been received by the specialty pharmacy from one of its customers, which include pharmacy benefit managers, insurance companies, government programs and group purchasing organizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the nine months ended September 30, 2022, as compared to the recent accounting pronouncements described in Note 1 of the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, that the Company believes are of s</us-gaap:SignificantAccountingPoliciesTextBlock>
    <bcrx:DescriptionOfCompanyPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMzM_01144fb4-bfe1-4ea2-b23b-9d4bae534397">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in 1986 and incorporated in Delaware in 1991, and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s marketed products include oral, once-daily ORLADEYO&#xae; for the prevention of hereditary angioedema (&#x201c;HAE&#x201d;) attacks and RAPIVAB&#xae; (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. ORLADEYO received regulatory approval in the United States in December 2020. ORLADEYO has also received regulatory approvals in multiple global markets. The Company is commercializing ORLADEYO in each of these territories directly or through distributors, except in Japan where Torii Pharmaceutical Co., Ltd., the Company&#x2019;s collaborative partner, has the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in exchange for certain milestone and royalty payments to the Company. In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada, Australia, Japan, Taiwan and Korea. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company&#x2019;s expectations for revenue and operating expenses, the Company believes its financial resources available at September&#160;30, 2022 will be sufficient to fund its operations for at least the next 12 months. The Company has sustained operating losses for the majority of its corporate history and expects that its 2022 expenses will exceed its 2022 revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company regularly evaluates other opportunities to fund future operations, including: (1) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (2) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestone payments; (3) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (4) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (5) reducing spending on one or more research and development programs, including by discontinuing development; and/or (6) restructuring operations to change its overhead structure. The Company may issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events and its decisions in the future.&lt;/span&gt;&lt;/div&gt;</bcrx:DescriptionOfCompanyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMzQ_3b18e4c4-a5f9-4c04-9489-6a4c0411cb99">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements should be read in conjunction with the financial statements for the year ended December&#160;31, 2021 and the notes thereto included in the Company&#x2019;s 2021 Annual Report on Form 10-K. Interim operating &lt;/span&gt;&lt;/div&gt;results are not necessarily indicative of operating results for the full year. The balance sheet as of December&#160;31, 2021 has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form 10-K.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjQ_e9da6aea-13e7-4569-92b1-67b877015518">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to the valuation of stock options, the ORLADEYO and Factor D inhibitors royalty financing obligations and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMzU_dc1add9a-3520-4043-9a40-0cc8049bbb94">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in December 2020, sales of peramivir to the Company&#x2019;s licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;) under the Company&#x2019;s procurement contract. In the United States, the Company ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. In the European Union, United Kingdom and elsewhere, the Company sells ORLADEYO to specialty distributors as well as hospitals and pharmacies, which collectively are considered its customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue for sales when its customers obtain control of the product, which generally occurs upon delivery. For ORLADEYO, the Company classifies payments to its specialty pharmacy customer for certain services provided by its customer as selling, general and administrative expenses to the extent such services provided are determined to be distinct from the sale of its product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or as a current liability. Overall, these reserves reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government and Managed Care Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company contracts with government agencies and managed care organizations or, collectively, third-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;establishment of a current liability. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) product distribution information obtained from the Company's specialty pharmacy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company&#x2019;s specialty pharmacy. These customers purchase the Company&#x2019;s product under contracts negotiated between them and the Company&#x2019;s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price the specialty pharmacy paid and the negotiated price paid by the contracted customers, which may be higher or lower than the specialty pharmacy&#x2019;s purchase price from the Company. The Company estimates chargebacks and adjusts gross product revenues and accounts receivable based on the estimates at the time revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment assistance and patient assistance programs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company is able to estimate the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#x2019;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product returns&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company does not provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has collaboration and license agreements with a number of third parties, as well as research and development agreements with certain government entities. The Company&#x2019;s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not probable at the inception of the agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the HHS (&#x201c;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMTg_5069224a-b27a-4054-b492-637edec4e629">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjU_0c2eb4a0-debd-4cde-9f1e-cb00222deebd">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash of $21 and $1,924 as of September&#160;30, 2022 and December&#160;31, 2021, respectively, reflects royalty revenue paid by Shionogi designated for interest on the PhaRMA Notes (defined in Note 6). Additionally, restricted cash of $1,423 and $1,421 as of September&#160;30, 2022 and December&#160;31, 2021, respectively, reflects collateral for a letter of credit the Company is required to maintain associated with the lease execution and build-out of its Birmingham research facilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="ibc1913ba4028440697583a0160c2c9a9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMTczNTY_0a8c8a60-df9b-4841-b24c-2bf2eb688231"
      unitRef="usd">21000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i2b656b9adf614afe8e4311bfc8c36b08_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMTczNjM_e70c4ebc-a997-41b5-a646-dce8469fee7b"
      unitRef="usd">1924000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="ie4bab20e161348dda0d3fc5277f3602c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMTc1Mzc_27f6bf51-dece-409f-a9dd-f481b2ba57dc"
      unitRef="usd">1423000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="iff682572ef0b4643862b85d792331a8b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMTc1NDQ_7b72ab75-6e1f-4b56-82f6-ff780589ad2b"
      unitRef="usd">1421000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMTk_1f20671a-3f8c-40ce-b26b-3c86f421ca08">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, certificates of deposits, municipal and corporate notes and bonds, and commercial paper, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 12 months. Some of the securities in which the Company invests may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are not collateralized. The Company has not realized any significant losses from its investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At September&#160;30, 2022, the Company believes that the cost of its investments is recoverable in all material respects.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <bcrx:MaturityPeriodOfHighQualityMarketableSecurities
      contextRef="i3c206d1885894084b6b64b92557dff74_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMTg3MTM_781c2e3a-d62e-4cd6-9d78-3ec6199d1b0c">P3Y</bcrx:MaturityPeriodOfHighQualityMarketableSecurities>
    <bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities
      contextRef="i3c206d1885894084b6b64b92557dff74_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMTg3NzU_cccf0489-e6b0-4116-8ba6-de9c3ae2cd9e">P12M</bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities>
    <bcrx:MaturityPeriodOfShortTermInvestment
      contextRef="i3c206d1885894084b6b64b92557dff74_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMjA0MTE_4e8cd441-cda7-4094-8d13-2ba641f49bff">P12M</bcrx:MaturityPeriodOfShortTermInvestment>
    <bcrx:LongTermInvestmentMaturityMinimum
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMjA1MDQ_629d8430-ac55-4f3c-941c-1e8b9f024c35">P12M</bcrx:LongTermInvestmentMaturityMinimum>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMzY_03e1feec-e707-4e4c-a24d-f58c4c79fe10">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other third-party distributors, hospitals and pharmacies in the European Union, United Kingdom and elsewhere and have standard payment terms that generally require payment within 30 to 90 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the HHS, and royalty receivables from the Company&#x2019;s partners, including Shionogi, Green Cross, and Torii.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monthly invoices are submitted to HHS related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not adjust its receivables for the effects of a significant financing component at contract inception if it expects to collect the receivables in one year or less from the time of sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides reserves against trade receivables for estimated losses that may result from a customer's inability to pay. Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company&#x2019;s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMTU_4ce05801-1bdf-47c9-9325-288f8ad703cd">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, labor, manufacturing overhead and shipping and handling costs on a first-in, first-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labelled products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s inventories are subject to expiration dating. The Company regularly evaluates the carrying value of its inventories and provides valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, the Company may experience spoilage of its raw materials and supplies. The Company&#x2019;s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjM_e65840f3-0b85-41c9-aaad-534049774318">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i30f04607b9fd4fbd8d1e3b4e116511df_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMjM5MTU_a990bc7e-08b8-480a-97e6-ce6df4edfebd">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4f4820f68b75491386429192e255c412_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMjQwMDM_7c5648dd-e996-46c5-b53c-c234cb360851">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iacbf3ec994f848c3afd3f6edf48b0963_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMjQwNjE_9b862fa3-40df-4b05-8883-973c124d9b36">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <bcrx:AccruedExpensesPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjg_01584f97-0501-4707-8073-c10bbc2e1958">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of September&#160;30, 2022 and December&#160;31, 2021, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/span&gt;&lt;/div&gt;</bcrx:AccruedExpensesPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjY_1828811d-3dac-4f3e-b428-7a7bbdcecb27">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including freight. In addition, shipping and handling costs for product shipments are recorded as incurred. Finally, cost of product sales may also include costs related to excess or obsolete inventory adjustment charges.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMTI_c5a75e68-1b40-4296-8b60-95e1d88547fb">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts, and estimates are adjusted, if required, based upon the Company&#x2019;s ongoing review of the level of services actually performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&lt;/span&gt;&lt;/div&gt;Deferred collaboration expenses represent sublicense payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#x2019;s academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjc_79ecebf6-be56-4593-97d5-559564afe8bf">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expense is primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other general and administrative costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising expenses related to ORLADEYO were $3,476 and $11,555 for the three and nine months ended September&#160;30, 2022, respectively, and $1,492 and $4,696 for the three and nine months ended September&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzA4MDQ_0e241716-a40e-49bd-b60a-6d2757a7ea67"
      unitRef="usd">3476000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzA4MTE_32d5c3fe-9f0c-45f4-bca1-0c27a85b973f"
      unitRef="usd">11555000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzA4NjA_5deca40a-14ba-401f-b7e1-51af2e53878d"
      unitRef="usd">1492000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzA4Njc_ed02a38b-6465-4f04-afd9-38b49c3d84b7"
      unitRef="usd">4696000</us-gaap:AdvertisingExpense>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjk_dcb354c4-82cf-436a-9b6f-185b9cd78d8e">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of September&#160;30, 2022. The Company accounts for lease obligations in accordance with ASU 2016-02: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#x2019;s Consolidated Balance Sheets represent payments over the lease term, which includes renewal options for certain real estate leases that the Company is likely to exercise. As part of the Company&#x2019;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of twelve months or less was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The discount rate used in the calculation of the Company&#x2019;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#x2019;s collateralized borrowing rate from lending institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not made any residual value guarantees related to its operating leases; therefore, the Company has no corresponding liability recorded on its Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjA_0b804a0f-1b59-4205-9aa1-aadfe64b11a5">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, the Company has outstanding performance-based stock options and restricted stock units for which no compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjE_442a909e-4b47-4457-a87e-cca089fe8e6e">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Expense and Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the three and nine months ended September&#160;30, 2022 was $24,775 and $72,634, respectively, and $14,115 and $40,514 for the three and nine months ended September&#160;30, 2021, respectively, and primarily relates to the royalty financing obligations (Note 6), the secured term loan borrowing from the Credit Agreement (Note 7) and the PhaRMA Notes (Note 6). Costs directly associated with the borrowings have been capitalized and are netted against the corresponding debt liabilities on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $(258) and $(597) for the three and nine months ended September&#160;30, 2022, respectively, and $(158) and $(369) for the three and nine months ended September&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the PhaRMA Notes and associated accrued interest payable was written-off into other income as a debt extinguishment (Refer to &#x201c;Note 6&#x2014;Royalty Monetizations&#x2014;RAPIACTA&#x2014;Non-Recourse Notes Payable &#x2013; Debt Extinguishment&#x201d; for additional information regarding the debt extinguishment).&lt;/span&gt;&lt;/div&gt;</bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock>
    <us-gaap:InterestExpenseDebt
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzM1OTU_3a4afab4-1987-47cd-8fc0-3816aabb480f"
      unitRef="usd">24775000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzM2MDI_5e2f871a-7a3a-4c74-bf31-09272aa221d8"
      unitRef="usd">72634000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzM2MjQ_e7d6bf4f-9baf-4021-8ff5-f2bd9ded6ded"
      unitRef="usd">14115000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzM2MzE_9bf594ae-f955-40b3-b527-ec38a07faae9"
      unitRef="usd">40514000</us-gaap:InterestExpenseDebt>
    <bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzQyMjA_a1262cdd-4c69-4d94-9806-2507d9e3154a"
      unitRef="usd">-258000</bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts>
    <bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzQyMjc_c55e9cc7-a553-4b0e-93b5-220ebcf34e62"
      unitRef="usd">-597000</bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts>
    <bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzQyNzY_e3b3e493-be89-4e45-8b57-db67aef55baf"
      unitRef="usd">-158000</bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts>
    <bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzQyODM_3ee59426-7863-46fb-8e05-1ec6cafa8504"
      unitRef="usd">-369000</bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts>
    <bcrx:InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMTM_419e377b-d9d7-4184-bdc0-5ecd673ee485">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Expense and Royalty Financing Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO, BCX9930, and another earlier stage Factor D inhibitor (BCX10013). Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.&lt;/span&gt;&lt;/div&gt;</bcrx:InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMzA_1aa40edb-b121-44bc-9cd0-fd503ac9d626">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in fiscal year 2021, the Company began accruing foreign income taxes as a result of increased nexus in foreign jurisdictions where historically the Company had no presence.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, starting in 2022, amendments to Section 174 of the Internal Revenue Code of 1986, as amended (&#x201c;IRC&#x201d;), will no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil. As a result of this tax law change, the Company has recorded a U.S. state tax provision for the nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMTQ_dfbb4452-6c00-41d2-9167-d0619a7ac287">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company&#x2019;s equity compensation plans were anti-dilutive. The calculation of diluted earnings per share does not include 26,236 and 25,918 shares of potential common stock for the three and nine months ended September&#160;30, 2022, respectively, and 28,472 and 26,131 shares of potential common stock for the three and nine months ended September&#160;30, 2021, respectively, as their impact would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzcwNDk_09fc552f-4b51-4e60-8256-002cfee2abff"
      unitRef="shares">26236000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzcwNTY_2db0c375-772f-4efe-a479-4727766ae336"
      unitRef="shares">25918000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzcxMzg_0bd5737f-c2b1-46cb-8fb5-2918ab941fef"
      unitRef="shares">28472000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzcxNDU_83d3a07a-bbe6-4ab1-8e4c-4da6d96eea89"
      unitRef="shares">26131000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMTc_04863f32-49d9-465c-b17b-2d968df9c2be">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income and recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. There were no realized gains or losses reclassified out of accumulated other comprehensive income for the nine months ended September 30, 2022.  For the nine months ended September 30, 2021, realized gains of $1 were reclassified out of accumulated other comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMTA5OTUxMTY2OTk0MA_714317eb-4b3d-4baf-9255-29fb901bf9ef"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfMzc5MDQ_03e6f564-ff9c-41b1-90a2-c24624a03292"
      unitRef="usd">-1000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <bcrx:ConcentrationOfMarketRiskPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMjI_b1cda0ef-a0cd-41c0-be54-180b04744a67">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Customers and Other Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s primary sources of revenue and cash flow are the sales of ORLADEYO in the United States and other global markets as well as sales of RAPIVAB (peramivir injection) under the Company's procurement contract with the Assistant Secretary for Preparedness and Response within HHS. Additionally, the Company receives reimbursement of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;galidesivir (formerly BCX4430) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ORLADEYO is distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. The specialty pharmacy&#x2019;s inability or unwillingness to continue these distribution activities could adversely impact the Company&#x2019;s business, results of operations and financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company is distributing ORLADEYO in other global markets directly or through distributors, except in Japan where Torii, the Company&#x2019;s collaborative partner, has the exclusive right to commercialize ORLADEYO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses has represented a significant portion of the Company&#x2019;s collaborative and other research and development revenues. All government funding for galidesivir is expected to expire in 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, HHS is the primary customer for RAPIVAB, and it has exercised the remaining option for the purchase of RAPIVAB under the procurement contract with the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, the Company&#x2019;s drug development activities are performed by a limited group of third-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks from Third-Party Manufacturing and Distribution Concentration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays or disruption in the manufacture or distribution of any product could adversely impact the future procurement stockpiling of the Company&#x2019;s product candidates and commercial revenue, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 12 months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables from sales of ORLADEYO are primarily due from one customer, resulting in a concentration of credit risk. Sales of ORLADEYO from the Company to the specialty pharmacy only occur once an order of product has been received by the specialty pharmacy from one of its customers, which include pharmacy benefit managers, insurance companies, government programs and group purchasing organizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.&lt;/span&gt;&lt;/div&gt;</bcrx:ConcentrationOfMarketRiskPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF8zNy9mcmFnOmU1ODZjNzUwZDkyMTQzZGZhZTE5NzQ5ZDAyM2QxODZmL3RleHRyZWdpb246ZTU4NmM3NTBkOTIxNDNkZmFlMTk3NDlkMDIzZDE4NmZfNDIwMzE_66eadb2e-d66f-4fe6-8e11-bef75d44854b">Recently Adopted Accounting PronouncementsThere have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the nine months ended September 30, 2022, as compared to the recent accounting pronouncements described in Note 1 of the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, that the Company believes are of s</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RleHRyZWdpb246MDc1ZTlmZjQ0N2U3NDIwNmE3ODA0NWU5ODkwNWIyMmZfODI_641615c8-da14-4c07-b761-ed0a2bd08b5a">Revenue&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the following revenues (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ORLADEYO&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RAPIVAB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Peramivir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaborative and other research and development revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaborative and other research and development revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;75,827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;191,282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110,012&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RleHRyZWdpb246MDc1ZTlmZjQ0N2U3NDIwNmE3ODA0NWU5ODkwNWIyMmZfODM_aadfd7c4-0cb4-4ecf-9c3f-c508364b1a2d">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the following revenues (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ORLADEYO&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RAPIVAB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Peramivir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaborative and other research and development revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaborative and other research and development revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;75,827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;191,282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110,012&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i01b1e25bb16a4e61b3726d6578c74362_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMy0xLTEtMS05MzYw_b8ebd9d5-aedc-45bf-8f3c-2907d4837542"
      unitRef="usd">65395000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i085d63dc06a84f6ea9de568acc4df142_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMy0zLTEtMS05MzYw_de7381ca-02a4-4b99-b556-1d9581303a4e"
      unitRef="usd">36711000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i451dda4c3a8e4ccfad33168494bc9c9d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMy00LTEtMS05MzYw_df84e61f-fb14-4175-839a-97856c553b48"
      unitRef="usd">179492000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iaae1596b0387405c82740b7390d33d38_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMy02LTEtMS05MzYw_91f1a685-6b95-4e4d-961a-919f9d796e6b"
      unitRef="usd">76023000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iadb0a3977d2e464381bb4a2a4912955b_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNC0xLTEtMS05MzYw_9dc57477-116a-4c80-9dec-9242815e5e42"
      unitRef="usd">6953000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i72fe97c0b03a4aefa6351d9bbfc48eb8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNC0zLTEtMS05MzYw_d4af9960-6a79-4b7f-8020-f35da8de96fa"
      unitRef="usd">2430000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id2b500470aa1440998f2b21760e6893f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNC00LTEtMS05MzYw_c089d02a-f644-463d-acc4-57f59bb666d0"
      unitRef="usd">7290000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8d1a5d14f8b040478c08a0ed5704b783_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNC02LTEtMS05MzYw_f377fc84-e3ac-47e7-a55a-9f19cb3f7fd3"
      unitRef="usd">7165000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i20a97685da3b4dc781181f5228701bd4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNS0xLTEtMS05MzYw_4840ec8f-b77b-4e91-abff-86a85bd7a45e"
      unitRef="usd">2865000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i95e09ca159fe4d35ad4cf6c7111aadae_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNS0zLTEtMS05MzYw_ed5ce43e-e554-4f3a-a319-bd0b94b433be"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6355a4b7fee3482482574de4cadc4f2c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNS00LTEtMS05MzYw_eb5d85db-5bc2-4d0e-b245-ad9f8a2d0d84"
      unitRef="usd">2865000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i530113c61c0045f5a77ebf99982dd4cf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNS02LTEtMS05MzYw_d499d951-0bc8-48d8-8f7e-4288009106c7"
      unitRef="usd">7254000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i02cd59e16e0149199ce28d859c3ac6a8_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNi0xLTEtMS05MzYw_44407b3b-2974-4ecd-bab6-ff4387ecf8db"
      unitRef="usd">75213000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i03da29ccbd9f4d09beeb6288fdf053b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNi0zLTEtMS05MzYw_44db92e9-4990-4185-9462-9f103de132b2"
      unitRef="usd">39141000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id38b2ee116544f90a76e9d8b6d33f39b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNi00LTEtMS05MzYw_b5135420-665a-40b8-8614-1f5e7c12e459"
      unitRef="usd">189647000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if885f6f8cf8d4e339f135dd75b604594_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNi02LTEtMS05MzYw_c5c46b73-5bb6-4113-9848-a5aab38fad83"
      unitRef="usd">90442000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9b2b8611a0384b2e8a19a43ecfab2135_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNy0xLTEtMS05MzYw_8b0972f7-adbb-4fb4-ba88-d6dce5e87779"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i06ca5f40fc4b4aa98634268fcf2525a0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNy0zLTEtMS05MzYw_2fad5670-4e44-4336-be58-cdcb7c64acd2"
      unitRef="usd">322000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie51f3d3839d1472ea8a99419a9e1d1dd_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNy00LTEtMS05MzYw_5e6278fa-3522-42a0-b70a-309db0ae4697"
      unitRef="usd">1487000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i69c7f898fb47496b80d856f7a82a5454_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfNy02LTEtMS05MzYw_84edf291-9da2-4fbb-8811-c71588ddacb0"
      unitRef="usd">-447000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7d334c267d664d22a3b7769ac993451a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfOC0xLTEtMS05MzYw_e4d3826a-9009-4c68-a9be-296900265ead"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8fa865c7a786428b8ce79ebf9351f4ad_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfOC0zLTEtMS05MzYw_d82d5e05-4116-4a4b-9e44-33604e87fb65"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9dd8066819384bae8b29a1bc99808b48_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfOC00LTEtMS05MzYw_cb6a38f8-2c9a-49d9-b405-85c764cb8b81"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9435042756cd4d408e47bff42738cf8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfOC02LTEtMS05MzYw_8f5f901a-5fd9-49ee-8ab1-cde22cb0433f"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i300f876718414e03a6d92b6eef13452b_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTAtMS0xLTEtOTM2MA_fc4ed698-32e1-4441-81fa-6317d4de26f9"
      unitRef="usd">14000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4a43835db50e40aa8dae8ed521e3d03c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTAtMy0xLTEtOTM2MA_0cac41ef-041e-43e4-96f6-31ec4b5a9157"
      unitRef="usd">1531000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibc7c54d81f614da2bf398d8589ddba3d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTAtNC0xLTEtOTM2MA_7f2d8925-a73c-4cba-925f-0bb97f6ef91c"
      unitRef="usd">148000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4ca21205297a4dce8632aec47144b369_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTAtNi0xLTEtOTM2MA_c125198b-0d56-4ced-af53-3c0fa10c1b21"
      unitRef="usd">5017000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i67cf7bf22deb4aff91b49db594f6a877_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTEtMS0xLTEtOTM2MA_dba9be61-3f3c-4c52-9363-04186d2edbf1"
      unitRef="usd">14000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7382589fe0034462aa011f377b6998da_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTEtMy0xLTEtOTM2MA_6894974a-a14c-420b-98fe-94c5425acfb9"
      unitRef="usd">1531000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6dde7334e062479ab641b4c89a0a55e4_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTEtNC0xLTEtOTM2MA_1beae52d-4f42-4312-9fef-dedfc57c9299"
      unitRef="usd">148000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i89dd57b2bc7948769d0753db905659dd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTEtNi0xLTEtOTM2MA_659323d6-0181-4233-bcbd-9908d44dac4f"
      unitRef="usd">5017000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTItMS0xLTEtOTM2MA_f21f44b3-0567-4611-a98f-647728e7387b"
      unitRef="usd">75827000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTItMy0xLTEtOTM2MA_948c06bd-aeec-4780-a225-4f6a0efd1fc7"
      unitRef="usd">40994000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTItNC0xLTEtOTM2MA_06b83279-d502-4177-93e1-ebfb117d0b33"
      unitRef="usd">191282000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80MC9mcmFnOjA3NWU5ZmY0NDdlNzQyMDZhNzgwNDVlOTg5MDViMjJmL3RhYmxlOmE2MTgyZmNlYjM5ZDQ3YzY4NzRlN2E4MGMzZWFlY2RjL3RhYmxlcmFuZ2U6YTYxODJmY2ViMzlkNDdjNjg3NGU3YTgwYzNlYWVjZGNfMTItNi0xLTEtOTM2MA_fccdee07-dac3-4f38-9c74-25bdd03222b3"
      unitRef="usd">110012000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RleHRyZWdpb246ZWE4N2YzMWU5NjBjNGNlYzgyMjUwZWM4OTljMjhmMDJfNjk1_5411bf54-06bc-4f1f-a754-024e0d8d5ac4">Investments&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair values of the Company&#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accrued&lt;br/&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accrued&lt;br/&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the scheduled maturity for the Company&#x2019;s investments at September&#160;30, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RleHRyZWdpb246ZWE4N2YzMWU5NjBjNGNlYzgyMjUwZWM4OTljMjhmMDJfNjk2_83e1e6aa-1df5-4718-8e60-7f84db5d00c2">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair values of the Company&#x2019;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accrued&lt;br/&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accrued&lt;br/&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iae7bd5bdeed04eb0a29ec0c7ed2a15cd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMi0xLTEtMS05MzYw_aef47285-8c3a-4174-87de-8c035868ab4b"
      unitRef="usd">205133000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="iae7bd5bdeed04eb0a29ec0c7ed2a15cd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMi0zLTEtMS05MzYw_4ed65118-f91a-4984-899e-1f6a7194ab68"
      unitRef="usd">284000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iae7bd5bdeed04eb0a29ec0c7ed2a15cd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMi01LTEtMS05MzYw_f75c472e-c9c5-4020-8603-c12d232c9731"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iae7bd5bdeed04eb0a29ec0c7ed2a15cd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMi03LTEtMS05MzYw_cbdf5871-80c2-4ad9-a316-b449c0fe7704"
      unitRef="usd">1074000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iae7bd5bdeed04eb0a29ec0c7ed2a15cd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMi05LTEtMS05MzYw_43ea5b67-6e8c-4ec0-9fcc-317b1ebc6315"
      unitRef="usd">204348000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9ae49712cd2e41b4952fd9e10638809f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMy0xLTEtMS05MzYw_03681575-6080-4135-8ccc-bd2b80e82bf3"
      unitRef="usd">7337000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i9ae49712cd2e41b4952fd9e10638809f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMy0zLTEtMS05MzYw_8484ab4f-4694-4b7a-b1b6-12832809d81a"
      unitRef="usd">37000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9ae49712cd2e41b4952fd9e10638809f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMy01LTEtMS05MzYw_d6f3cd0f-c906-40fe-9402-a4e21d0b9d67"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9ae49712cd2e41b4952fd9e10638809f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMy03LTEtMS05MzYw_291f22b6-9981-4f49-bded-063c0cfb9f68"
      unitRef="usd">64000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ae49712cd2e41b4952fd9e10638809f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfMy05LTEtMS05MzYw_e8e332a8-9e31-4361-872a-e51bec533bdc"
      unitRef="usd">7310000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id7cb4025c8734daeb09b21962b869678_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNC0xLTEtMS05MzYw_36cf66e8-57a3-4ef0-b918-3c3d42aa0e82"
      unitRef="usd">2655000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="id7cb4025c8734daeb09b21962b869678_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNC0zLTEtMS05MzYw_aee8960a-3d7f-41dd-9e1d-e6a60f128d40"
      unitRef="usd">10000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id7cb4025c8734daeb09b21962b869678_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNC01LTEtMS05MzYw_04fd1427-1975-40cc-82bf-05ba344a97c2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id7cb4025c8734daeb09b21962b869678_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNC03LTEtMS05MzYw_e002c944-8c4e-406f-93b0-0daf42c1a069"
      unitRef="usd">32000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7cb4025c8734daeb09b21962b869678_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNC05LTEtMS05MzYw_03ab4031-5e2d-4b61-85d1-56ff8c7476bc"
      unitRef="usd">2633000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNS0xLTEtMS05MzYw_861b73a8-42fd-4a8a-b4be-66c35bb4702e"
      unitRef="usd">215125000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNS0zLTEtMS05MzYw_c23583e5-acc3-406b-8f7b-1c749aad7ab9"
      unitRef="usd">331000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNS01LTEtMS05MzYw_b72483ea-c639-475c-b15f-b06eac97fd28"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNS03LTEtMS05MzYw_452690dc-ffd2-410e-9fea-db04f2371b63"
      unitRef="usd">1170000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjRiNWQ0OTkyOTkxMTQxYmVhZjE0MjU4N2QxZjBmNTBjL3RhYmxlcmFuZ2U6NGI1ZDQ5OTI5OTExNDFiZWFmMTQyNTg3ZDFmMGY1MGNfNS05LTEtMS05MzYw_43667cc9-1cc6-4cd3-83fe-9ad07418aed6"
      unitRef="usd">214291000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icba59a9ed8954f15bb323330c2072dc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMi0xLTEtMS05MzYw_7db640ee-f673-42d1-ab05-94678b3e599c"
      unitRef="usd">4043000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="icba59a9ed8954f15bb323330c2072dc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMi0zLTEtMS05MzYw_cc95416b-c3bd-4f0e-984a-67d8de2ffe89"
      unitRef="usd">17000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icba59a9ed8954f15bb323330c2072dc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMi01LTEtMS05MzYw_daf76fd9-caf3-4b18-9829-070236ffb1a3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icba59a9ed8954f15bb323330c2072dc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMi03LTEtMS05MzYw_18208e7b-c9f5-4cae-8592-2d68cf1dfd4c"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icba59a9ed8954f15bb323330c2072dc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMi05LTEtMS05MzYw_af374ccd-9d35-4a17-8639-eab779e19840"
      unitRef="usd">4053000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9834b9d88aa64e0e826bd49839d8f0a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMy0xLTEtMS05MzYw_bebfb2af-159d-4b12-b793-300f44cf4053"
      unitRef="usd">4294000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i9834b9d88aa64e0e826bd49839d8f0a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMy0zLTEtMS05MzYw_b71790cc-dd0c-4adb-8351-47deaa0fa7bf"
      unitRef="usd">40000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9834b9d88aa64e0e826bd49839d8f0a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMy01LTEtMS05MzYw_20e49bfe-e7be-4b39-9cb2-0fadacb7e0e4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9834b9d88aa64e0e826bd49839d8f0a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMy03LTEtMS05MzYw_79b4f83f-ee74-4b1f-845f-d9220198a0e0"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9834b9d88aa64e0e826bd49839d8f0a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfMy05LTEtMS05MzYw_e36f4cb5-b1a8-469e-8572-aa9df458aa6e"
      unitRef="usd">4329000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i138269de9639423b9754ab90611310ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNC0xLTEtMS05MzYw_c66f0075-d6f9-44f2-a83a-435674b783ee"
      unitRef="usd">1652000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i138269de9639423b9754ab90611310ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNC0zLTEtMS05MzYw_b1f4fb5e-aeab-498f-a774-bd9da8abcf88"
      unitRef="usd">8000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i138269de9639423b9754ab90611310ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNC01LTEtMS05MzYw_d227015a-d916-4c46-b5a8-98524d18de2a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i138269de9639423b9754ab90611310ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNC03LTEtMS05MzYw_4ed181c9-b89f-44ef-9418-9536107498d7"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i138269de9639423b9754ab90611310ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNC05LTEtMS05MzYw_8f1a180b-df4a-4673-a6f0-626167af246c"
      unitRef="usd">1659000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNS0xLTEtMS05MzYw_790e67bf-18ba-41ae-b2e6-bfe8dd61f469"
      unitRef="usd">9989000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNS0zLTEtMS05MzYw_f54b5a93-ae43-416d-a514-fe35e54d5471"
      unitRef="usd">65000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNS01LTEtMS05MzYw_d4207221-6a13-4964-8ce4-631a164c33d9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNS03LTEtMS05MzYw_65d24cbb-f89a-4d33-9766-5570ede4f463"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjU2Zjg0ZTAyYjE0ZjRkNmFhYzY4MGM4MTJhMWQ5NDE4L3RhYmxlcmFuZ2U6NTZmODRlMDJiMTRmNGQ2YWFjNjgwYzgxMmExZDk0MThfNS05LTEtMS05MzYw_51aaf0a1-3aa5-41be-8d7e-2f8b4552f7b7"
      unitRef="usd">10041000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecuritiesTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RleHRyZWdpb246ZWE4N2YzMWU5NjBjNGNlYzgyMjUwZWM4OTljMjhmMDJfNjk3_c078d663-bd3e-4536-92fd-7dae51fd43d8">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the scheduled maturity for the Company&#x2019;s investments at September&#160;30, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:HeldToMaturitySecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjdjMDU1ODk1OTM4YjQ1NmE5NTkyOTQ3NzEzNWUwYjc4L3RhYmxlcmFuZ2U6N2MwNTU4OTU5MzhiNDU2YTk1OTI5NDc3MTM1ZTBiNzhfMS0xLTEtMS05MzYw_caa1214c-0518-467b-b25a-fb813897f76d"
      unitRef="usd">179959000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjdjMDU1ODk1OTM4YjQ1NmE5NTkyOTQ3NzEzNWUwYjc4L3RhYmxlcmFuZ2U6N2MwNTU4OTU5MzhiNDU2YTk1OTI5NDc3MTM1ZTBiNzhfMS0zLTEtMS05MzYw_22430995-095c-47d8-bfc5-8fb4eb384465"
      unitRef="usd">3212000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <bcrx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjdjMDU1ODk1OTM4YjQ1NmE5NTkyOTQ3NzEzNWUwYjc4L3RhYmxlcmFuZ2U6N2MwNTU4OTU5MzhiNDU2YTk1OTI5NDc3MTM1ZTBiNzhfMi0xLTEtMS05MzYw_9c8cbc6d-1acb-4dc7-899e-899d6e7e45bb"
      unitRef="usd">34332000</bcrx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo>
    <bcrx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjdjMDU1ODk1OTM4YjQ1NmE5NTkyOTQ3NzEzNWUwYjc4L3RhYmxlcmFuZ2U6N2MwNTU4OTU5MzhiNDU2YTk1OTI5NDc3MTM1ZTBiNzhfMi0zLTEtMS05MzYw_f20c3a7f-7648-4150-aec0-ade78ea25d17"
      unitRef="usd">6829000</bcrx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjdjMDU1ODk1OTM4YjQ1NmE5NTkyOTQ3NzEzNWUwYjc4L3RhYmxlcmFuZ2U6N2MwNTU4OTU5MzhiNDU2YTk1OTI5NDc3MTM1ZTBiNzhfMy0xLTEtMS05MzYw_81850704-179c-4359-8d2e-0ae896e4452e"
      unitRef="usd">214291000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80My9mcmFnOmVhODdmMzFlOTYwYzRjZWM4MjI1MGVjODk5YzI4ZjAyL3RhYmxlOjdjMDU1ODk1OTM4YjQ1NmE5NTkyOTQ3NzEzNWUwYjc4L3RhYmxlcmFuZ2U6N2MwNTU4OTU5MzhiNDU2YTk1OTI5NDc3MTM1ZTBiNzhfMy0zLTEtMS05MzYw_d6885b47-7e3a-4104-9bc2-c65245d7482c"
      unitRef="usd">10041000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <bcrx:TradeReceivablesTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfNjAz_cc2575ab-ac4f-45be-be5d-3810aac5feab">Trade Receivables&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO and RAPIVAB. At September&#160;30, 2022 and December&#160;31, 2021, receivables related to sales of ORLADEYO were $39,565 and $27,384, respectively. At September&#160;30, 2022 and December&#160;31, 2021, receivables related to sales of RAPIVAB were $28 and $49, respectively. No reserve or allowance amounts were recorded as of both September&#160;30, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables from collaborations were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Billed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unbilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty receivables from partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Billed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unbilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty receivables from partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of both September&#160;30, 2022 and December&#160;31, 2021, the Company maintained a reserve of $701 related to royalties associated with Green Cross.</bcrx:TradeReceivablesTextBlock>
    <us-gaap:AccountsReceivableNet
      contextRef="i6d5cc209df4b4f158f63ba78067df1d3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfMjI0_e01514a5-20f4-41d6-8248-91730810c0cb"
      unitRef="usd">39565000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i0bf1868a8c07401995c9209a9fed2a20_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfMjMx_655376bb-4026-41f6-83a1-252c514e537d"
      unitRef="usd">27384000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i822a4f18efa9407ca27d5a5c54dbf5e2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfMzA4_76fda0f0-032d-44e9-b591-ee1bf0bd4dd1"
      unitRef="usd">28000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i00f15b2faead42f68b751bfd1a5a76bf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfMzE1_3c80e4d4-8c2c-477f-b648-bbfde69b6da6"
      unitRef="usd">49000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i3fad271ec831459885eb81d1bf350ac2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfMzMz_8f54a784-a831-47a6-8c79-4fdb47c20130"
      unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i1c255209851347d2823e94f1a619328e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfMzMz_c2942369-5260-4dbd-bab1-99dde6145227"
      unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfNjA0_8b5c05bc-f4e5-496a-a09b-d489aa8ff4ba">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables from collaborations were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Billed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unbilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty receivables from partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Billed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unbilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty receivables from partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i148b60adb92b488a9a9a9586b8ce630f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMi0xLTEtMS05MzYw_8e4a0465-5e0c-494c-a3ac-5bf1979bbec1"
      unitRef="usd">293000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i39ef3ff428bf4f4891cb088a64691907_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMi0zLTEtMS05MzYw_de26ac9f-f305-406c-b264-1139c56ad041"
      unitRef="usd">243000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i575f84670ae346f3b0aaf66dac4ce33a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMi01LTEtMS05MzYw_7b28fee8-27f1-4a56-a9f7-1419ba49506f"
      unitRef="usd">536000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i555cad33b5d44135b244268bf4d08939_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMy0xLTEtMS0xMzU3OQ_f169f31a-f8ec-4233-9624-afab1b941277"
      unitRef="usd">1893000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i6909fce5d6ea480fb5472075566b87fa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMy0zLTEtMS0xMzU2Mw_415f44ea-4468-4f1e-b994-850bb7a3662f"
      unitRef="usd">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ib207348a887d4eac8ea660147a235790_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMy01LTEtMS0xMzU4Nw_8a8960a4-9be4-4898-9d12-03c670254eac"
      unitRef="usd">1893000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i30df1d46204d4ed3bcab448f681a0f99_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMy0xLTEtMS05MzYw_1f14f93c-e6b4-4ac1-ae26-02889196fa16"
      unitRef="usd">588000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ibe28a0b9ba504c29a6bbfb22a00d691b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMy0zLTEtMS05MzYw_11e31b54-3e09-4535-80e1-c8e1d7a1a871"
      unitRef="usd">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i9164b1431b374f07841c05f4d2661cf0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfMy01LTEtMS05MzYw_d06653e5-42dc-41da-a7fa-d2398c9d0131"
      unitRef="usd">588000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ic5b5e996fc4f46a0bea68e7eae665edd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfNC0xLTEtMS05MzYw_7c93c1b9-2194-4eaf-84ac-1d12c987c303"
      unitRef="usd">2774000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i527a858d3bdd48b4bbbc58eaa0c86127_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfNC0zLTEtMS05MzYw_3db26d46-c0bf-46a9-b08d-428f3677c703"
      unitRef="usd">243000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOmY2MGE1NGJlZGYwNjQ0NjNiZGU1Mjc3ODA4ODZlNTNmL3RhYmxlcmFuZ2U6ZjYwYTU0YmVkZjA2NDQ2M2JkZTUyNzc4MDg4NmU1M2ZfNC01LTEtMS05MzYw_084f24ab-d065-4e85-bb68-ccf8f9f34ad8"
      unitRef="usd">3017000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i61c931a38b8f4fb79cd7b1bfc15541af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfMi0xLTEtMS05MzYw_4f48cf20-8d8f-48e3-8f5a-279a76d14c43"
      unitRef="usd">5000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ifba625b9dbe14b648921db96471dc959_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfMi0zLTEtMS05MzYw_a36d7dc1-86ad-46f7-b789-7766945d99e6"
      unitRef="usd">1670000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ib09e2423a7504296aafabf85a78b11e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfMi01LTEtMS05MzYw_a77e5d99-b289-47a1-abef-38cf92ed79e5"
      unitRef="usd">1675000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i06da809ae51d46f4a859c0e6d5105e1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfMy0xLTEtMS05MzYw_020f06ef-be50-4680-89bf-cc1c4d3ee23b"
      unitRef="usd">305000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ie681521de8e8461695ee96dbd9571fcb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfMy0zLTEtMS05MzYw_ceb062ce-1744-401f-95ed-04e2936ab6d5"
      unitRef="usd">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ie154d98fc18c4a1bb3006dded763756f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfMy01LTEtMS05MzYw_2da418f3-3e53-4694-894d-94b288e39338"
      unitRef="usd">305000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i97245d53c4b147daaf476637df025ab6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfNC0xLTEtMS05MzYw_19a23bfd-cc2e-4208-9e30-2c0626342659"
      unitRef="usd">310000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i9144542bf0074b97b464b99a2e251ddb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfNC0zLTEtMS05MzYw_f8175485-f459-4ffb-9548-685d135efd99"
      unitRef="usd">1670000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RhYmxlOjJmOTNlMDZmYjUxNjQ1MWViZmQ2YWY2NTZkMmIwZTlmL3RhYmxlcmFuZ2U6MmY5M2UwNmZiNTE2NDUxZWJmZDZhZjY1NmQyYjBlOWZfNC01LTEtMS05MzYw_6f646f64-dfb2-4406-bc76-de2d58a82a05"
      unitRef="usd">1980000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AccountsReceivableNet
      contextRef="i1ed0f773e01c46b0a1ec1a9b710e5c96_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfNTUx_c47d299f-85d7-4cdc-b756-170883d5db2d"
      unitRef="usd">701000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i3c2f2931216342fc952334687bc6784f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80Ni9mcmFnOmM3YWEyOWFhMTllYzQzNzdiMmQyNGYyYzI0ZWI2MWZiL3RleHRyZWdpb246YzdhYTI5YWExOWVjNDM3N2IyZDI0ZjJjMjRlYjYxZmJfNTUx_f62e8aba-6e27-42a7-ba51-a42f435f6aac"
      unitRef="usd">701000</us-gaap:AccountsReceivableNet>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RleHRyZWdpb246MWFmM2UyMjRkNDVhNGU3MzkxZTA1NmJjNDAxNzQyOTZfMjY4_1a9fd459-31d5-432f-999f-e646a39aee89">Inventory&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2022 and December&#160;31, 2021, the Company&#x2019;s inventory primarily related to ORLADEYO. Additionally, inventory included RAPIVAB and peramivir, which is manufactured for the Company&#x2019;s partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s inventories consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RleHRyZWdpb246MWFmM2UyMjRkNDVhNGU3MzkxZTA1NmJjNDAxNzQyOTZfMjY5_55b3af29-400e-4b3c-9209-e605dfb97b2a">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s inventories consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfMS0xLTEtMS05MzYw_a3670dee-36f8-43ca-af0a-0bb6e70d386a"
      unitRef="usd">8419000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfMS0zLTEtMS05MzYw_6792c2f4-770f-4f3e-9bb1-0ed82745bba2"
      unitRef="usd">5658000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfMi0xLTEtMS05MzYw_919c714f-e062-47b2-ab83-07776e98d644"
      unitRef="usd">15364000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfMi0zLTEtMS05MzYw_bdb746af-9e08-484c-af64-fad15def17ce"
      unitRef="usd">9669000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfMy0xLTEtMS05MzYw_0c04d94a-eb46-4719-ada3-b5ecbff9f132"
      unitRef="usd">3481000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfMy0zLTEtMS05MzYw_cc687aff-86ca-4bdb-a141-e5eff4a14b6d"
      unitRef="usd">709000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfNC0xLTEtMS05MzYw_d3eee699-35a8-4218-ad1b-644eead25013"
      unitRef="usd">27264000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfNC0zLTEtMS05MzYw_d7c0c728-e511-4d42-be62-6abb134a20e5"
      unitRef="usd">16036000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfNS0xLTEtMS05MzYw_63818b46-d04d-4027-80fd-0aeb34fcca01"
      unitRef="usd">245000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfNS0zLTEtMS05MzYw_d0e6233a-5b72-4d7d-8e8e-198d18807ff4"
      unitRef="usd">245000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfNi0xLTEtMS05MzYw_3bd7c83c-eafc-4818-ac12-3d0dece23475"
      unitRef="usd">27019000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF80OS9mcmFnOjFhZjNlMjI0ZDQ1YTRlNzM5MWUwNTZiYzQwMTc0Mjk2L3RhYmxlOjA1ZTIzYTA5MGZmNzQ4OTJiZDYyYzlmNzJmMDM1MmJhL3RhYmxlcmFuZ2U6MDVlMjNhMDkwZmY3NDg5MmJkNjJjOWY3MmYwMzUyYmFfNi0zLTEtMS05MzYw_b524819d-cfb0-47db-a8e3-156fdf1d2c06"
      unitRef="usd">15791000</us-gaap:InventoryNet>
    <bcrx:RoyaltyMonetizationTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTYxNDM_e318d706-c5b6-4a8b-952d-7180a1e6e9be">Royalty Monetizations&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RAPIACTA &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;9, 2011, the Company completed a $30,000 financing transaction to monetize certain future royalty and milestone payments under the Company&#x2019;s agreement with Shionogi (the &#x201c;Shionogi Agreement&#x201d;), pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of $22,691 from the transaction after transaction costs of $4,309 and the establishment of a $3,000 interest reserve account by JPR Royalty Sub LLC, a wholly-owned subsidiary of the Company (&#x201c;Royalty Sub&#x201d;), available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the transaction, the Company entered into a purchase and sale agreement dated as of March 9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement and (ii) the right to receive payments under a Japanese yen/U.S. dollar foreign currency hedge arrangement (as further described below, the &#x201c;Currency Hedge Agreement&#x201d;) put into place by the Company in connection with the transaction. Royalty payments are paid by Shionogi in Japanese yen, and any milestone payments will be paid in U.S. dollars. The Company&#x2019;s collaboration with Shionogi was not impacted as a result of this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Recourse Notes Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due on December 1, 2020 (the &#x201c;PhaRMA Notes&#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March 9, 2011 (the &#x201c;Indenture&#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14% per annum, payable annually in arrears on September 1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty Sub&#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2014, Royalty Sub was unable to pay the accrued interest obligation due September 3, 2013. Under the terms of the Indenture, Royalty Sub&#x2019;s inability to pay the full amount of interest payable in September 2013 by the next succeeding payment date for the PhaRMA Notes, which was September 1, 2014, constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the December 31, 2014 balance sheet and thereafter. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential foreclosure, the primary impact to the Company would be the loss of future royalty payments, if any, from Shionogi and legal costs associated with retiring the PhaRMA Notes. The PhaRMA Notes had a final legal maturity date of December&#160;1, 2020, at which time the outstanding principal amount of the PhaRMA Notes of $30,000, together with accrued and unpaid interest of $20,614, was due in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Recourse Notes Payable &#x2013; Debt Extinguishment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the royalty-bearing patents associated with RAPIACTA in Japan expired. Accordingly, the Company evaluated the current circumstances of the PhaRMA Notes, including (i) their non-recourse nature relative to the Company, (ii) the current state of default since September 1, 2014 and the legal maturity on December 1, 2020 and (iii) the loss of patent protection relative to RAPIACTA in Japan, upon which any significant repayment of the PhaRMA Notes is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;predicated. As a result, the Company determined that it was no longer the financial obligor, and as a result, the principal balance of $30,000 and associated accrued interest payable balance of $25,838 were written off, resulting in a gain on extinguishment recorded in other income (expense) for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ORLADEYO and Factor D Inhibitors&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;7, 2020, the Company and RPI 2019 Intermediate Finance Trust (&#x201c;RPI&#x201d;) entered into a Purchase and Sale Agreement (the &#x201c;2020 RPI Royalty Purchase Agreement&#x201d;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $125,000 in cash (the &#x201c;2020 RPI Royalty Sale&#x201d;). Under the 2020 RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the United States and certain key European markets (collectively, the &#x201c;Key Territories&#x201d;), and other markets where the Company sells ORLADEYO directly or through distributors (collectively, the &#x201c;Direct Sales&#x201d;) in an amount equal to: (i) 8.75% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 2.75% of annual net sales for annual net sales between $350,000 and $550,000. No royalty payments are payable on annual Direct Sales over $550,000. In addition, RPI will be entitled to receive 1.0% of global net sales, if any, of BCX9930.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2020 RPI Royalty Purchase Agreement, RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories (the &#x201c;Other Markets&#x201d;) equal to: (i) 20% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets; (ii) 20% of proceeds received on annual net sales of up to $150,000 in the Other Markets; and (iii) 10% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;19, 2021, the Company and RPI entered into (i) a Purchase and Sale Agreement (the &#x201c;2021 RPI Royalty Purchase Agreement&#x201d; and together with the 2020 RPI Royalty Purchase Agreement, the &#x201c;RPI Royalty Purchase Agreements&#x201d;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $150,000 in cash, and (ii) a Purchase and Sale Agreement with OCM IP Healthcare Holdings Limited, an affiliate of OMERS Capital Markets (&#x201c;OMERS&#x201d;) (the &#x201c;OMERS Royalty Purchase Agreement&#x201d; and collectively with the RPI Royalty Purchase Agreements, the &#x201c;Royalty Purchase Agreements&#x201d;), pursuant to which the Company sold to OMERS the right to receive certain royalty payments from the Company for a purchase price of an additional $150,000 in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2021 RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) 0.75% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 1.75% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000. No royalty payments are payable on Direct Sales over $550,000. RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to 3.0% of proceeds received by the Company on annual net sales of up to $150,000 in the Other Markets, and (iii) 2.0% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2021 RPI Royalty Purchase Agreement, RPI is also entitled to receive tiered, sales-based royalties on net product sales of BCX9930 and another earlier stage Factor D inhibitor (BCX10013) in an amount equal to: (i) 3.0% of worldwide aggregate annual net sales up to $1,500,000 and (ii) 2.0% of worldwide aggregate annual net sales between $1,500,000 and $3,000,000. No royalty payments are payable on annual net sales above $3,000,000. RPI is also entitled to receive tiered profit share amounts of up to 3.0% from certain other permitted sales in certain other markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The royalties payable under the 2021 RPI Royalty Purchase Agreement are in addition to the royalties payable to RPI under the 2020 RPI Royalty Purchase Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the OMERS Royalty Purchase Agreement, commencing with the calendar quarter beginning October 1, 2023, OMERS will be entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) 7.5% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 6.0% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000 (with no royalty payments payable on annual Direct Sales over $550,000) (the &#x201c;Regime A Royalty Rate&#x201d;). If annual Direct Sales for calendar year 2023 reach a specified amount set forth in the OMERS Royalty Purchase Agreement, then for each calendar quarter beginning on or after January 1, 2024, OMERS will be entitled to receive the Regime A Royalty Rate. If annual Direct Sales for calendar year 2023 are less than the specified amount, OMERS will be entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) 10.0% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 3.0% of annual net sales of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ORLADEYO for annual net sales between $350,000 and $550,000 (with no royalty payments payable on annual Direct Sales over $550,000) (the &#x201c;Regime B Royalty Rate&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the OMERS Royalty Purchase Agreement, OMERS is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to: (i) 20.0% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets, (ii) 20.0% of proceeds received by the Company on annual net sales of up to $150,000 in the Other Markets, and (iii) 10.0% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets. OMERS is also entitled to receive profit share amounts of up to 10% from certain other permitted sales in certain other markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2020 RPI Royalty Purchase Agreement, the Company is required to make royalty payments of amounts owed to RPI each calendar quarter following the first commercial sale of ORLADEYO in any country. Under the 2021 RPI Royalty Purchase Agreement, the Company is required to make payments to RPI in respect of net sales or sublicense revenue in each calendar quarter from and after October 1, 2021. Under the OMERS Royalty Purchase Agreement, the Company will be required to make payments to OMERS is respect of net sales or sublicense revenue in each calendar quarter from and after October 1, 2023. OMERS will no longer be entitled to receive any payments on the date in which aggregate payments actually received by OMERS equals either 142.5% or 155.0% of the $150,000 purchase price, depending on sales levels in calendar year 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the &#x201c;Royalty Sales&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Royalty Purchase Agreements, the Company has agreed to specified affirmative and negative covenants, including covenants regarding periodic reporting of information by the Company to RPI and OMERS, third-party audits of royalties paid under the Royalty Purchase Agreements, and restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness other than certain royalty sales and as is permitted to be incurred under the terms of the Company&#x2019;s Credit Agreement with Athyrium Opportunities III Co-Invest 1 LP. Refer to Note 7 for further details on the Credit Agreement. The restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness are eliminated after the achievement of certain specified milestones in the Royalty Purchase Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash consideration obtained pursuant to the Royalty Purchase Agreements is recorded in &#x201c;Royalty financing obligations&#x201d; on the Company&#x2019;s Consolidated Balance Sheets. The fair value for the royalty financing obligations at the time of the transactions was based on the Company&#x2019;s estimates of future royalties expected to be paid to the counterparty over the life of the arrangement. The Company subsequently records the obligations at its carrying value using the effective interest method. In order to amortize the royalty financing obligations, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. The Company periodically assesses the amount and timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success, and sales price, among others. To the extent such payments are greater or less than the Company&#x2019;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2022, the Company adjusted its forecasts related to its R&amp;amp;D programs and ORLADEYO sales. Accordingly, this impacted the amount and timing of expected royalties to be made under the RPI Royalty Purchase Agreements. As a result, the effective interest rate related to the 2020 RPI Royalty Purchase Agreement decreased from 25.5% to 23.1%, and the effective interest rate related to the 2021 RPI Royalty Purchase Agreement decreased from 12.1% to 11.0%. Additionally, the effective interest rate related to the OMERS Agreement increased from 8.5% to 10.6%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity within the Royalty financing obligations account (in thousands) as well as the effective interest rate as of September&#160;30, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 RPI&lt;br/&gt;Royalty&lt;br/&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021 RPI&lt;br/&gt;Royalty&lt;br/&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;OMERS&lt;br/&gt;Royalty&lt;br/&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash Interest expense on Royalty financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues paid and payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash Interest expense on Royalty financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues paid and payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash Interest expense on Royalty financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues paid and payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred issuance costs pursuant to the Royalty financing obligations, which consist primarily of advisory and legal fees, totaled $8,531 as of September&#160;30, 2022. The Royalty financing obligations liabilities and the associated deferred issuance costs are amortized using the effective interest method over the term of the arrangement, in accordance with the respective guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrent with entering into the 2021 RPI Royalty Purchase Agreement, the Company and RPI entered into a Common Stock Purchase Agreement (the &#x201c;Common Stock Purchase Agreement&#x201d;), pursuant to which the Company sold common stock to RPI for a premium of $4,269. This premium has been deferred and is being amortized through interest expense using the effective interest method over the term of the applicable arrangement. Refer to Note 9 for further details on the common stock sale premium.&lt;/span&gt;&lt;/div&gt;</bcrx:RoyaltyMonetizationTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id71eb7a7f4934c329e8946aad8843f79_I20110309"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODY_2faca55b-f127-46ea-8bbc-f779e2069fb3"
      unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i6cd2274f76d84f7d8aa1fecb06595801_D20210309-20210309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMzgy_c911998f-f9d7-49a3-ac3e-ee6003f58555"
      unitRef="usd">22691000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <bcrx:TransactionCosts
      contextRef="i6cd2274f76d84f7d8aa1fecb06595801_D20210309-20210309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNDMz_b50bb979-dc77-4602-9b6d-c9fe6d9b7c0f"
      unitRef="usd">4309000</bcrx:TransactionCosts>
    <bcrx:InterestReserve
      contextRef="i6cd2274f76d84f7d8aa1fecb06595801_D20210309-20210309"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNDYz_c185b219-bcf4-4cc3-92e1-9400212e2ab8"
      unitRef="usd">3000000</bcrx:InterestReserve>
    <bcrx:PrivatePlacementOfSeniorSecuredNotes
      contextRef="ifa8c84cacb9b47f0858154719b4d86b1_D20210309-20210309"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTU4OA_ba24a0bd-8d07-4094-975e-6f2bf7e96dd7"
      unitRef="usd">30000000</bcrx:PrivatePlacementOfSeniorSecuredNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9da1b8e68e3943f4b431a7f4b8c6ddb6_I20110309"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTY1MA_f222afdf-f6c9-4cf4-b77a-3817a7b24057"
      unitRef="number">0.140</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9da1b8e68e3943f4b431a7f4b8c6ddb6_I20110309"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMjE5OA_a087f5c3-0dc1-49df-8618-9c2884e310dd"
      unitRef="number">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SecuredDebt
      contextRef="i6a9d2be26d104c7f88a240ce0bdae3b0_I20201201"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNDI5NA_c0a71b35-5023-4c15-b1ce-995d99f78f17"
      unitRef="usd">30000000</us-gaap:SecuredDebt>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i6a9d2be26d104c7f88a240ce0bdae3b0_I20201201"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNDM0Mw_e46d29ae-cffa-4e30-885a-5f391c8eeaa3"
      unitRef="usd">20614000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ifc57076200334d0195d02ed18bd1d7f6_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNTAwOQ_d145efe8-2d4f-4ef8-87db-10a223a772a8"
      unitRef="usd">30000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic3555a1cac734984b0bc78b41179373c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNTA2Mw_998fbad0-c526-4233-9b27-95ca4a923ef8"
      unitRef="usd">25838000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i40eed59cc9974d4da70c7edd9d0d8c82_D20201207-20201207"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNTQ5Nw_098a2177-06f2-48d8-8457-8af844180d04"
      unitRef="usd">125000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="i659ab2cd433f43e38df5288340793caf_D20201207-20201207"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNTkxNQ_0454d435-046b-4a19-8533-fe0ea6fb19f5"
      unitRef="number">0.0875</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="id0d847dbf3cc433cb71781a71246c04d_D20201207-20201207"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjAwNQ_5fc1ebcc-29d1-45dc-aa1a-1728d384943b"
      unitRef="number">0.0275</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="i8229178c1776432b9a14327383dbd4e8_D20201207-20201207"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjA4MA_6bad363f-8531-42aa-ac9a-305541548f62"
      unitRef="number">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales
      contextRef="i6c43924485804171baf9b85f8c65941c_D20201207-20201207"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjE5NQ_194b9ff7-5047-4c4e-8d4c-b2308121458b"
      unitRef="number">0.010</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="i8038e6b568aa4157a7628b82914dffe6_D20201207-20201207"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjQ2NQ_27804227-9bfc-4635-8912-26cc2365dcf4"
      unitRef="number">0.20</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="i3a1f4d036f7c4e5698e71c2f543364b0_D20201207-20201207"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjYwMA_13d0cab9-fa8d-4342-8dd3-8e07f0868721"
      unitRef="number">0.20</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="i131aea96e86e4fbbbd650ebc98f6ffca_D20201207-20201207"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjY5NA_8dde0c6f-4cad-4d41-8321-dba19faa95e8"
      unitRef="number">0.10</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="if618ed9fbfce4a02b7658195a856d8be_D20201207-20201207"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjgwNQ_038035e7-b1d4-42d3-8865-68d07e2aff3e"
      unitRef="number">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i67142cf4c13a4d68bc0ac1f76af05df3_D20211119-20211119"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNzIzOQ_fee4a38d-70cc-43a2-a33c-3dbf0e6991ce"
      unitRef="usd">150000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="i7f1b22877b3740e68dd9cfbae1ff0365_D20211119-20211119"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNzgyNA_4ce2744f-2e75-4107-a8ae-6ba10b4f0433"
      unitRef="number">0.0075</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="i42c79576567c4b2bbc81a0de713c8389_D20211119-20211119"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNzkxNA_2885e17b-0581-4462-823b-db80576df8d2"
      unitRef="number">0.0175</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="i42c79576567c4b2bbc81a0de713c8389_D20211119-20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODAwMQ_5292a94d-9997-4afa-bd72-223de9ad47f2"
      unitRef="number">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="i1c82dcc5f02c4662947d1881f5cc203e_D20211119-20211119"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODIxOQ_2df09c58-6955-4857-8a02-517e49707f2a"
      unitRef="number">0.030</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="if9cf1579776d4680a6bf379ea0a42c2c_D20211119-20211119"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODMyOA_682712f0-1eae-409e-965c-ab9685b51447"
      unitRef="number">0.020</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="iab0a5cddb915447c9e805b68ffc9d835_D20211119-20211119"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODc0MQ_7904f59d-acc6-4a78-9f58-7067df572b40"
      unitRef="number">0.030</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="ibeeda3897a624890bc65185aab3a382f_D20211119-20211119"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODgxMg_34fa5a2b-6e3c-4b43-9da2-7bdaf870db4f"
      unitRef="number">0.020</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="i43d710969d584356a886f1c9563fef66_D20211119-20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODg5NA_ca6361de-1434-4613-a4e4-684593a4d233"
      unitRef="number">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold
      contextRef="iea24828b86d54f41a2b4874e96d088f2_D20211119-20211119"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfODk1Mg_da672764-24c8-49fd-abfa-a1ab8b468a4e"
      unitRef="usd">3000000000</bcrx:RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets
      contextRef="i7c6e9851b8104036bbcd12e9aa0bc4a8_D20211119-20211119"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfOTAyNQ_456080f3-859b-4bc8-a332-3ff5f8fb4859"
      unitRef="number">0.030</bcrx:RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales
      contextRef="i922a1d857b42485f92214971ed78a0da_D20211119-20211119"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfOTQ2Nw_3744944e-16b5-4dca-adf5-0f7f9c34698c"
      unitRef="number">0.075</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales
      contextRef="ie7f72565b0f5439abca0ea90d3a6f24b_D20211119-20211119"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfOTU1Nw_01c6a7a3-5df2-4bcb-9db8-abd9f30da7bb"
      unitRef="number">0.060</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales
      contextRef="i11b7628d9fda491980452daac486f097_D20211119-20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfOTY0OQ_b0ca583c-90c6-4d0c-a92c-5677faab19cd"
      unitRef="number">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales
      contextRef="i1b2bc1c2bed841eb99664d403903ea7f_I20211119"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTAxODQ_8c3f5deb-b5ad-4eca-af5c-92a71f88a854"
      unitRef="number">0.100</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales
      contextRef="i178ec38dd6014b1d9adf94656a10b03e_I20211119"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTAyNzQ_613a49f3-12d8-4c45-8080-9606b88e8fb4"
      unitRef="number">0.030</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales
      contextRef="i92914c34dfeb459cb7418faf28e8f5c5_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTAzNjY_de5ea6ac-e81e-44d7-88fe-515310d0d1e4"
      unitRef="number">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="i782dba101c4049a68737ea34eaa114a0_D20211119-20211119"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTA2Njk_3eecd63d-eb0b-43d1-a2e2-ea47ef3946f7"
      unitRef="number">0.200</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="i96ce4725997d4522ab18ef4f78970321_D20211119-20211119"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTA4MDQ_dafd5b8e-6a29-4ba6-a6cd-3fc1cb6d09a3"
      unitRef="number">0.200</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="ifd9066e5a18b494489a571f56afaf09a_D20211119-20211119"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTA5MTM_d99ea924-0b30-4526-821f-a421ce05497f"
      unitRef="number">0.100</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="i4d5e09b3fd4d49c3acbe8c9499ec13f9_D20211119-20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTEwMjQ_240efd76-4d9f-4402-83b0-748814e45df5"
      unitRef="number">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="i782dba101c4049a68737ea34eaa114a0_D20211119-20211119"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTExNzc_2d6a7fe2-db5a-4e79-98db-e0c9b4eb952e"
      unitRef="number">0.10</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice
      contextRef="i0a099c2a65d543edbf8358cc0e472f2a_D20211119-20211119"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTE5ODQ_062c691f-fac0-4ecf-a97a-e4ed37dd1f62"
      unitRef="number">1.425</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice
      contextRef="i1a14b6aff29e4ab0899284236dbee713_D20211119-20211119"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTE5OTA_06cf206e-74d2-47b9-b400-d832659109fb"
      unitRef="number">1.550</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount
      contextRef="i3387c2eb985849859a399492ce421ce8_I20211119"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTIwMDA_da337f6c-8ae7-4fd7-b9fd-2279e5c0bf81"
      unitRef="usd">150000000</bcrx:RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib7810c48b6754267aa2a3f2a660bf13e_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTUwMjY_6205f401-ee0e-48c9-a6bd-4d244fe1d07d"
      unitRef="number">0.255</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib01a977ea3bd4a78aca463e3dcbcae61_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTUwMzI_aac03459-c352-41e9-a9d0-1ef381d6e297"
      unitRef="number">0.231</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id6782cfa98ec4a439c817a6ffa240688_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTUxMzQ_cc1c4dce-db35-4d38-8641-7cac574ddbf5"
      unitRef="number">0.121</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie0126a3e3d9242d79ce8101efe7c2a9f_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjU5NzA2OTc4Mjk0OA_4b263677-47f4-4bcf-b529-d2d64eb510bd"
      unitRef="number">0.110</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib0dc4b1e9eb848818b47548abe6e3324_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjU5NzA2OTc4MzA2NA_0276b955-54b9-450f-a319-ba7d2cdd264a"
      unitRef="number">0.085</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i492a9e744ab44aecb99a707368b9137a_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfNjU5NzA2OTc4MzA3Mg_acc92db8-69f8-4198-8622-a9bf28e93208"
      unitRef="number">0.106</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <bcrx:RoyaltyFinancingObligationsTableTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTYxNDQ_a5cf3aa3-1364-4895-a472-44100827260d">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity within the Royalty financing obligations account (in thousands) as well as the effective interest rate as of September&#160;30, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 RPI&lt;br/&gt;Royalty&lt;br/&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021 RPI&lt;br/&gt;Royalty&lt;br/&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;OMERS&lt;br/&gt;Royalty&lt;br/&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash Interest expense on Royalty financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues paid and payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash Interest expense on Royalty financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues paid and payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash Interest expense on Royalty financing obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues paid and payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bcrx:RoyaltyFinancingObligationsTableTextBlock>
    <bcrx:FutureRoyaltiesPayable
      contextRef="ibede6ebb23bb41718df5c414f9e0d733_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMS0xLTEtMS05MzYw_949ed4cc-0c4c-4c6c-86d4-fddd3760705a"
      unitRef="usd">147224000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i7aa7623896fd466a8100ad400138b291_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMS0zLTEtMS05MzYw_2ec20ae4-6876-4a7b-a165-80ab9d9276ae"
      unitRef="usd">153377000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i3fe7ee6d739f433bac2aa26b00c08cb9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMS01LTEtMS05MzYw_3a460c47-ad6b-4dd2-8e40-5001598a3d31"
      unitRef="usd">148774000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMS03LTEtMS05MzYw_9db0cd6a-df3b-4723-9f78-fc35f368fde8"
      unitRef="usd">449375000</bcrx:FutureRoyaltiesPayable>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="ic215859d996647a59c854764e5c698e1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMi0xLTEtMS05MzYw_4def8534-d832-402a-bbb8-89d3141eb6fd"
      unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="ia0a54a935fad483f8a7abc4b9481af07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMi0zLTEtMS05MzYw_34aa96c7-0f1c-4643-a9ed-5b6a9e8b5ea9"
      unitRef="usd">34000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i2a395490d1fb4b4a89833e1ca81fdd7b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMi01LTEtMS05MzYw_3c0baee4-e993-4be7-8a59-11c1498912af"
      unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMi03LTEtMS05MzYw_2f64f15e-b4c7-4467-aa96-19b4ef31324e"
      unitRef="usd">34000</us-gaap:PaymentsOfFinancingCosts>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="ic215859d996647a59c854764e5c698e1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMy0xLTEtMS05MzYw_10117425-7a70-4e00-a5a8-b026ce55feac"
      unitRef="usd">10165000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="ia0a54a935fad483f8a7abc4b9481af07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMy0zLTEtMS05MzYw_bc49d2c9-f6b7-4d33-b2ae-99e5e4acec03"
      unitRef="usd">6327000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="i2a395490d1fb4b4a89833e1ca81fdd7b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMy01LTEtMS05MzYw_4e53f0cd-33f3-4ce7-b3b7-74ce573d9cfc"
      unitRef="usd">3157000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMy03LTEtMS05MzYw_289ca24d-af42-480e-a3ef-e4d2487879ce"
      unitRef="usd">19649000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:RoyaltiesRevenuesPaidAndPayable
      contextRef="ic215859d996647a59c854764e5c698e1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNC0xLTEtMS05MzYw_98d53cef-cd37-4aca-9d1b-587d31d22398"
      unitRef="usd">-4385000</bcrx:RoyaltiesRevenuesPaidAndPayable>
    <bcrx:RoyaltiesRevenuesPaidAndPayable
      contextRef="ia0a54a935fad483f8a7abc4b9481af07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNC0zLTEtMS05MzYw_ef88ded0-8485-471a-ad04-5cbc8cd2e631"
      unitRef="usd">-380000</bcrx:RoyaltiesRevenuesPaidAndPayable>
    <bcrx:RoyaltiesRevenuesPaidAndPayable
      contextRef="i2a395490d1fb4b4a89833e1ca81fdd7b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNC01LTEtMS05MzYw_7b6c5e7d-517e-4906-8a24-c182f41fda80"
      unitRef="usd">0</bcrx:RoyaltiesRevenuesPaidAndPayable>
    <bcrx:RoyaltiesRevenuesPaidAndPayable
      contextRef="ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNC03LTEtMS05MzYw_ce17dc20-3f6a-4bcb-b9ea-1aa52a76c7cc"
      unitRef="usd">-4765000</bcrx:RoyaltiesRevenuesPaidAndPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i3864fa52358945bfbd68481e97ea6545_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNS0xLTEtMS05MzYw_f72cca1e-7de0-412d-a922-3adda731e478"
      unitRef="usd">153004000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i2633d031d70949ebac044dd59a84d949_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNS0zLTEtMS05MzYw_0fee1f9c-28f2-4842-95e9-4119f76e0cb1"
      unitRef="usd">159290000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="id7bfbb0963cd492f8cc0ff3fbce8c491_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNS01LTEtMS05MzYw_69cf494a-456c-4454-b222-996078721bc2"
      unitRef="usd">151931000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i705ede78548e4661a484496cffb01473_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNS03LTEtMS05MzYw_6e398850-9efb-41b3-bf81-689f04ab6486"
      unitRef="usd">464225000</bcrx:FutureRoyaltiesPayable>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="i274b955cf1e1448988b54629cbefc21c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNi0xLTEtMS05MzYw_e493de48-23f6-4f03-9abc-24c858d69449"
      unitRef="usd">10462000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="i4b0b77fa77814d6686ce59c957db2ab2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNi0zLTEtMS05MzYw_fd6dc88b-02c4-4b86-82cc-75d22299fc9b"
      unitRef="usd">6020000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="i106ce134a512494ea43edc85bb29e49c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNi01LTEtMS05MzYw_ba06019e-b34a-49d1-b601-e3288cb2303b"
      unitRef="usd">3224000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNi03LTEtMS05MzYw_b5c02d71-0526-47c6-86c6-e1ab7d497e6f"
      unitRef="usd">19706000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:RoyaltiesRevenuesPaidAndPayable
      contextRef="i274b955cf1e1448988b54629cbefc21c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNy0xLTEtMS05MzYw_3c29683d-32e1-4107-978d-556b5e2a0470"
      unitRef="usd">-5764000</bcrx:RoyaltiesRevenuesPaidAndPayable>
    <bcrx:RoyaltiesRevenuesPaidAndPayable
      contextRef="i4b0b77fa77814d6686ce59c957db2ab2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNy0zLTEtMS05MzYw_bb3f594d-0fd5-4883-9f5c-ef295dff0d71"
      unitRef="usd">-501000</bcrx:RoyaltiesRevenuesPaidAndPayable>
    <bcrx:RoyaltiesRevenuesPaidAndPayable
      contextRef="i106ce134a512494ea43edc85bb29e49c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNy01LTEtMS05MzYw_811af588-605e-430d-9fe5-adcc7b3c7a47"
      unitRef="usd">0</bcrx:RoyaltiesRevenuesPaidAndPayable>
    <bcrx:RoyaltiesRevenuesPaidAndPayable
      contextRef="if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfNy03LTEtMS05MzYw_4e1a63c1-82bb-47e7-a216-47c919686832"
      unitRef="usd">-6265000</bcrx:RoyaltiesRevenuesPaidAndPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="ib7810c48b6754267aa2a3f2a660bf13e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOC0xLTEtMS05MzYw_bd09b12b-38cc-4428-8b80-b505cd9d2936"
      unitRef="usd">157702000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="id6782cfa98ec4a439c817a6ffa240688_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOC0zLTEtMS05MzYw_28d5798f-85d8-4dc0-9c50-f0a407a32f8a"
      unitRef="usd">164809000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="ib0dc4b1e9eb848818b47548abe6e3324_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOC01LTEtMS05MzYw_d7a0e5ea-533a-4f3b-b982-d8d1b1c2c066"
      unitRef="usd">155155000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="iaaaa54dd893e44a9ba927dae3ebc58fc_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOC03LTEtMS05MzYw_d891d4be-7658-4149-ba74-03de3ade25af"
      unitRef="usd">477666000</bcrx:FutureRoyaltiesPayable>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="ic550bdd44f464d7e8684a82d73605d43_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOS0xLTEtMS05ODgw_6a8fb162-e360-4a68-9ccb-807520ba9f62"
      unitRef="usd">9938000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="i1fe7d973553d4d5abc3a63e8fec38c3a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOS0zLTEtMS05ODg3_c1c3b570-1053-46a6-a9de-66a898701173"
      unitRef="usd">4903000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="i11cfeff79ad34520b776332a393c0b35_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOS01LTEtMS05ODk0_7abd77fc-68e5-42cd-a585-27cf00d22dcb"
      unitRef="usd">3619000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfOS03LTEtMS05ODk0_14f2e9e9-7194-40af-bfa1-5f54123e5ce4"
      unitRef="usd">18460000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:RoyaltiesRevenuesPaidAndPayable
      contextRef="ic550bdd44f464d7e8684a82d73605d43_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTAtMS0xLTEtOTg4MA_04e9574f-1ed6-4d31-b2f5-5dc46e26094a"
      unitRef="usd">-5837000</bcrx:RoyaltiesRevenuesPaidAndPayable>
    <bcrx:RoyaltiesRevenuesPaidAndPayable
      contextRef="i1fe7d973553d4d5abc3a63e8fec38c3a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTAtMy0xLTEtOTg4Nw_d8cd235d-e69f-464a-a4fd-784da3002a33"
      unitRef="usd">-508000</bcrx:RoyaltiesRevenuesPaidAndPayable>
    <bcrx:RoyaltiesRevenuesPaidAndPayable
      contextRef="i11cfeff79ad34520b776332a393c0b35_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTAtNS0xLTEtOTg5NA_08b4dd66-ddcd-4020-aff0-4eab77f31ab1"
      unitRef="usd">0</bcrx:RoyaltiesRevenuesPaidAndPayable>
    <bcrx:RoyaltiesRevenuesPaidAndPayable
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTAtNy0xLTEtOTg5NA_40dccf40-a8bb-410d-8798-3225f3439ab6"
      unitRef="usd">-6345000</bcrx:RoyaltiesRevenuesPaidAndPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="ib01a977ea3bd4a78aca463e3dcbcae61_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTEtMS0xLTEtOTg4MA_a74ab290-4395-4e8d-a861-67d0f14a2d94"
      unitRef="usd">161802000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="ie0126a3e3d9242d79ce8101efe7c2a9f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTEtMy0xLTEtOTg4Nw_945e89c1-209c-4091-8668-4de9164540a7"
      unitRef="usd">169204000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i492a9e744ab44aecb99a707368b9137a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTEtNS0xLTEtOTg5NA_7e4b411a-0300-4268-bc56-fc4e5ae4edbf"
      unitRef="usd">158774000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTEtNy0xLTEtOTg5NA_fe7d8de0-0b2c-456b-8020-1a8096c54b0a"
      unitRef="usd">489781000</bcrx:FutureRoyaltiesPayable>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib01a977ea3bd4a78aca463e3dcbcae61_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTAtMS0xLTEtOTM2MA_aac03459-c352-41e9-a9d0-1ef381d6e297"
      unitRef="number">0.231</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie0126a3e3d9242d79ce8101efe7c2a9f_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTAtMy0xLTEtOTM2MA_4b263677-47f4-4bcf-b529-d2d64eb510bd"
      unitRef="number">0.110</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i492a9e744ab44aecb99a707368b9137a_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RhYmxlOmJhNTE5ODYxZTM0NTQxMTk4MDAyYjExZGQ1ODFhZGRmL3RhYmxlcmFuZ2U6YmE1MTk4NjFlMzQ1NDExOTgwMDJiMTFkZDU4MWFkZGZfMTAtNS0xLTEtOTM2MA_acc92db8-69f8-4198-8622-a9bf28e93208"
      unitRef="number">0.106</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i86233c8a15e74c029b96ae45ad9b3911_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTU0MzA_169e0f63-9b2c-43b2-b761-3bb6f305e12f"
      unitRef="usd">8531000</us-gaap:DeferredFinanceCostsNet>
    <bcrx:SharesIssuedCommonStockPremium
      contextRef="i63012785f2d64008b6eb5c1c19199d9b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81Mi9mcmFnOjdmZDYyZmY2ZWFhMzRmODNiZGUyNjNkNmE3ZDA1YTJmL3RleHRyZWdpb246N2ZkNjJmZjZlYWEzNGY4M2JkZTI2M2Q2YTdkMDVhMmZfMTU5MTE_f2763923-f735-47d7-b2af-9cf8b29a9ac7"
      unitRef="usd">4269000</bcrx:SharesIssuedCommonStockPremium>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfOTc3NA_c7d5e2ea-3286-47e1-8830-2a785bdc6dc2">Debt&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;7, 2020, the Company entered into a $200,000 Credit Agreement (the &#x201c;Credit Agreement&#x201d;) with Athyrium Opportunities III Co-Invest 1 LP (&#x201c;Athyrium&#x201d;), as lender and as administrative agent for the lenders. Certain of the Company&#x2019;s direct and indirect subsidiaries are guarantors to the Credit Agreement. The Credit Agreement provides for an initial term loan in the principal amount of $125,000 (the &#x201c;Term A Loan&#x201d;), which was received by the Company on December&#160;7, 2020 and is recorded in &#x201c;Secured term loan&#x201d; on the Company&#x2019;s balance sheet as of September&#160;30, 2022. The Company used a portion of the proceeds from the Term A Loan to repay $43,298 of outstanding indebtedness, including accrued interest, under its prior credit facility with MidCap Financial Trust. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement also provided for two additional term loans, at the Company&#x2019;s option, in the respective principal amounts of $25,000 (the &#x201c;Term B Loan&#x201d;) and $50,000 (the &#x201c;Term C Loan&#x201d; and, collectively with the Term A Loan and the Term B Loan, the &#x201c;Term Loans&#x201d;). Having achieved all required revenue-based milestones, the Company exercised its option to draw upon the additional funding available under the Credit Agreement, borrowing the principal amounts of $25,000 under the Term B Loan and $50,000 under the Term C Loan. Both the Term B Loan and the Term C Loan were funded on July 29, 2022 in the aggregate principal amount of $75,000. The Term B Loan and the Term C Loan are subject to all the provisions under the Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 19, 2021, the Company entered into an amendment to the Credit Agreement (i) to permit the Company to enter into the 2021 RPI Royalty Purchase Agreement, the OMERS Royalty Purchase Agreement, and the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;other definitive documentation related thereto and to perform its obligations thereunder; (ii) to require the Company to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that the Company did not draw the Term B Loan or the Term C Loan, as applicable, by the end of the applicable period available to draw the Term B Loan or the Term C Loan, subject to certain exceptions set forth in the Credit Agreement; and (iii) to require the Company to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that the Company either (x) terminated the commitments in respect of the Term B Loan or the Term C Loan, as applicable, on or prior to the end of the applicable period available to draw the Term B Loan or the Term C Loan, or (y) prepays or repays, or is required to prepay or repay, voluntarily or pursuant to mandatory prepayment obligations under the Credit Agreement (e.g., with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions), all of the then-outstanding Term Loans, in each case, subject to certain exceptions set forth in the Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement provides for quarterly interest-only payments until the maturity date, with the unpaid principal amount of the outstanding Term Loans due and payable on the maturity date. For each of the first eight full fiscal quarters following December 7, 2020, the Company has the option to make the applicable interest payment in-kind (a &#x201c;PIK Interest Payment&#x201d;) by capitalizing the entire amount of interest accrued during the applicable interest period with the unpaid original principal amount outstanding on the last day of such period. The Term Loans will bear interest at a rate equal to the three-month LIBOR rate, which shall be no less than 1.75% and no more than 3.50% (&#x201c;LIBOR&#x201d;), plus 8.25%, or for each interest period in which a PIK Interest Payment is made, LIBOR plus 10.25%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three-month LIBOR was 2.31% as of June 28, 2022, the LIBOR measurement date for the three-month interest period beginning July 1, 2022. Accordingly, this LIBOR rate plus 10.25% was used to record interest expense for the three months ended September 30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three-month LIBOR was 3.67% as of September 28, 2022, the LIBOR measurement date for the three-month interest period beginning October 1, 2022.  As the LIBOR rate exceeds the LIBOR cap of 3.50%, the 3.50% cap plus 10.25% will be used to record interest expense for the three-month interest period beginning October 1, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions, the Company is required to make mandatory prepayments of the Term Loans with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events. The Company may make voluntary prepayments in whole or in part. Prepayments are subject to a premium equal to, (i) with respect to any voluntary prepayment and certain mandatory prepayments paid on or prior to the second anniversary of the applicable Term Loan borrowing date, the amount, if any, by which (a) the sum of (1) 102.00% of the principal amount of the Term Loan being prepaid plus (2) the present value of all interest that would have accrued on the principal amount of the Term Loan being prepaid through and including the second anniversary of the date of the borrowing of such Term Loan, plus 0.50%, exceeds (b) the principal amount of the Term Loan being prepaid; (ii) with respect to any prepayment made between the second and third anniversaries of the applicable Term Loan borrowing date, 2.00% of the principal amount of the Term Loan being prepaid; (iii) with respect to any prepayment made between the third and fourth anniversaries of the applicable Term Loan borrowing date, 1.00% of the principal amount of the Term Loan being prepaid; and (iv) with respect to any prepayment made after the fourth anniversary of the applicable Term Loan borrowing date, 0.00% of the principal amount of the Term Loan being prepaid. Upon the prepayment or repayment, including at maturity, of all or any of the Term Loans, the Company is obligated to pay an exit fee in an amount equal to 2.00% of the principal amount of the Term Loans prepaid or repaid. In addition, each Term Loan is subject to a 1.00% commitment fee at its respective borrowing date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement also contains representations and warranties and affirmative and negative covenants customary for financings of this type, as well as customary events of default. Certain of the customary negative covenants limit the ability of the Company and certain of its subsidiaries to, among other things, grant liens, make investments, incur additional indebtedness, engage in mergers, acquisitions, and similar transactions, dispose of assets, license certain property, distribute dividends, make certain restricted payments, change the nature of the Company&#x2019;s business, engage in transactions with affiliates and insiders, prepay other indebtedness, or engage in sale and leaseback transactions, subject to certain exceptions. Additionally, as of the last day of each fiscal quarter (a &#x201c;Test Date&#x201d;), beginning with the first Test Date occurring immediately after the Term C Loan is drawn, if applicable, the Company may not permit consolidated net revenues from ORLADEYO sales in the United States for the four-fiscal quarter period ending on such Test Date to be less than the specified amounts set forth in the Credit Agreement (collectively, the &#x201c;Revenue Tests&#x201d;). If the Company fails to satisfy the Revenue Tests as of any Test Date, it will have a one-time right (the &#x201c;Cure Right&#x201d;) to repay in full the entire &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amount of the Term C Loan outstanding at such time together with all accrued and unpaid interest thereon plus the prepayment premium, exit fee, and any other fees or amounts payable under the Credit Agreement at such time. In addition, the Credit Agreement contains a minimum liquidity covenant requiring the Company to maintain at all times, as applicable, at least $15,000 of unrestricted cash and cash equivalents if only the Term A Loan has been drawn; at least $20,000 of unrestricted cash and cash equivalents if the Term B Loan has been drawn but the Term C Loan has not been drawn; and at least $15,000 (or, if the Cure Right has been exercised, $20,000) of unrestricted cash and cash equivalents if the Term C Loan has been drawn, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A failure to comply with the covenants in the Credit Agreement could permit the lenders under the Credit Agreement to declare the outstanding principal as well as accrued interest and fees, to be immediately due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's obligations under the Credit Agreement are secured by a security interest in, subject to certain exceptions, substantially all of the Company's assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company had total borrowings of $200,000 under the Credit Agreement. Quarterly interest payments under the Credit Agreement for the nine months ended September 30, 2022 and 2021 totaled $15,311 and $11,815, respectively, and have been designated and accounted for as PIK Interest Payments and added to the outstanding principal balance of the borrowing. As of September&#160;30, 2022, borrowings, including the PIK Interest Payments, totaled $232,376. The principal balance of the borrowings, including PIK amounts, is accruing interest at an effective rate of 12.68%. The fair value of the debt approximates its carrying value based on prevailing interest rates as of the balance sheet date and is considered as Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2022, the Company incurred deferred debt fees and issuance costs associated with the Term B and Term C Loans of $3,428. As of September&#160;30, 2022, deferred debt fees and issuance costs associated with all Term Loans under the Credit Agreement totaled $12,509 and are being amortized as interest expense on an effective interest rate method over the remaining term of the Term Loans. When utilizing the effective interest method, in periods in which PIK interest is designated and those amounts are added to the outstanding principal balance of the borrowing, the amortization of the deferred debt fees and issuance costs is accretive. Deferred financing amortization of $(597) and $(369), was recognized for the nine months ended September 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement contains two provisions that, if deemed probable, would create the recognition of an embedded feature; however, at this time, the Company does not believe either provision is probable.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7b8c0ef1641d490bad48d0ce9744d424_I20201207"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNzA_e2b85925-35c5-40c2-87ff-cd5ffd48f847"
      unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i03bffbefba234cc0a1128fb5302a1f91_D20201207-20201207"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNDEx_04d72157-61dd-4ce8-b72b-f2d93c62be8b"
      unitRef="usd">125000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i7929cd2eb5634ff0ac5139d08ffc47a8_D20201207-20201207"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNjI4_a5827945-2d0f-4a27-a172-24f63b1ee335"
      unitRef="usd">43298000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ice4776aac34540989938d21b8dfb4e97_I20220729"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfODgw_c56e6a88-7075-4d59-8f90-0cd22ba3f4f6"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia003b9df8396437497d66b989248c2b6_I20220729"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfOTA3_52d52b49-52b0-4a7c-b10a-08944b253267"
      unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ice4776aac34540989938d21b8dfb4e97_I20220729"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNTQ5NzU1ODI2OTY5_c56e6a88-7075-4d59-8f90-0cd22ba3f4f6"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia003b9df8396437497d66b989248c2b6_I20220729"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNTQ5NzU1ODI2OTg3_52d52b49-52b0-4a7c-b10a-08944b253267"
      unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i709dd3e270264784bde603419255d61f_I20220729"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfMTA5OTUxMTYzODMzMg_9af24b6e-88f3-4289-8817-ef2d1c12ee99"
      unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
    <bcrx:DebtInstrumentLiborFloor
      contextRef="i7b8c0ef1641d490bad48d0ce9744d424_I20201207"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfMzU4Ng_d208aa77-4972-4fff-85ed-94db18e9b3b6"
      unitRef="number">0.0175</bcrx:DebtInstrumentLiborFloor>
    <bcrx:DebtInstrumentLiborCap
      contextRef="i7b8c0ef1641d490bad48d0ce9744d424_I20201207"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfMzYwNg_c7f3a197-2971-4924-b8a2-ec23e6742970"
      unitRef="number">0.0350</bcrx:DebtInstrumentLiborCap>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i15ce1d8574044e7da22ce59b9f6dd167_D20201207-20201207"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfMzYyNQ_dcd54430-2db7-4afe-99da-ccd4cbb48dad"
      unitRef="number">0.0825</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia232f6672e22447fb6af60f22e2ceb87_D20201207-20201207"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfMzcwOQ_55ccfb3a-ac1a-439e-a5dc-391fc1116b90"
      unitRef="number">0.1025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="icf6c8a213e4c4e488e6eb643867a2197_D20220628-20220628"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfMTA5OTUxMTY0MTAyMw_98c2a7ba-150c-4851-94c6-b2fe4d0b0e16"
      unitRef="number">0.1025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="icde5f4a46a1c4f8c83cf48af673b7a45_D20220928-20220928"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfMzg4NA_66adb30d-759c-4989-9ead-19ec792c3abf"
      unitRef="number">0.1025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments
      contextRef="i89ce560e3ccb4a498fdff95231d6e1c9_D20201207-20201207"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNDY5OQ_ed87ad3c-9a33-4962-81e6-68c670fef8c7"
      unitRef="number">1.0200</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfAccruedInterest
      contextRef="i89ce560e3ccb4a498fdff95231d6e1c9_D20201207-20201207"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNDk3Nw_f38a091a-e6d7-4434-993d-07025a666934"
      unitRef="number">0.0050</bcrx:DebtInstrumentPrepaymentFeePercentageOfAccruedInterest>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments
      contextRef="i74fcf15aaa914945ab7836b9ee0ad9e5_D20201207-20201207"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNTE3NA_009efdd5-9059-4a45-aaae-5185bc668fb1"
      unitRef="number">0.0200</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments
      contextRef="iad2a1f48ddac433db045de7d1a2ebd84_D20201207-20201207"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNTM2Mg_0eb8b95f-961b-4403-b989-e611ab046357"
      unitRef="number">0.0100</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments
      contextRef="id4ae9ab1e00c4d9bbb0a43e40f958d82_D20201207-20201207"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNTUzOQ_ba47aa8f-715d-4c22-9a9d-8703f0d493e1"
      unitRef="number">0.0000</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <bcrx:DebtInstrumentExitFeePercentageOfPrincipal
      contextRef="i7b8c0ef1641d490bad48d0ce9744d424_I20201207"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNTc1NA_48906017-4232-431f-aca6-3ad58aba2eb7"
      unitRef="number">0.0200</bcrx:DebtInstrumentExitFeePercentageOfPrincipal>
    <bcrx:DebtInstrumentCommitmentFeePercentage
      contextRef="i7b8c0ef1641d490bad48d0ce9744d424_I20201207"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNTg2Mg_80bbdc7c-27cd-4976-aacf-5ffd24ddc0a0"
      unitRef="number">0.0100</bcrx:DebtInstrumentCommitmentFeePercentage>
    <bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents
      contextRef="i48c8f87e596a4a9797c757c4107dca8e_I20201207"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNzYxMA_74c4ec69-eb5e-445f-bd3a-cecaf9ef61e8"
      unitRef="usd">15000000</bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents>
    <bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents
      contextRef="i029bc0b0132a43d3a133840d08bafae3_I20201207"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNzcwNA_0d9f0f5d-84d8-4e94-9af6-a52b1755b529"
      unitRef="usd">20000000</bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents>
    <bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents
      contextRef="i81bdcb366fcb440dac7cccb46bc6c432_I20201207"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNzgzNg_3f9052d4-a3e8-4921-9843-2b129ed9fa9a"
      unitRef="usd">15000000</bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents>
    <bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents
      contextRef="id1df07995b624c41ad1f4b2eb4c8b729_I20201207"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNzg4Mg_4c23d23f-f629-4dae-b128-c63c2d778eeb"
      unitRef="usd">20000000</bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i577b5813966249238ff1a37dcadb61ec_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfODQyNQ_10a3971f-22d7-4ce2-baa3-7dfd1cfddfdb"
      unitRef="usd">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:PaidInKindInterest
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNjU5NzA2OTc3NzUzMw_b9c1ffc8-0223-48f8-936b-90489dec7dfc"
      unitRef="usd">15311000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNjU5NzA2OTc3NzU0OQ_8ed1af3e-d926-4f83-b48a-9ad7d1099e4c"
      unitRef="usd">11815000</us-gaap:PaidInKindInterest>
    <us-gaap:LongTermDebt
      contextRef="i577b5813966249238ff1a37dcadb61ec_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfODc2Mg_19a809ec-636d-4eb6-b041-7544e5fbea33"
      unitRef="usd">232376000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i577b5813966249238ff1a37dcadb61ec_I20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfODg2NA_75027c4f-145a-46fb-9af2-91d22b390496"
      unitRef="number">0.1268</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="iad15e5ebbe854d989fa28f085ec20706_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNjU5NzA2OTc3NzY4OQ_736279b0-a89d-4cc6-a1e0-7fbac0f33a16"
      unitRef="usd">3428000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNjU5NzA2OTc3NzY4Mw_4e26ca52-1ebd-4e0c-830f-b681b6d91d09"
      unitRef="usd">12509000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNjU5NzA2OTc3Nzc2Nw_fa109f1c-b48f-4af9-b9b9-77002e6cc0dc"
      unitRef="usd">597000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81NS9mcmFnOjg1ZGM4M2NlZjBjMDQ0MjJhNjUyODJjY2QzNDgwNDVhL3RleHRyZWdpb246ODVkYzgzY2VmMGMwNDQyMmE2NTI4MmNjZDM0ODA0NWFfNjU5NzA2OTc3Nzc4Mw_bf4c3fc2-8c13-478e-9472-99ceab128988"
      unitRef="usd">369000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfMTAxMw_f8406d3c-97cd-4ab1-bfae-3327bd282207">Lease Obligations &lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of September&#160;30, 2022. Renewal options for the Company's leases range from 1 to 5 years in length and begin from 2023 through 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate lease expense under operating leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other supplemental information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s leases qualify as operating leases. The following table summarizes the presentation in the Consolidated Balance Sheets of the Company&#x2019;s operating leases: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfMi0xLTEtMS05MzYw_842fa9e2-603a-4d76-932f-26e9d70fccbc"&gt;Other Assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lease financing obligation &#x2013; current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lease financing obligation &#x2013; long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease assets are recorded net of accumulated amortization of $3,874 and $2,626 as of September&#160;30, 2022 and December&#160;31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities was $615 and $1,796 for the three and nine months ended September&#160;30, 2022, respectively, and $306 and $1,125 for the three and nine months ended September&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities as of September&#160;30, 2022, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i7c80142b202447dcb8ead43698b1102f_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfMjU4_5d374a27-ad8c-4ba9-8ac5-511422abde18">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i52f9872ea30d41b1879aa0576f67e92d_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfMjY0_9b4c49dc-79bb-4c95-aaf4-6cca2ba22e85">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfMTAxNA_ebe1f6db-9d11-4dff-a5c4-ce8f46ead2f4">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate lease expense under operating leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <bcrx:AggregateLeaseExpense
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmRlZmE2NjMyMmNjYTRkNGRiZWYyZmRlYzgwNzIzNDk4L3RhYmxlcmFuZ2U6ZGVmYTY2MzIyY2NhNGQ0ZGJlZjJmZGVjODA3MjM0OThfMi0yLTEtMS05MzYw_ee94ae31-ae6e-4c71-b4a1-1f213d150eb8"
      unitRef="usd">634000</bcrx:AggregateLeaseExpense>
    <bcrx:AggregateLeaseExpense
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmRlZmE2NjMyMmNjYTRkNGRiZWYyZmRlYzgwNzIzNDk4L3RhYmxlcmFuZ2U6ZGVmYTY2MzIyY2NhNGQ0ZGJlZjJmZGVjODA3MjM0OThfMi00LTEtMS05MzYw_11492b09-3e0c-4cae-aced-7ac88951fabb"
      unitRef="usd">393000</bcrx:AggregateLeaseExpense>
    <bcrx:AggregateLeaseExpense
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmRlZmE2NjMyMmNjYTRkNGRiZWYyZmRlYzgwNzIzNDk4L3RhYmxlcmFuZ2U6ZGVmYTY2MzIyY2NhNGQ0ZGJlZjJmZGVjODA3MjM0OThfMi02LTEtMS05MzYw_a4b4d4fd-2f0e-4352-a405-3640e942863a"
      unitRef="usd">1854000</bcrx:AggregateLeaseExpense>
    <bcrx:AggregateLeaseExpense
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmRlZmE2NjMyMmNjYTRkNGRiZWYyZmRlYzgwNzIzNDk4L3RhYmxlcmFuZ2U6ZGVmYTY2MzIyY2NhNGQ0ZGJlZjJmZGVjODA3MjM0OThfMi04LTEtMS05MzYw_4975b023-77e0-47dc-8492-673ab253caf3"
      unitRef="usd">1306000</bcrx:AggregateLeaseExpense>
    <bcrx:OtherSupplementalInformationRelatedToLeasesTableTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfMTAxNQ_766b061b-141c-402e-b613-5682b5ab0288">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other supplemental information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bcrx:OtherSupplementalInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjhhYTQ2MDA5ZDA5NDQxZDVhNDNkYTNhY2YwYzA3ZTEwL3RhYmxlcmFuZ2U6OGFhNDYwMDlkMDk0NDFkNWE0M2RhM2FjZjBjMDdlMTBfMS0yLTEtMS05MzYw_0bacf433-244c-4550-b3d0-9df5b8d5ebfc">P8Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjhhYTQ2MDA5ZDA5NDQxZDVhNDNkYTNhY2YwYzA3ZTEwL3RhYmxlcmFuZ2U6OGFhNDYwMDlkMDk0NDFkNWE0M2RhM2FjZjBjMDdlMTBfMS00LTEtMS05MzYw_3d9f1cef-35cc-4060-a406-f719d6b4ffab">P9Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjhhYTQ2MDA5ZDA5NDQxZDVhNDNkYTNhY2YwYzA3ZTEwL3RhYmxlcmFuZ2U6OGFhNDYwMDlkMDk0NDFkNWE0M2RhM2FjZjBjMDdlMTBfMi0yLTEtMS05MzYw_af379a57-9acd-4c13-9b92-ca38fdd94599"
      unitRef="number">0.109</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjhhYTQ2MDA5ZDA5NDQxZDVhNDNkYTNhY2YwYzA3ZTEwL3RhYmxlcmFuZ2U6OGFhNDYwMDlkMDk0NDFkNWE0M2RhM2FjZjBjMDdlMTBfMi00LTEtMS05MzYw_0b3f5162-6a8a-48c1-bd07-e6dfc2185e04"
      unitRef="number">0.112</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfMTAxNg_c7b54f13-48e2-49d4-86a2-6605fe6a75a8">The following table summarizes the presentation in the Consolidated Balance Sheets of the Company&#x2019;s operating leases: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfMi0xLTEtMS05MzYw_842fa9e2-603a-4d76-932f-26e9d70fccbc"&gt;Other Assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lease financing obligation &#x2013; current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lease financing obligation &#x2013; long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfMi0zLTEtMS05MzYw_aa91e255-f3b8-45fa-b9d3-56339ed4ab0d"
      unitRef="usd">6797000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfMi01LTEtMS05MzYw_d00d9e8f-a3a3-44f5-afc2-37250b4e499b"
      unitRef="usd">6472000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfNC0zLTEtMS05MzYw_2dd7f8e7-7a60-4473-b0c0-ed5e11c6d7c9"
      unitRef="usd">2196000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfNC01LTEtMS05MzYw_9099adbf-5f4c-4d2f-89c1-d65db4e41ef8"
      unitRef="usd">1819000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfNS0zLTEtMS05MzYw_f6b80e36-b0da-474f-b56f-4953415db978"
      unitRef="usd">5968000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfNS01LTEtMS05MzYw_9320d3bf-c055-4361-a108-8640ec1d31c4"
      unitRef="usd">5962000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfNi0zLTEtMS05MzYw_fd79a8f1-ff4a-482f-aade-984ad298d7e6"
      unitRef="usd">8164000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOmI5YzU1NzdkN2Y5YTRlMDNiNzhkNmY0YWZhODNmMTRmL3RhYmxlcmFuZ2U6YjljNTU3N2Q3ZjlhNGUwM2I3OGQ2ZjRhZmE4M2YxNGZfNi01LTEtMS05MzYw_496710aa-c625-451f-9511-5b2dd7a07078"
      unitRef="usd">7781000</us-gaap:OperatingLeaseLiability>
    <bcrx:OperatingLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfNzA1_5c238b20-4e72-4983-8966-d95414e3b318"
      unitRef="usd">3874000</bcrx:OperatingLeaseRightOfUseAssetAccumulatedAmortization>
    <bcrx:OperatingLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="ie20bac9cd8014f8cb989d999d452c248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfNzEy_cecd6556-8c08-401a-bfa5-07d51977bed1"
      unitRef="usd">2626000</bcrx:OperatingLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:OperatingLeasePayments
      contextRef="i861b143373254de4947eaa4bad2f89c6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfODIy_34f0f020-ab42-4fc1-8d9e-49d2b247030e"
      unitRef="usd">615000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfODI5_614587c2-29c4-4a74-b8a3-baec386b0628"
      unitRef="usd">1796000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ibd48b1f2e93847e98a513e14acbaccf0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfODc4_dba9333f-3c06-4183-84ef-cc9768c06e7f"
      unitRef="usd">306000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfODg1_de99e660-fbf5-43cc-88e2-ee8a3ff8e70b"
      unitRef="usd">1125000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RleHRyZWdpb246ZjkxOTkyODRiY2EzNDY3NGI4NjcwMmFkYzRkODkzYTNfMTAxNw_63f53e61-3ee7-4539-b4f6-e3840b9806bc">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities as of September&#160;30, 2022, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfMC0xLTEtMS05MzYw_d09697e7-abd3-419b-a9aa-8f4f40bcf481"
      unitRef="usd">684000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfMS0xLTEtMS05MzYw_cda5c3b6-4b44-4db3-a0f6-ab43db9f5d9d"
      unitRef="usd">2334000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfMi0xLTEtMS05MzYw_79c6db0d-12df-4dbf-98b4-156793a20231"
      unitRef="usd">1785000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfMy0xLTEtMS05MzYw_1a6eb2fa-d52e-47f3-be72-b74e4fe7209b"
      unitRef="usd">1441000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfNC0xLTEtMS05MzYw_b0f962b6-8fa2-43e5-afcc-99bbce47bc46"
      unitRef="usd">651000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <bcrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfNS0xLTEtMS05MzYw_e2635265-6fe2-42c1-9e3a-135bdf488422"
      unitRef="usd">6734000</bcrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfNi0xLTEtMS05MzYw_a2bb0c73-81eb-4287-a4b6-a733252b804e"
      unitRef="usd">13629000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfNy0xLTEtMS05MzYw_1ee64076-bc17-43fd-baab-f175f4363834"
      unitRef="usd">5465000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF81OC9mcmFnOmY5MTk5Mjg0YmNhMzQ2NzRiODY3MDJhZGM0ZDg5M2EzL3RhYmxlOjBlODM2ZGNiNDAxZTRlOTJiODEwZmNkY2Q2YzFkNWY5L3RhYmxlcmFuZ2U6MGU4MzZkY2I0MDFlNGU5MmI4MTBmY2RjZDZjMWQ1ZjlfOC0xLTEtMS05MzYw_0413c2f1-eaf2-4e34-8a4f-59c532f189fc"
      unitRef="usd">8164000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTY3NQ_8b0bd401-3047-4ea4-9b4c-23268a557409">Stockholders&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Equity&lt;/span&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;24, 2020, the Company filed a shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective on May 14, 2020 and allows the Company to sell up to $500,000 in securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 1, 2021, the Company filed an automatic shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective automatically upon filing and allows the Company to sell an indeterminate number of securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;19, 2021, concurrent with the Company entering into the 2021 RPI Royalty Purchase Agreement, the Company and RPI entered into the Common Stock Purchase Agreement, pursuant to which the Company issued 3,846,154 &lt;/span&gt;&lt;/div&gt;shares of the Company&#x2019;s common stock to RPI for an aggregate purchase price of $50,000, at a price of $13.00 per share, calculated based on the 20-day volume weighted average price. The $13.00 per share price represents a premium of $1.11 over the closing price of $11.89 of the Company&#x2019;s common stock on November&#160;17, 2021, the last trading day prior to the execution of the Common Stock Purchase Agreement. The premium of $4,269 paid by RPI on the purchase of the Company&#x2019;s common stock has been deferred and is being amortized as a component of interest expense of the 2021 RPI royalty financing obligation.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <bcrx:MaximumAggregateOfferingPrice
      contextRef="ief8dcbde5b0e41c3bb5a8ebe4a804426_I20200424"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMjQz_3dbc7bc2-4be8-4618-8f51-9db1f1fdd368"
      unitRef="usd">500000000</bcrx:MaximumAggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8832490c13ad4270a151ea2cb8adc636_D20211119-20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTEwMw_136f8507-faac-4ac0-8505-0dd44a12ca4e"
      unitRef="shares">3846154000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i8832490c13ad4270a151ea2cb8adc636_D20211119-20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTE4NQ_63b1eb1e-81cc-43eb-9b8c-be8f0dcf0617"
      unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i85cc5e9604864268a804d5d399fb8420_I20211119"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTIwMw_c564b3a2-e696-4a55-b2a2-56735583972a"
      unitRef="usdPerShare">13.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ic0f22034638c4665942e299d6fb219aa_I20211117"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTI4Mw_e637fecc-a957-4669-9328-4fb5a1caad20"
      unitRef="usdPerShare">13.00</us-gaap:SharesIssuedPricePerShare>
    <bcrx:SharesIssuedPricePerSharePremium
      contextRef="ic0f22034638c4665942e299d6fb219aa_I20211117"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTMyNg_f9cf96ec-2d50-421e-95c7-1fed23bc7972"
      unitRef="usdPerShare">1.11</bcrx:SharesIssuedPricePerSharePremium>
    <bcrx:SharesIssuedPricePerShareClosingPrice
      contextRef="ic0f22034638c4665942e299d6fb219aa_I20211117"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTM1NQ_c63bdc64-7c8f-4c0a-9479-f48701c6ffb1"
      unitRef="usdPerShare">11.89</bcrx:SharesIssuedPricePerShareClosingPrice>
    <bcrx:SharesIssuedCommonStockPremium
      contextRef="ic0f22034638c4665942e299d6fb219aa_I20211117"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82MS9mcmFnOmQwZDJkZTVjZWRiMzRjMzJhZDk2Nzg0MTE4NzRmY2JjL3RleHRyZWdpb246ZDBkMmRlNWNlZGIzNGMzMmFkOTY3ODQxMTg3NGZjYmNfMTQ5NA_d4cdcec3-6a98-4949-88ca-0bdda088a9d1"
      unitRef="usd">4269000</bcrx:SharesIssuedCommonStockPremium>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODM1NA_6cb45329-65ba-4b51-a817-3846f95c6451">Stock-Based Compensation&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company had three stock-based employee compensation plans: the Amended and Restated Stock Incentive Plan (&#x201c;Incentive Plan&#x201d;), the Amended and Restated Inducement Equity Incentive Plan (&#x201c;Inducement Plan&#x201d;) and the Amended and Restated Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The Incentive Plan was most recently amended and restated on April 18, 2022 and approved by the Company&#x2019;s stockholders on June 7, 2022. The Inducement Plan was most recently amended and restated by the Board of Directors on August 26, 2022. The ESPP was most recently amended and restated on April 1, 2021 and approved by the Company&#x2019;s stockholders on May 25, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense of $29,421 ($23,687 of expense related to the Incentive Plan, $4,604 of expense related to the Inducement Plan, and $1,130 of expense related to the ESPP) was recognized during the nine months ended September 30, 2022, while $26,140 ($19,973 of expense related to the Incentive Plan, $5,025 of expense related to the Inducement Plan and $1,142 of expense related to the ESPP) was recognized during the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was approximately $100,171 of total unrecognized compensation expense related to non-vested stock option and restricted stock unit awards granted by the Company as of September&#160;30, 2022. As of September&#160;30, 2022, the Company expected to recognize that expense as follows: $10,707 during the remainder of 2022, $35,987 in 2023, $31,537 in 2024, $19,524 in 2025 and $2,416 in 2026. In addition, the Company has outstanding performance-based stock options and restricted stock unit awards for which no compensation expense is recognized until &#x201c;performance&#x201d; has occurred and the award vests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants stock option awards, restricted stock and restricted stock units to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#x2019;s common stock at the date of grant. Commencing March 1, 2011, stock option awards and restricted stock units granted to employees generally vest 25% each year until fully vested after four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2014, the Company issued 1,250 performance-based stock options. These awards vest upon successful completion of specific development milestones. As of September&#160;30, 2022, 85% of these grants have vested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company issued 221 performance-based restricted stock unit awards. Contingent upon successful achievement of specific commercial or operational objectives in 2022, the awards become eligible for vesting at 50% on the first anniversary of the grant date and 25% on each of the second and third anniversaries of the grant date, until fully vested after three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option awards and restricted stock unit awards granted to non-employee directors of the Company generally vest over one year. Stock option awards granted to new non-employee directors when they first join the Company&#x2019;s Board of Directors generally vest, subject to the terms of the Incentive Plan, in 36 equal monthly installments over a three-year period measured from the grant date. All stock option awards have contractual terms of 10 years. Restricted stock unit awards granted to new non-employee directors when they first join the Company's Board of Directors generally vest, subject to the terms of the Incentive Plan, in three equal annual installments beginning on the first anniversary of the grant date. The vesting and exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related activity under the Incentive Plan is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Awards&lt;br/&gt;Available&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan amendment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock unit awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock unit awards cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option awards exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option awards cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For stock option awards granted under the Incentive Plan during the first nine months of 2022 and 2021, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table following the next subsection. The weighted average grant date fair value of these awards granted during the first nine months of 2022 and 2021 was $7.78 and $8.11, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. For restricted stock units granted under the Incentive Plan, the fair value of the awards was determined based on the market value of the Company&#x2019;s shares on the grant date. The weighted average grant date fair value of these awards granted during the first nine months of 2022 and 2021 was $13.18 and $10.17, respectively. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inducement Equity Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has the ability to grant stock option and restricted stock unit awards to newly-hired employees as inducements material to each employee entering employment with the Company. Awards granted to newly hired employees generally vest 25% each year until fully vested after four years and are subject to the terms and conditions of the Inducement Plan. Each stock option has a term of 10 years. The vesting and exercise provisions of all awards granted under the Inducement Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Inducement Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related activity under the Inducement Plan is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Awards&lt;br/&gt;Available&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan amendment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock unit awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock unit awards cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option awards exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option awards cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For stock option awards granted under the Inducement Plan during the first nine months of 2022 and 2021, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during the first nine months of 2022 and 2021 was $9.72 and $9.74, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. For restricted stock units granted under the Inducement Plan, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fair value of the awards was determined based on the market value of the Company&#x2019;s shares on the grant date. The weighted average grant date fair value of these awards granted during the first nine months of 2022 was $13.38. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method. No restricted stock unit awards were granted under the Inducement Plan during the first nine months of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the key assumptions used by the Company to value the stock option awards granted under all plans during the first nine months of 2022 and 2021, respectively. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#x2019;s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining term equal to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Assumptions for Stock Option Awards Granted to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employees and Directors under the Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has reserved a total of 7,975 shares of common stock to be purchased under the ESPP, of which 5,792 shares remain available for purchase as of September&#160;30, 2022. Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates, and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. During the nine months ended September&#160;30, 2022, and 2021, the Company issued 260 and 316 shares under the ESPP, respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#x201c;look-back&#x201d; option were determined using a Black-Scholes option pricing model.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <bcrx:ShareBasedPaymentArrangementNumberOfPlans
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODM2MA_eef6d924-3165-4fee-a02f-f98dceb2dd1e"
      unitRef="plan">3</bcrx:ShareBasedPaymentArrangementNumberOfPlans>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzI1_7c1c98ee-0be0-48cf-8017-035de380a1bd"
      unitRef="usd">29421000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzI5_cd037ac5-9a9b-49b5-bf64-5400e62b7898"
      unitRef="usd">23687000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzc0_b754022f-2665-4fd7-8ec2-d75c6f6d3e0a"
      unitRef="usd">4604000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibd71d21d51204504b4c1150f43b3bc59_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODI0_c855a088-8f68-4c7a-b76d-400af1741b2e"
      unitRef="usd">1130000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODk1_807f91e2-b268-419e-8e5e-7952e422a08b"
      unitRef="usd">26140000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id57db78843ad455581cbbe07f42c6f48_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODk5_a614028a-60a2-4f91-9850-61fcc3bf3644"
      unitRef="usd">19973000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3c2fb0c425f946d798549cf02852e9ea_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfOTQ0_5160387a-6121-4459-9da4-49d1abb96aa2"
      unitRef="usd">5025000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i861f5991bef64ba4ae244c970bd11b45_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfOTkz_bb842c87-929d-483c-ba71-4a687cef0dfe"
      unitRef="usd">1142000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMTA4Mg_6c1e257a-69fe-47c6-84d3-fe34beacb147"
      unitRef="usd">100171000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMTI5OA_419d5bcf-9293-4e1a-8cc5-22b262051815"
      unitRef="usd">10707000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMTMyOQ_d57434c4-90d8-4273-bc69-75d08cdb2a61"
      unitRef="usd">35987000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMTMzOQ_7a9ae09c-e2ba-4465-bab5-dfa00f771347"
      unitRef="usd">31537000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMTM0OQ_40099e81-0e03-4703-814e-000f35650fbc"
      unitRef="usd">19524000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour
      contextRef="idb265a8308724c57833eccc5d77be8aa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMTM2Mg_0caa463e-15c8-4223-ade3-62edba8e760d"
      unitRef="usd">2416000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i4b5364d1d1904b7bb97eaee357c6a65b_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjAyNA_b8699760-646d-484e-9013-2c270831e25a"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4b5364d1d1904b7bb97eaee357c6a65b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjA2Mg_740ff352-a90b-4700-b977-ad9b65f7ab50">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3bf5349aab0e46d5b3e8bc79f32bc420_D20141201-20141231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjA5Mg_219146ad-9958-49e6-a1d2-fedcb8575dbd"
      unitRef="shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i3bf5349aab0e46d5b3e8bc79f32bc420_D20141201-20141231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjIxOQ_0cea133b-32b0-4f59-b6d1-00de0b49fa6b"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="i462f026921bb4afe83030f8fadf9da13_D20220101-20220131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjI3Nw_afda35d7-ed01-4a6c-920e-4dbd6ac49f22"
      unitRef="shares">221000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib155b4c963014e029dd2f85fefc4a14e_D20220101-20220131"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjQ2NQ_d7398cd2-de16-423a-833b-458cf0cf8ff5"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i67e8248b60f64ce28584296c7129913e_D20220101-20220131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjUxNQ_5736b735-a9c0-4d31-a7e7-d7bfcf60f1f3"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="icacb2b425bc14f50b771626f8aa5b582_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjYwOA_d04827ff-378d-4422-8e9f-86c48c371eb2">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia6112bb62bc84e76a366906fa6013306_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMjczNA_a0e710b5-724d-4ac1-b5d2-339fc39383c4">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4e78b10dfe9d40829b789acc025a272e_D20220101-20220131"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODM1NQ_476e68a3-af8e-44d6-b3cc-3dddd27afbeb">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i597f21b52a2341598aca37ab541e979b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfMzA0NQ_01850a6d-381e-4c6a-8992-84551e3a9f4f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODM2Mw_dc0866e6-c240-4d58-8279-7ea01759682e">&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related activity under the Incentive Plan is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Awards&lt;br/&gt;Available&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan amendment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock unit awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock unit awards cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option awards exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option awards cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related activity under the Inducement Plan is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Awards&lt;br/&gt;Available&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan amendment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock unit awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock unit awards cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option awards exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option awards cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i33b8d296b67f42aa822d875c50677a2a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfMS0xLTEtMS05MzYw_88aea31e-e64f-4356-baae-a316461adf75"
      unitRef="shares">3651000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i33b8d296b67f42aa822d875c50677a2a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfMS0zLTEtMS05MzYw_8fab031b-ce59-4760-92b4-a447b6d97b89"
      unitRef="shares">28685000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i33b8d296b67f42aa822d875c50677a2a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfMS01LTEtMS05MzYw_5437a1ed-c6a8-4ec5-8ac7-d050f4729c56"
      unitRef="usdPerShare">7.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares
      contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfMi0xLTEtMS05MzYw_2c83f64b-b859-47ec-a137-9d5a8136bbb2"
      unitRef="shares">8000000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfMy0xLTEtMS05MzYw_c6a80e74-1fae-42ee-a2d7-36d566c093c7"
      unitRef="shares">681000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNC0xLTEtMS05MzYw_41172462-c5b9-47ac-a409-d68ad8d74dd5"
      unitRef="shares">218000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable
      contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNS0xLTEtMS05MzYw_05d6ed80-c9c0-403b-b41d-3542fe8541b3"
      unitRef="shares">813000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNS0zLTEtMS05MzYw_c6945b9d-8cef-4c8b-9f8c-f71a2e76f51a"
      unitRef="shares">813000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNS01LTEtMS05MzYw_4e105e44-be8c-493d-9fc9-17523f913d28"
      unitRef="usdPerShare">11.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNi0zLTEtMS05MzYw_684b7767-dee7-4fb4-8106-07dc0da8afc5"
      unitRef="shares">1334000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNi01LTEtMS05MzYw_21f34941-3c3f-4b72-99aa-47ccb66c8798"
      unitRef="usdPerShare">5.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable
      contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNy0xLTEtMS05MzYw_baf0756a-de91-4a70-90c0-2f2a0be52420"
      unitRef="shares">787000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNy0zLTEtMS05MzYw_4c88788f-b6f4-4df2-b4ff-91e961a2223c"
      unitRef="shares">787000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i1c326baf538b47e18ad26dc88e2c2491_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfNy01LTEtMS05MzYw_6a43b999-0a0f-43ea-b2d6-481b308881eb"
      unitRef="usdPerShare">10.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i2f2ae249b8c14d8c879f0c3632532318_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfOC0xLTEtMS05MzYw_e182c22e-d570-4640-8afe-536b82e07d46"
      unitRef="shares">11162000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2f2ae249b8c14d8c879f0c3632532318_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfOC0zLTEtMS05MzYw_802dfac5-6b4b-41d0-8a98-626f2752be79"
      unitRef="shares">27377000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2f2ae249b8c14d8c879f0c3632532318_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjUxOTUwNmZiYTM5YzRlNWViZGZmNTJlMzk2ZDIyMzFlL3RhYmxlcmFuZ2U6NTE5NTA2ZmJhMzljNGU1ZWJkZmY1MmUzOTZkMjIzMWVfOC01LTEtMS05MzYw_6fce1ad9-5160-4ca5-91d1-1fd2e860ba3b"
      unitRef="usdPerShare">8.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5250a5d435e4416ea19390c093e8d969_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNDAwMw_3ed6bed0-c134-4d3a-a9f9-8ff98db3ff33"
      unitRef="usdPerShare">7.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i91216e37813c427d9f33a23eb389ed62_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNDAxMA_f5637b16-8ed5-4373-a90d-2c0d50e0792b"
      unitRef="usdPerShare">8.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i41d42bfc79fc4caf8d758c368878895a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNDQ1Ng_32d114c7-e715-41f3-a301-a6c9b1853c83"
      unitRef="usdPerShare">13.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9c9a5b90264d44ee9f8599fe14b89e37_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNDQ2Mw_8347050a-849e-47df-8d8b-162ae01417b8"
      unitRef="usdPerShare">10.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="if2932078af7f45c0bfcbbbc172f1e3f7_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNDkwNw_3ac1aa98-da94-405c-b2ae-25144d94bb4f"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNDk0NQ_5ec830bc-a79a-449a-b100-70e2c0358bae">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNTA0OA_bccb0e83-5f6b-48d4-94a4-dfef9426a457">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i6e4a49026de84920a3819232a6a19cd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfMS0xLTEtMS05MzYw_13a8cda9-0e08-4581-b2b4-71656b11e58a"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6e4a49026de84920a3819232a6a19cd9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfMS0zLTEtMS05MzYw_5d4b60ba-839a-4c2c-bf5a-489ca84c55e1"
      unitRef="shares">4408000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6e4a49026de84920a3819232a6a19cd9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfMS01LTEtMS05MzYw_6a16b79a-a627-414b-be9c-43dbc464e89a"
      unitRef="usdPerShare">6.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares
      contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfMi0xLTEtMS0xMDY0Ng_0f6237f7-c533-429a-bec0-3f33ac510fb0"
      unitRef="shares">1926000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfMi0xLTEtMS05MzYw_6d2f0823-412c-4dd9-bc8e-27613a6de8e8"
      unitRef="shares">424000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfMy0xLTEtMS05MzYw_2ca06759-bb91-40eb-8546-cc0c01a99721"
      unitRef="shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable
      contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNC0xLTEtMS05MzYw_5c958a4c-f52a-444f-9faf-47c660aabb58"
      unitRef="shares">1381000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNC0zLTEtMS05MzYw_45690188-55ec-439a-a49a-277b3041a7e2"
      unitRef="shares">1381000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNC01LTEtMS05MzYw_8ca43823-40fc-41d7-8342-f091cc6749ca"
      unitRef="usdPerShare">13.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNS0zLTEtMS05MzYw_2785fca9-515e-43af-a677-942bdfacddbc"
      unitRef="shares">196000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNS01LTEtMS05MzYw_e0bdf765-4bba-4193-a606-50325d1020a6"
      unitRef="usdPerShare">3.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable
      contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNi0xLTEtMS05MzYw_5fd4eefd-6457-43f1-b94f-c0618083453c"
      unitRef="shares">323000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNi0zLTEtMS05MzYw_ee1a9c3b-f4fa-4ea0-b36f-388e4d96c922"
      unitRef="shares">323000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNi01LTEtMS05MzYw_f1cb928e-4a7a-483b-b980-a2a615a8b1ce"
      unitRef="usdPerShare">7.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i8d8b3a042362474cbb230d0362f4776c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNy0xLTEtMS05MzYw_e534f182-e1ac-404d-bd9e-1541b3dd521d"
      unitRef="shares">1346000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8d8b3a042362474cbb230d0362f4776c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNy0zLTEtMS05MzYw_1094bce4-da60-4baa-b296-5dc5c11cd0bc"
      unitRef="shares">5270000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8d8b3a042362474cbb230d0362f4776c_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOmUzMDRlYjk4YzA5MTQ1NTU5YTBhZTQ3YmQ0OGE2OTk4L3RhYmxlcmFuZ2U6ZTMwNGViOThjMDkxNDU1NTlhMGFlNDdiZDQ4YTY5OThfNy01LTEtMS05MzYw_5cd75049-3c6e-4d47-8d5a-878491c99b56"
      unitRef="usdPerShare">8.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i13db33977a904b03be5d11e9b117d150_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNTcxNQ_a6098c9f-fd2d-4254-b2de-b03ad7b0ceba"
      unitRef="usdPerShare">9.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3c2fb0c425f946d798549cf02852e9ea_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNTcyMg_0993ac49-e91c-456f-bbee-48afe32e67c8"
      unitRef="usdPerShare">9.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibdd2f542ee4f472fbd033582bf493f66_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNjE2MQ_3e81a2f4-fff7-435b-ab5d-ecdc7bc8b1de"
      unitRef="usdPerShare">13.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie6d5329452f640458e577180ba9077a1_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzA3Ng_d0312958-9626-4fa6-be90-4ae97e342815"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODM1Nw_878ab84d-86e1-4ae7-8621-0bfc4575a01e">&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Assumptions for Stock Option Awards Granted to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employees and Directors under the Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1c0bfd7955ac4b51957fb2e28260133d_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfMS0xLTEtMS05MzYw_db4c991c-4b80-46db-b22b-2d89e2cbe7cc">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9b8f1d28ff564258a3694150b17ecfbc_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfMS0zLTEtMS05MzYw_25861126-5bd6-4252-b97a-5dcb31cbd616">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1c0bfd7955ac4b51957fb2e28260133d_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfMi0xLTEtMS05MzYw_4ff3aa2b-9f32-41ae-862a-669935358a7e"
      unitRef="number">0.841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9b8f1d28ff564258a3694150b17ecfbc_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfMi0zLTEtMS05MzYw_7b95ac31-3295-4501-bb12-26857aeb8371"
      unitRef="number">0.842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1c0bfd7955ac4b51957fb2e28260133d_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfMy0xLTEtMS05MzYw_28f5cb1b-9543-4ca6-a84b-bed5d0343718"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9b8f1d28ff564258a3694150b17ecfbc_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfMy0zLTEtMS05MzYw_26a4f733-d668-4a36-b427-7ee97a1f3cdc"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1c0bfd7955ac4b51957fb2e28260133d_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfNC0xLTEtMS05MzYw_1de0b9ad-1490-44ae-b849-6f0141424b91"
      unitRef="number">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9b8f1d28ff564258a3694150b17ecfbc_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RhYmxlOjMxNTliNmRhYzI3OTQ0YThhYTNhZDMwMmU5OTc1ZGY1L3RhYmxlcmFuZ2U6MzE1OWI2ZGFjMjc5NDRhOGFhM2FkMzAyZTk5NzVkZjVfNC0zLTEtMS05MzYw_bca9be5c-a6ab-4287-9c70-bdaa903275c7"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i612bfa266c9d4fdaabd216b7743222f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzU1NA_50b5e948-0f29-491c-85a5-909a7355416c"
      unitRef="shares">7975000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i612bfa266c9d4fdaabd216b7743222f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzYyMQ_52981341-daa7-4065-9322-9bf99e1bd769"
      unitRef="shares">5792000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum
      contextRef="ibd71d21d51204504b4c1150f43b3bc59_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzcxMA_c2a25547-9d85-4f7c-bef4-7c826753b2aa"
      unitRef="number">0.15</bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum>
    <bcrx:PercentageOfCommonStockSharesBeginning
      contextRef="ibd71d21d51204504b4c1150f43b3bc59_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzc3MA_91373f76-f165-4f24-b1df-1e1942b6507e"
      unitRef="number">0.85</bcrx:PercentageOfCommonStockSharesBeginning>
    <bcrx:PercentageOfCommonStockSharesEnding
      contextRef="ibd71d21d51204504b4c1150f43b3bc59_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzc5Mw_375087b7-f844-454b-8d2f-73560d8cf587"
      unitRef="number">0.85</bcrx:PercentageOfCommonStockSharesEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="ibd71d21d51204504b4c1150f43b3bc59_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfNzg2Ng_3ee5a6dd-0d1a-4bfa-b0f4-12588a88a049"
      unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount
      contextRef="i612bfa266c9d4fdaabd216b7743222f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODAzNg_7b552c0e-9866-455a-aec5-1c66a44b1ae1"
      unitRef="usd">25000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODEzMg_d63dcd81-6540-49dc-9316-e573ddc254d9"
      unitRef="shares">260000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ia44a8f865f8c40aabd065315b6c462b4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82NC9mcmFnOmJhMzM0NDEzNWFhZjRjNjg5YWIxN2Q5MDY4ZDIyODFlL3RleHRyZWdpb246YmEzMzQ0MTM1YWFmNGM2ODlhYjE3ZDkwNjhkMjI4MWVfODEzOQ_1434f865-4a5a-4189-86bf-c104f751dde7"
      unitRef="shares">316000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfOTE3Mw_1d8f72ee-4c26-4982-bf5c-b7517f1fbf17">Collaborative and Other Relationships&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;National Institute of Allergy and Infectious Diseases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In September 2013, NIAID/HHS contracted with the Company for the development of galidesivir as a treatment for Marburg virus disease and subsequently, Yellow Fever and Ebola virus disease. On September&#160;15, 2021, the Company entered into an amendment to pay for certain additional costs, including additional manufacturing development costs and overhead, and to change the total value of the contract, as amended, to $47,315 from $45,931. This is the commencement of closing out the contract. All options under the contract have been awarded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, NIAID/HHS awarded the Company a contract, with potential aggregate funding of up to $43,908 if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir. NIAID/HHS made an initial award of $6,326 to the Company under this contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Biomedical Advanced Research and Development Authority&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In March 2015, BARDA/HHS awarded the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract includes a base contract of $16,265 to support galidesivir drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $39,120. As of September&#160;30, 2022, a total of $20,574 has been awarded under exercised options within this contract. The most recent development option was completed as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contracts with NIAID/HHS and BARDA/HHS are cost-plus-fixed-fee contracts. The Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress, and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the continuation of the contracts is based on the Company&#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects all government funding for its galidesivir program to expire in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In September 2018, HHS awarded the Company a $34,660 contract for the procurement of up to 50,000 doses of RAPIVAB (peramivir injection) over a five-year period. On August 25, 2022, the Company announced that HHS had exercised its remaining option under the contract to purchase 10,000 doses of RAPIVAB for $6,932. As of September&#160;30, 2022, the Company has delivered a total of 39,980 RAPIVAB doses of the 50,000 RAPIVAB doses available under the contract with HHS for a total of $27,714.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Torii Pharmaceutical Co., Ltd&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. On November&#160;5, 2019, the Company entered into a Commercialization and License Agreement with Torii (the &#x201c;Torii Agreement&#x201d;), granting Torii the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Torii Agreement, the Company received an upfront, non-refundable payment of $22,000. The Japanese National Health Insurance System&#x2019;s (&#x201c;NHI&#x201d;) approval of the addition of ORLADEYO to the NHI drug price list in April 2021 triggered a $15,000 milestone payment from Torii to the Company, which was received in May 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, under the Torii Agreement, the Company is entitled to receive tiered royalty payments, ranging from 20% to 40% of annual net sales of ORLADEYO in Japan during each calendar year. Torii&#x2019;s royalty payment obligations are subject to customary reductions in certain circumstances, but may not be reduced by more than 50% of the amount that otherwise would have been payable to the Company in the applicable calendar quarter. Torii&#x2019;s royalty payment obligations commenced upon the first commercial sale of ORLADEYO in Japan and expire upon the later of (i) the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMzYzNw_a3daa0dc-7723-4501-842e-5ed805a38078"&gt;ten&lt;/span&gt;th anniversary of the date of first commercial sale of ORLADEYO in Japan, (ii) the expiration of the Company&#x2019;s patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. The Company is responsible for supplying Torii with its required amounts of ORLADEYO. The activities of the parties pursuant to the Torii Agreement are overseen by a joint steering committee, composed of an equal number of representatives from each party to coordinate the development and commercialization of ORLADEYO in Japan. Torii launched ORLADEYO in Japan on April 23, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified performance obligations related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the $22,000 upfront consideration to the identified performance obligations using estimation approaches to determine the standalone selling prices under ASC Topic 606. Specifically, in determining the value related to the license, a valuation approach utilizing risk adjusted discounted cash flow projections was used, and an expected cost plus margin approach was utilized for the other performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shionogi &amp;amp; Co., Ltd&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to UAB on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Green Cross Corporation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross is responsible for all development, regulatory, and commercialization costs in Korea and the Company is entitled to share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In June 2000, the Company licensed a series of potent inhibitors of purine nucleoside phosphorylase from AECOM and IRL (together, the &#x201c;Licensors&#x201d;). The lead product candidate from this collaboration is forodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute this, or any other, product candidate that might arise from research on these inhibitors. The Company has the option to expand the agreement to include other inventions in the field made by the investigators or employees of the Licensors. Under this agreement, as amended and restated, the Company has agreed to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;use commercially reasonable efforts to develop these drugs, to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000 per indication) for future development and single digit royalties on net sales of any resulting product made by the Company, and to share a portion of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. The Licensors have also granted the Company an exclusive worldwide license of galidesivir for any antiviral use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The University of Alabama at Birmingham&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed by UAB with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements each have an initial 25-year term, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon three months&#x2019; notice and by UAB under certain circumstances. Upon termination, both parties shall cease using the other parties&#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross collaborations, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts received.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts
      contextRef="i6962c7b3c532429d9dc533d16085a1be_D20210915-20210915"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNDk2_f9ed595f-0775-4355-930a-f360431aae95"
      unitRef="usd">47315000</bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts>
    <bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts
      contextRef="i7e86c77b3f93473aba60a62ad6ac9c1a_D20130930-20130930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNTA0_d2ebc1e7-6f05-414b-a04c-d658aab3b3c1"
      unitRef="usd">45931000</bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts>
    <bcrx:CollaborativeAgreementContractCovenantMaximumAmountOfFunding
      contextRef="i9fe0f9acd7e14572953ee3262d1924ec_D20200801-20200831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNzAz_fab424e1-b135-4cca-a263-698124aa0e30"
      unitRef="usd">43908000</bcrx:CollaborativeAgreementContractCovenantMaximumAmountOfFunding>
    <bcrx:CollaborativeAgreementContractValue
      contextRef="i9fe0f9acd7e14572953ee3262d1924ec_D20200801-20200831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfODYy_11e71f91-c3d3-47cc-8cb3-f5aa8dd20c53"
      unitRef="usd">6326000</bcrx:CollaborativeAgreementContractValue>
    <us-gaap:GovernmentContractReceivable
      contextRef="i939d2e62994c419ba66434c3debb0192_I20150331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMTE4OA_24db70d6-1695-41ad-a0f3-3c3be7e851d2"
      unitRef="usd">16265000</us-gaap:GovernmentContractReceivable>
    <us-gaap:GovernmentContractReceivable
      contextRef="ie89d5e9da1fb4552906ccc29db0c6910_I20150331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMTI0NQ_fe62ef77-d41a-4db4-8026-f44cceff832b"
      unitRef="usd">22855000</us-gaap:GovernmentContractReceivable>
    <us-gaap:GovernmentContractReceivable
      contextRef="i5578f786012042cb8b526aad1347720f_I20150331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMTM3MQ_d6acaf6f-960d-4727-8701-42dd3a5a7c45"
      unitRef="usd">39120000</us-gaap:GovernmentContractReceivable>
    <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts
      contextRef="ic71ceab0e4b64e95b2df289f6f3faaec_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMTM5Ng_10a8db1a-da80-4c3f-a552-65e427733bf2"
      unitRef="usd">20574000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
    <bcrx:CollaborativeAgreementContractValue
      contextRef="id43ef6e8fa364fd8b928caaf91fbd1a6_D20180906-20180906"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMjI1OA_d68a9735-7b64-4e4c-8c3f-8bb9c37402e0"
      unitRef="usd">34660000</bcrx:CollaborativeAgreementContractValue>
    <bcrx:MaximumNumberOfProductsPermittedToBeObtainedDoses
      contextRef="i535cf829316841bfa7015ff15880d35a_D20180906-20180906"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMjI5OQ_6f78d068-7d75-4697-be53-8e9447c6b7b8"
      unitRef="dose">50000</bcrx:MaximumNumberOfProductsPermittedToBeObtainedDoses>
    <bcrx:ContractTerm
      contextRef="id43ef6e8fa364fd8b928caaf91fbd1a6_D20180906-20180906"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfOTE2OQ_9379ae1b-97af-4def-ac93-4b9d4d832b30">P5Y</bcrx:ContractTerm>
    <bcrx:NumberOfProductsObtainedDoses
      contextRef="i285e93f7aad44dada9abb5c04565a489_D20220825-20220825"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMTA5OTUxMTYzODkzMg_b377055d-02bb-4611-a943-0c0d0c468963"
      unitRef="dose">10000</bcrx:NumberOfProductsObtainedDoses>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i285e93f7aad44dada9abb5c04565a489_D20220825-20220825"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMTA5OTUxMTYzODk0MA_4c44c8a6-eb47-4967-8fba-92573349601e"
      unitRef="usd">6932000</us-gaap:ProceedsFromCollaborators>
    <bcrx:NumberOfProductsObtainedDoses
      contextRef="ic103b1fd563c46dbb16e1ab091c2bc47_D20220101-20220930"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNTQ5NzU1ODIzMDc5_0a03dd5e-9123-4d03-8c62-220df26bb3de"
      unitRef="dose">39980</bcrx:NumberOfProductsObtainedDoses>
    <bcrx:MaximumNumberOfProductsPermittedToBeObtainedDoses
      contextRef="ic103b1fd563c46dbb16e1ab091c2bc47_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMjQzNQ_d8b8e0b0-1e5b-4d4c-8df7-e0b65248bcb9"
      unitRef="dose">50000</bcrx:MaximumNumberOfProductsPermittedToBeObtainedDoses>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ic103b1fd563c46dbb16e1ab091c2bc47_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMjUwNQ_46ad263e-9028-4e34-a2e9-f6704e044595"
      unitRef="usd">27714000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i726cc8c2bd0b4ed78ad0a2c84ed2479c_D20191105-20191105"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMjg0MQ_8a823abf-123a-4de3-8093-3d67f7042cc1"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone
      contextRef="i2fb11f122dad4dbb93a70888951bbc85_I20191105"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMjk5MQ_eb13a3c9-f199-4432-b0bb-3ef746ca5916"
      unitRef="usd">15000000</bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone>
    <bcrx:RoyaltyRateIfMaintainsSakigakeDesignation
      contextRef="i4097a995127f49fa8ee4dd7b99237dda_I20191105"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMzE4NA_945d97a6-3989-495e-a40c-057a9ba4091d"
      unitRef="number">0.20</bcrx:RoyaltyRateIfMaintainsSakigakeDesignation>
    <bcrx:RoyaltyRateIfMaintainsSakigakeDesignation
      contextRef="iabfffedc39c340fabce60b94d0d32249_I20191105"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMzE5MA_f4401190-8ee2-450a-adb7-36a29657676a"
      unitRef="number">0.40</bcrx:RoyaltyRateIfMaintainsSakigakeDesignation>
    <bcrx:MaximumCustomaryReductionOnRoyaltyRate
      contextRef="i2fb11f122dad4dbb93a70888951bbc85_I20191105"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfMzM5NQ_56e68cce-c9d7-450f-b9c9-709b82cf36f8"
      unitRef="number">0.50</bcrx:MaximumCustomaryReductionOnRoyaltyRate>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i726cc8c2bd0b4ed78ad0a2c84ed2479c_D20191105-20191105"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNDUzNg_8a823abf-123a-4de3-8093-3d67f7042cc1"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <bcrx:MilestonePaymentMinimum
      contextRef="i90941783cef64f03915cc4e7222642e6_D20000601-20000630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNzE3OQ_165b3fe4-8414-490a-83d3-fe6462b70683"
      unitRef="usd">1400000</bcrx:MilestonePaymentMinimum>
    <bcrx:MilestonePaymentMaximum
      contextRef="i90941783cef64f03915cc4e7222642e6_D20000601-20000630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNzE5Mg_31af111f-7757-43d2-bae5-e035771f7440"
      unitRef="usd">4000000</bcrx:MilestonePaymentMaximum>
    <bcrx:AnnualLicenseFeeMinimum
      contextRef="i8cba6072ef5b463d92db14b5c09be6b9_I20000630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNzQ5Nw_17d5d5dc-f92d-4e4b-926a-78c0c069ee4d"
      unitRef="usd">150000</bcrx:AnnualLicenseFeeMinimum>
    <bcrx:AnnualLicenseFeeMaximum
      contextRef="i8cba6072ef5b463d92db14b5c09be6b9_I20000630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfNzUwMw_09f4db41-0c2a-4820-af9b-3da65f36f349"
      unitRef="usd">500000</bcrx:AnnualLicenseFeeMaximum>
    <bcrx:PeriodOfAgreement
      contextRef="ifba7c735102f46f692d875d1a37529f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfODQxNQ_232bef6e-8862-424f-abec-2d027539c94c">P25Y</bcrx:PeriodOfAgreement>
    <bcrx:RenewablePeriodOfAgreement
      contextRef="ifba7c735102f46f692d875d1a37529f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE0Y2QwNjljNTY1MDRlOTNhODgzYzkxNjUxMDEyMjgwL3NlYzphNGNkMDY5YzU2NTA0ZTkzYTg4M2M5MTY1MTAxMjI4MF82Ny9mcmFnOjNlOWVhZjNhNWNjYjQ2YzViY2M3NDUxMjI0MTkxMThhL3RleHRyZWdpb246M2U5ZWFmM2E1Y2NiNDZjNWJjYzc0NTEyMjQxOTExOGFfOTE3Mg_33245462-dd29-482b-9c9f-36531879eab8">P5Y</bcrx:RenewablePeriodOfAgreement>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>61
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M2U,239 D>! 3_)/LPOY"F:<NJ[;H;.S:.4$M-U[1P Z//$['"]N'RD@\P?5
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MF>!)#Y0MP/L+*<WSP)XEZK-C^!=02P,$%     @ 68)D59IZ5.JZ!P  ("P
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M[\F-^-*]A^JT-[%EH8!;<<:I=FR<&:(QQ=28(8%I/ID=?3(;6I/^EM?'FI1
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MBZ]?/\?GZ8&_5>[.1S]G>))-VW[$7]Z7WYX]18!<[8H>5\CA?[?NC:MK7 C
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M[>8%(!7($]$+K"LWO*T'(,A<:>_7IL*_W_1XG6L[!^C@PH$*+>&'W5#G?8M
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M._N8BJ"%[5E\/KI];-3!^H_)XV[O&LSD (NL.(]"5^;A7;\E%VQA7>"%$(M
M-+HC&S<Q/0J&*DEB3 G-:%!NB0)5 5'(MQ3H C")$>GSA'"CY3!FC9%F *87
M1TC<+W73C.$7<#6.#1DWY1%#H7IG9A!#=^9&B+2\7IVS()<8CA2MG@6!+N2!
MZ\15]7+*-3A<[#+>Y#5*SY] QL^Y(L(LJ, DZLK\3^]Z?)>PPC_!1ZJM5C.Q
MH(W; 9WX?74\2A;I"/"H*9%D)U9AQ1#%3B/B45Q18U@2QF=Q;0M(AD9?)Q/E
M+5HWEHIYYT"!L@?\;@"\93=*99;]>7=C$C1HH"FRIL$V"MS/!.=CQ"!*?%#T
ME@>),:11C#S#HX(B1'*H.&7 F8^3XKSR)EHE;*SBQX#Y;NA H\-)?V4?1H#[
M*RQ=@BXB(ZKVCO(K(UA=74>P8AS8 (F3-4CX=PY]*O!66T]Q/ E6,+ADMC'
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M&+JEA+<PLTG7DH/3Z.F02,S8)N9@-_IV;6GN3>2FITA!?Q)OJCZ%]#.B(?6
M[)K_S<>>T'NDJ,1]2L+(>!$G7L)>2D4S1[:\T%?T4)RHD; #HCQP4DA7(Y/$
MF0 ^.8L*H@2*%V\ :P?'92U)UHXDB,B$-\@_URP3LE2G67*#/8=(.,&;C15X
M)=*E[<"NDDP6&LFK1*$B)JJN/$>#A\H+J)+"MTPD)J0U&PN*;E<A#:&DM)S+
MYD2F/JZ!P0S,MF'8*Q&!= ,B.Z=;CI+5QK@L8!@55<]@B&)B0A\O)/8Y)S_2
M"PUA(J:G%G.'NZ[U?GRC'A619$B<P* ?=#'MSPI1TV9""CX_&#U8$5JTJ&I
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M#9E% 6O+%5&CY52E1.:4U@7-U_6 <CY025L(I2>A,S:BBPFN.)6X#%>"*ZI
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MSHR3Y"7FTENL EM)$)PM;LQ0-%&@)=HC&<$ZJ@'*3_&<$W]LP;_<A1EK$R+
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M92 DN_:.R^=ZG80F7[<:A^'GVY4.6,LJQ:3<:,+AR=V0=R^?]*]>/JD\_%/
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M+-U5W&=.ET/4[$#S*T7'73?@!?KKYOP_4$L#!!0    ( %F"9%7GGG,Z9P,
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MMQWZ$Y/[@LX-QQVY^NXX=D"V7:^=:%';3D/'EOJ6%7/Z44!I#$B_$T(_3TR
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MX.'XF?W:YTZYK)C!2R4>>&Z+:3 *(,<UJX5=JNT[W.?3=WR9$L:WL&W6=M,
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M*4M>YH<%_3Q0NP7T?:V4?9ZX#=K?T>PG4$L#!!0    ( %F"9%6&(OD,NQ0
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M\;S=>V<@-1.&&FJ[ZFYS:_<@OL/S^K*]1WM9+K=*5BMV30V'56[:NZZNKH#
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M_(CX[TCV"'#CX?'1<[8"O,X-IQ2\/AP>C9XW=2XOMJKD.#^<#"='S]EY9]%
M^N*!3_BMI=BD(HJ5N4Q!H">6EQV/:%TOA'5^J'J<# _'ST/]]DM= %>=>,#I
MK<L/S)6D;@EO0V;<),+VFGUZIPK:*TA%#&3'L2(\2Q(.8_/LGO8 V2OIMJEF
M\KADY Q-DU9[J+L2L;5'B,A]\TDQ@GZH&MTLA\/AR^/G:W7LGR",CTEE&#,W
M\G"MQ;T9WOELLWH-GR/"V(X\+=ZDZ'U'9-ZZGR:VIY-\LRV,=\-2+X-S3-J4
MFET'I$1?_7_-O]V^22[OO> BW.D*C@,#(4X"3 4BNT6BO&H-Z!=Z#32-\6[
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MIO)UVU)<:!696P-G=*K)X&CTREN]5:'DAKG82O_AI;W6 C9%UUPZ^D1Y4RV
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M:)EW++.<2=;LHU/MCX7*MZ: +:BPRQ,"O6(SUXD%FIHW<JQG+JS2&[I$Q'
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M3]D,JYGE@>L[66LJ?2B %RQ8U9*O*1"PI-DS!6'@H9C7&E1LW_-;5)-,)4"
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MSE ZI:8!>#\MT&NX'[1 <\'U_+]02P,$%     @ 68)D50P!"X-)#P  ?R@
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MX6Q4+H;C*/ @6ABN:$^JXIEO8=+C\]GB_(QLZOJN,]9/!"UMOYDF&J?&%KA
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M\6>)-:<2D&K?8.&BINQW;$UE07\CLKI]?^</V ]Q.$2YF5^"?(78($W8]RM
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MG0A"AL8EIB+ZE]XR^%_M',)G ,6'T3P?W[U/)A&RHWH0W$F2)2Y WP?-8UG
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M*>K+YM!VR8=M"CB?N;X#W"C;1?*^RDZ3AQT\^Y?_>'E^?O:=O$*?EM\]2@I
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MP!B<4/B S[%>GZZ*$K\"* (^(>.!X>K6Z3/$#)43 E,\R@Q'#&U,E]^QPEG
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M)JC0ICO#!\N4"P95"<A#JC,7Y1^1DO'.4+<.48^H7868)3E-<=*[8:SLXAZ
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M2#X'W2CO2R'-D+L-]1E:=E;C$G(A"^^^, X@'0*Z;8\M;^HB-Y>:4\,M=Y2
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M[*^K6!Z_K^)2G*]1:]-)E?A/C)/HMW$<U#RZH?>7'U&?J-=D*67*NYNL2U'
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M'V1Y] 0PX+<X_X_1_,J;J>[!/$V1OXH3V!2G)O;PZ"C[]I6VY\>K9"?9JP+
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M>409:2'T3L=C((%>)PI/>)=XW"M+@=E/5F(1$,>0F451L.,83'S',8B]<!;
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ML:8?"I3&@/8K(?1A80X8?U'FWP!02P,$%     @ 68)D5;X,-'-"!   E L
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M4+1DLEP26%>-)[U,.L;CDW[,+>T\2[O0TFX\F_8C;FGG3V;]@#M#\L: SYJ
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M3DO16R72XA]3U;=<W\PMG>V\6/.YN!AIZRI$_BA&LU]_P:'[NVG*(6$4$L:
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M--?EW#OU4 X%:9B^%>TE]'Z<P$PPY7Y1V^<&'LH:I475@XV"BO+N21[[.NP
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MU;\6<!V@GB^9VOULH:?Y_._-^PM02P,$%     @ 68)D50C\^1?E!   TR,
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ML\,=P1Z)TP!^?4-Y/XN3]+F.\CF>Q;]02P,$%     @ 68)D51LH[["Z @
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MM)5*UU^IO&"BUU[MUW\HM<^K:-F":A+5%*II5#.4YL;7EBW=)LJ6+EJVH)I
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MKAI*HU :@](XE"90-#=ZUF?'(;2AQ5!E#:51*(U!:1Q*$RB:&QJKK&/_W=.
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M[;_?E>R8%-RPP5YB?=QS=,^1[DVV,_;150#(GFJEW2RJ$)O+.'9%!;5P(].
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MP]C$VX"?!%9RK8V,DPGGSZ;S?3IP/",(**3*,&#]6L(0*#5$6L;?BM.I?VF
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MRXDS<L@,YK3F^JM8?X+64&ST<L&5_27K=JSGD+Q66A1M,!(4K&RN]*%=B(T
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MXN61M"Q(MC6'M <FU9'/W";J&(]<-U#/UXS)YX(^]]5_# 3_ 5!+ P04
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M-85J(:I%E&;F2--@,.IYOX(>L[Y'KP[Z5'X]N];.7U?=!TYH#P*J^:@6H)I
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MKR359>T 24)M#"C-A](HE,:@- ZEB8JFCI+VV.ZPQMS:H'#U!D7OC+!EK3M
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M]14NZNMD9#_BM*QN?*O@T30>JIF-=OJJX(='X^UR)Z>T4<U!-1?5/%3S42U
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M7W>E+C6O-L>FFR/?]W\ 4$L#!!0    ( %F"9%7]+-6EK@$  ,$;   :
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !9@F15VU\)5>\    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !9
M@F15F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( %F"9%6 ;J3<SP4  +\>   8
M  " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !9
M@F152S0%U@,&  !3&   &               @($3#@  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ 68)D50/]")#S @  1PH  !@
M         ("!3!0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( %F"9%6:>E3JN@<  " L   8              " @747  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !9@F15D2H8(5D&   =&@
M&               @(%E'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ 68)D57\49E#Q"0  KU0  !@              ("!]"4  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( %F"9%5RR2)<90(
M '<%   8              " @1LP  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " !9@F15W<!ODG0J  "'A@  &               @(&V
M,@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 68)D52K+
MMV]7 P  3 <  !@              ("!8%T  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( %F"9%7/#(:@800  'H*   9
M  " @>U@  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M68)D5>>><SIG P  A@@  !D              ("!A64  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " !9@F15$<<"]@8#  ":!@  &0
M            @($C:0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( %F"9%6&(OD,NQ0  ,Y)   9              " @6!L  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 68)D5:(.&)CP#@
M/2\  !D              ("!4H$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " !9@F15J?!R)/D$  !J#   &0              @(%Y
MD   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( %F"9%4#
M)Q59A0,  "()   9              " @:F5  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ 68)D5=9N))<[#   ["H  !D
M     ("!99D  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %F"9%5'"X[.U (  )H&   9              "
M@8KT  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 68)D
M50:2F@^U @  S 4  !D              ("!E?<  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " !9@F155RVCF+<#  "N"   &0
M        @(&!^@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( %F"9%6^##1S0@0  )0+   9              " @6_^  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 68)D51_HO2'F P  0@H
M !D              ("!Z (! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " !9@F15#!@6#&T'  "T.   &0              @($%!P$
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( %F"9%6[&7MZ
MD04   4I   9              " @:D. 0!X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ 68)D58+L3PZY!   )A<  !D
M ("!<10! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !9
M@F15;[9FT8$"  !W!@  &0              @(%A&0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( %F"9%4*1P-C*P,  ,D-   9
M          " @1D< 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#
M%     @ 68)D50C\^1?E!   TR,  !D              ("!>Q\! 'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !9@F15&RCOL+H"  #\
M!P  &0              @(&7) $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;%!+ 0(4 Q0    ( %F"9%5E5.PD?Q(  +X@ 0 9              " @8@G
M 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 68)D56B#
MFV_R!0  4B(  !D              ("!/CH! 'AL+W=O<FMS:&5E=',O<VAE
M970S-2YX;6Q02P$"% ,4    " !9@F15F8JA6\T+  #ACP  &0
M    @(%G0 $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M %F"9%4Z68/7200  .,8   9              " @6M, 0!X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ 68)D56=>MQ*B @  X@<  !D
M             ("!ZU ! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " !9@F15V[Q4NG$"   =!@  &0              @('$4P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( %F"9%7SV+ )WP(
M /<(   9              " @6Q6 0!X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ 68)D58Y@_V=< P  .PP  !D              ("!
M@ED! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !9@F15
M&&3K<J0#   D$   &0              @($570$ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( %F"9%76+&4]41$  %WR   9
M      " @?!@ 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ 68)D5::X"!^2"0  %G$  !D              ("!>'(! 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !9@F15\WW3A1D#  !P"
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M+G)E;'-02P$"% ,4    " !9@F15-U^>?.(#  !V'@  #P
M@ 'AD0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 68)D5?TLU:6N 0
MP1L  !H              ( !\)4! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ 68)D52;ZAZ>U 0  W!L  !,              ( !
MUI<! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #8 -@"Q#@  O)D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>281</ContextCount>
  <ElementCount>306</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>93</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders' Deficit (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Deficit (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Significant Accounting Policies and Concentrations of Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRisk</Role>
      <ShortName>Significant Accounting Policies and Concentrations of Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Trade Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/TradeReceivables</Role>
      <ShortName>Trade Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Royalty Monetizations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/RoyaltyMonetizations</Role>
      <ShortName>Royalty Monetizations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Lease Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligations</Role>
      <ShortName>Lease Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/CollaborativeandOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Significant Accounting Policies and Concentrations of Risk (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies</Role>
      <ShortName>Significant Accounting Policies and Concentrations of Risk (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRisk</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/Revenue</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/Investments</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Trade Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/TradeReceivablesTables</Role>
      <ShortName>Trade Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/TradeReceivables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/Inventory</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Royalty Monetizations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/RoyaltyMonetizationsTables</Role>
      <ShortName>Royalty Monetizations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/RoyaltyMonetizations</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Lease Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligationsTables</Role>
      <ShortName>Lease Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/LeaseObligations</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/StockbasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Significant Accounting Policies and Concentrations of Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails</Role>
      <ShortName>Significant Accounting Policies and Concentrations of Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/RevenueDetails</Role>
      <ShortName>Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/RevenueTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Investments- Fair Value of the Company's Investments by Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails</Role>
      <ShortName>Investments- Fair Value of the Company's Investments by Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Investments - Schedule of Maturity of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails</Role>
      <ShortName>Investments - Schedule of Maturity of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Trade Receivables (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/TradeReceivablesDetailsTextual</Role>
      <ShortName>Trade Receivables (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/TradeReceivablesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Trade Receivables - Summary of Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails</Role>
      <ShortName>Trade Receivables - Summary of Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/InventoryTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Royalty Monetizations (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual</Role>
      <ShortName>Royalty Monetizations (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/RoyaltyMonetizationsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Royalty Monetizations - Schedule of Royalty Financing Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails</Role>
      <ShortName>Royalty Monetizations - Schedule of Royalty Financing Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/Debt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Lease Obligations (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligationsDetailsTextual</Role>
      <ShortName>Lease Obligations (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/LeaseObligationsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Lease Obligations - Aggregate Lease Expense Under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails</Role>
      <ShortName>Lease Obligations - Aggregate Lease Expense Under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Lease Obligations - Other Supplemental Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails</Role>
      <ShortName>Lease Obligations - Other Supplemental Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Lease Obligations -Balance Sheets of the Company's Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails</Role>
      <ShortName>Lease Obligations -Balance Sheets of the Company's Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Lease Obligations - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Lease Obligations - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/StockholdersEquity</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockbasedCompensationDetailsTextual</Role>
      <ShortName>Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/StockbasedCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Stock-based Compensation - Stock Plan Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails</Role>
      <ShortName>Stock-based Compensation - Stock Plan Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails</Role>
      <ShortName>Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bcrx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Collaborative and Other Relationships (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails</Role>
      <ShortName>Collaborative and Other Relationships (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/role/CollaborativeandOtherRelationships</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: bcrx:RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial -  bcrx-20220930.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 1 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList -  bcrx-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="bcrx-20220930.htm">bcrx-20220930.htm</File>
    <File>bcrx-20220930.xsd</File>
    <File>bcrx-20220930_cal.xml</File>
    <File>bcrx-20220930_def.xml</File>
    <File>bcrx-20220930_lab.xml</File>
    <File>bcrx-20220930_pre.xml</File>
    <File>bcrx-20220930xexhibit104.htm</File>
    <File>bcrx-20220930xexx311.htm</File>
    <File>bcrx-20220930xexx312.htm</File>
    <File>bcrx-20220930xexx321.htm</File>
    <File>bcrx-20220930xexx322.htm</File>
    <File>exhibit101-biocrystxbcx993.htm</File>
    <File>exhibit102-biocrystxamendm.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="636">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>67
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bcrx-20220930.htm": {
   "axisCustom": 2,
   "axisStandard": 25,
   "contextCount": 281,
   "dts": {
    "calculationLink": {
     "local": [
      "bcrx-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bcrx-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bcrx-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bcrx-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bcrx-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bcrx-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 505,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://www.biocryst.com/20220930": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 8
   },
   "keyCustom": 84,
   "keyStandard": 222,
   "memberCustom": 68,
   "memberStandard": 22,
   "nsprefix": "bcrx",
   "nsuri": "http://www.biocryst.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://www.biocryst.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Investments",
     "role": "http://www.biocryst.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:TradeReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Trade Receivables",
     "role": "http://www.biocryst.com/role/TradeReceivables",
     "shortName": "Trade Receivables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:TradeReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Inventory",
     "role": "http://www.biocryst.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:RoyaltyMonetizationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Royalty Monetizations",
     "role": "http://www.biocryst.com/role/RoyaltyMonetizations",
     "shortName": "Royalty Monetizations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:RoyaltyMonetizationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Debt",
     "role": "http://www.biocryst.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Lease Obligations",
     "role": "http://www.biocryst.com/role/LeaseObligations",
     "shortName": "Lease Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Stockholders' Equity",
     "role": "http://www.biocryst.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Stock-based Compensation",
     "role": "http://www.biocryst.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Collaborative and Other Relationships",
     "role": "http://www.biocryst.com/role/CollaborativeandOtherRelationships",
     "shortName": "Collaborative and Other Relationships",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:DescriptionOfCompanyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Significant Accounting Policies and Concentrations of Risk (Policies)",
     "role": "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies",
     "shortName": "Significant Accounting Policies and Concentrations of Risk (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:DescriptionOfCompanyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.biocryst.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Revenue (Tables)",
     "role": "http://www.biocryst.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Investments (Tables)",
     "role": "http://www.biocryst.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Trade Receivables (Tables)",
     "role": "http://www.biocryst.com/role/TradeReceivablesTables",
     "shortName": "Trade Receivables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Inventory (Tables)",
     "role": "http://www.biocryst.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:RoyaltyFinancingObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Royalty Monetizations (Tables)",
     "role": "http://www.biocryst.com/role/RoyaltyMonetizationsTables",
     "shortName": "Royalty Monetizations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:RoyaltyFinancingObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Lease Obligations (Tables)",
     "role": "http://www.biocryst.com/role/LeaseObligationsTables",
     "shortName": "Lease Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://www.biocryst.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Significant Accounting Policies and Concentrations of Risk (Details)",
     "role": "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails",
     "shortName": "Significant Accounting Policies and Concentrations of Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:InvestmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "lang": "en-US",
      "name": "bcrx:LongTermInvestmentMaturityMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i861b143373254de4947eaa4bad2f89c6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Revenue (Details)",
     "role": "http://www.biocryst.com/role/RevenueDetails",
     "shortName": "Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i01b1e25bb16a4e61b3726d6578c74362_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Investments- Fair Value of the Company's Investments by Type (Details)",
     "role": "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails",
     "shortName": "Investments- Fair Value of the Company's Investments by Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.biocryst.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Investments - Schedule of Maturity of Investments (Details)",
     "role": "http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails",
     "shortName": "Investments - Schedule of Maturity of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i3fad271ec831459885eb81d1bf350ac2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Trade Receivables (Details Textual)",
     "role": "http://www.biocryst.com/role/TradeReceivablesDetailsTextual",
     "shortName": "Trade Receivables (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i3fad271ec831459885eb81d1bf350ac2_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Trade Receivables - Summary of Receivables (Details)",
     "role": "http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails",
     "shortName": "Trade Receivables - Summary of Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Inventory (Details)",
     "role": "http://www.biocryst.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i63012785f2d64008b6eb5c1c19199d9b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bcrx:SharesIssuedCommonStockPremium",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Royalty Monetizations (Details Textual)",
     "role": "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual",
     "shortName": "Royalty Monetizations (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i63012785f2d64008b6eb5c1c19199d9b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bcrx:SharesIssuedCommonStockPremium",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bcrx:RoyaltyFinancingObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "iaaaa54dd893e44a9ba927dae3ebc58fc_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bcrx:FutureRoyaltiesPayable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Royalty Monetizations - Schedule of Royalty Financing Obligations (Details)",
     "role": "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails",
     "shortName": "Royalty Monetizations - Schedule of Royalty Financing Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bcrx:RoyaltyFinancingObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "ib6ee066e4bc44ff9b1d675f8fd1040c4_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaidInKindInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Debt (Details)",
     "role": "http://www.biocryst.com/role/DebtDetails",
     "shortName": "Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaidInKindInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bcrx:OtherSupplementalInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Lease Obligations (Details Textual)",
     "role": "http://www.biocryst.com/role/LeaseObligationsDetailsTextual",
     "shortName": "Lease Obligations (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "ie20bac9cd8014f8cb989d999d452c248_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "bcrx:OperatingLeaseRightOfUseAssetAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i861b143373254de4947eaa4bad2f89c6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bcrx:AggregateLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Lease Obligations - Aggregate Lease Expense Under Operating Leases (Details)",
     "role": "http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails",
     "shortName": "Lease Obligations - Aggregate Lease Expense Under Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i861b143373254de4947eaa4bad2f89c6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bcrx:AggregateLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bcrx:OtherSupplementalInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Lease Obligations - Other Supplemental Information Related to Leases (Details)",
     "role": "http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails",
     "shortName": "Lease Obligations - Other Supplemental Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i861b143373254de4947eaa4bad2f89c6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i861b143373254de4947eaa4bad2f89c6_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Lease Obligations -Balance Sheets of the Company's Operating Leases (Details)",
     "role": "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails",
     "shortName": "Lease Obligations -Balance Sheets of the Company's Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Lease Obligations - Maturities of Operating Lease Liabilities (Details)",
     "role": "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Lease Obligations - Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "ief8dcbde5b0e41c3bb5a8ebe4a804426_I20200424",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bcrx:MaximumAggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.biocryst.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "ief8dcbde5b0e41c3bb5a8ebe4a804426_I20200424",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bcrx:MaximumAggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "idb265a8308724c57833eccc5d77be8aa_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bcrx:ShareBasedPaymentArrangementNumberOfPlans",
      "reportCount": 1,
      "unitRef": "plan",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Stock-based Compensation (Details Textual)",
     "role": "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
     "shortName": "Stock-based Compensation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i861b143373254de4947eaa4bad2f89c6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Stock-based Compensation - Stock Plan Activities (Details)",
     "role": "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails",
     "shortName": "Stock-based Compensation - Stock Plan Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i861b143373254de4947eaa4bad2f89c6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i1c0bfd7955ac4b51957fb2e28260133d_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)",
     "role": "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails",
     "shortName": "Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i1c0bfd7955ac4b51957fb2e28260133d_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i861b143373254de4947eaa4bad2f89c6_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Collaborative and Other Relationships (Details)",
     "role": "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
     "shortName": "Collaborative and Other Relationships (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "id43ef6e8fa364fd8b928caaf91fbd1a6_D20180906-20180906",
      "decimals": "-4",
      "lang": "en-US",
      "name": "bcrx:CollaborativeAgreementContractValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i41745e32b23b47e7a00caf0e1c1db339_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Stockholders' Deficit",
     "role": "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit",
     "shortName": "Consolidated Statements of Stockholders' Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "ib5d58b9fd63041f3bc17cf6fc173034b_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Deficit (Parenthetical)",
     "role": "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Deficit (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "if4d77eb238ef40f08b7089b92f74126b_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "bcrx:StockIssuedDuringPeriodSharesWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Significant Accounting Policies and Concentrations of Risk",
     "role": "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRisk",
     "shortName": "Significant Accounting Policies and Concentrations of Risk",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Revenue",
     "role": "http://www.biocryst.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx-20220930.htm",
      "contextRef": "i4f2d59e25fa44b5bbafc02fddc065474_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 93,
   "tag": {
    "bcrx_AECOMAndIRLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AECOM and IRL",
        "label": "AECOM and IRL [Member]",
        "terseLabel": "AECOM and IRL"
       }
      }
     },
     "localname": "AECOMAndIRLMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ASPRBARDAContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The potential value of the ASPR/BARDA Contract.",
        "label": "ASPRBARDA Contract [Member]",
        "terseLabel": "ASPRBARDA Contract"
       }
      }
     },
     "localname": "ASPRBARDAContractMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AccruedExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents accrued expenses policy.",
        "label": "Accrued Expenses [Policy Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedExpensesPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_AdditionalDevelopmentOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional development options that can be exercised by the Government.",
        "label": "Additional Development Options [Member]",
        "terseLabel": "Additional Development Options"
       }
      }
     },
     "localname": "AdditionalDevelopmentOptionsMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AfterFourthAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents after the fourth anniversary.",
        "label": "After Fourth Anniversary [Member]",
        "terseLabel": "After Fourth Anniversary"
       }
      }
     },
     "localname": "AfterFourthAnniversaryMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AggregateLeaseExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Lease Expense",
        "label": "Aggregate Lease Expense",
        "terseLabel": "Aggregate lease expense"
       }
      }
     },
     "localname": "AggregateLeaseExpense",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsAggregateLeaseExpenseUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortization of debt financing costs and original issue discounts.",
        "label": "Amortization Of Debt Financing Costs And Original Issue Discounts",
        "terseLabel": "Amortization of debt financing costs and original issue discounts"
       }
      }
     },
     "localname": "AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AmortizationOfDiscountAndPremiumOnInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to the discount and premium on investments.",
        "label": "Amortization of premium/discount on investments",
        "terseLabel": "Amortization of premium/discount on investments"
       }
      }
     },
     "localname": "AmortizationOfDiscountAndPremiumOnInvestments",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AnnualLicenseFeeMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual maximum license fee.",
        "label": "Annual License Fee Maximum",
        "terseLabel": "Annual license fee maximum"
       }
      }
     },
     "localname": "AnnualLicenseFeeMaximum",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AnnualLicenseFeeMinimum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent minimum annual license fee.",
        "label": "Annual License Fee Minimum",
        "terseLabel": "Annual license fee minimum"
       }
      }
     },
     "localname": "AnnualLicenseFeeMinimum",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AnnualNetSalesBetween150000And230000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales between $150,000 and $230,000.",
        "label": "Annual Net Sales Between $150,000 and $230,000 [Member]",
        "terseLabel": "Annual Net Sales Between $150,000 and $230,000"
       }
      }
     },
     "localname": "AnnualNetSalesBetween150000And230000Member",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesBetween15And3BillionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales between $1.5 and $3 billions.",
        "label": "Annual Net Sales Between $1.5 and $3 Billions [Member]",
        "terseLabel": "Annual Net Sales Between $1.5 and $3 Billions"
       }
      }
     },
     "localname": "AnnualNetSalesBetween15And3BillionsMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesBetween350000And550000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales between $350,000 and $550,000.",
        "label": "Annual Net Sales Between $350,000 and $550,000 [Member]",
        "terseLabel": "Annual Net Sales Between $350,000 and $550,000"
       }
      }
     },
     "localname": "AnnualNetSalesBetween350000And550000Member",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesOver230000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales over $230,000.",
        "label": "Annual Net Sales Over $230,000 [Member]",
        "terseLabel": "Annual Net Sales Over $230,000"
       }
      }
     },
     "localname": "AnnualNetSalesOver230000Member",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesOver3BillionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales over $3 billions.",
        "label": "Annual Net Sales Over $3 Billions [Member]",
        "terseLabel": "Annual Net Sales Over $3 Billions"
       }
      }
     },
     "localname": "AnnualNetSalesOver3BillionsMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesOver550000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales over $550,000.",
        "label": "Annual Net Sales Over $550,000 [Member]",
        "terseLabel": "Annual Net Sales Over $550,000"
       }
      }
     },
     "localname": "AnnualNetSalesOver550000Member",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesRangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Net Sales Range",
        "label": "Annual Net Sales Range [Axis]",
        "terseLabel": "Annual Net Sales Range [Axis]"
       }
      }
     },
     "localname": "AnnualNetSalesRangeAxis",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "bcrx_AnnualNetSalesRangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Net Sales Range",
        "label": "Annual Net Sales Range [Domain]",
        "terseLabel": "Annual Net Sales Range [Domain]"
       }
      }
     },
     "localname": "AnnualNetSalesRangeDomain",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesUnder150000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales under $150,000.",
        "label": "Annual Net Sales Under $150,000 [Member]",
        "terseLabel": "Annual Net Sales Under $150,000"
       }
      }
     },
     "localname": "AnnualNetSalesUnder150000Member",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesUnder15BillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales under $1.5 billions.",
        "label": "Annual Net Sales Under $1.5 Billion [Member]",
        "terseLabel": "Annual Net Sales Under $1.5 Billion"
       }
      }
     },
     "localname": "AnnualNetSalesUnder15BillionMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesUnder350000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales under $350,000.",
        "label": "Annual Net Sales Under $350,000 [Member]",
        "terseLabel": "Annual Net Sales Under $350,000"
       }
      }
     },
     "localname": "AnnualNetSalesUnder350000Member",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AthyriumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Athyrium Opportunities III Co-Invest 1 LP (\u201cAthyrium\u201d).",
        "label": "Athyrium [Member]",
        "terseLabel": "Athyrium"
       }
      }
     },
     "localname": "AthyriumMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AvailableForSaleDebtSecuritiesAccruedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of accrued interest in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Accrued Interest",
        "terseLabel": "Accrued Interest"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccruedInterest",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average maturity period of high quality marketable securities.",
        "label": "Average Maturity Period Of High Quality Marketable Securities",
        "terseLabel": "Average maturity period of high quality marketable securities (in months)"
       }
      }
     },
     "localname": "AverageMaturityPeriodOfHighQualityMarketableSecurities",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_BCX9930BCX10013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BCX9930 &amp; BCX10013",
        "label": "BCX9930 &amp; BCX10013 [Member]",
        "terseLabel": "BCX9930 &amp; BCX10013"
       }
      }
     },
     "localname": "BCX9930BCX10013Member",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_BCX9930Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents BCX9930.",
        "label": "BCX9930 [Member]",
        "terseLabel": "BCX9930"
       }
      }
     },
     "localname": "BCX9930Member",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_BaseContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The base contract of ASPR/BARDA to support BCX4430 drug manufacturing.",
        "label": "Base Contract [Member]",
        "terseLabel": "Base Contract"
       }
      }
     },
     "localname": "BaseContractMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_BetweenTheSecondAndThirdAnniversariesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents between the second and third anniversaries.",
        "label": "Between the Second and Third Anniversaries [Member]",
        "terseLabel": "Between the Second and Third Anniversaries"
       }
      }
     },
     "localname": "BetweenTheSecondAndThirdAnniversariesMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_BetweenTheThirdAndFourthAnniversariesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents after the third anniversary and before the fourth anniversary.",
        "label": "Between the Third and Fourth Anniversaries [Member]",
        "terseLabel": "Between the Third and Fourth Anniversaries"
       }
      }
     },
     "localname": "BetweenTheThirdAndFourthAnniversariesMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents collaborative agreement contract maximum amount if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of product.",
        "label": "Collaborative Agreement Contract Covenant Maximum Amount of Funding",
        "terseLabel": "Potential aggregate maximum amount of funding"
       }
      }
     },
     "localname": "CollaborativeAgreementContractCovenantMaximumAmountOfFunding",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_CollaborativeAgreementContractValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents collaborative agreement contract value.",
        "label": "Collaborative Agreement Contract Value",
        "terseLabel": "Collaborative agreement contract value"
       }
      }
     },
     "localname": "CollaborativeAgreementContractValue",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_CollaborativeAndOtherResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Collaborative and other research and development.",
        "label": "Collaborative and Other Research and Development [Member]",
        "terseLabel": "Collaborative and other research and development"
       }
      }
     },
     "localname": "CollaborativeAndOtherResearchAndDevelopmentMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.biocryst.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_CollateralForCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.",
        "label": "Collateral for Credit [Member]",
        "terseLabel": "Collateral for Credit"
       }
      }
     },
     "localname": "CollateralForCreditMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_CommonStockPurchaseAgreementWithRPIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on the Common Stock Purchase Agreement with RPI.",
        "label": "Common Stock Purchase Agreement with RPI [Member]",
        "terseLabel": "Common Stock Purchase Agreement with RPI"
       }
      }
     },
     "localname": "CommonStockPurchaseAgreementWithRPIMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ConcentrationOfMarketRiskPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents concentration of market risk policy.",
        "label": "Concentration of Market Risk [Policy Text Block]",
        "terseLabel": "Significant Customers and Other Risks"
       }
      }
     },
     "localname": "ConcentrationOfMarketRiskPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_ContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between the contract date and its expiration.",
        "label": "Contract Term",
        "terseLabel": "Contract term (in years)"
       }
      }
     },
     "localname": "ContractTerm",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the credit agreement.",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_DebtCovenantTermsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant Terms",
        "label": "Debt Covenant Terms [Axis]",
        "terseLabel": "Debt Covenant Terms [Axis]"
       }
      }
     },
     "localname": "DebtCovenantTermsAxis",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bcrx_DebtCovenantTermsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant Terms",
        "label": "Debt Covenant Terms [Domain]",
        "terseLabel": "Debt Covenant Terms [Domain]"
       }
      }
     },
     "localname": "DebtCovenantTermsDomain",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_DebtInstrumentCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The commitment fee percentage of the debt instrument.",
        "label": "Debt Instrument Commitment Fee Percentage",
        "terseLabel": "Debt instrument, commitment fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentCommitmentFeePercentage",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of unrestricted cash and cash equivalents required under the covenant of the debt instrument.",
        "label": "Debt Instrument Covenant Minimum Unrestricted Cash and Cash Equivalents",
        "terseLabel": "Debt instrument, covenant, minimum unrestricted cash and cash equivalents"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_DebtInstrumentExitFeePercentageOfPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of principal for exit fee of the debt instrument.",
        "label": "Debt Instrument Exit Fee Percentage of Principal",
        "terseLabel": "Debt instrument, exit fee, percentage of principal"
       }
      }
     },
     "localname": "DebtInstrumentExitFeePercentageOfPrincipal",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentLiborCap": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum LIBOR interest rate for debt instrument.",
        "label": "Debt Instrument Libor Cap",
        "terseLabel": "Debt instrument, LIBOR cap"
       }
      }
     },
     "localname": "DebtInstrumentLiborCap",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentLiborFloor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum LIBOR interest rate for debt instrument.",
        "label": "Debt Instrument Libor Floor",
        "terseLabel": "Debt instrument, LIBOR floor"
       }
      }
     },
     "localname": "DebtInstrumentLiborFloor",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of interest that would have accrued on principal voluntary paid for prepayment fee of the debt instrument.",
        "label": "Debt Instrument Prepayment Fee Percentage of Accrued Interest",
        "terseLabel": "Debt instrument, prepayment fee, percentage of accrued interest"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageOfAccruedInterest",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of principal paid voluntarily for prepayment fee of the debt instrument.",
        "label": "Debt Instrument Prepayment Fee Percentage of Principal Voluntary Payments",
        "terseLabel": "Debt instrument, prepayment fee, percentage of principal voluntary payments"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt securities maturing after one year through two years.",
        "label": "Maturing after one year through two years",
        "terseLabel": "Maturing after one year through two years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_DescriptionOfCompanyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of company policy.",
        "label": "Description of Company [Policy Text Block]",
        "terseLabel": "The Company"
       }
      }
     },
     "localname": "DescriptionOfCompanyPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized for Remainder of Fiscal Year",
        "terseLabel": "Compensation cost expected to be recognized for remainder of fiscal year"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share-based compensation nonvested awards compensation cost expected to be recognized next year.",
        "label": "Employee Service Share-Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Next Year",
        "terseLabel": "Compensation cost expected to be recognized next year"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Year Four",
        "terseLabel": "Compensation cost expected to be recognized year four"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Year Three",
        "terseLabel": "Compensation cost expected to be recognized year three"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Year Two",
        "terseLabel": "Compensation cost expected to be recognized year two"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan, (ESPP).",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents expected receivable from awards for research and development contracts.",
        "label": "Expected Receivable From Awards For Research and Development Contracts",
        "terseLabel": "Expected receivable from awards for research and development contracts"
       }
      }
     },
     "localname": "ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_FutureRoyaltiesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations for future royalties.",
        "label": "Royalty financing obligations",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Royalty financing obligations"
       }
      }
     },
     "localname": "FutureRoyaltiesPayable",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_FutureRoyaltiesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents future royalties payable.",
        "label": "Future Royalties Payable [Member]",
        "terseLabel": "Future Royalties Payable"
       }
      }
     },
     "localname": "FutureRoyaltiesPayableMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_GreenCrossCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Green Cross Corporation.",
        "label": "Green Cross Corporation [Member]",
        "terseLabel": "Green Cross Corporation"
       }
      }
     },
     "localname": "GreenCrossCorporationMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_IncentivePlanAndInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the incentive and inducement plans.",
        "label": "Incentive Plan and Inducement Plan [Member]",
        "terseLabel": "Incentive Plan and Inducement Plan"
       }
      }
     },
     "localname": "IncentivePlanAndInducementPlanMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Incentive Plan.",
        "label": "Incentive Plan [Member]",
        "terseLabel": "Incentive Plan"
       }
      }
     },
     "localname": "IncentivePlanMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_InducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the Inducement Plan.",
        "label": "Inducement Plan [Member]",
        "terseLabel": "Inducement Plan"
       }
      }
     },
     "localname": "InducementPlanMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_InterestAndOtherIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income (loss) recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income (loss) from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and other income",
        "terseLabel": "Interest and other income"
       }
      }
     },
     "localname": "InterestAndOtherIncomeLoss",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents interest expense and deferred financing costs.",
        "label": "Interest Expense and Deferred Financing Costs [Policy Text Block]",
        "terseLabel": "Interest Expense and Deferred Financing Costs"
       }
      }
     },
     "localname": "InterestExpenseAndDeferredFinancingCostsPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for interest expense and royalty financing obligation.",
        "label": "Interest Expense and Royalty Financing Obligation [Policy Text Block]",
        "terseLabel": "Interest Expense and Royalty Financing Obligations"
       }
      }
     },
     "localname": "InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_InterestReserve": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents interest reserve established as part of the royalty monetization.",
        "label": "Interest Reserve",
        "terseLabel": "Interest reserve"
       }
      }
     },
     "localname": "InterestReserve",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_JPRRoyaltySubLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents JPR Royalty Sub LLC.",
        "label": "JPR Royalty Sub LLC [Member]",
        "terseLabel": "JPR Royalty Sub LLC"
       }
      }
     },
     "localname": "JPRRoyaltySubLLCMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to laboratory equipment, office equipment and software.",
        "label": "Laboratory Equipment, Office Equipment and Software [Member]",
        "terseLabel": "Laboratory Equipment, Office Equipment and Software"
       }
      }
     },
     "localname": "LaboratoryEquipmentOfficeEquipmentAndSoftwareMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the assets and liabilities of the lessee's operating lease.",
        "label": "Lessee, Operating Lease, Assets and Liabilities [Table Text Block]",
        "terseLabel": "Balance Sheets of the Company's Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability To Be Paid After Year Four",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_LongTermInvestmentMaturityMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents long term investment maturity minimum.",
        "label": "Long term Investment Maturity Minimum",
        "terseLabel": "Long-term investment maturity, minimum (in years)"
       }
      }
     },
     "localname": "LongTermInvestmentMaturityMinimum",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_MaturityPeriodOfHighQualityMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents maturity period of high quality marketable securities.",
        "label": "Maturity Period Of High Quality Marketable Securities",
        "terseLabel": "Maturity period of high quality marketable securities (in years)"
       }
      }
     },
     "localname": "MaturityPeriodOfHighQualityMarketableSecurities",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_MaturityPeriodOfShortTermInvestment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity period of short term investment.",
        "label": "Maturity Period Of Short Term Investment",
        "terseLabel": "Maturity period of short term investment (in months)"
       }
      }
     },
     "localname": "MaturityPeriodOfShortTermInvestment",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_MaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.",
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPrice",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_MaximumCustomaryReductionOnRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum percentage of customary reductions allowed on royalty rate.",
        "label": "Maximum Customary Reduction On Royalty Rate",
        "terseLabel": "Maximum customary reduction on royalty rate"
       }
      }
     },
     "localname": "MaximumCustomaryReductionOnRoyaltyRate",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on the maximum number of doses of RAPIVAB permitted under the contract.",
        "label": "Maximum Number Of Products Permitted To Be Obtained Doses",
        "terseLabel": "Maximum number of products, doses"
       }
      }
     },
     "localname": "MaximumNumberOfProductsPermittedToBeObtainedDoses",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bcrx_MidCapFinancialServicesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents MidCap Financial Services, LLC entity.",
        "label": "MidCap Financial Services, LLC [Member]",
        "terseLabel": "MidCap Financial Services, LLC"
       }
      }
     },
     "localname": "MidCapFinancialServicesLLCMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_MilestonePaymentMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents milestone payment maximum.",
        "label": "Milestone Payment Maximum",
        "terseLabel": "Milestone payment maximum"
       }
      }
     },
     "localname": "MilestonePaymentMaximum",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_MilestonePaymentMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents milestone payment minimum.",
        "label": "Milestone Payment Minimum",
        "terseLabel": "Milestone payment minimum"
       }
      }
     },
     "localname": "MilestonePaymentMinimum",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_MilestoneRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Revenue",
        "label": "Milestone Revenue [Member]",
        "terseLabel": "Milestone revenue"
       }
      }
     },
     "localname": "MilestoneRevenueMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.biocryst.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents National Institute of Allergy and Infectious Diseases.",
        "label": "National Institute of Allergy and Infectious Diseases [Member]",
        "terseLabel": "National Institute of Allergy and Infectious Diseases"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non-cash interest expense on royalty financing obligation.",
        "label": "Non-cash Interest expense on Royalty financing obligations",
        "terseLabel": "Non-cash Interest expense on Royalty financing obligations"
       }
      }
     },
     "localname": "NonCashInterestExpenseOnRoyaltyFinancingObligation",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_NonEmployeeDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents non-employee directors of the company.",
        "label": "Non-employee Directors [Member]",
        "terseLabel": "Non-employee Directors"
       }
      }
     },
     "localname": "NonEmployeeDirectorsMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of noncash interest expense and amortization of debt issuance costs.",
        "label": "Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs",
        "terseLabel": "Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs"
       }
      }
     },
     "localname": "NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_NumberOfProductsObtainedDoses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Products Obtained Doses",
        "label": "Number Of Products Obtained Doses",
        "terseLabel": "Number of doses delivered, doses"
       }
      }
     },
     "localname": "NumberOfProductsObtainedDoses",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bcrx_OMERSCapitalMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on the rights of OMERS Capital Markets to receive certain royalty payments under the OMERS Royalty Purchase Agreement.",
        "label": "OMERS Capital Markets [Member]",
        "terseLabel": "OMERS Capital Markets"
       }
      }
     },
     "localname": "OMERSCapitalMarketsMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_OMERSRoyaltyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on OMERS Royalty Agreement.",
        "label": "OMERS Royalty Agreement [Member]",
        "terseLabel": "OMERS Royalty Agreement"
       }
      }
     },
     "localname": "OMERSRoyaltyAgreementMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ORLADEYOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents ORLADEYO.",
        "label": "ORLADEYO [Member]",
        "terseLabel": "ORLADEYO"
       }
      }
     },
     "localname": "ORLADEYOMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RevenueDetails",
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual",
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_OperatingLeaseAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on operating lease right-of-use assets.",
        "label": "Assets:",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "OperatingLeaseAssets",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bcrx_OperatingLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization on lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right of use Asset Accumulated Amortization",
        "terseLabel": "Operating lease, right-of-use asset, accumulated amortization"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_OtherSupplementalInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Supplemental Information Related to Leases",
        "label": "Other Supplemental Information Related to Leases [Table Text Block]",
        "terseLabel": "Other Supplemental Information Related to Leases"
       }
      }
     },
     "localname": "OtherSupplementalInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_PERAMIVIRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Peramivir",
        "label": "PERAMIVIR [Member]",
        "terseLabel": "Peramivir"
       }
      }
     },
     "localname": "PERAMIVIRMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_PercentageOfCommonStockSharesBeginning": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of common stock shares beginning.",
        "label": "Percentage of Common Stock Shares Beginning",
        "terseLabel": "Percentage of common stock shares, beginning"
       }
      }
     },
     "localname": "PercentageOfCommonStockSharesBeginning",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_PercentageOfCommonStockSharesEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of common stock shares ending.",
        "label": "Percentage of Common Stock Shares Ending",
        "terseLabel": "Percentage of common stock shares, ending"
       }
      }
     },
     "localname": "PercentageOfCommonStockSharesEnding",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of salary to purchase common stock maximum.",
        "label": "Percentage of Salary To Purchase Common Stock Maximum",
        "terseLabel": "Percentage of salary to purchase common stock, maximum"
       }
      }
     },
     "localname": "PercentageOfSalaryToPurchaseCommonStockMaximum",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_PerformancebasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents performance-based restricted stock units.",
        "label": "Performance-based Restricted Stock Units [Member]",
        "terseLabel": "Performance-based Restricted Stock Units"
       }
      }
     },
     "localname": "PerformancebasedRestrictedStockUnitsMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_PeriodOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents period of agreement.",
        "label": "Period of Agreement",
        "terseLabel": "Period of agreement (in years)"
       }
      }
     },
     "localname": "PeriodOfAgreement",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_PhaRMANotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents PhaRMA notes.",
        "label": "PhaRMA Notes Member]",
        "terseLabel": "PhaRMA Notes"
       }
      }
     },
     "localname": "PhaRMANotesMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_PikInterestPaymentIsMadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents PIK interest payment is made.",
        "label": "PIK Interest Payment is Made [Member]",
        "terseLabel": "PIK Interest Payment is Made"
       }
      }
     },
     "localname": "PikInterestPaymentIsMadeMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of potential milestone payments receivable if regulatory approval is granted.",
        "label": "Potential Milestone Payments Receivable If Regulatory Approval Before Milestone",
        "terseLabel": "Potential milestone payments receivable if regulatory approval before specified date"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_PriorToTheSecondAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents prior to the second anniversary.",
        "label": "Prior to the Second Anniversary [Member]",
        "terseLabel": "Prior to the Second Anniversary"
       }
      }
     },
     "localname": "PriorToTheSecondAnniversaryMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_PrivatePlacementOfSeniorSecuredNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents private placement of senior secured notes.",
        "label": "Private Placement Of Senior Secured Notes",
        "terseLabel": "Private placement of senior secured notes"
       }
      }
     },
     "localname": "PrivatePlacementOfSeniorSecuredNotes",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents proceeds from awards for research and development contracts.",
        "label": "Proceeds From Awards For Research And Development Contracts",
        "terseLabel": "Proceeds from awards for research and development contracts"
       }
      }
     },
     "localname": "ProceedsFromAwardsForResearchAndDevelopmentContracts",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_RAPIVABMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents RAPIVAB product.",
        "label": "RAPIVAB [Member]",
        "terseLabel": "RAPIVAB"
       }
      }
     },
     "localname": "RAPIVABMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/RevenueDetails",
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_RPI2019IntermediateFinanceTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents RPI 2019 Intermediate Finance Trust (RPI)..",
        "label": "RPI 2019 Intermediate Finance Trust [Member]",
        "terseLabel": "RPI 2019 Intermediate Finance Trust"
       }
      }
     },
     "localname": "RPI2019IntermediateFinanceTrustMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_RPI2021And2020IntermediateFinanceTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents RPI 2021 and 2020 Intermediate Finance Trust (RPI).",
        "label": "RPI 2021 and 2020 Intermediate Finance Trust [Member]",
        "terseLabel": "RPI 2021 and 2020 Intermediate Finance Trust"
       }
      }
     },
     "localname": "RPI2021And2020IntermediateFinanceTrustMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_RenewablePeriodOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents renewable period of agreement.",
        "label": "Renewable Period Of Agreement",
        "terseLabel": "Renewable period of agreement (in years)"
       }
      }
     },
     "localname": "RenewablePeriodOfAgreement",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_RoyaltiesMonetizationsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Monetizations",
        "label": "Royalties Monetizations [Table]",
        "terseLabel": "Royalties Monetizations [Table]"
       }
      }
     },
     "localname": "RoyaltiesMonetizationsTable",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bcrx_RoyaltiesRevenuesPaidAndPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents royalties revenues paid and payable.",
        "label": "Royalty revenues paid and payable",
        "terseLabel": "Royalty revenues paid and payable"
       }
      }
     },
     "localname": "RoyaltiesRevenuesPaidAndPayable",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_RoyaltyExpenseReversalOfExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of royalty expense (reversal of expense) during the period.",
        "label": "Royalty",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyExpenseReversalOfExpense",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_RoyaltyFinancingObligationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for royalty financing obligations.",
        "label": "Royalty Financing Obligations [Table Text Block]",
        "terseLabel": "Schedule of Royalty Financing Obligations"
       }
      }
     },
     "localname": "RoyaltyFinancingObligationsTableTextBlock",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_RoyaltyMonetizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty monetization transaction.",
        "label": "Royalty Monetization [Member]",
        "terseLabel": "Royalty Monetization"
       }
      }
     },
     "localname": "RoyaltyMonetizationMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_RoyaltyMonetizationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty monetization.",
        "label": "Royalty Monetization [Text Block]",
        "terseLabel": "Royalty Monetizations"
       }
      }
     },
     "localname": "RoyaltyMonetizationTextBlock",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_RoyaltyMonetizationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Monetizations",
        "label": "Royalty Monetizations [Line Items]",
        "terseLabel": "Royalty Monetizations [Line Items]"
       }
      }
     },
     "localname": "RoyaltyMonetizationsLineItems",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bcrx_RoyaltyMontizationsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Montizations",
        "label": "Royalty Montizations [Roll Forward]",
        "terseLabel": "Royalty Montizations [Roll Forward]"
       }
      }
     },
     "localname": "RoyaltyMontizationsRollForward",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expiration term of the royalty payments from first commercial date.",
        "label": "Royalty Payments Receivable Expiration Term From First Commercial",
        "terseLabel": "Royalty payments receivable, expiration term from first commercial (in years)"
       }
      }
     },
     "localname": "RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on the maximum dollar amount of net sales allowed for royalty payments.",
        "label": "Royalty Purchase Agreement Royalties Annual Net Sales Payment Threshold",
        "terseLabel": "Royalty purchase agreement, royalties, annual net sales payment threshold"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of net sales in certain markets for royalties to be paid under the royalty purchase agreement.",
        "label": "Royalty Purchase Agreement Royalties Maximum Tiered Profit Share Percentage On Permitted Sales In Other Markets",
        "terseLabel": "Royalty purchase agreement, royalties, maximum tiered profit share percentage on permitted sales in other markets"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of annual net sales for royalties to be paid under the royalty purchase agreement.",
        "label": "Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales",
        "terseLabel": "Royalty purchase agreement, royalties, percentage of annual net sales"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "he percentage of annual net sales of royalties to be paid under the royalty purchase agreement if sales are less than specified.",
        "label": "Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales Based On Reduction In Sales",
        "terseLabel": "Royalty purchase agreement, royalties, percentage of annual net sales, based on reduction in sales"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of net sales in key territories for royalties to be paid under the royalty purchase agreement.",
        "label": "Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales In Key Territories",
        "terseLabel": "Royalty purchase agreement, royalties, percentage of annual net sales in key territories"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of annual net sales in other markets of royalties to be paid under the royalty purchase agreement.",
        "label": "Royalty Purchase Agreement Royalties Percentage Of Annual Net Sales In Other Markets",
        "terseLabel": "Royalty purchase agreement, royalties, percentage of annual net sales in other markets"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of global annual net sales of royalties to be paid under the royalty purchase agreement.",
        "label": "Royalty Purchase Agreement Royalties Percentage of Global Annual Net Sales",
        "terseLabel": "Royalty purchase agreement, royalties, percentage of global annual net sales"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of the purchase price under the royalty purchase agreement.",
        "label": "Royalty Purchase Agreement Royalties Percentage Of Purchase Price",
        "terseLabel": "Royalty purchase agreement, royalties, percentage of purchase price"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of sublicense revenue in other markets of royalties to be paid under the royalty purchase agreement.",
        "label": "Royalty Purchase Agreement Royalties Percentage of Sublicense Revenue In Other Markets",
        "terseLabel": "Royalty purchase agreement, royalties, percentage of sublicense revenue in other markets"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the purchase price under the royalty purchase agreement.",
        "label": "Royalty Purchase Agreement Royalties Purchase Price Amount",
        "terseLabel": "Royalty purchase agreement, royalties, purchase price, amount"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_RoyaltyRateIfMaintainsSakigakeDesignation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.",
        "label": "Royalty Rate If Maintains Sakigake Designation",
        "terseLabel": "Royalty rate if maintains sakigake designation"
       }
      }
     },
     "localname": "RoyaltyRateIfMaintainsSakigakeDesignation",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents royalty receivable.",
        "label": "Royalty Receivable [Member]",
        "terseLabel": "Royalty Receivable"
       }
      }
     },
     "localname": "RoyaltyReceivableMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_RoyaltyReceivablesFromPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to royalty receivables from partners.",
        "label": "Royalty Receivables from Partners [Member]",
        "terseLabel": "Royalty receivables from partners"
       }
      }
     },
     "localname": "RoyaltyReceivablesFromPartnersMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure representing receivables from collaborations.",
        "label": "Schedule of Receivables from Collaborations [Table Text Block]",
        "terseLabel": "Summary of Receivables"
       }
      }
     },
     "localname": "ScheduleOfReceivablesFromCollaborationsTableTextBlock",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_SeniorCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents senior credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Senior Credit Facility [Member]",
        "terseLabel": "Senior Credit Facility"
       }
      }
     },
     "localname": "SeniorCreditFacilityMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Plan Amendment, Awards In Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Plan Amendment, Awards In Shares",
        "terseLabel": "Plan amendment (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPlanAmendmentAwardsInShares",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee Amount",
        "terseLabel": "Maximum number of shares per employee, amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents share based compensation arrangement by share based payment award options grants in period awards available.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Awards Available",
        "negatedLabel": "Awards available, stock option awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bcrx_ShareBasedPaymentArrangementNumberOfPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Number of Plans",
        "label": "Share-Based Payment Arrangement, Number of Plans",
        "terseLabel": "Number of plans"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNumberOfPlans",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "integerItemType"
    },
    "bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options forfeitures in period awards available.",
        "label": "Awards available, stock option awards cancelled (in shares)",
        "terseLabel": "Awards available, stock option awards cancelled (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bcrx_SharesIssuedCommonStockPremium": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on the amount of the common stock premium.",
        "label": "Shares Issued Common Stock Premium",
        "terseLabel": "Shares issued, common stock, premium"
       }
      }
     },
     "localname": "SharesIssuedCommonStockPremium",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual",
      "http://www.biocryst.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_SharesIssuedPricePerShareClosingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on the closing price.",
        "label": "Shares Issued Price Per Share Closing Price",
        "terseLabel": "Shares issued, price per share, closing price (in usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShareClosingPrice",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bcrx_SharesIssuedPricePerSharePremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "information on the premium over the closing price.",
        "label": "Shares Issued Price Per Share Premium",
        "terseLabel": "Shares issued, price per share, premium (in usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerSharePremium",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bcrx_ShionogiCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shionogi &amp; Co. Ltd.",
        "label": "Shionogi &amp; Co. Ltd. [Member]",
        "terseLabel": "Shionogi &amp; Co. Ltd."
       }
      }
     },
     "localname": "ShionogiCoLtdMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies and Concentrations of Risk",
        "label": "Significant Accounting Policies and Concentrations of Risk [Line Items]",
        "terseLabel": "Significant Accounting Policies and Concentration of Risk [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesAndConcentrationsOfRiskLineItems",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bcrx_SignificantAccountingPoliciesAndConcentrationsOfRiskTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies and Concentrations of Risk",
        "label": "Significant Accounting Policies and Concentrations of Risk [Table]",
        "terseLabel": "Significant Accounting Policies and Concentrations of Risk [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesAndConcentrationsOfRiskTable",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bcrx_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "bcrx_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrants Exercised",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_TermALoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term A loan.",
        "label": "Term A Loan [Member]",
        "terseLabel": "Term A Loan"
       }
      }
     },
     "localname": "TermALoanMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermBAndCLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term B And C Loan",
        "label": "Term B And C Loan [Member]",
        "terseLabel": "Term B And C Loan"
       }
      }
     },
     "localname": "TermBAndCLoanMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermBLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term B loan.",
        "label": "Term B Loan [Member]",
        "terseLabel": "Term B Loan"
       }
      }
     },
     "localname": "TermBLoanMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermCLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term C loan.",
        "label": "Term C Loan [Member]",
        "terseLabel": "Term C Loan"
       }
      }
     },
     "localname": "TermCLoanMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermLoanAAndBDrawnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term loan A and B drawn.",
        "label": "Term Loan A and B Drawn [Member]",
        "terseLabel": "Term Loan A and B Drawn"
       }
      }
     },
     "localname": "TermLoanAAndBDrawnMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermLoanADrawnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term loan A drawn.",
        "label": "Term Loan A Drawn [Member]",
        "terseLabel": "Term Loan A Drawn"
       }
      }
     },
     "localname": "TermLoanADrawnMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term loans A, B and C drawn and the Cure Right has been exercised.",
        "label": "Term Loans A, B and C Drawn and Cure Right Exercised [Member]",
        "terseLabel": "Term Loans A, B and C Drawn and Cure Right Exercised"
       }
      }
     },
     "localname": "TermLoansABAndCDrawnAndCureRightExercisedMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermLoansABAndCDrawnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term loans A, B and C drawn.",
        "label": "Term Loans A, B and C Drawn [Member]",
        "terseLabel": "Term Loans A, B and C Drawn"
       }
      }
     },
     "localname": "TermLoansABAndCDrawnMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_The2021RPIRoyaltyPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2021 RPI Royalty Purchase Agreement.",
        "label": "The 2021 RPI Royalty Purchase Agreement [Member]",
        "terseLabel": "The 2021 RPI Royalty Purchase Agreement"
       }
      }
     },
     "localname": "The2021RPIRoyaltyPurchaseAgreementMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ThirtysixEqualMonthlyInstallmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on the vesting period.",
        "label": "Thirty-six Equal Monthly Installments [Member]",
        "terseLabel": "Thirty-six Equal Monthly Installments"
       }
      }
     },
     "localname": "ThirtysixEqualMonthlyInstallmentsMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ToriiPharmaceuticalCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to Torii Pharmaceutical Co., Ltd.",
        "label": "Torii Pharmaceutical Co. [Member]",
        "terseLabel": "Torii Pharmaceutical Co. [Member]"
       }
      }
     },
     "localname": "ToriiPharmaceuticalCoMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TradeReceivablesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for trade receivables.",
        "label": "Trade Receivables [Text Block]",
        "terseLabel": "Trade Receivables"
       }
      }
     },
     "localname": "TradeReceivablesTextBlock",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_TransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents transaction costs associated with royalty monetization.",
        "label": "Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on 2021 RPI Royalty Agreement.",
        "label": "2021 RPI Royalty Agreement [Member]",
        "terseLabel": "2021 RPI Royalty Agreement"
       }
      }
     },
     "localname": "TwentyTwentyOneRPIRoyaltyAgreementMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TwentyTwentyRPIRoyaltyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on 2020 RPI Royalty agreement.",
        "label": "2020 RPI Royalty Agreement [Member]",
        "terseLabel": "2020 RPI Royalty Agreement"
       }
      }
     },
     "localname": "TwentyTwentyRPIRoyaltyAgreementMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_UABMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UAB",
        "label": "UAB [Member]",
        "terseLabel": "UAB"
       }
      }
     },
     "localname": "UABMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_USDepartmentOfHealthAndHumanServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States department of health and human services.",
        "label": "US Department of Health and Human Services [Member]",
        "terseLabel": "U.S. Department of Health and Human Services"
       }
      }
     },
     "localname": "USDepartmentOfHealthAndHumanServicesMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/RevenueDetails",
      "http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_Vest25PercentEachYearUntilFullyVestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents vest 25% each year until fully vested.",
        "label": "Vest 25% Each Year Until Fully Vested [Member]",
        "terseLabel": "Vest 25% Each Year Until Fully Vested"
       }
      }
     },
     "localname": "Vest25PercentEachYearUntilFullyVestedMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents vesting upon successful completion of specific development milestones.",
        "label": "Vest Upon Successful Completion of Specific Development Milestones [Member]",
        "terseLabel": "Vest Upon Successful Completion of Specific Development Milestones"
       }
      }
     },
     "localname": "VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember",
     "nsuri": "http://www.biocryst.com/20220930",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r40",
      "r42",
      "r97",
      "r98",
      "r216",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/RevenueDetails",
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r215",
      "r254",
      "r304",
      "r305",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r460",
      "r504",
      "r506",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails",
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r215",
      "r254",
      "r304",
      "r305",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r460",
      "r504",
      "r506",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r149",
      "r197",
      "r198",
      "r284",
      "r286",
      "r465",
      "r503",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.biocryst.com/role/RevenueDetails",
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual",
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r149",
      "r197",
      "r198",
      "r284",
      "r286",
      "r465",
      "r503",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.biocryst.com/role/RevenueDetails",
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual",
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r215",
      "r254",
      "r295",
      "r304",
      "r305",
      "r339",
      "r340",
      "r341",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r460",
      "r504",
      "r506",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails",
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r215",
      "r254",
      "r295",
      "r304",
      "r305",
      "r339",
      "r340",
      "r341",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r460",
      "r504",
      "r506",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails",
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r41",
      "r42",
      "r97",
      "r98",
      "r216",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/RevenueDetails",
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual",
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r152",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual",
      "http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by billing status of receivables.",
        "label": "Billing Status, Type [Axis]",
        "terseLabel": "Billing Status, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.",
        "label": "Legal Entity of Counterparty, Type [Axis]",
        "terseLabel": "Legal Entity of Counterparty, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31",
      "r429"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r487",
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable, after allowance for credit loss, total"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r153",
      "r154"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r45",
      "r46",
      "r47",
      "r490",
      "r511",
      "r512"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r47",
      "r55",
      "r56",
      "r57",
      "r101",
      "r102",
      "r103",
      "r385",
      "r425",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r429"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r350",
      "r351",
      "r352",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r307",
      "r354",
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvanceRoyaltiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance Royalties [Abstract]"
       }
      }
     },
     "localname": "AdvanceRoyaltiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based payment arrangement, expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r65",
      "r82",
      "r235",
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "negatedTerseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r10",
      "r94",
      "r139",
      "r142",
      "r147",
      "r177",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r382",
      "r386",
      "r396",
      "r427",
      "r429",
      "r468",
      "r488"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r29",
      "r94",
      "r177",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r382",
      "r386",
      "r396",
      "r427",
      "r429"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r163",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r167",
      "r168",
      "r482"
     ],
     "calculation": {
      "http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r160",
      "r164",
      "r184",
      "r472"
     ],
     "calculation": {
      "http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Total investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails",
      "http://www.biocryst.com/role/InvestmentsScheduleofMaturityofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r162",
      "r184"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r334",
      "r335",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BilledRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Billed amounts due for services rendered or products shipped. This element is distinct from Billed contracts receivables because this is based on noncontract transactions.",
        "label": "Billed Revenues [Member]",
        "terseLabel": "Billed"
       }
      }
     },
     "localname": "BilledRevenuesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r7",
      "r84"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r85",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r78",
      "r84",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r397"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r376",
      "r377",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative and Other Relationships"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationships"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r429"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding \u2013 186,411 as of September\u00a030, 2022 and 184,350 as of December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r50",
      "r52",
      "r53",
      "r63",
      "r477",
      "r498"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r296",
      "r303",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r67",
      "r465"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Product Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r229",
      "r236",
      "r237",
      "r239",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r93",
      "r99",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r245",
      "r246",
      "r247",
      "r248",
      "r409",
      "r469",
      "r470",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r13",
      "r240",
      "r470",
      "r486"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-term debt, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r212",
      "r245",
      "r246",
      "r407",
      "r409",
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r36",
      "r243",
      "r407",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r36",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r37",
      "r93",
      "r99",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r245",
      "r246",
      "r247",
      "r248",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r37",
      "r93",
      "r99",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r238",
      "r245",
      "r246",
      "r247",
      "r248",
      "r269",
      "r270",
      "r271",
      "r272",
      "r406",
      "r407",
      "r409",
      "r410",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r225",
      "r241",
      "r245",
      "r246",
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Debt instrument, unamortized discount (premium) and debt issuance costs, net, total"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Fair Value of the Company's Investments by Type"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r225",
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs, net, total"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r82",
      "r137"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r309",
      "r310",
      "r344",
      "r345",
      "r347",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r64",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r114",
      "r116",
      "r118",
      "r119",
      "r120",
      "r123",
      "r124",
      "r393",
      "r394",
      "r478",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r64",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r116",
      "r118",
      "r119",
      "r120",
      "r123",
      "r124",
      "r393",
      "r394",
      "r478",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation expense related to non-vested stock options and RSU awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r55",
      "r56",
      "r57",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r126",
      "r178",
      "r268",
      "r273",
      "r350",
      "r351",
      "r352",
      "r369",
      "r370",
      "r392",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r425",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r227",
      "r245",
      "r246",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r395",
      "r433",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r227",
      "r245",
      "r246",
      "r296",
      "r297",
      "r302",
      "r303",
      "r395",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r227",
      "r245",
      "r246",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r433",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r173",
      "r174",
      "r175",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r185",
      "r186",
      "r187",
      "r188",
      "r238",
      "r266",
      "r390",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r388",
      "r389"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "terseLabel": "Foreign currency losses, net"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r82",
      "r249",
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (loss) on extinguishment of debt, total"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentContractReceivable": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of receivables that are derived from government contracts.",
        "label": "Government Contract Receivable",
        "terseLabel": "Government contract receivable"
       }
      }
     },
     "localname": "GovernmentContractReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesTextBlock": {
     "auth_ref": [
      "r169",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity [Table Text Block]",
        "terseLabel": "Schedule of the Maturity of Investments"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r60",
      "r139",
      "r141",
      "r143",
      "r146",
      "r148",
      "r466",
      "r474",
      "r480",
      "r501"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r112",
      "r113",
      "r138",
      "r364",
      "r371",
      "r372",
      "r502"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r54",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r81",
      "r462"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "verboseLabel": "Interest payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedTerseLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r59",
      "r136",
      "r405",
      "r408",
      "r479"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r69",
      "r233",
      "r244",
      "r247",
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, debt, total"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r473",
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.biocryst.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.biocryst.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r28",
      "r429"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.biocryst.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r6",
      "r26",
      "r88",
      "r125",
      "r189",
      "r190",
      "r192",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.biocryst.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r28",
      "r191"
     ],
     "calculation": {
      "http://www.biocryst.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.biocryst.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r176",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments and other noncurrent assets.",
        "label": "Investments and Other Noncurrent Assets [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsAndOtherNoncurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Aggregate Lease Expense Under Operating Leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of the other party participating in a financial transaction.",
        "label": "Legal Entity Type of Counterparty [Domain]",
        "terseLabel": "Legal Entity Type of Counterparty [Domain]"
       }
      }
     },
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "verboseLabel": "2022 (remaining)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, operating lease, term of contract (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Lease Obligations"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r94",
      "r177",
      "r396",
      "r429",
      "r471",
      "r492"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r35",
      "r94",
      "r177",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r383",
      "r386",
      "r387",
      "r396",
      "r427",
      "r428",
      "r429"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r32",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r32",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r13",
      "r226",
      "r242",
      "r245",
      "r246",
      "r470",
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt, total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Secured term loan"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r37",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails",
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r48",
      "r51",
      "r57",
      "r61",
      "r83",
      "r94",
      "r104",
      "r106",
      "r107",
      "r108",
      "r109",
      "r112",
      "r113",
      "r117",
      "r139",
      "r141",
      "r143",
      "r146",
      "r148",
      "r177",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r394",
      "r396",
      "r475",
      "r496"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "terseLabel": "Notes payable, fair value disclosure"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r139",
      "r141",
      "r143",
      "r146",
      "r148"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails",
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease financing obligation"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease financing obligation"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease, liability, statement of financial position [extensible enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r414",
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Other assets [extensible enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsBalanceSheetsoftheCompanysOperatingLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r420",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual",
      "http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r419",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/LeaseObligationsDetailsTextual",
      "http://www.biocryst.com/role/LeaseObligationsOtherSupplementalInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r380",
      "r381",
      "r384"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r49",
      "r52",
      "r55",
      "r56",
      "r58",
      "r62",
      "r268",
      "r398",
      "r403",
      "r404",
      "r476",
      "r497"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r43",
      "r45"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on available for sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Paid-in-kind interest"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsScheduleofRoyaltyFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r70",
      "r72",
      "r161"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r73",
      "r373",
      "r374",
      "r375"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Acquisitions of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r334",
      "r335",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails",
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r334",
      "r335",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails",
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14",
      "r429"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds from collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt, total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from issuance of secured debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r75",
      "r93"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Net proceeds from secured term loans"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r70",
      "r71",
      "r161"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r74",
      "r349"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Net proceeds from common stock issued under stock-based compensation plans"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.biocryst.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r194",
      "r429",
      "r483",
      "r494"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r194",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesBillingStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from customers (or dealers) within the next year (or operating cycle, if longer) for goods or services that have been delivered or used, but not yet paid.",
        "label": "Receivables Billing Status [Domain]",
        "terseLabel": "Receivables Billing Status [Domain]"
       }
      }
     },
     "localname": "ReceivablesBillingStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r429",
      "r493",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "verboseLabel": "Total receivables"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r157",
      "r158",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Trade Receivables"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": {
     "auth_ref": [
      "r47",
      "r55",
      "r56",
      "r398",
      "r402",
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax",
        "terseLabel": "Reclassification from accumulated other comprehensive income, current period, before tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r76",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "terseLabel": "Repayments of lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Collaborative and Other Relationships [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r359",
      "r464",
      "r520"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r84",
      "r86"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r273",
      "r429",
      "r491",
      "r510",
      "r512"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r178",
      "r350",
      "r351",
      "r352",
      "r369",
      "r370",
      "r392",
      "r507",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r134",
      "r135",
      "r140",
      "r144",
      "r145",
      "r149",
      "r150",
      "r151",
      "r283",
      "r284",
      "r465"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails",
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.biocryst.com/role/RevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenue"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.biocryst.com/role/RevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Trade Receivables [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual",
      "http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r6",
      "r25",
      "r26",
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "verboseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r323",
      "r330",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Stock Plan Activities"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r306",
      "r308",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r334",
      "r335",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails",
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebt": {
     "auth_ref": [
      "r13",
      "r470",
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.",
        "label": "Secured Debt",
        "terseLabel": "Secured debt, total"
       }
      }
     },
     "localname": "SecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/RoyaltyMonetizationsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]",
        "terseLabel": "Awards Available"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Awards available, restricted stock awards cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "negatedLabel": "Awards available, restricted stock awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected Dividend Yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails",
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum number of shares per employee (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Performance-based restricted stock unit awards issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares of common stock authorized to be purchased (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Awards available, ending balance (in shares)",
        "periodStartLabel": "Awards available, beginning balance (in shares)",
        "terseLabel": "Number of common stock shares available for purchase (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual",
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Options outstanding, stock option awards cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price of stock option awards cancelled (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options outstanding, stock option awards granted ( in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Performance-based stock options issued in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value stock option awards (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, ending balance (in usd per share)",
        "periodStartLabel": "Weighted average exercise price, beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r334",
      "r335",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price of stock option awards exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price of stock option awards granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r313",
      "r336",
      "r337",
      "r338",
      "r339",
      "r342",
      "r353",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected Life in Years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationWeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Stock option awards remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share (in usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r87",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies and Concentrations of Risk"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRisk"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r55",
      "r56",
      "r57",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r126",
      "r178",
      "r268",
      "r273",
      "r350",
      "r351",
      "r352",
      "r369",
      "r370",
      "r392",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r425",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r126",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r14",
      "r15",
      "r268",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Employee stock purchase plan sales, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical",
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r268",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued during period, shares, new issues (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r268",
      "r273",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options outstanding, stock option awards exercised (in shares)",
        "terseLabel": "Exercise of stock options, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical",
      "http://www.biocryst.com/role/StockbasedCompensationStockPlanActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r14",
      "r15",
      "r268",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Employee stock purchase plan sales, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r268",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r94",
      "r156",
      "r177",
      "r396",
      "r429"
     ],
     "calculation": {
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets",
      "http://www.biocryst.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r253",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r273",
      "r274",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Equity Disclosure [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Equity Disclosure [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Trade Accounts Receivable"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r173",
      "r174",
      "r175",
      "r238",
      "r266",
      "r390",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/CollaborativeandOtherRelationshipsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r96",
      "r296",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Obligations of U.S. Government and its agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/InvestmentsFairValueoftheCompanysInvestmentsbyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnbilledRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or products shipped. This element is distinct from unbilled contracts receivables because this is based on noncontract transactions.",
        "label": "Unbilled Revenues [Member]",
        "terseLabel": "Unbilled"
       }
      }
     },
     "localname": "UnbilledRevenuesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/TradeReceivablesSummaryofReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/SignificantAccountingPoliciesandConcentrationsofRiskPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r334",
      "r335",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r334",
      "r335",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/StockbasedCompensationDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r115",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r114",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269825-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55295-109406"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r521": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r522": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r523": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r524": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r525": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r526": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r527": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r528": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r529": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r530": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r531": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r532": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r533": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001628280-22-028463-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-028463-xbrl.zip
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MKZTP&+0$HB4/SA*II VA_H9V>0!>B TVBCHJ.-><21&BL$)' /2, TO&>K4
M&UP+T^:",(XF%G,<H:,U("F/5(!WX'U:Q)AH+2P&" $F82"=C!<$P 6B)*?2
M*8\.@EO$6%8MY%10+63DS#'ND&\:"/&02*2>!L>YK7)'R/+ECI"?R1VYT0,T
M#YL)"#22)(1@3C(FK(R44H=2J,?9,TM"F!O9,S^1BW0SZJ78)C3$P08FO%6
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M:"ZL$8XXKXT3E&K+]:<:O]/:F,M,QE7707^_R.4-LOQ,(5428Y#6>VNU""*
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ME&B]ZME P1*EH@1JG+!"& MYKP#TZ-"J$KN2HXH+6>.RM")32]J*(".QCJ>
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MO3]\=&;P<<^2(UXPF:Q005LCA?6),"-9M!'J#M\<->E"\#.*)FDM=3$IX4!
M9$)XJXE#@^@FZ=NUQ6]1FG0A4 HGN1*!!IJ=&NU<KB8=(Y?:*U#RB_K@2PSE
MGW$P+'HGUY#,OS#Y.I99G^Z /SV*4+[%!W5>C#J=RWQX=C,WFQ^A#)^'B*<_
MWV#3WOD0KYG5$W]%)YP[#)\$QLAY*$\%Z7@TSFN;.',^#W,@7ZE #R_S-7]8
MOF+.W^;KVW.,FT?>Q\$@C3H81Y]W8B8-QMCGT>,C_7;\$#O]\VK6J>C@)?W>
M=W,9Y\6IGY46E-74+[NY.MC!*90/G:-)1375>1\.CT^=22%_H1CZ.LHRZIR
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M.&R$9(+*;WJ=Z?RD6LAB=Q@;9R#_:\; +&SNQ?5;M?A69_1.OJ!L^VJA9\)
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MZWK!"_XL'7_>+[(()A(CCDE$E$RY-=$B$%7X YNHL3?1J#Q KBW$.K4TE;K
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M("Y4 B?* T6)*HBD):4"*(IH&WEKM"HQD?55YA7'1(HRKTB9Y\D'< QP.&Q
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MOPJ@3=W^69YD5$H-KHUZ*I\ M"@-T8'WF0QQW 0G#$_2:J5*J<&ZP51GL=1
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M$8]@UQ+"3)I@K3&2RSQEN$U(4>!'JL!+K^4O"KQ"!5Z<X!<=5A(<=**, "^
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MWN$7%P>'I_UX/WCT^W-X\/M;LO=^/S0- -] MG?Y[OR81LH@I0U02GA 6:#
M."B I=1H+!6/UFP:UBY_I*CQ#Q$7[D#U08 J,YIK*#R7FC*%XN_$.N^(U=Q1
MHCM0W0A0O5P"58VQ-EX2$*34@%*!@ D$ >FQIT90Z0E+H J5W*%JJYN6=<#:
M >OFO/4-@#5@P5G E% N*7)!,ZA=$ @'FPK1_&V M</.FV G6L+.%,#4ACL
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MV"29^1 "[]^D/^SV^K.[L,-6D.D^K;&N?=WV"*+GJ\9;H )C%AS DK+DGPG
M4)B&O5*K+88:>O3HB=CAY-:#FCM0Z+"[(U-'IBTETWT:;YV(W281NV+K06*0
M\<0#0KD#J<T$,#SH*'&5U$$I3#W?/!'[8Q7N?K%'[+_F(]\C\(8M8F]?%[)Q
M>_+US15N]O*; NZW;KI%%5/,>&B5U90Z:5Q E&F)#;9$:%CU5O@ZAUS74N$;
MH?"+U4"T()Z2@ )P$JG4)!8!J8D$R& HO2-!&IV;Q,JM;A*[3:5W':QVL-K
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M=''H$F-:B3&R2XS9@+5TB3%?E1CSQ427U<08)S6QSFA'''682B>0PDY3)X)
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MR,A<\]&VNS\T5.2O.!C$6#*M&S,;S.R/Q\$[)KCG2%.?$&?2(N-D0B0?P#X
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MRAHQ$#?94G?(EF)-MM0*]*7)EKI5MM0WLY_FSG0/ZKL!M=P%F[CQ8-]8YT2
M7V@C**4W5;G^IB[P8\[)KQXH'P!-0AP4P/ZE1%?U.U<YM81SAG]=C#'+5EN^
MS!Y?F^=8*73> 0.ELII3C&,XKX.P_MA^L[/]'P#F MA[K[=?[^2?UBY:<')<
M%B?1L-]V%Q4O_20K(H<>?*C.E(IYO96#74'PLA>Z725@G-C^F?57UYZZ513!
M-0\/+MP@_I\+:!C6)]?D&4R.[YH!VX]UM5_&7ZN+8\+9W04T[I>(_L%%O\XS
MJ/GQ-UL?<KA>MW0;SN4/<(17I^L'&-EYZQP4BQ-;HG9[_0_PE3KEN6(I@*FH
M-\8HMP;Z<PY/C*N67S.>L?;2[HY+3/1A2^602'A/.=Z'O;%@UL&)XUDOSK_I
MF+CLQB]E,0=QDMQP74B'R]''T/IF'>-6M)>:.WR4D3.)=LYQ<N5L7KO-.INZ
M-+5A2X+=E.)WK8HW9HPJ;I-J>X];Z.5M%#_[>)Z#5UI_VCR\*E+XH-=OMS>O
MG?C"9E^*RI2JJ54!^<T2/EC%3WH D?Q18>"O%G]4;SX7*QGU>>U68C8YJU,3
M8]T BE7,>JV:YN"HT#O+N[&P=X'./4YZFH_*+6D!\/<TH->B#/IP*:23@>AJ
M<U'SK61K#.]50.<D+LO.9!V5Z/^;RR?,KO+$A+@Q<KDV50 H,@WX% ZEBRH(
M+0]L>E#MV3 N^'>[Q#/7GKYUVQVSIDK> >TZ6:PVZT:H7B:B-K.JX N ]9/"
MMCT*A*L2+<]LE3M7\X:/'*4UB,=I:VUBEWW=&JM7>>U$[^5%/^^^ZP$I]"\^
MS&S%J0,EF\KC</-<P<>V.NVS<DY71V(5&=T/* /950OV< !8?-9Z7<68CZ6J
M_J#R&%YT;9WT6[==)+9F/A]L5K'6U5DV)7)?/\]&IV>%E^>=.(REU:^,[M;+
MN#*^F^)QJF[!#LJL_UUF?==V+Q*,JPI3+2S6TPK"C+MSW;;N]:?&2)DLKIZL
MU-7CSTK?.$\@CK2L>%$52((O]:L*22/UICTX@:U<]LA(:3N;F<P<C5%_X',T
M<+!5ZO/LENJ&FN/_1ATW=VI&:\M.\O.<%3#__NNUX9W8L5?ER@A:Z5]4D%8_
M.C7\UG6O@9D;C^%F!;'.'I\&P'*Y>][NU!-QG=A=,SFC<.-*91D=;-])Q[0R
MHE=3CV8)7#<1>IX]GY/X\?J"?^Z>?:+K9U;3_D6=[I73@L;A2)UB?F5OYCPO
M@9^&F.)YA7D:)\1_KLNK3@H*W88.==Q^B,4S."BZ-MA#Q9-;SN0S>]KKSW5]
M5/[I!D&J7S2 [UZ5!FM]84*C,#$,Z^IVI<<E;VS4D]G^N0Q+V9<Z4D0&0SC?
M*FCY< $-Y"6I-=/QK)<WS8UIY"K-$P?;"F1T?,%9UNS,#NNPO6IALH93BJT-
M;(J -E7&*2QT*/$7![U6I@\XRU9#G9K5RYFGK7!17E'#0&MPTDZ%RW66L& P
MZS$>O2S'@F3E-\':]:KYFNRD496U479%W>.K,=Q]+I0".?.+SM5<6SNEZKH[
MB,JMGK6;^IA>O&,H*M68,3DO17FPUXUC%7=DD]=)F'91O'R%1EG*GK7>+KQC
M0I@\$='A]?Z47C=;M[DB2RN_)"]>EM+^],F7-W6A0ZYO#8HF>$-[X\'4^WOL
MC)DKM]AZ'-?,6NZJ FNUU%QWZ"[LLBEK<T2M,]Y8!0-S,N*K\01N3A7Y&19_
M1;N4@BLL)+FTT=3N6KP.NO'ZY\<?W=??XSYPH"KT>WM,2_!WO]?MY2K>!0^;
M@-41!<>+8RFC#8Y&%*1,B*<HD8Z$(!>3$H%S+;B;OX$@7@G),+6!1JX3-<1[
MX:A/CD@70IB/*G@3?>48W@Y@]<-.GBQ,:W9E%B\VOW>;KPIP7'\7\[UW.-^<
M^:TJ_G%"E0_X43+1)S-^/C/CH&Y4:^)FN1, B;[^O3H[L?[:R[&R-[6V;W.F
M9JGO]D</_II.V+Q-7%R)AR]'3;]RIE4.)%^Y"V[J5X"]!W96E8!>>%')38"]
MW>U>%':$K#AE;?)E=GH0C/[?L5NJ)*M7'1SQOM8A_&1S3'8Q1],T5CPSX.=@
MW&LV[L)OQ@X57ZS%2:[!8/J3>A*^Z?!Z>E?^_.8K_]S=(CW?O,+E>*.)$UCM
M*_8G$2?P ^_A;Z AR#@ZYB!>#?VQ]<#=^>JQ7O-G/TX7;AK_PRK0-6E0E8)8
M7;F\;P]/1L&)*Z(XX]WGM>)\NLWVWK\31V>'>&\G=/9RN8R=HY.]+Q\N]W;^
MA7=^$+L[_[9W3_]<4)QW=SPY.NB<'9W^@_?H.Y:5X[VS%VQ_9QOG-O=W/E[N
MO7]]M0N*\_[.ZV/)B23":Q0LX8A[K)!3DJ 8L*4N8.V$G5>:'97$:$>$UH1[
M$@P15'EG?+38&$L6E>8R_5_7B*]5$K_YIH<VO7;: _OA0R8CJB*YZZ$4Z'ZZ
MVV;W.%?T#LISA+V#;1-]0L:SA+S FN5*WY8NV$YK8.+,W@75WN1R=]'K=*I2
M8:-K]-8OQ?W;NX#WA<&OO]WAOF%8#OZQIIJ=8:@X6,X'\;?1/W[/T3X=>_5;
MNUOZ6;[T>]U8K=YF[>Q3[)>[IUIU+1-9?3Q1W)[A2GD;]N%/&+VY_OA9^>@_
MP[#X&>?/F. W?HR?D1L_^UJSA#ZCC'U7LU__C&.Y2IW]N>9 W*K9_Y0]5NTS
MV,I9)DK:T]@""3G6Y#?<(D441NV-'S4+C]+SS_GAWQ?LL_FM7^WZQU<K<84<
M.65^MW(#O%AT XSAX6<9\%YV>]QRO/?=%)-':[0L8'H^;)7KO58>[._K-7M9
MW[AQ2]QEN$]KSLA2YFQMAMMLD?MND6\@C[/^8[[>ZP94=]'[&%/ZVK [,2UH
M78\TZ 6EM0SZ[^E""YN9"O"WV^R;FX:^G WUK8F]3QL/V\.?;OQWEH%4_F]>
M!EKE;[SBPC"*4)B7@+L,%K?60>S_U[V&.#VTD@>P4F.[ P<$)HY$*IPCTO(H
MB6.*RB"%TEYQ)NF=Z3F_X2Q\7:)+8!ZWJ^(O88'49$5)R[[73W1R>/:Y WVC
MNP<?KH[.X+VGN^)HYQ]V^.60[WUYT]FC+_CNJ]TO1^]?=@[IF]/1=^!=%T?T
MG3P\./R\O_/GV2&%-K]T/L([3_=./["]5^\8]/7R\ NT^?[?TZ-7>VGW"G_^
MZ^#%</<M%KM?#B^/G8XNF""0C<$C+EQ".C&/J,$J<,V4X'1C2XI-9L0"?41U
MOWD?.1GAWAWDY4Z(/O?*^5.A0:V?%;6T"))E1[35/,EH38A":NL]#XEP>F>"
MS@:U?BQJ?9E!K1 5T\1;A*GEB#MCD!-"(A*,T(1A!D=5KDB\J<@BZ<T/1:T&
M<7Y2Q.&"A&"Y9S8SAOID V-$:FZX\\:;<&>*Z@9Q?BSBX%G$23IKOPDEE^]Q
MB1)(,V.145I(+P1S7&]L$64VN5FD#VX4I0:V5A.VK(U$&.DPTXICX36%OYQB
M!@-^!:;OS%+=P-:/A2TZ UN&)&*E%D@Z(Q"//" C"< 6,<D$9624;F-+R4U,
MV0JAUI+<RNOA4JMSV&_T*=.[C?M:^%UOC H.6V:4RJ'LDH/F[QRWH/D;0HT0
MKG%!K1-&[3V?<T&9X(7B2B%"I$7<:XS 6O?(4$XU$5'$XH+:-.+>$/45F'@H
MQ>JV]Q)/7LH53=$HCUVVWFU,5C(PJ8QSR7,=G6Y<-FLFY7,N&VZ3,1(C:7,1
M(*<2TIABE)@(5H=H9+(;6W23,[RB4O[D)310)S#F"EM+.,?&Z$0=)4KB*+5A
MJ7%QK)F$SKHX/-8F8&I1DIPC+EE V5^.A$H"8%A*&3#8"IO4K*J$-N?P$J1<
M!V)%(#QIASE(NX9]87$,0F% ;<T:C\":2?FL1R QI9+7'$5F/>(J*F2%L,@D
M8KQC2:7 LI03>>_[WB5*^9.*L?E[Q#S^72Z!VWIDUQJD*+9&20VJ(W,\>*4)
MT20)2C78!R[PQB6P5B#U=LXEP#7'T>N$G%(.\6@(RB5ED996"Q>4Y2)F8T'?
M'Z16[ZZED?*1E!L1L?&6"),B#TS8P'V27A%"K TV/KY+X)J"6HV WTK 9[T!
MH$[ZR%E$40BP-1*SR#)BD O8&>XX8RY.I4ZOI(@_>?&4#!3'[,F)D7%-X?^%
MRA7<O0V>)^H;?\":R>BL/R Z$4##<D@X3Q$/.")'N4 VF*0M#3AHWAS"/[V4
M"X8)85X2CS$725BEHDO&&$U#/H\;?\":23F=\\L;$XP@"#NO$==!(YU41)QJ
MC;$A&/2MXO43?(6D_"GDG1WTAK8SIO"<9)_=)U#@=HF(/Q^(8>HS50F1$1-N
MB#$^4MCJPGAF/1B5C;]@K4"L/>\OX!PKQQRB1A6ZE("<=1*EQ)E6T2<=<IB3
MV*1D63$$MT[I79=;C2<+#2Q8:KQWH-;RS*L9HY-P^*60< [K;>(.U@P:OLQ!
M0W"&1H- S\&($RV0X9+F^PY8^4@8=71CBYE-PN^=*O+HT-"(]<W!"DP[&B,A
M4G">#+9*1A.TDX&QQ(QKG!-K)M:SS@DG"!.<8B2EL(AC!V:+)!R1)*+RA$8N
MS,86T693<K5V<MT<^0^*#4EKD63262_DD3$X"Y@(00DG,>P;WK@TU@P;9ET:
M7G@NG6)(.+ !."$,&<TULL):QW2R0;.-+8,W.;]WJM:C0,.2HA]6VMOQIG=5
MZI#T1V2FWQ_Z\%1AS3CJX! D%C/-0?G1EAC+&9B_UH'A*Q['R=$@U^V1:YZ-
M0SML%$T*V> <XLEQY*S6*,C@HXA:*05:C<3W#L"\DZ2LT57,4Q5]++T5B>/D
MN>/6&BT9IU(GGZB@PN+'<6(THG\7T9_U4U!02X14."=I<L09D\A%H9$/WBDO
MN?4A^RGHLI++5\-)\<3%-@J2<I8U,X%P1:/5UA@.I[:)))#0D$:LFTS/.BE$
ME%2!O8&8H!1Q:C%R"L./V.24ULBE41M;9)/K>[LHF@-]#9#AE[L$5QFODC8:
M=$#%C70:!RUD4E93*[BXC8\BUX."?S5'^Z/#P*P_0O,8<@$V9(*E6:MW2&M"
MD%>Y\$8(UCN\L<6O\5/^NEKR_Q2B+G;;G0B"T(WW\D0\B4PQ%1CCGDH5I.2!
M4LN<4M)8;PSC@MC'#ZIHPK._"['VYRD9<K2]IM(B@[%!W$N-K'$142/A-U2*
M:,/2PK.;9-#5%7%07K447EFE):?::1^5R>&?#"P7;D.3@;$^(C['QZ!I$!&+
M?#\B$;?<(9,]#XQ)S*-6R4FQZB+^Y,73A*"QE)J8[/&W43MJ+'%P &NL'=>/
M[S]HQ/-[Q7..C,%)RW32B'IC$3?!(,=!6C6 L>3> 12351?/Y@1>AHAS)C"G
M2D@?>.!81ZY<2O ;EN,78A.KL&9R/N<;2"(93"P2*>08Q1B1MHX@'R*EWF'.
M6-K8(F(3W__2;_7X&%;:$_ \5XITI7[SI]BRW=#J#4]BO]6/@VC[_J3\*H T
M=7KGN:#\N'3E]Y4'^O8,K1Z.7;\!E^HC;J;L(:=LZ6T\*>;6=\_>/FOMQ'/;
M'Q8 Z*76?Z/M#"MH^.\%O*#U-O8_M7T<-&[$FS0<AG'22BJB.>$1,RN#H4["
MR GC@CX2O6NCQ-R>9?I@.RLPQ66X?P"CV#Y.GL<@C4:,1H(XYP1IDBR2C"A0
M6R.5*8=CWSN%M+%45E>.N>5,,Q&<P)%C:W6P4<<@*(DL8.:;1*JU$_*K&2''
MWGI.8D(8_HLXBQP9F21B)'KNA#5$E' &P9:52=4X#)<LH\XK+W@ ;):$!TM=
M8B;G06L3@K/LD0*.&C&\DQB.&--K,52)!FVH0%8QC[AW%L%/()7.&95D3(;X
M?-;J%17"YK!=QF'K+244"VJ4Y<%'+1FU ,.*<.Z8-(U;<.VDO#TCY9Y008QV
M" <A0<IC0#8)AIC'R1+LB:-D8TML8K*L],;&+W@77A;_O=[!)K/I.YCFE$_*
M)4I#=-PF..$<-V!H&)ZDU4HU+H*5 [07\RX"T"^-BY(@EHK:(B@R3+)L3&@9
M: PND66X")I(Z)]+]A73%.R3%#%FG$MJ+28DLY@[:<!VL8U;8>V 8=:M(+7A
M1G&++.$ #!0[9'2*R !&<"JL3\XLR:W0Y#ZMCES+D*LX,QZQI%P9ZR2'4]UK
M8[$5(O+&%;&"HCOGBB NVBAH0#QQBC@CF5<I)D#&D+Q0WE!CEN**: [UGTOX
ML[]1*$>=5X9K)4W 2K#@#!92F! :]\7:(<.L^P)6D5$6),)$$SC4&4/.NX",
MP3IP'JSG:4GNBR;UZ<[RJ[[BV+C)3W%+"IQJ!+\QF.?0NW"=6*W!/8!NY>;I
M]J7#ESDUJX+]U\_)7;!?$D<X8XI1D<L%&*ZBM=S90),V7C9<O.N%_:\7@D$H
M2?D6 L%AKA"7A" +%AV27"FJ0>G7JF+CU701_$>RM3JQ>8\AW3_X7JW!]@;;
MEX+M+G#M2*(Q)R2I:+05A$7"K8<)].F1>(@:;%\BML\ZZ\!:\UB"(F]CS.4C
M-4:64H'R10R.*9"4RT5PO&G,HB>_P?8[8GN#RPTN+P67>:*Y_@45R8)F)IRS
MR6.:0@!A%EP]DK.UP>7EX?*<)Q8P63.J# H"4\2)4LC P8NB2XX0%;!C;&.+
M&+))]2*%7 /,C=+=@/M*S<D=P!T@W>JDI4C:Y\![%P#4&1%.>BZI:^C,UP_<
MVW/9-3[$B!4*UK-<+54CXQ5'5+@0,*.4N@SN!&]BTH#[$AS]_QE:>!W\'=J?
MMD83NG<!>[_MJY^S +:[%[::87BLVMB6>Q ^XX44F(,1;+5FWA I0/@HU?B8
MLXU1L_E+]4R<V?Z'=K<:$BZ'Q"-##LV+M=<;QA9[X.U26ORM/82Y][?H4^L'
M[5Y:[=Z:7N,QNG#3^&<VWQ*T^EFH?]W]% <E>W6PW0W[.81UK]?U%_T^_"KC
M^W!P ._[H]/S'W\T>%_5X'WV+[09SG:_O(3V#P$\WYP>O=_E\!S9??7OZ?[.
M1VCO-3\ZW;X"(.[$_[ZY.GH?SAWE\NC]"[Y'#[_L OCOG?YQ"N^'?GR /KV[
MS&WL'W1.=T]/SG9W_DQ[IQ_)L>"$N"0X @7; _22A*S*/U(><=!!6,^KXQC0
M((;M? !B(7R0UCCM  ^,L(DEFG0"-/!.8S@$(YR'Y[ *P_Y%W-B:6H-%K*F1
MLR#&'.Y4R_'MM\WV3G!0#H36A$K%E><ZI$1-<-20F(1B8]7CH;;<3G3#MQ&V
M6'O8CH/M3[;=R6C[LM=_"TK"0?[W$]YR]%B#W1:EM8B$)!!71",=)48J:1Z<
M"!A[.K^%OG*85.=?NQM@?_U&U2.<+M>#Z<%)!!VQT^E=PA'=*@?LH#6X.(/N
M0BNM8?[8MONM3[9S$7,J??[-\]X9=/6J +'Z?=!J3T2EY:Y:PZOS^*R56X;?
M@J8YC&&JD<%-K122*FC+@S8[TZ3MQY;OV,&@G=KPA!VT_LH1_"T*3\WW\*0=
M^SG0_RH_%F*" ><V6X44X-7V]M^E8X-8'B_R6K7O+&C,+9#>GH.9_)3GH17:
M_>B')64 %JKZH=T]OQ@.-EOG_7:>HLY5Z_]<]/( X1>^&MN@#>MD^YLM=S%L
M=7OPG;S(6;79A*\/8&M4PX)>95WP4VQ!2Q\!TEN]_EQKH+U/OIT_KMN>;V?4
MP/#$#LMP\FNKQD?CG5Z _$3/#6V9G 3V1!Y?/(]E-Y9WY\TPJ#D26I<G;7_2
MNABV.WE+3.8^S\2S62S\JO94=M=8S:STQ9*P<3Z(OXW^\7MH#\X[]NJW=K?L
MUO*EW^O&:MU3G"^HBT6<JH]_OVR'X4E6=9_ARFBK(T3J-]<?/RL?S2F_U6<,
M/Q-2WO@Q?D9N_.QKS1+Z#.N;O_JU9K_^&<=-9YO./EQG;]?L-X*QOAV8J1:>
MO<9-Y@&B8G^EG$)OX_DPGKG8;S&\V<H*UHQI?=]YF7)FWM;&7O$)VS[K06>^
MQ/ _KO^?K>>]P<W5T^\R^*<T@]Z#AEG-W^O<N]C,X5WG\%6_-QB4&7S7[4?;
M&6_(5Z 8W9P0VLSFW6;SKU[V1S?3>;?I?#&RG,H<OLS*^[]9>;_+R;)FX<_7
M^ZKW'?2A-M3 N*KLN![TL%ORMXMQEFW$#['KV]\='[UF%W;73]7W7MBMRY7<
MO?-;;%0N"!=B#)A'ARTUT6.O8J"6"!^.7]\NS&+>.S;G.QMI-UFQ^<,.VH,U
MN8;[/K=:=0UW^J:]]_X?O'_P\0K^?-X]^.?S(;1S=/H"[YZ^XWOTG\]'IW^<
M[1W\L7 -M_?J-3G:^4?L'[R&/R\^[^V\;!^]?WD&;5SM'7Q@1SOP[U?0UWP-
MUYZKB6%CXHIJ@;1G-D=8<*15B/ C9D)+;1UW&UL4BTW"V%J4%7[<.(8&^!K@
M^S;P.=___"W4JRR2D3'2H-K=4&VV#$BF[12$:)0,R74&-*":,1&1)*TBAELG
M-:":7A9S9X-H#:*MP*A73Y7S_N+LHI/ML&+?3DS;["/X(X):%U>*L& ]P([,
M@%U2PN<RN\@;+Q#'%",M,4.>T$ 9]4:QS*G60%T#=3\/U-VEZ.R/QKKLP9O"
MNL:671H0LKGJ4B$)K0C2V%/$;3#(,B*1X]QXG*)2F&?*):P6];[;UZ1M<+#!
MP=49]0K X 0"9P&Q0;HE(IV8M6]9M,))A634'G%81F22]X@1Y4AT7C(BLM>.
M;[*E$6:O&!/-&E+L/N_USS.U;@3Q<C"#8TFY#WGNS\VH96SD1A'J XV92,\(
MFH*)!$NF-3:IN7%8>>RZFKMQP$QJ(I1 $FN,.&'Y[@&PRP7J-(XZ5V_8V%*;
MC"V+0VM-6?0:R6Y<ZC]2;&==ZIIK;AU/B$O#$7?*(D><1(1J1F'!@B9V8ZN1
MV49F'\UIO.H5NM=#S&>=R4$FY@-.R!LL$<>%L1I39'FD)&!G@E1+J]#=R/H*
M>TU_M+#/>4T;H;Z+4,\Z1JDAB5(XK(W)M+6)&]"V 2YA*3W.1/0I7X?+^WA%
M&U%^>L=VX_A[!$F>=?Q%'1FC5B,3&4@RDP1I12V*@KCH!6,N^&(\$[Q"A_-3
MB+-^GON2H#?#*HLUQ//>H'US4LF3K_47E'>@60JO%>/!1H>-H\1(ZK0T4NG&
MM;?JZ#0B:QNC$Y,^21DU$LHRQ&/"R!FB$?,L\%SB*&JZL44WI5A6-,H*W;4V
MDKTLR6Y<>P\MME_F<@"B-A);Q()*B),00+T@ 45I)4Z$ZL#QQM;]-8I&9G]>
MF6U<>RLHYK.N/<Q3()PJ1(S*<:+>HWS9AK!PEG%NC?)T::Z]1M97V+7WHX6]
M<>W=0ZAG77L18^H-YTA['D&H94*&.8QPL(E33RR69F.++?)GWCG@L1'E)W1L
M-ZZ]1Y!D,1<78V$I&4$BYM*3+KOV1( ?94K:*ZZD\\5X7EH>;A.W=SMYK"K(
MM:?Y+._F0_T9.<_O&X2]S*GY>>#<42FL9E@KRKU0FK'HO1=!*1>UM8U/=.5A
M_>V<3S37!53,:L1I EBWVB+'7412>B:<XPK3"+!.Q":A]_:*+E&H?O#M;0.I
M#:2N!*0VSNB'QLM99[2G3&@6!;(^5X7 TB&=E$,$5&!C;5#698.6D08K&ZQL
ML'*EL+(AA?B!,#KK['>P@@"C%GG)#.)*>.2(2,AA&:TW*@6JET *T8!H Z)/
M 43O=+OR@U&TH9MX*(B=O7KA@DJ#@T<)P!1Q@B,R"1 W.,P398HXF>N7;1*U
M&#EQY\#J!F$;A/VI$78% +:Y]'H$#)TGLI!2>6_ O/<2<1\8TBSGG-F %2?:
MQB"S=Y1O4O,S6/S7U&'\@043KR]I-2Y.V-0;6K=",TUGF\XV]8:^51MB)_JZ
MW! IY89(4VZH*3?TL#/8E!MJR@VMQVPVY8::<D--N:'5\@(]4<)2[ZPPUL2@
MC>")".<898QA3[&BP:OBYR&$,M)$P]W5W_..'IU^@/:WKPY/7^"CTS<?]\Y>
MGAQ^.>2[K^"[!W^>[+[_1^SMO. +_IZ#H[-]&,ONSI_MW8,W9WNO_J&'[U^>
M[L$X#K]\^+Q[]N+ST<Y'O'MPLEAN2 4G.8X1):D8XC009!T6R'"IM&-1&.,W
MMO@FYDVQH0;V&MC['MA[LA%KCX9I<Q%K'M:)2(<\<P'QE.\!-;=(JJ!#I"E%
M;3:VR+V9$1M :P!M=4:]>GI<DUO^F!@X1QMIDY(I&.1M KW.$0T82 W""E,F
M4W+$LF7GEC= V #A"HSZ+J%A/QH)?\;$^T=#O-GH+Z(IUE&!UF>20-S;B+0P
M%-$@M4\DI, S$U]3:*B!N9\"YE8 Y9YR?-:CH=QL?!9H<XI['Y )#%#.$H5T
M3BB(UBEE(@%#%Q=_G5@/?]U3H"MHR@S=G2%9,^Y,T-I:R6.FJ90N</@M_"YA
MRYN;AI5'KODR0RZZY*A-B B3Z50(14X9AAC&B7.?.$!61BYJ[ET$O.$^_WDE
MNW&F/[38?IG+6R3*9&K"$+#/-5P=TDP0Q%6(UN)DE4L@MJO$;M[([(K);.,O
M7D$QG_474QRY<2FBJ%R$TQE,"N,=12#@P7JG8-5Y4V9H767]3F6&?K"P-R[1
M>PCUK$M4&<>39@G%J'*)0)*0YB*A8"C%Q&B+([Z.<Z"I,K2RDKP"@MQX_1Y!
MD.>J##&9N'<".9*)ZZ3)=QN*(FM-2%SD%8[9=F;4K-#9_!3"JYLJ0W=$)<(
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M8TOHQ9C][_-%K)"[M)'/L;H0J;;8&6<%YIX:*YU+CE*+<9"&N$;97P&YG;T
M(20R D898A&;7 !%((TC0:#JD: LL3K7TUZ2JM_([NK*KB&2.\)A,S#%$U::
M$X_!# Q42N+3?57]1D:_1YNO+RFQE(+EH'0:?$Z6M<BJ9%&@S&AO B:,K-K9
M^A2\^1458'^:.>%N)E/#7]54-;T5.'OA1#2@1?M<-AA4K&BECBK:",@00VC\
M,"N!W'O/YZPBY<$D(LX@2@Q81=$FI,$V0B00ZHU6GF&VL44WE5K,?U^_"J9-
M+>@&-5<)-0555@L=F N!:\>=<U[H:"WV6A+:Q-T])C#.FITLD]L&+I''+B$X
MT@QR6 ?0<'5B4BFO"C#>/^ZN@<4&%AM8?!!>Z4:9?&C,G'4#8,T3Y=:A@*4
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M!X5S[DL"\U5'!_HJ**W!&$^$9<8;N"E50!A,;J^3Q3];L$QGN0<G.VN"V_3
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MZ+_D5KD.G3\OT+GDV[RS6)\I+'!NC0G"2& [4$E=+,%G5@J8HNH:-.P",E\
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M&[B5^.T2$3Z5A9=] ";HJ+))1#&3"9RE)A8L!A*9Y47",7I+[SH1H>/E^RB
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MI\.V#ML>);9Y^)^2*5DGLI3>!>^X23Z+'**R)7;8=C^P;=DM",?%D@R9&*U
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M1'"NBI#"^:"Q[ K@^W[(Z,>0/K%<=O5'/IWDDY!'MZ^]ZOJ*/[X\MT"9=P:
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MUUQ;KV(_?K^U!%L-)BVN9#P\1MRO]QK7>\%EN#3@>EC1Z2B?],_JD=\&D[0
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M98AF*1$9LR7!\$! ]W$B:AZR#4^>,JXV,]HB7^%N]W9ZOP&MS%FAL2S/@0>
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M&AK-K]WPZ./^M BIZ5U[L<F/&N<WQ!->ZGZ$#DY #?2,5!\KK!=6OM4[Q#V
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MU;+]U$PJG,=;;MT^5!D3E&7":1 GC@M;"O,"3:X40*./ETP(NV;DQL]^-+J
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MK#.1T3 2I&>$%<Y$8@J;!3]YJH5<"YDW_OHOPP#XT2T9H8.P#L*^"(2%)&T
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M\KHUY;40;G(N%E$2$VUH @Y@;HE62I.<)C(7/.8I]SP>(EX,?5\]]V>#MGX
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MI>DMQ,]ZK[TPJU)=+DFU^/ZCNT-5SF42W'@I<BHT S<^%9$%@Z89Z#HD-GD
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M)SUQXE(F4AU'>2R,8ZE,!<MBDU"6991_3WHV6.!G2\_[KR ],N&Q3K@$E\T
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MN8Z0J3%C\1H5EFSH&C?,N9MEVE >;IH*WP<'VFU!BDU3X8>!%2J'R;(\2AF
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M>74K,E_HP))4YD8A0[)T@";!CU1QDI!,,(WL\=9J U8D6\QCVW0<7MM-_"O
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M#5WO)^V=[3?[0EO<55VA18Z=<!V3N1)"2ZU5;B*6 V:/8BD2<96NT.;$V>G
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MA7"FK]/X%\Q@<%@*UXI=5K41#:$@/KI^=;_\!V8R"HGH43J?16AGLU0QY75
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MG>WVHV[?(5NR(O-QZ28.W^WST>9GA77Q%?QP__8-PUDG6RQV!T.,EK;6EU7
M<X6 X.3@&??B W\!'8F A2&)S'V35[3#GZ'0=>C1X!G@ #(H/KO>9["CI2.L
M%9>:TU#+,O304&.$W2+!11GHD\.=6O?QF7<=W[BB7JD['Y4HOOZ!/N4CT'B.
M TH=]V:%PYAOB,QT("^>D=4?3^"G . ^NX&;8#C31QN:-, 3[#8PFOA^!",
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M05G-43U\7R%6@!Y;4X<$U,^N;L9=F9]/4WM<%3S.CJ@J)8KP%U%A1=.*\3N
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MOPJMMV9,,D-FYZ6K]';,LG14:;I4TI/4H]T_D2281 D$V "1*?:GW_ S/ (
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MAEW<Y]#V!/CRH6$*LYHHO;"*%5+YSK/EK)I('R2XFM6MZ9@'8U%-TY%*9#3
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M;F%@.=>,[H5/T4'@P3YSTXT^9'H[ V/G9*E3E!V2>H$!UXU,;R1B1.IU?/;
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M1/K9O/J,-IC;#&5VG9A(G'I>400:PX_[Q?E*BR.4XNX(X).B&S=T!X<S(O%
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M&/" '!+.8_Q7FX[UH%8T!258-TNMH5A0X&'4+H;C#OLDVU<+E_:YXJS)?>2
MEOTF8\+]/O-WN'V=Y7C0M!1>,1U@][F(.TV_&>WKCBN [7'P&WZ\[ MWI009
M$K.DSO+Y!935J6:T;7G[+:?]$M[5$I+?8\XM0/O=L(+[Z;_3Z0\"KX,VA#.W
MZO:2[$BW)*M!PW._.G>V.F1RHSUAVL#;Y %%2IWQA>'Z:K]?_MP3Q[E+SNS+
M :!K_-8U*T2U,^.4XO A_NTBKY;9>%:ZS[M$5W7AO*"Y<UM:)"[RH+@($P=
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M&$7 Y I$78"IZJ?'HAMK(4WL#02!H&177%(1EA\]%7,(K0;"(8=Q0BX+SW0
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MD+GY]-'1FFXO&\KUV?;*]3.(1(&M=#Y&=E:8L+= BYGO7E<)H:14*'&&##5
M#@_Q._F\!7\>'?T4*"2WR.1QG1!2F?#Y^=N@!13Q<7@V< JUAQ%@2Z+MB^,;
M)=$^'#WC8ZIO6!S(#QA]?F\GE[YP#@]AYO6_8/9=KLB$3\))2'WD3+A,)!!<
MUVB+4*\!TV*1#EZFLE(\GO.@_//%&FHH"-<[J[BCQB)7/9=0['3XD]J&7%7S
M78#PO1#%127\^'10 S48[I:Y7PO_:-GP7J(KF/#H -Y1D8'HS[%Q7H_;.>$
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MS#.0:_OE>%EUDM9S"%>[@V*X?L@$C8+"$2IU&7 ?9*OE&#MB5!$60Z8%J-L
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MMB^<M$J1>U<^$6I[M2AASS8>[S=M4T8>1#,D\3VL9,/08(,JVV#>D3($N^"
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M-L(:JNA $TH:/#L]89Y/6!N9I,&L1KXQ7EM"[%,"X:.I<^8;(!CAN#@=8,W
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MHM./-)^D)0$>2TJP3]VM!..*@8+HT!*WT""UR/Q73;Y[)NJ']/.NV9P?L^!
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MB7)<TKFV#I TX3B1,%P[^4<!07<#XWD]=)7N&]SQG%( UIVI;H#!EW8!9'-
M$9?5-3:G7\]\()QF3EZOL@,P#HX?'."8:.\FC/]&751R*?@XB&@9?)A!9H'.
M >;J/I_L C:*R<C.\\FBRKGWLU/QHG[\W,3?[*<):[AULA""Y?1@P=1]EMT_
M6 'L[#9/)YFOU@9/%SR%T7^W;N\<<Y>(%CLL0/PQ'BF.#J:-G&0_"YQS]$'
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M$R5G,1;9).88(5X)@-,LFX1CVZ;_3R!>HCA8/*5+I6S/F/!;SSQGLF$=*%8
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M._,,BHMPM)1L9+(C&7$?+G"_I^YL3ZWS)/,&"3$\3&C 9!JDD^;K57P0.[P
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M!E4<XDS'*:4PG .QS)>M5JB9[@7.A4#R3=I/R I7<N^L'L)+\.$W(K8<O2=
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M<@E.IA1KIR<WIA'^:5%=,Y":I"HT)7H[4?R14/"NIMOB<E#.W7+^(72V;LY
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M18""REC%QMC -5BP,(V9.;M0X#>X.RI*PX'*IWX&BSJGG!K]*:B@3NO,TE0
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M!!LEOB];%=)#I17F#L?Y5<YP5ZRE<195YOX7A'T?>;_SKCL^*Z*0^$),7##
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MDO Y(AC[/GY?1RYL=XE)NG(V\,$D786-)G!!(%% N0V)Y%@N*;Q?R-#BFW,
M:HWS9E][=N?JMP]WSCN92IH7Z8IK-0$!CC3%N02/0ZH:6^O/L 1\.",S?0R=
MVK<@BQTR0(![EHY7:RNE!XE1FIN)[S5DR)$K)V%^^/O.D7^Z5R<Y%PA 9S7
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MD4LYJNM2^C0AW" 'R\IXX-U&'$3/J?T,X_3@X)=L #!@<D!DIU3^\PC^+]2
M^6!?.'9/M".+97[J808CC<\M/,6:O&G_U-'[]:V15<H8DZ H12HYOKC6<_>
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M*DMK0SK/_02IC%>QILYJI/@#&Q/$I1K$(_QI&F^9SD!(AJZS@$^KQ1I+*U8
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M]FB?.UMYC)=;/CRP48FSPG?8\<#3GO;>BOO1B$UN-(K@D:-,,;$*)FB_P4,
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M1AE_DX_&Y+H\" V-2 A+^UW@_KFQ-QJ>",9SW0@Y.,?HC1GJ";/YV:HV>6F
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MAIJFY?(T90[!5FH#?3>U0^QW*HMT\4%2@A!IJV^RJ'P!7ND4?=TH5 FQWFL
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MVGS)2A0;< G18;W,8952VEE("<: @A*@>8;:Q=^_?ZOP26R,$.9>B=GL^/R
M4R]W$7=%XG;">,(^.4+43[?V,V8@X314+"5+(^+;+%)=%]P'(+'C6-0H?/^J
MM(.K&]8QY1%"JQNBC'&+96F=<9 @X\F)/0J'-MB7X!UOAX[XPJEXA\=$FZO@
M\HR8'6"I?Y#NRMHO4K/>%6^M59EQ[R>.&5B12!6+X'&W.LJF0[^G-$,TVQ#T
M%O(3+TE7<K-PHAO=(JS#K 7JV6LXH#2J,F]W>-[HB+A?D/,3V2B[U2)1OX11
M!ABBP%<J6F$^O:7Q78C/X\QR5<9.);=H6'5 EHTC.1"T!U1*NC[G&=&R!Y:N
MGJB5-(_TV"8K56VOVUZ8OZL%8,1%]P0IL>Z-IT>1"-=;(?I3+ 'H]HK1OS.=
M("]N5#F$,UPV7<1'&O-PT!2%TO[@HLQTG3$]!9P;N'B$$*KLX+.<(/!+DCY^
M_.42D7_YW[//?/-;3A.V,H7Q58H43]5-AC'.Q2C5^)H 9%[9)ZB5&88&S7P2
M!#;3K"J:GQ4\ VP,3)9T' X>G"U]8;%:$=N+)9SS1#+<KA#K_Q4%DZC0(L:_
MQ[0S*(M:5 W#NZDUC/7(X.,^^<D&FGE>^MWVX[T@0VV*&S9J_-#JG(:']IJU
M/<TQ]=-#R7A(EC/>;L!+K"BJJXD.^G/S*_IIUN.-R1%@IO&<$Y@&;M5TV>?2
M9&>0J'*LG\V_:F2U$F%O8 2F.(*],'+LT!@$54&E_YH*EGN;8R,ES0K%S 2_
MD[>;L\IC(LP]LV#=(<9BH4]$#D\220&7E@E<Y$*F"=[;!*?9)>51A)QVXR(6
M)\U0<+JE5=][4Z0+%S6IKFG>>_GD:9KV-DV&Y\SKY4J0P;QGD0'&<H_9-0O\
M,L6>=5RWT1+1U36RG]/<_DY$U+W@4))_IN[ELWS">Q'*K_TH:+0<)'$Z!N&>
M,\&:5LQW@2.Z:>DKT7U-%)W,7,[&/:_A(&>P25"!WY%%G%;+7FDX;4&>MZ>9
M/4QG#"I[X$JO' 16JT5:.[41LG3FVX#&-"LG%N (22US&/A<@Z?0BZ!]_34:
ML]T7>=ORVBPKO4 R&A-&1/R,99K6T[[6DW?(2XE!8RZ]W1RC8VML2/XZS=0>
M15@H6&)P36JTEGVJ';8(\C91>(5&.MWD4T?D/N&;L!-0P2H+2C.*1_!89AO.
M3%/P&9J$&](PPR)86B"1US2X>QM<!ODLD;HXI7A^&ML]9\MBOFCK;OES>!KS
M/;(Z\'B3=]SK^(,0E]P8Q J88W.*;S^3WZ+SP)#-(':M&'I1EIO&?7^MYJM\
M&;0 UBXCU \Z]%TIU(/$):?&'GWV-,LOF/7$PS9H@B!JG/I']BR&(XZC[]-9
M2(6$)%J7LS1;YV5.1P76W;Y\#?^Z5[P&V?F.2GWO3*7QA<\SP]I$]-GK,NO@
M1;=?_AUOSUBYQ%0XPJ'*Q@B"*0P^'X',\(><A;\GUZ5:M40JXH '5^I&.-H\
MK[Q"-./<I+_!==SHEO,2R 6O*15^*[!&AX=!<$%DE>DO?4(JR%"3K2/(&@'B
M:J<XT*V0^N*M&N<^:/E;A"K\J"N739,B,*[,?,\6-=M9#>19"P/O6D926I74
MFV58N!?"8TV(DQ"+VR[!6A>"EJ@_%G&*/V.]%-F12J69[PTAI6M6V!?$9E[>
MT7!3PJ1EO:E8YO6Z.9Y]KYZ_TM?Z=R!V"]+A<K4AD*/"+ Q"5EF AWYNA(H9
M6Y5@E.@:+JVE@<.6"&$2ETO)%/:E97LYZ![9O[2!U!?PQK\H26.$4UC+^U6]
M&8K>SI!#A]?CPEA)?6%8ZQQ1CF&X%OX549?T&P8YC,A;'<_."4B*:.)M,G@>
MW.HB[STU1H3&B(=38\0=>):I,>+.-T:0?I*U1AY%-V:,+/.-:9A@P6X\7_%L
M"Y:0\>0#6AWV9IB_RK@MQR*WG#OSR1V2\"H'*(UINW4!J1R!!MIRG:6\T!B9
M3M)_X"XA\EV>FU#NBU7N2"L\9MPV_@4B(1"B;0\TT6W&6^-HNH_PAP8CU^VL
MQF%7;\ B]&-)1,G:AU$1GS$)NG!6_87_9/Q(=2)N1-K! 9LO4+58(/0>G3$R
MPSB-F6MR;E/0G"J[,?T+A<_MHJ7N@P9#P!\_8O0$J+65+E+6#<S+!MZVDXYD
M"W:0%O<DN WVLUR_O,FW]+[0L88>-'ZT++"[):UA .B)(J\+R]GE13,A"#]?
M3I21!'W@:7#BI]+)/O-PKEU5F1A]:B&2K@@*+'/1G@3;EV<JD"*6P5K$RW2Q
MP!;X*1VT9Z#EU:Q9(Z9[714(:W<& %^D3<.94BXIDF$CVWB(@H OPU8GT "'
MN((.(<G$F]40J%TL6 GP(""4<4P,45:E.=</+EWR$TG><)F9XLG0_A-I*<&K
MDNX<;-6C+,W)5</%L?69"]WE["M\>_YJEK9MNOC %*]95VC'D,OR%'RQ1< !
MG9[-MG#<2GQ;9-@J"5]Z"0]&<'Q4@2)7!I,O2&!#>1#_W*/.)CY6$,PM.9FQ
M0:&%HIH3SHP@WKW(7=)GTJS%W:;B"0A-"R^G"+:J(Q!RV]C@*Z*[X@_C5<6^
M14TJ^CLESF*WE3,4I.1'X@57#K9JVMB[S^LJY51+6W=K$HJZ!,])WASY95#P
MPJ?A269A#;?J:L=N8=!?##(,H]ZJ2&[1-HE=G1NU0'ZU3Z[X;[BO\<\\I\>G
MN/#7>O!2=*@6'S8YT^/6A%#SCGW &;%OS[_M)T]NX>?;O"![O*S?Q)@-&F'<
M,_?"TO@:=G3IZO9__/7TR</GR>S;E,@&4_WY15[6VU^<_OC/M"!-6/WYA_3#
MZI=M7>G/W\#J@)_Y1[@/)ACG\&SWP05V<!]TC/5W[&F_ZR!6<(T\P/VD][C:
M+!26[-&:]K;+PK)6Z96W__H6+OKMC^^3V7J;-G"E,D]G%W5ZF8M?7[H.?.*M
M0ZI;F(@-+K&PON&"-$6S>^^K(@<76E_KQZ*MUO87>*U7L.Q@I^3^R0=[U5JK
M.MZY>;DLP,3\DL[N-=SX6<S@-]X7P:%=Y_ ;'<JJ<47+-%9F,,UO$RQ(X!7M
M,[XNX=W];"WAATV.PU'SG_]O!7?0;]P7+5G3GV0Z!4/W4QEVEG5Q\R!E8PYT
M[&KMF;_+E'F*S)YSRKYBU/%P *^JNF"09;5<4I<M)NU@R6-(5:?:G:%-U(TW
M-(0--T^/E$E-*\])! 8T,ZE/PP^]$/A/BH'9#$:KLZO,3QT&M75%(XQ-@:_F
M59$F(5D:Z=^PYO/*>4KEI>\I@9?"45)O-1:>M<8@$#E=YDPFH/N>2=#-5I&O
M',_>.S<C__#D^=="]$3]_6?/3=Q('SA]CE/X%MM_7R>SUW JS$Z]HB#FFO$H
MA/$[+\L.1O2=(\HE6-K?8._CZ<G1/R.N!NS5ZQHKVV>>*XG,5X^LAU3*@SJ4
M_21FK7.O?\3++22GAPOOT!PE9"=C"2I*6 T'3K@9=@R92?+8%F&_@!"7$TH\
M&!.UI+C(_%5!#STQ_6DWU>X(?8^]BB7:Y(,;<7(>1+ZNHZ)4Z'OO[;T=@TH[
M.VXGDNK+E&;Y?+ ^\!!:6XN;DBI[A''LJ&::PJ>Q-"K6R@;;9RVG"=GCA/C
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MLO+\IU[5/G:,G0WK"VP4119>CQ!]9OO%(;KNIG-T<$3;NO_8!\R]Z6_28$+
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M<,;G/(,UCL>23SOQN]DLP$XM7JG:LO@,GC8++.I1 :Q23GTO5,+5"SU]!AA
M;+59"&'\:*)%+:,8)'X+AW6XJ,@#A@*V.TZ[YN-D97D&CSBT:QPSZ3@OIY'K
M*XTTCN'M>>+9%FJ:#SPWL!CD=9!AI5R/\QECSCC-\Z(@O!(8!FD1&VKF)9+%
M&V$1Z$T+BY(I0RA58+4B.T9%4+J+2OH</&$,(QP]=$\L^NA\AR,I0K.FOFBW
M0? LO(P]/L0:LJ *-VF%^K$9"*WX[0CYM5D_2BX1(4H5>@#BP4$7#0Q"3E;
MI]B2T$0EW5F&<HGNE/(JC9D *(%FTE(^J%>>'4VHD3](<D_D:2U8(,F^:% -
MP5.BEM9<3EDP5PL^J%\[\Z[XH!0H!'A\!Z-+:\SD52P$M ?&-.G#NH=#9AJ0
M>9[)<%8+ERER(ACK*SS&KTO$\+[ !HPB9XZ,HN 2J:3H>37E]=@I[FW(6&L^
MMO'V*4@&;Z'.9LA\T%:&7]>8UC)L(/%C^^S5V(1Q'9/ULJ+5PC9-#"4E)R/Z
M&81EX8DSPIWB=U]X2FKVE6>SC]-/='$A"FT"WHA(MVC,PVY7+HNAZ>8$[O'L
ME6=)B)H7M;@MU]X2:$_;DJD,#N.X(7DR%N'H&@%/X5L,7M-#V71/;JJ-;'?.
M3M,J:X2I8!YP:C*B>'=8.CB?[4K8T0F(YKG25.>+&M(T=4UX [7$8%#;E5>Z
MBAB";'VUH)="M'ECQH.W_0?JLU<*GP'X51]W4-493#J'Q$Q&@B]R),[+#!FI
MM@T&EPANH5GHR.ZR+!3MP#5;,%DQ]'5?GBK-26HE6@+P5=\(O2\F$ZF%]8?-
M&C\\?MY8B\$K)+93&IOG!&L2L>P9OQ0)G9B-(2+_*0EGP,$UTSA!R(\YQWF*
M@R!0K;Y,#V4",+(HBH'"T1?WW^X4'B$&V/&D.'"LB961#$I^F2ZVGBE0\ OH
M Z74# SO+_*#!N=B$QA]8)@/1?'[8(044V/H%/6F9,3PD0Q:7CUQP3=Z5.NA
M><_#P?^U0S(,2ZF/@H]S6.FE1IK]H1R%YFFEA4T/(Y3)2F*>CA(W)9?-[8/F
M911)&6>ICQ-'H(-#\)C0#ID""#Y>HIR>\9&:[@:<FZQ"1+O7,[&C$'UJ:8'-
M O8>5?A>:'/&6QGL<T:YH?FX(%"-^3"\(,'FFE")5VWRRKJ"GE'*%<Y Q_-:
M9&EBU")Q:LU06PXQ.NI@CGR0CE?#YL?4.N!\P28DS\E04\WQ>L(?M^.^&('!
MC#!-*Y6KQD?K[URLG;W$I62 '>]"YY%B.?[^\NT[#^608_]5A]!(V&RO8*E4
MJ$%^#OZ8_\JK5P'\$6%(8RY*$V'\$X8@0T<$/OT>UOXOKB[@WY&H'+'[H_)@
MVLHYAE#OGM3<\$.OH[WSQMMY^<*;VUE!_^91Q+D3/?OI1C(9;&O>^&:EJ#W?
M83J-M!YA+!NY#C7$A^Q)K)876Q:U3F/O$U4./TTS8%#NC708#1>]4H IK*7P
M!+MD2,;!L/X0N_79<6=.[M?+A'!'76" DW^NTE_2.D/[["D1R/AQZXHCM\V5
MEWE=Z1J4^+F/..VU.5&N/KYD(!\>XG\HI:")33D=,!N*U><\].0?W*G]AMYC
MA_B8H,"%P4F R$S<LG-J%BNW)H@+74U;-NLTRZM4^5H@I$0:($\%86SRSM[.
MT6W%VTCC73J!F[;"@ 2IQLNLT$AP*NC[@O[3J:!_!YYE*NC?^8(^^ =4MPEU
MG9B4AUSZJ[1I+;G-^6)!7K2<0RDU84KW3EZ"0[_U'8W1!=E!J+"U9X2/L$0'
MG*X;$XDANM2P%DECK-8;T=E04.;6(U%#;=M]7#B7R5$F,I/#V"L^7$?-,-X^
M[B6ET_43OCD6G V/X*[D7)<3G0=/74??UD$4=/(H\O^N)CA^I>@7NO(4=J*W
M_I:ZL]I#5?V*.?92J<$QU3KU3&'4RSXR365NWWVC[RZA*C%:+] W#['K)FV5
M,4$UPEOBMD?P(>UM#-;E\[RDLIQ*U*N#=.>TNDC5A\PA<3/7I&J?$?0R)8*?
M"9:A1[],P08EIQ,_'Z:_$38]&:!KY^0&9LB6Y+/*=.WDWYB4Y50=39R-!)75
MEQ2D2WY^3,V'-"D7 KD?%4<AJLY&,H+B\,,B1:>>6BG9]4TX&'5,$XRWXT=L
M$&:KE!PF88-6$A,2$*)B B-47Y#"C"%?NCJ7/=8P$G^ <!];\1;!@A'5OE0)
M9 Q,+]D\KX+D+P_4+I1W1."_@H<@&GA)PR3!OV<RSH^&QW(IJ0!EHM4N;.8!
MHM(T%4 )>2+N.]9P" 'E@]9C6->Y%'3[1=2W_&9XV1_\M+\ABA2?/_GQ_=L?
MW@2AM):;</!K+ZK !_ #\A%Y>A4DBJM],VJ ?^\JV<?:%I11-]QZ&Y)T(+I]
M2M;C!YDMKL/@ H?C KEV9=(-3$U95% /+_#X9H[0-,Q_XQ,<U$'D><U)#_W&
M61:SYGDJH_H$O<9551?9%=8FQG>2J.3LD-W3I,*U>]O40VCM!+,M*O5L)\1(
MT!U#45?02;AW<&CH<<GY(<\JFI<D@NN-/&T>E:^I:&HKY/BM;\]?Z=^24#UI
M5B2U5*.0!46F8:.MD86BUL$K\J73TANQ_2$&@PIK1+A!+AY,4:FJ5U1DI-9>
M;=PVOZ/-7?LJ7TET6]*1H*2!9+^EG>X6E\:A<-1'9D?0+)-\?(#EM?1EI Y*
M8^%/T%KL*XX.)@'\&ORZ$D2I26@S%P>JB#2=[\LDO]9DO)#XP-R)BHYCM]"1
MZALQ+HRFI.<CKK5]+WP.^[.(+:*5T@O'<TD-Y=8'82?<<$#R7O2=%F+U\:P<
M'5@VX^!LY!GQ89.R2A(V1CB(#4#(^";>,PG[:KZ-WB )CY^@Q>\/T<$Y,3_Y
M!A->BM'Q*R57\D2,@<3]C]45[.$O<2W/74&K;VCZE#; D(SZ$CP:JN/9MV"Q
MB4XFOG-*.AJ*@ [/H3S10L/CM=@D:[9D-H)4^=O)HXA-N\)=PF?C6L904X"K
M4_T>6U4Q2/K%):VG#$>CJH.CS:;5>RU]1/N<@#HPIX7+[D#L=/OBL+X$NSWD
M%;/'0\XB-0E%ZZL7>=C]%D45UF$6#[7R1!*[SLZ8$6/N)+T,LY3TD/4TM5T9
M. \.;D>_,.:3L^QL-&.M!DWIWS36[+)7MQELL,(5>Q[T0;Z[$H9%S"F41!Y7
MX5C"PI<%P\Z=GT(^FWH3>-1KC8AF<'9>>K2&T64HMX,5*0MD@R74$>$#&1I,
M^$#X?SRS$2 '?XV-_M++*@\<%=% +'V'(P4GRE#@[^#MU+4>H>$&C.Z%GO%B
MI7QV$G5)_4\*E)%A-(A12:V]'H7"BD6+U"F64C*66(4;SUD(P)I8](%/GPI*
MBN82LZS(KAE?3DE'J">7*'Y@'6&Z(L1GZ..X& Z>A/?7#]GA5D1[U%'CBU#,
M/ZX08-DL,23)NV3#0%/5^.)@4PP-*X]*<.()5I)1*Q9V&CFER@J'V4(UH$2'
M!V]:7\,$9U)YMCD@B:YEGT4I^K16B^!&<]E-NHTN*GE/Z^.R(-YPV)'1!H:Y
MQ@6)P4?[Z6.0B'1\BU*PWFH+SQ/QT5<;3B,4W/XEW*B1<GE,8H7I*M(ZE&UA
M4@@:XP1BI1*U\"J+BB7T'3N$9BU>A8V=P$HM*!?$H89$$ZG/>GAV/?DND\OZ
M]B7]F(6]7:9YP?4(RDJ[#<?#")*-86H!;8B+>!E@DC->PKEOA9&A,&HO(<0S
M8#C?MC8<IN/9*\]8>--2IME7]%Y_1!+K<GN)PU+C*Q>GGA%$XUM5?'S QE<
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M'WRU)4XMDA($/Y]5<NN/= "W^OK-"#6, @72 !5H">XGBH74-=+()#7MD5<
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M[MW;S/YX!@A*O"]X(_18 VQ_%-&A72&G"#9^5ZVX2RN89*<U(N;RH1;@F M
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M39?!*ME^4=#9$1HKA^>(1-##,VWO1+95LOCM-HL![(@X.L"(X^',(_-F$[H
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M318>Q''KKA%D&KU^B%<SRT"W"M"NZ/[<R,_'4\$*;B_P$GW^Y?\!4$L#!!0
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M2L@"(RPY:<"BYY:R/A-6@WD(&?AW2X8*!JC&AP/(@(]/[^$,9HLK;FK)O3:
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M?8KN+P01O89$-.6(3T1!G KHC 48$RV6MJ[V-@&;=G\WFFYXJ[R_=;#R1#H
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MUTSM1.MFZN\FDTM(-^.R_ND'E_ O/QY[M.;>?(=Q[$\@]9RD+B(HDAAW!,U
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MX JW<5$B/ZP-1,>H0P9A!=0^]6\!ZQGLLUTIJ6*HWX,0"\!Y>E,;B!V=/+6
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M6]\?-T6]1QF=RQ+FYH<_)C<^$)JXRAUB0;8?K$+82*69+D68.&V\"$)%)=$
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M/'QYHUO45='JH!1DZ]#I+)&NTL=$O F&!*8#2S*A@UJ[M-TN>)^#,;YWO7;
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MAM_;R^GE&*[35&>%:>?;DY4, C6.6%UJC2HAB(_*$2>4E]11X72[=/+[1CE
M4]T*:AAU(</*A\4?QJ-2U^!T/._1W?"7HVYXBH[D0%4INI>)#QSM#N6X%99+
M+EOUZ7G@ &C5V$>QI5<1;,62WC?PE":8BW;LB][0+4!5/!Q>"V3_A\&[Z^BN
MPBL)N/+A[WIPUIK$I,TD9I=QKP)<>R1D(G0,#FCDB;=J^_FXM'[/X>Z>E+Z)
M7&MOV*<?WY^\?O/?I_/M13JC3"K=0VPY4(02J9>8(I1;H+B@<9O;A:;??NY^
M??!*DA[5$5/M<]>7K_[+H:CG2#R+3I3N+RY$M#*<,L1I3TOE;ILAE(( [0Y6
M;SWVR>MK>R'5?L'F2/ O1BD3<T1,.,=T\$B@B!.+@A.7@!&C.,L"C?]LVM7(
M6?GX8U'?#D*K?8)YN]#71S\\F^T&RD5;VBP1X[(OY9EPBI:A>4Z##@%1A=RN
MX,6: 8["R*TFP8H=2M9AFE.W#:K5EFY[_1["EJVGB@=TNX,<:R_!Z]&A(XYT
MEJGD& 8B+6ABE<Y$.>D 5.0FMEN&]ZS=-3;KOI6[B?BZ5>KO0WRD4!3_L]@L
MHE8^^4@T31Q---PL I2+%N%YSDHR6#Z8:*7:.P/MN=Y4)66LU^]NDJQM["[5
MUX3I-X#A#!V:&^HFS 0Q<2OEK*:U=(VY)\MUIZ JRZA=:!=PTG[,8]-]-?EV
M^[*??H7Q+6@B9^0H1<.P5$*3PG#B=59$^: <,"\8WV897Q[GV-2]DQR[-;";
M58C=Q.;0\(^9:1(-X-J3/&++W)&L\6/.>*=:5M-^8*!C4_)NDJP8);!^O6&+
M]8:+&S!-S")'$XF0$6%*84G0+.!ZXYA0F6:KMMG [QOSV'1?3;X5T^G6K$.W
MH>%D>3*4&*$ID137(1NU)]$[DX6C/N1V_8_N'^?8U+V3'"LF'*Q?A5[V!X/K
M2AXVH;X8"!(HUPA/EXQP"83ZF RS5E!H=W;Y\%C'INJ=Y5DQ NB^A0<7'3$'
MN0A2DYH"^IJ:"%$ZTB:;2%#<$ 91.6I#9"VC %H/>6S*KR7=BM?&:U:C970J
M!AUMP01.H ",),&[3,#)S T =\L9JZT7]B/7^:[2K'ARVH2Y7ATK.:>!!15)
M9AX7'2$I">@A$B5TP'7("KU<[7^[#*"C.A#?7H1W];AUAX<K$ N_H 6,FIE_
MUT/O/YQC2^$OJV\'R=5.V;L!QRMM))I\1.=08L00B>4:#7VT!E@6+!G?JG/V
MH15X3V1&7?UM(K#*>OL5)75Q>;&PX&SFDD5-5.G!+EU&6TYP2G Y=XHRXZQO
M517R <W=&G3/^1';BGU40V:5(R+GO>WF0#+D[ 5D(GUI5)=UR;6RBFB;0TP2
MLM"IAO)N#OH$E;>US-:^>7][L33[]_AM\XOFYV5V'R'_5/[^_>.[*TE\^_;M
M+Z$_BN,?D^E?XNCB12.&58T?/L5S2)<#&.7Y;V?I=OWAV6D8],]F'WH-4]\?
M3&ZCG?0OO@P>/'O>><P7U[.]+87YP+<8L(]YP_<IH(N*NNNGO__<SU:@34JS
M%)%*G6)0*OFDG=5 HZ5Y9;N-C4:O6ZCU1JL/[J,1)GJ"?Z%Y1WG97TH[P4!S
M=,X NVY3OVFQUNMA*E6:O7KPQ]%@\'8T_N;'J2>#U4Y%0;1I"MRH1)S2B5#C
M-9<V)!K<AC-8-<ZC:KRSB=;6U)W=69:U[T)7YP7T."0;C78D<:-P(5:.6 F*
M*(-^H*.)0FB70KOZ^0=3Z^[R?SBI8B/A=9 G->_./#G-5VM;T\NKIX(1M)BQ
M@!Y]N6RU)+"D2<J!69'1Y%V.P]TY4VH=EJ=/@*K2KGWO^=MH^,I/SIMD?IA,
MWWS_@NX/G [7[WF]J$W*U ')5J/+XY@E-C)%>&(4J&>@;+N;L<W'?OIDV(?0
M:]^:7BU;'^$K#"_+\M5/)\.T6,4$1QO<98T3-R@''2*Q)58G0O)*F<RCW\1&
M63O0D6B_ICAKWXRNV:>H+RY51"LF1DFD9696N) [AY8.NDU,MHM^:+/);[Z/
MW:X8O'BM/OHIO,D9XK3_]4:_]QZ 2X)!.2*5Z#KBXHH>NU!%<4%Z:C/P;NOE
M/P#PZ=.\>[W4OC^\[X0]T8@3!4%4=I1(B/@^.ER)>=!4R9P=TYLX,(^UJ>2.
M/LONLEMEX.ZSJ>3:>FHY9"X-M20)4>(/$T4K/93*1IP+'D02JD:5N2=1D7(C
MA3Y4D7(3P1ZLQF ;D,^X(N5&.MRJV. V"C@86SQS-#+KB/.!H?'F$K$:7Q<9
MO*!@LS6B58V1Q\V232M2=D^23>1>O=S<-\3U8_;G=2&TY0)H00<PBF:BO42$
M,F3B59;$"N$$).<]:Q=XU&JXQUIV;",]C3H5<NT#TIL(3X>P'J0(B>-6&8C-
M7!%IT+?S/'M\.4R0Z/E1Y=KYRVU'/&HR5!-U]=H&I5#>&ER))LLU^OB**UXN
M'@5QP2>BK**>IFC1VVE%@7L&.3JMUQ)HQ3/4V\$@$5C,+DC"7,*9\92)D^@P
M<\3DT%;F<;G,[)$%HVWK'6PGPB[T.*=3&QC'%XRVD?#7!#-M([D.@]&TE2"8
M4T3AYD^D\HRXDE-&558.P,BPW++\<2JP53!:#?UM(K#:P6BW8G,\9=YH88@/
MI=2<%0B$9MPF=$Z:2:U,JE'NZ9'$,VTD]K7Q3)O(K'8PVJVHN  :O+61X.BE
M^K=6:()+=/B<,BP+F1)K=<;^-"()MU;>UC+;3S!:.;_?(:[LYC^O$"*V%LU2
MM)>6: S&TL&14VD5M\JE9"/*%LJ]6NK=?%#-BZ?KLW0:1-#>6\*HR>B&4D\L
M3IN$4G3;":.DJMU>?0V4NE=K;WV$DXMBUO>BTYZ5RK$Y)%Q@2L5O+]#TYC&S
M&")CT=9NWK4.RZ%;E&ZG]_LOR[:4=,5%_2IL93R* &GR%J7P;C*Y+(T>3G.I
M.OMY7G6V9[P0*D1/**= )*6.V$@C">AW<1]XLJPVW1]&=1RLJ"S]#H+(T/&_
M"FPJ<\:_7HTA]:>]9+2G45!B."O%I:,DWJ,$$G@HZ1&<R]H7[6O!' <;ZLBZ
M=@S9\DS#:/QV,!JA7930%K6:H3_B'-I% 8@K_9:M#Q(-&NUUX@\9$?>.\+2U
M6D]XM2.^5H!ZA9,/.7GM:"(Y98U.A<*=R!1O@T6?1*(04[N#Z]7//TYM;BJX
MBB%=JZ?YTD_ZDT]?QN#3Z?"??MPO1W<E*(?UP/,8J-0$DD;.V6")-4X3D87U
M-'E%9>[4J%N/[6F3HU--U*Z=<1ODA_%BTWD+-\*U3O.'<7\8^U_\X)^C =JI
M?OQC$>'<X]1P4W8CJ=$0D3)2XC.@*ZN,-MPRI5V["BH[0WG:M#F .FI'UK5$
M?Q+C^!+2(D:PIPU # &MV,@0M^696,8%\0[G(6W.4;4+NMMN_.=#FUT$7[N"
MQVW(;[[WUW*\)X-('K=5PH(N3C%0$BPM-TTT:1V%R+E=N<7V8QX=)ZH)N'9=
MY-LP7XTN+OK3.]3M26E]*H5!C2N%03E+I3)W:8AN,WX7$T_;;#)KACLZ[=<0
M:\5R("L1?H6A'T[GQ^2_#\L"->['*:22/G,R;/YZ\S^7_:]^T&QT3&N9.#@"
MS)8BP[Y4',N!(%M9ALQ3M.V2$7<$<H1DZ5(5*TZE=CZV7,+OQ^,?_>'9_$B5
M:XC114YP,P/TK9DB 45!N/(J!.% V%81W5O[.;?Q/&VZ5)?X"CI42'7MHXWS
M?_K#:TM':L.,%IQD**6Q<M"S7F9:!Y,S-S0LU_^KD.2ZC.(X5+^C=%<H?.L3
MR9MM\:Z/R)%^2@=&>)2E-*$!XE,N8(#3:$*FJE5)H@T[/Q[75<36$EVAWIV;
M_6Z66N:YMX:!(<HR2233:,Q2%HCED:E0H@]=MY>5CR;E;W\;0$V=K&!0Y4/1
MWX?^8C2>]O\-Z75_$LN>A2[S1?_R FV;YJ/SR[<F9?\WP!U-I:"YM41EI<JU
MK"0NH8-DM-6!9A16QYS:&/(QLJQ;O:W@W=9'JPO\)S.\3=CLG5(0@7H#B@GT
MNCE:S5&54"['RJUNMC([;X6N3*K[\!P'8ZI)? 4==FY<?GO"\S!JE911BA-A
MRG41,%P:M>5$.^9PIDXG5=LR70&CZYSD_2T2FTOUT+G(J^?1!/E*,%2)XC]I
M9*U4P(FC);E%@&!6)@W.=$J.0V0>5-/KO3S96+X=A-/<1G0C;:8-KDU2$K;6
M_Z%2D&OI[%X*["CPO1)""RVHHH1FBOC0[4)\,I,DG,LB*FIX[2)=^R7"FIR'
MO?-@ SG7SB&<17?=R7)%GYOY:(@U&2?''27.R42<QR4O2Q-MR\X5*Q]_:*-O
M6]&/JLJM@TC:8MHL O;>^M@?]*<_&MJFS""(+(F0ON0/V$2\#I8DHYWE''WG
M'&H?3ZW!<BP;>Q595PR4O _7^Y*],)Y3O@V^CK;YA[ =9KNOH\D6]-A9#1UL
M_@_BU"8'SZTD04;$*6AIBRC074)W-@DN=>2U3Z$.0Y,'C('#L&03Z5=O2CD]
M_S'N7V6/:6DY<-PEF0-&9(DS]<D9XKW,1L>LV7*P_;K>-K>>NW]CH*[01W4D
M5KM6R*_]],I_F1]%^<&B<?W[]Z_FX( +1D60Q%K)B;14$2NM(2!TC-YY"6!;
MJ?.AD8Y)P56EVL5J/AJ>3><W:)_QWS0+%+HL5 K%"+<A$!FD*]Z+)4HX$ZB3
MQ03JX&YR&<?1&'Z[RKAB+L4Z3(O>7"U0=67JK41T( -O9XT]0($=Q+V'16".
MSDJ3I**4Q%!*I.5R+45C1#N%,F-P?:*Z=DC2/DGPD/FV)PYL(N7J9>(0SLG[
MD5_TRZ0:I!(2+5-C*%JFR9?&]B7S/_I,I7,BM#O%67KP 7;T"L(>59)4]:IN
MB.7E#2S2!LHR9>A/2$.D84"LQNEEQ46)8\L*6I;QN_W@X]#:MI+JXEU[=0,+
MF&0@QDP<5Z)4L49;/V=<6:C.G#F)$VM7P'SIP<>AM6TE53N1N&%0B26^@4?)
M&)C3EN!N4/"@@^8 W8)2>]QG$]!':)<(M.+AQZ&]7236@;&[X@R& L.!<R*E
M!@O:\]P1YXP@,1G4DS:)F]JVS?&>;.\HWP[2BV\CFE.Z#::.G)M5> [CVNRJ
MJWM5OX.@.W!K5F)3.5BTV21AME0A$Q;7-8L6 3B:'5,N"M>J^MZC5/X#+LT^
M=+^)?&N;6)]@V!^-;\-:W+,JK8)(D63G2Q?XE$ON3R0^1",A2>Y,N\/+]6/L
M?^O>70&C^M+KX);Z9AV"65!%DBEDX0@O)>XD1R@!T")$XUZ'%"BEH789GV4,
MQ[)W[R3;BF4>5N%9A%RT0-31OGT7S6%V[=VT=(_*=Q!Q!SOV"F19:U%<#D)M
M+/6;7:DYA N;1>_$ QAN1>V[B'TI_8'=NFN=;R+9;@Z=TVC8I.0$/_SC-&?
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M<N/.'5I=+700.7,;V[^@+)Z03M!Q\6>XFA4)W@3.>H(Q=%J<(U%2163"Q3M
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M?(,>.9\Z"*/M;IZXD6;H3R%=315*+>_2UCQK5W947!T"94!B4IDKG5$0>XK
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MQ[G(.PG[>W.1=Y'44>8B:Q$$:B!V7!V+A\HR#PF8$$@A5I(2?+>.@&<Y%_D
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MOK$(5Q\G^(VT7HZ_X A&L^5HIJO;\=UH]JZ\OIM?AQYH;F3.*C,N,GD2MC;
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ME$UJ/=.G">&G?[EY7- ]*VH=6_D]/ ,\1(*TQ'WWU Y,]/14M D#IWEA>@(
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MYV3QLWBBHI@%--6FLP!23YO$* \ACJ,$1F&$N"^\1 96!XI3'4QM>=,B@G=
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M)S* OA\RB%(N88I%! /?#SCE*?(B)\>$TUU-;=(VDM:IPIO$"W4F!M<0F),
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M8JW&VR.OC6>=/2WSCOFUY;$.-%>%+&2BK*/ARSN2<5V,A;SJ7*RS,%#_(!%
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M4;JIK2;[RE6YQ,A&/9";, NVK2#(C(97H(F\J*[]KM2DU6J")?GNFO:QSP_
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M0IA#JB(!5<2I" 6/L] I=,)VX*GQ^>XIW)W^( JPIPFH57%N360W"7:;AT-
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MVNC]7>PU/-7?Q>'N'HS?6<ANI\;![=.R6.7_K#\''M LD(I"(D0&4< ))&&
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MX7 3:\F=DYBNH=GV^B 5HVZ3R[6C\ W8O 1&9\^1*H-.B\^ E6$$'3]N95#
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M>3"))FTZ^[;?I:J%]Y94>F&V+/;)QIJ#P7GJ0C)OJ\FF7/3M9E(^C3LIWE*
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M>D/S3&_@W G& A%?Q-(UU+B$8J'T$9'8W--G:_^1?OOUMMIH:DQPJC1AL(A
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M4%.S_8RDAK::ABB@DMFU,^-97.TXR@]: ]-1"]0ORZ5IBKX0FH>*EYS+@<N
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M;'?[-6<>=X[?-"FG*L*4X 2&,=8><1!KCYBI#"9Q$F4X#M,@YBZ6G.W 4R/
M';GK5G@[DO_[O^$HS/X*/DB5<]?42.N9L#/CAL!W8$H]A+86=)"F\J[H>#+/
MK(<=U29S!>/0$'.^O^?I[>I1%L;4*^2CMO:T9:=-O.63:9@J\X=%'?7*7W]H
M8[_4H]568/5?\SJA7/R_==V>^*M<W:D?],_[95']8;4J<K9>&1_YQ_*>5O';
M24J(%#2&*M6DASB6D"+"H$P)CDDFLBAPRO8>5?JID6:C)."-EF"U50S0C6:.
MIZ6CO@^69[!3G>6A3W:-WF!/<5!K#G[ZLBS+O]R ]AUH,0 [(%1TOP,#V.*P
MJ1RBL;@!#1I@%P[3-*X&Q.,I\EO,HZ^SZ5%E'_?$^RVFY>@<_4V$Z'W ]7JO
M/_)'XR\\%++:!-N&E\K"[)'0!WFGZH@K+5'53?CSHM+R5UK\PWBIJ<@"+K7=
M+^($:^,_2B&380!1'$8L#!1* ROCWZ]84UOEVG#SYT8S0%O5;K8!T3?@>:.>
MH;4F6G"A2:XT*IJ:2<N*39]J+9T/D7Q,N/4)W<C3.,IYWBMHE0(;K<#VK&JK
M%[A3H(F8-8M4I9M>]D"]&O[ZAO/G?&0X\CR.M!?UXU&Z?F[FHLW':DP+IA]!
M<P'6"TV[529$<?8[][63Y7U.+ XZ?8PV]K&H1X1.'*+Z?/I A2Q+I])H?Y=F
M\U6*VQ=9:-$__JFUR$MY7^1<SM*(9H0R F-&]1HOD@B2Q!3/SM*$)D$29VX;
M?"/*/C5#H)45T%I8(!MIP;,1UU!,9T%,S4GK4ACFJNMB^BZ+Z?&MN>9,^<W?
MA1'/HL\5U"S[5]3<O&4-#*#% 51 C%A>T__LC55[TZ/D$SA&'W1*G*MV#B!"
MOU7T]H7F\ZID_+(P:_1^(.GMD_&^_VG4*%=:UKR<49JD,8H#F$8HUDLA(9#0
M*(%Q(&(:**Q"N]S(O@),;3W;2 B,B&Z+D3/X=BO*D) .O"P<A*+?@(TN4"T+
M:+31O[.#W)G+^^+FB9"=AQ^55?N"<TB-O9_S-N7N=VIRUS7X\Z*.&K6R #%)
M@U"0#,J,*HBB*(8L#;F)$Y 9B; 4PJGISIMJ,S7F[>E)<%.I83X?PY<8]-WR
MY%U,Y8V9@+]AZV[L8-(V/FE1F:8/,L8<3Z0CP'6Z3,M/&6/:?/<;\"-4_P.]
M7Y>+36+'M^5\KN4QTLV"6-(D"2*(DR33*[%0$ <X@S%F&*5IE,G OJ1+]UA3
M6R?;@YM=<<'O1F#02.R>C'469_O#,0_HC73B-0IP[J=2'@ <-9=M'TB_IT$7
ML+ YXCGWB-'/;2[H<NHPYM(M?>OEONAW8UF\?I6K&0J2),V(A &*$M/H"T/&
M"#+YOS*A89J&RBGF;_?A4V/,C6RNI6]W\)*2)%&J%%2!,F$A:0J)"1#!H<!I
M@C)*1.)2-Z<W7J,5R\E;"6_,$?(5T-EY-GT!&7C1^+Q%X6L'"CVJ !^KZZW<
M[\ZC1Z[K>ZS4<0'?$]?TW.SFW!1N;$L'-K6 9XH'B&6,P0R1"*(019 037)A
M@#6KD8!*[)2(>WJ8J9%<*V6_,M]GH+3<H+X:H($_X@TVFW;'C8P>-YL[,?"U
MI7QZD'$WCCL5/=H>[K[:6X7NIM2/T+9+@!"#J<Q"B&@<0!;H?U 4Q#2)B39X
MK.JO71QI:E]_+>MNY)X+"UP&UL(/] 77P%QP#JG+99)<W\5K2R:[0S=^)Z?#
M&LCMZC-L+>13U:6<*B*/62?*6@^+ZLA758(2,I]]U([EZO53/I?%>[J2#]H.
MFS$6)J$D(4R%B7-/> 2QY$P[A2AC*>8(958%H,X\?VI468L(*AE!*Z3=1W\.
MP6YV](#+P)SH!HGU%WQ!\1-&42GYSP_+E__4=];VD/YA:P:=>]XHG_$%9=J/
M]])E_3R=W69KG\MR;<X\[]3[Y=/3<E$EH<XB&49QD";Z^Q6)J7%.M=&#0IBQ
M1*(XY*GVB%R<GHLC3NVSWF^TF3<B5\U[*Z'KPV,WK^@R['8.DE<P!^:"?1P_
M[^!8RUM7 ?#G.%ECX\F'NCS>J.Z4M?J'GI7]C?THY^!@[^O:6!YWJCHM+._6
MJW)%%R)?/)BH'C[#618'*@E@1(6V'%020H:U'Q9G2B1)$BE$G>C':?2I4=%1
M)$L5C5*"Y5;N&\",Y%7,2OU7QV 5M^FQHZG!0!^8LHXB,VK)#6?5LH.[7>0K
M\?T16"_4/)&9V]BC$ELO6 Y)KM]#^A'>-UFNBISKT=[3TG2P-?\R53U>Z-SX
MNJ=_>_MG7LZ(BB,1)!1BI!1$:1I"&F3Z'ZD*(T2#-'2K]]U?E*E1X5838*2M
MXJNJ'W;D!K\;R1U;UEXQ6W9D.,X<#,R,/N!W)L3KD?/$CE<(,BI57@_8(6]Z
M>&+/([EY]7Y(<3KP[..?YD<YBV+).0UBF,HTTBYK%D&<A02&8:J"6'$9(Z<$
M3+MAIT:.=7 JJX)3GYO@5+H-S;L!LI;;\2C/;@HLC_:\ SLPXUTHBGL#/E[
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MM^:H5%T#.ILM?F]6&+E8 K84O%J!V:)6-+.R+^A^''/#4X9+D1R9P=<@?CL
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MSJ[/[;EM-TO]]EGH#,OSAV:=_UK1LII5J[?O:EHT&P&WLMTH5W+>Z5#.IKR
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M-Y&\[CYAW\*$YM5QE[ 7=%R'<!^.\?S!=4_O[0[NJVS@#1Z\XGB9Z&@9L*U
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M<<Q)GAA=J+;M>&J35<L&DNR_ RTVT'*#1G#02 Y:T2UV?VW&P& 3?21D1^8
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M1KS/1X>_1,<<3VN&:A-\_!JF\XKK=_-?%DN<GLXONV"GB]>XG'[=>-]OYG0
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MS<\1!A2/N=8W*"C!H*3O832MWV:?_V+1&XSZUO:C+QK/$?T(<'-SZ[SZM/B
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MI71^=CZKL<E#4V.VC$5C+;$@(*A((C/TIQALG4"(Q%M Z9M/8NM,W+#OF3U
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M +U?+K[@<GU1^\:MZ8"NA_.7??8U15%'12>(LO(E*1X.A1DP%-!(:1@+OO6
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M$V^E;^8UR6@Z/ZW3MNA_N292R$32"V2 8VU 0BS6=I D1.,0,4K&N6_=9.@
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MM1&A\8:5WW$]$4:10:? E?DL:M:1 4=!#I0@HD 4BK9L3]"[0\B(#LQF.G\
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ML__SAU/XX8I:M)7:""XRWJT_X_+5XNQLNFV_6G> +$5F6T@FUMM:U9G %YN
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M9$!IZ\$SGB'%8GQ,]&GN-A2B_=ZZ ?58TC5C$.!1X??BMSXM*:2<2!E%8#*
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M5QM[U?U3B.21G.N:D0[%1O*TNU4\W_/EP]0"]7K6#^#>"!S!>VY?&'+::,F
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MAST"$TXR]X'V$NEX.5=?V! [LW(4JR=G18F&_.$AT5<W.70M]C#XVUD\1X?
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M:D1M+#D!AA6195+%M"Y&:KG_8=-C#9%W6^D-)N01&.PK<JY1N6DS:2WC4ML
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M<<$IB+Y.H>:&++M) 7QVT>0D'6K6&5(';678 +(AT)Y/(",P9@_X !LC3WX
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M,'AE>&AI8FET,3 T+FAT;>U:;X_B-A-_WT_ALNKU*D'"W]T]X)!8R/6H]I^
M:G6O*I,XQ+TDCFP'EG[ZCNV$A07VN&J[0)]GI<LEV)[,C'_SF[&=]H_]N][X
MR[V# AF%Z/[WJ^M!#Q5*MOU0Z]EV?]Q'G\<WUZANE2MHS'$LJ*0LQJ%M.[<%
M5 BD3)JV/9_/K7G-8GQJCX>V$E6W0\8$L3SI%3IM]0M<"?8Z/[1_+)50G[EI
M1&*)7$ZP)!Y*!8VGZ,$CXBLJE;)>/98L.)T&$E7+U2IZ8/PKG6'3+JD,22>7
MT[;-<]O6+VE/F+?HM#TZ0]3[6*"X?(GQA>NZM7.O[OOGDT:]YGI^Y8+4_7+]
M_/*/"BAI0W<S1LA%2#X6(AJ7 J+>W[RH)K(UIYX,FI5R^:?"6C])'F4)AW0:
M-[6VT.HSL"UK=EG(>/.LK/]:JJ7DXXB&B^;/8QH1@6[)' U9A..?BP(\7!*$
M4]]T%/0O F^$E^O'>:8-R EI3'+MC$K.8T G5*)*V:JW;=4_MVG3,LRG8)QD
M2;-L731 _(H-+OB3\%<WHOHM(VJUGXP:'G$9QPIGS33V"%>]"IU/@^%HC+HW
MSFT?_HW1^,X\.'W4O>VCH3,:=\?PX-S<7]]]T5VZOPX=1]VMNV.[(SYL..+/
M5$CJ+\Q/%#2)9;-VGKS^_#YW37V+:PJ=<4 %^D2YD*@+F/=T_$AF'B"$<.RA
M(1%2QY,3)2%;Z"[=*2=$W[V72L2[L\MJM=S*??+VIKPTRTO+#J=>H:,]5&G]
M4D2>=J9V6Z4A WA>(.:C$4DDB2:$&V("OQ)P:ZU^I$YU?)^XDLX(ZH,]A_4L
M. G\"O[4+ /.I3%@>++0\)T0.2<D1E>4]?@"@'X?8!YAEZ22NC@4132(72OW
M]Q'#N,>B!,>+8P"Q=FR?6^B!AB'%$1H%(-##,7I_U"XT#$8.#%?C0VN?!%*I
M6K63R*1#IS<8=Z]'^V7%RZU)\4 Y\-U9Y;S<VKR^#4BV.;K0>?CL#)WNZ) X
M+2+%B!GIZ(#/HP=A3E""N:3P-B!:&6"Y?\60)T L5-;KIE.8?%0OJJQ7.0$6
MWF;2,=#)N[/&AY;V_O]#\#5#L(@..;LJ'/)(FU,1J'##*M)T<$(BB'04J8?M
ML091)HA$/N-0:4*2)C0N(K*LW?!RN I*W8'Y>V4F0- >2QNUQCU(KBIT;N\>
MBFBL)O'3W= Y+)/2&+DL%A181!-*[O0HE2D.H6U&8AQ+H7I)# *\;*YT0#/H
MRM&4,<.N,QRF>!*2=9&&KCEQ"4VD[B=2WZ<N);&KUQ?S@+J!IFXE6A7'[M>8
MS4/B38EG1N=(PPH_"AL^"T,V%\ MEZV=H-C)(IWVA'>^?]A;3T_%.BS]?&\&
M&JG8!0Q5WN-?#@EK"Z%55=3Z*T=65@O +2=)B%VU#V?@Z4./V"6*Q[(TWPLH
M\=$-\=1J#-TIS!*>937@/*"MM8Y],B,A2S3/K7>V=F>^?PC1C.XF3$H6&;<<
M#6JK)X;:'HRE<;JDOV.KHP#-SJ-+%'<*P[B0;PDBCPDG0H0+E' VH]Z2F2&U
MAF'.XR81*]+5O038^&)>1B)0HSF)@.Q5=O!3>(0D#9&AI)@$K6_U/M&JC.4V
MG9$1,YE5!(RCB'F 2*0*=I,T]-ZQ***$S0F'_[U4$7Q1]6430+&>#JVJ&J/X
M?V$J^NUZ?[,R.,I0J9U<J(#K"91C1Q(8>I/X"7<XJSZW CLK8'0'>*90;N!E
M8[X5MUIKJ&@"Q&FBATA+%.XS!$980F#M*(I$FD ;\8B).Y-G](,*50H ?_F]
M+[WPJ6+6EJQ:?YH14#^Y"$C5+I>:*W%4V(_P M $68&XJ=0;S1IP<:HW[H%&
MW17-BQJ9JEVD4'JO-N6"I#K^C*B4IEHB(:"1LYBZ>8L0NK;720&#$'C%AK B
MU/9$TSV&U J43V.HI)A^7)$(/^BM<BOQ?'UC:'\YHIAE%%#+4X'CJ;"8D#6A
MVB"3]S9MDFQJU#!RU/)$4@E^0ABIH]APA0OV7&.J:4JPY\'H$C<3LWWCXNT/
MU+:O.@>WZ&$POG5&(Z0W$.X^'7X/[QG5!GBV@N!U>H/*('[:#O#UP> 3&^()
M+%3WV[=N6!\:*W,7$A^FQ7J:EY<+[]43\H29[P.:G(18;5KL/#//J+?\- 1/
M! O!S(TA.Y58O08\EYS@*2E-.,%?2]@'O#=Q.,<+47C-H_V=RNB+U"O^I:$<
MJ+($* IQ(D@SOVEY5$ :7#1IK+&@![76$Y.:E1GA^NPKTT(K9)J?E+;*1G$)
M2DDO?W/6;.DF6WJ;;?6Z56U4=S:7K<K.MI?$-FI6HWZYEUA;JVS4!L^(!,<?
M"[7"TUQJ2#:KR2.JK'.)0NESYQB_K*+F#2G%?(.A/SYPG&?8R-SP7[#P:G#7
M&WX9C=']Y^[PIMMS?A\/>MWK41$-;GO6%KNS*7Y&%Y6&II>7G5)6+BE\/V_M
M+N:V!>ZW)R?7XU^&["O9>#REX;NS^D5+Z.O&Z?,ACPO^6/E[BT@]R8F%4%_H
MS>336HZL8NXW*)!&DL4D8*D@N^SXEGV;7/8O0N28\? \A(OHY@I=C=XR@M;<
M4R];VX^U#N2?=;C]<_BLI9O_35>:\P-'+WS4V6=V>K#+I[:NGM>*\-T+EWT6
M-<<<AOOQU8D;<VS7_9Q;K7S8X=[U/8^J53^IU;5MOJ?77_9W_@902P,$%
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M"MQ9Q37+>(I'EID"?.=-E-L2*&4JG>-V02(%OY$8=T.GPS,!8S"D#FD)8Y!
MJBS2$,1*=(<E0EHVSU6:,U?3S[K_7%K9**$)%,IIY"M*?7/E<TS053(-!I+>
M"J89@6G.T$VPR6+3#4\%@H??#P0ERU2)(!->UD%M W\01[/=:%=E!CKA5"WA
M.M6U@$X 9R.";8!.$055B#M!EJ"L]1J3#1S<O:$!>Q'*L#9)U!H" *(!6L)P
M+MB3<I>S3)NY6Z+4RJER'C6<9YP>1KMA97L#;&YIS):U3P5OP[W#V_A.<)X_
M.QXDKTY<@ZBF1B"*,%FF<'O@7H3(73%N9< (8JXF6E(LF00P)UJYG'J06 &&
M)):D>Z%<JHVKT8^XTQH=P5)9DTJ!QXX= !M" FP1 )>W:<[+J60_@98^U!H2
MR2'O)$<',EJ1'(EX%V\5581E!"GI9\1=&]B-6");=AXHNS-0AH%HGO<1#0E*
M\U]11KU^O4<HY?N#TJ3;?T5^P-X,13^B%9+:YZ'4IGR;\MKMWH42WT2RU4@Q
ME9K:0@'X::9<8#U(R3+HH<IYS9>;G&NEY@%G32Y=8Z7=\#$U*G G;'%&*Q'V
MH:Z>."44MXHFH&+&#UF@)$VUHRP<5J8+*3MP)#:Z, @[T-"I0F6ITEISHG9,
M*QBQSN;H$6N#S9(&5Q-)@F!?])?B*]AVKW \V1\<-VQ[%\8[\]46FG=GNIU!
MC84P4X*PRITI.5$Z=\ YU94$8&[%$DR M^(3I95?4'Y_:%A:6@%W 5)Q5=P1
MW:A+0^:X;294U;8"I%VH1]+46!$,"!7J5)8H,S20C199T9(A$53?$;U86JH"
M>3\5_*;[@]\E#\L9UW4@*XJNS#*4B&J&N+@'2KU5-;$#^<;;AZN_@%=T!'&Z
M6&-.3.T?MV"7],!7TI(*Z.SS>QXV69;F80DVGH ] 6XTP!. G-@?R"TI,P9S
M&Q2T\6[*MM#R(/*^@"@IFYLTK2V%?B-U/J"U,,[C.1U!0I=+H:@YTV$'CW3)
M@&%0V#WIQG#LEV0X,Z#CA+)>V?4B6I5SMZHSB/P"YJ4(62'XHV'L!=/J1NKF
M .&>?/NK7?25.-^KC=C1WN'\O]Z(A0/&U2IIKVF*6',3J6O&(JQ]0?&Q5<6N
MK..H9+VQ;I7OPP.H+ KEO92?R D3@XJ"VH6"?4') ? ,"G9$\?A+]?1R$<K?
M:@7SPX*KRS0<-;SX_W[K=\OS=!1$):,"V&B+2YOE5$E H\G5JWW/7/(;2KZQ
M9 OI-Q2;X<!S>2ST18!KMBCQ@.$!:N,"'9U<,=NCX&Q*5'0!PE!)MF,%X)#^
M75T '_!2F$R341X\0'M*V7W_-D24Q#,+UF@CZC)P'7 3CJ<;@+5C#E3ES.B9
MI$18\FESRFX;>I1%I<U"HG6>FTB(_ Y\ ;?_2970_8)7?3[LH9KF"> G;0>N
MUKQR<K2\. %Q5YHO1JH,#@N=3AIE$^.]*4;T^G=&"0"50_/R,P J-J_?#'?[
M\>VPM_@OEB,WS=W0U/-BN^UHT#T\'C[:W.\FC[9]2NWPJ#M,7NZDMA=,CF;#
M,Z[BY9O686O9H4'.:%#=LE41$1U!8+KOG.B7;[_$@O<O -N0E]@[@*B8 $?#
M=OB$8 6=QAO?^42?/QMBZ83?[=?+=^:Z8W3[-.76)_W3K**PR"K,F$[.&$WU
MY'ORW+?RUO?DDVMLRA7EQY"/SW,E,W9Y*].:]O;L?:QYM_W4"WSY !UO?CI3
MF?CAT"@>R\[DUL<T:WP%PNVON_ )0%;[[2Z?^?ZF^8V? H6/DL[^ U!+ P04
M    " !9@F15[_.)]*4'  #5)   &    &)C<G@M,C R,C Y,S!X97AX,S$R
M+FAT;>U:;6_;.!+^?K^"Z^*Z*> WV<XE==( ;9)B ^RUO5X.Q7TZT")E$:%$
M+4G9\?WZ>X:47Q(GK7N][;K!%:@CB</A<.;A,T-*IS]=O#^__N>'2Y;[0K,/
M_WCSZ]4Y:W5ZO4_#\U[OXOJ"_7+]UU_9J-M/V+7EI5->F9+K7N_R78NU<N^K
M<:\WG\^[\V'7V&GO^F./5(UZVA@GN\*+UMDI/<&OY.+L3Z<_=3KLPJ1U(4O/
M4BNYEX+53I53]DE(=\,ZG4;JW%0+JZ:Y9X/^8, ^&7NC9CRV>^6U/%OJ.>W%
M^]->&.1T8L3B[%2H&5/B54N)Y&5R-#HZ/!X-^Z-D,.1B(M-)DAX/13H2XOA?
M"8SL03SV<7ZAY:M6H<I.+FG\\>BP\B=S)7P^3OK]/[>"W-EI9DJ/P2PZQ\NH
M8UL3MU,H\Z9"=VCR\M9WN%;3<ASFUXJJEN*IT<:.G_7#OQ-JZ62\4'HQ_OE:
M%=*Q=W+./IJ"ES^W'6+2<=*J+ HZ]6\9!PFW\VC_$?1H5<KE?)(!3>+R-E<3
MY=DPZ0[NSF WVU-X7MH_R/CSRX_75V^OSE]?7[U_]_==S?_=C1T]:.Q5F[TN
M?6[*!:"/D=LLE=:K;,%\SOWS9X?')SL'H.)"8+%TM,S\^#A9AD25 N$8=Y+C
M/VR627<YB>\_^EVW)/WN(;GABN5\)IF5,R7GH!F?*\=^J[D%;O4"SRMC/3,E
M>VMLP9)^YV_,9.R-,N=VX3S[D'-;\%367J5<NS:[*M,NHO7R*41KL'?1>L,=
M8H1H% MV4YJYEF**I1*"UH1*&)A0&B0.C,!5R3B65%UZ6TO, *DD9!7$D+,"
M=U9QS3*>XI%EI@#7>1/EM@1*F4KGN%V02,%O),;=T.GP3, 8#*E#2L(8)) J
MBQ0$L1+=88F0ELUSE>;,U?2S[C^75C9*: *%<AJYBM+>7/D<$W253(.!I+>"
M:49@FC-T$VRRV'3#4X'@\,>!H&29*A%DPLLZJ&W@#^)HMAOMJLQ )YPJ)5RG
MNA;0">!L1+ -T"FBH IQ)\@2E+5>8[*!@[LW-& O0@G6)HE:0P! -$!+&,X%
M>U+N<I9I,W=+E%HY5<ZC?O.,T\-H-ZQL;X#-+8W9LO:IX&VT=WB[OA.<Y\^.
M!\G1B6L0U=0(1!$FRQ1N#]R+$+DKQJT,&$',U41+BB63 .9$*Y=3#Q(KP)#$
MDG0OE$NU<37Z$7=:HR-8*FM2*?#8L0-@0TB +0+@\C;->3F5[#5HZ6.M(9$,
M>2<Y/)#1BN10Q+MXJZ@:+"-(23\C[MK ;L02V;+S0-F=@3(,1/.\CVA(4)K_
MAC+JY<L]0BG?'Y0FW?X1^0'[,A3\B%9(:E^&4IOR;<IKMWL72GP3R58CQ51J
M:@L%X*>9<H'U("7+H(<JYS5?;G*NE9H'G#6Y=(V5=L/'U*C G;#%&:U$V(.Z
M>N*44-PJFH"*&3]D@9(TU8ZR<%B9+J3LP)'8Y,(@[#Y#IPJ5I4IKS8G:,:U@
MQ#J;HT>L#39+&EQ-) F"?=%?BF]@V[W"\61_<-RP[5T8[\Q76VC>G>EV!C46
MPDP)PBIWIN1$Z=P!YU17$H"Y%4LP =Z*3Y16?D'Y_:%A:6D%W 5(Q55Q1W2C
M+@V9X[:94%7;"I!VH1Y)4V-%,"!4J%-9HLS00#9:9$5+AD10?4?T8FFI"N3]
M5/";[@]^ESPL9US7@:PHNC++4"*J&>+B'BCU5M7$#N0;;Q^N_@)>T1'$Z6*-
M.3&U?]R"7=(#7TE+*J"S+^]YV&19FH<EV'@"]@2XT0!/ ')B?R"WI,P8S&U0
MT,:[*=M"RX/(^PJBI&QNTK2V%/J-U/F UL(XC^=T_ A=+H6BYDR''3S2)0.&
M06'WI!O#L5^2X<R CA/*>F77BVA5SMVJSB#R"YB7(F2%X(^&L1=,JQNIFP.$
M>_+M;W;1-^)\KS9BAWN'\_]Z(Q8.&%>KI+VF*6+-3:2N&8NP]A7%QU85N[*.
MHY+UQKI5O@\/H+(HE/=2?B8G3 PJ"FH7"O8%)0? ,RC8$<7C+]73RT4H?ZL5
MS \+KB[3<-3PXO_[K=\MS]-1$)6,"F"C+2YMEE,E 8TF5Z_V/7/);RCYQI(M
MI-]0;(8#S^6QT%<!KMFBQ .&!ZB-"W1T<L5LCX*S*5'1!0A#)=F.%8!#^G=U
M 7S 2V$R349Y\ #M*67W_=L041+/+%BCC:C+P'7 33B>;@#6CCE0E3.C9Y(2
M8<FGS2F[;>A1%I4V"XG6>6XB(?([\ 7<_B=50O<K7O/YL(=JFB> G[0=N%KS
MRLGQ\N($Q%UIOABK,C@L=#IIE$V,]Z88TZO?&24 5 [-B\\ J-B\?BO<[<<W
MP][BOUB.W#1W0U//B^VVPT%W>#QZM+G?31YM^YS:T6%WE/QE)[6]8'(T&YYQ
M%2]?M8:M98<&.>-!=<M6141T!('IOG.B7[[_$@O>OP!L0UYB[P"B8@(<C=KA
M\X$5=!IO_. 3??YLA*43?N^^6KXSSQTCVZ?IMC[KFV8%A0568;9T:L9HFB<_
MDM>^AZ=^)'^<YTIF[.V*:=_'ZG;;,[W C \0[^8',I6)GP>-XP'L3&Y],K-&
M4Z#6_KH+GP!2M=_N\H6O;)K?^,%/^/3H[#]02P,$%     @ 68)D5?:4]@"W
M!   _!$  !@   !B8W)X+3(P,C(P.3,P>&5X>#,R,2YH=&WM6.MOVS80_[Z_
MXNI@:0I8+S^26'8#N+:#9NCB-%;1]=- 2Y1%E")5DH[C_?4[4G*2-LV6 5T?
MPX) H'0/WOWNP3-'3Z;S2?+N8@:%*3E<O'GQZFP"+2\(WG8G03!-IO R^?45
M]/PP@D01H9EA4A >!+/S%K0*8ZHX"#:;C;_I^E*M@N0RL*IZ 9=24S\S6>MD
M9+_@DY+LY*?1$\^#J4S7)14&4D6)H1FL-1,K>)M1_1X\K^&:R&JKV*HPT D[
M'7@KU7MV16JZ88;3DYV>45"_CP*WR6@IL^W)*&-7P++G+98M^WW2HX?=0=CO
MA8,C$I%H<'0TP'4>I5WZ>X1&!LA>RVBSY?1YJV3"*ZC=/^[U*S/<L,P4<12&
M/[<<W\DHE\+@9@J%ZV6MX[XFHE:HS,@*Q5&3H=?&(YRM1.S\:]6J=NRIY%+%
M>Z'[&UJ*EY.2\6W\-&$EU7!.-W I2R*>MC7&Q--4L;QFU.P/6F_B7C>U_4>H
MAS-!=_Y$'>O$[+I@2V:@V_&CCSUXG.TI(D_5-S)^,KM,SD[/)N/D;'Z.F7NY
M>#,^3R"9/^C)]V)Y= QO_(4_\6$QFSCKHVX_;'_W=H\7,)[.+Y+9](>">P?R
M(#R$^2DD+V>P&%^^&)_/%M[\MU>S=S">));2"</.8\O@7_>E]UE?S@2D4@B:
MVBX,&V8*, 6%UVNB$&"^A4M:265 YO""R8G::@,7!5$E2>G:L)1PW88SD?IP
M8.7V]XX[G7 XD65%Q-:]1<-G@*I/I2HA"KW7D$OE]JC08ID!%1FVZP6M#"V7
M5.WO18?AL!NVZQ9--.2,(\.-:0N:KA4>&H@!$1G,KM."B!7%WEZ63&OK!OY;
MS@P/ BBHHFC\7>MJEW;&H?EM^ 5%+K!\C!2TD&M-VS I&,U1/6YGV!6%>9ZS
ME"J+A-75N-@&_&98CHMJK?2:8 B-A-N*M/X<#>N"M-Z03%;V?+K+W?#8?&JT
M+XA:$D&U-[_F= OCU$7 YE,;Z<2TK9AE7%+M2.46W@NY0:16='^O?SQ\=/NM
M2);A4>EQFINX>[AKR S#(DSL1<??+#</HF<[+[[^]A_C<NAW>Q:'!"%O*B)?
M<RR/%-. VUR\R4]%/ZR9HG:(T#8RNJFMJ'M L!(41/V#[-E-H&^S^2:3FVA'
M@VX/0SD8VCS_+X2S\UV&DPEL2"5Q,<)6: A*9OC5A6<7:\)L+ZP4U3:L;4LF
MG .*H3&$8]!UA7'6;2>5,T%$:K^CPLP-N*Y7(=>:UUDAL?NY/?4G#<7_!P>&
M(4M.=^2E5!E5'L+)2:5IO%L,,Z8K3K8Q$PX4)S1LE"VE,;*,[3!Z9?L8]O/F
MA'594Y-OYU0_K&=5@P.JR78[-V3?D0*3W:?UCOU!^# Y]*,':5](;>!,KLU&
M9#1"_;S5;>T$FNR(.]4U1!_/I#9A[H$CJ[L3^U=,Y:B#+NWO]8Z&VCWOGUR?
M_')H@/D+GT/K\2-Q:I+,Y6"%?DO.,K .#W\L!+\N:C\6-A?8II@]+5S/>F ,
M^A^O&[RF> BXD0O.Y96;8:%73Z]? *3 M>O/G 9W[Q$J6=^BQ(IR8J-T[V;A
MMGY=OP]O1<@2BWAM[HO\S65$\ZSO1=P-S<F?4$L#!!0    ( %F"9%53NP_6
MI@0  +81   8    8F-R>"TR,#(R,#DS,'AE>'@S,C(N:'1MY5AM;]LV$/Z^
M7W%SL#0%K%?+>9'= *[MH &Z.(U5=/TT4!)E$95(C:3C>+]^1TI.FJ79,FSK
MRQ8$AJ1[X=USQX<'CK^?+:;)^\LYE+JNX/+MR]?G4^@YGO=N,/6\63*#5\F/
MKR%R_0 22;ABF@E.*L^;7_2@5VK=Q)ZWV6S<S< 5<N4E5YYQ%7F5$(JZN<Y[
MIV/S!7\IR4^_&W_O.# 3V;JF7$,F*=$TA[5B? 7O<JH^@.-T6E/1;"5;E1I"
M/PSAG9 ?V#5IY9KIBI[N_(R]]GWLV47&J<BWI^.<70/+7_182L@1S88T/4F/
MHL,B.SZ,ANE)<30LHF$49N'/ 0;IH7IKH_2VHB]Z->-.2<WZ<31L]&C#<EW&
M@>__T+-ZI^-"<(V+231N'UL?#ST1N4)G6C1HCIXTO=$.J=B*QS:_7NMJIYZ)
M2LAXS[=_(R-Q"E*S:AL_2UA-%5S0#5R)FO!G?84U<125K&@5%?N5MHO8UTT;
M_Q'ZJ1BGNWR"T"0QORE9RC0,0C>\G\'38L\0>2J_4/#3^55R?G8^G23GBPOL
MW*OEV\E% LGBT4R^ELB#8WCK+MVI"\OYU$8?#(9^_ZN/>[*$R6QQF<QGWQ3<
M.Y!/_$-8G$'R:@[+R=7+R<5\Z2Q^>CU_#Y-I8B2A[S]Y&_SKN42?S.6<0R8X
MIYEA8=@P78(N*;Q9$XD 5UNXHHV0&D0!+YF8RJW2<%D269.,KC7+2*7Z<,XS
M%PZ,W?[><1CZHZFH&\*W]BT8/0=T?29D#8'OO(%"2+M&@Q&+'"C/D:Z7M-&T
M3JG<WPL._=' [[<43104K$*%V]"6-%M+/#00 \)SF-]D)>$KBMQ>UTPIDP;^
M&\T<#P(HJ:08_,?1M2GM@L/P^S#ANA1\B\<(HM^':<EH 6>,$YXQ4L&B*%A&
MI4'!^.G2ZP-^TZS AV8MU9I@^;2 N]UH<CD:M9O19$)RT9BSZ6/M3L?T4N=]
M261*.%7.XJ:B6YAD%GW32WV4$]TW9D8QI<J*ZBU\X&*#**WH_M[P>/1DZFU(
MGN,QZ52TT/'@<$?&#$O"=>P$QU^L+P^"Y[LL/O_R]W$Y= >1P2%!R+O=4*PK
MW!H9MD%E^O"V-R7]9<TD-0.$,I51W;X*!@<$=X&$8'B0/[\M]%TGWW9Q5^W@
M9!!A*4]&IL?_"^4,O\IR,HYD5!-;(Z1!3= RQZ^V/+M:$V9XL)%4F;+VC9A4
M%: 9!H/D@((&ZZSZUJJX)0UTF-OAUO(4:JVKMBL$,I]=4_V.4-R_<%AHDE9T
M)TZ%S*ET$,Z*-(K&NX=1SE13D6W,N 7%&HTZ9ZG06M2Q&42O#8\AEW>GJ^V:
M5GPWH[I^.Z=J'$YUOENY$[M6Y.G\H2PZ=D_\Q\6^&SPJ^X?<>C;D-FQ$1B'4
M+WJ#WLZ@ZXXX;&X@N#^/FH9Y (YH/O\F"D+,9G\O.AHI^WO_P+IMFPZ)/TC2
M-RD^$9BNJVS3-9BMJ%@.)LW1-P/9YX#IFP'CD:GF_P[+#(G<CDUP(:[M# I1
M.WW^+60\2[:?X/*/;P :T=Y_Q))6>"1<TP=W G>;T;*U?V="4MR1:_W0Y$^N
M$;K?]D;#WJV<_@902P,$%     @ 68)D5<OZ"/L_'0  I,P  !X   !E>&AI
M8FET,3 Q+6)I;V-R>7-T>&)C>#DY,RYH=&WM7>MSVDBV_W[_BMZD[FQ2A;'!
MSB1.LJDB6+&9(=@%.+GYM-5(#?1&J!D]3)B__IYSNEL/7L:)'436.[6Q#5*K
M'^?Y.P^]_<?99;/_Y<IAXWCBLZOK]^U6DSTY.#S\?-P\/#SKG[&+_L<V.ZD>
MU5@_Y$$D8ZD"[A\>.ITG[,DXCJ>O#P]GLUEU=EQ5X>BPWSW$H4X.?:4B4?5B
M[\F[M_@)_"NX]^Y_WO[CX("=*3>9B"!F;BAX+#R61#(8L<^>B+ZR@P-S55--
MYZ$<C6-6/ZK7V6<5?I4W7'\?R]@7[^PX;P_UWV\/Z2%O!\J;OWOKR1LFO7\]
MD<='I\?UXQ<O!Z[[ZL3EQX/3TZ/:\0LNO-JKVFF]]N\:3/(0+M?W1/'<%_]Z
M,I'!P5C@\U^_K$_C-S/IQ>/7M:.C_WU2N"X6W^(#[LM1\)IF"]\.%:S-?.TJ
M7X6OGQ[1_][@-P=#/I'^_/4_^W(B(M81,]95$Q[\LQ+!#A]$(I1#?6$D_Q;P
M1'@X_3DSLX%Q?!D(.SL])>?;6 YDS&I'U=K;0[S>KFEY93P<P>(&*H[5Y'4-
M%Y=;A L;*L)[7T5MJU5\;K0^.5U67,#64_]/$L5R.-<?R<"#E=#9_?S%U'$Q
M_8M6CRVLZ&'G<;)R'L_BL8S8;T]?U>M';W8W$7TLGG!5R%&,O$[@A$*\"LZ=
MRQL1[G*3:'MJ;YY7F$<BB4=,#=D?B3]GM9,*B: *@VTD[H#O91 K-I@S'L"U
M$P7BZWWKLMG]TNNSJXM&]V.CZ5SW6\U&NU=AK4ZS6F&<G0F?SW@H&&S!U.P"
M@],1Y3Z<]RH,U:PLQX/;-4HX:*-8A1'S983'!1N)7T0@!GB<P!9/^0B>/H:S
M@G,J_QZ?IRLJSR[[ N>W[19'B3NVMU2(+?!J!?^$Z4A3'L9S!E?C5TU@(U!8
MC5$H!%D#SX#G/#&$67EL('PUPWFHD: A9C(>XVTR9*&(IL*-06(P>*@KH@@)
M 9\X%>%$QII]<9XP$<%A6J +Y(WT$N[[<V3$4I-"FS:K!&2@3Q$>ZNO=QKTK
M/2/IW2L%%]'V-?H77[JMZX_L\NKJLMN_[K3Z+:?'6JT6:UX>M#J?'- 8-=:^
M*B@(7P(= QDCPP2PG+&<5E E<0_,4F!'7#>0/S @+&^H0CH7LW3V3 :,N-'E
M4^[*>+[(1C*.%CG'\ M;<6O93[Q1W)/&B#R"W1^_9A_84)^<&+ F<"N'P$YJ
M!N[.;T]?O'KSG8;NKFSTVZPXUF)]UF$.Z\%_#OQ^\6M8\I\OG*[3Z.V2JBK,
MFF&:)3.#H5)@?JMX5W$%XZ2UPUC"O$@+<_#!11ASH-)%=5PTA,^$*R8#$" O
MR18^(F4=)=.I3Q>CQIX7QWLFG[,_%)Y=>.N@QS4]:L5:U ,1SX0(V'NIFN$\
MBMDU4!3W8=I-!:9TN]U<*2Y]R0?2![$%6FLRY<&\LG$_*C#)VV?Y00Q"V.PY
M>T63K&V8Y)^LK6>"LYN&\@:&22=GI@02P9K_Y$8P)QCY)(+A_Y]IC<]*+6]S
MRRV/F-UXQ+>?\4<^9R^LEU?TZNQJG6C*?WM:/ZF]X176J[;)H^O!B<IHO'36
M2X3XL\Z41GPM8Q"C[A:;V%.N%![WP.YF73"K51#1Q/$C(F7N\3(<\KZP!-"#
M#,JP896,<%M(#$2S8=5'J@W,1\$F<HV0,F(@^/K)&R#T,$<<]E.ZF\=\;TX'
MESTOP^D8DQM$#&KMU;JS@=^17]Q)2$E>!@*5]F8]W5$W6J763K6V*DHS%)/W
M84? EZ0Z"5G4X%W%+FJ8A.1JF,55D'9B3DHQ;S!4&+@M! _,9"381'ER"+*(
M#4,U83'L.EDH\',/7)#%,RD#C8%_<?J]_L6C^;W>_&9C'A&#WB@_"6(>PL/
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M1Q)Z0$P"9:*@3)W4Q%\+WN61OAF*?2WTMQ5'-,8PH2P@RKM);UF^E"8S 1^
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M-5.'\@K1?]P[/*7==[:JDF80PZ&VZ0)@G(643[3&4G\XU^D'UA@--=B 9(X
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M?2%5P6XH(:O>PB'JE(,2["Q6\F&3WW7E%LLK^D7$W.D^B3D'%$\HRO'^LR)
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MOD%@AIUT>A)Z+3<5O9:]0B# L5=4+PY[Y6/ZS948ZZ'KL(HD6 B:V3O6=2=
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MU5'98NFMD=JV)\R[Q84VFER5T5E3D9Y%QNF!:)V2654(DQL^4 M2VUFF.;.
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M,#(R,#DS,"YX<V102P$"% ,4    " !9@F15*-@?]:T5   3Q   %0
M        @ &=_P( 8F-R>"TR,#(R,#DS,%]C86PN>&UL4$L! A0#%     @
M68)D51Q)*WUN70  2=P# !4              ( !?14# &)C<G@M,C R,C Y
M,S!?9&5F+GAM;%!+ 0(4 Q0    ( %F"9%54TXE&#/4  +\+"@ 5
M      "  1YS P!B8W)X+3(P,C(P.3,P7VQA8BYX;6Q02P$"% ,4    " !9
M@F15N_']A7"&  !*T 4 %0              @ %=: 0 8F-R>"TR,#(R,#DS
M,%]P<F4N>&UL4$L! A0#%     @ 68)D59)YX9+2!P  -#   !P
M     ( ! .\$ &)C<G@M,C R,C Y,S!X97AH:6)I=#$P-"YH=&U02P$"% ,4
M    " !9@F15KIH@6+4'  #O)   &               @ $,]P0 8F-R>"TR
M,#(R,#DS,'AE>'@S,3$N:'1M4$L! A0#%     @ 68)D5>_SB?2E!P  U20
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J+6)I;V-R>7-T>&%M96YD;2YH=&U02P4&      T #0"$ P  :TD%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
